

BACKGROUND REVIEW DOCUMENT

In Vitro Cytotoxicity Test Methods for Estimating Acute Oral Systemic Toxicity

Volume 1 of 2

Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM)

National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM)

> National Institute of Environmental Health Sciences National Institutes of Health U. S. Public Health Service Department of Health and Human Services

THE INTERAGENCY COORDINATING COMMITTEE ON THE VALIDATION OF ALTERNATIVE METHODS and THE NTP INTERAGENCY CENTER FOR THE EVALUATION OF ALTERNATIVE TOXICOLOGICAL METHODS

In 1997, the National Institute of Environmental Health Sciences (NIEHS), one of the National Institutes of Health (NIH), established the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) to:

- Coordinate interagency technical reviews of new and revised toxicological test methods, including alternative test methods that reduce, refine, or replace the use of animals
- Coordinate cross-agency issues relating to validation, acceptance, and national and international harmonization of new, modified, and alternative toxicological test methods

On December 19, 2000, the ICCVAM Authorization Act (42 U.S.C. § 2851-2, 2851-5 [2000]) established ICCVAM as a permanent interagency committee of NIEHS under the National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM).

ICCVAM is comprised of representatives from 15 U.S. Federal regulatory and research agencies that use, generate, or disseminate toxicological information. ICCVAM conducts technical evaluations of new, revised, and alternative methods with regulatory applicability. The Committee promotes the scientific validation and regulatory acceptance of toxicological test methods that more accurately assess the safety or hazards of chemicals and products and that refine (decrease or eliminate pain and distress), reduce, and/or replace animal use. NICEATM administers ICCVAM and provides scientific and operational support for ICCVAM-related activities. More information about ICCVAM and NICEATM can be found on the ICCVAM/NICEATM web site (http://iccvam.niehs.nih.gov) or obtained by contacting NICEATM (telephone: [919] 541-2384, e-mail: iccvam@niehs.nih.gov).

The following Federal regulatory and research agencies are ICCVAM members:

Consumer Product Safety Commission Department of Agriculture Department of Defense Department of Energy Department of Health and Human Services • Agency for Toxic Substances and Disease Registry

- Food and Drug Administration
- National Cancer Institute
- National Institute of Environmental Health Sciences
- National Institutes of Health, Office of the Director
- National Institute of Occupational Safety and Health
- National Library of Medicine
- Department of the Interior

Department of Labor

Occupational Safety and Health Administration
Department of Transportation
Environmental Protection Agency



On the Cover

The ICCVAM/NICEATM graphic symbolizes the important role of new and alternative toxicological methods in protecting and advancing the health of people, animals, and our environment.

In Vitro Cytotoxicity Test Methods for Estimating Acute Oral Systemic Toxicity

Background Review Document

Volume 1 of 2

Prepared by The National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM)

National Institute of Environmental Health Sciences (NIEHS) P.O. Box 12233 Mail Drop: EC-17 Research Triangle Park, NC 27709

November 2006 NIH Publication No. 07-4518

National Institute of Environmental Health Sciences National Institutes of Health U.S. Public Health Service Department of Health and Human Services This document is available electronically at: <u>http://iccvam.niehs.nih.gov/methods/invitro.htm</u>

TABLE OF CONTENTS

| APPI | ENDIC | ES | | xiii |
|------|-------|---|---|--|
| LIST | OF FI | GURES | | xvi |
| LIST | OF TA | ABLES | | xvii |
| | | | IS AND ABBREVIATIONS | |
| ACK | NOWL | EDGME | NTS | XXV |
| PRE | FACE | | | xxix |
| EXE | CUTIV | E SUMM | ARY | xxxiii |
| 1.0 | NEU | TRAL R | ION AND RATIONALE FOR THE USE OF <i>IN VITRO</i> ED UPTAKE CYTOTOXICITY TEST METHODS TO ARTING DOSES FOR <i>IN VIVO</i> ACUTE ORAL | |
| | | | ESTING | 1-3 |
| | 1.1 | Cytoto Oral To 1.1.1 1.1.2 1.1.3 1.1.4 1.1.5 1.1.6 | cal Background and Rationale for the Use of <i>In Vitro</i> xicity Assays to Predict Starting Doses for Rodent Acute oxicity Tests | 1-4 1-6 1-7 1-9 1-10 1-11 |
| | 1.2 | Cytoto | xicity Test Methods to Predict Starting Doses for Acute oxicity Testing in Rodents Current Regulatory Testing Requirements for Acute Oral | 1-14 |
| | | 1.2.2 | Toxicity1.2.1.1Test Methods for Assessing Acute Oral ToxicityIntended Regulatory Uses for In Vitro Cytotoxicity Test | 1-16 |
| | | 1.2.3 | Methods Similarities and Differences in the Endpoints of <i>In Vitro</i> Cytotoxicity Test Methods and Rodent Acute Oral Toxicity Test Methods | |
| | | 1.2.4 | Use of <i>In Vitro</i> Cytotoxicity Test Methods in the Overall Strategy of Hazard Assessment | |

| | 1.3 | Scienti | Scientific Basis for the In Vitro NRU Test Methods | | | |
|-----|-------|----------------|---|------|--|--|
| | | 1.3.1 | Purpose and Mechanistic Basis of In Vitro NRU Test | | | |
| | | | Methods | 1-19 | | |
| | | 1.3.2 | Similarities and Differences in the Modes/Mechanisms of | | | |
| | | | Action for In Vitro NRU Test Methods Compared with the | | | |
| | | | Species of Interest | 1-20 | | |
| | | 1.3.3 | Range of Substances Amenable to the In Vitro NRU Test | | | |
| | | | Methods | 1-20 | | |
| 2.0 | TES | г метн | OD PROTOCOL COMPONENTS OF THE 3T3 AND NHK | | | |
| | IN V. | <i>ITRO</i> NF | RU TEST METHODS | 2-3 | | |
| | 2.1 | Basis f | for Selection of <i>In Vitro</i> NRU Cytotoxicity Test Methods | 2-4 | | |
| | | 2.1.1 | Guidance Document Rationale for Selection of In Vitro NRU | | | |
| | | | Cytotoxicity Test Methods | 2-4 | | |
| | | 2.1.2 | Guidance Document Rationale for Selection of Cell Types | | | |
| | 2.2 | Overv | iew of the 3T3 and NHK NRU Test Methods | 25 | | |
| | 2.2 | 2.2.1 | The 3T3 NRU Test Method | | | |
| | | 2.2.1 | 2.2.1.1 Initiating and Subculturing 3T3 Cells | | | |
| | | | 2.2.1.1 Preparation of Cells for 96-well Plate Assays | | | |
| | | | 2.2.1.2 <i>Reference Substance Application</i> | | | |
| | | 2.2.2 | The NHK NRU Test Method | | | |
| | | 2.2.2 | 2.2.2.1 Initiating and Subculturing NHK Cells | | | |
| | | | 2.2.2.2 Preparation of Cells for 96-well Plate Assays | | | |
| | | | 2.2.2.2 <i>Reference Substance Application</i> | | | |
| | | 2.2.3 | Measurement of NRU in the 3T3 and NHK Test Methods | | | |
| | 2.3 | Dosori | ptions and Rationales of the 3T3 and NHK NRU Test | | | |
| | 2.3 | Methods | | | | |
| | | 2.3.1 | Materials, Equipment, and Supplies | | | |
| | | 2.3.1 | 2.3.1.1 <i>3T3 Cells</i> | | | |
| | | | 2.3.1.2 <i>NHK Cells</i> | | | |
| | | | 2.3.1.3 <i>Tissue Culture Materials and Supplies</i> | | | |
| | | | 2.3.1.4 <i>Cell Culture Materials</i> | | | |
| | | | 2.3.1.5 <i>Equipment</i> | | | |
| | | | 2.3.1.6 <i>Culture Medium</i> | | | |
| | | 2.3.2 | Reference Substance Concentrations/Dose Selection | | | |
| | | | 2.3.2.1 Range Finder Test | | | |
| | | | 2.3.2.2 Definitive Test | | | |
| | | 2.3.3 | NRU Endpoints Measured | | | |
| | | | 2.3.3.1 NRU and Measurement | | | |
| | | | 2.3.3.2 Determination of IC_{50} , IC_{20} , and IC_{80} Values | 2-13 | | |
| | | 2.3.4 | Duration of Reference Substance Exposure | | | |
| | | 2.3.5 | Known Limits of Use | | | |
| | | | 2.3.5.1 Solubility/Precipitation/Volatility | | | |
| | | | 2.3.5.2 Biokinetic Determinations | | | |
| | | | 2.3.5.3 Organ-Specific Toxicity | | | |

| | | 2.3.5.4 | The Role of Cytotoxicity Tests in an In Vitro | |
|-----|----------|-------------|---|------|
| | | | Battery Approach for Possible Replacement of In | |
| | | | Vivo Acute Toxicity Testing | 2-15 |
| | 2.3.6 | Basis of t | he Response Assessed | |
| | 2.3.7 | | ate Positive, Vehicle, and Negative Controls | |
| | | 2.3.7.1 | Positive Control | |
| | | 2.3.7.2 | | |
| | | 2.3.7.3 | | |
| | 2.3.8 | | le Ranges of Control Responses | |
| | | 2.3.8.1 | Vehicle Controls as a Quality Control Tool | |
| | 2.3.9 | Nature of | Experimental Data Collected | |
| | | 2.3.9.1 | | |
| | | 2.3.9.2 | Information and Data Collected | 2-18 |
| | 2.3.10 | Data Stor | age Media | |
| | 2.3.11 | Measures | of Variability | 2-19 |
| | 2.3.12 | | for Analyzing NRU Data | |
| | 2.3.13 | Decision | Criteria for Classification of Reference Substances | 2-20 |
| | 2.3.14 | Informati | on and Data Included in the Test Report | 2-20 |
| 2.4 | Dronvid | | ponents of the <i>In Vitro</i> NRU Test Methods | |
| | | | | |
| 2.5 | | | ber of Replicate and Repeat Experiments for the | |
| | 3T3 and | d NHK NR | U Test Methods | 2-22 |
| 2.6 | Basis fo | or Modifica | ations to the 3T3 and NHK NRU Test Method | |
| | | | | 2-22 |
| | 2.6.1 | | Laboratory Evaluation Phase | |
| | | 2.6.1.1 | | |
| | | 2.6.1.2 | 3T3 Cell Growth | |
| | | 2.6.1.3 | NHK Cell Growth | 2-23 |
| | | 2.6.1.4 | Vehicle Control OD Limits | 2-24 |
| | | 2.6.1.5 | Precipitate Formation | |
| | | 2.6.1.6 | Dilution Factor | |
| | | 2.6.1.7 | Test Acceptance Criteria | 2-25 |
| | 2.6.2 | Phase Ib: | Laboratory Evaluation Phase | |
| | | 2.6.2.1 | NR Crystal Formation | |
| | | 2.6.2.2 | Heating of Reference Substance Solutions | 2-26 |
| | | 2.6.2.3 | Growth of Untreated Cells | |
| | | 2.6.2.4 | Correction of Reference Substance OD Values | 2-27 |
| | | 2.6.2.5 | Laboratory Error Rates | 2-28 |
| | | 2.6.2.6 | Resultant Protocol Changes for Phase II | 2-28 |
| | | 2.6.2.7 | Test Acceptance Criteria | 2-29 |
| | 2.6.3 | Phase II: | Laboratory Qualification Phase | 2-29 |
| | | 2.6.3.1 | Testing of Volatile Reference Substances | 2-29 |
| | | 2.6.3.2 | Atypical Concentration-Responses | |
| | | 2.6.3.3 | Hill Function | 2-33 |
| | | 2.6.3.4 | Insoluble Reference Substances | 2-33 |
| | | 2.6.3.5 | Inadequate Cell Growth in NHK Medium | 2-34 |

3.0

| | | 2.6.3.6 <i>Performance Standards for Media to Supp</i> <i>NHK Growth</i> | |
|------------|---------|---|--------|
| | | 2.6.3.7 <i>Test Acceptance Criteria for Phase II</i> | |
| | 2.6.4 | Phase III: Laboratory Testing Phase | |
| | 2.0.4 | 2.6.4.1 Required Cytotoxicity Values | |
| | | 2.6.4.2 <i>Revisions to Data Analysis Procedures</i> | |
| 2.7 | Difford | ences Between the 3T3 and NHK NRU Protocols for t | |
| 2.1 | | tion Study and the <i>Guidance Document</i> Standard Pro | |
| 2.8 | Overvi | ew of the Solubility Protocol | 2-37 |
| 2.9 | Basis o | f the Solubility Protocol | |
| | 2.9.1 | Initial Solubility Protocol Development | |
| | 2.9.2 | Basis for Modification of the Phase II Protocol | |
| 2.10 | Compo | onents of the Solubility Protocol | |
| | 2.10.1 | Medium, Supplies, and Equipment Required | |
| | | 2.10.1.1 Medium and Chemical Supplies | |
| | | 2.10.1.2 Equipment | |
| | | 2.10.1.3 <i>Procedures</i> | |
| | 2.10.2 | Data Collection | 2-41 |
| | 2.10.3 | Variability in Solubility Measurements | 2-41 |
| | 2.10.4 | Solubility Issues During the Testing of the Reference | |
| | | Substances | |
| | 2.10.5 | Analysis of Solubility Data | |
| 2.11 | Summa | ary | 2-42 |
| REF | ERENCE | E SUBSTANCES USED FOR VALIDATION OF TH | E 3T3 |
| AND | NHK NI | RU TEST METHODS | |
| 3.1 | Ration | ale for the 72 Reference Substances Selected for Test | ing3-3 |
| | 3.1.1 | Reference Substance Selection Criteria | |
| | 3.1.2 | Candidate Reference Substances | |
| | 3.1.3 | Selection of Reference Substances for Testing | |
| 3.2 | Charao | cteristics of the Selected Reference Substances | |
| | 3.2.1 | Source Databases Represented by the Selected Refere | |
| | | Substances | |
| | 3.2.2 | Chemical Classes Represented by the Selected Refere | ence |
| | | Substances | |
| | 3.2.3 | Product/Use Classes Represented by the Selected Ref | erence |
| | | Substances | |
| | 3.2.4 | Toxicological Characteristics of the Selected Referen | ce |
| | | Substances | |
| | | 3.2.4.1 <i>Corrosivity</i> | |
| | | 3.2.4.2 Toxicity Targets | |
| | | 3.2.4.3 <i>Metabolism</i> | |
| | 3.2.5 | Selection of Reference Substances for Testing in Phase | ses Ib |
| | | and II | |

| | | 3.2.6 | Unsuitable and Challenging Reference Substances | 3-34 | | |
|-----|------------|--|--|------------|--|--|
| | 3.3 | Refere 3.3.1 | nce Substance Procurement, Coding, and Distribution Exceptions | | | |
| | 3.4 | Refere | nce Substances Recommended by the <i>Guidance Document</i> | 3-35 | | |
| | 3.5 | | ary | | | |
| 4.0 | ASSI | ESS THE | UTE ORAL LD ₅₀ REFERENCE VALUES USED TO ACCURACY OF THE 3T3 AND NHK NRU TEST | 4-3 | | |
| | 4.1 | | ds Used to Obtain Rodent Acute Oral LD ₅₀ Reference | | | |
| | | Values 4.1.1 | Identification of Candidate Rodent Acute Oral LD ₅₀ Reference Data | | | |
| | | 4.1.2 | Criteria Used to Select Candidate Rodent Acute Oral Data for Determination of LD ₅₀ Reference Values | 4-5 | | |
| | | | 4.1.2.1 Final Exclusion Criteria 4.1.2.2 Assumptions Regarding Materials, Animals, and Methods | | | |
| | | | 4.1.2.3 <i>Calculation Reference LD</i> ₅₀ Values | | | |
| | | | 4.1.2.4 Use of Rat and Mouse Data | 4-7 | | |
| | 4.2 | Final F | Rodent Acute Oral LD ₅₀ Reference Values | 4-7 | | |
| | 4.3 | 4.3 Relevant Toxicity Information for Humans | | | | |
| | 4.4 | | ncy and Reliability of the Rodent Acute Oral LD ₅₀ Reference | | | |
| | | Values 4.4.1 4.4.2 | Variability Among the Acceptable LD ₅₀ Values Comparison of Rodent Acute Oral LD ₅₀ Reference Values | | | |
| | | 4.4.3 | with the Corresponding RC LD ₅₀ Values Comparison of the Variability Among Acceptable LD ₅₀ | | | |
| | | | Values to Those Obtained in Other Studies | | | |
| | 4.5 | | ary | | | |
| 5.0 | 3T3 | AND NH | K NRU TEST METHOD DATA AND RESULTS | 5-3 | | |
| | 5.1 | Study 5.1.1 5.1.2 5.1.3 | Timeline and Participating Laboratories Statements of Work (SOW) and Protocols Study Timeline Participating Laboratories | 5-3 5-4 | | |
| | 5.2 | | Reference Substances and GLP Guidelines | | | |
| | | 5.2.1 | Coded Reference Substances | 5-5 | | |
| | | 5.2.2 | Lot-to-Lot Consistency of Reference Substances | 5-5 | | |
| | 50 | 5.2.3 | Adherence to GLP Guidelines. | | | |
| | 5.3 | 313 an 5.3.1 | d NHK NRU Test Method Protocols Phase Ia: Laboratory Evaluation Phase | | | |

| | | 5.3.1.1 | Protocol Changes and the Effect on the Data | |
|-----|--------|--------------|--|---------|
| | 5.3.2 | | : Laboratory Evaluation Phase | |
| | | 5.3.2.1 | 0 35 | |
| | 5.3.3 | | Laboratory Qualification Phase | |
| | | 5.3.3.1 | Protocol Changes and the Effect on the Data | |
| | 5.3.4 | | : Main Validation Phase | |
| | | 5.3.4.1 | Protocol Changes and the Effect on the Data | 5-9 |
| 5.4 | | | luate Test Method Accuracy and Reliability | |
| | 5.4.1 | | | |
| | | 5.4.1.1 | Phase Ib PC Data Acceptance Limits | |
| | | 5.4.1.2 | 1 | |
| | 5 4 0 | 5.4.1.3 | 1 | |
| | 5.4.2 | Referenc | e Substance Data | 5-12 |
| 5.5 | | | aches to the Evaluation of 3T3 and NHK Data | |
| | 5.5.1 | | Il Analyses for Phase Ia Data | 5-27 |
| | | 5.5.1.1 | Outlier Determination for Replicate Well | |
| | | | Concentration Data | |
| | | 5.5.1.2 | Curve Fit Criteria | |
| | | 5.5.1.3 | Reproducibility Analyses for PC IC ₅₀ Values | |
| | 5.5.2 | | Il Analyses for Phase Ib Data | 5-28 |
| | | 5.5.2.1 | Outlier Determination for Replicate Well | |
| | | | Concentration Data | 5-28 |
| | | 5.5.2.2 | Reproducibility Analyses of the Reference | |
| | | ~ | Substance IC ₅₀ Values | |
| | 5.5.3 | | Il Analyses for Phase II Data | 5-28 |
| | | 5.5.3.1 | Outlier Determination for Replicate Well | |
| | | | Concentration Data | 5-28 |
| | | 5.5.3.2 | Reproducibility Analyses of the Reference | |
| | | | Substance IC ₅₀ Values | 5-28 |
| | | 5.5.3.3 | Comparison of 3T3 and NHK Test Results with | |
| | | a | the RC Millimole Regression | |
| | 5.5.4 | | Il Analyses for Phase III Data | 5-29 |
| | | 5.5.4.1 | Outlier Determination for Replicate Well | 5.00 |
| | | 5 5 4 0 | Concentration Data | |
| | | 5.5.4.2 | Reproducibility Analyses of the PC IC ₅₀ Data | 5-29 |
| | | 5.5.4.3 | Reproducibility Analyses of the Reference | |
| | | | <i>Substance</i> | 5 20 |
| | | 5 5 A A | IC_{50} Values | 5-30 |
| | | 5.5.4.4 | Comparison of 3T3 and NHK Test Results with the PC Millimole Personal | 5 21 |
| | 5.5.5 | Summor | the RC Millimole Regression y of the Data Used for Statistical Analyses | |
| | | | | |
| 5.6 | Summ | ary of NRI | U Test Results | 5-32 |
| 5.7 | Availa | bility of Da | ata | 5-38 |
| 5.8 | Solubi | lity Test R | esults | 5-38 |

| | | 5.8.1 5.8.2 | | y Data y and Volatility Effects in the Cytotoxicity Tests | | | |
|-----|--|--|---|--|--|--|--|
| | 5 0 | | | | | | |
| | 5.9 | | - | | | | |
| 6.0 | ACC | URACY | OF THE 3 | T3 AND NHK NRU TEST METHODS | 6-3 | | |
| | 6.1 | | Accuracy of the 3T3 and NHK NRU Test Methods for Predicting | | | | |
| | | | | al Toxicity | 6-5 | | |
| | | 6.1.1 | | egression Analyses for the Prediction of Rat Acute | 6.5 | | |
| | | (1) | | ⁰ Values from <i>In Vitro</i> IC ₅₀ Values | 6-44 6-3 6-5 6-5 6-8 6-10 6-12 6-12 6-12 6-13 6-13 6-13 6-13 6-17 6-17 6-17 6-17 6-17 6-20 6-22 6-22 6-22 6-24 6-24 | | |
| | | 6.1.2 | | son of Combined-Laboratory 3T3 and NHK | | | |
| | | | - | ons to the RC Millimole Regression | | | |
| | 6.2 | · | | er Substances for the RC Millimole Regression | | | |
| | | 6.2.1 | | tion of Outlier Substances | | | |
| | | 6.2.2 | | on of Outlier Substances | | | |
| | | | 6.2.2.1 | Physical Characteristics | | | |
| | | | 6.2.2.2 | Chemical Class | | | |
| | | | 6.2.2.3 | Solubility | | | |
| | | | 6.2.2.4 | Metabolism | | | |
| | | | 6.2.2.5 | Mechanism of Toxicity | 6-13 | | |
| | 6.3 | Improving the Prediction of <i>In Vivo</i> Rat Oral LD ₅₀ Values from <i>In</i> | | | | | |
| | 0.0 | <i>Vitro</i> I | | | | | |
| | | 6.3.1 | | Rat-Only Millimole Regression | | | |
| | | 6.3.2 | The RC I | Rat-Only Weight Regression | 6-17 | | |
| | 6.4 Accuracy of the 3T3 and NHK NRU Test Methods for Predictin | | | | | | |
| | | GHS Acute Oral Toxicity Categories | | | | | |
| | | 6.4.1 | | n of GHS Acute Oral Toxicity Category by the RC | | | |
| | | | IC ₅₀ Valu | es Using the RC Millimole Regression | 6-20 | | |
| | | 6.4.2 | Prediction | n of GHS Acute Oral Toxicity Category by the 3T3 | | | |
| | | | and NHK | NRU Test Methods Using the RC Rat-Only | | | |
| | | | | e Regression | 6-22 | | |
| | | | 6.4.2.1 | In Vitro – In Vivo Concordance Using the RC | | | |
| | | | | Rat-Only Millimole Regression | 6-22 | | |
| | | | 6.4.2.2 | Discordant Substances in the Prediction of GHS | | | |
| | | | | Acute Oral Toxicity Category by the 3T3 and | | | |
| | | | | NHK NRU Test Methods and the RC Rat-Only | | | |
| | | | | Millimole Regression | 6-24 | | |
| | | 6.4.3 | | n of GHS Acute Oral Toxicity Category by the 3T3 | | | |
| | | | | NRU Test Methods Using the RC Rat-Only | | | |
| | | | • | legression | 6-24 | | |
| | | | 6.4.3.1 | In Vitro – In Vivo Concordance Using the RC | | | |
| | | | (1 2 2 | Rat-Only Weight Regression | 6-25 | | |
| | | | 6.4.3.2 | Discordant Substances in the Prediction of GHS | | | |
| | | | | Acute Oral Toxicity Category by the 3T3 and NUK NBLI Test Matheda and the BC Bat Orbi | | | |
| | | | | NHK NRU Test Methods and the RC Rat-Only | ()7 | | |
| | | | | Weight Regression | 6-27 | | |

| | | 6.4.4 | Summary of the Regressions Evaluated | 6-27 | | | |
|-----|-----|---------|--|-------|--|--|--|
| | 6.5 | | | 6-28 | | | |
| | 6.6 | Metho | ds with the IC ₅₀ –LD ₅₀ Regressions for Prediction of Rodent Oral Toxicity In Vitro Cytotoxicity Methods Use of Mole-Based vs. Weight-Based Regressions for the Prediction of Toxicity for Low and High Molecular Weight | 6-31 | | | |
| | 6.7 | Salient | In Vitro Cytotoxicity Methods | | | | |
| | 6.8 | | andards | | | | |
| | 6.9 | Summ | mmary | | | | |
| 7.0 | REL | IABILIT | Y OF THE 3T3 AND NHK TEST METHODS | 7-3 | | | |
| | 7.1 | | Correlation of NRU Concentration-Response Slope with Rat 6-28 Attendality Dose-Response Slope 6-28 trengths and Limitations of the Use of In Vitro Cytotoxicity Test 6-31 Acthods with the IC ₅₀ -LD ₅₀ Regressions for Prediction of Rodent 6-31 .6.1 In Vitro Cytotoxicity Methods 6-31 .6.2 Use of Mole-Based vs. Weight-Based Regressions for the Prediction of Toxicity for Low and High Molecular Weight Substances 6-31 alient Issues of Data Interpretation 6-34 Comparison of NRU Test Results to Established Performance 6-40 BILITY OF THE 3T3 AND NHK TEST METHODS 7-3 Reference Substances Used to Determine the Reliability of the 3T3 7-40 NHK Test Methods 7-5 .2.1 Comparison of Laboratory-Specific IC ₅₀ -LD ₅₀ Linear Regression Analyses for the 3T3 and NHK Test Methods 7-5 .2.2 ANOVA Results for the 3T3 and NHK NRU Test Methods 7-5 .2.2.2 Differences Among the IC ₅₀ Values in Laboratories Using the 3T3 NRU Test Methods 7-21 .2.3 CV Results for the 3T3 and NHK NRU Test Methods 7-21 7.2.2.1 Differences Among the IC ₅₀ Values in | | | | |
| | 7.2 | 1 0 0 | | | | | |
| | | 7.2.1 | | | | | |
| | | 7.2.2 | ANOVA Results for the 3T3 and NHK NRU Test Methods | | | | |
| | | | 7.2.2.2 Differences Among the IC_{50} Values in | | | | |
| | | 7.2.3 | CV Results for the 3T3 and NHK NRU Test Methods | 7-21 | | | |
| | | | | | | | |
| | | | 1 1 1 | | | | |
| | | | 5 1 5 | | | | |
| | | | | | | | |
| | | 7.2.4 | Comparison of Maximum to Minimum IC ₅₀ Values Using | | | | |
| | | 7.2.5 | Comparison of Maximum:Minimum IC ₅₀ Ratios with the Maximum:Minimum LD ₅₀ Ratios | | | | |
| | | 7.2.6 | | 7-42 | | | |
| | 7.3 | | | 7-44 | | | |
| | | 7.3.1 | • | | | | |
| | | | | | | | |
| | | | | / -40 | | | |
| | | | Laboratories | 7-46 | | | |

| | 7.3.2 | | and Linear Regression Results for the NHK NRU | 7 10 |
|--------------|--------|--------------|--|------|
| | | 7.3.2.1 | hod Variation of SLS IC ₅₀ Values with Time | |
| | | 7.3.2.1 | Comparison of SLS IC_{50} values with Time Comparison of SLS IC_{50} Values Among the | /-40 |
| | | 1.3.2.2 | Laboratories | 7-48 |
| 7.4 | Labora | atory Conc | ordance for Solvent Selection | 7-50 |
| 7.5 | Summ | ary | | 7-52 |
| 3T3 / | AND NH | K NRU TE | ST METHOD DATA QUALITY | 8-3 |
| 8.1 | - | | Good Laboratory Practice Regulations | |
| | 8.1.1 | | es Followed for Cytotoxicity Testing | |
| | | 8.1.1.1 | Good Laboratory Practices | |
| | | 8.1.1.2 | Spirit of GLP | |
| | | 8.1.1.3 | Good Cell Culture Practices (GCCP) | |
| | 8.1.2 | Quality A | Assurance (QA) for NRU Cytotoxicity Test Data | |
| | | 8.1.2.1 | Coded Reference Substances | |
| | | 8.1.2.2 | Solubility Testing and Data Review | |
| | | 8.1.2.3 | NRU Cytotoxicity Test Tallies | 8-5 |
| | 8.1.3 | | es Followed for Rodent Acute Oral LD ₅₀ Data | |
| | | Collectio | n | 8-6 |
| | | 8.1.3.1 | Rodent Acute Oral LD_{50} Values Used in the | |
| | | | Registry of Cytotoxicity (RC) | 8-6 |
| | | 8.1.3.2 | Rodent Acute Oral LD ₅₀ Values Collected by | |
| | | | NICEATM from Other Sources | 8-6 |
| 8.2 | Result | s of Data Q | uality Audits | 8-6 |
| | 8.2.1 | | ments | |
| | 8.2.2 | | ments from the Laboratories | |
| | | 8.2.2.1 | BioReliance QA Statements | |
| | | 8.2.2.2 | FAL QA Statements | |
| | | 8.2.2.3 | $ECB\widetilde{C}$ QA Statements | |
| | | 8.2.2.4 | IIVS $Q\widetilde{A}$ Statements | |
| | | 8.2.2.5 | Other QA Information | |
| 8.3 | Effect | of Deviatio | ns or Non-compliance with GLPs | 8-9 |
| | 8.3.1 | | ry Error Rates | |
| | 8.3.2 | Failure R | ates for Definitive and PC Tests | 8-10 |
| | 8.3.3 | | ratory Reproducibility | |
| | 8.3.4 | Prediction | n of GHS Acute Oral Toxicity Categories | 8-12 |
| 8.4 | Availa | bility of La | boratory Notebooks | 8-12 |
| 8.5 | Summ | ary | | 8-13 |
| ОТН | | • | REPORTS AND REVIEWS OF <i>IN VITRO</i> | |
| - | | | C METHODS AND THEIR ABILITY TO | |
| | | | UTE TOXICITY AND OTHER TOXIC | |
| EFFI | ECTS | | | 9-3 |

| | 9.1 | Relev | ant Studies | | 9-3 |
|------|------|---------|-------------|---|------|
| | | 9.1.1 | Correlation | of NRU Cytotoxicity Values with Rodent | |
| | | | | | |
| | | | 9.1.1.1 | Peloux et al. (1992) | 9-4 |
| | | | 9.1.1.2 | Fautrel et al. (1993) | 9-5 |
| | | | 9.1.1.3 | Roguet et al. (1993) | 9-5 |
| | | | 9.1.1.4 | Rasmussen (1999) | 9-6 |
| | | | | Creppy et al. (2004) | 9-7 |
| | | 9.1.2 | | itro Cytotoxicity Data to Reduce the Use of | |
| | | | | Acute Oral Toxicity Testing | 9-7 |
| | | | | Halle et al. (1997): Animal Savings with the ATC | |
| | | | | Method Using Cytotoxicity Data | 9-7 |
| | | | | Spielmann et al. (1999): Animal Savings Using | |
| | | | | Cytotoxicity Data with the UDP | 9-9 |
| | | | | EPA (2004): U.S. EPA HPV Challenge Program Submission | 9-10 |
| | | 9.1.3 | | tions of 3T3 or NHK NRU Methods | |
| | | 9.1.5 | | Draize Eye Irritation | |
| | | | | Predicting Human Lethal Blood Concentrations | |
| | | | <i></i> | (<i>LC</i>) | 9-13 |
| | 0.2 | T., J., | | | |
| | 9.2 | - | | ific Reviews | 9-13 |
| | | 9.2.1 | | ute Toxicity Testing for the Classification and | 0.12 |
| | | | • | Chemicals | |
| | | 022 | | Seibert et al. (1996): ECVAM Workshop 16 | 9-13 |
| | | 9.2.2 | | <i>itro</i> Cytotoxicity Data for Estimation of Starting | 0.14 |
| | | | | Acute Oral Toxicity Testing | 9-14 |
| | | | | ICCVAM (2001a): Estimation of Animal Savings | 0.14 |
| | | | | <i>Using Cytotoxicity Data with the ATC Method</i> <i>ICCVAM (2001a): Estimation of Animal Savings</i> | 9-14 |
| | | | | Using Cytotoxicity Data with the UDP | 0.16 |
| | | 9.2.3 | | of 3T3 NRU Assay for Phototoxicity | |
| | | 9.2.5 | | NHK NRU Phototoxicity Assay | |
| | | | | | 9-17 |
| | 9.3 | | | tro Cytotoxicity Test Methods with Established | |
| | | | | ards | |
| | | 9.3.1 | | Document (ICCVAM 2001b) | |
| | | 9.3.2 | | ones (2003) | 9-19 |
| | | 9.3.3 | | x Project: Optimization and Pre-Validation of an | |
| | | | | st Strategy for Predicting Human Acute Toxicity | |
| | | | (Clemedsor | n 2005) | 9-19 |
| | 9.4 | Sumn | nary | | 9-20 |
| 10.0 | ANIN | MAL W | ELFARE CO | NSIDERATIONS (REFINEMENT, | |
| | | | | LACEMENT) | 10-3 |
| | 10.1 | Use of | 3T3 and NH | K NRU Test Methods to Predict Starting Doses | |
| | | | | ral Toxicity Assays | 10-4 |

| | 10.2 | Reduct | ion and Re | finement of Animal Use for the UDP | 10-4 |
|------|------|---------|--------------|---|-------|
| | | 10.2.1 | In Vivo Te | esting Using the UDP | 10-4 |
| | | | 10.2.1.1 | Main Test | 10-4 |
| | | | 10.2.1.2 | Limit Test | |
| | | 10.2.2 | Computer | Simulation Modeling of the UDP | 10-6 |
| | | 10.2.3 | Animal Sa | avings in the UDP When Using 3T3- and NHK- | |
| | | | Based Sta | rting Doses | 10-7 |
| | | | 10.2.3.1 | The Effect of the Dose-Mortality Slope on Animal | |
| | | | | Use | 10-7 |
| | | | 10.2.3.2 | Mean Animal Use for UDP Simulations – | |
| | | | | Comparison of Regressions and Predictions from | |
| | | | | the 3T3 and NHK NRU Test Methods | 10-9 |
| | | | 10.2.3.3 | Animal Savings in the UDP by GHS Acute Oral | |
| | | | | Toxicity Category Using 3T3- and NHK-Based | |
| | | | | Starting Doses | 10-9 |
| | | 10.2.4 | | nt of Animal Use for the UDP When Using 3T3- | |
| | | | | -Based Starting Doses | 10-15 |
| | | 10.2.5 | • | of the UDP Outcomes Using the IC ₅₀ -Based | |
| | | | Starting D | Ooses | 10-16 |
| | 10.3 | Reduct | ion and Re | finement of Animal Use in the ATC Method | 10-16 |
| | | 10.3.1 | | esting Using the ATC Method | |
| | | | 10.3.1.1 | Main Test | |
| | | | 10.3.1.2 | Limit Test | |
| | | 10.3.2 | | Simulation Modeling of the ATC Method | |
| | | 10.3.3 | - | avings for the ATC Method When Using 3T3- and | |
| | | | | ed Starting Doses | 10-18 |
| | | | 10.3.3.1 | The Effect of Dose-Mortality Slope on Animal | |
| | | | | Use | 10-18 |
| | | | 10.3.3.2 | Mean Animal Use for ATC Simulations – | |
| | | | | Comparison of Regressions and Predictions from | |
| | | | | the 3T3 and NHK NRU Test Methods | 10-20 |
| | | | 10.3.3.3 | Animal Savings in the ATC Method by GHS Acute | |
| | | | | Oral Toxicity Category Using the 3T3- and NHK- | |
| | | | | Based Starting Doses | 10-22 |
| | | 10.3.4 | Refineme | nt of Animal Use in the ATC Method When Using | |
| | | | | NHK-Based Starting Doses | 10-26 |
| | | 10.3.5 | | of the ATC Method Outcomes Using the IC ₅₀ - | |
| | | | | rting Doses | 10-27 |
| | 10.4 | The Im | pact of Acc | curacy on Animal Savings | 10-28 |
| | 10.5 | The Im | pact of Pre | evalence on Animal Savings | 10-30 |
| | 10.6 | Summa | nry | | 10-31 |
| 11.0 | PRAG | CTICAL | CONSIDE | RATIONS | 11-3 |
| | 11.1 | Transfe | erability of | the 3T3 and NHK NRU Test Methods | 11-3 |
| | | 11.1.1 | • | and Major Fixed Equipment | |

| | | 11.1.1.1 Facility Requirements | |
|------|--|--|---|
| | | 11.1.1.2 Cell Culture Laboratory | |
| | | 11.1.1.3 Major Equipment | |
| | 11.1.2 | Availability of Other Necessary Equipment and Supplies | s11-4 |
| | | | |
| | | 11.1.2.2 Cell Culture Materials and Supplies | |
| | | | |
| | 11.1.3 | Problems Specific to the NHK NRU Test Method | |
| 11.2 | 3T3 an | d NHK NRU Test Method Training Considerations | |
| | 11.2.1 | | |
| | | | |
| | | 1 0 0 1 | |
| | 11.2.2 | Training Requirements to Demonstrate Proficiency | |
| | | | |
| | 11.2.3 | Personnel Needed to Perform the In Vitro NRU Test Me | thods11-8 |
| 11.3 | Cost Co | onsiderations | |
| | 11.3.1 | | |
| | | 11.3.1.1 Equipment Costs | |
| | | | |
| | | | |
| | 11.3.2 | | |
| 11.4 | Time Considerations for Performing the 3T3 and NHK NRU Tests | | |
| | 11.4.1 | | |
| | 11.4.2 | The NHK NRU Test Method | |
| | 11.4.3 | Prequalification of NHK Medium | |
| | 11.4.4 | | |
| | 11.4.5 | The Limit Test | |
| 11.5 | Summa | ıry | 11-14 |
| REFE | ERENCE | S | |
| | | | |
| | 11.311.411.5 | 11.1.3 11.2 3T3 and 11.2.1 11.2.2 11.2.3 11.3 Cost Co 11.3.1 11.4 Time C 11.4.1 11.4.2 11.4.3 11.4.5 11.5 | 11.1.1.2 Cell Culture Laboratory |

APPENDICES

| Appendix A | NICEATM/ECVAM Validation Study Management | 4-1 |
|------------------------|--|--------------|
| Appendix B B1 | Validation Study Test Method Protocols (Phase III) | |
| B2 | Test Method Protocol for the Normal Human Epidermal Keratinocyte (NHK) Neutral Red Uptake Cytotoxicity Test | |
| B3 B4 | Test Method Protocol for Solubility Determination (Phase III) | -47 |
| Annondiv C | Validation Study Test Method Protocols (Phases Ia, Ib, and II) | |
| Appendix C C1 | Test Method Protocol for the BALB/c 3T3 Neutral Red Uptake | |
| C2 | Test Method Protocol for the Normal Human Epidermal Keratinocyte | C-3 -23 |
| C3 | Test Method Protocol for the BALB/c 3T3 Neutral Red Uptake Cytotoxicity Test (Phase Ib)C. | -41 |
| C4 | Test Method Protocol for the Normal Human Epidermal Keratinocyte (NHK) Neutral Red Uptake Cytotoxicity Test (Phase Ib)C- | -63 |
| C5 | Test Method Protocol for the BALB/c 3T3 Neutral Red Uptake Cytotoxicity Test (Phase II)C. | -85 |
| C6 | Test Method Protocol for the Normal Human Epidermal Keratinocyte (NHK) Neutral Red Uptake Cytotoxicity Test (Phase II)C-1 | 109 |
| Appendix D D1 D2 | SAS Codes I SAS Code for ANOVA and Contrasts I SAS Code for Regression Comparisons I | D-3 |
| Appendix E E1 | Neutral Red Dye Experiments | |
| E2 | in the NICEATM/ECVAM Evaluation of Cytotoxicity Assays I Neutral Red (NR) Dye Experiments – 3T3 Cells – IIVS E- | |
| E2 E3 | Neutral Red (NR) Dye Experiments – STS Cens – ITVS E- Neutral Red (NR) Dye Experiments – NHK Cells – IIVS E- | |
| E4 | Neutral Red (NR) Dye Experiments – 3T3 Cells – ECBC E- | |
| Appendix F | Reference Substance Information | F-1 |
| F1 F2 | NRU Test Information for the 72 Reference Substances | |
| F3 | Candidate Reference Substances | |
| Appendix G G1 G2 | Statement of Work (SOW) O A Validation Study For In Vitro Basal Cytotoxicity Testing O Procedures for Acquisition, Preparation, Solubility Testing, and O Distribution of Test Chemicals for a Validation Study for In Vitro O Basal Cytotoxicity Testing O Generative O | G - 3 |

| Appendix H | Rat and Mouse Oral LD ₅₀ Database | H-1 |
|------------|---|------|
| H1 | Rat and Mouse Oral LD ₅₀ Database | |
| H2 | Evaluation of the Candidate Reference Oral LD ₅₀ Data | 1-39 |
| Appendix I | In Vitro NRU Data | |
| I1 | 3T3 NRU Reference Substance Data | |
| I2 12 | NHK NRU Reference Substance Data | |
| I3 I4 | 3T3 NRU Positive Control (SLS) Data | |
| | NHK NRU Positive Control (SLS) DataI- | |
| Appendix J | LD ₅₀ and Toxicity Category Predictions | |
| J1 | 3T3 NRU Predictions: RC Millimole Regression | |
| J2 J3 | NHK NRU Predictions: RC Millimole Regression | |
| J3 J4 | 3T3 NRU Predictions: RC Rat-Only Millimole Regression NHK NRU Predictions: RC Rat-Only Millimole Regression | |
| J4 J5 | 3T3 NRU Predictions: RC Rat-Only Weight Regression | |
| J6 | NHK NRU Predictions: RC Rat-Only Weight Regression | |
| J7 | Comparison of Millimole Regression with Weight Regression | 5 2) |
| | Regarding Prediction of Toxicity (LD ₅₀) for Low or High Molecular | |
| | Weight Chemicals | J-34 |
| Appendix K | IC ₅₀ and LD ₅₀ Data for Regressions | K-1 |
| K1 | IC_{50} and LD_{50} Values Used for Laboratory-Specific Regressions | |
| K2 | IC_{50} and LD_{50} Values Used for Combined-Laboratory Regressions | |
| K3 | RC IC ₅₀ and LD ₅₀ Values for RC Substances with Rat Oral LD ₅₀ Data k | |
| K4 | Individual Laboratory LD ₅₀ Predictions: RC Rat-Only Millimole | |
| | Regression | K-33 |
| Appendix L | Outlier Information | L-1 |
| L1 | Outlier Characterization for the 3T3 and NHK NRU Test Methods | |
| | with the RC Millimole Regression | L-3 |
| L2 | Discordant Substances for GHS Acute Oral Toxicity Category | |
| | Predictions Using the 3T3 and NHK NRU Test Methods and RC Rat- | |
| T 2 | Only Regressions | L-9 |
| L3 | Analysis of Outliers by Halle (1998, 2003) for the RC Millimole | 17 |
| | Regression I | |
| | Acute Oral Toxicity Test Guidelines | |
| M1 | OECD UDP Test Guideline | |
| M2 | EPA UDP Test Guideline. | - |
| M3 M4 | OECD ATC Method Test Guideline | |
| M4 M5 | OECD FDP Test Guideline | |
| | | |
| Appendix N | UDP/ATC Simulation Modeling Results | N-1 |
| N1 | UDP Simulation Results Using Starting Doses One Default Dose Lower than the LD ₅₀ Predicted by the 3T3 and NHK NRU IC ₅₀ and the | |
| | RC Rat-Only Millimole Regression – 5000 mg/kg Upper Limit Dose | N_2 |
| | Ke Kat-Omy Minimole Regression – 5000 mg/kg Opper Limit D056 | 11-2 |

| N2 | UDP Simulation Results Using Starting Doses One Default Dose Lower than the LD ₅₀ Predicted by the 3T3 and NHK NRU IC ₅₀ and the | |
|------------|---|-------------|
| N3 | RC Rat-Only Weight Regression – 5000 mg/kg Upper Limit DoseN- ATC Simulation Results Starting at the Next Fixed Dose Below the LD ₅₀ Predicted by the 3T3 and NHK NRU IC ₅₀ and the RC Rat-Only | 13 |
| | Millimole Regression - 2000 mg/kg Upper Limit Dose | 23 |
| N4 | ATC Simulation Results Starting at the Next Fixed Dose Below the | |
| | LD ₅₀ Predicted by the 3T3 and NHK IC ₅₀ and the RC Rat-Only | |
| | Weight Regression – 2000 mg/kg Upper Limit DoseN- | 33 |
| Appendix O | Federal Register NoticesO |)-1 |
| 01 | 70FR14473 - Request for Nominations for an Independent Peer Review | |
| | Panel To Evaluate In Vitro Testing Methods for Estimating Acute Oral | _ |
| | Systemic Toxicity and Request for <i>In Vivo</i> and <i>In Vitro</i> DataO | -3 |
| O2 | 69FR61504 - Availability of Updated Standardized <i>In Vitro</i> | |
| | Cytotoxicity Test Method Protocols for Estimating Acute Oral Systemic Toxicity; Request for Existing <i>In Vivo</i> and <i>In Vitro</i> Acute | |
| | |)-5 |
| O3 | 69FR11448 - Notice of the Availability of Agency Responses to | U |
| | ICCVAM Test Recommendations for the Revised Up-and-Down | |
| | Procedure for Determining Acute Oral Toxicity and In Vitro Methods | |
| | 8 5 |)- 7 |
| O4 | 66FR49686 - Report of the International Workshop on In Vitro | |
| | Methods for Assessing Acute Systemic Toxicity; Guidance Document | |
| | on Using <i>In Vitro</i> Data to Estimate <i>In Vivo</i> Starting Doses for Acute | |
| 05 | Toxicity: Notice of Availability and Request for Public CommentO 65FR57203 - Notice of an International Workshop on <i>In Vitro</i> | -9 |
| 05 | Methods for Assessing Acute Systemic Toxicity, co-sponsored by | |
| | NIEHS, NTP and the U.S. Environmental Protection Agency (EPA): | |
| | Workshop Agenda and Registration Information | 11 |
| O6 | 65FR37400 - Notice of an International Workshop on In Vitro | |
| | Methods for Assessing Acute Systemic Toxicity, co-sponsored by | |
| | NIEHS, NTP and the U.S. Environmental Protection Agency (EPA): | |
| | Request for Data and Suggested Expert ScientistsO- | 15 |
| Appendix P | In Vitro Cytotoxicity Test Methods and the High Production | |
| | Volume (HPV) Challenge ProgramP | |
| P1 | Supplemental Acute Toxicity Protocol | -3 |
| P2 | Office of Pollution Prevention and Toxics (OPPT) Letters to | • • |
| | Manufacturers/Importers P | |
| Appendix Q | Additional UDP Simulation Modeling ResultsQ | -1 |
| Q1 | UDP Simulation Results for the RC Rat-Only Millimole Regression | |
| | Starting at the LD ₅₀ Predicted by the 3T3 and NHK NRU IC ₅₀ – 5000 mg/kg Upper Limit Dece | |
| Q2 | 5000 mg/kg Upper Limit Dose | -3 |
| Q2 | Starting at the LD ₅₀ Predicted by the 3T3 and NHK NRU IC ₅₀ LD ₅₀ $-$ | |
| | 5000 mg/kg Upper Limit DoseQ- | 13 |
| | | |

LIST OF FIGURES

| Figure 1-1 | RC Millimole Regression for In Vitro Cytotoxicity (IC _{50x}) and Rat and | |
|----------------------------------|---|------|
| - | Mouse Acute Oral LD ₅₀ Values for 347 Chemicals | 1-9 |
| Figure 1-2 | NICEATM/ECVAM Validation Study Phases | 1-13 |
| Figure 2-1 | Major Steps in the Performance of the NRU Test Methods | 2-7 |
| Figure 2-2 | 3T3 NRU OD for SLS as a Function of NR Concentration and | |
| | Duration | 2-26 |
| Figure 2-3 | SLS IC ₅₀ Values for Each NR Concentration and Incubation Duration (3T3 NRU) | 2-27 |
| Figure 2-4 | Representative Concentration-Response for 2-Propanol in a 3T3 NRU Range Finder Test | 2-30 |
| Figure 2-5 | Representative Concentration-Response for Aminopterin in a NHK NRU Range Finder Test | 2-31 |
| Figure 2-6 | Representative Concentration-Response for Aminopterin in a NHK | |
| - | NRU Definitive Test | 2-32 |
| Figure 2-7 | Flow Chart for Determination of Reference Substance Solubility in Medium, DMSO, or ETOH | 2-38 |
| Figure 3-1 | The Fifty-Eight (58) Selected RC Reference Substances on the RC | 00 |
| e | Millimole Regression | 3-27 |
| Figure 4-1 | Correlation of LD ₅₀ Values With the Reference LD ₅₀ Values for the 58 RC Chemicals | 4-14 |
| Figure 5-1 | Reference Substance IC ₅₀ Results for the 3T3 NRU Test Method by | |
| | Laboratory | 5-24 |
| Figure 5-2 | Reference Substance IC ₅₀ Results for the NHK NRU Test Method by Laboratory | 5-25 |
| Figure 5-3 | RC IC ₅₀ Values vs 3T3 NRU IC ₅₀ Values for 56 Substances in | |
| | Common | 5-37 |
| Figure 5-4 | RC IC ₅₀ Values vs NHK NRU IC ₅₀ Values for 57 Substances in | |
| | Common | |
| Figure 6-1 | Combined-Laboratory 3T3 and NHK NRU Regressions | |
| Figure 6-2 | Regression for 47 RC Substances Using RC Data | |
| Figure 6-3 | Regression for 47 RC Substances with the 3T3 and NHK Regressions | 6-9 |
| Figure 6-4 | RC Rat-Only Millimole Regression (a) and RC Rat-Only Weight | C 10 |
| F ¹ C F | Regression (b) | |
| Figure 6-5 | Correlation of Dose-Mortality Slope to Hill Function Slope | |
| Figure 6-6 | <i>In Vitro – In Vivo</i> Regressions for Phases Ib and II for ECBC | |
| Figure 6-7 | <i>In Vitro – In Vivo</i> Regressions for Phases Ib and II for FAL | |
| Figure 6-8 | <i>In Vitro – In Vivo</i> Regressions for Phases Ib and II for IIVS | 6-39 |
| Figure 7-1 | Mean Laboratory and Laboratory-Specific 3T3 and NHK NRU Regressions | 7-7 |
| Figure 7-2 | Frequency of Maximum:Minimum 3T3 NRU IC ₅₀ Ratios | |
| Figure 7-3 | Frequency of Maximum:Minimum NHK NRU IC ₅₀ Ratios | |
| Figure 7-4 | Comparison of Maximum:Minimum NRU IC ₅₀ Ratios to Maximum: | - |
| | Minimum LD ₅₀ Ratios | 7-41 |
| Figure 7-5 | SLS IC ₅₀ for Each Laboratory and Study Phase | 7-45 |

LIST OF TABLES

| Table ES-1 | Datasets Used for Validation Study Analyses | xxxvi |
|------------|---|-------|
| Table 1-1 | Summary of Current U.S. Legislation for Using Acute Toxicity Data | |
| | for Product Labeling | 1-14 |
| Table 1-2 | Regulatory Classification Systems for Acute Oral Toxicity | 1-15 |
| Table 2-1 | Measured VC OD ₅₄₀ Values and Targets | 2-17 |
| Table 2-2 | Refeeding/No Refeeding Data for the NHK NRU Test Method | 2-24 |
| Table 2-3 | Error Rates in Phase Ib by Laboratory and Test | |
| Table 2-4 | Cell Seeding Densities | |
| Table 2-5 | Comparison of Concentrations Tested in the Various Solubility | |
| | Protocols | 2-39 |
| Table 3-1 | GHS Classification Scheme for Acute Oral Toxicity | 3-3 |
| Table 3-2 | Reference Substances Used in the 3T3 and NHK NRU Test Methods | |
| | Validation Study - Sorted by Toxicity | 3-7 |
| Table 3-3 | Distribution of Candidate Substances and Reference Substances by | |
| | Source and Toxicity Category | 3-26 |
| Table 3-4 | Selected Substances: Distribution of RC Chemicals and RC Outliers | |
| | by Toxicity Category | 3-26 |
| Table 3-5 | Distribution of Chemical Class for the 72 Reference Substances by | |
| | Toxicity Category | 3-29 |
| Table 3-6 | Distribution of Product/Use Class for the 72 Reference Substances by | |
| | Toxicity Category | 3-31 |
| Table 3-7 | Reference Substances Metabolized to Active Metabolites | |
| Table 3-8 | Reference Substances Tested in Phases Ib and II | 3-33 |
| Table 4-1 | Internet-Accessible Databases Searched for LD ₅₀ Information | |
| Table 4-2 | Rodent Acute Oral Reference LD ₅₀ Values Listed by GHS Category | |
| Table 4-3 | GHS Category Matches for the Rodent Acute Oral LD ₅₀ Initial and | |
| | Reference Values | 4-12 |
| Table 4-4 | Maximum:Minimum LD ₅₀ Ratios by GHS Toxicity Category | 4-13 |
| Table 5-1 | Validation Study Timetable | |
| Table 5-2 | Reference Substances Affected by the Stopping Rule | 5-10 |
| Table 5-3 | Positive Control (PC) IC ₅₀ Results by Study Phase | |
| Table 5-4 | 3T3 NRU Test Method IC ₅₀ and Hill Slope Data by Laboratory | |
| Table 5-5 | NHK NRU Test Method IC ₅₀ and Hill Slope Data by Laboratory | |
| Table 5-6 | Key to Validation Study Reference Substances | |
| Table 5-7 | Datasets Used for Validation Study Analyses | |
| Table 5-8 | Comparison of 3T3 and NHK NRU IC ₅₀ Geometric Means | |
| Table 5-9 | Frequency of 3T3:NHK IC ₅₀ Ratios for Reference Substances | |
| Table 5-10 | Solubility Test Results (mg/mL) | |
| Table 5-11 | Reference Substances with Precipitate (PPT) and Volatility Issues | |
| Table 6-1 | Datasets Used for Accuracy Analyses | |
| Table 6-2 | Linear Regression Analyses of the 3T3 and NHK NRU and Rat Acute | |
| - | Oral LD ₅₀ Test Results | 6-6 |
| Table 6-3 | Outlier Substances for the RC and the 3T3 and NHK NRU Methods | - |
| | When the RC Millimole Regression is Used | 6-10 |

| Table 6-4 | Substances With Mechanisms of Toxicity Not Expected to Be Active | (15 |
|-----------------|---|-------|
| T-1-1- (5 | in the 3T3 or NHK Cells in Culture | 6-15 |
| Table 6-5 | Linear Regression Analyses to Improve the Prediction of Rodent | |
| | Acute Oral LD ₅₀ Values from <i>In Vitro</i> NRU IC ₅₀ Using the RC | < 1 B |
| T 11 ((| Database | 6-17 |
| Table 6-6 | Prediction of GHS Acute Oral Toxicity Category by the RC IC ₅₀ | |
| | Values and the RC Millimole Regression | 6-21 |
| Table 6-7 | Prediction of GHS Acute Oral Toxicity Category by the 3T3 and NHK | |
| | NRU Test Methods and the RC Rat-Only Millimole Regression | 6-23 |
| Table 6-8 | Prediction of GHS Acute Oral Toxicity Category by the 3T3 and NHK | |
| | NRU Test Methods and the RC Rat-Only Weight Regression | 6-26 |
| Table 6-9 | Comparison of Regressions and In Vitro NRU Test Methods for Their | |
| | Performance in Predicting GHS Acute Oral Toxicity Categories | |
| Table 6-10 | Reference Substances with Dose-Mortality and NRU Hill Slopes | 6-29 |
| Table 6-11 | Over- and Under- Prediction of Toxicity for Low and High Molecular | |
| | Weight Substances Using RC Rat-Only Weight and Millimole | |
| | Regressions | |
| Table 6-12 | Linear Regressions for 11 Substances Tested in Phases Ib and II | 6-36 |
| Table 7-1 | Reference Substances Excluded from Reproducibility Analyses | |
| | Because of Insufficient Cytotoxicity | 7-4 |
| Table 7-2 | Number of Reference Substances Tested vs Number of Reference | |
| | Substances Yielding IC ₅₀ Values from Each Laboratory, by GHS | |
| | Acute Oral Toxicity Category | 7-4 |
| Table 7-3 | Interlaboratory Reproducibility of the IC ₅₀ Values from the 3T3 NRU | |
| | Test Method | 7-8 |
| Table 7-4 | Reference Substances with Significant ANOVA Differences Among | |
| | Laboratories for the 3T3 NRU Test Method | 7-20 |
| Table 7-5 | Reproducibility of the IC ₅₀ Values from the NHK NRU Test Method | 7-22 |
| Table 7-6 | Reference Substances with Significant ANOVA Differences Among | |
| | Laboratories for the NHK NRU Test Method | 7-34 |
| Table 7-7 | Summary of CV Results for the 3T3 and NHK NRU Test Methods | 7-34 |
| Table 7-8 | Intralaboratory CV by Chemical Characteristics for the 3T3 and NHK | |
| | NRU Test Methods | 7-36 |
| Table 7-9 | Interlaboratory 3T3 and NHK NRU Test Method CV Values Sorted by | |
| | Chemical Characteristics | 7-38 |
| Table 7-10 | CV Values for 3T3 and NHK NRU Test Method IC ₅₀ Values and | |
| | Normalized IC ₅₀ Values | 7-43 |
| Table 7-11 | ANOVA Results for the SLS IC ₅₀ Values in the 3T3 NRU Test | |
| | Method | 7-47 |
| Table 7-12 | Linear Regression Analysis of SLS IC ₅₀ Values Over Time | |
| Table 7-13 | ANOVA Results for the SLS IC ₅₀ Values in the NHK NRU Test | - |
| | Method | 7-49 |
| Table 7-14 | Solvent Determinations by Laboratory | |
| Table 8-1 | SMT-Recommended Documentation for FAL | |
| Table 8-2 | Phase III Error Rates in the Transfer of Data to the EXCEL [®] Template | |
| | | |

| Table 8-3 | Definitive Test and Positive Control (PC) Test Failure Rates in Phase III | 8-10 |
|-------------|---|--------|
| Table 8-4 | Combined Definitive and Positive Control (PC) Test Success Rates for | |
| | the 3T3 and NHK Methods in Phase III. | 8-11 |
| Table 8-5 | CV Values for Definitive Tests | |
| Table 8-6 | GHS Acute Oral Toxicity Category Predictions by Laboratory | |
| Table 9-1 | Rat Acute Oral LD ₅₀ Ranges for Test Substances Used in Previous In | |
| | Vitro NRU Cytotoxicity Studies and the NICEATM/ECVAM Study | 9-4 |
| Table 9-2 | Chemical Classes Represented by the Substances Used in Published Studies for Correlation of <i>In Vitro</i> NRU Cytotoxicity with Rodent | |
| T_{-} | Acute Lethality | |
| Table 9-3 | EU Classes of Acute Oral Toxicity | 9-8 |
| Table 9-4 | Correct Identification of <i>In Vivo</i> Phototoxicants by the NHK NRU Phototoxicity Assay | 9-18 |
| Table 10-1 | Change in Animal Use with Dose-Mortality Slope for the UDP | 10-8 |
| Table 10-2 | Mean Animal Use in the UDP Using Starting Doses Based on the 3T3 | |
| | and NHK NRU Test Methods with the Different Regressions | .10-10 |
| Table 10-3 | Animal Use for the UDP by GHS Acute Oral Toxicity Category Using | |
| | Starting Doses Based on the 3T3 and NHK NRU Test Methods with | |
| | the RC Rat-Only Millimole Regression | .10-12 |
| Table 10-4 | Animal Use for the UDP by GHS Acute Oral Toxicity Category Using | |
| | Starting Doses Based on the 3T3 and NHK NRU Test Methods with | |
| | the RC Rat-Only Weight Regression | .10-14 |
| Table 10-5 | Animal Deaths in the UDP Using Starting Doses Based on the 3T3 and | |
| | NHK NRU Test Methods | |
| Table 10-6 | Change in Animal Use with Dose-Mortality Slope in the ATC Method | .10-19 |
| Table 10-7 | Animal Use for the ATC Method Using Starting Doses Based on the | |
| | 3T3 and NHK NRU Test Methods with the Different Regressions | .10-21 |
| Table 10-8 | Animal Savings for the ATC Method by GHS Acute Oral Toxicity | |
| | Category Using Starting Doses Based on the 3T3 and NHK NRU Test | |
| | Methods with the RC Rat-Only Millimole Regression | .10-23 |
| Table 10-9 | Animal Savings for the ATC Method by GHS Acute Oral Toxicity | |
| | Category Using Starting Doses Based on the 3T3 and NHK NRU Test | |
| | Methods with the RC Rat-Only Weight Regression | .10-25 |
| Table 10-10 | Animal Deaths for the ATC Method Using Starting Doses Based on | |
| | the 3T3 and NHK NRU Test Methods | |
| Table 11-1 | Costs for Major Laboratory Equipment | 11-9 |
| Table 11-2 | Costs for Cell Culture Materials and Commercial Laboratory In Vitro | |
| T 11 11 2 | Cytotoxicity Testing | |
| Table 11-3 | Commercial Prices for Conducting In Vivo Acute Rat Toxicity Testing | |
| Table 11-4 | Comparison of Time Needed for In Vitro and In Vivo Testing | .11-14 |

LIST OF ACRONYMS AND ABBREVIATIONS

| A-CUTE-TOX | A-Cute-Tox Project (EU Research & Development Integrated Project) |
|-------------------------|---|
| ADME | Absorption, distribution, metabolism, and elimination |
| ANOVA | Analysis of variance |
| ASTDR | Agency for Toxic Substances and Disease Registry |
| ASTM | American Society for Testing and Materials |
| ATC | Acute Toxic Class method |
| ATCC | American Type Culture Collection |
| ATWG | Acute Toxicity Working Group |
| BBB | Blood:brain barrier |
| BPE | Bovine pituitary extract |
| BRD | Background Review Document |
| °C | Degrees Celsius |
| CAS | Chemical Abstracts Service |
| CASRN | Chemical Abstracts Service Registry Number |
| CCOHS | Canadian Centre for Occupational Health and Safety (CCOHS) |
| CDER | U.S. FDA Center for Drug Evaluation and Research |
| CESARS | Chemical Evaluation Search and Retrieval System |
| CFU | Colony forming units |
| CHRIS | Chemical Hazard Response |
| CI | Confidence interval |
| CICADS | Concise International Chemical Assessment Documents |
| CIS | ILO Occupational Safety and Health Information Centre |
| CNS | Central nervous system |
| COLIPA | The European Cosmetic Toiletry and Perfumery Association |
| CPSC | U.S. Consumer Product Safety Commission |
| CSF | Colony stimulating factor |
| CTFA | Cosmetic, Toiletries and Fragrance Association |
| CV | Coefficient of variation |
| DART [®] /ETIC | Developmental and Reproductive Toxicology/Environmental |
| | Teratology Information Center |
| DEA | U.S. Drug Enforcement Administration |
| DHHS | U.S. Department of Health and Human Services |
| DIMDI | Deutsches Institut fur Medizinische Dokumentation und |
| | Information (The German Institute for Medical Documentation and |
| | Information) |
| DNA | Deoxyribose nucleic acid |
| DMEM | Dulbecco's Modification of Eagle's Medium |
| DMSO | Dimethyl sulfoxide |
| D-PBS | Dulbecco's phosphate buffered saline |
| DOD | U.S. Department of Defense |
| DOT | U.S. Department of Transportation |
| EC | European Commission |
| EC ₅₀ | Concentration of a substance that produces 50% of the maximum |
| | possible response for that substance |
| | - |

| ECBC | U.S. Army Edgewood Chemical Biological Center |
|------------------|--|
| ECETOC | European Centre for Ecotoxicology and Toxicology of Chemicals |
| EC/HO | European Commission/British Home Office |
| ECVAM | European Centre for the Validation of Alternative Methods |
| EDIT | Evaluation-guided development of new in vitro tests |
| EHC | Environmental Health Criteria |
| EHS | EPA's Extremely Hazardous Substance list |
| EPA | U.S. Environmental Protection Agency |
| ERG | Emergency Response Guidebook |
| ETOH | Ethanol (Ethyl alcohol) |
| EU | European Union |
| EXTONET | The Extension Toxicology Network |
| FAL | FRAME Alternatives Laboratory |
| FAO | UN Food and Agriculture Organization |
| FB1 | Fumonisin B1 |
| FDA | |
| | U.S. Food and Drug Administration |
| FDP | Fixed Dose Procedure |
| FIFRA | U.S. Federal Insecticide, Fungicide, and Rodenticide Act |
| FR | Federal Register |
| FRAME | Fund for the Replacement of Animals in Medical Experiments |
| GABA | Gamma amino butyric acid |
| GCCP | Good cell culture practices |
| GHS | Globally Harmonized System (of Classification and Labeling of |
| | Chemicals) |
| GLP | Good Laboratory Practices |
| gm | Grams |
| HBSS | Hanks' balanced salt solution |
| HPV | High Production Volume |
| hr | Hour(s) |
| HSDB | Hazardous Substances Data Bank |
| HSG | Health and Safety Guides |
| HTD | Highest tolerated dose |
| IARC | International Agency for Research on Cancer |
| IC_{20} | Concentration producing 20% inhibition of the endpoint measured |
| IC ₅₀ | Concentration producing 50% inhibition of the endpoint measured |
| IC ₈₀ | Concentration producing 80% inhibition of the endpoint measured |
| ICCVAM | Interagency Coordinating Committee for the Validation of Alternative |
| | Methods |
| ICSC | International Chemical Safety Cards |
| ID | Insufficient data |
| ID_{50} | Index of cytotoxicity; dose producing a 50% reduction in protein value |
| IIVS | Institute for <i>In Vitro</i> Sciences |
| ILO | International Labour Organisation |
| i.m. | Intramuscular |
| INVITOXX | <i>In Vitro</i> Techniques in Toxicology (ERGATT FRAME ECVAM Data |
| | bank) |
| | ounky |

| IOM | Institute of Medicine |
|--------------------------|--|
| IOM | Institute of Medicine |
| i.p. IPCS | Intraperitoneal |
| | International Programme on Chemical Safety |
| IRAG | Interagency Regulatory Alternatives Group |
| IRPTC | International Register of Potentially Toxic Chemicals |
| ISO | International Standards Organization |
| IUCLID | International Uniform Chemical Information Database |
| 1.V. | Intravenous |
| JECFA | Joint Expert Committee on Food Additives |
| JMPR KDM [®] | Joint Meeting on Pesticide Residues |
| KBM [®] | Keratinocyte basal medium |
| kg | Kilogram |
| K _{ow} | Octanol-water partition coefficient |
| L | Liter |
| LC | Lethal blood concentration |
| LD_{50} | Dose that produces lethality in 50% of test animals |
| LDH | Lactate dehydrogenase |
| MAS | Maximum average Draize score |
| MEIC | Multicentre Evaluation of In Vitro Cytotoxicity |
| MeSH [®] | Medical Subject Heading |
| μL | Microliters |
| μm | Micrometers |
| μM | Micromoles |
| mg | Milligram |
| MIT | Metabolic inhibition test |
| mL | Milliliter |
| mM | Millimolar |
| MMAS | Modified maximum average score |
| mmol | Millimoles |
| MPE | Mean photo effect |
| MSDS | Material Safety Data Sheets |
| MTT | 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide |
| Ν | Number (of substances) |
| NA | Not applicable |
| NADH | Nicotine adenine dinucleotide (reduced) |
| NC | Not calculated |
| NCS | Newborn calf serum |
| NCTR | U.S. FDA National Center for Toxicological Research |
| n.d. | Not detectable |
| NHK | Normal human epidermal keratinocytes |
| NICEATM | National Toxicology Program Center for the Evaluation of Alternative |
| | Toxicological Methods |
| NIEHS | U.S. National Institute of Environmental Health Sciences |
| NIH | U.S. National Institutes of Health |
| NIOSH | U.S. National Institute for Occupational Safety and Health |
| NLM | National Library of Medicine |
| | |

| ND | Notes and |
|----------------------|--|
| NR | Neutral red |
| NRU | Neutral red uptake |
| NTP | U.S. National Toxicology Program |
| OAT | Organic anionic transporters |
| OD | Optical density |
| OD_{540} | Optical density (absorbance) at a wavelength of 540 nm |
| OECD | Organisation for Economic Co-operation and Development |
| OHM/TADS | EPA Oil and Hazardous Materials/Technical Assistance Data |
| | System |
| OPP | U.S. EPA Office of Pesticide Programs |
| OPPTS | EPA Office of Prevention, Pesticides and Toxic Substances |
| ORD | U.S. EPA Office of Research and Development |
| OSHA | U.S. Occupational Safety and Health Administration |
| OTA | Ochratoxin A |
| PBS | Phosphate buffered saline |
| PC | Positive control |
| PDS | Pesticide Data Sheets |
| pg | Picogram |
| PG | Packing group |
| PIF | Photoinhibition factor |
| PIMS | Poisons Information Monographs |
| рК | Acid/base dissociation constant |
| PLS | Partial Least Squares (analysis) |
| PPIS | EPA Pesticide Product Information System |
| РРТ | Precipitate |
| QA | Quality assurance |
| QC | Quality control |
| QC R ² | Coefficient of determination |
| r _s | Spearman correlation coefficient |
| RC | Registry of Cytotoxicity |
| REACH | Registration, evaluation, authorisation and restriction of chemicals |
| RTECS® | Registry of Toxic Effects of Chemical Substances |
| RTK NET | The Right-to-Know Network |
| SD | Standard deviation |
| SIDS | OECD Screening Information Data Sets |
| SIS | Scientific Information Service |
| SLS | Sodium lauryl sulfate |
| SMT | Study management team |
| SOP | Standard operating procedure |
| 3T3 | BALB/c mouse fibroblasts, clone A31 (ATCC # CCL-163) |
| TESS | Toxic Exposure Surveillance System |
| TG | Test guideline |
| TRI | U.S. EPA Toxics Release Inventory |
| TSCA | Toxic Substances Control Act |
| UDP | Up-and-Down Procedure |
| UN | United Nations |
| UIN | |

| UNEP | United Nations Environment Programme |
|-------|---|
| USP | U.S. Pharmacopoeia |
| UV | Ultraviolet (light) |
| VC | Vehicle control |
| WHO | World Health Organization |
| XTT | 2,3-Bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5- carboxanilide |
| ZEBET | Zentralstelle zur Erfassung und Bewertung von Ersatz- und Ergänzungsmethoden zum Tierversuch (German Center for Documentation and Evaluation of Alternative Methods to Animal Experiments) |

November 2006

ACKNOWLEDGMENTS

The following individuals are acknowledged for their contributions to the in vitro acute toxicity test method review process.

Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) Acute Toxicity Working Group (ATWG)

Consumer Product Safety Commission (CPSC)

Kailash Gupta, D.V.M., Ph.D. Cassandra Prioleau, Ph.D. Marilyn Wind, Ph.D. (ATWG Chair, ICCVAM Vice Chair)

Department of Energy (DOE)

Po-Yung Lu, Ph.D.

Environmental Protection Agency (EPA)

Karen Hamernik, Ph.D. Masih Hashim, Ph.D. Marianne Lewis Elizabeth Margosches, Ph.D. Deborah McCall John Redden, Ph.D. Amy Rispin, Ph.D.

Food and Drug Administration (FDA)

Leonard Schechtman, Ph.D. (ICCVAM Chair) Kenneth Hastings, Ph.D. Abigail Jacobs, Ph.D. David Morse, Ph.D. Thomas Umbreit, Ph.D.

National Institute for Occupational Safety & Health (NIOSH)

Steven Reynolds, Ph.D.

National Institute of Environmental Health Sciences (NIEHS)

Rajendra Chhabra, Ph.D., D.A.B.T. William Stokes, D.V.M., D.A.C.L.A.M. (ICCVAM Executive Director; NICEATM Director) Raymond Tice, Ph.D. (NICEATM Deputy Director)

European Centre for the Validation of Alternative Methods (ECVAM) Liaisons

Silvia Casati, Ph.D. Pilar Prieto, Ph.D.

National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM)

Dave Allen, Ph.D. ILS, Inc.

Bradley Blackard, M.S.P.H. ILS, Inc.

Sue Brenzel ILS, Inc.

Thomas Burns, M.S. ILS, Inc.

Patricia Ceger, M.S. ILS, Inc.

Jeffery Charles, Ph.D., M.B.A., D.A.B.T. ILS, Inc.

Neepa Choksi, Ph.D. ILS, Inc.

Frank Deal, M.S. ILS, Inc. Linda Litchfield ILS, Inc.

Deborah McCarley NIEHS

Michael Paris ILS, Inc.

William Stokes, D.V.M., D.A.C.L.A.M. (Director) NIEHS

Judy Strickland, Ph.D., D.A.B.T. ILS, Inc.

Raymond Tice, Ph.D. (Deputy Director) NIEHS

Jim Truax, M.A. ILS, Inc.

Participants in the In Vitro Cytotoxicity Validation Study

NICEATM gratefully acknowledges the generous contributions of the individuals who directly participated in the NICEATM/ECVAM Validation Study. Their time and efforts are greatly appreciated.

BioReliance Corp. (Chemical Distribution) Martin Wenk, Ph.D. – Principal

Investigator

Institute for *In Vitro* Sciences (IIVS) (Lead Laboratory – Protocols)

Hans Raabe, M.S. – Study Director Greg Mun – Laboratory Manager Angela Sizemore – Research Technician Gregory O. Moyer – Research Technician John Harbell, Ph.D. – Scientific Director

U.S. Army Edgewood Chemical Biological Center (ECBC) (Testing Laboratory)

Cheng Cao, Ph.D. – Study Director Janna Madren-Whalley – Research Technician Chundakkadu Krishna, Ph.D. – Research Technician James J. Valdes, Ph.D. – Scientific Advisor

FRAME Alternatives Laboratory (FAL) University of Nottingham, UK (Lead Laboratory – Software)

Richard Clothier, Ph.D. – Study Director Nicola Bourne – Research Technician Monika Owen – Research Technician Rachel Budworth – Research Technician

Constella Group (Statistical Analyses)

Patrick Crockett, Ph.D. Eric Harvey, Ph.D. Wendell Jones, Ph.D. Robert Lee, M.S. Jessica L. Matthews, M.S. Michael Riggs, Ph.D. Janine Wilcox Nicole Williams

Statistical Consultant

Joseph Haseman, Ph.D.

NIEHS

Grace Kissling, Ph.D. – Contract Project Officer Molly Vallant - Contract Project Officer

Study Management Team (SMT) NICEATM

William Stokes, D.V.M., D.A.C.L.A.M. (NIEHS) – Director, NICEATM Raymond Tice, Ph.D. (NIEHS) – Deputy Director, NICEATM – Advisor Judy Strickland, Ph.D., D.A.B.T. (ILS, Inc.) – Project Coordinator Michael Paris (ILS, Inc.) – Assistant Project Coordinator Jeffrey Charles, Ph.D., D.A.B.T. (ILS, Inc.) – Advisor

ECVAM

Thomas Hartung, Ph.D., M.D. – Head of Unit from 2002 Silvia Casati, Ph.D. – Task Leader Michael Balls, D. Phil.– Head of Unit until June 2002 [This Page Intentionally Left Blank]

PREFACE

The Institute of Medicine estimates that more than 4 million poisonings occur annually in the United States (Institute of Medicine [IOM] 2004). In 2001, 30,800 deaths placed poisoning as the second leading cause of injury-related death behind automobile accidents (42,433 deaths) (IOM 2004). In order to ensure that all potentially hazardous substances have proper warning labels, regulatory agencies require determination of acute toxicity hazard potential of substances and products. This determination for oral acute toxicity hazard is currently made using a test that requires laboratory rats. Historically, lethality estimated by the LD₅₀ (i.e., the dose of a test substance that produces death in 50% of the animals tested) has been a primary toxicological endpoint in acute toxicity tests.

The conventional LD_{50} acute oral toxicity *in vivo* test method has been modified in various ways to reduce and refine¹ animal use in toxicity testing (OECD 2001a, c, d, e; EPA 2002a). Most recently, the LD_{50} was replaced, for hazard classification testing purposes, with the UDP, based on an Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) technical evaluation and formal ICCVAM recommendations (ICCVAM 2000, 2001c). This method now reduces animal use by over 70% compared to the previous method.

In 1999, at the request of the U.S. Environmental Protection Agency (EPA) Office of Pesticides, Prevention, and Toxic Substances, ICCVAM reviewed the validation status of *in vitro* methods for estimating acute oral toxicity. This request was based on studies published in recent years that showed a correlation between *in vitro* and *in vivo* acute toxicity. *In vitro* cytotoxicity methods have been evaluated as another means to reduce and refine the use of animals and these methods may be helpful in predicting *in vivo* acute toxicity. Since moving the starting dose closer to the LD_{50} reduces the number of animals necessary for the acute oral systemic toxicity test, the use of *in vitro* cytotoxicity assays to predict a starting dose close to the LD_{50} may reduce animal use.

In October of 2000, the International Workshop on *In Vitro* Methods for Assessing Acute Systemic Toxicity sponsored by the National Toxicology Program (NTP), the National Institute of Environmental Health Sciences (NIEHS) and the EPA was convened in Arlington, VA. The Organizing Committee invited 33 expert scientists from academia, industry, and government agencies to participate in the Workshop. Invited scientific experts and ICCVAM agency scientists were assigned to one of four Breakout Groups and prepared recommendations on the following:

- *In Vitro* Screening Methods for Assessing Acute Toxicity
- In Vitro Methods for Toxicokinetic Determinations
- In Vitro Methods for Predicting Organ Specific Toxicity
- Chemical Data Sets for Validation of In Vitro Acute Toxicity Test Methods

¹ A reduction alternative is a new or modified test method that reduces the number of animals required. A refinement alternative is a new or modified test method that refines procedures to lessen or eliminate pain or distress in animals or enhances animal well-being (ICCVAM 2003).

Workshop participants concluded that none of the proposed *in vitro* methods had been formally evaluated for reliability and relevance, and that their usefulness and limitations for generating information to meet regulatory requirements for acute toxicity testing had not been adequately assessed. However, an *in vitro* approach proposed by the German Center for Documentation and Evaluation of Alternative Methods to Animal Experiments (ZEBET) was recommended for rapid adoption so that data could be generated to establish its usefulness with a large number of chemicals (ICCVAM 2001a). In addition, a separate *Guidance Document on Using In Vitro Data to Estimate In Vivo Starting Doses for Acute Toxicity* (ICCVAM 2001b) was prepared to provide sample cytotoxicity protocols and instructions for using *in vitro* data to predict starting doses for acute *in vivo* systemic toxicity tests.

ICCVAM, which is charged with coordinating the technical evaluations of new, revised, and alternative test methods with regulatory applicability (ICCVAM Authorization Act of 2000, Public Law 106-545; available: http://iccvam.niehs.nih.gov/about/PL106545.pdf), agreed that in vitro basal cytotoxicity test methods should have a high priority for evaluation. The NTP Center for the Evaluation of Alternative Toxicological Methods (NICEATM) collaborated with the European Centre for the Validation of Alternative Methods (ECVAM), a component of the European Commission's Joint Research Centre, to further characterize the usefulness of *in vitro* cytotoxicity assays as predictors of starting doses for acute oral lethality assays. NICEATM and ECVAM designed a multi-laboratory validation study to evaluate the performance of two standardized *in vitro* basal cytotoxicity test methods using 72 reference substances with the ZEBET approach of using the Registry of Cytotoxicity (RC) regression model. Based on the procedures described in the Guidance Document (ICCVAM 2001b), the validation study used two mammalian cell types (i.e., BALB/c 3T3 mouse fibroblasts [3T3] and primary normal human epidermal keratinocytes [NHK]) for in vitro basal cytotoxicity test methods with a neutral red uptake (NRU) cell viability endpoint to predict starting doses for acute oral systemic toxicity test methods. The inclusion of human cells in the validation study also implements another workshop recommendation, that of evaluating whether cytotoxicity in human or rodent cells can be used to predict human acute toxicity.

The objectives identified for the validation study were to:

- Further standardize and optimize the *in vitro* NRU basal cytotoxicity protocols using 3T3 and NHK cells to maximize test method reliability (intralaboratory repeatability, intra- and inter-laboratory reproducibility)
- Assess the accuracy of the two standardized *in vitro* 3T3 and NHK NRU basal cytotoxicity test methods for estimating rodent oral LD₅₀ values across the five United Nations (UN) Globally Harmonized System of Classification and Labelling of Chemicals (GHS; UN 2005) categories of acute oral toxicity, as well as unclassified toxicities
- Estimate the reduction and refinement in animal use achievable from using the *in vitro* 3T3 and NHK NRU basal cytotoxicity test methods to identify starting doses for *in vivo* acute oral toxicity tests, assuming that no other information were available

• Develop high quality *in vivo* acute oral lethality and *in vitro* NRU cytotoxicity databases that can be used to support the investigation of other *in vitro* test methods necessary to improve the prediction of *in vivo* acute oral lethality

Scientists assembled for the ICCVAM-sponsored scientific peer review panel meeting ("Panel") on May 23, 2006 independently assessed the usefulness and limitations of the *in vitro* basal cytotoxicity test methods to predict starting doses for acute oral systemic toxicity test methods. The Background Review Document (BRD) on the two *in vitro* NRU test methods prepared by NICEATM and provided to the peer review panel and the public contains:

- 1. Comprehensive summaries of the data generated in the validation study
- 2. An analysis of the accuracy and reliability of the test method protocols
- 3. Related information characterizing the potential animal savings produced by using the *in vitro* basal cytotoxicity test methods as adjuncts to specific acute systemic toxicity test methods

The Panel also evaluated draft test method performance standards, protocols, and draft ICCVAM recommendations for test method uses and future studies. The public was invited to provide comments on the BRD and other documents and to attend the Panel meeting. Prior to the Panel meeting, public comments provided about the documents were provided to the Panel for their consideration. The BRD can be obtained from the ICCVAM/NICEATM Web site (<u>http://iccvam.niehs.nih.gov</u>) or by contacting NICEATM.

Following the conclusion of the Panel meeting, the ICCVAM and its Acute Toxicity Working Group (ATWG) considered the Panel report, the performance standards for the use of *in vitro* basal cytotoxicity test methods to predict starting doses for acute systemic toxicity test methods, and any public comments in preparation of its final test method recommendations for these *in vitro* basal cytotoxicity test methods. These recommendations will be made available to the public and provided to the U.S. Federal agencies for consideration, in accordance with the ICCVAM Authorization Act of 2000 (Public Law 106-545).

On behalf of the ICCVAM, we gratefully acknowledge the many contributions of all who participated in the *in vitro* cytotoxicity validation study and those who assisted in the preparation of the documents evaluated at the peer review meeting. We extend a special thanks to the participating laboratory Study Directors and scientists who worked diligently to provided critical data and information. We also thank the ECVAM scientists who participated in the management of the validation study and who provided valuable information, comments, and opinions throughout the study. The efforts of the ATWG members were instrumental in assuring a complete and informative BRD. The efforts of the NICEATM staff in coordinating the validation study, providing timely distribution of

information, and preparing the various documents are acknowledged and appreciated. We especially acknowledge Dr. Judy Strickland and Mr. Michael Paris for their coordination of the validation study and preparation of the BRD and other documents.

William S. Stokes, D.V.M. D.A.C.L.A.M. RADM, U.S. Public Health Service Director, NICEATM Executive Director, ICCVAM

Leonard Schechtman, Ph.D. Deputy Director for Washington Operations National Center for Toxicological Research U.S. Food and Drug Administration Chairman, ICCVAM

EXECUTIVE SUMMARY

This Background Review Document (BRD) reports the results of a validation study, organized and managed by the National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) and the European Centre for the Validation of Alternative Methods (ECVAM), conducted to characterize two *in vitro* basal cytotoxicity tests for determining starting doses for rodent acute oral toxicity assays. In conducting this validation study, the protocols for two *in vitro* neutral red uptake (NRU) assays using BALB/c mouse fibroblast 3T3 cells (3T3) and normal human epidermal keratinocytes (NHK) were standardized and optimized, and the LD₅₀ values for the reference substances were refined. The accuracy and reliability of the two *in vitro* NRU test methods were used to estimate the potential reduction in animal usage that could be accomplished by the use of either of these *in vitro* test systems. One outcome of this effort has been the generation of high quality *in vivo* lethality and *in vitro* tests.

The validation study showed that the 3T3 and NHK NRU test methods are not sufficiently accurate as stand-alone methods to correctly predict rodent acute oral toxicity. However, based on computer simulations for the reference substances tested in this study, the use of either of these two *in vitro* basal cytotoxicity test methods for the selection of starting doses for rodent acute oral toxicity testing has the potential to reduce the number of animals used per test and, in some cases, the number of substance-induced animal deaths.

Introduction and Rationale

Although *in vitro* basal cytotoxicity test methods are not currently regarded as suitable replacements for rodent acute oral toxicity tests (Spielmann et al. 1999; ICCVAM 2001a), such methods have been examined as a possible approach to reduce and refine² the use of animals for such testing. An international Multicentre Evaluation of *In Vitro* Cytotoxicity (MEIC) was initiated in 1983 to evaluate the relationship between in vitro cytotoxicity and acute human toxicity. Tests of 50 substances in 61 in vitro assays by multiple laboratories led to the identification of a battery of three human cell line assays whose cytotoxicity responses were highly correlated to human lethal blood concentrations (Bondesson et al. 1989; Clemedson et al 1996, 1996a; Ekwall et al. 1998a, 1998b, 2000). The Registry of Cytotoxicity (RC), initially published in 1998, is a database of 347 substances that currently consists of acute oral toxicity data from rats and mice and in vitro cytotoxicity data from studies using various mammalian cell types with a number of different toxic endpoints (Halle 1998, 2003). A regression formula, the RC millimole regression, constructed from these data was proposed by ZEBET, the German National Centre for the Documentation and Evaluation of Alternative Methods to Animal Experiments, as a method to reduce animal use by identifying the most appropriate starting doses for acute oral toxicity tests (Halle 1998, 2003; Spielmann et al. 1999).

² A reduction alternative is a new or modified test method that reduces the number of animals required. A refinement alternative is a new or modified test method that refines procedures to lessen or eliminate pain or distress in animals, or enhances animal well-being (ICCVAM 2003).

These, and other, initiatives to use *in vitro* cytotoxicity test methods to reduce animal use in acute toxicity testing were evaluated at the International Workshop on *In Vitro* Methods for Assessing Acute Systemic Toxicity, in October 2000 ("Workshop 2000"; ICCVAM 2001a). This workshop was organized by the U.S. Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) and NICEATM. Pursuant to this workshop, ICCVAM recommended (ICCVAM 2001a) further evaluation of the use of *in vitro* cytotoxicity data as one of the approaches that could be used to estimate the starting doses for rodent acute oral toxicity studies. The recommendations are based on preliminary information suggesting that this approach could reduce the number of animals used in such studies (i.e., reduction), minimize the number of animals that receive lethal doses (i.e., refinement), and avoid underestimating hazard. To assist in the adoption and implementation of the ZEBET approach, the *Guidance Document on Using In Vitro Data to Estimate In Vivo Starting Doses for Acute Toxicity* (hereafter referred to as *Guidance Document*; ICCVAM 2001b) was prepared by ICCVAM with the assistance of the workshop participants.

In its recommendations for further evaluations, ICCVAM concurred with the Workshop 2000 recommendation that near-term validation studies should focus on two standard basal cytotoxicity assays: one using a human cell NHK system and one using a rodent cell (3T3) system. Historical data for *in vitro* cytotoxicity testing using mouse 3T3 cells are available (e.g., Balls et al. 1995; Brantom et al. 1997; Gettings et al. 1991, 1994a, 1994b; Spielmann et al. 1991, 1993, 1996), as are historical data for *in vitro* basal cytotoxicity testing using NHK cells (e.g., Gettings et al. 1996; Harbell et al. 1997; Sina et al. 1995; Willshaw et al. 1994).

NICEATM, in partnership ECVAM, designed an international, multi-laboratory validation study to evaluate the reduction or refinement in animal use that could result from using cytotoxicity data from the 3T3 and NHK NRU test methods to estimate starting doses for two rodent acute oral toxicity test methods, the Up-and-Down Procedure (UDP; OECD 2001a; EPA 2002a) and the Acute Toxic Class (ATC) method (OECD 2001d). The NRU protocols, as presented in the *Guidance Document*, were the initial basis of the NICEATM/ECVAM validation study protocols. These protocols were originally derived from the BALB/c 3T3 Cytotoxicity Test, INVITTOX Protocol No. 46 (available at the FRAME-sponsored INVITTOX database [http://embryo.ib.amwaw.edu.pl/invittox/]), the 3T3 cell studies by Borenfreund and Puerner (1984, 1985) and the rat epidermal keratinocyte study of Heimann and Rice (1983). A detailed description of the 3T3 and NHK NRU test method protocols used in the NICEATM/ECVAM validation study is provided in **Section 2**.

Protocol Components

Many protocol components used in the validation study are similar for the 3T3 and NHK cells. The following procedures are common to both cell types:

- Testing was performed in four phases (Ia, Ib, II, and III)
- Preparation of reference substances and positive control
- Cell culture environment conditions
- Determination of test substance solubility
- Configuration of 96-well plates for testing samples
- 48-hour exposure to test substance
- Range finder and definitive testing

- Microscopic evaluation of cell cultures for toxicity
- Measurement of NRU
- Data analysis

The main differences in the test methods for the two cell types are:

- The conditions of propagation of the cells in culture
- The cell growth medium components
- The volumes of reference substance added to the 96-well plate

Three laboratories participated in testing the 72 reference substances in both cell types:

- ECBC: The U.S. Army Edgewood Chemical Biological Center (Edgewood, MD)
- FAL: Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory (Nottingham, UK)
- IIVS: The Institute for *In Vitro* Sciences (Gaithersburg, MD)

BioReliance Corporation (Rockville, MD) procured and distributed the coded reference substances and performed solubility tests prior to their distribution to the testing laboratories, but did not perform any of the *in vitro* tests.

Validation Reference Substances

The 72 reference substances were selected to represent: (1) the complete range of *in vivo* acute oral toxicity (encompassing all five GHS acute oral toxicity categories as well as lower toxicities [GHS; UN 2005]); (2) the types of substances regulated by various regulatory authorities; and (3) substances with human toxicity data and/or human exposure potential. To ensure that the complete range of toxicity was covered, 12 substances were selected for each of the five acute oral toxicity categories, with an additional 12 substances with lower toxicities (i.e., $LD_{50} > 5000 \text{ mg/kg}$). A discussion of the characteristics and sources of the reference substances can be found in **Section 3**. The selected reference substances had the following characteristics:

- 58 (81%) of the 72 substances were also included in the RC, and 38% (22/58) of these were outliers with respect to the RC millimole regression.
- 27 (35%) of the substances were pharmaceuticals, 17 (22%) were pesticides, 8 (10%) were solvents, and 5 (6%) were food additives. The remaining substances were used for a variety of manufacturing and consumer products. The number of assigned uses (77) is greater than the number of selected substances because some of the substances have more than one use.
- 57 (79%) were organic compounds and 15 (21%) were inorganic; wellrepresented classes of organic compounds included heterocyclics, carboxylic acids, and alcohols.
- 22 (31%) substances were known, or expected to have, toxicologically active metabolites.
- Many of the selected substances had multiple target organs/effects; including neurological, liver, kidney, and cardiovascular effects.

Table ES-1 reports the number of substances that were tested and the number of substances used for the various analyses performed.

| Use | 3T3 NRU ¹ | NHK NRU ¹ | Characteristics of Dataset |
|--|-------------------------|-------------------------|---|
| Testing | 72 | 72 | Substances tested |
| Comparison of laboratory IC ₅₀ -LD ₅₀ regressions to one another | 47 | 51 | RC substances with IC_{50} values from all laboratories and reference rat oral LD_{50} values |
| Comparison of combined-laboratory IC_{50} - LD ₅₀ regressions to a regression calculated with RC data | 47 | 47 | RC substances with IC_{50} values for both test methods from all laboratories and rat oral reference LD_{50} values |
| Prediction of GHS accuracy using IC ₅₀ values in IC ₅₀ -LD ₅₀ regressions; prediction of starting doses for acute oral toxicity test (UDP and ATC) simulations | 67 | 68 | Substances with IC_{50} values from at least one laboratory |
| Reproducibility of acceptable rat oral LD ₅₀ values | NA | NA | 62 substances with more than one acceptable rat oral LD ₅₀ value |
| Reproducibility of IC ₅₀ values | 64 | 68 | Substances with IC ₅₀ values from all laboratories |

Table ES-1Datasets Used for Validation Study Analyses1

Abbreviations: RC=Registry of Cytotoxicity; 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake; NA=Not applicable.

¹Number of substances.

Rodent Acute Oral Toxicity Reference Data

Because the 3T3 and NHK NRU test methods are intended to be used as adjuncts to rodent acute oral toxicity test methods, the LD_{50} values from rodent acute oral toxicity tests are the most appropriate reference data for evaluating the *in vitro* IC₅₀ values (i.e., the test chemical concentration that reduces cell viability by 50%). Rodent acute oral LD_{50} reference data for the 72 reference substances were obtained from the literature. It was not possible to limit the data to studies conducted under Good Laboratory Practice (GLP) guidelines (OECD 1998; EPA 2003a, 2003b; FDA 2003) because only 2% of the published data retrieved were from such studies. Although mouse toxicity data were initially considered for inclusion in the database, the accuracy analyses were restricted to rat data. A total of 459 acute rodent oral LD_{50} values were identified for the reference substances. Reference LD_{50} values for each substance were identified by excluding studies with the following characteristics:

- Feral rats
- Rats <4 weeks of age
- Anesthetized rats
- Test substance administered in food or capsule
- LD₅₀ reported as a range or an inequality

For substances with multiple LD_{50} values (i.e., from different sources), the rodent reference LD_{50} values for use in the validation study were determined by calculating a geometric mean of the available values for each reference substance. The reference LD_{50} values for 19 (26%) of the 72 substances varied sufficiently from the initial LD_{50} values that came from the RC

database and other summary sources, that the substances were reclassified into different GHS categories.

The reliability of the calculated rat acute oral LD_{50} reference values was assessed by comparison to other evaluations of the performance of rodent acute oral toxicity tests. For the 62 reference substances that had more than one LD_{50} value, the maximum:minimum ratios ranged from 1.1 to 25.9, with most below an order of magnitude.

Test Method Accuracy

Although the 3T3 and NHK NRU test methods are not intended to be used as replacements for rodent acute oral toxicity tests, they were evaluated for their ability to correctly predict the reference LD_{50} values (i.e., accuracy³). The rationale for evaluating the accuracy of LD_{50} predictions is that the current acute oral toxicity test methods (i.e., UDP, ATC, and Fixed Dose Procedure [FDP; OECD 2001c]) call for starting doses to be placed as close as possible and just below the true LD_{50} . When the starting dose is close to the true LD_{50} for a test substance, fewer animals are needed. When the starting dose is below the true LD_{50} , there is reduced pain and suffering because doses tend to be lower, and the test outcome bias is more conservative (i.e., higher toxicity). Regression models developed using IC_{50} and LD_{50} values were used to derive estimated LD_{50} values from 3T3 or NHK NRU IC_{50} values.

A number of different analyses were performed in an attempt to improve the estimation of the rat acute oral LD₅₀. IC₅₀-LD₅₀ regressions (in millimole units) were calculated for each *in vitro* cytotoxicity test method and participating laboratory using the 3T3 and NHK IC₅₀ values. Because the regressions for each NRU test method among laboratories were not significantly different from one another (for each NRU test method, p > 0.5), the regression for each NRU test method was based on data pooled across the laboratories. This combined-laboratory regression was then compared to the RC data using a regression based on RC IC₅₀ and LD₅₀ data for the 47 substances common to the validation study and the RC, with rat acute oral LD₅₀ reference values, and with both 3T3 and NHK IC₅₀ values produced by all three participating laboratories. The statistical comparison of slope and intercept (simultaneously) using an F test showed that neither the 3T3 regression nor the NHK regression was significantly different from the RC regression for the 47 substances (p =0.61 and 0.76 respectively). These outcomes support use of the RC millimole regression.

Reference substances that fit the RC millimole regression poorly (i.e., outliers) were evaluated to determine whether there were relationships between their outlier status and their physical or chemical characteristics. Because the IC_{50} -LD₅₀ regressions for the 3T3 and NHK NRU test methods yielded results that were not different from the RC regression for 47 substances, the RC millimole regression was preferred for analysis of outliers because it was based on a much larger data set and because it had established acceptance limits (Halle 1998, 2003). Certain chemical structural classes, boiling points, molecular weights, and log K_{OW} values were related with outliers, but solubility in the 3T3 or NHK medium and the cells' lack of xenobiotic metabolic capability did not correlate with outlier status. Because these *in*

³ Accuracy is the agreement between a test method result and an accepted reference value (ICCVAM 2003).

vitro NRU test methods are based upon basal cytotoxicity, the mechanism of toxicity was also considered as a characteristic to explain the presence of outliers. Twenty-two reference substances were neurotoxic or cardiotoxic and were not expected to be active in the 3T3 and NHK cell cultures. Of these 22 substances, 13 (59%) were outliers (i.e., they fit the RC millimole regression poorly) using the 3T3 NRU and 12 (55%) were outliers using the NHK NRU. These substances represented 13/28 (46%) and 12/31 (39%) of the outliers for the 3T3 and the NHK NRU test methods, respectively. More information on the outlier analysis is presented in **Section 6.2**.

The potential variation produced by combining the LD_{50} values of two rodent species in the RC millimole regression was eliminated by developing a regression based solely on RC substances with rat LD_{50} data (i.e., the RC rat-only millimole regression). The RC rat-only data were also converted to a weight basis for an additional regression, the RC rat-only weight regression, for applicability to mixtures or to substances for which molecular weight is unknown.

The accuracy of the *in vitro* NRU test methods when used with each of the IC_{50} -LD₅₀ regressions was characterized by determining the proportion of reference substances for which their GHS categories (based on rat acute oral LD₅₀ data) were correctly predicted. The accuracy of the RC rat-only millimole regression was 31% (21/67 reference substances) and 29% (20/68 reference substances) with the 3T3 and the NHK NRU test methods, respectively. The accuracy of the RC rat-only weight regression was similar, 31% with the 3T3 NRU test method (21/67 reference substances) and 31% with the NHK NRU test method (21/68 reference substances). The poor accuracy is due, in part, to the skewness of the reference substance set with respect to the fit of the reference substances to the regressions and to the differences between cell cultures and whole animal exposures. Each regression showed a general trend to underpredict the toxicity of the most toxic chemicals, and to overpredict the toxicity of the least toxic chemicals. A detailed discussion of the accuracy analyses is presented in **Section 6.4**.

Test Method Reliability

Reproducibility is the consistency of individual test results obtained in a single laboratory (intralaboratory reproducibility) or among different laboratories (interlaboratory reproducibility) using the same protocol and test samples. Reproducibility was evaluated using results from the 64 reference substances tested in 3T3 cells and the 68 substances tested in NHK cells that yielded replicate IC_{50} values in all three laboratories. Intra- and inter-laboratory reproducibility of the 3T3 and NHK NRU IC_{50} data was assessed using analysis of variance (ANOVA), coefficient of variation (CV) analysis, comparison of the laboratory-specific IC_{50} -LD₅₀ regressions, and comparison of maximum:minimum mean laboratory IC_{50} values. Reproducibility was generally better with the NHK NRU test method.

Although ANOVA results for the positive control (sodium lauryl sulfate [SLS]) IC_{50} values from the 3T3 NRU test method indicated that there were significant differences among laboratories (p =0.006) but not between study phases within laboratories (p >0.01), the data show (see **Figure 7-5**) that laboratory means and standard deviations from each testing phase overlap , and that the IC_{50} was stable between testing phases. The interlaboratory CV values for the various study phases ranged from 2 to 16%. ANOVA results for the SLS IC₅₀ from the NHK NRU test method showed significant differences among laboratories (p <0.001) and among study phases within laboratories (p \leq 0.001). The use of a different cell culture method at FAL was responsible for SLS IC₅₀ differences among the laboratories in Phases Ia and Ib. After harmonization of culture methods across laboratories, the laboratory means and standard deviations were similar for Phases II and III (see **Figure 7-5**). Interlaboratory CV values for the NHK NRU for Phases Ia and Ib, were 39% and 21%, respectively. Interlaboratory CV values for Phases II and III were 31% and 8%, respectively. The linear regression analyses of the SLS IC₅₀ over time (within each laboratory) for both NRU test methods indicated that IC₅₀ values generated over the 2.5-year duration of the study were stable.

For the reference substances, the similarity among the laboratories' LD₅₀ predictions (via regression) from IC_{50} values (see Figure 7-1) was considered significant with respect to the reproducibility analyses because these in vitro NRU test methods are proposed for use in determining starting doses for acute oral toxicity tests using the predicted LD_{50} . ANOVA showed significant laboratory differences for 23 substances with the 3T3 NRU test method (see Table 7-4) and six substances with the NHK NRU test method (see Table 7-6). Mean intralaboratory CV values were 26% for both NRU test methods, but the NHK NRU test method had a lower mean interlaboratory CV (28% vs. 47%). An analysis to determine the relationship, if any, between reference substance attributes and interlaboratory CV indicated that chemical class, physical form, solubility, and volatility had little effect. The CV seemed to be related instead to the GHS hazard category, the IC₅₀, and boiling point (see Section 7.2.3). However, the usefulness of these relationships is not known. Mean interlaboratory CV values were larger for substances in the most toxic GHS hazard categories than for substances in the other toxicity categories, especially with the 3T3 NRU test method. The mean interlaboratory CV for substances in the $LD_{50} \leq 5 \text{ mg/kg}$ (72%) and $5 < LD_{50} \leq 50$ mg/kg (78%) categories were larger than the mean overall interlaboratory CV (47%) with the 3T3 NRU test method. When the NHK NRU test method was used, the mean interlaboratory CV was 37% for substances with $LD_{50} \leq 5$ mg/kg, and 41% for substances with $5 < LD_{50} \leq 50$ mg/kg, and the mean overall interlaboratory CV was 28%. A Spearman correlation analysis indicated that the IC₅₀ was inversely correlated to interlaboratory CV for both the 3T3 (p =0.015) and NHK (p = 0.014) NRU test methods, and that boiling point was positively correlated to interlaboratory CV (p =0.007) for the 3T3 but not the NHK (p =0.809) NRU test method.

The maximum:minimum mean laboratory IC_{50} ratios for the 3T3 NRU test method ranged from 1.1 to 21.6, with 37 of 64 (58%) reference substances having ratios less than 2.5. The maximum:minimum mean laboratory IC_{50} ratios for the NHK NRU test method ranged from 1.0 to 107.6, with 58 of 68 (85%) reference substances having ratios less than 2.5.

Data Quality

The laboratories reported no significant deviations from the protocols, and deviations that did occur were acknowledged and addressed by the Study Directors. Tests that had deviations affecting the data were rejected by the Study Directors and repeated. The computation of test method and data collection errors showed that the non-GLP laboratory consistently had the

highest error rate and the lowest intralaboratory reproducibility for IC₅₀ results; however, the laboratory's GHS acute oral toxicity category predictions were comparable to that for the other laboratories.

An electronic copy of all data for the validation study can be obtained from NICEATM upon request by mail, fax, or e-mail to Dr. William S. Stokes, NICEATM, NIEHS, P. O. Box 12233, MD EC-17, Research Triangle Park, NC, 27709, (phone) 919-541-2384, (fax) 919-541-0947, (e-mail) <u>niceatm@niehs.nih.gov</u>.

Other Scientific Reports and Reviews

3T3 and NHK NRU methods have been evaluated for purposes other than the prediction of starting doses for acute toxicity studies (e.g., ocular irritancy; human lethal blood concentrations, *in vivo* phototoxicity). *In vitro* NRU cytotoxicity test methods using various cell types have been evaluated for their correlation with rodent lethality endpoints (e.g., rat/mouse intravenous[i.v.], intraperitoneal [i.p.], and oral toxicity). Peloux et al. (1992) and Fautrel et al. (1993) showed good correlations (r =0.88) of *in vitro* cytotoxicity with rodent i.p./i.v. and i.v. toxicity data, respectively. A 3T3 NRU test method has been validated by ECVAM for the identification of *in vivo* phototoxic potential.

No *in vitro* test methods have been validated for the prediction of acute oral toxicity. Estimations of animal savings using *in vitro* cytotoxicity data to estimate starting doses for the UDP did not use actual *in vitro* cytotoxicity data. Instead, animal savings were estimated by assuming that the *in vivo* starting dose equals the true LD₅₀, which is an approach that assumes that cytotoxicity data can perfectly predict *in vivo* lethality. These theoretical predictions of animal savings in the UDP ranged from 25-40% (ICCVAM 2001a), as compared with the average animal savings of 5.3-7.8% predicted using computer simulation modeling of the UDP for the reference substances tested in the NICEATM/ECVAM study. Halle et al. (1997) used the *in vitro* cytotoxicity data in the RC to determine that an animal savings of 32% can be attained for the ATC method by using the LD₅₀ predicted by the RC millimole regression as the starting dose. For the reference substances tested in the NICEATM/ECVAM validation study, most of which were a poor fit to the RC millimole regression, the average animal savings for the ATC, as determined by computer simulation modeling, was 4.8-10.2%.

Animal Welfare Considerations: Reduction, Refinement, and Replacement

Computer models were used to simulate testing of the reference substances using to the UDP and ATC test methods. In principle, animal savings with the FDP could be estimated even though death is not the primary endpoint, but the validation study did not include this analysis. The number of animals that would be used, and the number of animals that would survive or die during the UDP or ATC procedure, were determined for the default starting doses and compared with those when starting dose was based on LD_{50} values determined from IC_{50} values for each reference substance using the RC rat-only regressions.

Computer simulation of UDP testing showed that, for the reference substances used in this validation study, using the 3T3 or NHK NRU test methods and the RC rat-only millimole regression to identify the starting dose resulted in the use of fewer animals per test by an

average of 5.3% (0.50 animals) to 6.6% (0.53 animals), depending upon the assumed mortality-response slope and *in vitro* NRU test method used. The RC rat-only weight regression predicted mean animal savings of 6.0% (0.56 animals) to 7.8% (0.62 animals). When substances were grouped by GHS acute oral toxicity category, there were no animal savings for substances in the 50 <LD₅₀ \leq 300 mg/kg category because the default starting dose is in this range. The greatest animal savings were observed for substances with 2000 <LD₅₀ \leq 5000 mg/kg and LD₅₀ >5000 mg/kg because the limit test, which would be used for such substances, uses fewer animals that the main test. Animal savings for these toxicity categories using the RC rat-only millimole regression ranged from 11.3% (1.21 animals) to 20.3% (1.58 animals) per test. Use of the RC rat-only weight regression produced animal savings of 12.8% (1.38 animals) to 21.0% (1.63 animals) per test. Although the use of the 3T3 and NHK NRU test methods to estimate starting doses for the simulated UDP decreased the numbers of animals used per test, it did not change the numbers of animals that died.

Computer simulation of ATC testing showed that, for the reference substances used in this validation study, using the 3T3 or NHK NRU test methods and the RC rat-only millimole regression to identify the starting dose resulted in a savings of 4.8% (0.51 animals) to 7.3% (0.80 animals) per test, depending upon the assumed mortality-response slope and the *in vitro* NRU test method used. The use of the RC rat-only weight regression produced animal savings of 8.6% (0.91 animals) to 10.2% (1.09 animals). When substances were grouped by GHS acute oral toxicity category, there were no animal savings for substances in the 300 < $LD_{50} \leq 2000 \text{ mg/kg}$ category because this category contains the default starting dose for the ATC method. Animal savings were highest for substances with $5 < LD_{50} \le 50$ mg/kg and LD₅₀ >5000 mg/kg. The mean animal savings for both *in vitro* NRU test methods for substances with $5 < LD_{50} \le 50$ mg/kg ranged from 9.8% (1.15 animals) to 11.4% (1.33) animals) per test for the RC rat-only millimole regression. The greatest reduction in animal use would be for substances with $LD_{50} > 5000 \text{ mg/kg}$ because the limit test used fewer animals than the main test. Animal savings for these substances ranged from 17.1%, (2.03 animals) to 22.2% (2.66 animals) per test for the RC rat-only millimole regression. When the RC rat-only weight regression was used, the mean animal savings with both in vitro NRU test methods for substances with $5 < LD_{50} \le 50$ mg/kg ranged from 10.8% (1.25 animals) to 13.0% (1.51 animals) per test. Mean animal savings for substances with LD₅₀ >5000 mg/kg ranged from 24.8% (2.94 animals) to 27.7% (3.33 animals) per test. The use of IC_{50} values to estimate starting doses for the ATC tests refined animal use by producing fewer animal deaths by approximately 0.5 to 0.6 animals per test.

Simulations for the UDP and ATC method showed that the use of cytotoxicity results to estimate starting doses did not significantly alter the GHS categorizations compared with the categories determined using default starting doses. This concordance was 97 to 99% for the 3T3 and NHK NRU test methods.

Practical Considerations

Practical issues with respect to the implementation of these *in vitro* NRU test methods include the need for, and availability of, appropriate cell culture equipment, training and expertise, cost, and time expenditure. The ECVAM Good Cell Culture Practice Task Force Report 1 (Hartung et al. 2002) encourages the establishment of laboratory practices and

principles that will reduce uncertainty in the development and application of *in vitro* test methods.

All equipment and supplies are readily available, and the *in vitro* NRU test methods are easily transferable to laboratories experienced with mammalian cell culture techniques. Much of the training and expertise needed to perform the 3T3 and NHK NRU test methods are common to people with mammalian cell culture experience. Additional technical training would not be intensive because these methods are similar in general performance to other *in vitro* mammalian cell culture assays. GLP training should be provided to laboratory personnel (including study directors and principal investigators) to ensure proper adherence to test protocols and data documentation and verification procedures.

Prices for commercial *in vitro* NRU cytotoxicity testing to determine the IC_{50} for one substance ranged from \$1120 to \$1850. It is not clear if the price of an *in vivo* test would be reduced if it were preceded by an *in vitro* cytotoxicity test to set the starting dose. Thus, use of these test methods may not reduce the overall cost of rodent acute oral toxicity testing and may increase the cost, but their use has the potential to reduce the number of animals and the time needed for a study. The greatest savings in time and animals will occur if the IC_{50} data determine that the rodent acute oral toxicity limit test should be performed, rather than the main test. Based on the cost and technical procedures associated with cell culture maintenance, the 3T3 NRU test method is less expensive and less complicated to conduct than the NHK NRU test method.

| 1.0 | NEUT | CODUCTION AND RATIONALE FOR THE USE OF <i>IN VITRO</i> FRAL RED UPTAKE CYTOTOXICITY TEST METHODS TO DICT STARTING DOSES FOR <i>IN VIVO</i> ACUTE ORAL | |
|-----|---|--|--|
| | | ICITY TESTING | 1-3 |
| 1.1 | Histo | rical Background and Rationale for the Use of <i>In Vitro</i> Cytotoxicity | |
| | Assay | vs to Predict Starting Doses for Rodent Acute Oral Toxicity Tests | 1-4 |
| | 1.1.1 | The Multicentre Evaluation of In Vitro Cytotoxicity (MEIC) Program | 1-4 |
| | 1.1.2 | An International Evaluation of Selected In Vitro Toxicity Test Systems | |
| | | for Predicting Acute Systemic Toxicity | 1-6 |
| | 1.1.3 | The Registry of Cytotoxicity (RC) | |
| | 1.1.4 | The ZEBET Initiative to Reduce Animal Use | 1-9 |
| | 1.1.5 | The International Workshop on In Vitro Methods for Assessing Acute | |
| | | Systemic Toxicity | |
| | 1.1.6 | The NICEATM/ECVAM In Vitro NRU Cytotoxicity Validation Study | . 1-11 |
| 1.2 | Regul | atory Rationale and Applicability for the Use of <i>In Vitro</i> | |
| | | oxicity Test Methods to Predict Starting Doses for Acute Oral | |
| | - | Unity 1 cst Michous to 1 fearch Starting Doses for Acute Of an | |
| | Toxic | ity Testing in Rodents | 1-14 |
| | Toxic 1.2.1 | ity Testing in Rodents | |
| | | ity Testing in Rodents | 1-14 |
| | 1.2.1 | ity Testing in Rodents Current Regulatory Testing Requirements for Acute Oral Toxicity | 1-14 |
| | 1.2.1 1.2.2 | ity Testing in Rodents Current Regulatory Testing Requirements for Acute Oral Toxicity Intended Regulatory Uses for <i>In Vitro</i> Cytotoxicity Test Methods | 1-14 1-16 |
| | 1.2.1 1.2.2 | ity Testing in Rodents Current Regulatory Testing Requirements for Acute Oral Toxicity Intended Regulatory Uses for <i>In Vitro</i> Cytotoxicity Test Methods Similarities and Differences in the Endpoints of <i>In Vitro</i> Cytotoxicity | 1-14 1-16 |
| | 1.2.1 1.2.2 1.2.3 | ity Testing in Rodents Current Regulatory Testing Requirements for Acute Oral Toxicity Intended Regulatory Uses for <i>In Vitro</i> Cytotoxicity Test Methods Similarities and Differences in the Endpoints of <i>In Vitro</i> Cytotoxicity Test Methods and Rodent Acute Oral Toxicity Test Methods | 1-14 1-16 1-17 |
| 1.3 | 1.2.1 1.2.2 1.2.3 1.2.4 | ity Testing in Rodents Current Regulatory Testing Requirements for Acute Oral Toxicity Intended Regulatory Uses for <i>In Vitro</i> Cytotoxicity Test Methods Similarities and Differences in the Endpoints of <i>In Vitro</i> Cytotoxicity Test Methods and Rodent Acute Oral Toxicity Test Methods Use of <i>In Vitro</i> Cytotoxicity Test Methods in the Overall Strategy of Hazard Assessment | 1-14 1-16 1-17 1-18 |
| 1.3 | 1.2.1 1.2.2 1.2.3 1.2.4 | ity Testing in Rodents Current Regulatory Testing Requirements for Acute Oral Toxicity Intended Regulatory Uses for <i>In Vitro</i> Cytotoxicity Test Methods Similarities and Differences in the Endpoints of <i>In Vitro</i> Cytotoxicity Test Methods and Rodent Acute Oral Toxicity Test Methods Use of <i>In Vitro</i> Cytotoxicity Test Methods in the Overall Strategy of Hazard Assessment | 1-14 1-16 1-17 1-18 1-18 |
| 1.3 | 1.2.1 1.2.2 1.2.3 1.2.4 Scient 1.3.1 | ity Testing in Rodents | 1-14 1-16 1-17 1-18 1-18 |
| 1.3 | 1.2.1 1.2.2 1.2.3 1.2.4 | ity Testing in Rodents Current Regulatory Testing Requirements for Acute Oral Toxicity Intended Regulatory Uses for <i>In Vitro</i> Cytotoxicity Test Methods Similarities and Differences in the Endpoints of <i>In Vitro</i> Cytotoxicity Test Methods and Rodent Acute Oral Toxicity Test Methods Use of <i>In Vitro</i> Cytotoxicity Test Methods in the Overall Strategy of Hazard Assessment | 1-14 1-16 1-17 1-18 1-18 1-18 |

[This Page Intentionally Left Blank]

1.0 INTRODUCTION AND RATIONALE FOR THE USE OF *IN VITRO* NEUTRAL RED UPTAKE CYTOTOXICITY TEST METHODS TO PREDICT STARTING DOSES FOR *IN VIVO* ACUTE ORAL TOXICITY TESTING

Poisoning is a more serious public health problem than generally recognized. The Institute of Medicine (IOM) estimates that more than 4 million poisoning episodes occur annually in the United States (IOM 2004). In 2001, poisoning (30,800 deaths) placed second behind automobile accidents (42,433 deaths) as the leading cause of injury-related death (IOM 2004). To reduce the risk for accidental poisonings, various regulatory agencies in the United States (e.g., the Environmental Protection Agency [EPA], the Consumer Products Safety Commission [CPSC]), require the testing of marketed products for acute oral toxicity in rodents. Increasing societal concerns about animal use have lead to the development and evaluation of alternative *in vitro* test methods that might refine, reduce, or replace acute oral toxicity test methods¹.

The purpose of this background review document (BRD) is to:

- Describe a validation study organized and managed by the National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) and the European Centre for the Validation of Alternative Methods (ECVAM) to evaluate the ability of two *in vitro* basal cytotoxicity test methods to predict starting doses for rodent acute oral toxicity tests
- Provide the results of an evaluation of the accuracy and reliability of the two *in vitro* basal cytotoxicity test methods, as well as of the animal savings that would occur if these test methods were used to predict the starting dose.

The structure of the BRD follows the requested structure of the *ICCVAM² Guidelines for the Nomination and Submission of New, Revised, and Alternative Test Methods* (ICCVAM 2003).

This section provides:

- A historical perspective of scientific efforts to develop and evaluate the ability of *in vitro* cytotoxicity test methods to refine, reduce, or replace acute oral toxicity test methods
- A general review of reported correlations between *in vitro* cytotoxicity and acute oral lethality in rodents
- The regulatory requirements for rodent acute oral toxicity testing
- The scientific basis of using *in vitro* basal cytotoxicity test methods to predict the starting doses for rodent acute oral toxicity assays

¹ A reduction alternative is a new or modified test method that reduces the number of animals required. A refinement alternative is a new or modified test method that refines procedures to lessen or eliminate pain or distress in animals or enhances animal well-being (ICCVAM 2003).

² The Interagency Coordinating Committee for the Validation of Alternative Methods

• The intended regulatory uses and applicability of *in vitro* basal cytotoxicity test methods

1.1 Historical Background and Rationale for the Use of *In Vitro* Cytotoxicity Assays to Predict Starting Doses for Rodent Acute Oral Toxicity Tests

This section provides the historical background and rationale for the NICEATM/ECVAM validation study by summarizing several major studies promoted by the European Union (EU) to investigate the properties and capabilities of cell-based methods to predict acute toxicity. The Multicentre Evaluation of In Vitro Cytotoxicity (MEIC) Program was initiated in 1983 to compare *in vitro* methods to acute oral lethality in humans (Section 1.1.1). In 1992-1993, the Fund for the Replacement of Animals in Medical Experiments (FRAME) conducted an international evaluation of selected in vitro toxicity test systems for predicting acute systemic toxicity (Section 1.1.2). Dr. Willi Halle published a monograph regarding the development of the Registry of Cytotoxicity (RC) database to evaluate whether basal cytotoxicity data could accurately predict acute oral lethality in rats and mice (Section 1.1.3). ECVAM organized a workshop in 1994 to evaluate the use of in vitro data for the classification and labeling of chemicals and reviewed the assessment of acute oral toxicity using in vitro data. Workshop participants suggested that the use in vitro data to determine starting doses for acute oral toxicity tests would reduce the use of animals. The German Center for Documentation and Evaluation of Alternative Methods to Animal Experiments (ZEBET) then recommended that in vitro basal cytotoxicity data be used with the RC millimole regression, which is referred to as the ZEBET approach (Section 1.1.4), to determine starting doses for acute oral toxicity tests. Section 1.1.5 provides background on an international workshop that reviewed and evaluated the EU studies above and Section 1.1.6 describes the NICEATM/ECVAM in vitro cytotoxicity validation study that expands upon the EU studies.

1.1.1 <u>The Multicentre Evaluation of *In Vitro* Cytotoxicity (MEIC) Program</u> The Scandinavian Society for Cell Toxicology established the MEIC program in 1983 to investigate the ability of *in vitro* cytotoxicity test methods to predict acute oral lethality in humans (Bondesson et al. 1989). MEIC was based on the following assumptions:

- In vitro cell culture systems could be used to model in vivo acute oral toxicity.
- The basal cytotoxicity detected by these *in vitro* test methods is responsible for a large proportion of *in vivo* toxic effects³.

The MEIC program was an open study that invited laboratories worldwide to participate in testing 50 reference substances using laboratory-specific *in vitro* cytotoxicity assays. Although the MEIC management team requested that all participating laboratories test chemicals with high purity, no effort was made to assure that the substances tested were purchased from the same supplier or were of the same purity (Clemedson et al. 1996a). Minimal methodological directives were provided so as to maximize protocol diversity among the 96 participating laboratories.

³ Basal, or general, cytotoxicity was described as toxicity resulting from interference with basic cellular structures and functions, such as cell membranes, metabolism, ion regulation, and cell division that are common to all human and animal cells.

The reference substances were selected to represent different chemical classes for which reference acute oral lethality data existed in humans (i.e., lethal doses, kinetics, and lethal blood/serum concentrations [LC]) and rodents (oral median lethal dose [LD₅₀] values) (Bondesson et al. 1989). The MEIC management team collected human data from clinical and forensic toxicology handbooks and case reports of human poisonings (Ekwall et al. 1998a). The resulting data were presented and analyzed in a series of 50 MEIC Monographs. Rat and mouse oral LD₅₀ data were collected from the Registry of Toxic Effects for Chemical Substances (RTECS[®])⁴.

The 50 reference substances were tested in as many as 61 different *in vitro* assays (Ekwall et al. 1998b). The metric of interest was the IC_{50} (i.e., the concentration that inhibited the response measured by 50%) for the endpoint measured. Of the 20 test methods that used human-derived cells, 18 used cell lines and two used primary cell cultures. Of the 21 test methods that used mammalian (but other than human) cells, 12 used cell lines and nine used primary cell cultures. Eighteen test methods were ecotoxicological in nature and two used cell-free systems. Cell viability and/or cell growth were the endpoints of choice in the majority of the cell-based systems. The chemical exposure duration ranged from 5 minutes to 6 weeks, but most frequently was 24 hours (Clemedson et al. 1996).

The ability of the *in vitro* IC_{50} data to predict human acute oral lethality was assessed using human LC values compiled from three different data sets (Ekwall et al. 2000):

- Clinically measured acute lethal serum concentrations
- Acute LC values measured post-mortem
- Peak LC values derived from approximate LC₅₀ curves over time after exposure

A partial least squares (PLS) analysis indicated that the IC₅₀ data generated from as many as 61 test methods predicted the three sets of LC data well ($R^2=0.77$, 0.76, and 0.83, $Q^2=0.74$, 0.72, and 0.81, respectively, where R^2 is the determination coefficient and Q^2 is the predicted variance according to cross-validation in the PLS model used). A two component PLS model using rat and mouse oral LD₅₀ values less accurately predicted human LC values ($R^2=0.65$, $Q^2=0.64$). These results suggested that *in vitro* basal cytotoxicity assays might be more effective in estimating human acute oral lethality than rodent acute oral toxicity test methods.

Because the MEIC study showed that the *in vitro* test methods with the best predictivity generally used human cell lines (Ekwall et al. 1998b), the MEIC management team identified a battery of *in vitro* assays using three human cell lines that had maximal performance for predicting peak acute LC values in humans (R^2 =0.79 and Q^2 =0.76) (Ekwall et al. 2000). However, it was concluded that improvements in the prediction of human acute oral lethality were necessary before *in vitro* cytotoxicity assays could replace animal tests. To adjust for lethality produced by mechanisms other than basal cytotoxicity, the Evaluation-guided Development of New *In Vitro* Tests (EDIT) program was proposed to address targeted

⁴ RTECS[®] was originally published by the U.S. National Institute for Occupational Safety and Health (NIOSH) and is currently licensed to MDL Information Systems, Inc.

development of *in vitro* test methods for other endpoints, including biokinetics (e.g., gut absorption, distribution, clearance), biotransformation, and target organ toxicity (Clemedson et al. 2002).

1.1.2 <u>An International Evaluation of Selected *In Vitro* Toxicity Test Systems for Predicting Acute Systemic Toxicity</u>

FRAME organized an international collaborative study conducted in 1992 - 1993 to evaluate the prediction of rodent acute oral lethality by *in vitro* test methods (Fentem et al. 1993)⁵. The objective of the study was to identify *in vitro* systems and strategies that could be used for the classification and labelling of new chemicals, thereby reducing, and possibly replacing, the use of animals for acute oral toxicity testing.

The 42 substances tested in the study comprised a diverse group of organic and inorganic chemical classes, including surfactants, pharmaceuticals, and pesticides (Fentem et al. 1993). *In vitro* toxicity assays using different mammalian cell lines, exposure periods, and toxicity endpoints were evaluated, including:

- Two cell proliferation assays (total protein in mouse BALB/c 3T3 fibroblast cells and MTT⁶ reduction in Chinese hamster fibroblastoid V79 cells after a 72-hour exposure period)
- Two cytolethality assays (MTT reduction in V79 cells and lactate dehydrogenase [LDH] release from primary rat hepatocytes after a 24-hour exposure period)
- A cell function assay (myotube contractility inhibition in rat skeletal muscle cells)

The resulting *in vitro* IC_{50} data were linearly regressed against the lowest available rat or mouse oral LD_{50} values for each test substance. There were no significant differences among the IC_{50} - LD_{50} regressions for the different *in vitro* test methods.

A subset of 26 to 40 of the 42 test substances, based on the availability of European Union (EU) hazard classification data, was used to evaluate two approaches for using *in vitro* IC_{50} data to classify chemicals into the four hazard categories used by the EU for acute oral toxicity labelling (Fentem et al. 1993). One approach used the IC_{50} values obtained from the five different *in vitro* test methods for each test substance to predict the LD_{50} value and hazard category from the IC_{50} -LD₅₀ regression. The accuracy of hazard classification for the five *in vitro* tests was from 43 to 65%. The other approach used toxicokinetic parameters for 31 to 38 substances to convert the IC_{50} values to effective dose (i.e., ED_{50}) values. Hazard classification accuracy was 43 to 55%.

⁵ The collaborative study was conducted by the Institute of Toxicology, Kiel, Germany; the University of Nottingham, United Kingdom; and the Gesellschaft für Strahlen- und Umweltforschung, Neuherberg, Germany (Society for Radiological and Environmental Research, which later changed its name to Center for Environmental and Health Research [Forschungszentrum für Umwelt und Gesundheit])

⁶ MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide is metabolized by the mitochondrial succinate dehydrogenase of proliferating cells to yield a purple formazan reaction product.

In addition, to ensure that a variety of toxic mechanisms were evaluated during *in vitro* testing, the lowest predicted LD_{50} or ED_{50} from the results of a battery of three tests: a cell proliferation assay (total protein for 3T3 cells); a cytotoxicity/cytolethality assay using primary rat hepatocytes (LDH release); and the rat skeletal muscle cell contractility assay, was used also. The lowest predicted LD_{50} or ED_{50} of the three tests was then used to predict toxicity classification. The accuracy of classification using this approach was 48% for the ED_{50} and 45% for the predicted LD_{50} values.

Based on the results obtained, a battery of *in vitro* tests was recommended for classifying chemicals for their acute lethal potency in rodents (Fentem et al. 1993). The first order test in the battery measures basal cytotoxicity. This study observed no major differences in the performances of the *in vitro* test methods that measure inhibition of cell growth regardless of the cell line (V79, 3T3-L1, or BALB/c 3T3), exposure duration (24-72 hours), or endpoint measurement technique (MTT reduction, neutral red uptake [NRU], or protein concentration). The second order test in the battery assesses hepatocyte-specific toxicity and the role of biotransformation in cytotoxic activity. Co-cultures of rodent hepatocytes with proliferating cells such as 3T3 cells were recommended because the use of hepatocytes alone would not indicate that a chemical requires bioactivation to produce its toxic effects. The third order test in the battery detects chemicals that interfere with electrically excitable membranes at non-cytotoxic concentrations (e.g., a contractility assay using primary cultures of rat muscle cells) (Fentem et al. 1993).

1.1.3 <u>The Registry of Cytotoxicity (RC)</u>

The RC is a database of acute oral LD_{50} values for rats and mice obtained from RTECS[®], and published IC₅₀ values from *in vitro* cytotoxicity assays that used a variety of cell lines and cytotoxicity endpoints for substances with known molecular weights (Halle 1998, 2003). The main purpose for compiling the RC was to evaluate, using data from substances with a wide range of rodent acute oral toxicities, whether basal cytotoxicity (averaged over various cell types, cell lines, and/or toxicity endpoints) accurately predicted acute oral lethality in rats and mice. The RC currently contains data for 347 different substances (Halle 1998, 2003) and efforts are underway to increase the number to 500 (ICCVAM 2001a). The RC does not contain data on chemical mixtures.

The RC contains cytotoxicity data for substances that met the following criteria (Halle 1998, 2003):

- At least two different IC₅₀ values needed to be available, from studies using either different cell types, different cell lines, or different cytotoxicity endpoints
- Data had to be generated using mammalian cells only (although data from studies using hepatocytes or related cells were excluded)
- The chemical exposure duration had to be at least 16 hours, with no upper limit

The following cytotoxicity endpoints were accepted:

Cell proliferation: cell number; cell protein; DNA content; DNA synthesis; ³H-thymidine intake; colony formation

- Cell viability/metabolic indicators: metabolic inhibition test (MIT-24); mitochondrial reduction of tetrazolium salts into an insoluble (MTT) or soluble (2,3-bis(2-methoxy-4-nitro-5- sulfophenyl)-2H-tetrazolium-5carboxanilide [XTT]) dye
- Cell viability/membrane indicators: NRU; trypan blue exclusion; cell attachment; cell detachment
- Differentiation indicators, such as functional and/or morphological changes among and within cells


IC₅₀ values (1,912) for 347 substances were obtained from 157 original publications (Halle 1998, 2003). The two to 32 IC₅₀ values for each substance were averaged as geometric means to produce one IC_{50x} value for each substance. The rodent LD₅₀ values used in the RC were obtained from RTECS[®]. For the first 117 substances, designated as the training data set (RC-I), LD₅₀ values were not revised when subsequent issues of RTECS[®] reported lower values⁷. For the most recent 230 substances, designated as the verification set (RC-II), the LD₅₀ values were taken from the 1983/84 RTECS[®] publication. Whenever obtainable, oral LD₅₀ data from mice were used (65 values). Combining rat and mouse data in the regression was deemed to be justified when separate regressions for the mouse and rat LD₅₀ values against the IC_{50x} values did not result in significant differences between the slopes and intercepts of the two regressions (Halle 1998, 2003).


To develop a model for the prediction of acute oral LD_{50} values from IC_{50x} values, Halle (1998, 2003) calculated a linear regression from pairs of the log-transformed IC_{50x} values (in mM) and log transformed rodent oral LD_{50} values (in mmol/kg) (see **Figure 1-1**). Molar concentrations were used to allow for a comparison among chemicals based on the number of molecules rather than formula weights. The regression, referred to here as the *RC millimole regression*, has the following formula:

$\log LD_{50} \text{ (mmol/kg)} = 0.435 \text{ x} \log IC_{50x} \text{ (mM)} + 0.625$

To identify an acceptability range for practical use and research purposes, the acceptable prediction interval for the LD_{50} was empirically defined as approximately one-half an order of magnitude on either side of the best-fit linear regression (i.e., $\pm \log 5$, or ± 0.699) (Halle 1998, 2003). This interval was based on eight linear regressions calculated for *in vitro* mammalian cell cytotoxicity data using various endpoints and oral LD_{50} values from rat, mouse, or rat and mouse from five publications. The prediction interval approximates the predicted LD_{50} range for the eight regressions across about eight orders of magnitude of IC₅₀ values. When this approach was used, 73% (252/347) of the RC substances fall within the prediction interval.

 $^{^{7}}$ RTECS[®] published the lowest LD₅₀ reported for a substance and updates the information periodically.





Abbreviations: RC=Registry of Cytotoxicity; IC_{50x} =Geometric mean (of multiple endpoints and cell types) test substance concentration that reduces cell viability by 50%; LD_{50} =Dose producing death in 50% of the animals tested.

The heavy line shows the fit of the data to a linear regression model, $\log (LD_{50}) = 0.435 \times \log (IC_{50x}) + 0.625$; r=0.67. The thinner lines show the empirical prediction interval (± log 5, or ±0.699) that is based on the anticipated precision for the prediction of LD_{50} values from cytotoxicity data (Halle 1998, 2003).

1.1.4 The ZEBET Initiative to Reduce Animal Use

ECVAM organized a workshop in 1994 to evaluate the use of *in vitro* data for the classification and labeling of chemicals (Seibert et al. 1996). Workshop participants reviewed information on the assessment of acute oral toxicity using *in vitro* data and concluded that, for *in vitro* data to be used most effectively, the following information would be necessary:

- The active concentration *in vitro* (i.e., the actual concentration available to the cultured cells)
- The *in vitro* concentrations that produce basal cytotoxicity, hepatocyte toxicity, and selective cytotoxicity (i.e., effects on cell-specific functions such as transport processes or cell-to-cell communication)
- The effect of biokinetic processes on acute oral toxicity in rodents
- *In vitro* tests that provide the physicochemical parameters needed to estimate equivalent body doses from *in vitro* data

The concept that *in vitro* data could be used to determine the starting doses for rodent acute oral toxicity tests, so as to reduce the number of animals used, was first discussed at this workshop (Seibert et al. 1996). At that time, draft Organisation for Economic Co-operation and Development (OECD) sequential rodent acute oral toxicity test guidelines (TGs) were available; these included the:

- Acute Toxic Class method (ATC; OECD draft Test Guideline [TG] 423 [ICCVAM 2001a])
- Up-and-Down Procedure (UDP; OECD draft TG 425 [ICCVAM 2001a])
- Fixed Dose Procedure (FDP; OECD draft TG 420 [ICCVAM 2001a])

Final OECD TGs now exist for these rodent acute oral toxicity tests. The number of animals needed depends upon the choice of the starting dose because the number of consecutive dosing steps, and thus the number of animals used, is reduced as the starting dose more closely approximates the true toxicity class for the ATC or the FDP, or the true LD_{50} for the UDP.

The ZEBET approach involves using an IC_{50} value from an *in vitro* basal cytotoxicity test with the RC millimole regression to predict an LD_{50} value for use as a starting dose for the ATC or UDP (Spielmann et al. 1999). Using simulation results performed to evaluate the draft UDP test method, ZEBET predicted that the use of *in vitro* cytotoxicity assays to predict a starting dose equivalent to the LD_{50} had the potential to reduce animal use in the UDP by 25-40%, depending upon the slope of the concentration response curve and the stopping rule applied (Spielmann et al. 1999; ICCVAM 2001a).

1.1.5 <u>The International Workshop on *In Vitro* Methods for Assessing Acute Systemic Toxicity</u>

In 2000, the U.S. National Institute of Environmental Health Sciences (NIEHS), the NTP, and the EPA jointly sponsored an International Workshop on *In Vitro* Methods for Assessing Acute Systemic Toxicity (hereafter known as Workshop 2000). This workshop evaluated:

- The ZEBET approach using the RC millimole regression to estimate LD₅₀ values and set starting doses for *in vivo* testing
- A testing strategy proposed by the European Center for the Validation of Alternative Methods (ECVAM) (Siebert et al. 1996)
- Other initiatives for reducing animal use in rodent acute oral toxicity testing by using *in vitro* cytotoxicity test methods (ICCVAM 2001a)

The Workshop 2000 participants concluded that no *in vitro* cytotoxicity test methods (or battery of *in vitro* cytotoxicity test methods) existed that could replace the current *in vivo* acute oral toxicity test methods (ICCVAM 2001a). Furthermore, they concluded that none of the *in vitro* models reviewed had been adequately evaluated for reliability and relevance, and their usefulness and limitations for generating information for acute toxicity testing had not been assessed. However, there was agreement that: (1) in the near-term, *in vitro* basal cytotoxicity studies, and (2) further development, optimization, and validation of *in vitro* test methods that considered target organ specificity and *in vivo* factors like adsorption, distribution, metabolism, and excretion (ADME) that modulate the lethality of a xenobiotic were needed (ICCVAM 2001a). Furthermore, the approach proposed by ZEBET (i.e., the use

of *in vitro* basal cytotoxicity test methods to predict the starting dose for the sequential rodent acute oral toxicity test methods) (Halle 1998, 2003; Spielmann et al. 1999) was recommended for rapid adoption so that data could be generated to establish its usefulness with a larger number of substances (ICCVAM 2001a). To assist in the adoption and implementation of the ZEBET approach, several workshop participants prepared the *Guidance Document on Using In Vitro Data to Estimate In Vivo Starting Doses for Acute Toxicity* (hereafter referred to as *Guidance Document*; ICCVAM 2001b).

The *Guidance Document* recommended testing 10 to 20 RC substances (of high purity) from the RC in a candidate *in vitro* basal cytotoxicity assay to be used for predicting starting doses for acute oral lethality tests (ICCVAM 2001b). The substances were to cover a wide range of toxicities and fit the RC prediction model (i.e., the linear regression line) as closely as possible. The *in vitro* test methods recommended and provided as examples were NRU assays using 3T3 and normal human epidermal keratinocytes (NHK) cells. The IC₅₀ results from testing the selected substances would be used to calculate a regression against the LD₅₀ values used by the RC. If the resulting regression were parallel to the RC millimole regression and within the $\pm \log 5$ (i.e., ± 0.699) prediction interval for the RC, the *Guidance Document* recommended using the *in vitro* cytotoxicity assay to predict starting doses for LD₅₀ assays. If the regression from the *in vitro* assay did not meet these criteria, then the *Guidance Document* advised either (a) adjusting the slope or (b) using the NRU protocols offered in the *Guidance Document* (considered the most efficient approach).

Based on the conclusions and recommendation of the Workshop 2000 participants, ICCVAM subsequently recommended that near-term validation studies should focus on two *in vitro* basal cytotoxicity assays: one using human cells and one using rodent cells. Human cells are of interest because a principal aim of rodent acute oral toxicity testing is to predict potential lethality in humans, while rodent cells may be a better predictor of lethality in rats and mice (ICCVAM 2001a).

1.1.6 <u>The NICEATM/ECVAM *In Vitro* NRU Cytotoxicity Validation Study</u> In response to the ICCVAM recommendation, NICEATM and ECVAM designed an independent⁸ multi-laboratory validation study to evaluate *in vitro* basal cytotoxicity, measured as NRU, as a predictor of acute oral lethality in rodents and potentially in humans. Based on historical *in vitro* cytotoxicity data for mouse BALB/c 3T3 fibroblast cells (e.g., Balls et al. 1995; Brantom et al. 1997; Gettings et al. 1991, 1994a, 1994b; Spielmann et al. 1991, 1993, 1996) and NHK cells (e.g., Gettings et al. 1996; Harbell et al. 1997; Sina et al. 1995; Willshaw et al. 1994), it was decided that these two cells types should be the focus of this validation effort.

The primary aim of this validation study was to determine if the NRU IC₅₀ concentration of a test substance in either 3T3 or NHK cells could be used to estimate the rodent LD₅₀, as a means for predicting the starting doses for rodent acute oral toxicity studies. A secondary aim was to determine the extent to which the NRU IC₅₀ in either 3T3 or NHK cells could be used

⁸ "Independent" is used here to indicate that neither NICEATM nor ECVAM, nor its members, had a monetary interest in the test methods.

to estimate the blood serum concentrations associated with acute oral lethality in humans. This evaluation will be the focus of a future ECVAM report.

The specific objectives for this validation study were to:

- Further standardize and optimize the *in vitro* NRU basal cytotoxicity protocols using 3T3 and NHK cells to maximize test method reliability (intralaboratory repeatability, intra- and inter-laboratory reproducibility)
- Assess the accuracy of the two standardized *in vitro* 3T3 and NHK NRU basal cytotoxicity test methods for estimating rodent oral LD₅₀ values across the five United Nations (UN) Globally Harmonized System of Classification and Labelling of Chemicals (GHS; UN 2005) categories of acute oral toxicity, as well as unclassified toxicities
- Estimate the reduction and refinement in animal use achievable from using the *in vitro* 3T3 and NHK NRU basal cytotoxicity test methods to identify starting doses for *in vivo* acute oral toxicity tests, assuming that no other information were available
- Develop high quality *in vivo* acute oral lethality and *in vitro* NRU cytotoxicity databases that can be used to support the investigation of other *in vitro* test methods necessary to improve the prediction of *in vivo* acute oral lethality

1.1.6.1 *Study Design*

The planning phase of the validation study included the selection of reference substances for testing, which is described in **Section 3**, and the identification of rodent oral LD₅₀ values for the reference substances, which is described in **Section 4**. The validation study proceeded in several phases (see **Figure 1-2**) so that the Study Management Team (SMT) could evaluate the reproducibility of results after each phase and refine the protocols, if necessary, before proceeding to the next phase. The resulting NRU data collected were used to evaluate linear regression formulas for the prediction of LD₅₀ values from IC₅₀ values (see **Section 6**). Computer simulation modeling of acute oral toxicity test outcomes was then performed to determine potential animal savings using the NRU-predicted starting doses compared with the default starting dose for the UDP and the ATC (see **Section 10**). Study management and study participant information is provided in **Appendix A**.

Figure 1-2NICEATM/ECVAM Validation Study Phases

Phase Ia: Laboratory Evaluation

Development of a positive control database for each laboratory

- Perform at least 10 replicate NRU tests of the positive control substance (sodium lauryl sulfate [SLS]) with each cell type.
- Calculate mean IC_{50} value ± 2 standard deviations for each cell type for each laboratory.
- Establish acceptance criteria for positive control performance in future assays.

∜

Phase Ib: Laboratory Evaluation

Limited substance testing to demonstrate the reliability of the protocol

- Each laboratory tests the same three coded substances three times with each cell type. There was one substance each from low, medium, and high GHS toxicity categories.
- Refine protocols and repeat, if necessary, until acceptable intra- and inter-laboratory reproducibility is achieved.

∜

Phase II: Laboratory Qualification

Evaluation of protocol refinements

- Each laboratory tests nine coded substances covering the range of GHS toxicity categories, with three replicate tests per substance in each test method.
- Assure that corrective actions taken in Phase I have achieved the desired results.
- Further refine protocols and re-test, if necessary, to achieve acceptable reliability.
- Finalize protocols for Phase III.

∜

Phase III: Laboratory Testing Phase

Test of optimized protocols

• Each laboratory tests 60 coded substances in three replicate tests using the finalized protocol for each test method.

Abbreviations: NRU=Neutral red uptake; GHS=Globally Harmonized System of Classification and Labelling of Chemicals (UN 2005)

1.2 Regulatory Rationale and Applicability for the Use of *In Vitro* Cytotoxicity Test Methods to Predict Starting Doses for Acute Oral Toxicity Testing in Rodents

1.2.1 Current Regulatory Testing Requirements for Acute Oral Toxicity

The major regulatory need for acute oral toxicity testing is for the hazard classification and labeling of products, which is intended to alert handlers and consumers to potential toxicity hazards. The LD_{50} values from acute oral toxicity tests using rodents are used to place substances in various toxicity categories that, in turn, invoke the associated hazard phrases to be used on product labels. **Table 1-1** shows the current U.S. legislation requiring the use of acute oral toxicity test protocol requirements and classification systems used by each U.S. regulatory agency. Also included in this table is the UN Harmonized Integrated Classification System for Human Health and Environmental Hazards of Chemical Substances and Mixtures, which provides guidance to regulatory agencies on the use of the GHS (UN 2005) as an internationally comprehensible system for hazard communication (OECD 2001b).

Table 1-1Summary of Current U.S. Legislation for Using Acute Toxicity Data for
Product Labeling

| Legislation (Year of Initial Enactment) | U.S. Regulatory Agency | Substances Regulated |
|---|---------------------------|------------------------|
| Federal Insecticide, Fungicide and Rodenticide Act (FIFRA; 1947) | EPA | Pesticides |
| Federal Hazardous Substances Act (1964) | CPSC | Household products |
| Occupational Safety and Health Act (1970) | OSHA | Workplace materials |
| Federal Hazardous Material Transportation Act (1975) | DOT | Transported substances |

Abbreviations: EPA=U.S. Environmental Protection Agency; CPSC=U.S. Consumer Product Safety Commission; FIFRA=Federal Insecticide, Fungicide, and Rodenticide Act; OSHA=U.S. Occupational Safety and Health Administration; DOT=U.S. Department of Transportation.

Note: The U.S. Food and Drug Administration (FDA) does not require data for from acute lethality testing, and discourages the use of animals for such testing (FDA 1993).

In addition to classification and labeling, acute oral toxicity test results may be used for:

- Establishing dosing levels for repeated dose toxicity studies or other toxicity studies
- Identifying potential target organs
- Providing information related to the mode of toxic action
- Aiding in the diagnosis and treatment of toxic reactions
- Providing information for comparison of toxicity and dose response among substances in a specific chemical or product class
- Aiding in the standardization of biological products
- Aiding in judging the consequences of single, high accidental exposures in the workplace, home, or from accidental release
- Serving as a standard for evaluating alternatives to animal tests

| Tuble I a Regulatory Clussification Systems for Real Oral Toxicity | Table 1-2 | Regulatory Classification Systems for Acute Oral Toxicity |
|--|-----------|--|
|--|-----------|--|

| Regulatory Agency (Authorizing Act) | Animals | Endpoint | Classification |
|--|---------------|-----------------------------------|--|
| EPA (FIFRA) | Use current | Death ¹ | I - $LD_{50} \leq 50 \text{ mg/kg}$ |
| | EPA or | | II - $50 < LD_{50} \le 500 \text{ mg/kg}$ |
| | OECD | | III - $500 < LD_{50} \le 5000 \text{ mg/kg}$ |
| | protocol | | IV - LD ₅₀ >5000 mg/kg |
| CPSC (Federal Hazardous | White rats, | Death ¹ within 14 days | Highly toxic - $LD_{50} \leq 50 \text{ mg/kg}$ |
| Substances Act) | 200-300 g | for \geq half of a group of | Toxic - 50 mg/kg $<$ LD ₅₀ $<$ 5 g/kg |
| | | ≥ 10 animals | |
| OSHA (Occupational | Albino rats, | Death ¹ , duration not | Highly toxic - $LD_{50} \leq 50 \text{ mg/kg}$ |
| Safety and Health Act) | 200-300 g | specified. | Toxic - $50 < LD_{50} < 500 \text{ mg/kg}$ |
| DOT (Federal Hazardous | Male and | Death ¹ within 14 days | Packing Group 1 - $LD_{50} \leq 5 \text{ mg/kg}$ |
| Material Transportation | female young | of half the animals | Packing Group II - 5 < LD ₅₀ ≤50 mg/kg |
| Act) | adult albino | tested. Number of | Packing Group III - LD ₅₀ <500 mg/kg (liquid) |
| | rats | animals tested must be | LD ₅₀ <200 mg/kg (solid) |
| | | sufficient for | |
| | | statistically valid | |
| | | results. | |
| OECD Guidance for Use | Protocols not | Not specified | I - $LD_{50} \leq 5 \text{ mg/kg}$ |
| of GHS (2001b) | specified | | II - 5 < $LD_{50} \le 50 \text{ mg/kg}$ |
| | | | III - $50 < LD_{50} \le 300 \text{ mg/kg}$ |
| | | | IV - $300 < LD_{50} \le 2000 \text{ mg/kg}$ |
| | | | V - $2000 < LD_{50} \le 5000 \text{ mg/kg}$ |
| | | | Unclassified - LD ₅₀ >5000 mg/kg |

Abbreviations: EPA=U.S. Environmental Protection Agency; OECD=Organisation for Economic Co-operation and Development; LD₅₀=Dose producing death in 50% of the animals tested; CPSC=U.S. Consumer Product Safety Commission; FIFRA=Federal Insecticide, Fungicide, and Rodenticide Act; OSHA=U.S. Occupational Safety and Health Administration; DOT=U.S. Department of Transportation; GHS=Globally Harmonized System of Classification and Labelling of Chemicals (UN 2005).

¹Guidance Document on the Recognition, Assessment and Use of Clinical Signs as Humane Endpoints for Experimental Animals Used in Safety Evaluation calls for humane killing of moribund animals (OECD 2000). Moribund animals that are humanely euthanized are accepted as deaths.

1.2.1.1 Test Methods for Assessing Acute Oral Toxicity

The current internationally recognized test methods for acute oral toxicity testing are the FDP (OECD 2001c), the ATC (OECD 2001d), and UDP (OECD 2001a; EPA 2002a) (see **Appendix M** for test method guidelines). Information on toxic doses and signs of acute toxicity and target organs can be obtained using any of these three methods. All three methods are sequential tests in which the outcome of testing one or more animals at the first dose is used to determine the second dose that should be tested. The FDP differs from the UDP and ATC in that it involves using more animals per dose, and the primary endpoint of interest is evident toxicity⁹ rather than lethality. Both the FDP and the ATC methods provide a range estimate of the LD₅₀ for classification purposes. The UDP generally provides a point estimate of the LD₅₀ with a confidence interval (EPA 2002a).

Each of the test method guidelines includes a limit test in which up to five or six animals are tested at the limit, or upper bound, dose depending on the dose chosen (OECD 2001a, c, d, e; EPA 2002a). The limit test can be performed using 2000 or 5000 mg/kg, depending on the regulatory need.

1.2.2 Intended Regulatory Uses for the *In Vitro* Cytotoxicity Test Methods *In vitro* cytotoxicity test methods currently cannot serve as replacements for acute oral toxicity tests in animals. However, such test methods can be used as adjuncts for rodent acute oral toxicity tests. The current test guidelines for acute oral toxicity tests recommend using information from structurally-related substances and the results of any other toxicity tests (EPA 2002b), including *in vitro* cytotoxicity test method (OECD 2001a, c, d; EPA 2002a) to select the starting *in vivo* dose. The 3T3 and NHK NRU test methods may be used as part of this weight-of-evidence approach to select starting doses in order to reduce and refine the use of animals for acute oral toxicity testing.

Section 10 presents computer simulation analyses that characterize the extent of animal reduction and refinement that may occur by using the *in vitro* NRU test methods to estimate the starting doses for the UDP and the ATC method, by estimating the numbers of animals used and the numbers of animal that die. These simulations determined (1) the numbers of animals used when using the default starting dose and, (2) the number of animals used when using a starting dose determined from the *in vitro* NRU test methods. These calculations determined the reduction in animal use that can be achieved when using the *in vitro* NRU test methods. To characterize the extent of refinement produced using the NRU-determined starting dose, the number of animals that would have died with the NRU-determined starting dose was compared with the number of animals that would have died when using the default starting dose at which evident toxicity occurs in relationship to the LD₅₀, the FDP will not be considered further in this document. However, the use of *in vitro* cytotoxicity data to determine starting doses may also reduce the use of animals in the FDP.

⁹ *Evident toxicity* is a general term describing clear signs of toxicity following administration of the test substance, such that the next highest fixed dose would result in the development of severe toxic signs, and probably mortality (ICCVAM 2000).

1.2.3 Similarities and Differences in the Endpoints of the *In Vitro* Cytotoxicity Test Methods and Rodent Acute Oral Toxicity Test Methods

The endpoint measured in the *in vitro* NRU test methods is cell death. Neutral red dye is taken up and accumulated only by live cells; the primary measure of interest is the IC₅₀ (i.e., the test substance concentration that causes a 50% inhibition of NRU). In contrast, the endpoint measured in acute oral toxicity assays is usually animal morbidity or death. Cell death and animal death may have similar mechanistic bases because all cells, regardless of whether they are in animals or *in vitro* cell cultures, have similar cellular mechanisms; for example, energy production and maintenance of cell membrane integrity.

Death of an animal death and death of a cultured cell due to toxicity both involve interference with vital cell processes or physical injury. Cell death in a culture system involves the death of a single cell type, but through mechanisms that also operate in the animal. In contrast, cellular injury in an animal, if sufficiently widespread or in a critical process, can lead to injury or loss of function of other cell types in a tissue not directly affected by the treatment, resulting in organ failure. Major organ system failures (e.g., liver and kidney failure), gastrointestinal corrosion, and bone marrow depression, can be fatal. Examples of mechanisms leading to such organ failures are disruption of membrane structure or function, inhibition of mitochondrial function, disturbance of protein turnover, and disruption of energy production (Gennari et al. 2004). Alternatively, the tissue injury could affect non-exposed vital organs or tissues through interference with homeostatic signaling mechanisms (Gennari et al. 2004). For example, respiratory depression leading to death may be due to depression of the central nervous system (CNS) rather than a direct assault on the respiratory system itself.

Animal and cell culture systems are also different with respect to how a substance or toxicant is delivered to the cell and how it is distributed within the cell, metabolized, and excreted. After oral administration, animals must absorb the toxicant from the gastrointestinal tract, which involves the passage through membranes, many of which are selective with respect to what molecules they will allow to pass. The toxicant may or may not be bound to serum proteins, thereby reducing its availability to the target organ. The toxicant may be metabolized before, during, and/or after its distribution to the target organs, or the toxicant or its metabolites may be excreted before reaching the target organ or reacting with its components. As a consequence, the most critical target organs may not be exposed to the active metabolite, or be exposed for only a limited time or to a relatively small fraction of the administered dose.

In contrast, in a cell culture system, the test substance is applied directly to the target cells and the only membranes that must be passed are those of the target cell and its subcellular organelles. No absorption and distribution by other cellular systems is required. Cell culture systems may or may not include serum proteins, which could reduce the availability of toxicant to the target site. For example, the 3T3 cell culture medium includes serum while the NHK cell culture medium does not. 3T3 and NHK cells have little to no capacity to metabolize xenobiotic compounds, and added cell-free metabolic activation systems, such as rat liver homogenates, may not accurately mimic all phases of *in vivo* metabolism. Excretion from the cell culture milieu is not a consideration because anything excreted from the cell remains in the culture medium and is available to the other cells in the culture. As a result, the cells in culture (as opposed to cells in an animal) may be exposed to a test substance for the entire duration of the test protocol.

Animals and cell culture systems may also differ with respect to the target on which a toxicant acts. If a toxicant acts in a specialized organ system *in vivo*, it may not produce a toxic effect by the same mechanism in cultured cells that are derived from a tissue different from the target organ. For example, a substance that affects a neuroreceptor-mediated pathway in animals would not be expected to produce a similar toxicity in 3T3 or NHK cells, which are derived from fibroblasts and skin cells, respectively, and do not contain similar neuroreceptors; if toxicity is seen in these cell cultures, it may be from a different mechanism or in a different concentration relationship than *in vivo*. Even if a neurotoxin were applied to neuronal cells in culture, the cultured cells may not respond in the same way as neuronal cells in an animal because cells in culture, especially cell lines, may not retain the same functionalities as cells *in vivo*.

1.2.4 <u>Use of *In Vitro* Cytotoxicity Test Methods in the Overall Strategy of Hazard</u> <u>Assessment</u>

In the overall strategy of hazard or safety assessment, the intended regulatory use of the *in vitro* NRU test methods is to reduce and refine the use of animals in current acute toxicity assays. The *in vitro* systems would serve as adjuncts to the *in vivo* test methods but are not intended as replacements for the rodent acute oral toxicity test methods. For the OECD alternative acute oral toxicity assays (the ATC and UDP), the number of animals used depends on the starting dose. The number of dosing steps (and animals) is reduced if the starting dose is close to the true toxicity class (ATC) or the true LD₅₀ (UDP) (Spielmann et al. 1999; ICCVAM 2001b).

As noted earlier, Spielmann et al. (1999) and the *Guidance Document* (ICCVAM 2001b) suggest that the RC millimole regression analysis be used with *in vitro* cytotoxicity data to predict starting doses for the ATC and UDP. The RC millimole regression cannot be applied to unknown substances or to mixtures (e.g., product formulations) because such materials cannot be assigned molecular weights. Therefore, the NICEATM/ECVAM validation study also evaluated the classification accuracy and the reduction in animal use associated with a regression based on weight units (with IC₅₀ in μ g/mL and LD₅₀ in mg/kg) (see **Section 10**). This regression would potentially be appropriate for predicting the starting dose for mixtures and undefined substances.

1.3 Scientific Basis for the *In Vitro* NRU Test Methods

Cytotoxicity has been defined as the adverse effects resulting from interference with structures and/or processes essential for cell survival, proliferation, and/or function (Ekwall 1983). Ekwall (1983) described the concept of "basal cell functions" (mitochondrial activity, plasma membrane integrity, etc.) that virtually all cells possess and suggested that, for most substances, toxicity is a consequence of non-specific alterations in those cellular functions, which may then lead to adverse effects on organ-specific functions and/or death of the organism. These effects may involve the integrity of membranes and the cytoskeleton, cellular metabolism, the synthesis and degradation or release of cellular constituents or products, ion regulation, and cell division.

Ekwall (1983) and others (e.g., Grisham and Smith 1984) concluded that, because the actions of substances that produce injury and death are ultimately exerted at the cellular level, *in vitro* cytotoxicity assays might be useful for the prediction of acute lethality potency, as well. Considerable research has been undertaken to develop and evaluate *in vitro* tests for use as screens and as potential replacements for rodent LD₅₀ tests, and numerous groups have reported good agreement between *in vitro* cytotoxicity and animal lethality (see reviews by Phillips et al. 1990; Garle et al. 1994; Guzzie 1994). However, none of the proposed *in vitro* models have been evaluated in any formal studies for reliability and relevance, and their usefulness and limitations for generating information to meet regulatory requirements for acute toxicity testing data have not been assessed.

1.3.1 Purpose and Mechanistic Basis of the *In Vitro* NRU Test Methods

A number of basal cytotoxicity endpoints can be used to measure cell death or interference with cell proliferation. The NRU test methods were chosen for the NICEATM/ECVAM validation study because they were recommended in the *Guidance Document* for the purpose of obtaining cytotoxicity information to determine starting doses for rodent acute oral toxicity assays (ICCVAM 2001b). Both the 3T3 and NHK NRU test methods were reproducible in previous validation studies (ICCVAM 2001b). In addition, both cell types are easily obtainable from commercial sources and the *Guidance Document* provided preliminary evidence that these assays could reproduce the RC millimole regression. Additionally, the assays can be automated and they require no radioactivity or highly dangerous reagents (see **Section 2** for protocol discussion and **Appendix B** for protocols).

Neutral red is a weakly cationic water-soluble supravital dye that stains living cells (Borenfreund and Puerner 1985). It readily diffuses through the plasma membrane and concentrates in lysosomes where it electrostatically binds to the anionic lysosomal matrix. Toxicants can alter the cell surface or the lysosomal membrane to cause lysosomal fragility and other adverse changes that gradually become irreversible. Thus, cell death and/or inhibition of cell growth decreases the amount of neutral red retained by the culture. Borenfreund and Puerner (1985) were the first to publish a protocol for the NRU assay using 3T3 cells as a method to objectively quantify toxicity previously assessed by subjective, visual observation. The NRU assay, which was standardized for a 96-well plate format, correlated two measurements of toxicity from the exposure of 3T3 cells to six surfactants: (1) a visual morphological evaluation of the cells under an inverted phase microscope, and (2) a quantitative measurement of NRU. The visual evaluation was designed to identify the highest concentration of toxicant that causes only minimal morphological changes (i.e., the highest tolerated dose [HTD]). Because Borenfreund and Puerner (1985) found that the HTD in the NRU test was comparable to the concentration that produced 10% inhibition (i.e., the IC_{10}) compared with the controls, the IC_{10} value was deemed to be a good index for comparing the relative toxicities of experimental agents. The assay was described as a rapid, reliable, inexpensive, and reproducible *in vitro* test method for screening potentially toxic agents (Borenfreund and Puerner 1985). Furthermore, the authors suggested that the test method was a good candidate for inclusion in a battery of assays for toxicity screening with the purpose of reducing the use of animals for toxicity tests.

1.3.2 <u>Similarities and Differences in the Modes/Mechanisms of Action for the *In Vitro* <u>NRU Test Methods Compared with the Species of Interest</u></u>

Although the ultimate species of interest for acute oral toxicity concerns is humans, labeling and hazard identification requirements are based on rodents. There are differences between humans and rodents in terms of absorption, distribution, metabolism, excretion, and the intrinsic sensitivity of target organs to xenobiotic compounds. The differences are largely substance-specific and quantitative, although there are a number of substances where the human may produce metabolites not seen in the rodent and vice versa. *In vitro* cytotoxicity studies have also noted differences in sensitivity between human cells and other mammalian cells (Clemedson et al. 1996b). It is important to note that, for certain chemicals, there can also be large differences in sensitivity among different human cell types and cell lines (Clemedson et al. 1996b, 1998a, b).

Because of the differences in sensitivity between humans and rodents, it might be likely that cultured human cells would predict human lethality better than cultured rodent cells and that cultured rodent cells would predict rodent lethality better than human cells. Ekwall et al. (1998b) showed that *in vitro* cytotoxicity test methods using human cell lines generally predicted human toxicity more accurately than did test methods using nonhuman mammalian cells.

In addition to being derived from different species, there are several other differences between 3T3 and NHK cells, all of which may contribute to differences in sensitivity.

- 3T3 cells are an immortal line, while the NHK cells are primary cells.
- The cells originate from different tissues; 3T3 cells are derived from embryonic fibroblasts, while the NHK cells are isolated from neonatal foreskin tissue.
- NHK cells grow more slowly in culture than the 3T3 cells (i.e., after seeding into 96-well plates, NHK cells require 48-72 hours for growth to the appropriate confluence while 3T3 cells require approximately 24 hours; see **Appendix B**).
- NHK cells have greater ability to metabolize xenobiotic compounds, in that they exhibit minimal cytochrome P450 activity (Babich et al. 1991), whereas 3T3 cells have practically no ability to metabolize xenobiotic compounds (INVITTOX 1991).

1.3.3 <u>Range of Substances Amenable to the *In Vitro* NRU Test Methods</u> The *in vitro* NRU test methods can be applied to a wide range of substances as long as they can be dissolved in the cell culture medium or in a nontoxic solvent (at the concentration used), and do not react with the culture medium. Although these test methods may to be applicable to mixtures, none were evaluated in this validation study. The toxicity of substances that act by mechanisms not expected to be active in 3T3 or NHK cells (e.g., those that are specifically neurotoxic or cardiotoxic) will likely be underpredicted by these test methods. Therefore, until more appropriate cell lines are developed, the results from basal cytotoxicity testing with such substances may not be relevant for predicting *in vivo* effects. Insoluble substances or those unstable in aqueous environments are not compatible with the test systems. Volatile substances may yield acceptable results if CO₂ permeable plastic film is used to seal the test plates. Testing for corrosive substances is unnecessary since there is no regulatory requirement for acute oral toxicity testing for known corrosives. The 3T3 NRU test method may underestimate the toxicity of substances that are highly bound to serum proteins because the culture medium contains 5% serum during substance exposure. The toxicity of substances that specifically affect lysosomes may be overestimated because they may affect NRU binding, and therefore, retention, in the cell. Red substances (and other colored substances) that absorb light in the optical density range of NR may interfere with the test if they remain inside the cell in sufficient amounts after washing and are soluble in the NR solvent.

[This Page Intentionally Left Blank]

| 2.0 | TEST METHOD PROTOCOL COMPONENTS OF THE 3T3 ANI NHK <i>IN VITRO</i> NRU TEST METHODS | |
|-------------|--|-------|
| 2.1 | Basis for Selection of <i>In Vitro</i> NRU Cytotoxicity Test Methods | |
| | 2.1.1 <i>Guidance Document</i> Rationale for Selection of <i>In Vitro</i> NRU | |
| | Cytotoxicity Test Methods | 2-4 |
| | 2.1.2 <i>Guidance Document</i> Rationale for Selection of Cell Types | |
| 2.2 | Overview of the 3T3 and NHK NRU Test Methods | 2-5 |
| L. L | 2.2.1 The 3T3 NRU Test Method | |
| | 2.2.2 The NHK NRU Test Method | |
| | 2.2.3 Measurement of NRU in the 3T3 and NHK Test Methods | |
| 2.3 | Descriptions and Rationales of the 3T3 and NHK NRU Test Method | ls2-9 |
| 2.0 | 2.3.1 Materials, Equipment, and Supplies | |
| | 2.3.2 Reference Substance Concentrations/Dose Selection | |
| | 2.3.3 NRU Endpoints Measured | |
| | 2.3.4 Duration of Reference Substance Exposure | |
| | 2.3.5 Known Limits of Use | |
| | 2.3.6 Basis of the Response Assessed. | |
| | 2.3.7 Appropriate Vehicle, Positive, and Negative Controls | |
| | 2.3.8 Acceptable Ranges of Control Responses | |
| | 2.3.9 Nature of Experimental Data Collected | |
| | 2.3.10 Data Storage Media | |
| | 2.3.11 Measures of Variability | |
| | 2.3.12 Methods for Analyzing NRU Data | |
| | 2.3.13 Decision Criteria for Classification of Reference Substances | |
| | 2.3.14 Information and Data Included in the Test Report | 2-20 |
| 2.4 | Proprietary Components of the <i>In Vitro</i> NRU Test Methods | 2-22 |
| 2.5 | Basis for the Number of Replicate and Repeat Experiments for the | |
| | 3T3 and NHK NRU Test Methods | 2-22 |
| 2.6 | Basis for Modifications to the 3T3 and NHK NRU Test Method | |
| | Protocols | 2-22 |
| | 2.6.1 Phase Ia: Laboratory Evaluation Phase | 2-22 |
| | 2.6.2 Phase Ib: Laboratory Evaluation Phase | 2-25 |
| | 2.6.3 Phase II: Laboratory Qualification Phase | 2-27 |
| | 2.6.4 Phase III: Laboratory Testing Phase | 2-35 |
| 2.7 | Differences Between the 3T3 and NHK NRU Test Method Protocols for the Validation Study and the <i>Guidance Document</i> Standard Prot | |
| 2.8 | Overview of the Solubility Protocol | 2-37 |
| 2.9 | Basis of the Solubility Protocol | 2-38 |
| | | |

| | 2.9.1 Ir | nitial Solubility Protocol Development | |
|------|----------|---|------|
| | 2.9.2 B | asis for Modification of the Phase II Protocol | 2-39 |
| 2.10 | Compon | ents of the Solubility Protocol | 2-40 |
| | 2.10.1 N | fedium, Supplies, and Equipment Required | |
| | 2.10.2 D | ata Collection | 2-41 |
| | 2.10.3 V | ariability in Solubility Measurement | 2-41 |
| | | olubility Issues During the Testing of the Reference Substances | |
| | | nalysis of Solubility Data | |
| 2.11 | Summar | ·y | 2-42 |

2.0 TEST METHOD PROTOCOL COMPONENTS OF THE 3T3 AND NHK *IN VITRO* NRU TEST METHODS

The *Guidance Document* (ICCVAM 2001b) recommended that the following be incorporated into any *in vitro* cytotoxicity protocol used to predict rodent acute oral lethality:

- A cell line (or primary cells) that divides rapidly (e.g., with a doubling time of <24 hours)
- An initial seeding density that allows for exponential cell growth throughout the exposure period
- An exposure period that spans at least one cell cycle
- Appropriate positive control (PC) and vehicle control (VC) substances for which toxicity and lack of toxicity, respectively, has been well characterized by the performing laboratory
- Solvents that are used only at concentrations that do not cause significant toxicity to the cell system over the entire period of the assay
- A well-established, quantifiable cytotoxicity endpoint that has good interlaboratory reproducibility
- Tests that are compatible with at least 96-well plates and equipment (e.g., spectrophotometric microplate reader) that allow a quick and precise measurement of the endpoint of interest
- Use of a progression factor in the concentration-response experiment that yields graded effects between 0% and 100% cytotoxicity

Section 2.1 provides the basis for the selection of the *in vitro* 3T3 and NHK NRU test methods. Section 2.2 provides descriptions of the NRU protocols applicable to this validation study. Section 2.3 provides details for performing the 3T3 and NHK NRU test methods and explains the rationales for the various test method components, and Section 2.4 describes any 3T3 and NHK NRU test method proprietary aspects. Section 2.5 discusses the basis for the replicate and repeat tests conducted during validation of these two test methods. Section 2.6 details the modifications and revisions made during the first two phases of the validation study which contributed to the development of the final protocol used in Phase III. Section 2.7 describes the differences between the protocols used in this study and the protocols outlined in the *Guidance Document*. Sections 2.8, 2.9, and 2.10 provide details on the solubility protocol evaluated during the validation study and used to identify the appropriate solvent for dissolving the reference substances.

The 3T3 and NHK NRU test method protocols were provided to the three laboratories that participated in the validation study (see **Section 5.6.3** for additional laboratory information). These were:

- The U.S. Army Edgewood Chemical Biological Center (ECBC)
- The FRAME Alternatives Laboratory (FAL)
- The Institute for *In Vitro* Sciences (IIVS)

A fourth laboratory (BioReliance Corporation, Rockville, MD) was used to procure and distribute the coded reference substances, and to perform solubility tests on the validation study reference substances prior to their distribution to the participating laboratories.

2.1 Basis for Selection of the *In Vitro* NRU Cytotoxicity Test Method

As stated in **Section 1**, in agreement with the recommendations of the Workshop 2000 participants (ICCVAM 2001a), ICCVAM made the following recommendations and forwarded them to U.S. Federal agencies along with the Workshop 2000 Report (ICCVAM 2001a) and *Guidance Document* (ICCVAM 2001b).

"ICCVAM concurs with the Workshop recommendation that near-term validation studies should focus on two standard cytotoxicity assays: one using a human cell system and one using a rodent cell system. Since the murine BALB/c 3T3 cytotoxicity assay has been evaluated for only a limited number of chemical classes, there is merit in determining its usefulness with a broader array of chemical classes. Cell lines established from the rat rather than the mouse might also be considered, as most acute oral toxicity testing is conducted in this species. Human cell lines should also be considered since one of the aims of toxicity testing is to make predictions of potential toxicity in humans. Future validation studies should therefore compare rodent and human *in vitro* data with one another, with rodent *in vivo* data, and with human *in vivo* data. Correlations between *in vitro* and *in vivo* data might help in selecting cytotoxicity assays for further evaluation". (ICCVAM 2001a)

Based on this recommendation and the *Guidance Document* recommendation, NICEATM and ECVAM selected the 3T3 and NHK NRU basal cytotoxicity test methods for validation.

2.1.1 <u>Guidance Document Rationale for Selection of In Vitro NRU Cytotoxicity Test</u> <u>Methods</u>

The *Guidance Document* (ICCVAM 2001b) provided the basic approach for the use of *in vitro* NRU basal cytotoxicity test methods to predict starting doses for rodent acute oral toxicity assays using the RC millimole regression. The 3T3 and NHK NRU test method protocols used in the validation study were derived from those proposed in the *Guidance Document*.

2.1.2 <u>Guidance Document Rationale for Selection of Cell Types</u>

The Workshop 2000 participants (ICCVAM 2001a) concluded that there were no significant differences between the basal cytotoxicity results obtained using permanent mammalian cell lines, primary human cells (e.g., NHK cells), or the IC_{50x} approach of Halle and Spielmann (Halle 1998, 2003; Spielmann et al. 1999; Halle and Spielmann 1992). Further, the *Guidance Document* recommended that *in vitro* basal cytotoxicity test methods not use hepatocytes (or related metabolically competent cells) or other types of highly differentiated cells because they may not give the best prediction of acute lethality for the large variety of chemicals likely to be tested (ICCVAM 2001b). However, it was recognized that, ultimately, simple predictive systems (*in vitro* or *in silico*) would be needed for early identification of those substances likely to be metabolized to more toxic or less toxic species than the parent chemical as well as those that were likely to exhibit cell-specific toxicity (e.g., Fentem et al. 1993; Seibert et al. 1996; Curren et al. 1998; Ekwall et al. 1999).

Established rodent cell lines were recommended for validation because (ICCVAM 2001b):

- It was assumed that such cells would give the best prediction of rat and mouse acute oral lethality (i.e., like correlates with like).
- The use of a readily available, easy to culture, immortalized cell line for *in vitro* cytotoxicity testing would accelerate the development of a database that can be used to analyze the usefulness of this approach.

Human cells also offer potential advantages. As determined in the MEIC project, the *in vitro* test methods with the best predictivity for peak acute LC values in humans generally used human cell lines (Ekwall et al. 1998b). Thus, a long-term advantage of using human cells is that *in vitro* human cell cytotoxicity data can be added to human toxicity databases to facilitate the development of test methods that may better predict acute oral human lethality.

3T3, an immortalized mouse fibroblast cell line, and NHK, primary human cells, were selected as representative rodent and human cells, respectively, for the NICEATM/ECVAM validation study. Historical data for the 3T3 NRU test were available from a variety of studies, including controlled and blinded validation studies, indicating the reliability of this test method (Gettings et al. 1991, 1992, 1994a, 1994b; Spielmann et al. 1991, 1993, 1996; Balls et al. 1995; Brantom et al. 1997). NHK cells have also been used in validation studies for basal cytotoxicity test methods with good results (Willshaw et al. 1994; Sina et al. 1995; Gettings et al. 1996; Harbell et al. 1997).

2.2 Overview of the 3T3 and NHK NRU Test Methods

The *Guidance Document* (ICCVAM 2001b) includes a proposed 3T3 NRU test method protocol based on the 3T3 Cytotoxicity Test (INVITTOX Protocol No. 46; available from the FRAME-sponsored INVITTOX database [http://embryo.ib.amwaw.edu.pl/invittox/]), which in turn was based on the Borenfreund and Puerner (1985) protocol, as elaborated on in Spielmann et al. (1991, 1996). This protocol was updated based on experience obtained during the validation of the 3T3 NRU Phototoxicity Test (INVITTOX Protocol No. 78; also available at the FRAME INVITTOX database). The RC millimole regression for prediction of acute oral rat and mouse toxicity (Halle 1998, 2003; Spielmann et al. 1999) was included as the prediction model (ICCVAM 2001b; see Section 1.1.2).

The NHK NRU protocol provided in the *Guidance Document* was based on the protocol used by IIVS, which was based on a NRU protocol of Borenfreund and Puerner (1984) and a rat epidermal keratinocytes protocol (Heimann and Rice 1983). Formulations for the media and solutions, and general NHK cell culture techniques, correspond to Clonetics[®] products from the CAMBREX Corporation.

The protocol components for the 3T3 and NHK NRU test methods used in this validation study are similar (see **Figure 2-1**). The nature of the NRU response is described in **Section 1.3.1**. **Figure 2-1** provides an overview to the major steps for performance of the *in vitro* NRU test methods. The following procedures are common to both cell types:

- Preparation of substances and the PC
- Cell culture environmental conditions
- Determination of test substance solubility
- 96-well plate configuration for testing samples

- Range finder and definitive tests
- Microscopic evaluation of cell cultures for toxicity based on morphological alterations
- Procedures for measurement of NRU
- Data analysis procedures

The main protocol differences between the two cell lines are:

- The conditions of propagation of the cells in culture (e.g., time needed to reach appropriate confluence)
- The growth media components
- The volumes of substances applied to the 96-well plates
- The number of cell divisions undergone by each cell line during exposure to a test substance

2.2.1 <u>The 3T3 NRU Test Method</u>

2.2.1.1 *Initiating and Subculturing 3T3 Cells*

Each laboratory initially prepared a large pool of 3T3 cells (described further in **Section 2.3.1.1**), cryogenically preserved multiple ampules of these cells in liquid nitrogen, and periodically removed an ampule when needed. Although the NRU protocols used for each study phase provided cell culture density guidelines for subculturing the cells, each laboratory refined the final seeding density to achieve optimal growth.

Cryopreserved 3T3 cells were thawed, resuspended in a culture medium containing Dulbecco's Modification of Eagle's Medium (DMEM) supplemented with non-heat-inactivated 10% newborn calf serum (NCS), transferred into tissue culture flasks (25 or 75-80 cm²), and incubated at 37 °C \pm 1 °C, 90% \pm 5% humidity, and 5.0% \pm 1% CO₂/air. When cells reached 50 to 80% confluence (as estimated from a visual inspection of cell density), they were removed from the flask by trypsinization. A single-cell suspension was added to new flasks for propagation and the cells were passaged/subcultured at least two times¹ before seeding into 96-well plates for testing. This study did not evaluate the potential effects that cell passage number may have on the performance of the 3T3 NRU test method.

¹ 3T3 cells were maintained in culture for approximately two months (approximately 18 passages) and used for the NRU test. The *Guidance Document* (ICCVAM 2001b) did not provide a rationale for using 18 passages as the limit, but it was probably recommended to maintain homogeneity of the 3T3 cell population (i.e., decrease the potential of the population to drift genetically). The more passages the cells undergo, the more likely their response to chemical stress may change.

Figure 2-1 Major Steps in the Performance of the NRU Test Methods

- (1) Cells (3T3 or NHK) are seeded into 96-well plates to form a sub-confluent monolayer; plates are incubated at 37 °C (24 hours for 3T3 cells; 48-72 hours for NHK cells)
- (2) Culture medium is removed (3T3 cells only)

↓

(3) Reference substances in the appropriate solvents are added to the cells; cells are exposed for 48 hours at 37 °C over a range of eight (8) concentrations

↓

(4) Cells are evaluated microscopically for toxicity based on morphological appearance

₩

(5) Treatment medium is removed; cells are washed once with Dulbecco's Phosphate Buffered Saline (D-PBS); Neutral Red (NR) dye medium is added (3T3 cells: 25 μg/mL NR dye; NHK cells: 33 μg/mL NR dye); plates are incubated for 3 hours at 37 °C

∜

(6) NR medium is discarded; cells are washed once with D-PBS; NR desorbing fixative is added to the wells

∜

(7) Plates are shaken for 20 minutes at room temperature

.

(8) NR absorption is measured at optical density (OD) 540 ± 10 nm

₽

₽

(9) NRU is calculated as a percent of vehicle control values to define IC₂₀, IC₅₀, and IC₈₀ concentrations $(\mu g/mL)^2$

Abbreviations: NRU=Neutral red uptake; 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; IC₂₀, IC₅₀, IC₈₀=Substance concentration that reduces cell viability by 20, 50, and 80%, respectively.

 $^{^{2}}$ IC₅₀ values are used for estimating the LD₅₀ value of a reference substance. The IC₂₀ and IC₈₀ values were determined for possible use in estimating human lethal concentrations in blood.

2.2.1.2 Preparation of Cells for 96-well Plate Assays

After subculturing the cells, $100 \ \mu$ L of the cell suspension $(2.0 - 3.0 \times 10^3 \text{ cells/well})$ were placed in the appropriate wells and $100 \ \mu$ L of cell-free culture medium were dispensed into the 36 peripheral wells (blanks). The peripheral wells were in rows 1 and 8 and columns 1 and 12 (See **Figure 1** in **Appendix B1** or **B2**). Peripheral wells were used only for blanks because they may be subjected to more evaporation than interior wells. The *Guidance Document* authors (and the SMT and Study Directors) concluded that such conditions would ultimately affect cell growth in these wells. One plate was prepared for each reference substance. The cells were incubated for 24 ± 2 hours at 37 °C and checked visually to be sure that approximately a 50% confluent monolayer was present at the time of substance application.

2.2.1.3 *Reference Substance Application*

After the appropriate incubation period to achieve a half-confluent monolayer, the medium was removed and 50 μ L of culture medium with 10% NCS were added to each well. Then, 50 μ L treatment medium containing the appropriate substance concentrations were added for a final concentration of 5% NCS. The cells were then incubated at 37 °C for 48 ±0.5 hours. At the end of the incubation period, the cells were microscopically evaluated for changes in morphology and their appearance was documented (as per Visual Observation Codes in the protocol) prior to measurement of NRU.

2.2.2 <u>The NHK NRU Test Method</u>

2.2.2.1 Initiating and Subculturing NHK Cells

Cryopreserved NHK cells (ampules of cryopreserved cells were obtained from CAMBREX Corporation and stored in liquid nitrogen until needed) were thawed, resuspended in serum-free keratinocyte complete growth medium (see Section 2.3.1.4 for components of the medium), transferred into tissue culture flasks (25 cm^2 without fibronectin-collagen coating), and incubated at $37 \text{ °C} \pm 1 \text{ °C}$, $90\% \pm 5\%$ humidity, and $5.0\% \pm 1\%$ CO₂/air. When the cells reached 50 to 80% confluence (as estimated from a visual inspection of cell density), they were removed from the flask by trypsinization and prepared for subculturing into the 96-well plates. Care was taken to prevent the keratinocyte cultures from becoming 100% confluent as this may lead to cell differentiation, which would alter the intrinsic sensitivity of these cells to cytotoxic substances. To minimize potential sources of experimental variability, the laboratories used the same lot of Clonetics[®] cells throughout the validation study, the same brand of growth medium and supplements (and concentrations of supplements), and cells were not used beyond their second passage. The protocols for each study phase provided cell culture density guidelines, but each laboratory refined the final seeding densities to achieve appropriate growth.

2.2.2.2 Preparation of Cells for 96-well Plate Assays

After subculturing the cells, $125 \ \mu\text{L}$ of the cell suspension $(2.0 - 2.5 \times 10^3 \text{ cells/well})$ were placed in the appropriate wells and $125 \ \mu\text{L}$ of cell-free culture medium were dispensed into the peripheral wells (blanks). One plate per reference substance was prepared. The cells were incubated at 37 °C for 48-72 hours and checked to be sure that cultures were at 20 to 50% confluence at the start of exposure to the reference substance.

2.2.2.3 Reference Substance Application

To add the reference substances, $125 \ \mu\text{L}$ of culture medium containing the appropriate reference substance concentrations were added to the existing $125 \ \mu\text{L}$ of culture medium in the test wells. The cells were then incubated at 37 °C for 48 ± 0.5 hours. At the end of the exposure period, the cells were microscopically evaluated for changes in morphology and their appearance was documented (as per Visual Observation Codes in the protocol [see **Appendices B1** and **B2**]) prior to measurement of their NRU.

2.2.3 Measurement of NRU in the 3T3 and NHK Test Methods

The treatment medium was removed from the 96-well plates, the cells were rinsed with phosphate buffered saline (PBS), and 250 μ L NR dye medium was added to the wells (25 μ g NR/mL for 3T3 cells; 33 μ g NR/mL for NHK cells). The plates were then incubated (37 °C ±1 °C, 90% ±5% humidity, and 5.0% ±1% CO₂/air) for three hours. After incubation, the NR medium was removed, the cells were rinsed with PBS, and 100 μ L of the desorb solution were applied. The plates were shaken on a microtiter plate shaker for 20 to 45 minutes to extract NR from the cells and to form a homogeneous solution. The optical density (OD) of the resulting colored solution was measured (within 60 minutes of adding the desorb solution) at 540 nm ±10 nm (OD₅₄₀) in a spectrophotometric microtiter plate reader, using the blank wells as reference. Data from the plate reader were transferred to a Microsoft[®] EXCEL[®] (Microsoft Corporation, Redmond, WA, USA) spreadsheet template (hereafter know as EXCEL[®] template) designed by the SMT and the testing laboratories for statistical analyses.

2.3 Descriptions and Rationales of the 3T3 and NHK NRU Test Methods

The protocols used in Phases I, II, and III of the validation study (**Appendices B** and **C**) are modifications of the protocols reported in the *Guidance Document* (ICCVAM 2001b). The participating laboratories provided comments and recommendations during the development of these protocols. The following information is specific to the protocols used in this validation study.

2.3.1 <u>Materials, Equipment, and Supplies</u>

2.3.1.1 *3T3 Cells*

The CCL-163, 3T3 BALB/c mouse fibroblast, cell line, clone 31 from the American Type Culture Collection (ATCC), Manassas, VA, USA, was used. The 3T3 cells, an immortalized mouse fibroblast cell line, were procured from the ATCC by IIVS at passage 64. IIVS cultured the cells to expand their number and cryogenically preserved them as a pool at passage number 69. ECBC and FAL received frozen ampules of cells at passage number 69 from IIVS, propagated the cells, and cryopreserved multiple ampules of cells at a slightly higher passage number to establish their working cell banks for use throughout the study. Each laboratory determined the doubling time for the 3T3 cell line prior to NRU testing in Phase Ia as required by the protocol in **Appendix C1**. The following doubling times were reported: 18.6 hours by ECBC; 17 hours by FAL; and 17 hours by IIVS. No other doubling time measurements were made. The extent of cell confluence was monitored during the study to identify when the cultures were in exponential growth.

2.3.1.2 *NHK Cells*

A single lot of pooled donor, primary neonatal foreskin keratinocyte (NHK) cells (Clonetics[®] # CC-2507; lot # 1F0490N) from CAMBREX Bio Science Walkersville, Inc., Walkersville, MD, USA, was used throughout the validation study. Keratinocytes from other sources would be acceptable if they meet the growth requirements identified in the protocols. Each laboratory determined the doubling time for the NHK cells prior to testing in Phase Ia (as required by the protocol in **Appendix C2**). The following doubling times were reported: 21 hours by ECBC; 10 hours by FAL; and 15.8 hours by IIVS. No other doubling time measurements were made. The extent of cell confluence was monitored during the study to identify when the cultures were in exponential growth.

2.3.1.3 *Tissue Culture Materials and Supplies*

The 3T3 and NHK NRU test methods require general tissue culture materials and supplies (see **Appendices B1** and **B2** [protocols] for formulations, and concentrations of solutions and media). Both test methods used the same materials for solubility testing (**Section 2.8.1**). Freshney (2000) provides information on all aspects of cell culture, including materials, supplies, and equipment needed. The following materials were needed for both test methods:

- Trypsin (0.05%)
- PBS
- Hanks' Balanced Salt Solution (HBSS) without Ca²⁺ and Mg²⁺
- NR dye
- Glacial acetic acid
- Dimethyl sulfoxide (DMSO) [analytical grade]
- Ethanol (ETOH) [100% non-denatured for test substance preparation]
- Distilled water

2.3.1.4 *Cell Culture Materials*

Laboratory items needed include the following:

- Sterile, disposable tissue culture plasticware (e.g., 25 cm²,75-80 cm² flasks; multiwell/microtiter [96-well] plates; petri dishes) [Note: The laboratories in this study used tissue culture plasticware from various suppliers.]
- Cryogenic ampules
- Pipettes, pipettors, pipette tips
- Multichannel solution reservoirs
- Centrifuge tubes
- Microporous sterilization filters
- General plastic containers
- Glass tubes (for preparation of substance dilutions)

2.3.1.5 Equipment

Performance of the NRU tests requires a laboratory equipped with a designated cell culture area. Essential equipment for cell culture work and the NRU test methods include:

- Incubator (37 °C \pm 1 °C, 90% \pm 5% humidity, 5.0% \pm 1% CO₂/air)
- Laminar flow clean bench/cabinet (standard: "biological hazard")
- Water bath $(37 \text{ }^{\circ}\text{C} \pm 1 \text{ }^{\circ}\text{C})$
- Inverted phase contrast microscope (with 10X to 40X objectives)
- Centrifuge (capable of 220 x g)
- Laboratory balance (capable of measuring to 10 mg)

- Spectrophotometer for reading 96-well plates (i.e., microtiter plate reader) equipped with 540 nm ±10 nm filter
- Shaker for microtiter plates
- Cell counter or hemocytometer
- Pipetting aid (e.g., vacuum pipettor unit)
- Pipettes, pipettors (multi-channel and single channel, multichannel repeater pipette)
- Waterbath sonicator
- Refrigerator
- Freezer (to at least -70 °C)
- Cryostorage container (and liquid nitrogen supply)
- Magnetic stirrer
- Antistatic bar ionizer
- Personal computer
- Osmometer
- pH meter

2.3.1.6 Culture Medium

For 3T3 Cells

DMEM containing high glucose (4.5 gm/L) and supplemented with NCS, L-glutamine, penicillin, and streptomycin was used for the 3T3 cells. Heat-inactivated serum was not used in this study. Heat-inactivation of serum is often used to destroy heat-labile components such as complement factors, and microbial contaminants such as mycoplasma (Hyclone[®] 1996; Mediatech, Inc. 2006). However, some heat-labile complement factors can also be inactivated by the standard cell culture practice of warming serum-containing medium to 37 °C prior to use, and mycoplasma can be eliminated by filtering the medium (e.g., using 0.1 µm pore-size rated filters). Heating serum to 56 °C (heat-inactivation temperature) can destroy other heat-labile components can diminish the capacity of the serum to promote attachment of cells to culture vessel surfaces and to support cell growth. An additional confounding factor is that the procedure for heat-inactivation is highly precise, and deviation from the basic protocol can create additional issues such as protein denaturation and serum turbidity.

For NHK Cells

Although the contents of the NHK basal culture medium are proprietary, the formulation is based on a commercially available, non-proprietary basal medium (MCDB 153 medium formulation [Tsao et al. 1982]; e.g., MCDB 153 medium - SIGMA-ALDRICH product number #M 7403 <u>http://www.sigmaaldrich.com/sigma/datasheet/m7403dat.pdf</u>). The laboratories recommended this medium for use with the CAMBREX Clonetics[®] NHK cells because they all had access to this supplier. Other media are acceptable for NHK NRU testing if the performance standards prescribed in the media prequalification protocol are met (see **Appendix B4** and **Section 2.6.3.5**).

The serum-free culture medium used for NHK cells was Clonetics[®] keratinocyte basal medium (KBM[®]) supplemented with KBM[®] SingleQuots[®] (epidermal growth factor, insulin, hydrocortisone, antimicrobial agents, bovine pituitary extract [BPE]) and Calcium SingleQuots[®]

(calcium) [all from CAMBREX Corporation] to make keratinocyte complete growth medium. Although the keratinocyte complete growth medium is a defined serum-free medium, it contains BPE collected from bovine pituitary glands. BPE contains growth factors and hormones, and is added to serum-free medium as a mitogenic supplement. Variability in the composition of the BPE could be a factor in cell growth kinetics. However, it is suggested that the undefined BPE components could be replaced with defined growth supplements, such as insulin, epidermal growth factor, and fibroblast growth factor, without adversely affecting the cellular proliferation rates and general physiology of human keratinocytes (Life Technologies, Inc. 1997).

2.3.2 <u>Reference Substance Concentrations/Dose Selection</u>

Each laboratory weighed and dissolved the reference substances on the same day as the start of the exposure period. The highest concentration of dissolved reference substance was identified using the solubility protocol and designated as the 2X stock solution. All reference substance dilutions for an assay were serially derived from this stock solution (see *Guidance Document* for serial dilution methods).

2.3.2.1 Range Finder Test

A range finder 3T3 or NHK NRU test was performed to determine the concentrations of a reference substance to be used for the definitive (concentration-response) test (see Section 2.3.2.2). The range finder test used eight concentrations of the reference substance prepared by diluting the stock solution using log intervals to cover a large concentration range (e.g., 1:10, 1:100, 1:1000, etc.; up to eight orders of magnitude). The highest concentrations applied to the cells were 10 mg/mL for substances dissolved in culture medium and 1 mg/mL in medium for substances dissolved in DMSO, unless precluded by solubility. ETOH was not used as a solvent for any of the substances in the validation study (see Sections 2.8, 2.9, and 2.10).

If the range finder test did not produce cytotoxicity, then a second range finder test was conducted at higher concentrations (e.g., the highest concentration would be >10 mg/mL if in medium, >1 mg/mL if in DMSO) unless precluded by solubility. If the substance being tested was insoluble or poorly soluble, then more stringent solubility procedures were employed to increase the stock concentration (to the maximum concentration specified in **Appendices B1** and **B2**). If the range finder test produced a biphasic dose-response curve³ for NR uptake, the concentrations selected for the definitive tests covered the response range that included the lowest concentration that reduced viability by 50% (see Section 2.6.3.2).

2.3.2.2 Definitive Test

The concentration-response determination is referred to as the definitive test because it is used to determine the IC₅₀ value of the substance being tested. The concentration closest to the calculated IC₅₀ value in the range finder test served as the midpoint of the eight concentrations tested in the definitive test. In the absence of other information (e.g., knowledge of the slope of the toxic response), the recommended dilution factor was 1.47 ($^{6}\sqrt{10}$), which divides a log interval into six equidistant steps (e.g., 10, 14.7, 21.5, 31.6, 46.4, 68.1, 100). The *Guidance Document* considered a progression factor of 1.21 ($^{12}\sqrt{10}$) to be the

³ A biphasic dose-response curve is a dose-response in which cytotoxicity increases (as dose increases), plateaus, and then increases again.

smallest factor practically achievable, and this was the lowest required concentration interval. The PC was tested similarly to the reference substances in the definitive test and the same recommended dilution factors were used (dilution factor at the discretion of the Study Director).

A definitive test was considered successful if it met all of the test acceptance criteria outlined in the NRU protocols. Definitive tests were repeated as per the protocols if the test failed to meet all of the test acceptance criteria. **Section 2.5** addresses the basis for replicate testing.

If minimal or no cytotoxicity was observed in the range finder test, the maximum concentration for the definitive test was determined as follows:

- For Substances Prepared in NHK or 3T3 Medium: A review of the RC chemicals used in this validation study showed that, among water-soluble chemicals, glycerol had the highest reported IC₅₀ value (57 mg/mL). To capture this value, and that of other relatively non-toxic chemicals, the highest concentration of a substance applied to the cells in the definitive test was either 100 mg/mL (using 200 mg/mL 2X stock) or the maximum soluble dose if the substance was not soluble at that concentration.
- For Substances Prepared in DMSO: Based on the maximum concentration of DMSO that could be added to culture medium without causing cytotoxicity (i.e., 0.5%), the highest concentration of a substance that could be applied to the cells in the definitive test was 2.5 mg/mL. In the event that the reference substance was not soluble at this concentration, the highest soluble concentration was used.

2.3.3 NRU Endpoints Measured

2.3.3.1 *NRU and Measurement*

After cells were exposed to the reference substance or the controls (PC; VC) for 48 hours, they were washed and incubated with the NR dye at 37 °C for an additional three hours. The dye was eluted from the cells using a desorb solution and the OD of the resulting solutions were measured using a spectrophotometric microtiter plate reader. Because NR is absorbed by healthy cells, the amount of dye eluted, as measured by the spectrophotometer, is proportional to NRU and thus to the number of live cells present at culture termination. The OD data from the spectrophotometer were recorded on the EXCEL[®] template. Relative cell viability for each reference substance and the PC was determined using six replicate wells (six wells [minimum of four scorable] in the 96-well plate) per concentration. Cells treated with the VC were considered to have 100% cell viability (i.e., the mean OD of the VC wells = 100% viability). Cell viability in other test wells was computed in reference to the mean VC OD value (i.e., [well OD/mean VC OD] x 100 = % viability).

2.3.3.2 Determination of IC_{50} , IC_{20} , and IC_{80} Values

 IC_{50} values were determined from the concentration-response curve using a Hill function, which is a four parameter logistic mathematical model relating the concentration of a substance to the response (typically following a sigmoidal shape). Modifications to the Hill function used in later phases of the study are described in **Section 2.6.3**.

Data from the EXCEL[®] template were transferred to a template designed by the SMT for GraphPad PRISM[®] 3.0, a commercially available statistical software (GraphPad Software, Inc., San Diego, CA, USA – hereafter known as PRISM[®] template). The PRISM[®] template used the Hill function to calculate the IC₅₀, IC₂₀, and IC₈₀ concentrations, reported as μ g/mL of reference substance in solution. IC₂₀ and IC₈₀ data were collected for potential use in designing a prediction model for estimating human lethal blood concentrations.

2.3.4 <u>Duration of Reference Substance Exposure</u>

The SMT and laboratory representatives reevaluated the reference substance exposure duration recommended in the *Guidance Document* (ICCVAM 2001b) before initiating the study. The *Guidance Document* recommended an exposure of 24 hours for the 3T3 cells and 48 hours for the NHK cells. However, Riddell et al. (1986) showed large differences in cytotoxicity for 3T3 cells in response to some chemicals, depending on whether the exposure duration was 24 or 72 hours. Although the toxicity induced by substances that damage, for example, cell membranes is likely to be observed in a relatively shorter time, the toxic effects of substances that interfere with cell functions/processes specifically relating to DNA replication (e.g., protein and nucleic acid synthesis) and cell division (e.g., mitotic spindle formation) are more pronounced after longer exposure periods. This occurs because cells are affected only at certain phases of the cell cycle.

IIVS conducted studies to evaluate the effect of exposure durations of 24, 48, and 72 hours and of 48 and 72 hours on the sensitivity of 3T3 cells and NHK, respectively, to six chemicals selected from the list in Riddell (1986). Because the closest fit to the RC millimole regression occurred when a 48-hour exposure duration was used, this exposure duration was selected for use with both cell types in the validation study (Curren et al. 2003) (see **Appendix E**).

2.3.5 Known Limits of Use

2.3.5.1 *Solubility/Precipitation/Volatility*

In vitro test methods cannot be used for substances that cannot be dissolved in media, DMSO, or ETOH at a sufficiently high concentration to induce cytotoxicity in excess of 50%. Also, chemicals that are unstable or exothermic in water cannot be adequately tested with these *in vitro* test methods (as well as *in vivo* methods).

Precipitation of a test substance in the dosing solution or in the culture medium after the substance to be tested has been added can affect the concentration-response and thus reduce the accuracy of the calculated IC_{50} . Some reference substances used in the validation study had precipitates in their medium/DMSO 2X concentrations prior to dilution for application to the test wells. Precipitates were also observed for some substances in a number of test wells after addition of the media/DMSO 1X solutions (see Section 5.8 and Table 5-11) to the cultures and/or at the end of the exposure period.

Volatility was detected for a number of reference substances during the range finder tests by observance of cross contamination (i.e., high cytotoxicity) in VC wells. Plate sealers were used during the definitive tests to control volatility (see **Section 2.6.3** – *Testing Volatile Reference Substances*), and could be used during the range finder tests if the Study Director suspected that the reference substance might be volatile. The use of plate sealers required

additional laboratory training, and some volatile substances were difficult to test even with the use of plate sealers. Furthermore, some test substances (e.g., organic solvents) may react chemically with the plastic in the sealers.

2.3.5.2 Biokinetic Determinations

The Workshop 2000 report (ICCVAM 2001a) discussed the role of chemical biokinetics *in vivo* vis-a-vis acute toxicity, as illustrated in the following quote:

"Results obtained from *in vitro* studies in general are often not directly applicable to the *in vivo* situation. One of the most obvious differences between the situation *in vitro* and *in vivo* is the absence of processes regarding absorption, distribution, metabolism and excretion (i.e., biokinetics) that govern the exposure of the target tissue in the intact organism. The concentrations to which *in vitro* systems are exposed may not correspond to the actual situation at the target tissue after *in vivo* exposure. In addition, the occurrence of metabolic activation and/or saturation of specific metabolic pathways or absorption and elimination mechanisms may also become relevant for the toxicity of a compound *in vivo*. This may lead to misinterpretation of *in vitro* data if such information is not taken into account. Therefore, predictive studies on biological activity of compounds require the integration of data on the mechanisms of action with data on biokinetic behavior."

The 3T3 and NHK NRU test methods do not account for biokinetics.

2.3.5.3 Organ-Specific Toxicity

The Workshop 2000 report also addressed concerns about the *in vitro* prediction of organspecific toxicity, and identified the organ systems for which failure after acute exposure could lead to lethality (i.e., liver, central nervous system, kidney, heart, lung, and hematopoietic system) (ICCVAM 2001a). Each organ system was reviewed individually. Although the 3T3 and NHK NRU test methods do not assess organ-specific toxicity, they may be useful in a test method battery such as that proposed by the Workshop 2000 participants (see **Section 2.3.5.4**).

2.3.5.4 The Role of Cytotoxicity Tests in an In Vitro Battery Approach for Possible Replacement of In Vivo Acute Toxicity Testing

A five-step *in vitro* testing scheme was proposed for a test battery that may eventually be demonstrated to be an adequate replacement for rodent acute oral toxicity test methods for regulatory purposes (ICCVAM 2001a).

- Step 1: Perform a physico-chemical characterization and biokinetic modeling.
- Step 2: Evaluate basal cytotoxicity using, for example, the 3T3 or NHK NRU test methods.
- Step 3: Evaluate the potential that metabolism will mediate the basal cytotoxicity effect.
- Step 4: Assess the test substance's effect on energy metabolism.
- Step 5: Assess the ability of the test substance to disrupt epithelial cell barrier function.

The Workshop 2000 participants suggested that implementation of the 5-step testing scheme would require the following:

- Identification of the most appropriate cell culture systems to use based on accuracy, reproducibility, cost, and availability
- Development of a standardized protocol for each test method used in each of the five steps, and validation of each test method using that protocol
- Development of prediction models for the relevant human toxic levels required by regulatory agencies
- Evaluation of the test battery using substances that are appropriate for all endpoints, and then test sufficient substances to develop a prediction model
- Validation of the entire testing scheme and the prediction model

2.3.6 Basis of the Response Assessed

Neutral red is a weakly cationic, water-soluble, supravital dye that stains living cells by readily diffusing through the cell membranes and concentrating in lysosomes. The intensity of the dye desorbed from the cells in a culture is directly proportional to the number of living cells. Cell death and/or growth inhibition decreases the amount of neutral red taken up by the culture (see Section 1.3.1).

2.3.7 Appropriate Positive, Vehicle, and Negative Controls

2.3.7.1 *Positive Control*

The *Guidance Document* recommended sodium lauryl sulfate (SLS; Chemical Abstracts Service Registry Number [CASRN] 151-21-3) as an appropriate PC for *in vitro* cytotoxicity test methods (ICCVAM 2001b), and historical data are available (e.g., Spielmann et al. 1991). A PC test plate was included with every 3T3 and NHK NRU test method assay and was treated the same as any reference substance assay plate.

The historical mean PC IC₅₀, standard deviation (SD), and acceptance limits, were determined separately for each laboratory (see **Table 5-3**), based on their individual historical databases (see **Figure 1-2**). The acceptable range for the PC IC₅₀ was based on the statistical approach recommended in the *Guidance Document*. In Phase Ib, the IC₅₀ limits accepted for the PC tests were within two SD of the historical mean PC IC₅₀ value. In the Phase II studies, the IC₅₀ limits for PC tests were within 2.5 SD of the historical mean value (i.e., from Phases Ia and Ib). In Phase III, the IC₅₀ limits used for the PC were within 2.5 standard deviations of the mean PC IC₅₀ from Phases I and II. The exception to this was the FAL NHK data, where only the Phase II data were used as the basis for establishing the acceptable PC range. The SLS data produced by FAL during Phase I was not used in subsequent historical database compilations because FAL used a modified cell culture protocol in Phase II (see **Section 2.6.2.6**).

2.3.7.2 Vehicle Control

The VC consisted of complete DMEM (see **Appendix B1**) for 3T3 cells and complete growth medium (Clonetics[®] KBM[®] with supplements [see **Appendix B2**]) for NHK cells when the reference substances were dissolved in culture medium. For reference substances dissolved in DMSO, the VC consisted of medium with the same amount of DMSO (0.5% [v/v]) as was applied to the 96-well test plate.

2.3.7.3 Negative Control

Negative control cultures (i.e., those that were not exposed to the solvent) were not used in this validation study. Neither DMSO, at the concentration used, nor the culture medium affected the performance of the 3T3 and NHK NRU test methods.

2.3.8 <u>Acceptable Ranges of Control Responses</u>

The *Guidance Document* established an absolute value (i.e., uncorrected for blank absorbance) range of the OD₅₄₀ for the VC to indicate whether the cells seeded in the 96-well plate had grown with a normal doubling time during the assay. A mean OD₅₄₀ \geq 0.3 was recommended as the acceptable range of VC responses and was made a test acceptance criterion for both cell types at the start of the study. However, prior to Phase II, this was rescinded as a test acceptance criterion. The protocols for Phases II and III provide a range of OD values for use as guidance in future studies with these test methods (**Table 2-1**).

| Laboratory | Phase Ia | Phase Ib | Phase II | Phase III | | | | | |
|---------------------------|----------------------|--------------------------------------|--------------------------|----------------------------|--|--|--|--|--|
| 3T3 NRU Test Method | | | | | | | | | |
| Target Range ² | $0.3 \le OD \le 1.1$ | $0.30 \le \text{OD} \le 0.80$ | $0.103 \le OD \le 0.813$ | 0.103≤ OD ≤0.813 | | | | | |
| ECBC | 0.326 - 0.457 | 0.214 - 0.839 | 0.217 - 0.730 | 0.191 - 0.797 | | | | | |
| FAL | 0.490 - 0.780 | 0.247 - 0.742 | 0.289 - 0.768 | 0.126 - 1.161 | | | | | |
| IIVS | 0.336 - 0.538 | 0.319 - 0.598 | 0.307 - 0.578 | 0.256 - 0.544 | | | | | |
| | | NHK NRU Test Me | ethod | | | | | | |
| Target Range ² | $0.3 \le OD \le 1.1$ | $0.60 {\leq} \text{OD} {\leq} 1.70$ | $0.35 \leq OD \leq 1.50$ | $0.205 \leq OD \leq 1.645$ | | | | | |
| ECBC | 0.863 - 2.312 | 0.788 - 1.282 | 0.139 - 1.175 | 0.114 - 1.344 | | | | | |
| FAL | 0.484 - 1.698 | 0.146 - 1.706 | 0.110 - 1.292 | 0.183 - 1.347 | | | | | |
| IIVS | 0.550 - 1.883 | 0.487 - 1.001 | 0.201 - 0.841 | 0.430 - 0.834 | | | | | |

Table 2-1Measured VC OD540 Values1 and Targets

Abbreviations: VC=Vehicle control; OD₅₄₀=Optical density at 540 nM; 3T3=BALB/c 3T3 fibroblasts; NRU=Neutral red uptake; NHK=Normal human epidermal keratinocytes; ECBC=Edgewood Chemical Biological Center; FAL=Fund for Replacement of Animals in Medical Experiments Alternatives Laboratory; IIVS=Institute for *In Vitro* Sciences. ¹Lowest to highest OD values for tests that meet test acceptance criteria.

²Ranges used for all laboratories. Ranges for Phases Ia and Ib were test acceptance criteria. Ranges for Phases II and III were used as target ranges, rather than as test acceptance criteria.

In Phase III, 99.5% (914/919) of all 3T3 mean VC OD values and 97% (913/944) of all NHK mean VC OD values were within the target ranges. Most OD values outside the ranges were from range finding tests and were usually the result of volatile reference substances affecting the VC cells adjacent to the highest reference substance concentration wells.

The VC OD values had a tendency to be lower in Phases II and III as compared to Phases Ia and Ib. Protocol revisions made throughout Phases Ia, Ib, and II (as listed below) most likely contributed to the differences in the OD values. Possible explanations for changes in OD values for the 3T3 cells include:

- Some tests in Phases Ia and Ib exhibited NR crystals that caused higher OD readings.
- Cell seeding densities were revised from 2.5×10^3 cells/well to a range of $2.0 3.0 \times 10^3$ cells/well.

Possible explanations for changes in OD values for the NHK cells include:

- The minimum percent confluence of cells necessary before the reference substance could be applied was reduced from 30% to 20% confluence.
- Cell growth was reduced in some tests in the later study phases as a result of medium and supplement issues (e.g., certain lots of basal medium and medium supplements for NHK cells did not provide optimum growth conditions for the keratinocytes).

2.3.8.1 *Vehicle Controls as a Quality Control Tool*

To check for systematic cell seeding errors and reference substance volatility, VCs were placed both at the left side (row 2) and the right side (row 11) of the 96-well plate (see **Figure 1** in **Appendix B1**). Volatile reference substances generally affected the left side VC, which was next to the highest reference substance concentration in the 96-well plate. The test acceptance criterion for the VC was that the means for the left and the right set of VCs had to be within 15% of the mean of all VCs. This criterion, which was adopted from the protocols in the *Guidance Document* (ICCVAM 2001b), was used for reference substances and the PC in all phases of the validation study.

2.3.9 <u>Nature of Experimental Data Collected</u>

Each laboratory maintained a study workbook to document all aspects of the study and included the raw data for all steps of each assay (e.g., cell growth, test substance treatment, weighing and dilution of reference substances), as well as for all solubility studies.

2.3.9.1 NRU OD Measurements

At the conclusion of the NRU desorb step, the OD of the resulting colored solution in each well of the 96-well plates was measured at 540 ± 10 nm in a spectrophotometric microtiter plate reader. Each laboratory followed its in-house Standard Operating Procedure (SOP) for use of the microplate readers. These SOPs included instructions for operation and calibration of the instruments. Critical specifications such as alignment, accuracy, reproducibility, and linearity were included as standard parameters for review and routine calibration. Raw OD data from the plate reader was electronically transferred to the EXCEL[®] template. The template converted the raw data from each treatment well (six wells/reference substance concentration) to derived data by subtracting the mean blank OD value (two blank wells/reference substance concentration) from each reference substance well OD. There were 12 VC wells and 20 associated blank wells. The corrected VC OD values were used to calculate the mean VC OD, which was then used to calculate relative viability (% of mean VC OD) in each test well for the reference substance or PC. The percent viability values were then transferred to the PRISM[®] template to calculate the IC₂₀, IC₅₀, and IC₈₀ values.

2.3.9.2 Information and Data Collected

Originals of the raw data (i.e., the Study Workbook and computer printouts of absorbance readings from the plate reader) and copies of other raw data, such as instrument logs, were collected and archived under the direction of the Study Director according to Good Laboratory Practice (GLP)-compliant procedures.

The Study Director/technicians entered the following information into the EXCEL[®] template:

• Testing identification for: test facility, chemical code, study number, 96-well plate number, experiment number

- Reference substance preparation: solvent used, solvent concentration in dosing solutions, highest stock concentration, dilution factor, pH of 2X dosing solutions, medium clarity/color, presence/absence of precipitate in 2X solutions, PC concentration range
- Cell line/type: cell supplier, lot number, cryopreserved passage number, passage number in assay
- Cell culture conditions: medium, supplements, suppliers and lot numbers, serum concentrations
- Timeline: dates of cell seeding, dose application, OD₅₄₀ determination
- Raw data: OD values from each well from the microtiter plate reader
- Test results: mean corrected OD_{540} value, Hill function R^2 value, logs of IC_{20} , IC_{50} , and IC_{80} (PRISM[®] template presents data as logs of the IC_x ; EXCEL[®] converts values to $\mu g/mL$)
- Test acceptance criteria: acceptable number of values on each side of the IC₅₀ (i.e., number of points >0 and \leq 50% viability, and >50 and <100% viability), acceptable percent difference for the VCs, acceptable Hill function R² value (coefficient of determination) and calculated IC₅₀ concentration for the PC
- Visual observations: protocol codes for cell culture conditions for all reference substance concentrations (i.e., relative level of cell cytotoxicity, cell morphology, presence of precipitate)

2.3.10 Data Storage Media

Raw and derived data from the NRU tests were saved in the EXCEL[®] template file format provided by the SMT. All EXCEL[®] and PRISM[®] files were copied and transferred to compact disks. NICEATM and the laboratories printed copies of all data sheets (stored at NICEATM and at the testing facilities), and included copies in the laboratories' final reports.

2.3.11 <u>Measures of Variability</u>

Each 96-well plate used in the NRU tests had three main measures of variability.

- Each plate contained VCs on each end of the plate (columns 2 and 11) (see Figure 1 in Appendix B1 for plate map). The difference between the mean NRU OD for each VC column and mean of the pooled VC wells was used as a test acceptance criterion. The Study Director rejected the test if the difference was greater than 15%, which indicated cross-contamination from a volatile substance or possible cell seeding errors.
- A mean relative viability was determined for each concentration of the substance tested along with the SD and coefficient of variation (%CV=SD/mean x 100).
- 3) Macros were included in the EXCEL[®] template to perform an outlier test (Dixon and Massey 1981) on the data for the six replicate wells for each concentration. Outliers (i.e., individual well values that exceeded the 99% confidence interval [CI] for the replicate wells) were highlighted and could be excluded from the resulting analysis to improve curve fit. The Study Director made the decision as to whether or not to remove outliers and provided a justification for the decision.

Other test-to-test measures of variability were considered in this study.

- Each set of assays for reference substances included a PC plate. If the SLS PC test did not meet test acceptance criteria, then the tests for the associated reference substances were rejected. The SMT recommended testing a manageable number of definitive test plates (e.g., 4 to 6) with each PC to limit the number of definitive NRU tests rejected for PC failure. In this validation study, 4.2% of all definitive tests performed were rejected because the PC failed (i.e., the PC IC₅₀ was outside the acceptable confidence limits).
- SDs and CVs were determined for mean IC_{50} values from replicate tests. Replicate testing included three definitive tests for each reference substance, each performed on a different day.

2.3.12 <u>Methods for Analyzing NRU Data</u>

Relative cell viability for each reference substance concentration was calculated using the ODs of the six replicate values (minimum of four acceptable replicate wells) per test concentration. Relative cell viability was expressed as a percentage of the mean VC OD. Absolute OD data from the microtiter plate reader was transferred to the EXCEL[®] template for performance of these calculations. Where possible, the concentration range (eight concentrations) tested for each reference substance ranged from no effect to 100% toxicity.

The IC_{20} , IC_{50} , and IC_{80} values were determined from the concentration-response curve using the PRISM[®] template and applying a Hill function to the % viability data. The IC_{20} and IC_{80} values were calculated for potential use in the development of a human prediction model (reported elsewhere).

2.3.13 Decision Criteria for Classification of Reference Substances

The 3T3 and NHK NRU test methods will not be used to classify reference substances in hazard categories but rather to aid in setting the starting dose for sequential rodent acute oral toxicity test methods (i.e., the UDP and ATC) (see Section 10 for an analysis of the estimated animal savings). The RC millimole regression procedure was used to predict a rodent LD_{50} value from an NRU IC₅₀ value. Section 6.3 addresses the accuracy of the 3T3 and NHK NRU test methods for predicting GHS hazard categories when used with IC₅₀-LD₅₀ regressions, calculated using a subset of the RC data (i.e., substances with rat oral LD₅₀ data).

2.3.14 Information and Data Included in the Test Report

Test and Control Substances

With the exception of the PC, the laboratories tested coded substances and had minimal information about the test substances' properties (see **Section 3.3** for the reference substance information provided to the laboratories). The following describes the test and test substance information that should be included in an NRU test method report.

- Chemical name(s) and synonyms, if known
- The CASRN, if known
- Formula weight, if known
- Purity and composition of the substance or preparation (in percentage[s] by weight)
- Physicochemical properties (e.g., physical state, volatility, pH, stability, chemical class, water solubility)

• Solubilization of the test/control substances (e.g., vortexing, sonication, warming, grinding) prior to testing, if applicable

Information Concerning the Sponsor and the Test Facility

- Name and address of the sponsor, test facilities, study director, and participating laboratory technicians
- Justification of the test method and specific protocol used

Test Method Integrity

The procedure used to ensure the integrity (i.e., accuracy and reliability) of the test method over time (e.g., use of the PC data)

Criteria for an Acceptable Test

- Acceptable VC differences between each column of wells and the mean of both columns
- Acceptable concurrent PC ranges based on historical data (include the summary historical data)
- Number of toxic points on either side of the IC₅₀ (i.e., number of points >0 and \leq 50% viability and >50 and <100% viability)

Test Conditions

- Experiment start and completion dates
- Details of test procedures used
- Test concentration(s) used and how they were derived
- Cell type used and source of cells
- Description of modifications made to the test procedure
- Reference to historical data of the test model (e.g., solvent and PCs)
- Description of the evaluation criteria used

Results

• Tabulation of data from individual test samples (e.g., IC₅₀ values for the reference substance and the PC, absolute and derived OD readings, reported in tabular form, including data from replicate repeat experiments as appropriate, and the means and standard deviations for each experiment)

Description of Other Effects Observed

• Cell morphology, precipitate, NR crystals, etc.

Discussion of the Results

Conclusion

Quality Assurance (QA) Statement for GLP-Compliant Studies

• A statement describing all inspections and other QA activities during the study, and the dates results were reported to the Study Director. This statement will also serve to confirm that the final report reflects the raw data.

During the validation study, the GLP-compliant laboratories, IIVS and ECBC, followed additional reporting requirements provided in the relevant GLP guidelines (e.g., OECD 1998; EPA 2003a, b; FDA 2003).

The SMT and laboratories developed standard forms for data collection (i.e., EXCEL[®] and PRISM[®] templates). The solubility test form was derived from a standard form provided by IIVS. The EXCEL[®] template was an adaptation of a template format presented in the *Guidance Document* (ICCVAM 2001b).

2.4 Proprietary Components of the *In Vitro* NRU Test Methods

The only proprietary components used in these test methods are the NHK cells and the NHK basal culture medium obtained from CAMBREX Clonetics[®]. All other components are readily available through various scientific product suppliers.

Section 2.3.1.2 describes the NHK cells used in the study and provides the only commercial source. All laboratories throughout the entire study used cells from the same lot. Procedures used to verify the integrity of the NHK cells included comparison of positive control data across laboratories and observations of cell growth throughout the study. If a laboratory reported a problem with the cells, the SMT and Study Directors evaluated the testing parameters to decide if the problem was cell-oriented or if other factors influenced the problem. **Section 2.6.3.5** provides information concerning the resolution of cell-related issues and revisions made to the protocols to address such difficulties.

Section 2.10.1.1 and Appendices B2 and B4 provide information about the NHK growth medium, supplements, and commercial source. Problems arose with the keratinocyte growth medium during the study and resolutions and outcomes are addressed in Sections 2.6.3.5, 2.6.3.6, 5.3.4, and 11.1.2.2.

Although this study used proprietary components for the NHK NRU test method, cells and medium from the commercial source used in the study are not required for implementation of this test method.

2.5 Basis for the Number of Replicate and Repeat Experiments for the 3T3 and NHK NRU Test Methods

The study protocols required each laboratory to test each coded reference substance in at least one range finding test using a log dilution factor, and in at least three definitive tests on three different days using a smaller dilution factor than used in the range finding test. Assays were performed over a number of days to evaluate day-to-day variation. Laboratories tested each coded reference substance until three definitive tests met the test acceptance criteria. Additional testing was often dictated by:

- Chemical issues (low toxicity, volatility, insolubility, and precipitation)
- PC failure
- Technical difficulties such as NR crystal formation

A stopping rule for insoluble reference substances was incorporated into the protocols for Phase III to limit the number of retests (see **Appendices B1** and **B2**):

"If the most rigorous solubility procedures have been performed and the assay cannot achieve adequate toxicity to meet the test acceptance criteria after three definitive tests, then the Study Director may end all testing for that particular chemical."

2.6 Basis for Modifications to the 3T3 and NHK NRU Test Method Protocols

2.6.1 <u>Phase Ia: Laboratory Evaluation Phase</u>

All protocol revisions were implemented during Phase Ia unless otherwise stated.

2.6.1.1 NR Dye Crystals

NR dye crystals formed in the 96-well test plates when used at 50 μ g/mL (OD values measured in the blanks increased from ~ 0.05 to 0.10) in both NRU test procedures. Troubleshooting efforts included incubating the NR medium overnight; centrifuging and filtering the NR medium prior to application to the 96-well plates; and reducing the concentration of NR dye. The laboratories performed tests using a reduced NR concentration of 33 μ g/mL. Since there were no quantitative differences in results between tests with 50 μ g/mL and tests with 33 μ g/mL NR, the SMT accepted tests with both concentrations.

Protocol Revision: The NR dye concentration was reduced to 33 μ g/mL for both cell types in subsequent test Phases.

2.6.1.2 *3T3 Cell Growth*

The growth rate of 3T3 cells (as determined by monolayer confluence) was slower than expected. As a result, the cells required more time in culture to obtain the proper density after seeding.

Protocol Revision: The 3T3 cells must be passaged 2-3 times after thawing before being used for the test. The protocol also emphasized attainment of the appropriate percentage of cell confluence (not more than 50% for 3T3 cells) required at the time the cells were exposed to the reference substance, rather than using the time in culture as the guide.

2.6.1.3 NHK Cell Growth

The NHK cells had an additional growth problem that manifested as a ring of dead/dying cells around the center of the wells. Troubleshooting efforts included evaluating various brands of 96-well plates (laboratories were not required to use the same brand of plates) and eliminating the change of medium prior to reference substance treatment. All laboratories participated in evaluating the effect of changing (i.e., refeeding) or not changing (i.e., no refeeding) the medium by performing a small study with the PC (SLS). Tests were performed: 1) after refeeding the cells with fresh medium, and 2) by adding SLS to the medium already on the cells. Control ODs were generally higher in the tests in which the medium was not replenished, but sensitivity to SLS was generally unchanged (see **Table 2-2**). FAL was experiencing difficulties in NHK cell growth at this stage of the study which may account for the difference in the refeeding and no refeeding SLS IC₅₀ values. The SMT accepted tests with refeeding and those without refeeding (for Phase Ia) as long as they met the test acceptance criteria.

IIVS presented detailed information on the ring of dead cells issue (Raabe 2004). The laboratory showed that the ring of cell death coincided with the formation of a meniscus resulting from the residual medium left in the well after removal of the spent medium. The problem was resolved by eliminating the removal of medium before applying test chemical rather than requiring a standard brand of 96-well plates.

Protocol Revision: Step 2 of the NHK NRU test method was eliminated (change of medium prior to addition of reference substance). The volume of medium (with cells) was changed from 250 μ L/well to 125 μ L/well.

| | EC | BC | II | VS | FAL | | |
|--|-----------------|-----------------|-------------------|------------------|-----------------|------------------|--|
| | Refeed | No Refeed | Refeed | No Refeed | Refeed | No Refeed | |
| Number of Test Plates | 4 | 4 | 6 | 6 | 2 | 4 | |
| Absolute OD ¹ for VC | 0.265 ±0.151 | 0.621 ±0.322 | 0.885 ± 0.057 | 1.12 ± 0.033 | 1.41 ±0.127 | 1.24 ± 0.430 | |
| OD ¹ for SLS IC ₅₀ | 0.102 ±0.079 | 0.282 ±0.165 | 0.415 ±0.029 | 0.533 ±0.017 | 0.696 ±0.065 | 0.606 ±0.217 | |
| SLS IC ₅₀ $(\mu g/mL)^1$ | 3.33 ±0.47 | 3.23 ±0.61 | 3.41 ±0.58 | 3.49 ±0.39 | 6.21 ±0.88 | 8.14 ±0.40 | |

Table 2-2 Refeeding/No Refeeding Data for the NHK NRU Test Method

Abbreviations: NHK=Normal human epidermal keratinocyte; NRU=Neutral red uptake; ECBC=Edgewood Chemical Biological Center; IIVS=Institute for *In Vitro* Sciences; FAL=Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory; VC=Vehicle control; OD=Optical density; SLS=Sodium lauryl sulfate. Note: OD values for SLS IC₅₀ were extrapolated from the concentration-response curve data

¹Mean \pm standard deviation (uncorrected for blank absorbance

FAL, in contrast to the other two laboratories, used 80 cm² culture flasks for culturing the thawed cells from the ampules of cryogenically-preserved pool of cells and encountered difficulties in obtaining a satisfactory number of adhering NHKs.

Protocol Revision (FAL only): Culture flasks were coated with fibronectin-collagen to promote cell adherence.

2.6.1.4 *Vehicle Control OD Limits*

In Phase I, the acceptable range of VC OD values designated in the protocols $(0.3 \le \text{OD} \le 1.1)$ were frequently unattainable in both test methods. Despite this, the Study Directors reported that the cells were adequately responsive. The SMT withdrew the VC OD limits as a test acceptance criterion.

Protocol Revision for Phase Ib: OD ranges were provided as guidelines for each cell type based on OD data from all laboratories, a review of the concentration-response data, and the ability of each test to pass the other test acceptance criteria. Each laboratory developed its own VC OD acceptability range based on its historical data.

2.6.1.5 *Precipitate Formation*

During solubility testing, it was observed that some substances, when tested at the same concentrations, precipitated in the 3T3 medium but not in the NHK medium. When a liquid reference substance (i.e., 2-propanol) produced this effect, the precipitate was attributed to the protein in the serum in the 3T3 medium rather than insolubility.

Protocol Revision: The reference substances were dissolved in 3T3 medium without NCS to make the 2X solutions. The dissolved 2X reference substance was added to medium containing 10% NCS to reach the final 5% NCS and 1X reference substance concentrations.

2.6.1.6 Dilution Factor

After a range finder test was performed, the definitive tests were to be performed using a $^{6}\sqrt{10}=1.47$ dilution scheme centered on the IC₅₀ that was calculated from the range finder. In Phase Ia, the Study Directors, for various reasons related to the specific substance being

tested, sometimes deviated from this requirement and used other dilution factors. The SMT agreed that the dilution factor requirements should be modified to allow more flexibility in setting up tests. The SMT accepted data generated using dilution factors other than the recommended 1.47 for definitive tests if all other test acceptance criteria were met. The use of smaller dilution factors generally increased the number of concentrations in the 10% to 90% viability range, which improved the precision of the IC₅₀ calculation.

Protocol Revision: The $^{6}\sqrt{10}=1.47$ dilution scheme was a suggested starting range, rather than a specific test acceptance criterion in subsequent test Phases.

2.6.1.7 *Test Acceptance Criteria*

The test acceptance criteria at the beginning of Phase Ia were:

- The IC₅₀ for SLS had to be within the 95% CI of the historical PC mean established by the Test Facility (*rescinded after commencement of Phase Ia*)
- The OD₅₄₀ of the VCs (with blank subtracted) had to be ≥ 0.3 and ≤ 1.1 (*rescinded after commencement of Phase Ia*)
- Mean OD values of the left and right VCs (columns 2 and 11 in the 96-well test plate) must not differ by more than 15% from the mean of all VC OD values
- At least two cytotoxicity values, one on either side of the IC₅₀ but between 10% and 90% viability, needed to be present (*added after commencement of Phase Ia*)
- The Hill function curve fits ($R^2 > 0.9 \text{ or } 0.8 < R^2 < 0.9$) were evaluated on a case by case basis for acceptability by the SMT (*added after commencement of Phase Ia*).

2.6.2 <u>Phase Ib: Laboratory Evaluation Phase</u>

All protocol revisions developed during Phase Ia were implemented during Phase Ib unless otherwise stated.

2.6.2.1 NR Crystal Formation

FAL and ECBC routinely observed NR crystals forming in the 96-well test plates in the 3T3 NRU tests when 33 µg/mL NR was used. All laboratories tested 25 and 33 µg/mL NR concentrations and 2- and 3-hour NR incubation periods to determine which NR concentration and incubation period would provide optimal NRU measurements without crystal formation. In addition to determining whether NRU had reached a plateau at these concentrations and incubation times, the laboratories also determined whether the response to SLS differed under these conditions. Crystals were observed only at 33 µg/mL NR when present for three hours. **Figure 2-2** shows that the average OD results were similar for all NR concentrations and incubation periods tested. **Figure 2-3** shows that the SLS IC₅₀ values were equivalent at the different NR concentrations and incubation periods. To minimize changes to the 3T3 protocol, the NRU concentration was lowered from 33 to 25 µg/mL, while the NR incubation period was maintained at three hours. The NR concentration and the incubation period was maintained at 33 µg/mL and three hours, respectively.

Protocol Revision for Phase II: The NR concentration for the 3T3 NRU test method was reduced to $25 \ \mu$ g/mL for the three-hour incubation period. Revised methods for preparation

of the NR dye solution included filtration of the solution, maintenance of the solution at 37 °C prior to application to the cells, and application of the NR solution to the cells within 15 minutes after removing it from 37 °C. Also, cells were observed during the NR incubation period to monitor possible crystal formation.

2.6.2.2 Heating of Reference Substance Solutions

The laboratories had difficulty solubilizing arsenic trioxide, one of the reference substances used in Phase Ib. Heating and mechanical applications for increasing the laboratory's ability to solubilize substances into culture medium were reviewed and revised.

Protocol Revision for Phase II: The duration range for heating a stock solution at 37 °C (if heating is needed) was increased from 5 to 10 minutes to 5 to 60 minutes.





Figure 2-2 3T3 NRU OD for SLS as a Function of NR Concentration and Duration

Abbreviations: OD=Optical density; NR=Neutral red; SLS=Sodium lauryl sulfate; 3T3=BALB/c 3T3 fibroblasts; NRU=Neutral red uptake; h=Hours. Note: Error bars are one standard deviation.

Figure 2-3 SLS IC₅₀ Values for Each NR Concentration and Incubation Duration (3T3 NRU)



Abbreviations: SLS=Sodium lauryl sulfate; IC_{50} =Test substance concentration that reduces cell viability by 50%; NR=Neutral red; 3T3=BALB/c 3T3 fibroblasts; NRU=Neutral red uptake; ECBC=Edgewood Chemical Biological Center; IIVS=Institute for *In Vitro* Sciences; FAL=Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory.

Note: SLS range is mean IC_{50} value \pm one standard deviation.

Protocol Revision for Phase II: The duration range for heating a stock solution at 37 °C (if heating is needed) was increased from 5 to 10 minutes to 5 to 60 minutes.

2.6.2.3 Growth of Untreated Cells

VC OD values were frequently lower than specified in the Phase I acceptance criteria. Phases Ia and Ib incorporated the acceptance limits shown in **Table 2-1** for the VC, but the limits were rescinded as test acceptance criteria for Phase II because the laboratories frequently failed to meet them even though cell growth and responsiveness to SLS was adequate.

Protocol Revision for Phase II: The specified VC OD range was eliminated as a test acceptance criterion. The OD data (all laboratories combined) from the VCs for both cell types was used to calculate OD ranges that would serve as guidelines for other tests (see **Section 2.2.9).**

2.6.2.4 Correction of Reference Substance OD Values

Each reference substance concentration was applied to six treatment wells and to two cellfree wells (i.e., blank wells) used to generate the background OD_{540} values to adjust for potential interference with the NR dye. The mean blank well OD (absolute OD) for each reference concentration was subtracted from the reference substance concentration ODs to provide the corrected OD for each replicate well.

2.6.2.5 Laboratory Error Rates

The SMT determined the Phase 1b error rates (number of tests with errors/total number of tests conducted) for each laboratory (**Table 2-3**) and compiled a list of the types of errors encountered. The vast majority of errors were transcriptional and typographical errors in the data sheets provided to the SMT.

Table 2-3Error Rates1 in Phase Ib by Laboratory and Test

| Laboratory | NRU Test Method | | | | | |
|------------|-----------------|-------------|--|--|--|--|
| v | 3T3 | NHK | | | | |
| ECBC | 1/9 (10%) | 4/17 (23%) | | | | |
| FAL | 42/45 (93%) | 12/29 (41%) | | | | |
| IIVS | 1/20 (5%) | 1/20 (5%) | | | | |

Abbreviations: NRU=Neutral red uptake; 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; ECBC=Edgewood Chemical Biological Center; FAL=Fund for the Replacement of Animals In Medical Experiments Alternatives Laboratory; IIVS=Institute for *In Vitro* Sciences

Note: Most errors were transcriptional and typographical and not technical.

¹Number of tests with errors/total number of tests (some data files had more than one error)

2.6.2.6 Resultant Protocol Changes for Phase II

Following the completion of Phases Ia and Ib, IIVS sponsored a weeklong laboratory training exercise for the cytotoxicity testing laboratories to help standardize the level of training among the technical staff and to identify any further 3T3 and NHK NRU protocol revisions that might be needed. Protocol revisions made because of this exercise included:

- Multi-channel repeater pipettes can be used for dispensing cells into the 96well plates and dispensing plate rinse solutions, NR medium, and desorb solution but are not accurate enough to dispense the PC or the reference substances to the treatment wells.
- Use of 8-channel reservoirs for applying dosing solutions to the wells so that multi-channel single delivery pipettes could be used
- Use of a standardized length of time that the HBSS rinse remains on the cell monolayers in flasks during the cell subculture step
- Protection of plates from light during the shaking step for NR extraction; all laboratories will cover plates with a light-impermeable barrier (e.g., aluminum foil) during this step
- Allow plates to stand for at least five minutes after the shaking step is complete and eliminate any bubbles in media observed in the wells before measuring the OD
- Change the allowable seeding density range for 3T3 NRU test method from 2.5×10^3 cells/well to $2 3 \times 10^3$ cells/well
- Change the NHK culture flask size used at FAL for start-up of cryopreserved cells from 80 cm² to 25 cm² (the size the other laboratories had been using), and discontinue using a fibronectin-collagen coating.

2.6.2.7 *Test Acceptance Criteria*

The test acceptance criteria were revised as follows:

- The IC₅₀ for SLS (PC) should be within 2 SDs (approximately 95%) of the historical mean established by each laboratory in Phase Ia.
- The mean OD values of the left and right VCs (columns 2 and 11 in the 96well test plate) should not differ by more than 15% from the mean of all VC OD values on that plate.
- At least one calculated cytotoxicity value should be between 10% and 50% viability, and one value between 50% and 90% viability.
- The Hill function curve fit ($R^2 > 0.9$ or $0.8 < R^2 < 0.9$) should be evaluated on a case-by-case basis for acceptability by the SMT.
- VC OD criteria were based on Phase Ia data (mean ± two SDs): 0.3 to 0.8 for the 3T3 test method, and 0.6 to 1.7 for the NHK NRU test method (requirement for use of VC OD criteria as test acceptance criteria was rescinded after commencement of Phase Ib)

2.6.3 <u>Phase II: Laboratory Qualification Phase</u>

All protocol and acceptance criteria revisions were implemented during Phase II unless otherwise stated.


2.6.3.1 *Testing of Volatile Reference Substances*


When 2-propanol was tested in 3T3 and NHK cells, vapors from the highest concentration wells contaminated the adjacent VC wells and also appeared to affect some lower concentration wells (i.e., the wells exhibited unexpectedly reduced levels of NRU). An example range finder concentration-response curve is shown in **Figure 2-4**. Such tests failed the VC criterion. When lower concentrations were used to avoid contaminating the VC wells adjacent to the highest concentration, the toxicity was inadequate to produce an IC₅₀. To address this problem, IIVS repeated their tests using film plate sealers, which isolated individual wells from one another; this was sufficient to prevent the cross-well contamination, and acceptable results were obtained. Based on these data, the SMT recommended to the other two laboratories that film plate sealers be used when testing 2-propanol.

FAL had previous experience layering mineral oil on the culture media in a well to prevent volatile substances from escaping, and provided 2-propanol test data where mineral oil had been added to each well. The data showed that the average oil vs. film IC_{50} values were not significantly different. However, there was less variability in the NRU data when using the film sealer so the SMT recommended this methodology.

A >15% difference between the mean VC OD of all VC cells and the mean OD of each VC columns on opposite ends of the test plate was used as a general indicator of substance volatility in the test if the VC adjacent to the highest test concentration had a significantly reduced OD value.

Protocol Revision: The SMT included the use of film sealers in the Phase III protocols when testing suspected volatile compounds.





| 96-WELL | PLATE MAP |
|---------|-----------|
| JO WELL | |

| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
|---|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Α | Blank |
| В | Blank | VC1 | C1 | C2 | C3 | C4 | C5 | C6 | C7 | C8 | VC2 | Blank |
| С | Blank | VC1 | C1 | C2 | C3 | C4 | C5 | C6 | C7 | C8 | VC2 | Blank |
| D | Blank | VC1 | C1 | C2 | C3 | C4 | C5 | C6 | C7 | C8 | VC2 | Blank |
| Е | Blank | VC1 | C1 | C2 | C3 | C4 | C5 | C6 | C7 | C8 | VC2 | Blank |
| F | Blank | VC1 | C1 | C2 | C3 | C4 | C5 | C6 | C7 | C8 | VC2 | Blank |
| G | Blank | VC1 | C1 | C2 | C3 | C4 | C5 | C6 | C7 | C8 | VC2 | Blank |
| Н | Blank |

CORRECTED ABSORBANCE (Sample OD₅₄₀ - Mean Blank OD₅₄₀)

| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
|---|--------|--------|--------|--------|-------|--------|--------|--------|--------|--------|--------|--------|
| А | 0.000 | -0.002 | -0.001 | -0.001 | 0.000 | -0.003 | 0.001 | 0.002 | 0.002 | -0.001 | -0.002 | -0.003 |
| В | 0.002 | 0.080 | -0.001 | 0.070 | 0.124 | 0.206 | 0.296 | 0.389 | 0.291 | 0.301 | 0.343 | 0.002 |
| С | -0.001 | 0.067 | 0.004 | 0.059 | 0.109 | 0.171 | 0.284 | 0.334 | 0.237 | 0.308 | 0.337 | -0.004 |
| D | 0.003 | 0.058 | 0.003 | 0.056 | 0.110 | 0.163 | 0.243 | 0.271 | 0.246 | 0.251 | 0.283 | 0.002 |
| Е | 0.003 | 0.077 | 0.001 | 0.067 | 0.106 | 0.092 | 0.218 | 0.252 | 0.328 | 0.250 | 0.290 | 0.003 |
| F | -0.004 | 0.068 | -0.002 | 0.050 | 0.110 | 0.164 | 0.216 | 0.289 | 0.336 | 0.267 | 0.281 | -0.001 |
| G | -0.004 | 0.071 | 0.003 | 0.053 | 0.122 | 0.147 | 0.204 | 0.226 | 0.263 | 0.295 | 0.330 | -0.003 |
| Н | 0.004 | 0.000 | 0.001 | 0.001 | 0.000 | 0.003 | -0.001 | -0.002 | -0.002 | 0.001 | 0.001 | -0.002 |

Abbreviations: 3T3=BALB/c 3T3 fibroblasts; VC=Vehicle control; C1 to C8=Test substance concentrations (C1-highest concentration, C8-lowest concentration); OD₅₄₀=Optical density at 540 nm; A to H=Row identification.

Note: %Difference of the two VC columns from the average VC was 63%. The mean corrected optical density (OD) for VC1, adjacent to the highest 2-propanol concentration, was 0.070, while that for VC2, adjacent to the lowest 2-propanol concentration, was 0.310. Setting the mean VC OD to 100% viability shifted the toxicity curve such that lower concentrations of 2-propanol seemed to be less toxic to the cells than the VCs (i.e., >100%).


Error bars are ± 1 standard deviation.

2.6.3.2 Atypical Concentration-Responses

Atypical concentration-responses are defined for this study as response curves that differ from a basic sigmoidal shaped curve. Curves that show a biphasic response as well as those that exhibited a plateau-like response at toxicity levels than 100% were considered atypical.

Two of the laboratories observed biphasic concentration-responses in the range finder tests for aminopterin and colchicine. When the range finder tests produced a biphasic response (see **Figure 2-5** for an example), the SMT advised the laboratories to focus the definitive tests on the lowest concentrations that produced at least a 50% loss in viability. Although doing so eliminated the biphasic response in the definitive tests, the highest tested concentrations did not reduce cell viability to 0% (see **Figure 2-6**). This effect with colchicine was very reproducible across laboratories in the NHK NRU test, but only FAL achieved this biphasic type of response with colchicine in the 3T3 NRU test. Aminopterin produced similar concentration-responses in the NHK NRU test at ECBC and FAL, but not at IIVS. In the 3T3 NRU test, only FAL obtained a biphasic response with aminopterin.

Figure 2-5 Representative Concentration-Response for Aminopterin in a NHK NRU Range Finder Test



Abbreviations: NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake. Representative dose-response for aminopterin in a NHK range finder test. Laboratories were instructed to focus the definitive tests on the lowest concentration that produced a 50% reduction in viability in the range finder test.




Figure 2-6 Representative Concentration-Response for Aminopterin in a NHK NRU Definitive Test

Abbreviations: NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake. Note that the maximum reduction in cell viability plateaued at about 75%

Biphasic concentration-responses are not uncommon. Calabrese (2005) states that numerous mechanistic explanations (including hormesis⁴) could account for biphasic response curves. Such concentration-responses could be because the substance acts through more than one mechanism of action (e.g., one mechanism that is active at low test substance concentrations and other mechanism[s]) that are effective at higher concentrations). Conolly and Lutz (2004) also provide examples of pharmacological and toxicological data sets of biologically based mechanisms that could explain biphasic responses. These examples include:

- Membrane receptor subtypes with opposite downstream effects
- Receptor-mediated gene expression
- Induction of DNA repair and "co-repair" of background DNA damage
- Modulation of the cell cycle

Although non-linear responses could also be due to technical error (e.g., improper dosing, unacceptable media, contamination), the responses seen in this study were reproducible, and there was no evidence to suggest that technical errors were involved. The SMT assumed that these responses were based on the chemicals' mechanisms of action. For example, colchicine binds to microtubular protein and interferes with function of mitotic spindles, which arrests cell division (NLM 2003). Aminopterin blocks the use of folic acid by the cells, inhibiting metabolism, RNA production, and protein synthesis, which is lethal during the S phase of the cell cycle by (NLM 2002). The variability of IC_{50} results for these substances among the laboratories may be due to different levels of cell confluence in the cultures at the time of treatment.

⁴ Hormesis is a dose-response characterized by a compound's ability to produce an opposite effect at low doses compared with its effect at high doses (e.g., stimulatory at low doses and inhibitory at high doses).

2.6.3.3 Hill Function

The Hill function used in the various phases of this study was defined as follows:

 $Y = Bottom + \frac{Top - Bottom}{1 + 10^{(logEC50 - logX)HillSlope}}$

where Y=response (i.e., % viability), X is the substance concentration producing the response, Bottom is the minimum response (0% viability, maximum toxicity), Top is the maximum response (maximum viability), EC_{50} is the substance concentration at the response midway between Top and Bottom, and HillSlope describes the slope of the curve. When Top=100% viability and Bottom=0% viability, the EC_{50} is the equal to the IC₅₀.

Responses that do not achieve 100% cytotoxicity with increasing substance concentration do not fit the Hill function well. The R² values from such tests often failed the acceptance criterion. To obtain a better model fit, the Bottom parameter was estimated without constraints (the previous practice was to use Bottom=0). However, when Bottom \neq 0, the EC₅₀ reported by the Hill function was not the same as the IC₅₀ because the Hill function relies on EC_{50,} which is defined as the point midway between the Top and Bottom responses. Thus, the Hill function calculation using the Prism[®] software was rearranged to calculate the IC₅₀ as follows:

$$\log IC_{50} = \log EC_{50} - \frac{\log \left(\frac{Top - Bottom}{Y - Bottom} - 1\right)}{HillSlope}$$

where IC_{50} is the concentration producing 50% toxicity, EC_{50} is the concentration producing a response midway between the Top and Bottom responses; Top being the maximum response (maximum survival), Bottom is the minimum response (0% viability, maximum toxicity), Y=50 (i.e., 50% response), and HillSlope describes the slope of the response. The X from the standard Hill function equation is replaced, in the rearranged Hill function equation, by the IC_{50} .

IIVS performed the recalculations for their NHK NRU colchicine tests and the SMT performed the necessary recalculations for the other laboratories. Tests that were recalculated by the SMT are noted in the data summaries.

Protocol Revision: The protocol was revised to state that if a range finding test produces a biphasic response, then the concentrations selected for the subsequent tests should cover the most toxic dose-response range.

2.6.3.4 Insoluble Reference Substances

Lithium carbonate was insoluble in 3T3 medium. Only ECBC managed to expose 3T3 cells to sufficient lithium carbonate to produce three tests that met the acceptance criteria. Precipitate was reported for two of those tests at the three highest concentrations in the wells. Because the third highest concentration, 510.2 μ g/mL, was approximately the IC₅₀ (average was 564 μ g/mL), the true IC₅₀ for lithium carbonate may actually be lower than was

calculated, and therefore the LD_{50} value would be underestimated. However, the data were reproducible and were not discarded.

Protocol Revision for Phase III: The protocol was revised to allow an increase in the stirring/rocking duration in an incubator from one to three hours if cytotoxicity in the range finder test was limited by solubility. Also, a *Stopping Rule for Insoluble Chemicals* was added (see **Section 2.5** and **Appendices B1** and **B2**) so that the laboratories would not continue repeated testing of insoluble substances in order to obtain three acceptable definitive tests.

2.6.3.5 Inadequate Cell Growth in NHK Medium

IIVS and FAL had several NHK NRU test failures that were attributed to poor cell growth. The SMT compiled KBM[®] and SingleQuot[®] lot numbers that the laboratories were using, along with the laboratory assessments of NHK cell growth. The information was used to identify the lots that produced adequate growth. The SMT also obtained quality assurance and quality control test results from CAMBREX Clonetics[®] on the lots of KBM[®], but the information provided was inadequate for determining how the medium would perform in the NHK NRU test method.

Resolution: A protocol for prequalifying the medium was developed (see **Appendix B4**). For Phase III, the SMT asked IIVS to prequalify new lots of KBM[®] and SingleQuots[®] for use by all laboratories.

2.6.3.6 *Performance Standards for Media to Support NHK Growth*

A prequalification-of-medium protocol (**Appendix B4**) was developed and used by IIVS to test several different lots of medium and supplements to find combinations that maintained the typical growth characteristics of the NHK cells used in this study. The laboratories then reserved samples of the acceptable lots at CAMBREX so that testing would not be interrupted due to unavailability of adequate materials.

Test Acceptance Criteria for Prequalifying Media Using SLS

- The fit of the SLS dose-response to the Hill model should be $R^2 \ge 0.85$ (i.e., from PRISM[®] software).
- The difference between the mean of all VCs and (a) the left mean VC, and (b) the right mean VC should be $\leq 15\%$.
- At least one concentration should exhibit >0% and ≤50% viability and at least one should exhibit >50% and <100% viability.
- After meeting all other acceptability criteria, the SLS IC_{50} must be within the historical range (± 2.5 SD) established by the laboratory.

Other Criteria for Prequalifying Media (for consideration by a Study Director)

- General observations: rate of cell proliferation; percent confluence; number of mitotic figures per field; colony formation; distribution of cells in the flask; absence or presence of contamination
- Cell morphology observations should include overall appearance (e.g., good, fair, poor), and presence of abnormal cells

- Mean corrected OD₅₄₀ of the VCs (e.g., are the values high/low when compared to historical data)
- Cell morphology and confluence of the VC wells at the end of the 48-hour treatment
- Cell doubling time, as compared to the doubling time with the previous batches of medium
- 2.6.3.7 Test Acceptance Criteria for Phase II
 - The IC₅₀ for SLS (PC) should be within 2.5 SDs of the historical mean established by the laboratory (*Phases Ia and Ib*)
 - Mean OD values of the left and right VCs (columns 2 and 11 in the 96-well test plate) do not differ by more than 15% from the mean of all VC well OD values. At least one calculated cytotoxicity value ≥10% and ≤50% viability and at least one value >50% and ≤90% viability
 - $R^2 \ge 0.90$. The test fails if $R^2 < 0.80$. If the $0.80 \le R^2 < 0.90$, the SMT evaluates the model fit (Note: The Study Director makes this determination for non-validation studies.)

2.6.4 <u>Phase III: Laboratory Testing Phase</u>

The changes below were made in the Phase III protocols based on the data and results in Phase II.

2.6.4.1 *Required Cytotoxicity Values*

Obtaining at least one calculated cytotoxicity value >0% and \leq 50% viability and at least one that is >50% and <100% viability may be difficult or unattainable for substances with steep dose responses.

Protocol Revision: The test acceptance criterion was qualified so that tests with only one concentration between 0 and 100% viability were acceptable if the smallest practical dilution factor (i.e., 1.21) was used and all other test acceptance criteria were met.

Tests for three reference substances were accepted that met this new criterion in the 3T3 NRU test method: diquat dibromide (1/9 tests); epinephrine bitartrate (2/9 tests); 1,1,1-trichloroethane (2/8 tests). No NHK tests required the use of these criteria (i.e., one point between 0% and 100% viability at the lowest dilution factor).

2.6.4.2 Revisions to Data Analysis Procedures

The following revisions to data analysis procedures were made in Phase III NRU protocols:

- If the Bottom parameter of the Hill function was fit to a value <0%, then the parameter was set to zero (0) for the IC calculations.
- If toxicity plateaued above 20% viability (i.e., toxicity was <80%), the IC₈₀ was not determined. The IC₂₀ and IC₅₀ values were calculated from the range of available toxic responses.
- The requirement for substance dose-responses to fit the Hill equation with $R^2 \ge 0.90$ was rescinded. The Hill equation was used to characterize the shape of the response rather than to establish an acceptance criterion. The PC acceptance criterion was modified to $R^2 \ge 0.85$.

2.7 Differences Between the 3T3 and NHK NRU Protocols for the Validation Study and the *Guidance Document* Standard Protocols

As the validation study progressed through Phases I and II, the protocols provided in the *Guidance Document* (ICCVAM 2001b) were optimized to address problems that were encountered during the validation study phases. Changes to the *Guidance Document* protocols are described below.

- 3T3 cell seeding density for 96-well plates was decreased from 1×10^4 cells/well to $2.0 3.0 \times 10^3$ cells/well.
- The calcium concentration in NHK medium was changed from 0.15 mM to 0.10 mM. The test laboratories had expressed concern that cell differentiation would occur at the higher concentration and requested a lower concentration. CAMBREX Clonetics[®], the supplier of the NHK cells and NHK medium used in this study, normally grows NHK cells in 0.15 mM calcium and has seen no differentiation. The supplier agreed that the cells would grow well at 0.10 mM but should not be cultured at concentrations <0.10 mM in order to avoid morphological and growth rate changes (CAMBREX technical division, personal communication).
- NHK cells were subcultured once prior to being distributed to the test wells, rather than for three passages. The laboratories expressed concern about the possibility of cell differentiation with subsequent passages in culture.
- The highest recommended final concentrations of DMSO and ETOH in the culture media were reduced from 1% to 0.5%. IIVS performed experiments with both cell types to determine the concentration necessary to avoid solvent toxicity. 3T3 cells were tested with 0.5, 1, and 2% ETOH and DMSO at 0.1, 0.2, 0.3, 0.4, 0.5, 1, and 2% concentrations. The 0.5% concentrations of both solvents were chosen as optimal because that concentration of ETOH produced no toxicity. Although 0.5% DMSO produced slight toxicity (i.e., cells were 91% viable as compared to the control cells; See Appendix E1), this concentration was chosen by the SMT and laboratories as an acceptable trade-off between slight toxicity and the ability to test substances at higher concentrations, and was used throughout the study for all reference substances that needed solvents other than culture medium (see Curren et al. 2003). DMSO was the preferred solvent if the test substance was not soluble in culture medium, and ETOH was not used in this study.
- The pH of the reference substance solutions was not adjusted with NaOH or HCl regardless of whether solutions became acidic or basic (optimum mammalian cell culture pH is approximately 7.4 [Freshney, 2000]) upon addition of the test substance because some of the basal cytotoxicity produced by test substances may be due to pH effects. See **Appendix F1** for pH values of the reference substances in culture medium.
- The CO_2 concentration in the incubator was reduced from 7.5% to 5.0% because the laboratories were already set up to use 5% CO_2 , which is a typical optimum CO_2 concentration for mammalian cell culture.
- Washing and fixing the cells with a formaldehyde solution prior to NR elution from the cells was eliminated. Formaldehyde disposal was problematic in FAL's regulatory environment. The SMT and the laboratories agreed that the

use of formaldehyde was unnecessary because the NR desorb solution (1% glacial acetic acid, 50% ETOH, and 49% H_2O) adequately fixed the cells to the test plate (INVITTOX 1991).

- Reference substance exposure time for the 3T3 cells was extended from 24 hours to 48 hours (see Section 2.2.4 and Appendix E1).
- Cell culture seeding densities for subculture were provided as guidance, rather than as strict cell number ranges. The laboratories determined adequate cell densities (see **Table 2-4**) based on their own experience with the growth of the cells in the wells, and the time needed to reach the appropriate level of confluence needed for addition of the test substance, the VC, and PC.

| Protocol | 3T3 cells/cm ² subculture to flasks | 3T3 cells/well 96-well Plate | NHK cells/cm ² subculture to flasks | NHK cells/well 96-well Plate |
|---------------------------------------|--|---------------------------------|--|---------------------------------|
| <i>Guidance Document</i> ² | 1.25×10^4 | 2.5×10^3 | 3.5×10^3 | $2 - 2.5 \times 10^3$ |
| Phase Ia | $0.42 - 1.68 \times 10^4$ | 2.5×10^{3} | $2.5 - 9x10^3$ | $2 - 2.5 \times 10^3$ |
| Phase Ib | $0.42 - 1.68 \times 10^4$ | 2.5×10^3 | $2.5 - 9x10^3$ | $2 - 2.5 \times 10^3$ |
| Phase II | $0.42 - 1.68 \times 10^4$ | $2 - 3x10^{3}$ | $2.5 - 9x10^3$ | $2 - 2.5 \times 10^3$ |
| Phase III | $0.42 - 1.68 \times 10^4$ | $2 - 3x10^3$ | $2.5 - 9x10^3$ | $2 - 2.5 \times 10^3$ |

Table 2-4Cell Seeding Densities1

Abbreviations: 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes ¹Cell numbers determined by Coulter Counter or hemocytometer ²ICCVAM (2001b)

2.8 Overview of the Solubility Protocol

The SMT, with assistance from the laboratories, developed a solubility protocol to provide guidance for determining the most appropriate solvent for each test substance. The solubility protocol was based on an EPA guideline (EPA 1998) that involved testing for solubility in a particular solvent, beginning at a relatively high concentration and proceeding to successively lower concentrations by adding more solvent as necessary for dissolution. Testing stopped when, upon visual observation, the procedure produced a clear solution with no cloudiness or precipitate. The order of selection priority was culture medium, DMSO, and ETOH. Each laboratory tested the solubility of each reference substance using this protocol and provided the data to the SMT prior to initiating cytotoxicity testing. The SMT analyzed the solubility data provided by BioReliance and each testing laboratory, and designated the solvent to be used by all laboratories for each reference substance. This eliminated one potential variable in the NRU test results among laboratories.

The solubility protocol used by the *in vitro* laboratories required the sequential testing of reference substances in the various solvents at concentrations that would be equivalent to the concentration that would be applied to the cell cultures. The solubility flow chart in **Figure 2-7** shows, for example, that 2 mg/mL medium and 200 mg/mL DMSO or ETOH were equivalent concentrations because they yielded 1 mg/mL in cell culture. Medium was diluted by one-half when applied to cultures. The 0.5% [v/v] final concentrations were achieved by diluting DMSO and ETOH by 200-fold. At each concentration, the following mixing procedures were employed, as necessary, to completely dissolve the reference substance in

the sequence: vortex (1 to 2 minutes); sonication (up to 5 minutes); warming to 37 °C (5 to 60 minutes [NRU protocols allow warming to be extended to three hours if cytotoxicity in the range finder test was limited by solubility]). If the reference substance was still not dissolved, the next lower concentration, or a different solvent, was tested.

Figure 2-7 Flow Chart for Determination of Reference Substance Solubility in Medium¹, DMSO, or ETOH

| Tier | 1 | | 2 | | 3 | | 4 | | 5 |
|--|------------------------|--------------------------|--------------------------|------------|--------------------------|------------|--------------------------|------------|--------------------------|
| | | | | | | | | | |
| Concentration in 3T3 and NHK Media | Start Here 20 mg/mL | Incomplete solubility | 2 mg/mL | | ➡ 0.20 mg/mL | | | | |
| | | | Incomplete solubility | | Incomplete solubility | - | | | |
| Concentration in DMSO | | | 200 mg/mL | | 20 mg/mL | | 2 mg/mL | | ►0.2 mg/mL |
| | | | Incomplete solubility | | Incomplete solubility | | Incomplete solubility | | Incomplete solubility |
| Concentration in Ethanol | | | 200 mg/mL | Incomplete | 20 mg/mL - | Incomplete | 2 mg/mL | Incomplete | 0.2 mg/mL End |
| | | | | | | | | | |
| Concentration on Cells | 10 mg/mL | | 1 mg/mL | | 0.1 mg/mL | | 0.01 mg/mL | | 0.001 mg/mL |

Abbreviations: DMSO=Dimethyl sulfoxide; ETOH=Ethanol; 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes.

Note: DMSO is U.S.P. analytical grade. ETOH is U.S.P. analytical grade (100% non-denatured). ¹3T3 Medium - DMEM (Dulbecco's Modification of Eagle's Medium) with supplements; NHK medium - KBM[®] (Keratinocyte Basal Medium) with supplements (from CAMBREX Clonetics[®]).

2.9 Basis of the Solubility Protocol

The solubility protocol used by BioReliance, which tested solubility of the reference substances prior to testing by the *in vitro* laboratories, is provided in **Appendix G**. The protocol is based largely on information from the literature and Internet searches for solubility procedures, the experience of the SMT and IIVS, and solubility and IC_{50} information from the RC chemicals database (Halle 1998, 2003). The only formal solubility protocol discovered was the EPA Product Properties Test Guideline, OPPTS 830.7840 Water Solubility Column Elution Method; Shake Flask Method (EPA 1998).

2.9.1 Initial Solubility Protocol Development

BioReliance evaluated the solubility of each reference substance in cell culture media at 2000, 400, and 200 mg/mL, and if not soluble at those concentrations, in DMSO and then ETOH, at the same concentrations (initial protocol). It was apparent that these concentrations were not low enough when the laboratory was unable to achieve solubility for arsenic

trioxide. The solubility protocol was revised twice to lower the range of concentrations tested (see **Table 2-5**). An extra tier of concentrations $\leq 1 \text{ mg/mL}$ was added for poorly soluble and insoluble substances. The protocol used by the laboratories was further revised to reduce the number of steps required (by testing in log units) and to test in tiers using concentrations that reflected the concentrations anticipated in the cell cultures (see **Figure 2-7**).

| Solubility | Concentrations Tested (mg/mL) | | | | | | | | |
|---|-------------------------------|----------------------------------|----------------------------------|------------------|----------------------|------------------------------|--|--|--|
| Protocol Version | Step 1 Step 2 | | Step 3 | Step 4 | Step 5 | Steps 6-10 | | | |
| BioReliance (1 st) (4/26/02) and Phase Ia | 2,000 | 400 | 200 | NA | NA | NA | | | |
| BioReliance (2 nd) (9/17/02) | 200 | 40 | 20 | 10 | 2 | NA | | | |
| BioReliance (3 rd) (10/11/02) | 200 | 40 | 20 | 10 | 2 | 1, 0.5, 0.25, 0.125, 0.05 | | | |
| Phases Ib, II, III for cytotoxicity laboratories | 20 Medium | 2 Medium 200 DMSO 200 ETOH | 0.2 Medium 20 DMSO 20 ETOH | 2 DMSO 2 ETOH | 0.2 DMSO 0.2 ETOH | NA | | | |

Table 2-5Comparison of Concentrations Tested in the Various Solubility Protocols

Abbreviations: DMSO=Dimethyl sulfoxide; ETOH=Ethanol; Medium=Cell culture medium; NA=Not applicable Note: DMSO is U.S.P. analytical grade. ETOH is U.S.P. analytical grade (100% non-denatured).

In Phases Ib and II, the SMT used the data from BioReliance to select the solvents to be used for testing the various chemicals. When it became apparent that the laboratories sometimes obtained different solubility results than those reported by BioReliance, the SMT used the cytotoxicity results from the laboratories to determine the solvents to be used for Phase III reference substances.

The final protocol provided a tiered approach for determining the 2X stock concentration for each reference substance (see **Figure 2-7**). This protocol had the advantage of reducing the number of steps for testing (compared to that used by BioReliance) (see **Appendix B3**).

2.9.2 <u>Basis for Modification of the Phase II Protocol</u>

All three testing laboratories found arsenic trioxide (tested in Phase Ib) less soluble (see **Table 5-10**) than was reported by BioReliance (BioReliance values: 0.25 mg/mL in 3T3 medium and 0.05 mg/mL in NHK medium). This chemical was not soluble using the procedures in the initial solubility protocol. IIVS warmed the stock solution (at least 200 μ g/mL for 2X) for longer than the protocol specified (i.e., 30 to 50 minutes) but still had persistent, small, undissolved particles. ECBC obtained a clear solution (highest 2X concentration was 30 to 50 μ g/mL), but found precipitated particles after the solution stood at room temperature. Sonication time was increased to 15 to 30 minutes, and heating time to approximately 30 minutes to get a finer suspension. This procedure achieved a more homogeneous mixture, resulting in more uniform serial dilutions and a more even application of the reference substance to the cells. FAL stirred the suspension (approx. 20 to 90 μ g/mL) in the CO₂ incubator for 1.5 to 2 hours to get clear medium.

Protocol Revision for Phase II: The duration of the heating step was altered from 5 to 20 minutes to 5 to 60 minutes.

2.10 Components of the Solubility Protocol

2.10.1 <u>Medium, Supplies, and Equipment Required</u>

- 2.10.1.1 Medium and Chemical Supplies
 - <u>3T3 culture medium</u>: DMEM without L-glutamine and containing Hanks' salts and high glucose [4.5gm/l]; L-glutamine, 200 mM; NCS
 - <u>NHK culture medium</u>: Keratinocyte Basal Medium without Ca⁺⁺ (KBM[®], Clonetics[®] CC-3104); KBM[®] SingleQuots[®] medium supplements (Clonetics[®] CC-4131): epidermal growth factor, insulin, hydrocortisone, bovine pituitary extract; Calcium SingleQuots[®] (Clonetics[®] CC-4202); penicillin/streptomycin solution (antimicrobial agents)
 - United States Pharmacopoeia (U.S.P.) analytical grade DMSO
 - U.S.P. analytical grade (100%, non-denatured) ETOH

2.10.1.2 Equipment

- Waterbath (37 °C)
- Sonication apparatus
- Vortex mixer
- Micropipettors
- Balance (capable of weighing 10 mg)
- pH meter

2.10.1.3 *Procedures*

The Phase III solubility protocol required the dissolving of approximately 10 mg of reference substance in approximately 0.5 mL medium (both 3T3 and NHK media were used) for a final concentration of 20 mg/mL (see **Appendix B3**). In order, the mixture was vortexed for 1 to 2 minutes, sonicated for up to 5 minutes, and warmed to 37 °C for 5 to 60 minutes, as necessary, to dissolve the substance. The endpoint for dissolution was a clear solution with no noticeable precipitate. If the reference substance was not soluble in medium at 20 mg/mL, then more medium was added to a concentration of 2 mg/mL (i.e., a total volume of approx. 5 mL) (Step 2). The mixing procedures were repeated as necessary to dissolve the reference substance did not dissolve, approximately 10 mg reference substance was added to approximately 0.5 mL DMSO in an attempt to dissolve it at a concentration of 200 mg/mL (Step 3). If the reference substance was not dissolved, the same concentration was attempted in 100% ETOH (Step 4). Step 5 began in the same way, with 0.2 mg/mL medium and then progressed to 20 mg/mL DMSO, and then 20 mg/mL ETOH.

Determination of reference substance solubility was limited to visual observation of the resulting solution. If a solution appeared clear, then solubility testing ceased. If particles were visible or if the solution appeared cloudy, then more stringent mixing and/or heating procedures were employed. If necessary, the solubility procedure proceeded to the next solvent/concentration tier. The duration of the solubility test was dependent on the procedures used to achieve solubility. Some reference substances were immediately solubilized (e.g., liquids) and others required up to 60 minutes of heating and agitation or sonication.

2.10.2 Data Collection

All laboratories (including the reference substance distribution laboratory, BioReliance) used a worksheet designed to capture the solubility information for each reference substance. The endpoint for each step was a visual observation of the solution, a documented comment describing the observation, the concentration, and a conclusion of soluble or insoluble. Each worksheet contained:

- Reference substance code number and physical description
- Solvent used (3T3 medium, NHK medium, DMSO, ETOH)
- Amount of reference substance (mg) used in the initial stage
- Volume of solvent added and final volume (mL)
- Test substance concentration ($\mu g/mL$) in the solvent
- pH and color of the solution
- Mechanical procedures used (vortexing, sonication, heating), duration, and temperature
- Comments (soluble/insoluble at the particular concentration; visual observations; reactivity with solvent)

The solubility test information and data from the laboratories were transferred via email to the SMT and stored on the NICEATM server and as hard-copy printouts. Each laboratory also maintained electronic and hard-copy files of its data.

2.10.3 <u>Variability in Solubility Measurements</u>

Solubility determinations were not replicated because within-laboratory results were not expected to vary. Comparison of the results to determine inter-laboratory concordance for the 72 reference substances (see Section 5.8 for results) provided a measure of variability among the laboratories and information about the reproducibility of the solubility determinations (see Section 7.4).

2.10.4 <u>Solubility Issues During the Testing of the Reference Substances</u>

Substance solutions were monitored throughout all aspects of the test procedures, and observations were documented. The lowest concentration of the substance in a 2X solution that contained observable precipitates, particles, globules, or oily droplets, was documented in the EXCEL[®] template. After substance exposure, all wells of the 96-well test plates were observed microscopically and scored using a visual observation code. The code addressed growth characteristics and the presence or absence of precipitates (see **Appendix B** [test method protocols] for the observation codes used). For solubility issues, the Study Directors made determinations of test acceptance based on the recommended concentration levels and the presence of precipitates, their scientific expertise, and test acceptance criteria.

2.10.5 Analysis of Solubility Data

During Phase III, the SMT used the solubility data from all laboratories to determine the solvents to be used for each chemical (see Section 5.8 for solubility results and SMT selections). If the solubility of an individual reference substance was different in 3T3 medium and NHK medium, the same solvent would be used for both test methods, rather than having different solvents for each method. For example, if solubility in one culture medium was ≥ 2 mg/mL and solubility in the other was < 2 mg/mL, and the substance was soluble in DMSO at 200 mg/mL, the SMT would select DMSO as the solvent for both test methods (each test method using its respective culture medium).

Solubilizing sufficient reference substance to produce cytotoxicity was challenging for relatively insoluble, low toxicity, substances such as lithium carbonate (in the 3T3 NRU test method) but generally was not a problem for toxic substances that did not require as high a concentration to kill cells. Some insoluble and highly toxic reference substances were problematic, however, because the amount of powdered reference substance added to solvent was very small, and laboratory personnel found it difficult to determine the presence of solute particles in solution. Arsenic trioxide is an example of such a solute (see Section 2.9.2).

2.11 Summary

The *Guidance Document* NRU protocols were used as the basis of the validation study protocols. The SMT and participating laboratories made initial modifications to the protocols prior to implementation of the study. Other protocol modifications were made after commencement of testing and were the result of recommendations from the laboratories and the SMT, based on their experience with the initial protocols. The resulting optimized protocols were used in the main testing phase (Phase III) of the study.

The protocol components used in the validation study were similar for the 3T3 and NHK cells. The following procedures were common to the NRU protocols for both cell types:

- Testing was performed in four phases (Phases Ia, Ib, II, and III)
- Preparation of reference substances and positive control
- Cell culture environment conditions
- Determination of test substance solubility
- Configuration of 96-well plates for testing samples
- 48-hour exposure to test substance
- Range finder and definitive testing
- Microscopic evaluation of cell cultures for toxicity
- Measurement of NRU
- Data analysis

The main differences in the test methods for the two cell types were:

- The conditions of propagation of the cells in culture
- The cell growth medium components
- The volumes of reference substance added to the 96-well plate

A solubility protocol was developed which allowed the laboratories to identify the most appropriate solvent and appropriate limit concentrations for each test substance.

Three laboratories participated in testing the 72 reference substances in both cell types and one additional laboratory procured and distributed the coded reference substances and performed solubility tests prior to their distribution to the testing laboratories.

| 3.0 | | CRENCE SUBSTANCES USED FOR VALIDATION OF THE 3T3 NHK NRU TEST METHODS | 3-3 | | | | | | | |
|-----|--|--|------|--|--|--|--|--|--|--|
| 3.1 | Rationale for the 72 Reference Substances Selected for Testing | | | | | | | | | |
| | 3.1.1 | Reference Substance Selection Criteria | 3-3 | | | | | | | |
| | 3.1.2 | Candidate Reference Substances | 3-4 | | | | | | | |
| | 3.1.3 | Selection of Reference Substances for Testing | 3-5 | | | | | | | |
| 3.2 | Chara | acteristics of the Selected Reference Substances | 3-6 | | | | | | | |
| | 3.2.1 | Source Databases Represented by the Selected Reference Substances | 3-6 | | | | | | | |
| | 3.2.2 | Chemical Classes Represented by the Selected Reference Substances | 3-28 | | | | | | | |
| | 3.2.3 | Product/Use Classes Represented by the Selected Reference | | | | | | | | |
| | | Substances | 3-28 | | | | | | | |
| | 3.2.4 | Toxicological Characteristics of the Selected Reference Substances | 3-28 | | | | | | | |
| | 3.2.5 | Selection of Reference Substances for Testing in Phases Ib and II | 3-32 | | | | | | | |
| | 3.2.6 | Unsuitable and Challenging Reference Substances | 3-34 | | | | | | | |
| 3.3 | Refer | ence Substance Procurement, Coding, and Distribution | 3-34 | | | | | | | |
| | 3.3.1 | - | | | | | | | | |
| 3.4 | Refer | ence Substances Recommended by the <i>Guidance Document</i> | 3-35 | | | | | | | |
| 3.5 | Summary | | | | | | | | | |

[This Page Intentionally Left Blank]

3.0 REFERENCE SUBSTANCES USED FOR VALIDATION OF THE 3T3 AND NHK NRU TEST METHODS

3.1 Rationale for the 72 Reference Substances Selected for Testing

This section describes the procedures used to select the 72 reference substances selected for testing in Phase Ia of the validation study.

3.1.1 <u>Reference Substance Selection Criteria</u>

The SMT (see **Appendix A**) selected reference substances for testing using a process based on general recommendations made by Workshop 2000 participants (ICCVAM 2001a). The following criteria were used:

- The toxicities of the reference substances should be evenly distributed across the expected range of rodent LD₅₀ values, using the GHS classification for acute oral toxicity as a guide (UN 2005).
- The reference substances should cover a wide range of structural and use classes, and be relevant to the needs of the various user communities.
- Substances with human toxicity data and/or human exposure potential (i.e., substances of interest to society) should be included. Substances with human acute toxicity data were particularly important to ECVAM for determining the relationship of the NRU IC₅₀ values to human blood/serum LC.

Table 3-1 shows the GHS scheme for classifying substances into six toxicity categories (five with measured LD_{50} ranges and an unclassified category with LD_{50} values greater than 5000 mg/kg) based on acute rodent oral LD_{50} values (UN 2005). The SMT used this scheme for the classification of candidate substances to assure that the reference substances selected for the validation study represented the full range of acute oral toxicity.

| Category | LD ₅₀ (mg/kg) |
|--------------|---------------------------|
| 1 | $LD_{50} \leq 5$ |
| 2 | $5 < LD_{50} \le 50$ |
| 3 | $50 < LD_{50} \le 300$ |
| 4 | $300 < LD_{50} \le 2000$ |
| 5 | $2000 < LD_{50} \le 5000$ |
| Unclassified | LD ₅₀ >5000 |

Table 3-1 GHS Classification Scheme for Acute Oral Toxicity

Abbreviations: UN=United Nations; GHS=Globally Harmonized System of Classification and Labelling of Chemicals (UN 2005).

 LD_{50} =Dose that produces lethality in 50% of the test animals.

For the purposes of the initial toxicity classification, the rodent oral LD_{50} values for the individual substances were obtained from readily available toxicological databases. These rodent oral LD_{50} values were re-evaluated in **Section 4** for the purpose of identifying the most appropriate reference LD_{50} values to use for the accuracy analyses (i.e., determine to

what extent there is agreement between a test method result and an accepted reference value [see Section 6.3]). Rat LD_{50} data were preferred because:

- The current acute oral toxicity test guidelines recommend using rats (OECD 2001a, c, d; EPA 2002a)
- The majority of LD₅₀ data used in the RC millimole regression were from studies using rats (282 rat data points and 65 mouse data points) (Halle 1998, 2003)
- The great majority of acute oral systemic toxicity testing is performed with rats

Mouse oral LD_{50} values were used (10 substances) for the initial toxicity classification when rat data were unavailable, however, mouse data were not used in the regression analyses presented in **Section 6**. The toxicological databases, in order of preference, were:

- The RC, which contains LD₅₀ values that came largely from the 1983/84 RTECS[®] (Halle 1998, 2003). The RC is a database of acute oral LD₅₀ values for rats and mice obtained from RTECS[®] and IC₅₀ values from *in vitro* cytotoxicity assays using multiple cell lines and cytotoxicity endpoints for chemicals with known molecular weights.
- The current RTECS[®] (MDL Information Systems 2001, 2002)
- The current Hazardous Substances Data Bank (HSDB; U.S. National Library of Medicine [NLM] 2001, 2002).

To insure that a wide range of structural and use classes were selected, reference substances of interest to the various U.S. regulatory agencies, as determined from substance lists received from the various agencies, were included. Substances with human toxicity data and/or human exposure potential were chosen by mining publicly available databases (e.g., the NTP test database, the MEIC database) for potential candidates.

3.1.2 <u>Candidate Reference Substances</u>

The process of identifying the 72 reference substances started with the compilation of a database of 116 candidates. The intent of the SMT was to compile a database with at least 12 substances in each GHS toxicity category that also met the other selection criteria, and then to prioritize the substances within each category to select the 72 to be tested. As recommended by Workshop 2000 (ICCVAM 2001a), the following publicly available databases and other sources were used to identify candidate substances:

- The MEIC program, which collected human toxicity data and *in vitro* toxicity data from 61 test methods for 50 substances (Ekwall et al. 1998)
- The EDIT program, which targeted development of *in vitro* test methods for endpoints other than basal cytotoxicity; includes 20 chemicals that are a subset of the MEIC chemicals
- The RC (Halle 1998, 2003), which contains *in vitro* cytotoxicity and *in vivo* rodent LD₅₀ data for 347 substances
- The Toxic Exposure Surveillance System (TESS) (Litovitz et al. 2000), which compiles reports of toxic human exposures from poison control centers throughout the United States
- Pesticides recommended for consideration by the EPA Office of Pesticide Programs (OPP)

- The *Guidance Document* (ICCVAM 2001b), which reported *in vitro* NRU results for 11 RC substances using protocols similar to those to be used in the validation study
- The U.S. NTP test database, which contains information on the toxicity of substances relevant to human exposure (NTP 2002)
- The EPA High Production Volume (HPV) Challenge Program list of chemicals. The HPV is a voluntary testing program to provide the public with a complete set of baseline health and environmental effects data for each chemical that is manufactured within or imported into the United States at amounts >1 million pounds/year (EPA 2000a)

The candidate substances from the list of 116 that were not selected as reference substances to use in the validation study are listed in **Appendix F3**, grouped by GHS category, along with the rat or mouse oral LD_{50} value, the database(s) or other source(s) used to identify the substance as a potential candidate, and the type of product and/or use for the substance.

3.1.3 <u>Selection of Reference Substances for Testing</u>

Using the candidate substance database, 72 reference substances (12 GHS-unclassified substances and 12 substances from each of the five GHS acute oral toxicity hazard categories) were selected. This number of substances per GHS category was considered adequate by the ICCVAM Acute Toxicity Working Group (ATWG), ICCVAM, ECVAM, and the SMT to accurately evaluate the performance of these two *in vitro* NRU test methods for identifying the starting dose for rodent acute oral toxicity tests across the range of toxic levels that would be encountered during testing. The criteria used for prioritizing the candidate substances were:

- The availability of rodent acute oral toxicity data
- The availability of human acute oral toxicity data and/or relevance for human exposure
- The level of volatility (because the cells are exposed for 48 hours while incubated at 37 °C in 96-well plates, volatilization from wells containing a volatile reference substance would affect the accuracy of the IC₅₀ calculation and potentially contaminate other wells)
- Not a controlled substance according to the U.S. Drug Enforcement Agency (DEA). Excluding substances that are listed in DEA Schedules I and II from consideration obviates the requirement for U.S. laboratories to obtain a DEA license and adhere to the DEA substance storage and control procedures
- Practical considerations such as cost and disposal

If more than 12 candidate substances in a GHS category met the above criteria, then selection was based on two further considerations. One consideration was the distribution of substance toxicities within each toxicity category so as to select substances that represented the entire range of toxicity within each category. Another consideration, which applied only to candidate substances selected from the RC database, was the fit of the toxicity to the RC millimole regression. Substances with the best fit to the RC millimole regression were preferentially selected to prevent the entire set of reference substances from having proportionally more "outlier" substances (i.e., greater than one-half log from the RC millimole regression) than the entire RC database.

The final list of selected reference substances is sorted by GHS acute oral toxicity category in **Table 3-2**.

3.2 Characteristics of the Selected Reference Substances

The physical/chemical and toxicological information in **Appendix F** may be useful for characterizing the performance of the *in vitro* NRU test methods for various chemical types (e.g., chemical class, toxic effect class). Appendix F1 lists the reference substances in alphabetical order with information on the CASRN, purity, supplier, pH (of the highest concentration tested in NRU), and concentrations tested. Appendix F2 provides the reference substances in alphabetical order, and information on physical/chemical characteristics such as molecular weight, chemical class, water solubility, acid/base dissociation constant (pK), boiling point, and octanol-water partition coefficient (log K_{ow}), a measure of lipid solubility. Although test substance concentration and toxicity may be heavily influenced by molecular charge and surface activity (ICCVAM 2006), these attributes were not characterized because this type of information is not readily available. Appendix F2 also includes the major toxic effects attributed to each chemical, ability to pass the blood:brain barrier (BBB), metabolic activation/inactivation (whether or not it is metabolized, or the identification of the metabolites), and mechanism of lethality (where known) for each of the reference substances. The remainder of this section summarizes selected characteristics of the reference substances.

3.2.1 <u>Source Databases Represented by the Selected Reference Substances</u> The primary sources of substances were well represented in the final list of reference substances. **Table 3-3** shows the distribution of reference substances by GHS category from each of the source lists. Forty-two (58%) of the 72 substances were MEIC chemicals (17 of the 42 MEIC chemicals [40%] were also EDIT chemicals), 46 (64%) were involved in human poisonings as reported by TESS, 51 (71%) have been evaluated by the NTP, and 18 (25%) are listed in the EPA's HPV Challenge Program. Some substances were present in more than one database.

The other major source of reference substances was the RC, which contributed 58 (81%) of the 72 chemicals, as shown in **Table 3-4**. Because the RC millimole regression was used to identify outlier substances (see **Section 6.2**), the fit of the RC substances to this regression was relevant (Halle 1998, 2003). Halle (1998, 2003) defined outliers as those chemicals with log IC₅₀-log LD₅₀ points that were >0.699 (i.e., log 5) from the RC millimole regression. **Table 3-4** shows the number of RC outliers selected for testing and the corresponding number of outliers in the RC. Although the percentage of outliers in several GHS categories is similar to the percentage in the RC, the total percentage of RC outliers in the set of reference substances (i.e., 38% [22/58]) is greater than the percentage in the RC (i.e., 27% [95/347]). This occurred because the fit to the RC millimole regression was not the major deciding factor during selection of the 72 reference substances.

| GHS Category ¹ /Substance | Rodent Oral LD ₅₀ ² (mg/kg) | Source ³ | Product/Use ⁴ | Molecular Weight (g/mol) | log Kow ⁵ | Chemical Class ⁶ | Molecular Structure | | | | |
|---|---|---|--|-----------------------------|----------------------|--|---|--|--|--|--|
| | $LD_{50} \leq 5 mg/kg$ | | | | | | | | | | |
| Mercury II chloride | 1 | MEIC, EDIT, RC (outlier), TESS, NTP | Preservative; Manufacturing; Insecticide | 271.50 | 0.22 | Inorganic compound; Mercury compound; Chlorine compound | CI——Hg | | | | |
| Triethylenemelamine | 1 | RC (outlier), NTP | Manufacturing; Insect chemosterilant | 204.23 | -0.54 | Organic compound; Heterocyclic compound | $ \xrightarrow{N_{N}}_{N_{N}} \xrightarrow{N_{N}}_{N} \xrightarrow{N}_{N} \xrightarrow{N}_{N$ | | | | |
| Sodium selenate | 2** | TESS, NTP | Feed additive | 188.90 | NA | Inorganic compound; Sodium compound; Selenium compound | 0 Na ⁺ 0 ==Se: 0. 0. Na ⁺ | | | | |
| Busulfan | 2 | RC (outlier), NTP | Pharmaceutical (antineoplastic) | 246.31 | -0.52 | Organic compound; Alcohol; Acyclic hydrocarbon; Sulfur compound | H,C, ,0 0, ,CH, 0, ,0 0, ,CH, 0, ,0 0, ,CH, | | | | |

| GHS Category ¹ /Substance | Rodent Oral LD ₅₀ ² (mg/kg) | Source ³ | Product/Use ⁴ | Molecular Weight (g/mol) | log Kow ⁵ | Chemical Class ⁶ | Molecular Structure |
|---|---|---------------------------|----------------------------|-----------------------------|----------------------|--|--|
| Cycloheximide | 2 | RC (outlier), NTP | Antibiotic Fungicide | 281.40 | 0.55 | Organic compound; Heterocyclic compound | H ₃ C _H H ₃ C O H O NH |
| Disulfoton | 2 | RC (outlier), EPA, NTP | Pesticide (insecticide) | 274.42 | 4.02 | Organic compound; Organophosphorous compound; Sulfur compound | H ₃ C 0 cH ₃ H ₃ C 0 cH ₃ |
| Parathion | 2 | RC (outlier), EPA, NTP | Pesticide (insecticide) | 291.28 | 3.83 | Organic compound; Organophosphorous compound; Sulfur compound | 0N+ 0 - P - 0 CH3 |
| Strychnine | 2* | MEIC, TESS, EPA | Pesticide (rodenticide) | 334.40 | 1.93 | Organic compound; Heterocyclic compound | |

| GHS Category ¹ /Substance | Rodent Oral LD ₅₀ ² (mg/kg) | Source ³ | Product/Use ⁴ | Molecular Weight (g/mol) | log Kow ⁵ | Chemical Class ⁶ | Molecular Structure |
|---|---|---------------------------------|---|-----------------------------|----------------------|---|--|
| Aminopterin | 3** | RC | Pharmaceutical (antineoplastic); Pesticide (rodenticide) | 476.45 | NA | Organic compound; Heterocyclic compound | |
| Phenylthiourea | 3 | RC (outlier), NTP | Pesticide (rodenticide) | 152.20 | 0.71 | Organic compound; Sulfur compound; Urea | NH2 |
| Epinephrine bitartrate | 4** | RC (outlier), NTP (HCl salt) | Pharmaceutical (adrenergic) | 333.30 | -1.52 | Organic compound; Alcohol; Amine | |
| Physostigmine | 5* | EHS | Pharmaceutical (anticholinesterase) | 275.40 | NA | Organic compound; Carboxylic acid; Heterocyclic compound | H ₃ C N H ₃ C H ₃ |

| GHS Category ¹ /Substance | Rodent Oral LD ₅₀ ² (mg/kg) | Source ³ | Product/Use ⁴ | Molecular Weight (g/mol) | log Kow ⁵ | Chemical Class ⁶ | Molecular Structure | | | | |
|---|---|--------------------------------------|--------------------------------------|-----------------------------|----------------------|---|--|--|--|--|--|
| | $5 < LD_{50} \le 50 mg/kg$ | | | | | | | | | | |
| Colchicine | 6** | MEIC, RC, TESS, NTP | Pharmaceutical (gout suppressant) | 399.45 | 1.03 | Organic compound; Polycyclic compound | $H_{3C} \xrightarrow{O} H_{3C} \xrightarrow{O} H_{3$ | | | | |
| Potassium cyanide | 10 | MEIC, EDIT, RC (outlier), TESS | Electroplating | 65.12 | NA | Inorganic compound; Potassium compound; Nitrogen compound | К = N | | | | |
| Dichlorvos | 17* | TESS, EPA, NTP, HPV | Pesticide (insecticide) | 220.98 | 1.43, 1.45 | Organic compound; Organophosphorous compound | | | | | |
| Digoxin | 18** | MEIC, EDIT, RC (outlier), TESS | Pharmaceutical (antiarrhythmic) | 780.90 | 1.26 | Organic compound; Polycyclic compound; Carbohydrate | | | | | |

| GHS Category ¹ /Substance | Rodent Oral LD ₅₀ ² (mg/kg) | Source ³ | Product/Use ⁴ | Molecular Weight (g/mol) | log Kow ⁵ | Chemical Class ⁶ | Molecular Structure |
|---|---|--------------------------------------|--|-----------------------------|----------------------|---|--------------------------------------|
| Fenpropathrin | 18* | EPA | Pesticide (insecticide) | 349.43 | 6.0 @ 20° C | Organic compound; Nitrile; Ester; Ether | |
| Endosulfan | 18* | TESS, EPA, NTP | Pesticide (insecticide) | 406.91 | 3.83 | Organic compound; Heterocyclic Compound; Sulfur compound | |
| Arsenic III trioxide | 20 | MEIC, EDIT, RC, TESS, EPA, NTP | Pesticide (insecticide) | 197.80 | NA | Inorganic compound; Arsenical | 0 _{`As} _0 _{As} _0 |
| Thallium I sulfate | 29** | MEIC, EDIT, RC (outlier), TESS | Pesticide (rodenticide/insecticide) | 504.80 | NA | Inorganic compound; Metal; Sulfur compound | о о о о о о т |

| GHS Category ¹ /Substance | Rodent Oral LD ₅₀ ² (mg/kg) | Source ³ | Product/Use ⁴ | Molecular Weight (g/mol) | log Kow ⁵ | Chemical Class ⁶ | Molecular Structure |
|---|---|---|---|-----------------------------|----------------------|--|---|
| Sodium arsenite | 41* | TESS, NTP | Pesticide (herbicide, insecticide, fungicide) | 129.90 | NA | Inorganic compound; Arsenical; Sodium compound | 0 11 As 0' Na* |
| Triphenyltin hydroxide | 44 | RC, EPA, NTP, HPV | Pesticide (fungicide/insecticide) | 367.02 | NA | Organic compound; Organometallic compound | |
| Sodium dichromate dihydrate | 50 | RC, EPA, GD, NTP | Oxidizing agent | 298.00 | NA | Inorganic compound; Sodium compound; Chromium compound | 0 0 0 0 11/ Na+ H ₂ O 0 0 0 Na+ H ₂ O |
| Nicotine | 50 | MEIC, EDIT, RC (outlier), TESS, EPA, NTP | Pharmaceutical (stimulant) | 162.020 | 1.17 | Organic compound; Heterocyclic compound | Walking CH3 |

| GHS Category ¹ /Substance | Rodent Oral LD ₅₀ ² (mg/kg) | Source ³ | Product/Use ⁴ | Molecular Weight (g/mol) | log Kow ⁵ | Chemical Class ⁶ | Molecular Structure | | | | |
|---|---|---|----------------------------------|-----------------------------|----------------------|--|---------------------|--|--|--|--|
| | $50 < LD_{50} \le 300 \text{ mg/kg}$ | | | | | | | | | | |
| Paraquat | 58 | MEIC, EDIT, RC (outlier), TESS, EPA | Pesticide (herbicide) | 257.20 | -4.22 @ pH 7.4 | Organic compound; Heterocyclic compound | CI. | | | | |
| Hexachlorophene | 61 | MEIC, RC, TESS, NTP | Disinfectant | 406.91 | 6.91 | Organic compound; Cyclic hydrocarbon; Phenol | | | | | |
| Lindane | 76 | MEIC, EDIT, RC (outlier), EPA, NTP | Pesticide (insecticide) | 290.80 | 3.72 | Organic compound; Halogenated hydrocarbon | | | | | |
| Cadmium II chloride | 88 | RC, TESS, GD, NTP | Consumer; Industrial products | 183.31 | NA | Inorganic compound; Cadmium compound | CI / CI—Cd | | | | |

| GHS Category ¹ /Substance | Rodent Oral LD ₅₀ ² (mg/kg) | Source ³ | Product/Use ⁴ | Molecular Weight (g/mol) | log Kow ⁵ | Chemical Class ⁶ | Molecular Structure |
|---|---|---|------------------------------------|-----------------------------|----------------------|--|--|
| Verapamil HCl | 108 | MEIC, EDIT, RC (outlier), TESS, NTP | Pharmaceutical (antiarrhythmic) | 491.08 | 3.79 | Organic compound; Amine | w |
| Haloperidol | 128* | MEIC, TESS | Pharmaceutical (antipsychotic) | 375.90 | 3.36 | Organic compound; Ketone | |
| Sodium oxalate | 155 | MEIC, EDIT, RC, TESS, NTP | Paints; Cleaners | 134.00 | NA | Organic compound; Carboxylic acid; Sodium compound | 0 Na ⁺ 0 ⁻ 0 ⁻ Na ⁺ |
| Phenobarbital | 163 | MEIC, RC (outlier), TESS, NTP | Pharmaceutical (anticonvulsant) | 232.23 | 1.47 | Organic compound; Heterocyclic compound | |

| GHS Category ¹ /Substance | Rodent Oral LD ₅₀ ² (mg/kg) | Source ³ | Product/Use ⁴ | Molecular Weight (g/mol) | log Kow ⁵ | Chemical Class ⁶ | Molecular Structure |
|---|---|--|---|-----------------------------|----------------------|--|--|
| Sodium I fluoride | 180 | MEIC, RC, TESS, EPA, NTP | Electroplating; Water fluoridation | 41.99 | NA | Inorganic compound; Sodium compound; Fluorine compound | Na ⁺ F [.] |
| Caffeine | 192 | MEIC, RC (outlier), TESS, NTP, HPV | Pharmaceutical (stimulant); Food additive | 194.20 | -0.07 | Organic compound; Heterocyclic compound | H ₃ C N N N CH ₃ CH ₃ |
| Diquat dibromide | 231 | MEIC, RC, TESS | Pesticide (herbicide) | 362.10 | -3.05 | Organic compound; Heterocyclic compound | H ₂ O Br ⁻ |
| Cupric sulfate * 5 H2O | 300 | MEIC, RC, TESS, EPA, NTP | Pesticide (insecticide/fungicide) | 249.70 | NA | Inorganic compound; Sulfur compound; Metal | H ₂ O//////////////////////////////////// |

| GHS Category ¹ /Substance | Rodent Oral LD ₅₀ ² (mg/kg) | Source ³ | Product/Use ⁴ | Molecular Weight (g/mol) | log Kow ⁵ | Chemical Class ⁶ | Molecular Structure | | | | |
|---|---|-------------------------------------|------------------------------------|-----------------------------|----------------------|---|-------------------------------|--|--|--|--|
| | $300 < LD_{50} \le 2000 \text{ mg/kg}$ | | | | | | | | | | |
| Amitriptyline HCl | 319 | MEIC, EDIT, RC, TESS | Pharmaceutical (antidepressant) | 313.90 | 5.04 | Organic compound; Polycyclic compound | HCI HCI CH ₃ | | | | |
| Phenol | 414 | MEIC, RC, TESS, EPA, NTP, HPV | Disinfectant | 94.11 | 1.46 | Organic compound; Phenol | но | | | | |
| Propranolol HCl | 470** | MEIC, RC, TESS, GD | Pharmaceutical (antiarrhythmic) | 295.80 | 3.09 | Organic compound; Alcohol; Amine; Polycyclic compound | | | | | |
| Chloral hydrate | 479 | MEIC, RC, TESS, NTP | Pharmaceutical (sedative) | 165.40 | 0.99 | Organic compound; Alcohol | | | | | |

| GHS Category ¹ /Substance | Rodent Oral LD ₅₀ ² (mg/kg) | Source ³ | Product/Use ⁴ | Molecular Weight (g/mol) | log Kow ⁵ | Chemical Class ⁶ | Molecular Structure | |
|---|---|-------------------------|------------------------------------|-----------------------------|----------------------|---|---------------------|--|
| Glutethimide | 600 | MEIC, RC, TESS | Pharmaceutical (sedative) | 217.30 | 1.9 | Organic compound; Heterocyclic compound | O CH3 | |
| Atropine sulfate | 623 | MEIC, EDIT, RC, TESS | Pharmaceutical (antimuscarinic) | 694.80 | 1.83 | Organic compound; Heterocyclic compound | | |
| Valproic acid | 1695 ** | RC, MEIC, TESS, NTP | Pharmaceutical (anticonvulsant) | 144.20 | 2.75 | Organic compound; Carboxylic acid; Lipids | | |

| GHS Category ¹ /Substance | Rodent Oral LD ₅₀ ² (mg/kg) | Source ³ | Product/Use ⁴ | Molecular Weight (g/mol) | log Kow ⁵ | Chemical Class ⁶ | Molecular Structure |
|---|---|-------------------------------------|-------------------------------------|-----------------------------|----------------------|--|--|
| Meprobamate | 794* | MEIC, TESS | Pharmaceutical (antidepressant) | 218.30 | NA | Organic compound; Carboxylic acid | |
| Acetylsalicylic acid | 1000 | MEIC, EDIT, RC, TESS, NTP | Pharmaceutical (analgesic) | 180.20 | 1.19 | Organic compound; Carboxylic acid; Phenol | OH O O CH ₃ |
| Lithium I carbonate | 1187 ⁷ | MEIC, RC, TESS, NTP (Cl salt) | Pharmaceutical (mood stabilizer) | 73.89 | NA | Inorganic compound; Lithium compound; Alkylies; Carbon compound | 0 0. Li ⁺ Li ⁺ |
| Procainamide | 1950 [*] | MEIC, TESS | Pharmaceutical (antiarrythmic) | 271.79 | NA | Organic compound; Carboxylic acid; Amide | н ₂ N |

| GHS Category ¹ /Substance | Rodent Oral LD ₅₀ ² (mg/kg) | Source ³ | Product/Use ⁴ | Molecular Weight (g/mol) | log Kow ⁵ | Chemical Class ⁶ | Molecular Structure | |
|---|---|------------------------------|---|--|----------------------|---|---------------------|--|
| Carbamazepine | 1957 [*] | MEIC, TESS | Pharmaceutical (antiepileptic) | 236.30 | 2.45 | Organic compound; Heterocyclic compound | H ₂ N 0 | |
| | | | 2000 < 1 | LD ₅₀ ≤5000 mg/kg | 3 | | | |
| Acetaminophen | 2404 | MEIC, EDIT, RC, TESS, NTP | Pharmaceutical (analgesic) | 151.20 | 0.8 | Organic compound; Amide | HO HO CH3 | |
| Potassium I chloride | 2602 | MEIC, RC, TESS, NTP | Pharmaceutical (electrolyte); Manufacturing | (electrolyte); 74.55 NA Potassium compound | | Inorganic compound; Potassium compound; Chlorine compound | K⁺ Cŀ | |
| Boric aid | 2660 [*] | TESS, EPA, NTP | Pesticide (insecticide) | 61.83 | NA | Inorganic compound; Boron compound; Acids | он но — в он | |

| GHS Category ¹ /Substance | Rodent Oral LD ₅₀ ² (mg/kg) | Source ³ | Product/Use ⁴ | Molecular Weight (g/mol) | log Kow ⁵ | Chemical Class ⁶ | Molecular Structure |
|---|---|--------------------------------------|---|--------------------------------|----------------------|--|--|
| Carbon tetrachloride | 2799 | MEIC, RC, TESS, NTP, HPV | Solvent | 153.82 | 2.83 | Organic compound; Halogenated hydrocarbon | |
| Dimethylformamide | 2800 | RC, GD, NTP, HPV | Solvent | 73.10 | -1.01 | Organic compound; Amide; Carboxylic acid | H ₃ C N I CH ₃ |
| Sodium chloride | 2998 | MEIC, EDIT, RC, TESS, EPA, NTP | Pharmaceutical (electrolyte); Food additive | (electrolyte); 58.44 NA Sodium | | Inorganic compound; Sodium compound; Chlorine compound | Na⁺ Cŀ |
| Citric Acid | 3000* | EPA, NTP, HPV | Food additive | 192.10 | -1.72 | Organic compound; Carboxylic acid | о ОН НО ОН ОН |

| GHS Category ¹ /Substance | Rodent Oral LD ₅₀ ² (mg/kg) | Source ³ | Product/Use ⁴ | Molecular Weight (g/mol) | log Kow ⁵ | Chemical Class ⁶ | Molecular Structure |
|---|---|--------------------------------|--------------------------------|-----------------------------|----------------------|--|---------------------|
| Chloramphenicol | 3393 | MEIC, RC, NTP | Pharmaceutical (antibiotic) | 323.14 | 1.14 | Organic compound; Alcohol; Cyclic hydrocarbon; Nitro compound | |
| Lactic acid | 3730 | RC, NTP, HPV | Food additive | 90.08 | -0.72 | Organic compound; Carboxylic acid | н ₃ с он |
| Acetonitrile | 3798 | RC, NTP, HPV | Solvent | 41.05 | -0.34 | Organic compound; Nitrile | H C—C≡N H |
| Xylene (mixed isomers) | 4300 | MEIC, RC, TESS, NTP, HPV | Solvent | 106.17 | 3.12 - 3.2 | Organic compound; Cyclic hydrocarbon | CH3 CH3 |

| GHS Category ¹ /Substance | Rodent Oral LD ₅₀ ² (mg/kg) | Source ³ | Product/Use ⁴ | Molecular Weight (g/mol) | log Kow ⁵ | Chemical Class ⁶ | Molecular Structure |
|---|---|-------------------------------------|--------------------------|-----------------------------|----------------------|---|--|
| Trichloroacetic acid | 4999 | RC, NTP | Fixative | 163.40 | 1.33 | Organic compound; Carboxylic acid | |
| | | | LD ₅₀ |) >5000 mg/kg | | | I |
| 2-Propanol | 5843 | MEIC, RC, TESS, EPA, NTP, HPV | Disinfectant | 60.10 | 0.05 | Organic compound; Alcohol | он Н ₃ с сн ₃ |
| Gibberellic acid | 6305 | RC, EPA, NTP | Plant growth regulator | 346.38 | 0.24 | Organic compound; Polycyclic compound | |
| Propylparaben | 6326** | RC (outlier), NTP | Food additive | 180.20 | 3.04 | Organic compound; Carboxylic acid; Phenol | но |

| GHS Category ¹ /Substance | Rodent Oral LD ₅₀ ² (mg/kg) | Source ³ | Product/Use ⁴ | Molecular Weight (g/mol) | log Kow ⁵ | Chemical Class ⁶ | Molecular Structure |
|---|---|--------------------------------------|--------------------------------|-----------------------------|----------------------|---|---------------------|
| 5-Aminosalicylic acid | 7749** | RC (outlier), NTP | Pharmaceutical (antibiotic) | 153.10 | 1.32 | Organic compound; Carboxylic acid; Phenol | H ₂ N OH |
| Ethylene glycol | 8567 | MEIC, EDIT, RC, TESS, NTP, HPV | Antifreeze | 62.07 | -1.36 | Organic compound; Alcohol | ноон |
| Diethyl phthalate | 8602 | RC (outlier), NTP, HPV | Plasticizer | 222.20 | 2.47 | Organic compound; Carboxylic acid | |
| Sodium hypochlorite | 8910 ⁸ | TESS, NTP | Disinfectant | 74.44 | NA | Inorganic compound; Sodiumcompound; Oxygen compound; Chlorine compound | CIONa* |

| GHS Category ¹ /Substance | Rodent Oral LD ₅₀ ² (mg/kg) | Source ³ | Product/Use ⁴ | Molecular Weight (g/mol) | log Kow ⁵ | Chemical Class ⁶ | Molecular Structure |
|---|---|--------------------------------------|--------------------------|-----------------------------|----------------------|---|-----------------------|
| 1,1,1-Trichloroethane | 10298 | MEIC, RC, NTP, HPV | Solvent | 133.41 | 2.49 | Organic compound; Halogenated hydrocarbon | CI CI CI |
| Dibutyl phthalate | 11998 | RC (outlier), NTP, HPV | Plasticizer | 278.30 | 4.9 | Organic compound; Carboxylic acid | "s ^c ~ |
| Glycerol | 12691 | RC, GD, NTP, HPV | Solvent | 92.09 | -1.76 | Organic compound; Alcohol | но он |
| Methanol | 13012 | MEIC, EDIT, RC, TESS, NTP, HPV | Solvent | 32.04 | -0.77 | Organic compound; Alcohol | H H H H H |

| GHS Category ¹ /Substance | Rodent Oral LD ₅₀ ² (mg/kg) | Source ³ | Product/Use ⁴ | Molecular Weight (g/mol) | log Kow ⁵ | Chemical Class ⁶ | Molecular Structure |
|---|---|--|--------------------------|-----------------------------|----------------------|------------------------------|---------------------|
| Ethanol | 14008 | MEIC, RC (outlier), TESS, EPA, NTP, HPV | Solvent | 46.07 | -0.31 | Organic compound; Alcohol | н₃с ∕∕он |

Abbreviations: GHS=Globally Harmonized System of Classification and Labelling of Chemicals (UN 2005); LD_{50} =Dose that produces lethality in 50% of the test animals; K_{ow} =Octanol:water partition coefficient; EDIT=Evaluation-guided Development of New *In vitro* Test Batteries (substances in EDIT program are a subset of the MEIC substance set); EPA=Pesticides registered with the Environmental Protection Agency; EHS=EPA's Extremely Hazardous Substance list; HPV=High Production Volume chemicals (i.e., those that are imported into or produced in the United States in amounts \geq 1,000,000 lbs/year); GD=*Guidance Document* (ICCVAM 2001b); MEIC=Multicentre Evaluation of *In Vitro* Cytotoxicity; NA=Non applicable; NTP=National Toxicology Program; RC=Registry of Cytotoxicity with the chemicals classified as regression outliers shown in parentheses; TESS=Toxic Exposure Surveillance System (Litovitz et al. 2000); HSDB=Hazardous Substances Data Bank; RTECS[®]=Registry of Toxic Effects of Chemical Substances.

*From RTECS[®] (MDL Information Systems 2002).

**Mouse.

¹GHS category designation for the substance (e.g., LD₅₀ <5 mg/kg)

²LD₅₀ data are from the Registry of Cytotoxicity (Halle 1998, 2003) and are for rats, unless otherwise noted. The LD₅₀ values are rounded to the nearest whole number.

³Sources used to identify candidate chemicals.

⁴Product/use categories from HSDB (NLM 2002) or RTECS[®](MDL Information Systems 2002). Pharmaceutical uses from Gilman et al. (1985) or Thomson PDR[®] (2004).

⁵From HSDB (NLM 2001, 2002) or Material Safety Data Sheets.

⁶Based on Medical Subject Heading [MeSH[®]] descriptors (NLM 2005).

⁷Mouse data for lithium sulfate (Halle 1998, 2003).

⁸From HSDB (NLM 2002).

| GHS Category (mg/kg) | Reference Substances/ Candidate Substances | | EDIT Reference/ EDIT Candidates | TESS Reference/ TESS Candidates | NTP Reference/ NTP Candidates | HPV Reference/ HPV Candidates |
|---------------------------|---|-------|------------------------------------|------------------------------------|----------------------------------|----------------------------------|
| $LD_{50} \leq 5$ | 12/13 | 2/2 | 1/1 | 3/3 | 5/9 | 0/0 |
| $5 < LD_{50} \leq 50$ | 12/15 | 6/6 | 5/5 | 9/10 | 8/11 | 2/5 |
| $50 < LD_{50} \le 300$ | 12/26 | 11/17 | 4/5 | 11/19 | 9/18 | 1/3 |
| $300 < LD_{50} \le 2000$ | 12/38 | 12/29 | 3/5 | 12/27 | 5/23 | 1/5 |
| $2000 < LD_{50} \le 5000$ | 12/12 | 6/6 | 2/2 | 6/6 | 12/12 | 6/6 |
| LD ₅₀ >5000 | 12/12 | 5/5 | 2/2 | 5/5 | 12/12 | 8/8 |
| Total | 72/116 | 42/65 | 17/20 | 46/70 | 51/85 | 18/27 |

Table 3-3 Distribution of Candidate Substances and Reference Substances by Source¹ and Toxicity Category

Abbreviations: GHS=Globally Harmonized System of Classification and Labelling of Chemicals (UN 2005); LD_{50} =Dose that produces lethality in 50% of the test animals; MEIC=Multicentre Evaluation of *In Vitro* Cytotoxicity; EDIT=Evaluation-Guided Development of *In vitro* Tests; TESS=Toxic Exposure Surveillance System; NTP=U.S. National Toxicology Program; HPV=U.S. Environmental Protection Agency (EPA) High Production Volume program. ¹Substances may have been selected from more than one source (see **Table 3-2** and **Appendix F3**).


Table 3-4 Selected Substances: Distribution of RC Chemicals and RC Outliers¹ by Toxicity Category


| GHS Category | RC Outliers/ | | Candidate and Selected Substances | | | | | | |
|----------------------------|-----------------|-------------------------|-----------------------------------|--|--|--|--|--|--|
| (mg/kg) | Total Chemicals | Candidate Substances | RC Reference / RC Candidates | RC Reference Outliers/ RC Reference Chemicals | | | | | |
| $LD_{50} \leq 5$ | 10/11 (91%) | 13 | 9/10 | 8/9 (89%) | | | | | |
| $5 < LD_{50} \le 50$ | 15/26 (58%) | 15 | 8/10 | 4/8 (50%) | | | | | |
| $50 < LD_{50} \le 300$ | 24/70 (34%) | 26 | 11/18 | 5/11 (45%) | | | | | |
| $300 < LD_{50} \le 2000$ | 14/139 (10%) | 38 | 9/29 | 0/9 (0%) | | | | | |
| $2000 < LD_{50} \leq 5000$ | 12/57 (21%) | 12 | 10/10 | 0/10 (0%) | | | | | |
| LD ₅₀ >5000 | 20/44 (45%) | 12 | 11/11 | 5/11 (45%) | | | | | |
| Total | 95/347 (27%) | 116 | 58/88 | 22/58 (38%) | | | | | |

Abbreviations: RC=Registry of Cytotoxicity; GHS=Globally Harmonized System of Classification and Labelling of Chemicals (UN 2005); LD_{50} =Dose that produces lethality in 50% of the test animals.

¹Chemicals falling outside the log 5 (i.e., $\geq \pm 0.699$) prediction interval for the RC millimole regression (Halle 1998, 2003).

Among the 58 RC substances selected for use in the validation study, 22 (38%) were outliers for the RC millimole regression. Toxicity¹ was underpredicted for 17 (77%) of these outlier substances and overpredicted (i.e., predicted LD_{50} was lower than measured *in vivo* LD_{50}) for the remaining five (23%). For the 95 outlier substances in the RC, the number of substances for which toxicity was over- or under-predicted was approximately the same. Toxicity was underpredicted for 49 (52%) outliers and overpredicted for 46 (48%) outliers (Halle 1998, 2003). **Figure 3-1** shows the 58 RC chemicals selected for testing, in addition to the 289 RC chemicals that were not selected, and the RC millimole regression. In the figure, the outliers are those points outside the RC prediction interval. For the 58 RC substances selected for testing, the majority (17/22) of the outliers are below the RC millimole regression line.





Abbreviations: RC=Registry of Cytotoxicity; LD_{50} =Dose that produces lethality in 50% of the test animals; IC_{50} =Test substance concentration that reduces cell viability by 50%. The 58 RC chemicals tested in the NICEATM/ECVAM validation study are shown by *. The RC regression, log (LD_{50}) = 0.435 x log (IC_{50x}) + 0.625, is shown by the bold line. The lighter lines show the ± log 5 (i.e., ±0.699) prediction interval (Halle 1998, 2003). The open boxes represent the 289 chemicals not included in the validation study.

¹ Toxicity is inversely proportional to LD_{50} . High LD_{50} values reflect low toxicity and low LD_{50} values reflect high toxicity

3.2.2 <u>Chemical Classes Represented by the Selected Reference Substances</u>

Medical subject heading (MeSH[®]) descriptors from the NLM were used to determine chemical class designations for the selected substances. Of the 72 reference substances, 57 (79%) were organic and 15 (21%) were inorganic. The number of substances in the organic (79) and inorganic (31) subclasses is greater than the number of substances in each class because some of the substances are classified in more than one subclass. The most commonly represented classes of organic compounds were heterocyclics (14/57, 25%), carboxylic acids (14/57, 25%), and alcohols (10/57, 18%). **Table 3-5** shows the distribution of the substances among the GHS toxicity categories. The 14 heterocyclics were evenly distributed among the first four GHS toxicity categories for LD₅₀ ≤2000 mg/kg with the majority of the heterocyclics (11/14) in the categories for LD₅₀ >300 mg/kg. The majority of the carboxylic acids (12/14) and alcohols (8/10) had an LD₅₀ >300 mg/kg, while the majority of the inorganics (10/15) had an LD₅₀ <300 mg/kg.

3.2.3 Product/Use Classes Represented by the Selected Reference Substances Product and use information was obtained from HSDB (NLM 2002) or RTECS[®] (MDL Information Systems 2002). The number of assigned uses (77) is greater than the number of selected substances because some of the substances have more than one use. **Table 3-6** shows the distribution of products and uses of the selected substances according to their GHS categories. Pharmaceutical (27/77; 35%) and pesticide (17/77; 22%) uses were observed most frequently. The toxicity category of 300 < LD₅₀ ≤2000 mg/kg had the highest number of pharmaceuticals. Every toxicity category except LD₅₀ >5000 mg/kg had at least four substances with pharmaceutical uses. The majority of pesticides (16/17; 94%) had an LD₅₀ <300 mg/kg. The next most frequent uses were as solvents (8/77; 10%) and food additives (5/77; 6%); LD₅₀ >2000 mg/kg contained most of the substances with solvent (8/8; 100%) and food additive (4/5; 80%) uses.

3.2.4 <u>Toxicological Characteristics of the Selected Reference Substances</u>

3.2.4.1 *Corrosivity*

The intent of the SMT was to prioritize only those substances with low corrosivity because guidelines for acute systemic toxicity testing indicate that corrosive or severely irritating substances need not be tested (OECD 2001a, c, d). The UN and U.S. Department of Transportation Packing Group (DOT PG) classification system was used to classify the corrosivity hazard associated with the candidate substances. However, after substance selection was completed and testing had begun, the SMT learned that the PG classification system was also based on hazards other than corrosivity (e.g., dermal and inhalation toxicity, flammability, etc.). Therefore, the selected substances were not actually prioritized by corrosivity. Subsequent information on the corrosivity of the selected substances was obtained from HSDB (NLM 2004) and the Material Safety Data Sheets (MSDS) provided with the purchased substances. Seven substances that were not identified by the DOT PG classification system had corrosive notations. The MSDS notations for lactic acid, sodium hypochlorite, sodium oxalate, and trichloroacetic acid indicated that these substances should carry a corrosive label. Chloral hydrate, mercury II chloride, and potassium cyanide were noted by HSDB to be corrosive to eyes or skin.

| Chemical Class ¹ | | | GHS Acute Oral | Toxicity Category (| (mg/kg) | | Total |
|-----------------------------|---------------------|--------------------------|----------------------------|--------------------------|---------------------------|------------------------|-------|
| Chemical Class | LD ₅₀ ≤5 | 5 < LD ₅₀ ≤50 | 50 < LD ₅₀ ≤300 | $300 < LD_{50} \le 2000$ | $2000 < LD_{50} \le 5000$ | LD ₅₀ >5000 | Iotai |
| Organic | | | | | | | |
| Carboxylic acid | 1 | 0 | 1 | 4 | 4 | 4 | 14 |
| Heterocyclic compound | 5 | 2 | 4 | 3 | 0 | 0 | 14 |
| Alcohol | 2 | 0 | 0 | 2 | 1 | 5 | 10 |
| Phenol | 0 | 0 | 1 | 2 | 0 | 2 | 5 |
| Polycyclic compound | 0 | 2 | 0 | 2 | 0 | 1 | 5 |
| Sulfur compound | 4 | 1 | 0 | 0 | 0 | 0 | 5 |
| Amine | 1 | 0 | 1 | 1 | 0 | 0 | 3 |
| Cyclic hydrocarbon | 0 | 0 | 1 | 0 | 1 | 1 | 3 |
| Halogenated hydrocarbon | 0 | 0 | 1 | 0 | 1 | 1 | 3 |
| Organophosphorous compound | 2 | 1 | 0 | 0 | 0 | 0 | 3 |
| Amide | 0 | 0 | 0 | 1 | 2 | 0 | 3 |
| Nitrile | 0 | 1 | 0 | 0 | 1 | 0 | 2 |
| Acyclic hydrocarbon | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Carbohydrate | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Ester | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Ether | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Ketone | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Lipid | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Nitro compound | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Organometallic compound | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Sodium compound | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Urea | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Total Organics | 17 | 11 | 11 | 16 | 11 | 14 | 79 |

Table 3-5Distribution of Chemical Class for the 72 Reference Substances by Toxicity Category

| Chemical Class ¹ GHS Acute Oral T | | | Toxicity Category (mg/kg) | | | Total | |
|--|---------------------|----------------------|----------------------------|--------------------------|---------------------------|------------------------|--------|
| Chemitan Chuss | LD ₅₀ ≤5 | $5 < LD_{50} \le 50$ | 50 < LD ₅₀ ≤300 | $300 < LD_{50} \le 2000$ | $2000 < LD_{50} \le 5000$ | LD ₅₀ >5000 | I otal |
| Inorganic | | | | | | | |
| Sodium compound | 1 | 2 | 1 | 0 | 1 | 1 | 6 |
| Chlorine compound | 1 | 0 | 1 | 0 | 2 | 1 | 5 |
| Arsenical | 0 | 2 | 0 | 0 | 0 | 0 | 2 |
| Metal | 0 | 1 | 1 | 0 | 0 | 0 | 2 |
| Potassium compound | 0 | 1 | 0 | 0 | 1 | 0 | 2 |
| Sulfur compound | 0 | 1 | 1 | 0 | 0 | 0 | 2 |
| Acid | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Alkalies | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Boron compound | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Cadmium compound | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Carbon compound | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Chromium compound | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Fluorine compound | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Lithium compound | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Mercury compound | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Nitrogen compound | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Oxygen compound | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Selenium compound | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Total Inorganic | 4 | 9 | 7 | 2 | 6 | 3 | 31 |

Table 3-5 Distribution of Chemical Class for the 72 Reference Substances by Toxicity Category

Abbreviations: GHS=Globally Harmonized System of Classification and Labelling of Chemicals (UN 2005).

¹Based on the Medical Subject Heading [MeSH[®]] descriptor (NLM 2005). Some substances are counted more than once because they appear in more than one subclass under the organic or inorganic classes.

| Product/Use Class ¹ | GHS Acute Oral Toxicity Category (mg/kg) | | | | | | |
|--------------------------------|--|-------------------------|---------------------------|--------------------------|------------------------------|------------------------|-------|
| T Toduct Osc Class | LD ₅₀ ≤5 | 5< LD ₅₀ ≤50 | 50< LD ₅₀ ≤300 | $300 < LD_{50} \le 2000$ | 2000< LD ₅₀ ≤5000 | LD ₅₀ >5000 | Total |
| Antibiotic/fungicide | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Antifreeze | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Consumer/industrial products | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Disinfectant | 0 | 0 | 1 | 1 | 0 | 2 | 4 |
| Electroplating | 0 | 2 | 0 | 0 | 0 | 0 | 2 |
| Fluoridation | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Feed additive | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Fixative | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Food additive | 0 | 0 | 1 | 0 | 3 | 1 | 5 |
| Manufacturing | 1 | 0 | 0 | 0 | 1 | 0 | 2 |
| Oxidizing agent | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Paints, cleaners | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Pesticide | 5 | 7 | 4 | 0 | 1 | 0 | 17 |
| Pharmaceutical | 4 | 3 | 4 | 11 | 4 | 1 | 27 |
| Plant growth regulator | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Plasticizer | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Preservative | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Solvent | 0 | 0 | 0 | 0 | 4 | 4 | 8 |

Distribution of Product/Use¹ Class for the 72 Reference Substances by Toxicity Category Table 3-6

Abbreviations: GHS=Globally Harmonized System of Classification and Labelling of Chemicals (UN 2005). ¹Product/use information from Hazardous Substances Data Bank (NLM 2002) or Registry of Toxic Effects of Chemical Substances ([RTECS[®]], MDL Information Systems 2002). Some substances are counted more than once because they appear in more than one use category.

3.2.4.2 *Toxicity Targets*

As shown in **Appendix F2**, the most common toxicological effects in humans or rodents were neurological (40 substances); 26 cause central nervous system (CNS) depression, seven produce CNS stimulation, four produce CNS affects such as encephalopathy, and three affect the peripheral nervous system. Other common target systems include the liver (17 substances), kidney (15 substances), and cardiovascular system (10 substances). No target organ information was available for gibberellic acid. Among the 72 reference substances, 27 had more than one toxicity target.

3.2.4.3 *Metabolism*

Table 3-7 shows the 22 reference substances that are known or expected to produce active/toxic metabolites *in vivo*. In contrast, dichlorvos, fenpropathrin, meprobamate, phenylthiourea, and sodium dichromate are rapidly metabolized to less toxic compounds. Because the NHK and 3T3 cells have little (Babich 1991) or no (INVITTOX 1991) metabolic capability, respectively, metabolites of these compounds would not be expected to be present *in vitro*. **Appendix F2** provides for more information on the metabolism (activation/inactivation) of the selected reference substances.

| | Active Metabolites Expected | | | |
|----------------------|--------------------------------|-----------------|------------------|----------------------|
| Acetaminophen | Carbamazepine | Digoxin | Methanol | Carbon tetrachloride |
| Acetonitrile | Chloral hydrate | Disulfoton | Parathion | Triethylenemelamine |
| Acetylsalicylic acid | Cycloheximide | Ethanol | Procainamide HCl | Valproic acid |
| Amitriptyline HCl | Dibutyl phthalate | Ethylene glycol | Verapamil HCl | |
| Busulfan | Diethyl phthalate | Glutethimide | | |

Table 3-7 Reference Substances Metabolized to Active Metabolites

3.2.5 <u>Selection of Reference Substances for Testing in Phases Ib and II</u>

Based on the *Guidance Document* (ICCVAM 2001b) recommendation that 10 to 20 substances be tested to qualify candidate *in vitro* cytotoxicity tests for determining starting doses for rodent acute oral toxicity assays, 12 reference substances were chosen from among the 72 reference substances for testing in Phases Ib and II (see **Table 3-8**). The criteria for choosing these reference substances, in order of importance, were:

- Two reference substances must be included from each of the five GHS toxicity categories and the unclassified category.
- The log LD_{50} (mmol/kg) must be within the prediction interval (±0.699) of the RC millimole regression. The *Guidance Document* (ICCVAM 2001b) recommends that reference substances for evaluating an *in vitro* basal cytotoxicity test to use with the RC millimole regression fit the regression as closely as possible.
- MEIC chemicals must be included. Cytotoxicity data from these phases (and Phase III of this study), and the available human toxicity information for the MEIC chemicals, could be used to build a prediction model for estimating

human LC values. The Phase Ib reference substances arsenic trioxide and ethylene glycol are also EDIT chemicals (subset of MEIC chemicals).

If more than two substances in a GHS category met the above criteria, reference substances were selected so that the LD_{50} was as close to the RC millimole regression as possible and/or to represent the full range of toxicity in each GHS category.

| Reference Substances | CASRN | RC Reference No. | MEIC Reference No. | Rodent Oral LD ₅₀ ¹ (mg/kg) | Observed – Predicted log LD ₅₀ ² |
|---|------------|------------------------|--------------------------|---|--|
| $LD_{50} \leq 5 mg/kg$ | | | | | |
| Aminopterin | 54-62-6 | 3 | NA | 3 | -0.652 |
| Sodium selenate | 13410-01-0 | NA | NA | 1.6^{3} | NA |
| $5 < LD_{50} \le 50 mg/kg$ | | | | | |
| Colchicine | 64-86-8 | 6 | 60 | 6 ⁴ | -0.593 |
| Arsenic III trioxide | 1327-53-3 | 153 | 26 | 20 | -0.591 |
| $50 < LD_{50} \le 300 \text{ mg/kg}$ | | | | | |
| Cadmium II chloride | 10108-64-2 | 81 | NA | 88 | 0.011 |
| Sodium I fluoride | 7681-49-4 | 106 | 14 | 180 | -0.109 |
| $300 < LD_{50} \le 2000 \text{ mg/kg}$ | | | | | |
| DL-Propranolol HCl | 350-60-90 | 54 | 23 | 470^{4} | -0.023 |
| Lithium I carbonate | 544-13-2 | 327^{4} | 20 | $1187^{4,5}$ | -0.256^4 |
| $2000 < LD_{50} \le 5000 \text{ mg/kg}$ | | | | | |
| Potassium I chloride | 7447-40-7 | 346 | 50 | 2602 | 0.085 |
| Chloramphenicol | 56-75-7 | 91 | 45 | 3393 | 0.441 |
| <i>LD</i> ₅₀ >5000 mg/kg | | | | | |
| 2-Propanol | 67-63-0 | 128 | 10 | 5843 | 0.396 |
| Ethylene glycol | 107-21-1 | 360 | 7 | 8567 | 0.321 |

| Table 3-8Reference Substance | inces Tested in Phases Ib and II |
|------------------------------|----------------------------------|
|------------------------------|----------------------------------|

Abbreviations: CASRN=Chemical Abstracts Service Registry Number; RC=Registry of Cytotoxicity; MEIC=Multicentre Evaluation of *In Vitro* Cytotoxicity; NA=Not applicable (i.e., substances not included in the RC and/or MEIC studies); RTECS[®]=Registry of Toxic Effects of Chemical Substances.

¹From the RC (Halle 1998, 2003) unless otherwise indicated. Data are for rats unless otherwise indicated.

²Available only for substances included in the RC. This figure characterizes the log LD_{50} deviation from the RC regression. Outliers are > ±0.699 from the regression line.

³RTECS[®] (MDL Information Systems 2002).

⁴Mouse data.

⁵For lithium sulfate.

Only nine of the 72 reference substances met all three criteria. In the most toxic category (i.e., $LD_{50} \le 5$ mg/kg), only one RC chemical, aminopterin, was within 0.699 of the RC millimole regression. Sodium selenate was selected as the second reference substance in this category even though its fit to the RC millimole regression was not known. Neither aminopterin nor sodium selenate were MEIC chemicals. For the $50 < LD_{50} \le 300$ mg/kg category, cadmium chloride was selected over the MEIC chemicals cupric sulfate $5H_2O$, diquat dibromide, sodium oxalate, and hexachlorophene because it fit the RC millimole regression better than the four MEIC chemicals (the observed LD_{50} minus log predicted LD_{50} values were -0.534 to -0.337).

3.2.6 <u>Unsuitable and Challenging Reference Substances</u>

Several reference substances could not be adequately tested for cytotoxicity in 3T3 cells and/or NHKs in from one to all three of the laboratories. The following reference substances did not produce sufficient toxicity at soluble concentrations for calculation of an IC_{50} at the highest concentrations tested under the testing conditions used in the study (see also **Tables 5-2**, **5-4**, and **5-5**):

- Carbon tetrachloride (no 3T3 or NHK NRU IC₅₀ data from ECBC, FAL, or IIVS)
- Xylene (no 3T3 or NHK NRU IC₅₀ data from ECBC or FAL)
- Methanol (no 3T3 NRU IC₅₀ data from ECBC, FAL, or IIVS; no NHK NRU IC₅₀ data from ECBC)
- Lithium carbonate (no 3T3 NRU IC₅₀ data from FAL or IIVS)
- 1,1,1-Trichloroethane (no 3T3 NRU IC₅₀ data from FAL or IIVS; no NHK NRU IC₅₀ data from ECBC)
- Valproic acid (no 3T3 NRU IC₅₀ data from ECBC or FAL; no NHK NRU IC₅₀ data from ECBC, FAL, or IIVS)

Other reference substances were difficult to test because of volatility or lack of toxicity, but three acceptable tests could be obtained after a number of trials.

- Acetonitrile and 2-propanol were highly volatile and nontoxic, so that even with the use of film plate sealers, from one to seven tests failed the VC and data points test acceptance criteria at each laboratory.
- Disulfoton failed at least one test in both test methods at ECBC and FAL because of inadequate toxicity (i.e., an IC_{50} could not be detected) and insolubility. All laboratories reported precipitate in the test plates for 3T3 and NHK NRU tests. IIVS had no failed tests in either test method.
- Dibutyl phthalate failed one 3T3 NRU test at ECBC and one NHK NRU test at FAL because of inadequate toxicity and solubility.
- Lindane failed one 3T3 NRU test at FAL because of inadequate toxicity and solubility and one because of its volatility.
- Parathion failed one test because of inadequate toxicity and solubility in both test methods and one NHK NRU test because of volatility at FAL.
- Diethyl phthalate failed one NHK NRU test because of volatility at FAL.
- Digoxin (all laboratories), gibberellic acid (ECBC and FAL), and strychnine (ECBC and FAL) failed at least one 3T3 NRU test because of inadequate toxicity and solubility.

3.3 Reference Substance Procurement, Coding, and Distribution

BioReliance collected information from the suppliers of the reference substances on their analytical purity, composition, and stability (see **Appendix F1**), tested the reference substances for solubility, packaged them into 4 g aliquots for shipment to the testing laboratories, and archived two additional samples. All reference substances were given a random number code that was unique for each testing facility to conceal the identities from the testing laboratories. Approximately 100 g of the PC substance, SLS, was distributed, uncoded, to each laboratory and one additional sample was archived.

Reference substances were packaged so as to minimize damage during transit, and shipped under appropriate storage conditions and according to the appropriate regulatory transportation procedures. Testing facilities were notified upon shipment in order to prepare for receipt. With the exception of the PC substance which was shipped directly to the Study Directors, the reference substances were shipped to the test facility Safety Officers. Shipments were accompanied by a sealed information packet containing the appropriate health and safety procedures (i.e., MSDS or equivalent documentation with information regarding the proper protection for handling, procedures for dealing with accidental ingestion or contact with skin or eyes, and for containing and recovering spills), and a code disclosure key. Also provided was a data sheet giving a minimum of essential information needed by the testing laboratory for each reference substance, including color, odor, physical state, weight or volume of sample, specific density for liquid reference substances, and storage instructions. The shipment directed the Safety Officer to:

- Notify BioReliance and the SMT upon receipt of reference substances
- Retain the health and safety package and provide the coded reference substances and chemical data sheets with minimum essential information to the laboratory Study Director without revealing the identities of the test substances
- Notify the SMT if test facility personnel open the health and safety packet at any time, for any reason, during the study
- Return the unopened health and safety package to BioReliance after testing is completed

3.3.1 Exceptions

The Safety Officer for ECBC required the information on reference substance codes before the substances were shipped in order to satisfy the facility's environmental procedures and requirements. The reference substance codes were stored in a classified safe located in the Safety Office which was in a building separate from the cytotoxicity testing laboratory, and were to be opened only by the Safety Officer. The ECBC Safety Officer opened the sealed health and safety packets for lithium carbonate and ethanol upon receipt of those substances because the code information for these substances was not included in the list originally provided. ECBC cytotoxicity testing personnel did not have direct access to the reference substance codes.

3.4 Reference Substances Recommended by the *Guidance Document*

The *Guidance Document* specifically recommended testing the following 11 substances to validate candidate *in vitro* basal cytotoxicity assays: sodium dichromate dihydrate, cadmium chloride, *p*-phenylenediamine, DL-propranolol HCl, trichlorfon, ibuprofen, nalidixic acid, salicylic acid, antipyrene, dimethylformamide, and glycerol (ICCVAM 2001b). Of these 11 substances (see **Appendix F3** and **Section 3.1.2**), five (sodium dichromate dihydrate, cadmium chloride, DL-propranolol HCl, dimethylformamide, and glycerol) were chosen for testing after the candidate substances were prioritized as described in **Section 3.1.3**. The seven that were not selected did not satisfy the selection criteria (e.g., not MEIC chemicals, not identified as high exposure risk in TESS)

3.5 Summary

Seventy-two reference substances were selected for testing in the NICEATM/ECVAM validation study. These substances were selected to represent: (1) the complete range of *in vivo* acute oral LD_{50} values; (2) the types of substances regulated by the various regulatory authorities; and (3) those with human toxicity data and/or human exposure potential. To insure that the complete range of toxicity was covered, the GHS (UN 2005) was used to select 12 substances for each acute oral toxicity category and 12 unclassified substances. The set of selected reference substances had the following characteristics:

- Thirty-five percent (27/77 uses) were pharmaceuticals, 22% (17/77 uses) were pesticides, 10% (8/77 uses) were solvents, and 6% (5/77 uses) were food additives. The remaining substances were used for a variety of manufacturing and consumer products.
- In terms of relevance of the substances to human exposure, 58% (42/72) were included in the MEIC study (substances chosen because of availability of human lethality data), 24% (17/72) were included also in the EDIT program (EDIT substances are a subset of the MEIC substances), 64% (46/72) had human exposure data reported by TESS, 71% (51/72) had been evaluated by NTP, and 25% (18/72) were on the EPA HPV list.
- Eighty-one percent (58/72) of the substances were in the RC and 38% (22/58) of these were outliers with respect to the RC millimole regression. The RC millimole regression underpredicted the toxicity of 77% (17/22) of the outliers and overpredicted the toxicity of 23% (5/22). For the 95 outlier substances in the RC, however, the number of substances for which toxicity was over- or under-predicted was approximately the same (i.e., toxicity was underpredicted for 49 [52%] outliers and overpredicted for 46 [48%] outliers [Halle 1998, 2003]).
- Seventy-nine percent (57/72) were organic compounds and 21% (15/72) were inorganic. The most commonly represented classes of organic compounds were heterocyclics (25%, 14/57), carboxylic acids (25%, 14/57), and alcohols (18%, 10/57).
- Nineteen substances (26%, 19/72,) were known to have active metabolites and three others were expected to have active metabolites based on their chemical structures.
- Many of the substances produced toxicity in more than one organ system. The most common target systems were neurological (40 substances), liver (17 substances), kidney (15 substances), and cardiovascular (10 substances). No target organ information was available for one substance (gibberellic acid).

| 4.0 | ASSE | ENT ACUTE ORAL LD ₅₀ REFERENCE VALUES USED TO ISS THE ACCURACY OF THE 3T3 AND NHK NRU TEST HODS | 4-3 |
|-----|----------------|---|------|
| 4.1 | Meth | ods Used to Obtain Rodent Acute Oral LD ₅₀ Reference Values | 4-3 |
| | 4.1.1 4.1.2 | Identification of Candidate Rodent Acute Oral LD ₅₀ Reference Data Criteria Used to Select Candidate Rodent Acute Oral Data for | 4-3 |
| | | Determination of LD ₅₀ Reference Values | 4-5 |
| 4.2 | Final | Rodent Acute Oral LD ₅₀ Reference Values | 4-7 |
| 4.3 | Relev | ant Toxicity Information for Humans | 4-8 |
| 4.4 | Accui | racy and Reliability of the Rodent Acute Oral LD ₅₀ Reference | |
| | Value | °S | 4-13 |
| | 4.4.1 | Variability Among the Acceptable LD ₅₀ Values | 4-13 |
| | 4.4.2 | Comparison of Rodent Acute Oral LD ₅₀ Reference Values with the | |
| | | Corresponding RC LD ₅₀ Values | 4-14 |
| | 4.4.3 | Comparison of the Variability Among Acceptable LD ₅₀ Values to | |
| | | Those Obtained in Other Studies | 4-15 |
| 4.5 | Sumn | nary | 4-16 |

[This Page Intentionally Left Blank]

4.0 RODENT ACUTE ORAL LD₅₀ REFERENCE VALUES USED TO ASSESS THE ACCURACY OF THE 3T3 AND NHK NRU TEST METHODS

The procedures and analyses presented in this section were designed to identify the most accurate rodent acute oral LD_{50} values for the 72 reference substances used in the validation study. These values were needed to ensure that the reference substances were correctly placed within the different GHS toxicity categories and to provide a data set against which to compare the predicted LD_{50} values estimated using the IC_{50} data obtained from the 3T3 and NHK NRU test methods (see **Section 6**). The predicted LD_{50} values are used to determine the starting dose for rodent acute oral toxicity tests and the more accurate the prediction, the fewer the number of rodents that would be used in an acute oral toxicity test (see **Sections 1.0** and **1.2.2**).

4.1 Methods Used to Obtain Rodent Acute Oral LD₅₀ Reference Values

4.1.1 Identification of Candidate Rodent Acute Oral LD₅₀ Reference Data

No animal testing was performed to obtain the rodent oral acute LD_{50} reference data for this validation study. To identify reference data for the 72 substances, rat acute oral LD_{50} studies were located using literature searches, secondary references, and electronic database searches. Literature searches were conducted in PubMed (U.S. NLM) and the Institute of Scientific Information (ISI) Web of Science[®] (Thomson Scientific, Philadelphia, PA) using each chemical name and "lethal dose 50" as search terms. Secondary references included NTP technical reports, Toxicological Profiles from the Agency for Toxic Substances and Disease Registry (ATSDR), Cosmetic Ingredient Reviews by the Cosmetics Industry Council, pesticide handbooks, the Merck Index, and various other summary sources. **Table 4-1** lists the electronic databases searched to locate references for rat oral LD₅₀ values. Rat LD₅₀ data were preferred because:

- The current acute oral toxicity test guidelines recommend using rats (OECD 2001a, c, d; EPA 2002a)
- The majority of LD₅₀ data used in the RC millimole regression were from studies using rats (282 rat data points and 65 mouse data points) (Halle 1998, 2003)
- The majority of acute oral systemic toxicity testing is performed with rats

Table 4-1 Internet-Accessible Databases Searched for LD₅₀ Information

| Database/Source ¹ | Sponsor(s) |
|--|---|
| Agency for Toxic Substances and Disease Registry (ATSDR) | U.S. Department of Health and Human Services (DHHS) |
| Center for Drug Evaluation and Research (CDER) | U.S. Food and Drug Administration (FDA) |
| CHEMFINDER | CambridgeSoft Corporation |
| Chemical Carcinogenesis Research Information System (CCRIS); National Cancer Institute (NCI) Website | NCI; National Institutes of Health (NIH); DHHS |
| Chemical Evaluation Search and Retrieval System (CESARS) | Michigan Department of Natural Resources; Ontario Ministry of the Environment; Canadian Centre for Occupational Health and Safety (CCOHS) CHEMpendium [™] |
| Chemical Hazard Response (CHRIS) | U.S. Coast Guard |

| Database/Source ¹ | Sponsor(s) |
|--|--|
| Chemical Ingredients Database | U.S. Environmental Protection Agency (EPA) Office of Pesticide Programs (OPP); California EPA Department of Pesticide Regulation |
| CHEMINDEX; CHEMINFO | (CCOHS) CHEMpendium [™] |
| ChemRTK High Production Volume (HPV) Challenge Program; OPPT Chemical Fact Sheets; Chemical Information Collection and Data Development | EPA Office of Pollution Prevention and Toxics (OPPT) |
| CIS Chemical Information | World Health Organization (WHO) International Programme on Chemical Safety (IPCS); CCOHS; International Labour Organisation (ILO) Occupational Safety and Health Information Centre (CIS) |
| Concise International Chemical Assessment Documents (CICADS) | WHO IPCS; CCOHS; ILO; United Nations Environment Programme (UNEP) |
| Consumer Product Safety Commission Website Deutsches Institut fur Medizinische Dokumentation und Information (DIMDI) [The German Institute for Medical Documentation and Information]; Registry of Cytotoxicity (RC) | U.S. Consumer Product Safety Commission (CPSC) Zentralstelle zur Erfassung und Bewertungvon Ersatz- und Erganzungsmethoden zum Tierversuch (ZEBET) [German Centre for the Documentation and Validation of Alternative Methods] |
| Developmental and Reproductive Toxicology/Environmental Teratology Information Center (DART [®] /ETIC) | EPA; The National Library of Medicine (NLM); The National Institute of Environmental Health Sciences (NIEHS); National Center for Toxicological Research (NCTR) |
| Emergency Response Guidebook (ERG 2000) | Transport Canada; U.S. Department of Transportation (DOT); Secretariat of Communications and Transportation of Mexico |
| Environmental Health Criteria (EHC) monographs; Health and Safety Guides (HSG); International Agency for Research on Cancer (IARC) | WHO IPCS; CCOHS |
| European Centre for the Validation of Alternative Methods (ECVAM) Scientific Information Service (ECVAM SIS) | European Commission Joint Research Centre |
| HAZARDTEXT [®] ; MEDITEXT [®] ; INFOTEXT [®] ; SARATEXT [®] ; REPROTEXT [®] ; REPROTOX [®] | TOMES Plus [®] , MICROMEDEX, Greenwood Village, CO |
| Integrated Risk Information System (IRIS) International Chemical Safety Cards (ICSC) IPCS/EC Evaluation of Antidotes Series | EPA Office of Research and Development (ORD) WHO IPCS; CCOHS; Commission of the European Union (EU) |
| International Uniform Chemical Information Database (IUCLID) | European Chemicals Bureau |
| Joint Expert Committee on Food Additives (JECFA); Joint Meeting on Pesticide Residues (JMPR); Pesticide Data Sheets (PDS) | WHO IPCS; CCOHS; Food and Agriculture Organization (FAO) of the United Nations |
| Material Safety Data Sheets (MSDS) | Interactive Learning Paradigms, Incorporated |
| Multicentre Evaluation of In Vitro Cytotoxicity (MEIC) | Scandinavian Society for Cell Toxicology |
| The National MSDS Repository | MSDSSEARCH, Inc. |
| National Toxicology Program (NTP) Chemical Health and Safety Database | NIEHS |
| National Transportation Library | DOT |
| New Jersey Hazardous Substance Fact Sheets | New Jersey Department of Health and Senior Services |
| Oil and Hazardous Materials/Technical Assistance | EPA Office of Waste and Water Management |

Table 4-1 Internet-Accessible Databases Searched for LD₅₀ Information

| Database/Source ¹ | Sponsor(s) |
|---|--|
| Data System (OHM/TADS) | |
| Organisation for Economic Co-operation and Development (OECD) Screening Information Data Sets (SIDS) | IPCS; CCOHS; International Register of Potentially Toxic Chemicals (IRPTC); UNEP |
| Pesticide Action Network Pesticide Database | Pesticide Action Network North America |
| Pesticide Product Information System (PPIS) | EPA Office of Pesticide Programs (OPP) |
| Poisons Information Monographs (PIMs) | IPCS; CCOHS |
| Registry of Toxic Effects of Chemical Substances (RTECS [®]);NIOSH Pocket Guide to Chemical Hazards | National Institute for Occupational Safety and Health (NIOSH) |
| SCORECARD | Environmental Defense |
| The EXtension TOXicology NETwork (EXTOXNET) | University of California, Davis; Oregon State University; Michigan State University; Cornell University; University of Idaho |
| The Right-to-Know Network (RTK NET) | Office of Management and Budget Watch; Center for Public Data access |
| Toxic Chemical Release Inventory (TRI); GENE-TOX | The National Library of Medicine (NLM) |
| Toxic Substances Control Act Test Submissions (TSCATS) | EPA OPPT |
| TOXLINE [®] ; Hazardous Substances Data Bank (HSDB); ChemIDplus | NLM (TOXNET) |

Table 4-1 Internet-Accessible Databases Searched for LD₅₀ Information

Abbreviations: LD_{50} =Dose lethal to 50% of the animals tested

¹Includes public and proprietary databases

A total of 195 references containing LD_{50} data retrieved through these searches were reviewed and evaluated. Information regarding the materials, animals, and methods used to derive the 491 LD_{50} values reported by these references were compiled and are provided in **Appendix H1**. **Appendix H2** provides a narrative characterization and evaluation of the LD_{50} values.

4.1.2 <u>Criteria Used to Select Candidate Rodent Acute Oral Data for Determination of LD₅₀ Reference Values</u>

This effort was to designed to derive a set of high quality reference oral LD₅₀ values from data that were collected using standardized protocols, accompanied by documentation showing that established testing procedures were followed in compliance with national and international GLP guidelines (OECD 1998; FDA 2003; EPA 2003a,b). After a review of the collected data, the SMT determined that a requirement for GLP compliance would eliminate 99% (452 of the 459 values remaining after exclusion of 30 duplicate values and two erroneous values) of the oral LD₅₀ values.

The SMT then considered limiting the selection of LD_{50} values to those from studies that used the specifications for animals recommended by the current acute oral toxicity test guidelines. The current guidelines recommend using young adult rats, 8 to 12 weeks of age, of a common laboratory strain (e.g., Sprague-Dawley) and the most sensitive sex (OECD 2001a, c, d; EPA 2002a). Female animals are recommended if there is no information from which to determine the most sensitive sex. A limited number of LD_{50} values were available from animals that fit this description; only 3% (14/459) of the oral LD_{50} values were determined using 8 to 12 week old female laboratory rats. An additional 15 LD_{50} values were obtained from female rats in an appropriate weight range (age not provided in the reference) for that age range (~ 176-250 g according to Charles River [http://www.criver.com], Harlan [http://www.harlan.com/us/index.htm], and Taconic Farms

[http://www.taconic.com/anmodels/spragued.htm] websites). Thus, only 6% (29/459) of the acute oral LD₅₀ values in the database, covering 21 of the 72 reference substances (29%), were from studies that used the strain, sex, and age of rats recommended by current test guidelines (OECD 2001a; EPA 2002a).

4.1.2.1 *Final Exclusion Criteria*

Because so few studies met the initial criteria (i.e., GLP compliance and use of animals recommended by current acute oral toxicity test guidelines), the database was reviewed and evaluated to derive alternative criteria for the development of reference LD_{50} values. For this evaluation, the SMT looked for commonalities among the data records that, when selected, provided a comparable data set for each chemical. Review of the available data indicated that the majority of acute oral toxicity tests were conducted by gavage to unanesthetized, young adult laboratory rats of both genders. Thus, the selection process was revised to exclude studies that reflected the following, less typical, materials, animals, and methods in order to compile a homogenous set of reference LD_{50} values for each chemical. The studies excluded were those with:

- Feral rats
- Rats <4 weeks of age
- Anesthetized rats
- Test chemical administered in food or capsule
- LD₅₀ reported as a range or inequality

Data from feral rats were excluded because the health status and age of these animals was uncertain. All laboratory rat strains/stocks were deemed acceptable on the assumption that they were healthy and provided with adequate care and housing during testing. Data from neonates and weanlings were excluded because their sensitivity to chemical toxicity may differ from that of adults. Four weeks was considered the minimum acceptable age because rats are typically weaned at approximately three weeks of age (Barrow 2000). Data from feeding experiments or experiments that involved administration of the chemical in capsules were also excluded because gavage is the most common mode of administration for acute oral studies and the rate of gastrointestinal absorption for these other methods is likely to be different (Nebendahl 2000). Because LD_{50} point estimates are required for the prediction model, LD_{50} values reported as ranges or inequalities were unacceptable.

4.1.2.2 Assumptions Regarding Materials, Animals, and Methods

The level of detail for describing the materials, animals, and methods for the LD_{50} studies varied greatly. For example, some studies reported only that white rats were used, while others provided complete information on stock/strain, gender, and age of animals. Details on other protocol components such as the number of animals tested per dose group, method of administration, doses administered, clinical signs, and times of death varied as well. In order to use as much of the available data as possible, the following assumptions were made if a study report did not state otherwise:

- Rats were young adults of a common laboratory strain
- Rats were not anesthetized
- Oral route of administration was by gavage

4.1.2.3 *Calculation of Reference LD*₅₀ Values

If a substance had multiple LD_{50} values after the application of the exclusion criteria, the outliers at the 99% level (Dixon and Massey 1981) were excluded. A geometric mean and 95% confidence limits were calculated from the remaining values, and used as the reference LD_{50} . A geometric mean was used because it is the antilog of the mean of the logarithm of the values and is less affected than the arithmetic mean by extreme values. The use of a geometric mean also corresponds with the approach used for the RC millimole regression to derive a single IC_{50} value from multiple IC_{50} values (Halle 1998, 2003), and with the approach used to derive the IC_{50} value for each chemical for the *in vitro - in vivo* regressions evaluated in the NICEATM/ECVAM validation study (see Section 6).

In addition to the statistical evaluation of outliers, an extreme value, which was not a statistical outlier but was based on biological plausibility, was identified for trichloroacetic acid. This chemical had five reported LD_{50} values ranging from 400-8900 mg/kg after applying the exclusionary criteria. The lowest value (400 mg/kg) was rejected as biologically implausible because up to 1000 mg/kg/day had been used in an oral chronic rodent carcinogenicity study with no, or only minimal, toxicity (EPA 1996).

4.1.2.4 Use of Rat and Mouse Data

If no rat oral LD_{50} values could be found for a reference substance, mouse acute oral LD_{50} values were evaluated using the same approach as was used for rat values. Because an IC_{50} - LD_{50} regression model using only rat data was preferable, the three reference substances (i.e., epinephrine bitartrate, colchicine, and propylparaben) for which mouse values only were available were not used for the evaluations of accuracy (**Section 6**) or animal reduction (**Section 10**).

4.2 Final Rodent Acute Oral LD₅₀ Reference Values

After the application of the exclusionary criteria, there were 385 acceptable rodent acute oral LD_{50} values from which to calculate reference LD_{50} values. **Table 4-2** shows the reference LD_{50} value for each substance in descending order of toxicity, presented both as mg/kg and as mmol/kg. Data are presented as mmol/kg in order to be consistent with the RC approach. The RC millimole regression used units of mmol/kg for the LD_{50} and mM for the IC_{50} (see **Section 1.1.3**). Also shown for each substance are the 95% confidence limits around the geometric mean, the ratio of the maximum to the minimum acceptable value, the number of LD_{50} values used to calculate the reference value, the number of LD_{50} values available (not including duplicate values or erroneous values), and the LD_{50} value initially used for hazard classification of the reference substance (see **Table 3-2**).

Table 4-2 lists the reference substances grouped by GHS acute oral toxicity category (UN 2005) using the reference LD_{50} values that were derived as described above. The initial categorization for this study, which used the LD_{50} values in the far right column of **Table 4-2** (i.e., values reported in **Table 3-2**, which come from the RC unless otherwise specified), placed 12 substances in each toxicity category. **Table 4-3** compares the number of substances in each GHS toxicity category based on their reference LD_{50} values with the number in each

category based on the initial LD_{50} values. The initial and reference LD_{50} values placed 53 (74%) of the substances in the same GHS category. Nineteen substances (26%) were reclassified based on the reference LD_{50} values (this value is the sum of the numbers in the discordant cells in **Table 4-3**). Compared with the initial LD_{50} value, the reference LD_{50} value was higher for 18 (25%) and lower for only one (1%) of the substances.

Of the 19 reference substances that were reclassified because of the reference LD_{50} values, five substances originally assigned to the most toxic, $LD_{50} \leq 5$ mg/kg, category (i.e., aminopterin, mercury chloride, busulfan, parathion, and strychnine) were moved to the next, less toxic, category ($5 < LD_{50} \leq 50$ mg/kg). In the $5 < LD_{50} \leq 50$ mg/kg category, four substances (dichlorvos, fenpropathrin, sodium dichromate dihydrate, and nicotine) moved to the less toxic $50 < LD_{50} \leq 300$ mg/kg category, and one (triphenyltin hydroxide) moved two categories to $300 < LD_{50} \leq 2000$ mg/kg. In the $50 < LD_{50} \leq 300$ category, four substances (haloperidol, caffeine, copper sulfate pentahydrate, and sodium oxalate) moved to a lower toxicity category ($300 < LD_{50} \leq 2000$ mg/kg). Only carbamazepine moved from the $300 < LD_{50} \leq 2000$ mg/kg category to the $2000 < LD_{50} \leq 5000$ mg/kg category. In the $2000 < LD_{50} \leq 5000$ mg/kg category. In the $2000 < LD_{50} \leq 5000$ mg/kg category, citric acid, trichloroacetic acid and dimethylformamide moved to the next lower toxicity category ($LD_{50} > 5000$ mg/kg). In the $LD_{50} \geq 5000$ mg/kg category, 5-aminosalicylic acid moved to the higher toxicity, $2000 < LD_{50} \leq 5000$ mg/kg category. This was the only substance that moved to a more toxic category

4.3 Relevant Toxicity Information for Humans

The relevance of rodent acute oral LD₅₀ data to human LC values was assessed by the MEIC program (Ekwall et al. 1998b), which used mouse and rat oral LD_{50} data from RTECS[®] (Ekwall et al. 1998a). Mean lethal doses in humans were collected primarily from handbooks containing human clinical toxicity information (Ekwall et al. 1998a) supplemented, when necessary, by an in-house compendium from the Swedish Poisons Information Centre. Ekwall et al. (1998b) calculated least squares linear regressions for the prediction of the mean human LC values by rat and/or mouse oral LD₅₀ data for the 50 MEIC substances using units of log mol/kg. They reported a correlation of $R^2 = 0.607$ for the rat oral LD₅₀ prediction of mean human LC values and $R^2 = 0.653$ for the mouse oral LD₅₀ prediction of mean human LC values. It is important for comparisons of MEIC data with rodent LD₅₀ values to note that the MEIC human values are not lethal doses, and therefore not equivalent to LD₅₀ values. Many of the values (if not the majority) are blood concentrations that were associated with morbidity or mortality, and usually do not reflect the actual dose consumed by the patient. These are not necessarily the peak blood concentrations, but only the concentrations at the time of ascertainment, which could have ranged from immediately after onset of medical treatment to post-mortem. The MEIC organizers readily admitted that they could not relate the blood concentrations to the administered dose.

The relevance of the NRU data collected in the NICEATM/ECVAM validation study to the prediction of human acute toxicity will be addressed elsewhere by ECVAM in a separate evaluation.

| GHS Category ¹ / Reference Substance | Reference Acute Oral LD ₅₀ ^{2,3} (mg/kg) | 95% Confidence Interval ⁴ (mg/kg) | Reference Acute Oral LD ₅₀ Range ⁵ (mg/kg) | Reference Acute Oral LD ₅₀ ² (mmol/kg) | 95% Confidence Interval ⁴ (mmol/kg) | Maximum: Minimum Value ⁶ | N | Initial Rodent Acute Oral LD ₅₀ ^{3,7} (mg/kg) |
|--|---|---|---|---|---|---|----|--|
| | | | $LD_{50} \leq 5 mg/k$ | | | | - | - |
| Cycloheximide | 2 | NC | 1-2.5 | 0.00711 | NC | 2.5 | 3 | 2 |
| Phenylthiourea | 3 | NC | 3 | 0.0197 | NC | NC | 1 | 3 |
| Sodium selenate | 3 | NC | 1.6-5.98 | 0.0159 | NC | 3.7 | 2 | 2 ⁸ |
| Epinephrine bitartrate | 4 (mouse) | NC | 4 | 0.0196 | NC | NC | 1 | 4 (mouse) |
| Triethylenemelamine | 4 | 1-25 | 1-13 | 0.0120 | 0.0037-0.12 | 13.0 | 4 | 1 |
| Physostigmine | 5 | NC | 5 | 0.0182 | NC | NC | 1 | 5 ⁸ |
| Disulfoton | 5 | 2-10 | 2.3-12.6 | 0.0182 | 0.009-0.036 | 5.5 | 6 | 2 |
| | | | $5 < LD_{50} \le 50 mg$ | /kg (N=12) | | | | • |
| Parathion | 6 | 3-12 | 1.8-30 | 0.0209 | 0.010-0.041 | 16.7 | 10 | 2 |
| Strychnine | 6 | NC | 2.35-16.2 | 0.0188 | NC | 6.9 | 3 | 2 ⁸ |
| Aminopterin | 7 | NC | 7 | 0.016 | NC | NC | 1 | 3 (mouse) |
| Potassium cyanide | 7 | 5-10 | 5-10 | 0.111 | 0.077-0.15 | 2.0 | 7 | 10 |
| Busulfan | 12 | NC | 1.9-29 | 0.049 | 0.008-0.38 | 15.3 | 4 | 2 |
| Colchicine | 15 (mouse) | NC | 5.886-29 | 0.0375 | NC | 4.9 | 3 | 6 (mouse) |
| Thallium I sulfate | 25 | NC | 25 | 0.0495 | NC | NC | 1 | 29 (mouse) |
| Arsenic III trioxide | 25 | 10-64 | 13-81.5 | 0.127 | 0.050-0.32 | 6.3 | 5 | 20 |
| Endosulfan | 28 | NC | 18-43 | 0.068 | NC | 2.4 | 2 | 18 ⁸ |
| Digoxin | 28 | NC | 28 | 0.0362 | NC | NC | 1 | 18 (mouse) |
| Mercury II chloride | 40 | 27-60 | 12-92 | 0.148 | 0.010-0.22 | 7.7 | 10 | 1 |
| Sodium arsenite | 44 | 36-53 | 36-53 | 0.336 | 0.28-0.40 | 1.5 | 5 | 41 ⁸ |
| | | | $50 < LD_{50} \le 300 \text{ m}$ | g/kg (N=12) | | | | · |
| Sodium dichromate dihydrate | 51 | 44-58 | 34.17-64.5 | 0.193 | 0.17-0.22 | 1.9 | 11 | 50 |
| Dichlorvos | 59 | 40-88 | 17-97.5 | 0.266 | 0.18-0.40 | 5.7 | 9 | 17 ⁸ |
| Nicotine | 70 | 68-72 | 68-71 | 0.430 | 0.42-0.44 | 1.0 | 4 | 50 |
| Fenpropathrin | 76 | 57-100 | 48.5-164 | 0.217 | 0.16-0.29 | 3.4 | 9 | 18 ⁸ |
| Hexachlorophene | 82 | 68-98 | 56-215 | 0.202 | 0.17-0.24 | 3.8 | 19 | 61 |
| Paraquat | 93 | 65-132 | 57-115 | 0.498 | 0.35-0.71 | 2.0 | 5 | 58 |
| Lindane | 100 | 78-129 | 88-125 | 0.344 | 0.27-0.44 | 1.4 | 4 | 76 |
| Verapamil HCl | 111 | NC | 108-114 | 0.226 | NC | 1.1 | 2 | 108 |

Table 4-2 Rodent Acute Oral Reference LD₅₀ Values Listed by GHS Category¹

| GHS Category ¹ / Reference Substance | Reference Acute Oral LD ₅₀ ^{2,3} (mg/kg) | 95% Confidence Interval ⁴ (mg/kg) | Reference Acute Oral LD ₅₀ Range ⁵ (mg/kg) | Reference Acute Oral LD ₅₀ ² (mmol/kg) | 95% Confidence Interval ⁴ (mmol/kg) | Maximum: Minimum Value ⁶ | N | Initial Rodent Acute Oral LD ₅₀ ^{3,7} (mg/kg) |
|--|---|---|---|---|---|---|------------------|--|
| Sodium I fluoride | 127 | 92-175 | 64-279 | 3.020 | 2.19-4.16 | 4.4 | 12 | 180 |
| Cadmium II chloride | 135 | 88-208 | 88-211 | 0.738 | 0.48-1.14 | 2.4 | 5 | 88 |
| Diquat dibromide | 160 | NC | 121-231 | 0.466 | NC | 1.9 | 3 | 231 |
| Phenobarbital | 224 | NC | 162-318 | 0.966 | NC | 2.0 | 3 | 163 |
| | | | 300 < LD ₅₀ ≤2000 i | | | | | |
| Caffeine | 310 | 256-374 | 192-483 | 1.59 | 1.32-1.93 | 2.5 | 10 | 192 |
| Triphenyltin hydroxide | 329 | 208-520 | 46.4-1200 | 0.896 | 0.57-1.42 | 25.9 | 15 | 44 |
| Haloperidol | 330 | NC | 128-850 | 0.877 | NC | 6.6 | 2 | 128 ⁸ |
| Amitriptyline HCl | 348 | NC | 320-380 | 1.18 | NC | 1.2 | 2 | 319 |
| Propranolol HCl | 466 | NC | 466 | 1.575 | NC | NC | 1 | 470 (mouse) |
| Cupric sulfate • $5 H_2O$ | 474 | 269-836 | 236.2-960 | 1.90 | 1.08-3.35 | 4.1 | 6 | 300 |
| Phenol | 548 | 434-692 | 317-1500 | 5.82 | 4.82-7.68 | 4.7 | 14 | 414 |
| Lithium carbonate | 590 | 479-728 | 525-710 | 7.98 | 6.5-9.9 | 1.4 | 4 | 1187 (mouse; sulfate salt) |
| Glutethimide | 600 | NC | 600 | 2.76 | NC | NC | 1 | 600 |
| Sodium oxalate | 633 | NC | 558-707 | 4.724 | NC | 1.3 | 2 ¹¹ | $155 (mouse)^9$ |
| Chloral hydrate | 638 | 391-1040 | 479-863 | 3.86 | 2.36-6.29 | 1.8 | 4 | 479 |
| Atropine sulfate | 819 | 641-1045 | 600-1136 | 1.21 | 0.95-1.54 | 1.9 | 7 | 623 |
| Valproic acid | 995 | NC | 670-1480 | 6.91 | NC | 2.2 | 2 | 1695 (mouse) |
| Meprobamate | 1387 | 1291-1489 | 1286-1522 | 6.35 | 5.92-6.82 | 1.2 | 6 | 794 ⁸ |
| Acetylsalicylic acid | 1506 | 1224-1854 | 616-2840 | 8.36 | 6.8-10.3 | 4.6 | 14 ¹¹ | 1000 |
| Procainamide HCl | 1950 | NC | 1950 | 8.286 | NC | NC | 1 | 1950 ⁸ |
| | | 2 | $000 < LD_{50} \leq 5000$ | mg/kg (N=11) | • | • | • | |
| Acetaminophen | 2163 | NC | 1944-2404 | 14.3 | NC | 1.2 | 2 | 2404 |
| Potassium I chloride | 2799 | NC | 2600-3020 | 37.6 | NC | 1.2 | 2 | 2602 |
| Carbamazepine | 2805 | NC | 1957-4025 | 11.9 | NC | 2.1 | 2 | 1957 ⁸ |
| Boric aid | 3426 | 2617-4486 | 2660-5140 | 55.4 | 42.3-72.6 | 1.9 | 6 | 2660 ⁸ |
| 5-Aminosalicylic acid | 3429 | NC | 2800-4200 | 22.4 | NC | 1.5 | 2 | 7749 (mouse) |
| Chloramphenicol | 3491 | NC | 2500-5000 | 10.8 | NC | 2.0 | 3 | 3393 |
| Acetonitrile | 3598 | 2951-4375 | 1320-8120 | 87.6 | 71.9-107 | 6.2 | 26 | 3798 |
| Lactic acid | 3639 | NC | 3543-3730 | 40.3 | NC | 1.1 | 2 | 3730 |

Table 4-2 Rodent Acute Oral Reference LD₅₀ Values Listed by GHS Category¹

| GHS Category ¹ / Reference Substance | Reference Acute Oral LD ₅₀ ^{2,3} (mg/kg) | 95% Confidence Interval ⁴ (mg/kg) | Reference Acute Oral LD ₅₀ Range ⁵ (mg/kg) | Reference Acute Oral LD ₅₀ ² (mmol/kg) | 95% Confidence Interval ⁴ (mmol/kg) | Maximum: Minimum Value ⁶ | N | Initial Rodent Acute Oral LD ₅₀ ^{3,7} (mg/kg) |
|--|---|---|---|---|---|---|----|--|
| Carbon tetrachloride | 3783 | 3024-4732 | 2350-10054 | 24.6 | 20-31 | 4.3 | 15 | 2799 |
| Sodium chloride | 4046 | 2917-5623 | 3000-6140 | 69.3 | 50-96 | 2.0 | 5 | 2998 |
| Xylene | 4667 | 1294-16827 | 1537-8620 | 43.9 | 12-158 | 5.6 | 4 | 4300 |
| | | | LD ₅₀ >5000 mg/ | (kg (N=14) | | | | |
| 2-Propanol | 5105 | 4624-5636 | 4500-5840 | 84.9 | 77-94 | 1.3 | 6 | 5843 |
| Trichloroacetic acid | 5229 | 2745-9961 | 3320-8900 | 32.0 | 16.8-61.0 | 2.7 | 4 | 4999 |
| Dimethylformamide | 5309 | 3548-7925 | 2800-7182 | 72.6 | 49-108 | 2.6 | 6 | 2800 |
| Citric Acid | 5929 | NC | 3000-11700 | 30.9 | NC | 3.9 | 2 | 3000 ⁸ |
| Gibberellic acid | 6040 | NC | 5780-6300 | 17.4 | NC | 1.1 | 2 | 6305 |
| Propylparaben | 6332 (mouse) | NC | 6332 | 35.1 | NC | NC | 1 | 6326 (mouse) |
| Ethylene glycol | 7161 | 6266-8204 | 4000-9900 | 115.4 | 101-132 | 2.5 | 16 | 8567 |
| Methanol | 8710 | 6223-12218 | 5628-12880 | 272 | 194-381 | 2.3 | 6 | 13012 |
| Dibutyl phthalate | 8892 | 6180-12794 | 7499-12436 | 31.9 | 22-46 | 1.7 | 4 | 11998 |
| Diethyl phthalate | 9311 | NC | 8600-10100 | 41.9 | NC | 1.2 | 2 | 8602 |
| Sodium hypochlorite | 10328 | NC | 8200-13000 | 62.8 | NC | 1.6 | 2 | 8910 ¹⁰ |
| Ethanol | 11324 | 8610-14894 | 7060-17775 | 245.7 | 187-323 | 2.5 | 8 | 14008 |
| 1,1,1-Trichloroethane | 12078 | 10000-14588 | 9600-16000 | 90.5 | 75-109 | 1.7 | 6 | 10298 |
| Glycerol | 19770 | 10495-37154 | 12600-27650 | 215 | 114-403 | 2.2 | 4 | 12691 |

Table 4-2Rodent Acute Oral Reference LD50 Values Listed by GHS Category1

Abbreviations: LD₅₀=dose lethal to 50% of the animals tested; GHS=Globally Harmonized System of Classification and Labelling of Chemicals

(UN 2005); N=Number of acceptable values used for geometric mean; NC=Not calculated.

¹Categorized using the reference oral LD₅₀.

²Based on a geometric mean of acceptable LD_{50} values from adult laboratory rats unless otherwise specified.

³Values rounded to the nearest whole number.

 4 For the geometric mean of the acceptable LD₅₀ values, NC is used for substances with three acceptable values or less, which was considered

too few for calculation of a valid confidence interval.

⁵Range of acceptable oral LD₅₀ values.

⁶Ratio of minimum acceptable LD_{50} to maximum acceptable LD_{50} .

⁷Values rounded to the nearest whole number. Values are from the RC unless otherwise specified; rat data unless otherwise specified.

⁸RTECS[®] (MDL Information Systems 2002).

 9 RC reference for rat oral LD₅₀ of 155 mg/kg is Shrivastava et al. (1992), which references Klinger and Kersten (1961). Klinger and Kersten (1961) indicate the value was determined by intraperitoneal administration to mice.

¹⁰HSDB (NLM 2002).

¹¹An erroneous value obtained from the literature was not included.

| Initial LD ₅₀ | | Reference LD ₅₀ (mg/kg) | | | | | | | Reference LD ₅₀ | Reference LD ₅₀ |
|-------------------------------|---------------------|------------------------------------|------------------------|--------------------------|---------------------------|------------------------|-------|-------|-------------------------------|-------------------------------|
| (mg/kg ¹) | LD ₅₀ ≤5 | $5 < LD_{50} \leq 50$ | $50 < LD_{50} \le 300$ | $300 < LD_{50} \le 2000$ | $2000 < LD_{50} \le 5000$ | LD ₅₀ >5000 | Total | Match | Lower | Higher |
| $LD_{50} \leq 5$ | 7 | 5 | 0 | 0 | 0 | 0 | 12 | 58% | 0% | 42% (5) |
| $5 < LD_{50} \le 50$ | 0 | 7 | 4 | 1 | 0 | 0 | 12 | 58% | 0% | 42% (5) |
| 50 < LD ₅₀ ≤300 | 0 | 0 | 8 | 4 | 0 | 0 | 12 | 67% | 0% | 33% (4) |
| 300 < LD ₅₀ ≤2000 | 0 | 0 | 0 | 11 | 1 | 0 | 12 | 92% | 0% | 8% (1) |
| 2000 < LD ₅₀ ≤5000 | 0 | 0 | 0 | 0 | 9 | 3 | 12 | 75% | 0% | 25% (3) |
| LD ₅₀ >5000 | 0 | 0 | 0 | 0 | 1 | 11 | 12 | 92% | 8% | 0% (0) |
| Total | 7 | 12 | 12 | 16 | 11 | 14 | 72 | 74% | 1% | 25% (18) |

Table 4-3 GHS Category Matches for the Rodent Acute Oral LD₅₀ Initial and Reference Values

Abbreviations: GHS=Globally Harmonized System of Classification and Labelling of Chemicals (UN 2005); LD₅₀=Dose lethal to 50% of animals tested.

Note: Shaded cells show the number of chemicals for which both LD_{50} categories agree.

¹Initial LD₅₀ values were used for reference substance selection and were obtained from the RC (Halle 1998, 2003), RTECS[®] (MDL Information Systems 2002), and HSDB (NLM 2002) (see **Table 3-2**).

4.4 Accuracy and Reliability of the Rodent Acute Oral LD₅₀ Reference Values

Accuracy (concordance) is the closeness of agreement between a test method result and an accepted reference value (in this case to the rodent acute oral LD_{50} measurement) (ICCVAM 2003). Because there are insufficient data to permit a comparison between rodent and human lethal doses, the accuracy of rodent acute oral LD_{50} values for predicting the oral LD_{50} in humans cannot be determined. Acute toxicity testing in rodents leads to a relative ranking of the toxicity of chemicals for regulatory purposes, with the default assumption that the rodent values and ranking are predictive of the human values and ranking.

The among laboratory reproducibility of the reference LD_{50} values determined in this section may be judged by evaluating the range of acceptable LD_{50} values for each reference substance and by comparing the values (and their variability) with the variability of LD_{50} values derived from controlled acute oral toxicity studies.

4.4.1 <u>Variability Among the Acceptable LD₅₀ Values</u>

The variability among the acceptable rodent acute oral LD_{50} values used to calculate the reference LD_{50} value for each reference substance was assessed by calculating the ratio of the maximum to the minimum value (see **Table 4-2**). For the 62 reference substances with more than one acceptable LD_{50} value, the maximum:minimum ratio ranged from 1.1 to 25.9, with a mean of 4.3 and a median of 2.2. The maximum:minimum ratios were greater than 10 for four substances: triethylenemelamine, parathion, busulfan, and triphenyltin hydroxide. The low LD_{50} values for triethylenemelamine, busulfan, and parathion may have contributed to the high maximum:minimum ratios. The four LD_{50} values for triethylenemelamine ranged from 1 to 13 mg/kg, the four values for busulfan ranged from 1.9 to 29 mg/kg, and the 10 values for parathion ranged from 1.8 to 30 mg/kg.

Table 4-4 shows the maximum:minimum LD_{50} ratios by toxicity category. The more toxic substances (i.e., $LD_{50} \leq 50$ mg/kg) tended to have higher maximum:minimum ratios than substances with lower toxicity (i.e., $LD_{50} > 50$ mg/kg). This is anticipated because small day-to-day, or laboratory-to-laboratory variations in weighing and dosing the lower concentrations would have a higher impact on the chemicals being administered in low doses than those being administered in the high dose range.

Table 4-4Maximum:Minimum LD50 Ratios by GHS Toxicity Category


| GHS Category (LD ₅₀ in mg/kg) | Mean Maximum:Minimum LD ₅₀ Ratio | Median Maximum:Minimum LD ₅₀ Ratio | Range of Maximum:Minimum LD ₅₀ Ratio | Ν |
|---|---|---|---|----|
| $LD_{50} \leq 5$ | 6.2 | 4.6 | 2.5 - 13.0 | 4 |
| $5 < LD_{50} \le 50$ | 7.1 | 6.3 | 2.0 - 16.7 | 9 |
| $50 < LD_{50} \le 300$ | 2.4 | 1.9 | 1.1 - 5.7 | 12 |
| $300 < LD_{50} \le 2000$ | 4.6 | 2.2 | 1.2 - 25.9 | 13 |
| $2000 < LD_{50} \le 5000$ | 2.6 | 2.0 | 1.2-22.3 | 11 |
| LD ₅₀ >5000 | 2.3 | 2.3 | 1.1 - 3.9 | 13 |

Abbreviations: LD_{50} =Dose lethal to 50% of animals tested; GHS-Globally Harmonized System of Classification and Labelling of Chemicals (UN 2005); N=Number of chemicals with more than one acceptable LD_{50} value after application of the exclusion criteria described in **Section 4.1.2**.

4.4.2 <u>Comparison of Rodent Acute Oral LD₅₀ Reference Values with the Corresponding</u> <u>RC LD₅₀ Values</u>

The correspondence of the rodent acute oral LD_{50} reference values with the RC LD_{50} values for the 58 reference substances in common with the RC are shown on a log scale in **Figure 4-1**. Not surprisingly, a Spearman correlation analysis for the two sets of log transformed values yielded a significant correlation (p <0.0001) with a correlation coefficient, r_s, of 0.97. **Figure 4-1** shows that the LD_{50} reference values tended to be higher than the RC LD_{50} values. One factor in this difference is that the majority of LD_{50} values used in the RC were from the 1983/84 RTECS[®], which contains the lowest LD_{50} value found for a particular chemical without regard to the available methodological information, without consideration of whether it is an outlier with respect to the other available values, and without scientific review before publication. Thus, because the reference LD_{50} values are based on the geometric mean from multiple studies, it is not surprising that these values tended to be higher than the single values in the RC database.

Figure 4-1 Correlation of LD₅₀ Values With the Reference LD₅₀ Values for the 58 RC Chemicals



Abbreviations: LD_{50} =Dose lethal to 50% of animals tested; RC=Registry of Cytotoxicity. The diagonal line shows the 1:1 relationship.

When comparing the reference LD_{50} values to the RC values, the substances with the largest differences were busulfan, triphenyltin hydroxide, and mercury chloride (see Figure 4-1).

- The LD₅₀ reference value for busulfan was six times that of the RC value (12 mg/kg vs. 1.9 mg/kg). The RC value (from 1983/84 RTECS[®]) was from a paper by Schmahl and Osswald (1970) in which they cited a rat oral LD₅₀ of 1.86 mg/kg. The literature also contained rat oral LD₅₀ values of 28 and 29 mg/kg for male and female Sprague-Dawley rats, respectively (Matsuno et al. 1971).
- The LD₅₀ reference value for triphenyltin hydroxide was 7.5 times the RC LD₅₀ (329 mg/kg vs. 44 mg/kg). The 15 LD₅₀ values used to determine the reference value included the RC value, and had a wide range, 44-1200 mg/kg. Because of the large variation in the data, which was evenly distributed throughout the range neither the highest nor the lowest values were outliers.
- The LD₅₀ reference value for mercury chloride was 40 mg/kg, while the RC value was 1 mg/kg. The RC value was from a summary document that reported the rat oral LD₅₀ as a range of 1-5 mg/kg (Worthing and Walker 1991). Because it was reported as a range, it was excluded from the calculation of the reference value (see Section 4.1.2.1). The remaining 11 values ranged from 12 to 160 mg/kg. The highest value (160 mg/kg) was considered an outlier when compared to the other 10 values and therefore excluded from the reference value calculation.
- 4.4.3 <u>Comparison of the Variability Among Acceptable LD₅₀ Values to Those Obtained</u> <u>in Other Studies</u>

The variation seen here for 62 reference substances is not atypical, considering the results of other studies that examined the variation among rodent acute oral LD_{50} values derived for the same substance. For example, Weil and Wright (1967) showed that LD_{50} values varied by as much as five-fold for the 10 substances tested in eight laboratories using exactly the same protocol. Another international study involving 65 participating laboratories in eight countries that did not control the LD_{50} protocols among laboratories, reported maximum:minimum ratios from 3.6 to 11.3 (with LD_{50} values ranging from 44 to 5420 mg/kg) for five substances (Hunter et al. 1979). The chemicals tested, and the LD_{50} ranges were:

| ٠ | PCP ¹ | 44-523 mg/kg |
|---|-------------------|----------------|
| • | Sodium salicylate | 800-4150 mg/kg |
| • | Aniline | 350-1280 mg/kg |
| • | Acetanilide | 805-5420 mg/kg |
| ٠ | Cadmium chloride | 70-513 mg/kg |

The results of a follow-on study in which the same substances were tested by 100 laboratories in 13 countries showed that adherence to a specific protocol reduced the range of maximum:minimum LD_{50} ratios from 3.6 to 11.3 to 2.4 to 8.4 (Zbinden and Flury-Roversi 1981).

¹ Compound undefined in the publication.

Although the LD₅₀ data collected from the literature for the NICEATM/ECVAM validation study used various rat strains, sexes, observation durations, and calculation methods for estimating the LD₅₀, the variation in LD₅₀ values for individual substances was similar to the data of the earlier cited studies. The current study found four of the 62 substances with multiple LD₅₀ values had maximum:minimum LD₅₀ values higher than that reported by Hunter et al. (1979) (i.e., >11.3), and three of those were in the highest toxicity category. Hunter et al. (1979) also observed that the largest variation was associated with the more highly toxic substances.

4.5 Summary

To enable the comparison of *in vitro* NRU data with rodent acute oral toxicity data, LD_{50} reference values for the 72 reference substances were calculated using data obtained from the literature, database searches, and secondary references. Rat acute oral LD_{50} values were preferred, but mouse acute oral LD_{50} values were collected for three substances with no available or acceptable rat data. The 491 LD_{50} values that were retrieved comprised 485 rat LD_{50} values and six mouse values. It was not possible to identify a high quality data set produced under GLP guidelines because only 3% of the data records were in GLP compliance. Instead, as described in **Section 4.1.2.1**, a homogenous set of LD_{50} values for each substance was identified by applying specific exclusion criteria related to the materials, animals, and methods used for each study.

After analysis of the acceptable values for outliers, the remaining 385 values were used to derive rodent acute oral LD_{50} reference values by calculation of a geometric mean of the values for each substance. As a result of this procedure, the LD_{50} reference values for 19 of the 72 reference substances were sufficiently different from the values that were used in the RC and other summary sources, so that they were reclassified into different GHS oral toxicity categories.

Because there is no reference standard against which to evaluate the accuracy of the rodent acute oral toxicity test, the reliability of the LD_{50} reference values was assessed by comparison to other evaluations of the performance of this test method. The maximum:minimum ratio of the acceptable values for the 62 reference substances that had more than one LD_{50} value ranged from 1.1 to 25.9, and the ratios for four of the substances were greater than one order of magnitude.

| 5.0 | 3T3 AND NHK NRU TEST METHOD DATA AND RESUL | TS 5-3 |
|-----|---|----------|
| 5.1 | Study Timeline and Participating Laboratories | |
| | 5.1.1 Statements of Work (SOW) and Protocols | |
| | 5.1.2 Study Timeline | |
| | 5.1.3 Participating Laboratories | |
| 5.2 | Coded Reference Substances and GLP Guidelines | |
| | 5.2.1 Coded Reference Substances | |
| | 5.2.2 Lot-to-Lot Consistency of Reference Substances | |
| | 5.2.3 Adherence to GLP Guidelines | |
| 5.3 | 3T3 and NHK NRU Test Method Protocols | |
| | 5.3.1 Phase Ia: Laboratory Evaluation Phase | |
| | 5.3.2 Phase Ib: Laboratory Evaluation Phase | |
| | 5.3.3 Phase II: Laboratory Qualification Phase | |
| | 5.3.4 Phase III: Main Validation Phase | |
| 5.4 | Data Used to Evaluate Test Method Accuracy and Reliability | y 5-10 |
| | 5.4.1 PC Data | |
| | 5.4.2 Reference Substance Data | |
| 5.5 | Statistical Approaches to the Evaluation of 3T3 and NHK Da | ata 5-26 |
| | 5.5.1 Statistical Analyses for Phase Ia | |
| | 5.5.2 Statistical Analyses for Phase Ib | |
| | 5.5.3 Statistical Analyses for Phase II | |
| | 5.5.4 Statistical Analyses for Phase III | |
| | 5.5.5 Summary of the Data Used for Statistical Analyses | |
| 5.6 | Summary of NRU Test Results | |
| 5.7 | Availability of Data | |
| 5.8 | Solubility Test Results | |
| | 5.8.1 Solubility Data | |
| | 5.8.2 Solubility and Volatility Effects in the Cytotoxicity Tests | 5-43 |
| 5.9 | Summary | |

[This Page Intentionally Left Blank]

5.0 3T3 AND NHK NRU TEST METHOD DATA AND RESULTS

This section summarizes the IC₅₀ results generated by testing 72 coded reference substances (see **Section 3**) in the 3T3 and NHK NRU test method protocols. These IC₅₀ values were used to evaluate the accuracy (also known as concordance - see **Section 6**) of the two *in vitro* cytotoxicity test methods for predicting *in vivo* GHS acute oral toxicity categories and their reliability (intra- and inter-laboratory reproducibility - see **Section 7**). The individual test data for the passing and failing tests are provided in **Appendix I** for the reference substances and the PC. The raw data for each test (in EXCEL[®] and PRISM[®] files) are available upon request from NICEATM on compact disk(s), as are the laboratory reports. Requests can be made by mail, fax, or e-mail to Dr. William S. Stokes, NICEATM, NIEHS, P. O. Box 12233, MD EC-17, Research Triangle Park, NC, 27709, (phone) 919-541-2384, (fax) 919-541-0947, (e-mail) niceatm@niehs.nih.gov.

Section 5.1 discusses the timeline for the validation study, the study participants, and their roles in the study. **Section 5.2** documents the use of coded reference substances and the GLP compliance by the participating laboratories. **Section 5.3** discusses the protocol revisions that were made during the study and the effect the revisions had on the results. **Section 5.4** presents the IC₅₀ data collected during each phase to assess the reliability and accuracy (relevance) of the NRU methods. **Section 5.5** presents the statistical analyses performed. **Section 5.6** summarizes the results of IC₅₀ comparisons of the 3T3 and NHK methods. **Section 5.7** offers information about the availability of all the data (e.g., raw OD data from all tests, laboratory reports), and **Section 5.8** presents the solubility test results for the reference substances from all laboratories.

5.1 Study Timeline and Participating Laboratories

5.1.1 <u>Statements of Work (SOW) and Protocols</u>

The SMT provided the laboratories with SOWs for each test method prior to initiation of testing (see **Appendix G**), and proposed dates for completion of the various aspects of the study (e.g., transfer of data, provision of reports). The SOWs defined the following:

- Project objectives
- Management and key personnel
- Required facilities, equipment, and supplies
- Quality assurance requirements
- Test phases and schedules
- Products (e.g., reports) required
- Report preparation

The SOW for BioReliance contained all of the above requirements, and also included requirements for:

- Reference substance acquisition, coding, preparation, and distribution
- Solubility testing

The SMT, in consultation with the laboratories, prepared Test Method Protocols for each phase of the study. Cytotoxicity testing in each phase of the validation study was initiated in each laboratory when the SMT received a signed protocol specific for that phase from the

Study Director. Solubility testing for the Phases I and II substances was performed prior to cytotoxicity testing for those substances; most of the solubility testing for the Phase III substances was performed toward the end of Phase II and during the early part of Phase III.

5.1.2 <u>Study Timeline</u>

The actual timeline of the study is shown in **Table 5-1**. The SMT modified the original timeline presented in the SOWs because of a number of factors, such as, protocol revisions, side studies, difficulties with acquisition of medium, etc.

| Event | BioReliance | ECBC | FAL | IIVS |
|--|--|----------|----------|----------|
| Receipt of SOW from SMT | Jun 2002 | Jun 2002 | Jun 2002 | Jun 2002 |
| Procurement of Test Substances | Jul 2002 - Jan 2003 | NA | NA | NA |
| Solubility Testing Completed | Jul 2002 - Jan 2003 | Dec 2003 | Dec 2003 | Jan 2004 |
| Distribution of Reference Substances Phase Ia Phase Ib Phase II Phase III | Jul 2002 Sep 2002 Nov 2002 Feb - Mar 2003 | NA | NA | NA |
| Initiation of Phase Ia | NA | Aug 2002 | Aug 2002 | Aug 2002 |
| Completion of Phase Ia | NA | Nov 2002 | Nov 2002 | Oct 2002 |
| Initiation of Phase Ib | NA | Dec 2002 | Dec 2002 | Dec 2002 |
| Completion of Phase Ib | NA | May 2003 | May 2003 | May 2003 |
| Initiation of Phase II | NA | Jun 2003 | Jun 2003 | Jun 2003 |
| Completion of Phase II | NA | Nov 2003 | Nov 2003 | Nov 2003 |
| Initiation of Phase III | NA | Dec 2003 | Dec 2003 | Dec 2003 |
| Completion of Phase III | NA | Dec 2004 | Dec 2004 | Jan 2005 |

Table 5-1Validation Study Timetable

Abbreviations: ECBC=Edgewood Chemical Biological Center; FAL=Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory; IIVS=Institute for *In Vitro* Sciences; SOW=Statement of Work; SMT=Study Management Team; NA=Not applicable.

Note: BioReliance distributed the reference substances and performed solubility testing. ECBC, FAL, and IIVS tested the reference substances for solubility and *in vitro* cytotoxicity.

5.1.3 <u>Participating Laboratories</u>

- BioReliance Corporation 14920 Broschart Road Rockville, Maryland 20850-3349 Study Director: Dr. Martin Wenk
- U.S. Army Edgewood Chemical Biological Center (ECBC) Molecular Engineering Team Aberdeen Proving Ground, MD 21010 Study Director: Dr. Cheng Cao

- Institute for *In Vitro* Sciences (IIVS) 21 Firstfield Road Suite 220 Gaithersburg, MD 20878 Study Director: Mr. Hans Raabe
- Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory (FAL)
 Queens Medical Centre, University of Nottingham
 Nottingham NG7 2UH
 United Kingdom
 Study Director: Dr. Richard Clothier

5.2 Coded Reference Substances and GLP Guidelines

5.2.1 <u>Coded Reference Substances</u>

BioReliance acquired 73 substances (72 reference substances and one PC substance) from reputable commercial sources (see **Appendix F1**). All but eight of the reference substances were >99% pure (see **Section 8.1.2.1**). BioReliance coded each substance with a unique, random identification number when repackaging them into smaller units for distribution to the laboratories. These units were given an additional code unique to the respective cytotoxicity laboratories, so that they could be provided in a blinded fashion (see **Section 3.4** for distribution procedures). The coded substance units were packaged and shipped such that their identities were concealed; however, all laboratories knew the identity of the positive control. The SMT revealed the codes for each phase after all laboratories had submitted their data and reports for that phase. The laboratories periodically required additional aliquots of reference substance, and BioReliance provided these aliquots from the original stock of reference substance in the same manner that the original aliquots were provided.

5.2.2 Lot-to-Lot Consistency of Reference Substances

Each substance was purchased as a single lot, and each laboratory received aliquots from this same lot throughout the validation study. The reference substance suppliers provided certificates of analysis for each lot, along with the MSDS documents containing substance, physical, and safety and handling information.

5.2.3 Adherence to GLP Guidelines

BioReliance, ECBC, and IIVS, followed GLP procedures for all testing, with the exception of tests designed to resolve technical challenges (e.g., formation of NR crystals; use of film plate sealers for volatile substances; slow growth of cells). The laboratories submitted all data to their respective quality assurance units (as per GLP requirements) and copies of the data were submitted to NICEATM. FAL followed most of the GLP guidelines, but did not employ independent quality assurance reviews of laboratory procedures or documentation. The Study Director for FAL performed all data reviews and provided copies to NICEATM. Hard copy printouts and electronic versions of all data are available at NICEATM.

5.3 3T3 and NHK NRU Test Method Protocols

The protocols for the 3T3 and NHK NRU test methods used during Phase III laboratory testing were the result of modifications and revisions to the *Guidance Document* (ICCVAM 2001b) protocols, the optimization of the protocols used in the laboratory evaluation Phases Ia and Ib, and the laboratory qualification phase (Phase II) (see Section 2.6). Figure 1-2

provides an outline of the study phases, and identifies where repeated observations were carried out to permit protocol evaluation and comparison. **Sections 2.2** and **2.3** address the similarities and differences between the 3T3 and NHK protocols. The remaining subsections in **Section 5.3** address the modifications to the protocols used in each phase, and how those modifications affected each data set.

5.3.1 <u>Phase Ia: Laboratory Evaluation Phase</u>

During Phase Ia, each laboratory established an historical database for the PC substance, SLS. No reference substances were tested in this phase. Ten concentration-response tests were performed using SLS and no more than two tests were performed/day. The resulting data were used to calculate the acceptable response limits for the SLS IC₅₀ for use during Phase Ib testing.

Section 2.6.1 summarizes issues that occurred during Phase I and addresses protocol changes made after the initiation of Phase Ia. The specific changes to the protocols for both cell systems are summarized below, along with the impact these changes had on the test data. Changes made in the protocols during Phase Ia were incorporated into the Phase Ib protocols.

5.3.1.1 Protocol Changes and the Effect on the Data

- *NR Dye Crystals:* Reduced the NR dye concentration for both cell types. No subsequent tests failed because of NR crystal formation. The background OD values decreased and this was not interpreted as a negative effect on the data.
- *3T3 Cell Growth*: Modified cell culture conditions for 3T3 cells to improve cell growth characteristics. No apparent effect on the data was detected.
- *NHK Cell Growth (96-well plates):* Removed the cell culture refeeding step performed prior to reference substance addition. Although the OD values for the vehicle controls became higher, the SLS IC₅₀ results were similar whether or not the cells were re-fed.
- *NHK Cell Growth (in culture flasks)*: FAL coated their culture flasks with fibronectin-collagen prior to seeding thawed cells. This may have affected the SLS data from FAL because it had the highest SLS IC₅₀ values of the three laboratories (7.45 µg/mL vs. 4.03 µg/mL for ECBC and 3.68 µg/mL for IIVS). The fibronectin-collagen coating procedure was eliminated, and subsequent SLS data and IC₅₀ results from FAL were comparable to the data from the other two laboratories.
- *OD Limits*: Eliminated the VC OD range as a test acceptance criterion. The SMT decided to accept tests that had VC ODs outside the originally preset range if all other test acceptance criteria were met. Test data were not adversely affected by relaxing this criterion.
- *Dilution Factor*: The SMT accepted data generated using dilution factors other than the recommended 1.47 for definitive tests if all other test acceptance criteria were met. The use of smaller dilution factors generally increased the number of data points between 10 90% viability, and the precision of the IC₅₀ calculation was improved.

5.3.2 <u>Phase Ib: Laboratory Evaluation Phase</u>

Phase Ib was designed to determine whether the protocol revisions following Phase Ia were effective in improving intra- and inter-laboratory reproducibility, and to determine whether

the laboratories could obtain reproducible results when testing coded reference substances of various toxicities. Three coded reference substances representing the full range of toxicity were tested: arsenic trioxide (high toxicity: $5 < LD_{50} \le 50$ mg/kg), propranolol HCl (medium toxicity: $300 < LD_{50} \le 2000$ mg/kg), and ethylene glycol (low toxicity: $LD_{50} > 5000$ mg/kg) (see **Section 3.3.5** for the selection of substances to be tested in Phases Ib and II). Because Phase Ib was part of the laboratory evaluation phase, the SMT decided that three substances would be sufficient, and that it was not necessary to represent all GHS acute oral toxicity categories. Each substance was tested in all laboratories at least once in a range finding experiment, and then in three, acceptable definitive tests performed on three different days. **Section 2.6.2** summarizes the technical challenges that arose during this phase and addresses protocol changes made after initiation of Phase Ib. The specific changes made in the 3T3 and NHK protocols, along with the effect the changes had on the test data, are summarized below.

5.3.2.1 Protocol Changes and the Effect on the Data

- *NR Dye Crystals*: Reduced the concentration of NR in the 3T3 method. The OD values and SLS IC₅₀ results were similar in four exploratory experiments regardless of the NR concentration or NRU incubation time. The elimination of NR crystals reduced the background OD values without affecting the sensitivity of the procedure.
- *VC OD Range*: Used new VC OD ranges for guidance (e.g., as target values to assess cell growth), rather than as a test acceptance criterion, for the remainder of the study. This increased the number of tests that met the acceptance criteria. Relative toxicities did not change. The test data were not adversely affected by the removal of this criterion.

5.3.3 <u>Phase II: Laboratory Qualification Phase</u>

The results from Phase II were used to determine whether the protocol revisions from Phase Ib were effective in improving intra- and inter-laboratory reproducibility, and whether the laboratories could obtain reproducible results when testing a larger set of substances covering a wider range of physical/substance characteristics and toxicities. Nine coded reference substances were tested: aminopterin, cadmium chloride, chloramphenicol, colchicine, lithium carbonate, potassium chloride, 2-propanol, sodium fluoride, and sodium selenate. These substances (with the exception of sodium selenate) are included in the RC, and were selected because they fit the RC millimole regression line (i.e., they were within the acceptance intervals established by Halle [1998, 2003]). The RC is a database of acute oral LD₅₀ values for rats and mice obtained from RTECS[®] and IC₅₀ values from *in vitro* cytotoxicity assays using multiple cell lines and cytotoxicity endpoints for substances with known molecular weights (Halle 1998, 2003). Sodium selenate was selected because of its high toxicity, despite the fact that it was not in the RC, because there were no other substances in the highest GHS acute oral toxicity category, other than aminopterin, that were within the RC millimole regression acceptance intervals. Each laboratory tested each substance at least once in a range finding experiment, and then in three acceptable definitive tests performed on different days.

Section 2.6.2 summarizes the technical issues that arose during this phase and the protocol changes made prior to Phase II. The specific changes made in the 3T3 and NHK NRU protocols, along with the effect the changes had on the test data, are summarized below.

5.3.3.1 Protocol Changes and the Effect on the Data

- *Blank Wells*: Added reference substance to blank wells of the test plate to determine if reference substance affected (i.e., increased OD values) compared to medium-filled blank wells. There was no apparent effect on the test data as there were no noticeable differences in OD values between blanks with culture medium or culture medium and reference substance.
- *VC OD Range*: Eliminated the VC OD range as an acceptance criterion. There was no apparent effect on test data from not restricting the OD values to a preset range.
- *Harmonization of Laboratory Techniques*: Made revisions to the Phase II protocols as a result of the harmonization training by the testing laboratories (see **Section 2.6.2.6**). There was no apparent effect on the test data from IIVS and ECBC, but there was an improvement in the FAL data quality (e.g., fewer lost OD values due to cell seeding errors, more uniform OD values for six replicate wells per reference substance).
- *3T3 Cell Seeding Density*: Added a range of cell seeding densities to be used by the laboratories. This optimized the cell confluence at the end of chemical exposure and no apparent effects on the data were detected because of this modification.
- *NHK Cell Growth from Cryopreserved Stock Cells*: Eliminated the use of fibronectin-collagen coating of 80-cm² flasks for the initial propagation of NHK cells. By doing this, FAL achieved better cell growth, lower IC₅₀ values for the PC, and better agreement of the mean SLS IC₅₀ values with those of the other laboratories.
- *Volatile Substances*: Added the use of a CO₂ permeable plate sealer to control volatility (as identified by cross contamination of the control wells). The use of plate sealers for volatile substances was incorporated into the Phase III protocols.
- R^2 Acceptance Criterion: Relaxed the R² criterion for the fit of the doseresponse data to the Hill function. Some tests that did not meet the original criterion were accepted by the SMT after determining that even though the curve fit was not optimum, it adequately conveyed the toxicity of the substance (i.e., an IC₅₀ could be calculated with an adequate number of toxicity points between 0 and 100% viability).
- Unusual Concentration-Response: Revised the Hill function calculation to address substances that produced a concentration-response in which toxicity plateaued before reaching 0% viability. This modification allowed for a curve fit to the Hill function for such substances, and thus a better estimation of their IC₅₀ values.
- *PC IC₅₀ Range*: Expanded the SLS IC₅₀ acceptable range, which resulted in additional tests in Phase II being acceptable. Expanding the PC range reduced the number of reference substance retests, and thereby qualified additional

definitive tests as acceptable because they would not fail simply because the PC was out of the pre-set range.

5.3.4 <u>Phase III: Main Validation Phase</u>

The purpose of Phase III was to generate high quality *in vitro* cytotoxicity data using the 3T3 and NHK NRU test methods with protocols that were optimized based on the experience and results in Phases I and II. Sixty coded reference substances were tested; 46 of these were RC substances that covered a broad range of toxicity. The reference substances in Phase III spanned all five GHS toxicity categories and unclassified substances. Each substance was tested in each laboratory at least once in a range finding experiment, and then in three acceptable definitive tests performed on different days.

Section 2.6.4 addresses protocol changes made before the initiation of Phase III. The specific changes made in the 3T3 and NHK protocols, along with the effect the changes had on the test data, are summarized below.

5.3.4.1 Protocol Changes and the Effect on the Data

- *Prequalification of NHK Culture Medium*: Included a protocol for prequalifying NHK culture medium and supplements. This prevented the participating laboratories from using medium and supplements that did not support adequate growth of the cells.
- Stopping Rule for Testing: Added this rule for reference substances that were insoluble (i.e., $<200 \ \mu g/mL$) and/or did not produce sufficient cytotoxicity for the calculation of an IC₅₀. This rule allowed testing to end for substances that produced no IC₅₀ data after three definitive tests. Substances for which an IC₅₀ was not produced by one or more laboratories are presented in **Table 5-2**. Carbon tetrachloride did not produce an IC₅₀ in any of the laboratories in either the 3T3 or the NHK NRU test methods, and methanol did not produce an IC₅₀ in the 3T3 NRU test method.
- Acceptable Range for Dose-Response Data Points: Modified the test acceptance criterion for the number of data points required on the toxicity curve. The criterion was changed from requiring a minimum of two points (at least one >0% and \leq 50% viability, and at least one >50% and <100% viability) to one point >0% and <100% viability, if the smallest practical dilution factor (i.e., 1.21) was used, and all other test acceptance criteria were met. This reduced the number of failed experiments for substances with very steep concentration-response curves, without reducing the quality of the IC₅₀ data. For the 3T3 NRU test method, diquat dibromide (1/9 definitive tests), epinephrine bitartrate (2/9 definitive tests), and 1,1,1-trichloroethane (2/8 definitive tests) had such steep dose-responses that some acceptable tests met these revised criteria. None of the NHK NRU tests needed the revised criteria.
- R^2 Acceptance Criterion: Rescinded the R² criterion for the fit of the Hill function. The SMT determined that the R² criterion was best used to characterize the shape of the concentration-response curve rather than to establish a criterion for test acceptability. This reduced the number of failed experiments without affecting the calculation of the IC₅₀ values as long as an

adequate number of toxicity points between 0 and 100% viability were obtained.

- *PC Acceptance Criteria*: Modified the PC acceptance criterion for Hill function fit.
- *Hill Function Analysis*: Altered the PRISM[®] template for the Hill function analysis to perform calculations for IC_x values in two ways: (1) constraining Bottom parameter to zero, and (2) fitting the Bottom parameter. As a result of the changes and efforts by the laboratories to use dilution schemes that captured the entire concentration-response range, very few tests in Phase III had R² <0.9.
- *Biphasic Dose-Response in Range Finder Test*: Provided guidance for proceeding with definitive testing when a biphasic dose-response was obtained in the range-finder test. The definitive test was to focus on the lowest concentrations that produced responses around 50% viability (See Section 2.6.3.2).

| | Tes | sting Stopped | l No IC ₅₀ D | ata | | | | | |
|--------------|------------|--------------------------------------|--|---|---|--|--|--|--|
| 3T3 I | NRU Test M | ethod | NHK NRU Test Method | | | | | | |
| ECBC | FAL | IIVS | ECBC | FAL | IIVS | | | | |
| Х | Х | Х | Х | Х | Х | | | | |
| | Х | | | | | | | | |
| | Х | | | | | | | | |
| Х | Х | Х | Х | | | | | | |
| Х | | | | Х | Х | | | | |
| | | Х | | | | | | | |
| Х | Х | | Х | Х | | | | | |
| | ECBC X | 3T3 NRU Test MeECBCFALXXXXXXXXXXXIXI | 3T3 NRU Test MethodECBCFALIIVSXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX | 3T3 NRU Test MethodNHKECBCFALIIVSECBCXX | ECBCFALIIVSECBCFALXXX | | | | |

Abbreviations: 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake; ECBC=Edgewood Chemical Biological Center; FAL=Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory; IIVS=Institute for *In Vitro* Sciences.

¹Substances that did not provide sufficient cytotoxicity for the calculation of an IC_{50} in one or more laboratories (identified by X).

5.4 Data Used to Evaluate Test Method Accuracy and Reliability

This section first presents the acceptable PC data and IC_{50} results from each laboratory for each phase of the validation study, and then presents the reference substance IC_{50} results and Hill Slopes from each phase. The individual test data for both passing and failing tests are provided in **Appendix I** for the PC and reference substances. Accuracy (concordance for the prediction of GHS acute oral toxicity category) and reliability assessments are provided in **Sections 6** and 7, respectively.

5.4.1 <u>PC Data</u>

A summary of the acceptable SLS data IC_{50} results used to calculate quality control acceptance limits for each test method in each laboratory are provided in **Table 5-3**. The SLS IC_{50} results were used to calculate acceptable limits for each laboratory to use in subsequent study phases. One of the test acceptance criteria for each reference substance test was that the associated SLS IC_{50} must be within the acceptance limits. The individual test data for both passing and failing PC tests are provided in **Appendix I3** for the 3T3 and in **Appendix I4** for the NHK methods.

| | | ECI | BC | | | FA | L | | IIVS | | | | | | |
|------------------|-------------------------------------|----------------------------------|------------------------|----|-------------------------------------|----------------------------------|----------------------|----|-------------------------------------|----------------------------------|----------------------|----|--|--|--|
| Study Phase | Mean IC ₅₀ (µg/mL) | Standard Deviation (µg/mL) | Acceptance Limits N | | Mean IC ₅₀ (µg/mL) | Standard Deviation (µg/mL) | Acceptance Limits | N | Mean IC ₅₀ (µg/mL) | Standard Deviation (µg/mL) | Acceptance Limits | Ν | | | |
| 3T3 NRU | l | | | | | | | | | | | | | | |
| Ia ² | 38.3 | 4.71 | 28.8 - 47.7 | 15 | 42.3 | 8.56 | 25.2 - 59.5 | 25 | 40.9 | 3.19 | 34.5 - 47.3 | 12 | | | |
| Ib ³ | 41.3 | 5.99 | 26.4 - 56.3 | 12 | 43.2 | 4.68 | 31.5 - 54.9 | 17 | 42.1 | 3.40 | 33.6 - 50.6 | 13 | | | |
| II ⁴ | 41.2 | 4.20 | 30.8 - 51.6 | 29 | 45.9 | 7.50 | 27.2 - 64.7 | 36 | 40.6 | 3.50 | 31.8 - 49.3 | 21 | | | |
| III ⁵ | 41.6 | 3.41 | NA | 65 | 41.1 | 6.23 | NA | 26 | 41.5 | 3.74 | NA | 22 | | | |
| NHK NR | U | | | | | | | | | | | | | | |
| Ia ² | 4.03 | 1.32 | 1.40 - 6.67 | 15 | 7.45 | 3.07 | 1.34 - 13.6 | 18 | 3.68 | 0.555 | 2.57 - 4.79 | 30 | | | |
| Ib ³ | 3.65 | 0.98 | 1.22 - 6.10 | 11 | 5.35 | 2.32 | $0^6 - 11.1$ | 15 | 3.57 | 0.59 | 2.10 - 5.04 | 17 | | | |
| II ⁴ | 3.59 | 1.41 | 0.07 - 7.11 | 22 | 3.20 | 1.05 | 0.57 - 5.82 | 15 | 3.78 | 0.73 | 1.94 - 5.61 | 26 | | | |
| III ⁵ | 3.03 | 0.75 | NA | 57 | 3.45 | 0.90 | NA | 35 | 3.12 | 0.53 | NA | 20 | | | |

Table 5-3Positive Control (PC)¹ IC₅₀ Results by Study Phase

Abbreviations: 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake; ECBC=Edgewood Chemical Biological Center; FAL=Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory; IIVS=Institute for *In Vitro* Sciences; N=Number of acceptable tests; NA=Not applicable

¹PC was sodium lauryl sulfate (SLS).

²Values generated from Phase Ia data were used as acceptance criteria for Phase Ib tests; Acceptance limits = Mean ± 2 X standard deviation.

³Values generated from Phases Ia and Ib data were used as acceptance criteria for Phase II tests; Acceptance limits = Mean ± 2.5 X standard deviation.

⁴Values generated from Phases Ia, Ib, and II data were used as acceptance criteria for Phase III tests; Acceptance limits = Mean ± 2.5 X standard deviation.

⁵Values generated from Phase III test data.

⁶Calculation of lower limits yielded a negative value, so that lower limit was set at 0 and later revised to 0.1 µg/mL.

5.4.1.1 Phase Ib PC Data Acceptance Limits

The SLS IC₅₀ acceptance limits for Phase Ib testing were calculated using the Phase Ia data. The data sets from each laboratory were examined for outliers using the method of Dixon and Massey (1981), but none were identified. The acceptance limits for the SLS IC₅₀ values for each laboratory and test method were the mean ± 2 SD.

5.4.1.2 *Phase II PC Data Acceptance Limits*

The IC₅₀ values from the Phase Ia and Ib SLS tests were used to calculate laboratory-specific and test method-specific quality control acceptance limits for Phase II. Phase Ib tests that had SLS IC₅₀ values outside of the acceptance limits were considered acceptable if they met all other test acceptance criteria. For any day during which there was more than one SLS test (for any one method and laboratory), the IC₅₀ values were averaged to better reflect day-today variation and avoid overweighting the overall mean with multiple values from a single day. Outliers at the 99% level were removed and the remaining values were used to calculate the mean ± 2.5 SD acceptance limits. The acceptance limits were expanded from 2 SD in Phase Ib to 2.5 SD for Phase II to allow for the fact that the SDs decrease as more data are collected.

5.4.1.3 Phase III PC Data Acceptance Limits

The IC₅₀ values from the Phase I and II SLS tests were used to calculate laboratory-specific and method-specific quality control acceptance limits for Phase III data. The SLS IC₅₀ values outside the acceptance limits were considered acceptable if the tests met all other acceptance criteria. For any day for which there was more than one SLS test (for any one method and laboratory), the IC₅₀ values were averaged to better reflect day-to-day variation and avoid overweighting the overall mean with multiples values from a single day. ANOVA was used to compare the Phase Ia, Ib, and II data within each laboratory to determine whether the SLS IC₅₀ for each method and laboratory was changing over the course of the study. For PC data that were not significantly different from phase to phase at p <0.05, the IC₅₀ values were used to calculate the mean ± 2.5 SD as the acceptance limits for Phase III. The only significant differences in SLS values seen between study phases (p <0.0002) were the FAL results for NHK. This difference was attributed to the changes in cell culture practices between Phases Ib and II (see **Section 5.3.3**). Thus, only the Phase II SLS IC₅₀ values were used to calculate the acceptance limits for Phase III NHK data at FAL.

5.4.2 <u>Reference Substance Data</u>

Reference substance data and results from the individual 3T3 and NHK tests (both acceptable and unacceptable) from each laboratory are presented in **Appendices I1** and **I2**. **Tables 5-4** and **5-5** summarize the IC₅₀ and Hill Slope data from the acceptable 3T3 and NHK tests, respectively, for each reference substance and laboratory. The Hill Slope data are provided for supplemental information on the concentration-response characteristics for each reference substance, but were not used for reliability or accuracy analyses. These tables are organized alphabetically by substance name and provide substance class (based on the NLM Medical Subject Heading [MeSH index]), arithmetic mean IC₅₀ and SD for each laboratory, arithmetic mean Hill Slope and SD for each laboratory, and the number of tests used to produce the mean values. **Figure 5-1** graphically presents the 3T3 IC₅₀ data from **Table 5-4**, and **Figure 5-2** presents the NHK IC₅₀ data from **Table 5-5**. The reference substances in **Figures 5-1** and **5-2** are ordered by ascending IC₅₀ (lowest value [most toxic] to highest value [least toxic]) using the 3T3 IC₅₀ values from IIVS (the lead laboratory for the study). This allows a simple comparison of each reference substance value from each laboratory. **Table 5-6** provides the numerical key to the reference substances in **Figures 5-1** and **5-2**.

Because of their low toxicity and/or low solubility, some substances were not sufficiently toxic for calculation of an IC₅₀ value. For the 3T3 NRU test method, no IC₅₀ values were obtained for carbon tetrachloride or methanol in any laboratory (see Table 5-4). ECBC was the only laboratory that obtained IC_{50} values for lithium carbonate, and IIVS was the only laboratory that obtained IC₅₀ values for xylene. Only one acceptable test (and IC₅₀ value) was obtained for disulfoton at FAL, for 1,1,1-trichloroethane at ECBC, and for valproic acid at IIVS. FAL did not achieve sufficient toxicity for the calculation of an IC₅₀ for gibberellic acid in any 3T3 NRU tests performed. For the NHK NRU test method (see Table 5-5), there was insufficient toxicity in all tests in all laboratories for a calculation of an IC₅₀ for carbon tetrachloride. Only one laboratory achieved sufficient toxicity for the calculation of an IC_{50} for 1,1,1-trichloroethane (ECBC) and xylene (IIVS). One laboratory, ECBC, failed to achieve sufficient toxicity for the calculation of an IC_{50} for methanol. All of these substances, with the exception of methanol, produced precipitate in the cell culture medium. The solvent used for methanol was DMSO, and because the amount of DMSO that could be used in the cell culture was limited to 0.5%, the amount of DMSO that could be used to dissolve methanol was also limited. The differences among laboratories regarding their ability to attain a high enough concentration to achieve an IC_{50} for some substances may be due to the differing perceptions of the laboratory personnel regarding whether or not the substance was sufficiently dissolved, or differences in the techniques used to dissolve the substances.

| | Chaminal | Phase | | | ECB | С | | | | IIVS | | | | | | | |
|-------------------------|---|-----------------------|--|--|-----|----------------------------|-----------------|--|--|------|----------------------------|-----------------|--|--|---|----------------------------|-----------------|
| Substance | Chemical Class ⁵ | in which Tested | IC ₅₀ ¹ μg/mL | SD ² (IC ₅₀) | N | Hill Slope ³ | SD ⁴ | IC ₅₀ ¹ μg/mL | SD ² (IC ₅₀) | N | Hill Slope ³ | SD ⁴ | IC ₅₀ ¹ μg/mL | SD ² (IC ₅₀) | N | Hill Slope ³ | SD ⁴ |
| Acetaminophen | Amide | III | 40.8 | 9.12 | 3 | -1.53 | 0.354 | 66.2 | 23.0 | 3 | -1.23 | 0.503 | 43.4 | 11.4 | 3 | -1.55 | 0.165 |
| Acetonitrile | Nitrile | III | 6433 | 129 | 3 | -2.29 | 0.648 | 9690 | 5634 | 3 | -1.55 | 0.196 | 9330 | 1217 | 3 | -2.63 | 0.245 |
| Acetylsalicylic acid | Carboxylic Acid; Phenol | III | 646 | 61.5 | 3 | -1.75 | 0.473 | 1234 | 298 | 3 | -1.99 | 0.393 | 401 | 62.0 | 3 | -1.31 | 0.167 |
| Aminopterin | Heterocyclic | II | 0.005 | 0.001 | 3 | -2.00 | 0.395 | 0.012 | 0.005 | 3 | -3.36 | 1.59 | 0.005 | 0.001 | 3 | -1.46 | 0.198 |
| 5-Aminosalicylic acid | Carboxylic Acid; Phenol | III | 1467 | 203 | 3 | -1.82 | 0.267 | 2070 | 334 | 3 | -2.33 | 0.809 | 1557 | 179 | 3 | -1.64 | 0.326 |
| Amitriptyline HCl | Polycyclic | III | 6.03 | 1.38 | 3 | -2.47 | 0.668 | 7.86 | 2.20 | 3 | -2.98 | 0.446 | 7.81 | 1.38 | 3 | -4.48 | 0.916 |
| Arsenic III Trioxide | Arsenical | Ib | 2.41 | 0.782 | 4 | -1.94 | 0.204 | 1.04 | 0.070 | 4 | -3.02 | 2.09 | 4.09 | 2.23 | 3 | -1.62 | 0.285 |
| Atropine sulfate | Heterocyclic | III | 54.1 | 29.6 | 3 | -1.32 | 0.480 | 133 | 41.1 | 3 | -2.20 | 0.695 | 70.0 | 5.7 | 3 | -1.27 | 0.165 |
| Boric acid | Boron compound; Acid | III | 1497 | 484 | 3 | -1.14 | 0.039 | 3987 | 693 | 3 | -1.86 | 0.654 | 1202 | 581 | 3 | -1.71 | 0.677 |
| Busulfan | Alcohol; Sulfur compound; Acyclic hydrocarbon | III | 40.4 | 19.3 | 3 | -0.515 | 0.003 | 321 | 180 | 3 | -1.14 | 0.802 | 43.7 | 1.77 | 3 | -0.627 | 0.164 |
| Cadmium II chloride | Cadmium compound; Chlorine compound | П | 0.480 | 0.066 | 3 | -1.85 | 0.529 | 0.400 | 0.129 | 3 | -3.05 | 0.743 | 0.817 | 0.427 | 3 | -2.45 | 0.449 |
| Caffeine | Heterocyclic | III | 133 | 13.3 | 3 | -1.11 | 0.097 | 157 | 81.7 | 3 | -0.866 | 0.250 | 191 | 14.4 | 3 | -1.27 | 0.077 |
| Carbamazepine | Heterocyclic | III | 83.0 | 12.0 | 3 | -1.94 | 0.539 | 152 | 56.9 | 3 | -3.50 | 1.27 | 91.8 | 11.0 | 3 | -2.34 | 0.307 |
| Carbon tetrachloride | Halogenated hydrocarbon | III | NA | NA | - | NA | NA | NA | NA | - | NA | NA | NA | NA | - | NA | NA |
| Chloral hydrate | Alcohol | III | 151 | 15.6 | 3 | -1.73 | 0.172 | 241 | 25.1 | 3 | -2.16 | 0.597 | 170 | 19.9 | 3 | -1.68 | 0.084 |
| Chloramphenicol | Alcohol; Nitro compound; Cyclic hydrocarbon | П | 55.3 | 12.4 | 4 | -0.779 | 0.057 | 273 | 82.2 | 4 | -1.16 | 0.249 | 156 | 27.9 | 3 | -0.952 | 0.036 |
| Citric acid | Carboxylic acid | III | 473 | 138 | 3 | -1.89 | 0.423 | 1148 | 143 | 4 | -3.68 | 0.407 | 865 | 160 | 3 | -2.51 | 0.530 |

| | Chamical | Phase | | | ECB | С | | | | FAL | | | IIVS | | | | | |
|------------------------------|---|-----------------------|--|--|-----|----------------------------|-----------------|--|--|-----|----------------------------|-----------------|--|--|---|----------------------------|-----------------|--|
| Substance | Chemical Class ⁵ | in which Tested | IC ₅₀ ¹ μg/mL | SD ² (IC ₅₀) | N | Hill Slope ³ | SD ⁴ | IC ₅₀ ¹ μg/mL | SD ² (IC ₅₀) | N | Hill Slope ³ | SD ⁴ | IC ₅₀ ¹ μg/mL | SD ² (IC ₅₀) | Ν | Hill Slope ³ | SD ⁴ | |
| Colchicine | Polycyclic | II | 0.021 | 0.002 | 4 | -1.69 | 0.049 | 0.093 | 0.042 | 3 | -1.61 | 1.80 | 0.028 | 0.0003 | 3 | -1.69 | 0.255 | |
| Cupric sulfate pentahydrate | Sulfur compound; Metal | III | 82.7 | 3.18 | 3 | -4.85 | 0.700 | 123 | 54.0 | 4 | -17.7 | 15.5 | 5.72 | 1.75 | 3 | -5.71 | 1.14 | |
| Cycloheximide | Heterocyclic | III | 0.125 | 0.057 | 3 | -1.19 | 0.167 | 0.647 | 0.451 | 3 | -1.53 | 0.128 | 0.109 | 0.025 | 3 | -0.937 | 0.158 | |
| Dibutyl phthalate | Carboxylic acid | III | 23.5 | 3.98 | 3 | -3.37 | 1.27 | 191 | 94.5 | 4 | -0.965 | 0.140 | 20.7 | 1.37 | 3 | -2.62 | 0.283 | |
| Dichlorvos | Organophos- phorous | III | 9.83 | 3.42 | 3 | -1.32 | 0.297 | 32.8 | 2.07 | 3 | -3.42 | 1.00 | 18.3 | 2.09 | 3 | -2.13 | 0.439 | |
| Diethyl phthalate | Carboxylic acid | III | 85.5 | 29.0 | 3 | -1.11 | 0.340 | 147 | 37.8 | 3 | -2.03 | 0.422 | 106 | 25.3 | 3 | -2.35 | 0.824 | |
| Digoxin | Polycyclic; Carbohydrate | III | 351 | 137 | 3 | -2.11 | 2.05 | 892 | 319 | 3 | -3.26 | 2.21 | 317 | 67.9 | 2 | -3.04 | 1.52 | |
| Dimethyl- formamide | Amide; Carboxylic acid | III | 5343 | 515 | 3 | -1.96 | 0.087 | 5483 | 517 | 3 | -1.80 | 0.143 | 4900 | 183 | 3 | -1.87 | 0.102 | |
| Diquat dibromide monohydrate | Heterocyclic | III | 3.87 | 0.887 | 3 | -1.59 | 0.197 | 36.1 | 35.5 | 3 | -11.5 | 10.1 | 5.39 | 1.36 | 3 | -3.00 | 0.784 | |
| Disulfoton | Organophos- phorous; Sulfur compound | Ш | 137 | 74.9 | 3 | -2.06 | 1.88 | 11200 | NA | 1 | -1.22 | NA | 60.4 | 52.5 | 3 | -2.23 | 1.08 | |
| Endosulfan | Heterocyclic Sulfur compound | III | 5.27 | 3.01 | 3 | -0.669 | 0.243 | 15.2 | 11.9 | 4 | -0.762 | 0.221 | 3.61 | 1.53 | 3 | -0.871 | 0.636 | |
| Epinephrine bitartrate | Alcohol; Amine | III | 51.5 | 6.16 | 3 | -5.99 | 3.08 | 63.4 | 6.63 | 3 | -45.1 | 32.0 | 63.4 | 1.91 | 3 | -4.74 | 1.51 | |
| Ethanol | Alcohol | III | 5360 | 1754 | 3 | -1.33 | 0.104 | 8420 | 1205 | 3 | -1.88 | 0.128 | 6413 | 345 | 3 | -1.99 | 0.372 | |
| Ethylene glycol | Alcohol | Ib | 18325 | 1658 | 4 | -3.79 | 4.08 | 31650 | 7453 | 4 | -1.70 | 0.166 | 25900 | 3081 | 3 | -1.67 | 0.079 | |
| Fenpropathrin | Nitrile; Ester; Ether | III | 22.6 | 2.41 | 3 | -2.54 | 0.350 | 42.4 | 26.8 | 4 | -1.44 | 0.645 | 16.7 | 2.03 | 3 | -2.53 | 0.495 | |
| Gibberellic acid | Polycyclic | III | 8027 | 908 | 3 | -1.95 | 0.678 | NA | NA | - | NA | NA | 7657 | 745 | 3 | -1.66 | 0.087 | |
| Glutethimide | Heterocyclic | III | 167 | 7.00 | 3 | -1.3 | 0.045 | 284 | 20.7 | 3 | -1.47 | 0.131 | 125 | 9.25 | 4 | -1.20 | 0.163 | |
| Glycerol | Alcohol | III | 20000 | 2987 | 3 | -2.02 | 0.273 | 38878 | 28238 | 4 | -2.27 | 1.29 | 27833 | 10882 | 3 | -1.87 | 0.306 | |
| Haloperidol | Ketone | III | 5.32 | 0.649 | 3 | -2.34 | 0.445 | 7.99 | 0.655 | 3 | -4.99 | 0.378 | 5.47 | 0.654 | 3 | -1.86 | 0.048 | |

| | | Phase | | | ECB | С | | | | FAL | | | IIVS | | | | | |
|-------------------------|--|-----------------------|--|--|-----|----------------------------|-----------------|--|--|-----|----------------------------|-----------------|--|--|----|----------------------------|-----------------|--|
| Substance | Chemical Class ⁵ | in which Tested | IC ₅₀ ¹ μg/mL | SD ² (IC ₅₀) | N | Hill Slope ³ | SD ⁴ | IC ₅₀ ¹ μg/mL | SD ² (IC ₅₀) | N | Hill Slope ³ | SD ⁴ | IC ₅₀ ¹ μg/mL | SD ² (IC ₅₀) | Ν | Hill Slope ³ | SD ⁴ | |
| Hexachlorophene | Cyclic hydrocarbon Phenol | III | 5.02 | 2.41 | 3 | -1.62 | 0.189 | 5.35 | 1.75 | 3 | -1.17 | 0.322 | 3.06 | 0.289 | 3 | -1.66 | 0.217 | |
| Lactic acid | Carboxylic acid | Ш | 2943 | 315 | 3 | -4.13 | 1.54 | 3487 | 561 | 3 | -6.62 | 3.23 | 2790 | 259 | 3 | -3.64 | 1.09 | |
| Lindane | Halogenated hydrocarbon | III | 125 | 119 | 3 | -0.737 | 0.231 | 266 | 94.8 | 4 | -1.26 | 1.283 | 90.4 | 111 | 5 | -1.46 | 0.262 | |
| Lithium I carbonate | Alkalies; Inorganic carbon; Lithium compound | П | 564 | 67.6 | 3 | -1.59 | 0.313 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Meprobamate | Carboxylic acid | III | 353 | 49.7 | 3 | -1.16 | 0.438 | 877 | 128 | 4 | -1.32 | 0.270 | 386 | 9.02 | 3 | -1.12 | 0.133 | |
| Mercury II chloride | Mercury compound; Chlorine compound | III | 3.45 | 0.177 | 3 | -4.18 | 0.988 | 5.99 | 1.87 | 3 | -4.34 | 1.11 | 3.51 | 0.120 | 3 | -4.16 | 1.31 | |
| Methanol | Alcohol | III | NA | NA | - | NA | NA | NA | NA | - | NA | NA | NA | NA | - | NA | NA | |
| Nicotine | Heterocyclic | III | 272 | 65.3 | 3 | -1.58 | 0.357 | 412 | 136 | 3 | -12.0 | 6.99 | 450 | 54.7 | 3 | -49.6 | 70.9 | |
| Paraquat | Heterocyclic | III | 21.3 | 7.29 | 3 | -1.32 | 0.341 | 24.9 | 16.5 | 3- | -4.10 | 3.13 | 23.7 | 15.2 | 3 | -1.92 | 0.581 | |
| Parathion | Organophos- phorous; Sulfur compound | Ш | 22.7 | 12.1 | 3 | -1.89 | 1.33 | 141 | 98.7 | 4 | -1.62 | 0.520 | 22.0 | 4.94 | 3 | -1.55 | 0.562 | |
| Phenobarbital | Heterocyclic | III | 634 | 134 | 3 | -1.43 | 0.177 | 726 | 255 | 3 | -1.84 | 0.851 | 476 | 111 | 4 | -1.67 | 0.418 | |
| Phenol | Phenol | III | 50.2 | 10.9 | 3 | -1.46 | 0.318 | 104 | 24.8 | 3 | -1.55 | 0.205 | 58.1 | 6.78 | 3 | -1.41 | 0.259 | |
| Phenylthiourea | Sulfur compound; Urea | III | 30.1 | 19.8 | 3 | -0.781 | 0.218 | 239 | 65.8 | 3 | -0.890 | 0.206 | 89.0 | 21.9 | 3 | -1.40 | 0.127 | |
| Physostigmine | Carboxylic acid; Heterocyclic | III | 28.2 | 14.9 | 3 | -1.51 | 0.595 | 37.8 | 1.93 | 3 | -7.22 | 1.04 | 20.4 | 6.71 | 4 | -1.70 | 0.157 | |
| Potassium I chloride | Potassium compound; Chlorine compound | II | 3352 | 468 | 4 | -3.32 | 1.17 | 3842 | 1198 | 5 | -4.31 | 2.27 | 3710 | 417 | 3 | -2.87 | 0.147 | |

| | Chaminal | Phase | | | ECB | С | | | | FAL | | | IIVS | | | | |
|-----------------------------------|---|-----------------------|--|--|-----|----------------------------|-----------------|--|--|-----|----------------------------|-----------------|--|--|---|----------------------------|-----------------|
| Substance | Chemical Class⁵ | in which Tested | IC ₅₀ ¹ μg/mL | SD ² (IC ₅₀) | N | Hill Slope ³ | SD ⁴ | IC ₅₀ ¹ μg/mL | SD ² (IC ₅₀) | N | Hill Slope ³ | SD ⁴ | IC ₅₀ ¹ μg/mL | SD ² (IC ₅₀) | N | Hill Slope ³ | SD ⁴ |
| Potassium cyanide | Potassium compound; Nitrogen compound | Ш | 15.3 | 3.76 | 3 | -1.48 | 0.677 | 159 | 81.9 | 3 | -1.03 | 0.152 | 18.9 | 0.950 | 3 | -3.43 | 0.488 |
| Procainamide HCl | Carboxylic acid; Amide | III | 400 | 15.3 | 3 | -12.4 | 1.91 | 431 | 4.73 | 3 | -45.6 | 18.4 | 497 | 39.3 | 3 | -19.9 | 13.1 |
| 2-Propanol | Alcohol | Π | 2610 | 240 | 2 | -1.80 | 0.001 | 3970 | 139 | 3 | -1.65 | 0.241 | 4110 | 161 | 3 | -1.93 | 0.160 |
| Propranolol HCl | Alcohol | Ib | 13.6 | 4.37 | 4 | -2.54 | 0.627 | 13.5 | 6.85 | 4 | -3.31 | 2.53 | 17.6 | 3.78 | 3 | -3.45 | 1.44 |
| Propylparaben | Carboxylic acid; Phenol | III | 20.9 | 3.33 | 3 | -1.23 | 0.259 | 51.8 | 14.8 | 3 | -1.45 | 0.442 | 17.1 | 2.10 | 3 | -1.24 | 0.245 |
| Sodium arsenite | Sodium compound; Arsenical | III | 0.496 | 0.028 | 3 | -1.43 | 0.087 | 1.44 | 0.819 | 3 | -3.79 | 1.22 | 0.683 | 0.117 | 3 | -1.90 | 0.535 |
| Sodium chloride | Sodium compound; Chlorine compound | Ш | 4790 | 233 | 3 | -1.55 | 0.182 | 4625 | 611 | 4 | -2.67 | 0.620 | 4877 | 457 | 3 | -2.03 | 0.366 |
| Sodium dichromate dihydrate | Sodium compound; Chromium compound | III | 0.603 | 0.087 | 3 | -1.64 | 0.136 | 0.657 | 0.244 | 3 | -5.01 | 1.51 | 0.547 | 0.092 | 3 | -1.93 | 0.194 |
| Sodium I fluoride | Sodium compound; Fluorine compound | II | 61.3 | 5.55 | 3 | -5.06 | 1.50 | 96.1 | 17.7 | 3 | -4.40 | 0.971 | 82.0 | 5.81 | 3 | -2.73 | 0.850 |
| Sodium hypochlorite | Sodium compound Oxygen compound; Chlorine compound | III | 823 | 108 | 3 | -2.57 | 1.12 | 805 | 367 | 3 | -4.13 | 3.05 | 2005 | 872 | 4 | -3.20 | 0.279 |
| Sodium oxalate | Sodium compound; Carboxylic acid | Ш | 42.0 | 17.3 | 3 | -1.83 | 0.380 | 31.0 | 8.66 | 3 | -3.11 | 0.367 | 49.5 | 26.3 | 4 | -2.32 | 0.592 |
| Sodium selenate | Sodium compound; Selenium compound | II | 12.7 | 1.62 | 3 | -1.59 | 0.217 | 54.2 | 10.4 | 3 | -3.76 | 0.968 | 36.5 | 5.23 | 3 | -1.65 | 0.112 |

| | Chemical | Phase I in | | | ECB | С | | | | FAL | | | IIVS | | | | |
|----------------------------|---------------------------------|-----------------|--|--|-----|----------------------------|-----------------|--|--|-----|----------------------------|-----------------|--|--|---|----------------------------|-----------------|
| Substance | Class ⁵ | which Tested | IC ₅₀ ¹ μg/mL | SD ² (IC ₅₀) | N | Hill Slope ³ | SD ⁴ | IC ₅₀ ¹ μg/mL | SD ² (IC ₅₀) | N | Hill Slope ³ | SD ⁴ | IC ₅₀ ¹ μg/mL | SD ² (IC ₅₀) | N | Hill Slope ³ | SD ⁴ |
| Strychnine | Heterocyclic | III | 389 | 80.9 | 3 | -2.51 | 0.728 | 124 | 20.3 | 3 | -5.85 | 0.922 | 83.5 | 5.35 | 3 | -6.49 | 2.12 |
| Thallium I sulfate | Sulfur compound; Metal | III | 2.81 | 0.671 | 3 | -1.02 | 0.201 | 13.4 | 10.4 | 4 | -0.714 | 0.302 | 6.27 | 1.75 | 3 | -0.752 | 0.081 |
| Trichloroacetic acid | Carboxylic acid | III | 762 | 99.1 | 3 | -1.66 | 0.118 | 1220 | 72.1 | 3 | -2.22 | 0.089 | 801 | 114 | 3 | -1.77 | 0.130 |
| 1,1,1-Trichloro- ethane | Halogenated hydrocarbon | III | 41100 | NA | 1 | -2.38 | NA | 21250 | 2357 | 3 | -31.5 | 32.1 | 9827 | 180 | 3 | -21.8 | 8.47 |
| Triethylene- melamine | Heterocyclic | III | 0.086 | 0.009 | 3 | -0.567 | 0.018 | 1.45 | 0.265 | 3 | -1.88 | 1.04 | 0.169 | 0.049 | 3 | -0.615 | 0.138 |
| Triphenyltin hydroxide | Organo- metallic compound | III | 0.026 | 0.004 | 3 | -1.66 | 0.257 | 0.026 | 0.021 | 3 | -4.78 | 3.37 | 0.015 | 0.008 | 3 | -1.46 | 0.149 |
| Valproic acid | Carboxylic acid; Lipids | III | 547 | 67.1 | 3 | -2.24 | 0.742 | 1807 | 175 | 3 | -4.07 | 0.766 | 574 | NA | 1 | -1.24 | NA |
| Verapamil HCl | Amine | III | 32.2 | 5.82 | 3 | -4.43 | 1.362 | 34.6 | 1.72 | 3 | -29.1 | 18.6 | 38.9 | 4.20 | 3 | -5.00 | 0.935 |
| Xylene | Cyclic hydrocarbon | III | NA | NA | - | NA | NA | NA | NA | - | NA | NA | 724 | 87.1 | 3 | -1.91 | 0.473 |

Table 5-4**3T3 NRU Test Method IC**₅₀ and Hill Slope Data by Laboratory

Abbreviations: ECBC=Edgewood Chemical Biological Center; FAL=Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory; IIVS=Institute for *In Vitro* Sciences; SD=Standard deviation; N=Number of data points; NA=Not available (i.e., IC₅₀ values or Hill Slope values could not be generated [see notes in **Appendix I** for more information])

¹Arithmetic mean.

²Standard deviation of IC₅₀.

³Arithmetic Mean of Hill Slope values.

⁴Standard deviation of Hill Slope values.

⁵Chemical class assigned is based on the classification of the National Library of Medicine's Medical Subject Heading (MeSH), http://www.nlm.nih.gov/mesh/meshhome.html.

| | Chemical | Phase | | | ECB | C | | | | FAL | ı | | | | IIVS | | |
|-------------------------|---|-----------------------|--|-----------------|-----|----------------------------|-----------------|--|-----------------|-----|----------------------------|-----------------|--|-----------------|------|----------------------------|-----------------|
| Substance | Class ⁵ | in which Tested | IC ₅₀ ¹ μg/mL | SD ² | N | Hill Slope ³ | SD ⁴ | IC ₅₀ ¹ μg/mL | SD ² | N | Hill Slope ³ | SD ⁴ | IC ₅₀ ¹ μg/mL | SD ² | N | Hill Slope ³ | SD ⁴ |
| Acetaminophen | Amide | III | 558 | 80.7 | 3 | -1.09 | 0.108 | 447 | 83.7 | 3 | -1.09 | 0.646 | 571 | 79.0 | 3 | -1.20 | 0.154 |
| Acetonitrile | Nitrile | III | 10868 | 7824 | 4 | -2.61 | 0.424 | 10153 | 1960 | 4 | -5.95 | 3.34 | 9290 | 413 | 3 | -2.79 | 0.306 |
| Acetylsalicylic acid | Carboxylic Acid; Phenol | III | 631 | 19.9 | 3 | -1.94 | 0.367 | 694 | 98.3 | 3 | -1.85 | 0.324 | 514 | 79.1 | 3 | -1.97 | 0.083 |
| Aminopterin | Heterocyclic | Π | 889 | 182 | 3 | -2.03 | 0.375 | 545 | 42.2 | 3 | -1.27 | 0.225 | 611 | 70.7 | 2 | -1.72 | 0.547 |
| 5-Aminosalicylic acid | Carboxylic Acid; Phenol | III | 29.9 | 6.52 | 3 | -3.45 | 0.806 | 78.2 | 42.3 | 3 | -7.96 | 6.90 | 48.8 | 7.90 | 3 | -3.66 | 0.629 |
| Amitriptyline HCl | Polycyclic | III | 10.8 | 3.34 | 3 | -1.79 | 0.236 | 7.57 | 5.43 | 3 | -1.43 | 0.479 | 10.9 | 1.04 | 3 | -2.27 | 0.278 |
| Arsenic III Trioxide | Arsenical | Ib | 7.77 | 2.54 | 4 | -2.67 | 0.470 | 2.55 | 1.92 | 6 | -1.78 | 1.14 | 20.9 | 6.4 | 3 | -2.02 | 0.338 |
| Atropine sulfate | Heterocyclic | III | 85.4 | 10.5 | 3 | -1.26 | 0.307 | 104 | 88.2 | 3 | -2.90 | 3.48 | 83.2 | 21.0 | 3 | -1.21 | 0.101 |
| Boric acid | Boron compound; Acid | III | 440 | 138 | 3 | -1.19 | 0.233 | 517 | 378 | 3 | -0.752 | 0.117 | 464 | 11 | 3 | -1.33 | 0.194 |
| Busulfan | Alcohol; Sulfur compound; Acyclic hydrocarbon | III | 253 | 68.2 | 3 | -0.783 | 0.323 | 268 | 193 | 3 | -1.50 | 0.357 | 313 | 37.2 | 3 | -1.66 | 0.459 |
| Cadmium II chloride | Cadmium compound; Chlorine compound | П | 2.20 | 0.823 | 5 | -4.01 | 1.25 | 1.88 | 1.22 | 3 | -3.36 | 3.14 | 1.86 | 0.151 | 3 | -4.65 | 1.38 |
| Caffeine | Heterocyclic | III | 817 | 256 | 3 | -1.44 | 0.504 | 591 | 186 | 3 | -1.06 | 0.499 | 574 | 7.81 | 3 | -1.28 | 0.117 |
| Carbamazepine | Heterocyclic | III | 66.1 | 8.4 | 3 | -1.15 | 0.307 | 253 | 325 | 3 | -2.57 | 2.53 | 63.9 | 5.27 | 3 | -1.34 | 0.444 |
| Carbon tetrachloride | Halogenated hydrocarbon | III | NA | NA | - | NA | NA | NA | NA | - | NA | NA | NA | NA | - | NA | NA |
| Chloral hydrate | Alcohol | III | 140 | 34.2 | 3 | -1.55 | 0.378 | 159 | 50.1 | 3 | -1.33 | 0.105 | 112 | 1.73 | 3 | -1.42 | 0.123 |
| Chloramphenicol | Alcohol; Nitro compound; Cyclic hydrocarbon | Π | 318 | 142 | 3 | -1.51 | 0.794 | 414 | 182 | 4 | -1.16 | 0.091 | 367 | 79.7 | 3 | -0.917 | 0.249 |
| Citric acid | Carboxylic acid | III | 526 | 82.4 | 3 | -1.62 | 0.158 | 312 | 51.6 | 4 | -1.25 | 0.249 | 433 | 22.3 | 3 | -1.62 | 0.080 |

| | | Phase | | | ECB | С | | | | FAL | 1 | | | | IIVS | | |
|------------------------------|---|-----------------------|--|-----------------|-----|----------------------------|-----------------|--|-----------------|-----|----------------------------|-----------------|--|-----------------|------|----------------------------|-----------------|
| Substance | Chemical Class ⁵ | in which Tested | IC ₅₀ ¹ μg/mL | SD ² | N | Hill Slope ³ | SD ⁴ | IC ₅₀ ¹ μg/mL | SD ² | N | Hill Slope ³ | SD ⁴ | IC ₅₀ ¹ μg/mL | SD ² | N | Hill Slope ³ | SD ⁴ |
| Colchicine | Polycyclic | II | 0.005 | 0.002 | 3 | -2.15 | 1.39 | 0.008 | 0.001 | 3 | -3.16 | 1.96 | 0.008 | 0.002 | 3 | -13.8 | 11.0 |
| Cupric sulfate pentahydrate | Sulfur compound; Metal | III | 190 | 19.6 | 3 | -6.16 | 3.16 | 195 | 12.5 | 3 | -3.85 | 0.328 | 207 | 7.09 | 3 | -5.69 | 0.871 |
| Cycloheximide | Heterocyclic | III | 0.053 | 0.012 | 3 | -1.24 | 0.152 | 0.120 | 0.094 | 3 | -0.850 | 0.388 | 0.071 | 0.013 | 3 | -1.54 | 0.178 |
| Dibutyl phthalate | Carboxylic acid | III | 28.3 | 7.64 | 3 | -1.40 | 0.295 | 47.4 | 34.3 | 3 | -1.02 | 0.352 | 22.0 | 1.32 | 3 | -1.33 | 0.197 |
| Dichlorvos | Organophos- phorous | III | 8.56 | 2.28 | 3 | -1.17 | 0.147 | 12.4 | 3.74 | 3 | -2.29 | 2.33 | 12.2 | 0.416 | 3 | -1.50 | 0.214 |
| Diethyl phthalate | Carboxylic acid | III | 174 | 14.4 | 3 | -2.21 | 0.358 | 71.5 | 67.3 | 3 | -1.67 | 0.637 | 189 | 33.1 | 3 | -1.97 | 0.242 |
| Digoxin | Polycyclic; Carbohydrate | III | 0.0054 | 0.0007 | 3 | -2.00 | 0.127 | 0.0001 | 0.00002 | 3 | -1.38 | 0.684 | 0.004 | 0.0003 | 3 | -4.59 | 1.73 |
| Dimethyl- formamide | Amide; Carboxylic acid | III | 9353 | 155 | 3 | -3.67 | 0.273 | 7817 | 100 | 3 | -2.85 | 0.590 | 6397 | 202 | 3 | -3.00 | 0.161 |
| Diquat dibromide monohydrate | Heterocyclic | III | 3.59 | 0.825 | 3 | -1.44 | 0.051 | 6.77 | 3.73 | 4 | -1.38 | 0.488 | 3.84 | 0.313 | 3 | -1.10 | 0.139 |
| Disulfoton | Organophos- phorous; Sulfur compound | Ш | 140 | 27.0 | 3 | -1.65 | 1.15 | 808 | 213 | 3 | -0.841 | 0.452 | 186 | 59.2 | 3 | -0.836 | 0.209 |
| Endosulfan | Heterocyclic Sulfur compound | III | 3.44 | 0.573 | 3 | -1.68 | 0.438 | 1.42 | 0.701 | 4 | -1.19 | 0.369 | 2.19 | 0.437 | 3 | -2.20 | 0.242 |
| Epinephrine bitartrate | Alcohol; Amine | III | 115 | 10.8 | 3 | -7.37 | 2.10 | 81.7 | 28.4 | 3 | -8.39 | 5.81 | 75.0 | 12.2 | 3 | -4.90 | 2.81 |
| Ethanol | Alcohol | III | 8290 | 390 | 3 | -2.13 | 0.035 | 12013 | 2286 | 3 | -1.82 | 0.635 | 10250 | 867 | 3 | -2.29 | 0.185 |
| Ethylene glycol | Alcohol | Ib | 38000 | 4681 | 3 | -3.22 | 0.650 | 49800 | 4371 | 3 | -3.02 | 0.188 | 40000 | 5341 | 4 | -2.56 | 0.444 |
| Fenpropathrin | Nitrile; Ester; Ether | III | 3.73 | 1.01 | 3 | -1.42 | 0.486 | 2.23 | 0.616 | 3 | -4.37 | 4.45 | 1.82 | 0.310 | 3 | -1.78 | 0.617 |
| Gibberellic acid | Polycyclic | III | 2850 | 402 | 3 | -2.45 | 0.372 | 2940 | 276 | 3 | -5.90 | 2.69 | 2807 | 121 | 3 | -3.30 | 1.104 |
| Glutethimide | Heterocyclic | III | 187 | 64.3 | 3 | -1.47 | 0.616 | 170 | 24.1 | 3 | -1.29 | 0.145 | 176 | 27.5 | 3 | -1.54 | 0.237 |
| Glycerol | Alcohol | III | 34267 | 15399 | 3 | -3.32 | 1.97 | 18023 | 8334 | 3 | -1.62 | 0.521 | 29033 | 4596 | 3 | -2.69 | 0.511 |
| Haloperidol | Ketone | III | 3.69 | 1.01 | 3 | -0.964 | 0.206 | 3.72 | 1.81 | 3 | -0.732 | 0.097 | 3.29 | 1.15 | 3 | -0.840 | 0.100 |

| | | Phase | | | ECB | С | | | | FAL | ı | | | | IIVS | | |
|-------------------------|--|-----------------------|--|-----------------|-----|----------------------------|-----------------|--|-----------------|-----|----------------------------|-----------------|--|-----------------|------|----------------------------|-----------------|
| Substance | Chemical Class ⁵ | in which Tested | IC ₅₀ ¹ μg/mL | SD ² | N | Hill Slope ³ | SD ⁴ | IC ₅₀ ¹ μg/mL | SD ² | N | Hill Slope ³ | SD ⁴ | IC ₅₀ ¹ μg/mL | SD ² | Ν | Hill Slope ³ | SD ⁴ |
| Hexachlorophene | Cyclic hydrocarbon Phenol | III | 0.027 | 0.004 | 3 | -2.21 | 0.301 | 0.046 | 0.020 | 3 | -2.91 | 0.662 | 0.021 | 0.002 | 3 | -2.36 | 0.059 |
| Lactic acid | Carboxylic acid | III | 1290 | 52.9 | 3 | -2.36 | 0.306 | 1320 | 60.8 | 3 | -3.25 | 0.328 | 1313 | 138 | 3 | -3.23 | 0.408 |
| Lindane | Halogenated hydrocarbon | III | 19.1 | 3.14 | 3 | -3.02 | 0.969 | 23.2 | 7.09 | 3 | -2.24 | 0.315 | 15.6 | 2.4 | 3 | -2.61 | 0.265 |
| Lithium I carbonate | Alkalies; Inorganic carbon; Lithium compound | П | 411 | 119 | 3 | -1.95 | 0.456 | 486 | 95.7 | 3 | -1.78 | 1.31 | 535 | 31.6 | 3 | -2.64 | 0.164 |
| Meprobamate | Carboxylic acid | III | 761 | 116 | 3 | -1.90 | 0.695 | 163 | 189 | 3 | -0.806 | 0.206 | 624 | 84.2 | 3 | -2.04 | 0.170 |
| Mercury II chloride | Mercury compound; Chlorine compound | III | 6.87 | 1.04 | 3 | -16.3 | 4.95 | 5.4 | 1.02 | 3 | -17.8 | 13.1 | 5.35 | 0.09 | 3 | -17.8 | 3.31 |
| Methanol | Alcohol | III | NA | NA | - | NA | NA | 1133 | 213 | 3 | -1.79 | 0.874 | 2100 | 226 | 3 | -1.86 | 0.297 |
| Nicotine | Heterocyclic | III | 94.3 | 24.7 | 3 | -0.654 | 0.092 | 134 | 78.4 | 3 | -0.668 | 0.077 | 112 | 27.7 | 3 | -0.733 | 0.047 |
| Paraquat | Heterocyclic | III | 48.3 | 6.03 | 3 | -1.04 | 0.158 | 96.6 | 37.2 | 3 | -1.34 | 0.326 | 53.4 | 5.52 | 3 | -1.47 | 0.034 |
| Parathion | Organophos- phorous; Sulfur compound | III | 34.0 | 10.0 | 3 | -1.60 | 0.640 | 31.2 | 11.9 | 3 | -1.18 | 0.200 | 29.0 | 8.34 | 3 | -1.85 | 0.956 |
| Phenobarbital | Heterocyclic | III | 693 | 180 | 3 | -1.10 | 0.214 | 360 | 95.5 | 3 | -0.976 | 0.229 | 381 | 69.9 | 3 | -1.68 | 0.353 |
| Phenol | Phenol | III | 59.1 | 21.4 | 3 | -0.919 | 0.084 | 93.2 | 5.97 | 3 | -1.15 | 0.209 | 80.8 | 5.12 | 3 | -0.915 | 0.029 |
| Phenylthiourea | Sulfur compound; Urea | III | 363 | 58 | 3 | -1.55 | 0.726 | 401 | 83.6 | 3 | -3.49 | 1.91 | 272 | 71.7 | 3 | -1.00 | 0.053 |
| Physostigmine | Carboxylic acid; Heterocyclic | III | 164 | 5.51 | 3 | -3.05 | 0.552 | 212 | 238 | 3 | -3.81 | 2.44 | 139 | 8.74 | 3 | -2.97 | 0.135 |
| Potassium I chloride | Potassium compound; Chlorine compound | II | 2560 | 432 | 3 | -2.23 | 0.383 | 2287 | 631 | 3 | -1.09 | 0.163 | 1990 | 161 | 3 | -2.05 | 0.165 |

| | Chemical | Phase | | | ECB | С | | | | FAL | | | | • | IIVS | | |
|-----------------------------------|---|-----------------------|--|-----------------|-----|----------------------------|-----------------|--|-----------------|-----|----------------------------|-----------------|--|-----------------|------|----------------------------|-----------------|
| Substance | Class ⁵ | in which Tested | IC ₅₀ ¹ μg/mL | SD ² | N | Hill Slope ³ | SD ⁴ | IC ₅₀ ¹ μg/mL | SD ² | N | Hill Slope ³ | SD ⁴ | IC ₅₀ ¹ μg/mL | SD ² | N | Hill Slope ³ | SD ⁴ |
| Potassium cyanide | Potassium compound; Nitrogen compound | III | 29.3 | 6.9 | 3 | -1.21 | 0.241 | 89.0 | 100 | 3 | -1.10 | 0.319 | 16.9 | 2.21 | 3 | -1.37 | 0.154 |
| Procainamide HCl | Carboxylic acid; Amide | III | 1480 | 200 | 3 | -3.56 | 0.813 | 1787 | 221 | 3 | -4.22 | 1.57 | 2027 | 229 | 3 | -4.42 | 0.459 |
| 2-Propanol | Alcohol | II | 5263 | 583 | 3 | -2.01 | 0.173 | 4273 | 1139 | 3 | -2.31 | 0.211 | 7087 | 480 | 3 | -3.01 | 0.406 |
| Propranolol HCl | Alcohol | Ib | 38.3 | 4.54 | 3 | -3.44 | 0.559 | 43.8 | 2.52 | 3 | -2.72 | 1.461 | 28.6 | 3.28 | 4 | -2.09 | 0.413 |
| Propylparaben | Carboxylic acid; Phenol | III | 18.1 | 2.42 | 3 | -1.18 | 0.122 | 18.6 | 2.84 | 3 | -1.58 | 0.399 | 13.8 | 1.21 | 3 | -1.20 | 0.065 |
| Sodium arsenite | Sodium compound; Arsenical | III | 0.79 | 0.248 | 3 | -1.69 | 0.222 | 0.336 | 0.187 | 3 | -1.54 | 0.317 | 0.470 | 0.066 | 3 | -1.96 | 0.197 |
| Sodium chloride | Sodium compound; Chlorine compound | III | 3583 | 263 | 3 | -2.43 | 0.153 | 1118 | 1388 | 3 | -1.96 | 0.371 | 3470 | 300 | 3 | -2.47 | 0.208 |
| Sodium dichromate dihydrate | Sodium compound; Chromium compound | III | 0.784 | 0.113 | 3 | -2.35 | 0.282 | 0.851 | 0.302 | 4 | -3.52 | 1.49 | 0.576 | 0.100 | 3 | -2.32 | 0.199 |
| Sodium I fluoride | Sodium compound; Fluorine compound | II | 48.7 | 6.92 | 3 | -2.50 | 0.263 | 39.7 | 9.61 | 3 | -2.60 | 1.04 | 53.7 | 6.82 | 4 | -2.71 | 0.150 |
| Sodium hypochlorite | Sodium compound Oxygen compound; Chlorine compound | III | 1863 | 581 | 3 | -5.19 | 1.14 | 1243 | 576 | 3 | -2.78 | 1.27 | 1633 | 180 | 3 | -3.86 | 0.211 |
| Sodium oxalate | Sodium compound; Carboxylic acid | III | 355 | 54.9 | 3 | -4.00 | 1.99 | 350 | 147 | 4 | -6.10 | 6.40 | 360 | 94.6 | 3 | -3.13 | 0.555 |
| Sodium selenate | Sodium compound; Selenium compound | II | 7.47 | 0.861 | 3 | -1.78 | 0.529 | 16.1 | 9.55 | 3 | -3.07 | 0.456 | 10.0 | 1.33 | 3 | -1.75 | 0.226 |

| | Chemical | Phase in | | | ECB | С | | | | FAL | | | |] | IIVS | | |
|----------------------------|---------------------------------|-----------------|--|-----------------|-----|----------------------------|--------|--|-----------------|-----|----------------------------|--------|---|-----------------|------|----------------------------|--------|
| Substance | Class ⁵ | which Tested | IC ₅₀ ¹ μg/mL | SD ² | N | Hill Slope ³ | SD^4 | IC ₅₀ ¹ μg/mL | SD ² | N | Hill Slope ³ | SD^4 | IC ₅₀ ⁻¹ μg/mL | SD ² | N | Hill Slope ³ | SD^4 |
| Strychnine | Heterocyclic | III | 100 | 76.6 | 4 | -1.30 | 0.729 | 52.5 | 28.0 | 3 | -1.60 | 0.260 | 55.1 | 3.43 | 3 | -1.47 | 0.466 |
| Thallium I sulfate | Sulfur compound; Metal | III | 0.198 | 0.100 | 3 | -2.08 | 1.01 | 0.153 | 0.031 | 3 | -2.64 | 0.639 | 0.127 | 0.020 | 3 | -2.90 | 0.338 |
| Trichloroacetic acid | Carboxylic acid | III | 348 | 63.5 | 3 | -1.36 | 0.241 | 541 | 150 | 3 | -1.34 | 0.411 | 394 | 50.8 | 3 | -1.48 | 0.103 |
| 1,1,1-Trichloro- ethane | Halogenated hydrocarbon | III | 8137 | 591 | 3 | -14.0 | 6.08 | NA | NA | - | NA | NA | NA | NA | - | NA | NA |
| Triethylene- melamine | Heterocyclic | III | 1.69 | 0.950 | 3 | -0.838 | 0.076 | 2.03 | 0.471 | 3 | -1.37 | 0.471 | 2.13 | 0.480 | 3 | -1.95 | 0.369 |
| Triphenyltin hydroxide | Organo- metallic compound | III | 0.021 | 0.007 | 3 | -2.46 | 0.698 | 0.007 | 0.007 | 3 | -3.55 | 1.68 | 0.011 | 0.003 | 3 | -3.34 | 0.396 |
| Valproic acid | Carboxylic acid; Lipids | III | 468 | 116 | 3 | -1.31 | 0.252 | 702 | 160 | 3 | -1.83 | 0.455 | 430 | 71.5 | 3 | -1.24 | 0.115 |
| Verapamil HCl | Amine | III | 60.5 | 13.6 | 3 | -1.72 | 0.238 | 79.4 | 33.9 | 3 | -1.88 | 0.915 | 66.2 | 5.57 | 3 | -2.53 | 0.221 |
| Xylene | Cyclic hydrocarbon | III | NA | NA | - | NA | NA | NA | NA | - | NA | NA | 486 | 185 | 3 | -2.88 | 1.99 |

Abbreviations: ECBC=Edgewood Chemical Biological Center; FAL=Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory; IIVS=Institute for *In Vitro* Sciences; SD=Standard deviation; N=Number of data points; NA=Not available (i.e., IC₅₀ values or Hill Slope values could not be generated [see notes in **Appendix I** for more information])

¹Arithmetic mean.

²Standard deviation of IC₅₀.

³Arithmetic Mean of Hill Slope values.

⁴Standard deviation of Hill Slope values.

⁵Chemical class assigned is based on the classification of the National Library of Medicine's Medical Subject Heading (MeSH), http://www.nlm.nih.gov/mesh/meshhome.html.




Figure 5-1 Reference Substance IC₅₀ Results for the 3T3 NRU Test Method by Laboratory

Abbreviations: ECBC=Edgewood Chemical Biological Center; FAL=Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory; IIVS=Institute for *In Vitro* Sciences.

Points show the mean arithmetic IC_{50} (µg/mL) for each reference substance from each laboratory. Error bars show the standard deviation. Data were sorted in ascending order of 3T3 IC_{50} values from IIVS (lead laboratory in the validation study). **Table 5-6** provides the numerical key for reference substance identification.




Figure 5-2 Reference Substance IC₅₀ Results for the NHK NRU Test Method by Laboratory

Abbreviations: ECBC=Edgewood Biological Center; FAL=Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory; IIVS=Institute for *In Vitro* Sciences.

Points show the mean arithmetic IC_{50} (µg/mL) for each reference substance from each laboratory. Error bars show the standard deviation. Data were sorted in ascending order of 3T3 IC_{50} values from IIVS (lead laboratory in the validation study). **Table 5-6** provides the numerical key for reference substance identification.

| No | Reference Substance | No | Reference Substance | No | Reference Substance | No | Reference Substance |
|----|---------------------------------|----|------------------------|----|----------------------|----|-----------------------|
| 1 | Aminopterin | 19 | Propylparaben | 37 | Strychnine | 55 | Citric acid |
| 2 | Triphenyltin hydroxide | 20 | Propranolol HCl | 38 | Phenylthiourea | 56 | Boric acid |
| 3 | Colchicine | 21 | Dichlorvos | 39 | Lindane | 57 | 5-Aminosalicylic acid |
| 4 | Cycloheximide | 22 | Potassium cyanide | 40 | Carbamazepine | 58 | Sodium hypochlorite |
| 5 | Triethylenemelamine | 23 | Physostigmine | 41 | Diethyl phthalate | 59 | Lactic acid |
| 6 | Sodium dichromate dihydrate | 24 | Dibutyl phthalate | 42 | Glutethimide | 60 | Potassium I chloride |
| 7 | Sodium arsenite | 25 | Parathion | 43 | Chloramphenicol | 61 | 2-Propanol |
| 8 | Cadmium II chloride | 26 | Paraquat | 44 | Chloral hydrate | 62 | Sodium chloride |
| 9 | Hexachlorophene | 27 | Sodium selenate | 45 | Caffeine | 63 | Dimethylformamide |
| 10 | Mercury II chloride | 28 | Verapamil HCl | 46 | Digoxin | 64 | Ethanol |
| 11 | Endosulfan | 29 | Acetaminophen | 47 | Meprobamate | 65 | Gibberellic acid |
| 12 | Arsenic III trioxide | 30 | Busulfan | 48 | Acetylsalicylic acid | 66 | Acetonitrile |
| 13 | Diquat dibromide monohydrate | 31 | Sodium oxalate | 49 | Nicotine | 67 | 1,1,1-Trichloroethane |
| 14 | Haloperidol | 32 | Phenol | 50 | Phenobarbital | 68 | Ethylene glycol |
| 15 | Cupric sulfate pentahydrate | 33 | Disulfoton | 51 | Procainamide HCl | 69 | Glycerol |
| 16 | Thallium I sulfate | 34 | Epinephrine bitartrate | 52 | Valproic acid | 70 | Lithium I carbonate |
| 17 | Amitriptyline HCl | 35 | Atropine sulfate | 53 | Xylene | 71 | Carbon tetrachloride |
| 18 | Fenpropathrin | 36 | Sodium I fluoride | 54 | Trichloroacetic acid | 72 | Methanol |

Table 5-6Key to Validation Study Reference Substances¹

Abbreviations: No=Number. ¹As used in **Figures 5-1** and **5-2**.

5.5 Statistical Approaches to the Evaluation of 3T3 and NHK Data

The statistical approaches used for data evaluation are reviewed in the following sections for each phase of the validation study. **Section 2.2.3** discussed the endpoint measurements for the 3T3 and NHK test methods. The OD values of each of six replicate wells ([minimum of four] in the 96-well plate) per test concentration (eight concentrations/reference substance or PC) were used to determine relative cell viability in relation to the mean VC OD on the same plate. The cell viability values calculated for the replicate wells for each concentration were used to determine the concentration-response curve (percent viability vs. log concentration) for each test. The IC₅₀ value was determined from fitting the curve to a Hill function.

5.5.1 <u>Statistical Analyses for Phase Ia Data</u>

The laboratories reported the IC_{50} results for SLS in $\mu g/mL$. The SMT used the results from the acceptable tests to calculate means and SDs for each method at each laboratory.

5.5.1.1 Outlier Determination for Replicate Well Concentration Data

A test for outliers at the 99% level (Dixon and Massey 1981) was used to determine the presence of outlier OD values among the six replicate wells for each reference substance concentration. The SMT applied the outlier test to the Phase Ia data when extreme values were noted. Outliers were excluded from the data set, and the IC_{50} was recalculated. The raw data files include all data provided by the laboratories, including the excluded outlier OD values. Because the protocol required a minimum of four acceptable test wells per reference substance concentration, no more than two wells of the six replicates could be excluded.

5.5.1.2 *Curve Fit Criteria*

After the completion of Phase Ia testing, a curve fit criterion was implemented for test acceptance following a visual review of the fit of the OD data to the Hill function curve. The SMT considered the fit of the concentration-response curve to the Hill function to be acceptable when $R^2 > 0.9$. A fit of $R^2 < 0.8$ was considered unacceptable and the data from that test were rejected. Curves with a fit of $0.8 < R^2 < 0.9$ were evaluated visually for goodness of fit and accepted if the SMT concluded that there were sufficient data points between 0 and 100% cytotoxicity, and a reasonable shape to the curve, to calculate a reasonably accurate IC_{50} value. Each test with a curve fit in this range was analyzed on a case-by-case basis, and no standard pass/fail criterion was developed. [Note: The use of a curve fit criterion for Phase III test results. An R^2 value ≥ 0.85 was maintained as a test acceptance criterion for the PC because its fit to the Hill function was well characterized.]

5.5.1.3 *Reproducibility Analyses for PC IC*₅₀ Values

To evaluate reproducibility of the IC₅₀ values for the PC for each test method, within and between the laboratories, the SMT considered the American Society of Testing and Materials (ASTM) Standard E691-99, Standard Practice for Conducting an Interlaboratory Study to Determine the Precision of a Test Method (ASTM 1999). This method uses two statistics, h and k, to judge the consistency of means and variances between laboratories. However, a minimum of six laboratories is required for this type of analysis and the SMT decided that it could not be appropriately applied to three laboratories. The variability of the PC IC₅₀ results obtained from each test and laboratory was assessed using CV analysis and one-way ANOVA. Dividing the SD by the arithmetic mean IC_{50} value, and multiplying by 100 produced the CV. CV values were calculated for the acceptable tests within each laboratory to determine intralaboratory reproducibility. To compare the variation among laboratories, the CV was calculated using the arithmetic mean IC₅₀ values from each of the three laboratories. Although no criterion for an acceptable CV was determined for this study, ECVAM recently used CV <30% as an acceptable range for both intra- and inter-laboratory reproducibility (Zuang et al. 2002; Fentem et al. 2001). Although CV < 30% was intended to reflect an acceptable maximum for normal biological variability, the range was not supported by data.

For the ANOVA, IC₅₀ values were first converted to mM units and then log-transformed to obtain normal distributions. One-way ANOVA was performed with SAS PROC GLM

software (SAS Institute 1999; see **Appendix D1** for example SAS code). A significance level of p < 0.01 was used to test results between the laboratories in order to be conservative with respect to identifying laboratory differences.

5.5.2 <u>Statistical Analyses of Phase Ib Data</u>

5.5.2.1 Outlier Determination for Replicate Well Concentration Data

For consistency of replicate well concentration data, the SMT applied the same outlier test used for the Phase Ia data (Dixon and Massey 1981) when extreme OD values were noted. If the extreme value was an outlier at the 99% level, it was excluded from the data set, and the IC_{50} was recalculated. All data are available in the data files provided by the laboratories, including the excluded outlier OD values.

5.5.2.2 Reproducibility Analyses of the Reference Substance IC₅₀ Values

One-way ANOVA and CV analyses were used to assess method reproducibility within and among laboratories. For the ANOVA, the IC₅₀ values were first converted to mM units and then log-transformed to obtain normal distributions. One-way ANOVA was performed with SAS PROC GLM (SAS Institute 1999; see **Appendix D1** for example SAS code). A significance level of p < 0.01 was used to test results between the laboratories in order to be conservative with respect to identifying laboratory differences. When the ANOVA detected significant differences among the laboratories, contrast analyses were performed to determine which laboratory was different from the others. These analyses compared the results of each laboratory with those of the other two laboratories. A significant difference in response among the laboratories was indicated by p < 0.01.

CV values were calculated for each reference substance by dividing the SD by the arithmetic mean IC_{50} value and multiplying by 100. CV values were calculated for the acceptable tests in each laboratory to determine intralaboratory reproducibility. To compare the variation among laboratories, the CV was calculated using the arithmetic mean IC_{50} values from each of the three laboratories.

As an additional approach to the assessment of interlaboratory reproducibility for each test substance, the maximum:minimum IC_{50} ratios (i.e., the maximum arithmetic mean laboratory IC_{50} value compared to the minimum arithmetic mean laboratory IC_{50} value) were calculated. This approach is similar to the calculation of maximum:minimum LD_{50} ratios for examining reproducibility of reference LD_{50} values (see Section 4.4.1).

5.5.3 <u>Statistical Analyses of Phase II Data</u>

5.5.3.1 Outlier Determination for Replicate Well Concentration Data

The Dixon and Massey (1981) outlier test was incorporated into the EXCEL[®] templates to assess the consistency of replicate well data for each reference substance concentration. Outliers at the 99% level were highlighted and the Study Director was offered the option of removing the value from subsequent calculations (e.g., mean OD of the six replicates; % viability; IC_{50}).

5.5.3.2 *Reproducibility Analyses of the Reference Substance IC*₅₀ Values

The intra- and inter-laboratory reproducibility of the IC_{50} values were assessed using the acceptable tests to calculate the mean IC_{50} , SD, and CV for each substance, method, and

laboratory, as described in Section 5.5.2.2. One-way ANOVAs and calculations of maximum:minimum IC₅₀ ratios were performed as described in Section 5.5.2.2.

5.5.3.3 Comparison of 3T3 and NHK Test Results with the RC Millimole Regression To compare the 3T3 and NHK test results for the reference substances to those of the RC millimole regression, each IC₅₀ value was transformed to mM units for the calculation of geometric mean IC₅₀ values. The use of geometric means corresponded with the approach used to obtain single IC₅₀ values from multiple IC₅₀ values for the RC millimole regression (Halle 1998, 2003). The log geometric mean IC₅₀ values (in mM) of the 11 RC substances tested during Phases Ib and II (see **Table 3-8**) were used with the log RC LD₅₀ values, after transformation to log mmol/kg units (see **Appendices J1** and **J2**), to calculate least squares linear regressions for the data from each test method and laboratory. Each of these method/laboratory regressions was compared to the RC millimole regression using an F test with SAS PROC REG (SAS Institute 1999; see **Appendix D2** for example SAS code). An F test with a significance level of p <0.01 was used to determine whether the joint comparison of slope and intercept indicated that the method/laboratory regressions were significantly different from the RC millimole regression.

As an alternate analysis, a least squares linear regression using IC_{50} and LD_{50} values from the RC was constructed for the 11 RC substances (*the RC-11 regression*) tested in Phases Ib and II. Each of these method/laboratory regressions was compared to the RC-11 regression using an F test with SAS PROC GLM (SAS Institute 1999; see **Appendix D2** for example SAS code) at a significance level of p <0.01. This was used to determine whether the comparisons of slope and intercept indicated that the laboratory regressions were significantly different from the RC-11 regression.

5.5.4 <u>Statistical Analyses of Phase III Data</u>

5.5.4.1 Outlier Determination for Replicate Well Concentration Data

The laboratories used the Dixon and Massey (1981) outlier test at the 99% level that was incorporated into the EXCEL[®] templates to test for outlier values among replicate well data at the different reference substance concentrations. The Study Director had the option of excluding the outliers from the data set, which were highlighted by the template, and subsequent calculations. All data are available in the data files provided by the laboratories, including the outlier OD values.

5.5.4.2 *Reproducibility Analyses of the PC IC*₅₀ *Data*

A number of analyses were performed to determine whether the SLS IC_{50} values were reproducible across study phases. The SLS IC_{50} values used to access variability were different from those shown in **Table 5-3**. To get an assessment of the true variation of SLS IC_{50} values, the reproducibility analyses included additional IC_{50} values from SLS tests that did not meet the IC_{50} acceptance limits (see **Table 5-3**) for each laboratory and study phase if they passed all other test acceptance criteria. If more than one SLS test was performed on a single day (for any test method and laboratory), the IC_{50} values were averaged to determine a single IC_{50} for the day. This prevented multiple data values from a single day from overly influencing the mean for each phase. CV analyses were performed as described in **Section 5.5.1** using the arithmetic mean SLS IC_{50} values for each method, laboratory, and study phase. For the remaining analyses of reproducibility, the IC_{50} values were first log-transformed to obtain normal distributions. One-way ANOVAs were performed with SAS PROC GLM (SAS Institute 1999; see **Appendix D1** for example SAS code) for each method using study phase and laboratory as individual variables. A significance level of p <0.01 was used to test for a statistical difference among the laboratory and/or phase results.

To determine whether there was a linear time trend for the SLS IC_{50} data, linear regression analyses using a least squares method were performed for each laboratory and method using SAS PROC REG (SAS Institute 1999). Time was expressed as an index for each test. The index number of each SLS test reflected its order of testing without respect to the time lapsing between tests. For example, the first SLS test was assigned a time index of 1 and the second SLS test was assigned a time index of 2 whether it occurred the day after the first test or one week after the first test. The slopes of the linear regressions were judged to be statistically significant at p <0.05, which indicated that the IC_{50} had changed significantly over time.

5.5.4.3 *Reproducibility Analyses of the Reference Substance IC*₅₀ Values

CV, one-way ANOVA analyses, and maximum: minimum IC₅₀ ratios were performed to assess the intra- and/or inter-laboratory reproducibility of the Phase III reference substance data, as described in Section 5.5.2.2. An additional evaluation to determine whether normalizing the reference substance IC_{50} to the SLS IC_{50} would reduce interlaboratory variability was performed using five substances (for each test method) for which the ANOVAs indicated significant interlaboratory differences. The reference substance IC_{50} values were normalized to the SLS IC₅₀ by calculating the reference substance IC₅₀:SLS IC₅₀ ratio. CVs were calculated for each substance using the mean ratios from each laboratory. To determine whether this normalization reduced variability among the laboratories, the CVs for the substance IC_{50} :SLS IC_{50} ratios were compared to the CVs for the substance IC_{50} . In addition, the geometric mean IC_{50} values were used to calculate least squares linear regression models after log transforming the data. Linear regressions were fit for each method and laboratory using the log-transformed reference LD₅₀ values from Table 4-2 (in mmol/kg), with log IC₅₀ in mM. To detect differences among the linear regressions in each laboratory, two models were fit for each method. The first was a full model that included effects for laboratory and interactions, and generated a regression line for each substance in each laboratory, by test method. The second model, which was considered to be a reduced model, assumed that one model fit all the laboratories. A goodness of fit F test was performed to compare the full and reduced models for each method. A significance level of p <0.01 was used to test whether the regressions among laboratories were significantly different from one another. The following criteria were established for selection of data for use in the regression analyses for each test method:

- The substance was included in the RC
- All three laboratories reported IC₅₀ values
- There was an associated rat oral reference LD₅₀ value (see **Table 4-2**)

There were 47 reference substances that fit these criteria for the 3T3 and 51 test substances that fit the criteria for the NHK test methods.

5.5.4.4 Comparison of 3T3 and NHK Results with the RC Millimole Regression To determine whether the IC_{50} values determined in the validation study were significantly different from the RC values, the laboratory-specific regression values for each method were combined using the geometric means of the laboratory-specific geometric mean IC_{50} values in mM and the reference LD_{50} in mmol/kg. Thus, there was one regression analysis with pooled laboratory data for the 3T3 NRU test method and another regression analysis (also with pooled data) for the NHK NRU test method. A third linear regression was calculated using the IC_{50} and LD_{50} values from the RC. The IC_{50} values and LD_{50} values were logtransformed for the regression calculations. The following criteria were established for the selection of substances to be used for the regression analyses:

- The substance was included in the RC
- All three laboratories reported IC₅₀ values for both the 3T3 and NHK NRU test methods
- There was an associated rat oral reference LD₅₀ value (see **Table 4-2**)

Forty-seven substances met these criteria. Two models were fit for each test method to detect differences between the NRU regression and the 47 RC substance regression. The first regression model was a full model that included effects for the RC and the NRU regression, and generated one regression line each for the RC and the NRU test method. The second (reduced) model assumed that a single model fit the combined RC and NRU IC₅₀ data. The RC regression for the 47 reference substances was compared to the combined laboratory regression for each NRU test method using an F test to simultaneously compare slopes and intercepts. The NRU regressions were statistically different from the RC regressions if p < 0.01.

To assess the accuracy of the NRU methods and the associated IC_{50} -LD₅₀ regressions, a predicted LD₅₀ was calculated for each reference substance using its laboratory geometric mean IC_{50} in two analyses:

- The RC rat-only millimole regression calculated from the 282 RC substances with rat LD₅₀ values, using units of mM for the IC₅₀ and mmol/kg for the LD₅₀ (see Section 6.4.2)
- The RC rat-only weight regression calculated from the 282 RC substances with rat LD_{50} values, using units of μ g/mL for the IC₅₀ and mg/kg for the LD_{50} (see Section 6.4.3)

The LD_{50} values predicted from the regression analyses were used to predict GHS acute oral toxicity categories (see **Section 6.4**). The accuracy of the predictions was determined by calculating the proportion of substances for which the predicted GHS toxicity category matched the GHS toxicity category. The LD_{50} predictions from these regression models were also used to determine starting doses for acute systemic toxicity test simulations for the purpose calculating animal use and savings that would be achieved using the NRU test methods. The simulation modeling methods, and results from the UDP and ATC methods, are described in **Section 10**.

5.5.5 <u>Summary of the Data Used for Statistical Analyses</u>

Table 5-7 summarizes the number of substances that were tested and the number of substances used for the various analyses performed to determine the accuracy and reliability of the *in vitro* NRU test methods.

| Use | 3T3 NRU Test Method ¹ | NHK NRU Test Method ¹ | Characteristics of Dataset |
|---|--|--|--|
| Testing | 72 | 72 | Substances tested |
| Comparison of laboratory IC_{50} - LD ₅₀ regressions to one another | 47 | 51 | RC substances with IC ₅₀ values from all laboratories and reference rat oral LD ₅₀ values |
| Comparison of combined- laboratory IC ₅₀ -LD ₅₀ regressions to a regression calculated with RC data | 47 | 47 | RC substances with IC ₅₀ values for both test methods from all laboratories and rat oral reference LD ₅₀ values |
| Prediction of GHS accuracy using IC_{50} values in IC_{50} -LD ₅₀ regressions; prediction of starting doses for acute oral toxicity test (UDP and ATC) simulations | 67 | 68 | Substances with IC ₅₀ values from at least one laboratory |
| Reproducibility of acceptable rat oral LD ₅₀ values | NA | NA | 62 substances with more than one acceptable rat oral LD_{50} value |
| Reproducibility of IC50 values | 64 | 68 | Substances with IC ₅₀ values from all laboratories |
| Comparison of reproducibility of IC_{50} values with reproducibility of LD_{50} values | 53 | 57 | Substances with IC ₅₀ values from all laboratories and more than one acceptable rat oral LD ₅₀ value |

Table 5-7Datasets Used for Validation Study Analyses1

Abbreviations: RC=Registry of Cytotoxicity; 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake; NA=Not applicable. ¹Number of substances.

5.6 Summary of NRU Test Results

Table 5-8 shows the 3T3 and NHK IC₅₀ values as geometric means of the geometric mean laboratory values, as a basis to compare the 3T3 and NHK NRU IC₅₀ values for each reference substance. The substances in **Table 5-8** are organized by ascending 3T3 NRU IC₅₀ values (as was done for **Figures 5-1** and **5-2**). For each method, the table provides the geometric mean IC₅₀ (combined across laboratories) in μ g/mL, the ratio of the geometric mean IC₅₀ to the SLS IC₅₀, and the 3T3 IC₅₀:NHK IC₅₀ ratios. Geometric means were used for this comparison because they were used for both the IC₅₀ and LD₅₀ regression analyses (see **Sections 5.5.3.3**, **5.5.4.3**, and **5.5.4.4**). The 3T3 and NHK NRU IC₅₀ values were compared using the ratios of their geometric means. The IC₅₀ values for each reference substance were also compared to the IC₅₀ for SLS using the ratio of reference substance geometric mean IC₅₀ to SLS geometric mean IC₅₀.

| | 3T3 | NRU | NHK | NRU | |
|------------------------------|--|--|--|--|------------------------------------|
| Reference Substance | Geometric Mean ¹ IC ₅₀ (µg/mL) | Ratio Geometric Mean IC ₅₀ to SLS IC ₅₀ | Geometric Mean ¹ IC ₅₀ (µg/mL) | Ratio Geometric Mean IC ₅₀ to SLS IC ₅₀ | IC ₅₀ Ratios 3T3:NHK |
| Carbon tetrachloride | NA | NA | NA | NA | NA |
| Methanol | NA | NA | 1529 ³ | 383.2 | NA |
| Aminopterin | 0.006 | 0.0001 | 669 | 167.7 | 0.00001 |
| Triphenyltin hydroxide | 0.017 | 0.0004 | 0.01 | 0.003 | 1.7 |
| Colchicine | 0.034 | 0.001 | 0.007 | 0.002 | 4.9 |
| Cycloheximide | 0.187 | 0.004 | 0.073 | 0.02 | 2.6 |
| Triethylenemelamine | 0.272 | 0.007 | 1.85 | 0.5 | 0.1 |
| Cadmium II chloride | 0.518 | 0.01 | 1.84 | 0.5 | 0.3 |
| Sodium dichromate dihydrate | 0.587 | 0.01 | 0.721 | 0.2 | 0.8 |
| Sodium arsenite | 0.759 | 0.02 | 0.477 | 0.1 | 1.6 |
| Arsenic trioxide | 1.96 | 0.05 | 5.26 | 1.3 | 0.4 |
| Mercury II chloride | 4.12 | 0.1 | 5.8 | 1.5 | 0.7 |
| Hexachlorophene | 4.19 | 0.1 | 0.029 | 0.01 | 144.5 |
| Thallium I sulfate | 5.74 | 0.1 | 0.152 | 0.04 | 37.8 |
| Haloperidol | 6.13 | 0.1 | 3.36 | 0.8 | 1.8 |
| Endosulfan | 6.35 | 0.2 | 2.13 | 0.5 | 3.0 |
| Amitriptyline HCl | 7.05 | 0.2 | 8.96 | 2.2 | 0.8 |
| Diquat dibromide monohydrate | 8.04 | 0.2 | 4.48 | 1.1 | 1.8 |
| Propranolol | 13.9 | 0.3 | 35.3 | 8.8 | 0.4 |
| Dichlorvos | 17.7 | 0.4 | 10.7 | 2.7 | 1.7 |
| Paraquat | 20.1 | 0.5 | 61.6 | 15.4 | 0.3 |
| Fenpropathrin | 24.2 | 0.6 | 2.43 | 0.6 | 10.0 |
| Physostigmine | 25.8 | 0.6 | 88.5 | 22.2 | 0.3 |
| Propylparaben | 26.1 | 0.6 | 16.6 | 4.2 | 1.6 |
| Sodium selenate | 29 | 0.7 | 10.2 | 2.6 | 2.8 |
| Potassium cyanide | 34.6 | 0.8 | 29 | 7.3 | 1.2 |
| Verapamil HCl | 34.9 | 0.8 | 66.5 | 16.7 | 0.5 |
| Parathion | 37.4 | 0.9 | 30.3 | 7.6 | 1.2 |
| Sodium oxalate | 37.7 | 0.9 | 337 | 84.5 | 0.1 |
| Sodium lauryl sulfate (SLS)* | 41.7 | 1.0 | 3.99 | 1.0 | 10.5 |
| Cupric sulfate pentahydrate | 42.1 | 1.0 | 197 | 49.4 | 0.2 |
| Acetaminophen | 47.7 | 1.1 | 518 | 129.8 | 0.1 |
| Dibutyl phthalate | 49.7 | 1.2 | 28.7 | 7.2 | 1.7 |
| Epinephrine bitartrate | 59 | 1.4 | 87.4 | 21.9 | 0.7 |
| Phenol | 66.3 | 1.6 | 75 | 18.8 | 0.9 |
| Atropine sulfate | 76 | 1.8 | 81.8 | 20.5 | 0.9 |
| Busulfan | 77.7 | 1.9 | 260 | 65.2 | 0.3 |
| Sodium I fluoride | 78 | 1.9 | 49.8 | 12.5 | 1.6 |
| Phenylthiourea | 79 | 1.9 | 336 | 84.2 | 0.2 |
| Carbamazepine | 103 | 2.5 | 83.2 | 20.9 | 1.2 |

Table 5-8 Comparison of 3T3 and NHK NRU IC₅₀ Geometric Means

| | 3T3 | NRU | NHK | NRU | |
|-----------------------|--|--|--|--|------------------------------------|
| Reference Substance | Geometric Mean ¹ IC ₅₀ (µg/mL) | Ratio Geometric Mean IC ₅₀ to SLS IC ₅₀ | Geometric Mean ¹ IC ₅₀ (µg/mL) | Ratio Geometric Mean IC ₅₀ to SLS IC ₅₀ | IC ₅₀ Ratios 3T3:NHK |
| Diethyl phthalate | 107 | 2.6 | 120 | 30.1 | 0.9 |
| Lindane | 108 | 2.6 | 18.7 | 4.7 | 5.8 |
| Chloramphenicol | 128 | 3.1 | 348 | 87.2 | 0.4 |
| Disulfoton | 133 | 3.2 | 270 | 67.7 | 0.5 |
| Caffeine | 153 | 3.7 | 638 | 159.9 | 0.2 |
| Strychnine | 158 | 3.8 | 62.5 | 15.7 | 2.5 |
| Glutethimide | 174 | 4.2 | 174 | 43.6 | 1.0 |
| Chloral hydrate | 183 | 4.4 | 133 | 33.3 | 1.4 |
| Nicotine | 361 | 8.7 | 107 | 26.8 | 3.4 |
| Procainamide HCl | 441 | 10.6 | 1741 | 436.3 | 0.3 |
| Digoxin | 466 | 11.2 | 0.001 | 0.0003 | 466000.0 |
| Meprobamate | 519 | 12.4 | 357 | 89.5 | 1.5 |
| Lithium I carbonate | 562 ² | 13.5 | 468 | 117.3 | 1.2 |
| Phenobarbital | 573 | 13.7 | 448 | 112.3 | 1.3 |
| Acetylsalicylic acid | 676 | 16.2 | 605 | 151.6 | 1.1 |
| Xylene | 721 ² | 17.3 | 466 ² | 116.8 | 1.5 |
| Citric acid | 796 | 19.1 | 400 | 100.3 | 2.0 |
| Trichloroacetic acid | 902 | 21.6 | 413 | 103.5 | 2.2 |
| Valproic acid | 916 | 22.0 | 512 | 128.3 | 1.8 |
| Sodium hypochlorite | 1103 | 26.5 | 1502 | 376.4 | 0.7 |
| 5-Aminosalicylic acid | 1667 | 40.0 | 46.7 | 11.7 | 35.7 |
| Boric acid | 1850 | 44.4 | 421 | 105.5 | 4.4 |
| Lactic acid | 3044 | 73.0 | 1304 | 326.8 | 2.3 |
| Potassium I chloride | 3551 | 85.2 | 2237 | 560.7 | 1.6 |
| 2-Propanol | 3618 | 86.8 | 5364 | 1344.4 | 0.7 |
| Sodium chloride | 4730 | 113.4 | 1997 | 500.5 | 2.4 |
| Dimethylformamide | 5224 | 125.3 | 7760 | 1944.9 | 0.7 |
| Ethanol | 6523 | 156.4 | 10018 | 2510.8 | 0.7 |
| Gibberellic acid | 7810 ³ | 187.3 | 2856 | 715.8 | 2.7 |
| Acetonitrile | 7951 | 190.7 | 9528 | 2388.0 | 0.8 |
| 1,1,1-Trichloroethane | 17248 | 413.6 | 8122 ² | 2035.6 | 2.1 |
| Ethylene glycol | 24317 | 583.1 | 41852 | 10489.2 | 0.6 |
| Glycerol | 24655 | 591.2 | 24730 | 6198.0 | 1.0 |

Comparison of 3T3 and NHK NRU IC₅₀ Geometric Means Table 5-8

Abbreviations: 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake; SLS=Sodium lauryl sulfate; NA=Not available.

Reference substances are ordered by 3T3 NRU IC_{50} values.

 1 Geometric mean IC₅₀ of the laboratory geometric mean values. 2 Data available from only one laboratory.

³Data available from only two laboratories.

*Acceptable positive control (SLS) values from all study phases: N=293 for the 3T3 NRU and N=281 for the NHK NRU.

Table 5-8 shows that there are nine reference substances for which the 3T3 and NHK NRU IC₅₀ values differ by at least one order of magnitude (i.e., 3T3 IC₅₀:NHK IC₅₀ ≤ 0.1 or ≥ 10): aminopterin, triethylenemelamine, hexachlorophene, thallium sulfate, fenpropathrin, sodium oxalate, acetaminophen, digoxin, and 5-aminosalicylic acid. The IC_{50} values for SLS, also differed by slightly more than one order of magnitude in the two NRU test methods (41.7 µg/mL for 3T3 and 3.99 µg/mL for NHK). One test method was not more consistently sensitive (i.e., produced lower IC_{50} values) than the other for these nine reference substances. The 3T3 NRU test method was more sensitive than the NHK NRU test method for four of the nine substances: aminopterin, triethylenemelamine, sodium oxalate, and acetaminophen. The NHK NRU test method was more sensitive than the 3T3 NRU test method for five substances: hexachlorophene, thallium sulfate, fenpropathrin, digoxin, and 5-aminosalicylic acid. Despite the normalization procedure, the reference substance IC₅₀:SLS IC₅₀ ratios for the two methods were still greater by at least one order of magnitude for six of the nine substances (aminopterin, triethylenemelamine, hexachlorophene, sodium oxalate, acetaminophen, and digoxin) and the order of magnitude difference increased for all six substances. A number of factors could potentially be responsible for these differences between the 3T3 and NHK NRU IC₅₀ values:

- Cell culture conditions (i. e., the 3T3 treatment medium contains serum while the NHK treatment medium does not; differences in cell density in the treatment medium)
- Differences in sensitivity between the fibroblast cell line and primary keratinocytes
- Differences in sensitivity between human and mouse cells
- Differences in metabolic activity between the cell types

These factors may affect the results for some substances more than others. For example, a substance that binds to serum proteins would be less available to the 3T3 cells (which have serum in their growth medium) than to NHK cells (which are grown without serum). No additional testing was performed to investigate the differences between the 3T3 and NHK NRU IC₅₀ values.

Two substances, digoxin and aminopterin, have IC_{50} values that differ by five orders of magnitude between the two NRU test methods. Digoxin was much more toxic to the NHK cells and aminopterin was more toxic to the 3T3 cells. Both substances are known substrates for organic anionic transporters (OAT) (ICCVAM 2006). Such transporters are important for *in vivo* toxicity responses in terms of the ability of challenge substances to be absorbed, reach target tissues, accumulate, or be excreted. The differential susceptibilities of the 3T3 and NHK cells may be explained by differential functioning of OAT between the cell types. Although species and tissue differences in OAT have been reported (Sekine et al. 2000; Miyazaki et al. 2004), the reason for these differential sensitivities is not known.

The 3T3 IC₅₀:NHK IC₅₀ ratios shown in **Table 5-8** were used to determine the frequency distributions shown in **Table 5-9**. These distributions indicate that the 3T3 and NHK NRU IC₅₀ values were within one order of magnitude of each other for 85% of the reference substances (obtained by adding 38.9% and 45.8% for the $0.1 < IC_{50}$ ratio ≤ 1 and $1 < IC_{50}$ ratio ≤ 10 ranges). Ninety-three percent of the reference substances have 3T3 and NHK NRU

 IC_{50} values within two orders of magnitude of each other (obtained by adding 4.2% each for the $10 \le IC_{50}$ ratio ≤ 100 and $0 < IC_{50}$ ratio ≤ 0.1 ranges to the 85% above).

Table 5-9Frequency of 3T3:NHK IC50 Ratios1 for Reference Substances

| 3T3:NHK IC ₅₀ Ratio Range | Number of Substances | % of Substances |
|--------------------------------------|-------------------------|--------------------|
| IC ₅₀ Ratio <0.00001 | 1 | 1.4 |
| $0 < IC_{50}$ Ratio ≤ 0.1 | 3 | 4.2 |
| $0.1 < IC_{50}$ Ratio ≤ 1 | 28 | 38.9 |
| 1 < IC ₅₀ Ratio <10 | 33 | 45.8 |
| $10 \leq IC_{50}$ Ratio < 100 | 3 | 4.2 |
| $100 \leq IC_{50}$ Ratio < 1000 | 1 | 1.4 |
| IC_{50} Ratio ≥ 1000 | 1 | 1.4 |
| Not Available | 2 | 2.8 |

Abbreviations: 3T3=Neutral red uptake using BALB/c 3T3 fibroblasts; NHK= Neutral red uptake using normal human epidermal keratinocytes.

Note: Compiled using reference substance data from Table 5-7.

Correlations of the mean IC₅₀ values for the reference substances common to the RC database with the IC₅₀ values (i.e., geometric mean of IC₅₀ values obtained from the literature for various basal cytotoxicity endpoints and cell types) from the RC (Halle 1998, 2003) are shown in **Figure 5-3** (3T3 values) and **Figure 5-4** (NHK values). Although the validation study tested 58 RC substances in common with the RC, IC₅₀ values were obtained for 56 substances using the 3T3 NRU test method and 57 substances using the NHK NRU test method. Spearman correlation analyses of the log-transformed IC₅₀ data (in mM) indicated that the NRU IC₅₀ values were significantly correlated with the RC IC_{50x} values (p<0.001, for both the 3T3 and NHK NRU test methods). The Spearman correlation coefficient, r_s, was 0.93 for the 3T3 values and 0.86 for the NHK values.




Figure 5-3 RC IC₅₀ Values vs 3T3 NRU IC₅₀ Values for 56 Substances in Common

Abbreviations: RC=Registry of Cytotoxicity; 3T3=BALB/c 3T3 fibroblasts; NRU=Neutral red uptake; r_s =Spearman correlation coefficient; n=Number of substances; mM=Millimolar.

The diagonal line indicates the predicted values for a 1:1 correspondence. No IC_{50} values were obtained for carbon tetrachloride or methanol because of insufficient toxicity. The Registry of Cytotoxicity IC_{50} values are geometric means of IC_{50} values obtained from the literature for various basal cytotoxicity endpoints and cell types.




Figure 5-4 RC IC₅₀ Values vs NHK NRU IC₅₀ Values for 57 Substances in Common

Abbreviations: RC=Registry of Cytotoxicity; NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake; r_s =Spearman correlation coefficient; n=Number of substances; mM=Millimolar. The diagonal line indicates the predicted values for a 1:1 correspondence. No IC₅₀ values were obtained for methanol because of insufficient toxicity. The Registry of Cytotoxicity IC₅₀ values are geometric means of IC₅₀ values obtained from the literature for various basal cytotoxicity endpoints and cell types.

5.7 Availability of Data

All data were provided to the SMT as electronic files and paper copies. The laboratories also maintained copies of all raw data and the electronic files. The individual test data and IC_{50} results for both passing and failing tests are provided in **Appendix I** for the reference substances and the PC.

5.8 Solubility Test Results

A solubility protocol (see Section 2-8 and Appendix B3) designed to identify the solvent that would provide the highest concentration of a reference substance for *in vitro* testing was evaluated. Each laboratory performed solubility tests on all reference substances. However, to avoid the use of different solvents by the laboratories when testing the same substance, which might increase the variability of the IC₅₀ results among the laboratories, the SMT assigned the solvents to be used (see **Table 5-10**). The objectives of the solubility testing were to evaluate the utility and appropriateness of the solubility protocol, and to evaluate the concordance among laboratories in selecting the solvents for each of the 72 reference substances.

| | | BioRel | iance ¹ | | | | ECB | C^3 | | | FAI | L ³ | | | IIVS | 8 ³ | |
|-----------------------|----------------------------|----------------|--------------------|------|-------------------------------|----------------------------|----------------------------|-------|------|----------------------------|----------------------------|----------------|------|----------------------------|----------------------------|----------------|------|
| Reference Substance | 3T3 ⁴ Medium | NHK⁵ Medium | DMSO | ЕТОН | SMT ² Selection | 3T3 ⁴ Medium | NHK ⁵ Medium | DMSO | ЕТОН | 3T3 ⁴ Medium | NHK ⁵ Medium | DMSO | ЕТОН | 3T3 ⁴ Medium | NHK ⁵ Medium | DMSO | ЕТОН |
| Phase I | | | | | | | - | - | | | - | - | | | | - | |
| Arsenic III trioxide | 0.25 | 0.05 | <2 | <2 | Medium | 0.0256 | 0.0256 | <0.2 | <0.2 | 0.1356 | 0.1356 | <0.2 | <0.2 | <0.026 | <0.026 | <0.2 | <0.2 |
| Ethylene glycol | 400 | 400 | NT | NT | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 20 | 20 | NT | NT |
| Propranolol HCl | <2 | 10 | 200 | 20 | DMSO | 0.2 | 2 | 200 | NT | 20 | 20 | 200 | NT | 20 | 2 | NT | NT |
| Phase II | | | | | L | I | L | | I | | | | L | I | L | | |
| Aminopterin | 2 | 2 | NT | NT | DMSO | 2.0 | <2 | 200 | NT | <2 | 2 | 200 | NT | 0.2 | 0.2 | 200 | NT |
| Cadmium II chloride | <2 | <2 | 200 | <200 | DMSO | <2 | <2 | 200 | NT | <2 | <2 | 200 | NT | <0.2 | <0.2 | 20 | <20 |
| Chloramphenicol | 2 | 2 | 400 | <200 | DMSO | 2.0 | <2 | 200 | NT | <2 | <2 | 200 | NT | 0.2 | 0.2 | 20 | 20 |
| Colchicine | 400 | 400 | NT | NT | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 20 | 20 | NT | NT |
| Lithium I carbonate | 0.25 | 10 | <2 | NT | Medium | 0.2 | 2.0 | <20 | <20 | 0.2 | 2 | <200 | <200 | 0.2 | 2 | <2 | <2 |
| Potassium I chloride | 200 | 200 | NT | NT | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 20 | 20 | NT | NT |
| 2-Propanol | 400 | 400 | 400 | 400 | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 20 | 20 | NT | NT |
| Sodium I fluoride | 20 | 20 | <200 | <200 | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 20 | 20 | NT | NT |
| Sodium selenate | 200 | 200 | <200 | <200 | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 20 | 20 | NT | NT |
| Phase III | | | 11 | | L | <u></u> | I | 1 | I | | 1 | 1 | I | <u></u> | | | 1 |
| Acetaminophen | 10 | 10 | 400 | <200 | DMSO | 2 | 2 | NT | NT | 2 | 2 | NT | NT | <2 | <2 | 200 | NT |
| Acetonitrile | 400 | 400 | 400 | 400 | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 20 | 20 | NT | NT |
| Acetylsalicylic acid | 10 | 10 | 400 | 200 | DMSO | 2 | 2 | NT | NT | <2 | <2 | 200 | NT | 2 | 2 | NT | NT |
| 5-Aminosalicylic acid | 2 | 2 | <200 | <200 | Medium | 2 | 2 | NT | NT | 2 | 2 | NT | NT | 2 | 2 | NT | NT |
| Amitriptyline HCl | 200 | 200 | NT | NT | DMSO | <2 | <2 | 200 | NT | <2 | <2 | 200 | NT | 0.2 | 0.2 | 200 | NT |

| | | BioRel | iance ¹ | | | | ECB | C^3 | | | FAI | 3 | | | IIVS | S ³ | |
|--------------------------------|----------------------------|----------------------------|--------------------|-------|-------------------------------|----------------------------|----------------------------|-------|------|----------------------------|----------------------------|-----------------|------|----------------------------|----------------------------|----------------|------|
| Reference Substance | 3T3 ⁴ Medium | NHK ⁵ Medium | DMSO | ЕТОН | SMT ² Selection | 3T3 ⁴ Medium | NHK ⁵ Medium | DMSO | ЕТОН | 3T3 ⁴ Medium | NHK ⁵ Medium | DMSO | ЕТОН | 3T3 ⁴ Medium | NHK ⁵ Medium | DMSO | етон |
| Atropine sulfate | 200 | 200 | NT | NT | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 20 | 20 | NT | NT |
| Boric aid | 40 | 40 | 200 | <200 | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 2 | 2 | NT | NT |
| Busulfan | <2 | <2 | 40 | <200 | DMSO | <2 | <2 | 200 | NT | <2 | <2 | 50 ⁶ | <200 | <0.2 | <0.2 | 20 | <200 |
| Caffeine | 10 | 10 | 20 | NT | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 20 | 20 | NT | NT |
| Carbamazepine | <2 | <2 | 40 | <200 | DMSO | 0.2 | 0.2 | 20 | 20 | <2 | <2 | 200 | NT | <0.2 | <0.2 | 2 | <20 |
| Carbon tetrachloride | 2 | 10 | NT | NT | DMSO | 20 | 20 | NT | NT | <0.2 | <0.2 | 2 | NT | 20 | 20 | NT | NT |
| Chloral hydrate | 400 | 400 | NT | NT | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 20 | 20 | NT | NT |
| Citric acid | 400 | 400 | NT | NT | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 20 | 20 | NT | NT |
| Cupric sulfate pentahydrate | 1 | 0.5 | <2 | 2 | Medium | 2 | 0.2 | <200 | <200 | 2 | 2 | NT | NT | 0.2 | 0.2 | <200 | NT |
| Cycloheximide | 20 | 20 | 400 | <200 | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 2 | 2 | NT | NT |
| Dibutyl phthalate | <2 | <2 | 400 | 400 | DMSO | <2 | <2 | 200 | NT | <2 | <2 | 200 | NT | <2 | <2 | 200 | NT |
| Dichlorvos | 10 | 10 | NT | NT | DMSO | 2 | 2 | NT | NT | <2 | <2 | 200 | NT | 2 | 2 | NT | NT |
| Diethyl phthalate | <2 | <2 | 400 | 400 | DMSO | <2 | <2 | 200 | NT | 0.2 | < 0.2 | 200 | NT | <2 | <2 | 200 | NT |
| Digoxin | 0.05 | 0.05 | 200 | < 200 | DMSO | <2 | <2 | 200 | NT | <0.2 | < 0.2 | 200 | NT | <2 | <2 | 200 | NT |
| Dimethylformamide | 400 | 400 | NT | NT | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 20 | 20 | NT | NT |
| Diquat dibromide monohydrate | 200 | 200 | NT | NT | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 20 | 20 | NT | NT |
| Disulfoton | <2 | <2 | 500 | NT | DMSO | <2 | <2 | 200 | NT | <2 | <2 | 200 | NT | <2 | <2 | 200 | NT |
| Endosulfan | < 0.05 | < 0.05 | 40 | NT | DMSO | <0.2 | <0.2 | 20 | <200 | <0.2 | <0.2 | 2 | <200 | <0.2 | <0.2 | 20 | <200 |
| Epinephrine bitartrate | 400 | 400 | NT | NT | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 2 | 2 | NT | NT |
| Ethanol | 200 | 200 | NT | NT | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 20 | 20 | NT | NT |

| | | BioRel | iance ¹ | | | | ECB | C ³ | | | FAI | 3 | | | IIVS | 3 | |
|---------------------|----------------------------|----------------------------|--------------------|------|-------------------------------|----------------------------|----------------------------|----------------|------|----------------------------|----------------------------|------|------|----------------------------|----------------------------|------|------|
| Reference Substance | 3T3 ⁴ Medium | NHK ⁵ Medium | DMSO | ЕТОН | SMT ² Selection | 3T3 ⁴ Medium | NHK ⁵ Medium | DMSO | ЕТОН | 3T3 ⁴ Medium | NHK ⁵ Medium | DMSO | ЕТОН | 3T3 ⁴ Medium | NHK ⁵ Medium | DMSO | етон |
| Fenpropathrin | <20 | <20 | 500 | NT | DMSO | <2 | <2 | 200 | NT | <0.2 | <0.2 | 200 | NT | <2 | <2 | 200 | NT |
| Gibberellic acid | 10 | 10 | NT | NT | Medium | 2 | 2 | NT | NT | 2 | 2 | NT | NT | 2 | 2 | NT | NT |
| Glutethimide | <2 | <2 | 500 | NT | DMSO | <2 | <2 | 200 | NT | <2 | <2 | 200 | NT | <2 | <2 | 200 | NT |
| Glycerol | 400 | 400 | NT | NT | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 20 | 20 | NT | NT |
| Haloperidol | <20 | <20 | 40 | NT | DMSO | <0.2 | <0.2 | 20 | <20 | <0.2 | <0.2 | 20 | <20 | <2 | <2 | 20 | <20 |
| Hexachlorophene | 0.05 | < 0.05 | 400 | 400 | DMSO | <2 | <2 | 200 | NT | <2 | <2 | 200 | NT | <2 | <2 | 200 | NT |
| Lactic acid | 200 | 200 | NT | NT | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 20 | 20 | NT | NT |
| Lindane | < 0.05 | < 0.05 | 400 | <200 | DMSO | <2 | <2 | 200 | NT | <2 | <2 | 200 | NT | <0.2 | <0.2 | 20 | <200 |
| Meprobamate | 1 | 1 | 200 | NT | DMSO | 2 | 2 | 200 | NT | 2 | 2 | 200 | NT | <0.2 | <0.2 | 200 | NT |
| Mercury II chloride | 0.125 | 0.125 | 400 | <200 | DMSO | <2 | <2 | 200 | NT | <2 | <2 | 200 | NT | <0.2 | < 0.2 | 200 | NT |
| Methanol | 40 | 40 | 400 | 400 | DMSO | 20 | 20 | NT | NT | 20 | 20 | NT | NT | <2 | <2 | 200 | NT |
| Nicotine | 400 | 400 | NT | NT | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 20 | 20 | NT | NT |
| Paraquat | 400 | 400 | NT | NT | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 20 | 20 | NT | NT |
| Parathion | 0.05 | < 0.05 | 400 | 400 | DMSO | <2 | <2 | 200 | NT | <2 | <2 | 200 | NT | <2 | <2 | 200 | NT |
| Phenobarbital | 2 | 2 | 200 | <200 | DMSO | 2 | 2 | NT | NT | <2 | <2 | 200 | NT | <2 | <2 | 200 | NT |
| Phenol | 40 | 40 | 400 | 400 | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 20 | 20 | NT | NT |
| Phenylthiourea | 2 | 2 | 400 | <200 | DMSO | 2 | <2 | 200 | NT | 20 | 20 | NT | NT | <2 | <2 | 200 | NT |
| Physostigmine | 2 | 2 | 400 | 200 | DMSO | 2 | 2 | NT | NT | <2 | <2 | 200 | NT | <2 | <2 | 200 | NT |
| Potassium cyanide | 400 | 400 | NT | NT | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 20 | 20 | NT | NT |
| Procainamide HCl | 200 | 200 | NT | NT | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 20 | 20 | NT | NT |

| | | BioRel | iance ¹ | | | | ECB | C^{3} | | | FAI | L ³ | | | IIVS | S ³ | |
|--------------------------------|----------------------------|----------------------------|--------------------|--------|-------------------------------|----------------------------|----------------------------|---------|------|----------------------------|----------------------------|----------------|------|----------------------------|----------------------------|----------------|------|
| Reference Substance | 3T3 ⁴ Medium | NHK ⁵ Medium | DMSO | ЕТОН | SMT ² Selection | 3T3 ⁴ Medium | NHK ⁵ Medium | DMSO | ЕТОН | 3T3 ⁴ Medium | NHK ⁵ Medium | DMSO | ЕТОН | 3T3 ⁴ Medium | NHK ⁵ Medium | DMSO | ЕТОН |
| Propylparaben | 0.25 | 0.25 | 400 | 400 | DMSO | <2 | <2 | 200 | NT | <2 | <2 | 200 | NT | <2 | <2 | 200 | NT |
| Sodium arsenite | 400 | 400 | NT | NT | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 20 | 20 | NT | NT |
| Sodium chloride | 200 | 200 | NT | NT | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 20 | 20 | NT | NT |
| Sodium dichromate dihydrate | 400 | 400 | NT | NT | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 20 | 20 | NT | NT |
| Sodium hypochlorite | 200 | 200 | NT | NT | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 20 | 20 | NT | NT |
| Sodium oxalate | < 0.05 | 20 | 0.125 | < 0.05 | Medium | <0.2 | 20 | 0.2 | <2 | 20 | 20 | NT | NT | <0.2 | <0.2 | <0.2 | <0.2 |
| Strychnine | < 2 | <2 | 2 | 2 | Medium | 0.2 | <0.2 | 2 | 2 | 0.2 | 0.2 | <200 | <200 | <0.2 | <0.2 | <0.2 | <0.2 |
| Thallium I sulfate | 1 | 0.5 | <2 | <2 | Medium | 0.2 | 0.2 | <200 | <200 | <0.2 | <0.2 | <0.2 | <0.2 | 0.2 | 0.2 | <20 | <200 |
| Trichloroacetic acid | 200 | 200 | NT | NT | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 20 | 20 | NT | NT |
| 1,1,1-Trichloroethane | 10 | 10 | 400 | 400 | Medium | 20 | 20 | NT | NT | 20 | 20 | NT | NT | 20 | 20 | NT | NT |
| Triethylenemelamine | <2 | <2 | 2 | <20 | DMSO | 0.2 | 0.2 | <200 | <200 | <0.2 | <0.2 | 2 | <2 | <0.2 | <0.2 | <0.2 | <0.2 |
| Triphenyltin hydroxide | < 0.05 | < 0.05 | 10 | <20 | DMSO | <0.2 | <0.2 | 2 | <20 | <0.2 | <0.2 | 2 | <200 | <2 | <2 | 2 | <20 |
| Valproic acid | 10 | 2 | NT | NT | DMSO | 2 | 2 | NT | NT | <2 | <2 | 200 | NT | 2 | <2 | 200 | NT |
| Verapamil HCl | < 0.05 | 0.25 | 200 | NT | DMSO | <2 | <2 | 200 | NT | <2 | <2 | 200 | NT | <0.2 | <0.2 | 20 | NT |
| Xylene | 1 | 1 | 500 | NT | DMSO | <2 | <2 | 200 | NT | 2 | <2 | 200 | NT | <2 | <2 | 200 | NT |

 Abbreviations: 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; SMT=Study Management Team; ECBC=Edgewood Chemical Biological Center; FAL=Fund for the Replacement of Animals in

 Medical Experiments Alternatives Laboratory; IIVS=Institute for In Vitro Sciences; DMSO=Dimethyl sulfoxide; ETOH=ethanol; NT=Not tested.

Note: Table sorted by study phase and alphabetical by substance.

¹The solubility protocol used was different from that used by the testing laboratories.

²Solvents selected by the SMT for cytotoxicity testing. The BioReliance results were used to determine solvents for Phases I and II. Results from all laboratories were used to determine solvents for Phase III. 3T3 and NHK media were treated as a single solvent. If a substance insoluble in one medium, and not the other, and soluble in DMSO, then DMSO was selected for use with both cell types.

³Used protocol in Figure 2-7.

⁴Dulbecco's Modification of Eagle's Medium.

5Keratinocyte Growth Medium (KGM® from CAMBREX Clonetics®).

⁶The results were obtained using a deviation from the standard protocol. Laboratories agreed on solvent. Laboratories did not agree on solvent. **bold** Protocol did not provide enough guideline information to select a single solvent.

5.8.1 <u>Solubility Data</u>

BioReliance evaluated the solubility of the reference substances, first in media, then in DMSO, and then in ETOH, at 400 and 200 mg/mL. Based on their experience, a solubility protocol was developed for the testing laboratories. This revised protocol required testing at lower concentrations, and use of the various solvents at concentrations that would be equivalent when applied to the cell cultures (see **Table 2-5**). The solubility flow chart (**Figure 2-7**) illustrates the tests for solubility in 3T3 and NHK medium, DMSO, and ETOH. **Table 5-10** provides the solubility test results.

5.8.2 <u>Solubility and Volatility Effects in the Cytotoxicity Tests</u>

The laboratories reported solubility results for the stock solutions of reference substance for each 3T3 and NHK test. Prior to the addition of the NR dye medium, the laboratories visually observed the test cultures and documented noticeable precipitate. **Table 5-11** illustrates the existence of solubility issues (in both the 3T3 and NHK NRU test methods) as evidenced by the observation of precipitates with some reference substances. **Sections 3.2.6** and **5.4.2** provide additional information on ability of the laboratories to achieve sufficient toxicity for the calculation of an IC₅₀ in the presence of limited solubility. **Table 5-11** also notes the presence of volatility, as indicated by the use of film plate sealers during incubation.

| | 3 | T3 NRU T | est Metho | d | NHK NRU Test Method | | | | |
|-----------------------------|---------------------------------|---------------------------------|--|------------|---------------------------------|---------------------------------|--|------------|--|
| Reference Substances | PPT in 2X Stock Dilutions | PPT in 1X Plate Dilutions | PPT in Stock and Plate Dilutions | Volatility | PPT in 2X Stock Dilutions | PPT in 1X Plate Dilutions | PPT in Stock and Plate Dilutions | Volatility | |
| Acetonitrile | | | | Х | | | | Х | |
| Aminopterin | | Х | | | Х | | | | |
| 5-Aminosalicylic acid | X | | | | | | | | |
| Arsenic III trioxide | X | | | | Х | | | | |
| Cadmium II chloride | | Х | | | | | Х | | |
| Carbamazepine | | | Х | | | | | | |
| Carbon tetrachloride | | | Х | | Х | | | | |
| Citric acid | | | | | | Х | | | |
| Cupric sulfate pentahydrate | | | | | | Х | | | |
| Dibutyl phthalate | | Х | | | | | Х | | |
| Dichlorvos | | | | Х | | | | Х | |
| Diethyl phthalate | Х | | | | | | Х | | |
| Digoxin | | | Х | | | | | | |
| Dimethylformamide | | | | | | Х | | | |
| Disulfoton | | | Х | | | | Х | | |
| Endosulfan | X | | | Х | | | | Х | |
| Ethanol | | | | Х | | | | Х | |
| Fenpropathrin | | | Х | | | | Х | | |
| Gibberellic acid | X | | | | Х | | | | |
| Glutethimide | | | | | Х | | | | |
| Lindane | | | Х | Х | | | Х | | |
| Lithium I carbonate | Х | | | | Х | | | | |
| Nicotine | | | | Х | | | | Х | |
| Parathion | Х | | | | | | Х | | |
| Phenol | | | | Х | | | | Х | |
| Potassium I chloride | | Х | | | | | | | |
| Potassium cyanide | | Х | | Х | | | | Х | |

Table 5-11Reference Substances with Precipitate (PPT) and Volatility Issues1

Х

Х

Х

Х

| | 3 | T3 NRU T | Cest Metho | d | NHK NRU Test Method | | | | |
|----------------------|---------------------------------|---------------------------------|--|------------|---------------------------------|---------------------------------|--|------------|--|
| Reference Substances | PPT in 2X Stock Dilutions | PPT in 1X Plate Dilutions | PPT in Stock and Plate Dilutions | Volatility | PPT in 2X Stock Dilutions | PPT in 1X Plate Dilutions | PPT in Stock and Plate Dilutions | Volatility | |
| 2-Propanol | | | | Х | | | | Х | |
| Sodium arsenite | | Х | | | | | | Х | |
| Sodium chloride | | | | | | Х | | | |
| Sodium I fluoride | | Х | | | | Х | | | |

X

Х

Х

Х

Х

Х

Х

Table 5-11 **Reference Substances with Precipitate (PPT) and Volatility Issues**¹

Xylene Abbreviations: 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake; PPT=Precipitate. Note: Table sorted alphabetical by reference substance.

Х

¹Results are based on at least one laboratory having precipitate or volatility issues with a substance. Volatility was denoted by the use of plate sealers during testing. 2X stock dilutions are prepared for each of 8 test substance concentrations. 1X plate dilutions are the result of diluting the 2X stock solutions with medium in the 96-well plates.

5.9 Summary

Sodium hypochlorite

1,1,1-Trichloroethane

Sodium oxalate

Strychnine Trichloroacetic acid

Valproic acid

Verapamil HCl

- The BioReliance, ECBC, and IIVS laboratories performed the 3T3 and NHK NRU tests in compliance with GLP guidelines.
- The quality and consistency of the reference substances was maintained • during the study by the central purchase and distribution of individual lots of reference substances to the testing laboratories.
- Modifications and revisions made to the protocols during Phases I and II • contributed to the optimization of the final protocols used in Phase III of the study. As a general rule, the protocol changes enhanced the performance of the methods and allowed more tests to meet the acceptance criteria.
- FAL improved the quality of its NHK data prior to Phase II testing by modifying the methods used to propagate the cells. Positive control IC_{50} data in Phases II and III from FAL more closely resemble the data from the other laboratories.
- Summary test data and IC_{50} results are presented in tabular and graphic formats. Comparisons of 3T3 NRU IC50 values to NHK NRU IC50 values show that the values for 85% of the reference substances are within one order of magnitude of each other. Digoxin and aminopterin yielded differences of up to five orders of magnitude when the IC_{50} values of the 3T3 and NHK NRU test methods were compared.
- Although each laboratory followed the same solubility protocol, they sometimes obtained different results. This may have been due to the subjective judgment of whether or not solubility was achieved. Additionally, the laboratories may have used solubility procedures that were beyond the level of detail in the solubility protocol.

| 6.0 | ACCU | URACY OF THE 3T3 AND NHK NRU TEST METHODS | 6-3 |
|-----|--------|---|------|
| 6.1 | | cacy of the 3T3 and NHK NRU Test Methods for Predicting Rodent Oral Toxicity | 6-5 |
| | | Linear Regression Analyses for the Prediction of Rat Acute Oral LD ₅₀ Values from <i>In Vitro</i> IC ₅₀ Values | |
| | 6.1.2 | Comparison of Combined-Laboratory 3T3 and NHK Regressions to the RC Millimole Regression | |
| 6.2 | Analy | vis of Outlier Substances for the RC Millimole Regression | 6-9 |
| 0.2 | 6.2.1 | Identification of Outlier Substances. | |
| | 6.2.2 | Evaluation of Outlier Substances | |
| 6.3 | | oving the Prediction of <i>In Vivo</i> Rat Oral LD ₅₀ Values from <i>In Vitro</i> | |
| | | Data | |
| | | The RC Rat-Only Millimole Regression | |
| | 6.3.2 | The RC Rat-Only Weight Regression | 6-17 |
| 6.4 | | acy of the 3T3 and NHK NRU Test Methods for Predicting GHS | (10 |
| | | e Oral Toxicity Categories | 6-18 |
| | 6.4.1 | Prediction of GHS Acute Oral Toxicity Category by the RC IC ₅₀ | 6.20 |
| | 617 | Values Using the RC Rat-Only Millimole Regression | 0-20 |
| | 6.4.2 | Prediction of GHS Acute Oral Toxicity Category by the 3T3 and NHK NRU Test Methods Using the RC Rat-Only Millimole Regression | 6-22 |
| | 6.4.3 | Prediction of GHS Acute Oral Toxicity Category by the 3T3 and NHK | |
| | | NRU Test Methods Using the RC Rat-Only Weight Regression | 6-24 |
| | 6.4.4 | Summary of the Regressions Evaluated | 6-27 |
| 6.5 | | elation of NRU Concentration-Response Slope with Rat Lethality | |
| | Dose- | Response Slope | 6-28 |
| 6.6 | | gths and Limitations of the Use of <i>In Vitro</i> Cytotoxicity Test | |
| | | ods with the IC ₅₀ –LD ₅₀ Regressions for Predictions of Rodent Acute Foxicity | 6_31 |
| | 6.6.1 | In Vitro Cytotoxicity Methods | 6-31 |
| | 6.6.2 | Use of Mole-Based vs. Weight-Based Regressions for the Prediction | 0 51 |
| | 0.0.2 | of Toxicity for Low and High Molecular Weight Substances | 6-31 |
| 6.7 | Salier | it Issues of Data Interpretation | 6-34 |
| 6.8 | Comp | oarison of NRU Test Results to Established Performance Standards | 6-34 |
| 6.9 | - | nary | |
| | Sami | J | |

[This Page Intentionally Left Blank]

6.0 ACCURACY OF THE 3T3 AND NHK NRU TEST METHODS

This section discusses the accuracy of the 3T3 and NHK NRU test methods for predicting the rodent acute oral toxicity (the LD_{50}) of chemicals. Accuracy, the agreement between a test result and an accepted reference value, is a critical component of the evaluation of the validation status of a method (ICCVAM 2003). Although the 3T3 and NHK NRU test methods are not suitable as replacements for acute oral toxicity assays, the rationale for evaluating the accuracy of LD_{50} predictions from the *in vitro* IC₅₀ values is that the animal savings produced by using these *in vitro* test methods to predict starting doses for acute oral toxicity assays will be greatest when the starting dose is as close as possible to the "true" LD_{50} value (see **Section 10** for the evaluation of the potential reduction of animal use).

The ability of the 3T3 and NHK NRU test methods to correctly predict rodent acute oral toxicity is based on the validity of the *in vivo* – *in vitro* (i.e., IC_{50} -LD₅₀) regression model. The IC_{50} -LD₅₀ regression establishes the relationship between the *in vitro* IC_{50} values and the LD₅₀ values that will be used to set the starting doses for the computer-simulated acute oral toxicity assays in this study (see **Section 10**). The regressions generated by the three laboratories for each NRU test method were not statistically different, and the data from the 3T3 and NHK NRU test methods were combined (using a geometric mean IC_{50} of the three individual laboratory geometric mean IC_{50} values) into single regressions (see **Section 6.1**). Only rat LD₅₀ data were used for these regressions to reduce the variation that would be produced by combining data from multiple species. **Table 6-1** describes the datasets used for the analyses in **Sections 6.1** through **6.4**.

To test the assumption in the *Guidance Document* that the RC millimole regression can be obtained using a basal cytotoxicity method with a single cell type and cytotoxicity endpoint (ICCVAM 2001b), the regressions for each NRU test method (3T3 and NHK) were compared with regressions for the same substances that were calculated using the RC IC₅₀ and LD₅₀ values (see **Section 6.1**). Because the 3T3 and NHK regressions were not statistically different from the RC regressions for the same chemicals, the RC data were used to develop a regression to predict LD₅₀ values from the NRU-generated IC₅₀ values because this regression was based on a larger number of substances than the NICEATM/ECVAM regressions (see **Section 6.3**).

The RC millimole regression was used to identify outlier substances (i.e., those that did not fit the regression within the established acceptance limits; see **Section 6.2**) tested in the validation study because:

- Acceptance limits for the RC millimole regression had been established
- The 3T3 and NHK NRU IC₅₀ rat oral LD₅₀ regressions were not significantly different from the RC regressions calculated for the same substances
- Use of the RC regressions allow a comparison of the outlier substances determined using RC data to those determined using the 3T3 and NHK data

| Use | 3T3 NRU ¹ | NHK NRU ¹ | Characteristics of Dataset |
|---|-------------------------|-------------------------|--|
| Testing with NRU test methods | 72 | 72 | Substances tested; 58 substances were common to the RC |
| Comparison of laboratory IC ₅₀ -LD ₅₀ regressions to one another | 47 | 51 | RC substances with IC_{50} values from all laboratories and reference rat oral reference LD_{50} values |
| Comparison of combined-laboratory IC_{50} -LD $_{50}$ regressions to a regression calculated with RC data | 47 | 47 | RC substances with IC ₅₀ values for both test methods from all laboratories and reference rat oral LD ₅₀ values |
| RC millimole regression | NA | NA | RC IC ₅₀ (mM) and RC oral LD ₅₀ (mmol/kg) values for 347 substances (282 rat and 65 mouse LD ₅₀ values) |
| RC rat-only millimole regression | NA | NA | RC IC ₅₀ (mM) and RC oral LD_{50} values (mmol/kg) for 282 substances with rat oral LD_{50} data |
| RC rat-only weight regression | NA | NA | RC IC ₅₀ (μ g/mL) and RC oral LD ₅₀ values (mg/kg) for 282 substances with rat oral LD ₅₀ data |
| Analysis of outliers for the RC millimole regression | 70 | 71 | Substances with IC_{50} values from at least one laboratory |
| Prediction of GHS accuracy using IC_{50} values in RC rat-only regressions | 67 | 68 | Substances with IC_{50} values from at least one laboratory and rat oral LD_{50} reference values |

Datasets Used for Accuracy Analyses¹ Table 6-1

Abbreviations: RC=Registry of Cytotoxicity; 3T3=BALB/c 3T3 fibroblasts; NA=Not applicable; NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake. ¹Number of substances.

To improve upon the RC millimole regression's¹ ability to accurately predict LD₅₀ values from IC_{50} values, and to also make this approach relevant to the testing of mixtures and substances without known molecular weights, two regressions were calculated (see Section **6.3**). The first regression – the RC rat-only millimole regression – uses the 282 (of 347) substances in the RC dataset that had reported rat LD_{50} values. The LD_{50} data for the regression were limited to one species to decrease the variability in LD₅₀ values that would occur if the data from more than one species were combined. Rats were selected because they are the preferred species for acute oral toxicity testing (EPA 2002b; OECD 2001a; OECD 2001d) (see Section 6.3.1). The RC rat-only millimole regression was transformed to one based on weight units (mg/kg body weight for LD₅₀ and μ g/mL for IC₅₀) in order to make the regression equation more generally applicable to the testing of mixtures and substances of unknown molecular weights.

¹ The RC millimole regression was created using rat and mouse oral LD_{50} values from RTECS[®] and IC₅₀ values from in vitro cytotoxicity assays using multiple cell lines and cytotoxicity endpoints for 347 substances with known molecular weights (Halle 1998, 2003)

The ability of the 3T3 and NHK NRU IC₅₀ data to correctly predict rat acute oral LD₅₀ values based on using the RC rat-only millimole regression and the RC rat-only weight regression, was evaluated by determining the extent to which the appropriate GHS acute oral toxicity category was identified for each reference substance (see **Section 6.4**). The rationale for evaluating the accuracy of LD₅₀ predictions is that the acute oral toxicity test methods (i.e., UDP, FDP, and ATC) call for starting doses to be placed as close as possible and just below the true LD₅₀. When the starting dose is close to the true LD₅₀ for a test substance, fewer animals are needed. When the starting dose is below the true LD₅₀, there is reduced pain and suffering because doses tend to be lower, and the test bias is more conservative. This approach permits an assessment of accuracy that is specific to each GHS hazard classification category. The discordant reference substances from the predictions of GHS category are presented in **Appendix L2**.

The remainder of **Section 6** discusses physical, chemical, and biological, characteristics of substances that may have an impact on the accuracy of the 3T3 and NHK methods.

6.1 Accuracy of the 3T3 and NHK NRU Test Methods for Predicting Rodent Acute Oral Toxicity

The rat LD_{50} values provided in **Section 4.2** are used as the reference values for assessing the ability of the 3T3 and NHK test methods to accurately predict acute oral toxicity². The accuracy of the two *in vitro* cytotoxicity test methods is assessed in two ways: (1) by the goodness of fit of the *in vitro* IC₅₀ data to the rat LD_{50} data in linear regression analyses, and (2) by the concordance (i.e., extent of agreement) between the GHS acute oral toxicity categories (UN 2005) assigned based on rat LD_{50} data and those predicted using *in vitro* IC₅₀ values.

6.1.1 Linear Regression Analyses for the Prediction of Rat Acute Oral LD₅₀ Values from *In Vitro* IC₅₀ Values

As described in Section 5.5.4.3, linear regressions for each laboratory and *in vitro* method were calculated using log IC_{50} values (mM) versus the corresponding reference log LD_{50} values (mmol/kg) identified in Table 4-2. The reference substances used to calculate each of the laboratory regressions met the following criteria for each test method:

- The substance was included in the RC
- All three laboratories reported IC₅₀ values
- There was an associated rat acute oral LD₅₀ reference value (see **Table 4-2**).

There were 47 and 51 reference substances that fit these criteria for the 3T3 and NHK test methods, respectively. The slopes for the all of the laboratory-specific regressions were statistically significantly different from zero (p <0.0001), which indicates a significant correlation between *in vitro* IC₅₀ values and the corresponding rat acute oral LD₅₀ values. Comparison of the individual laboratory regressions to one another using the goodness of fit

 $^{^2}$ Toxicity is inversely proportional to LD₅₀. High LD₅₀ values reflect low toxicity and low LD₅₀ values reflect high toxicity

F-test for regression slopes and intercepts described in **Section 5.5.4.3** indicated that the laboratory-specific regressions for either NRU method were not significantly different from one another. For the 3T3 method, p=0.605 for the slope comparisons and p=0.947 for the intercept comparisons. For the NHK method, p=0.792 for the slope comparisons and p=0.999 for the intercept comparisons.

Because the individual laboratory regressions were not significantly different, the laboratory data were combined into a single regression for each method using the geometric mean of the mean IC₅₀ values determined by each laboratory for each substance (see the "Combined-laboratory" regressions in **Table 6-2** and **Figure 6-1**). The combined-laboratory 3T3 regression yielded a better fit to the reference LD₅₀ data (R^2 =0.579) than the NHK regression (R^2 =0.463).

| Table 6-2 | Linear Regression Analyses of the 3T3 and NHK NRU and Rat Acute |
|-----------|---|
| | Oral LD ₅₀ Test Results ¹ |


| Laboratory | Ν | Slope | Intercept | \mathbb{R}^2 | | | | | | | |
|----------------------------------|----|---------|-----------|----------------|--|--|--|--|--|--|--|
| 3T3 NRU | | | | | | | | | | | |
| $ECBC^{2}$ | 47 | 0.573 | 0.541 | 0.613 | | | | | | | |
| FAL^2 | 47 | 0.539 | 0.373 | 0.519 | | | | | | | |
| IIVS ² | 47 | 0.552 | 0.507 | 0.586 | | | | | | | |
| Combined-laboratory ³ | 47 | 0.561 | 0.475 | 0.579 | | | | | | | |
| | | NHK NRU | | | | | | | | | |
| $ECBC^{2}$ | 51 | 0.491 | 0.412 | 0.480 | | | | | | | |
| FAL^2 | 51 | 0.428 | 0.407 | 0.422 | | | | | | | |
| IIVS ² | 51 | 0.483 | 0.416 | 0.478 | | | | | | | |
| Combined-laboratory ³ | 51 | 0.470 | 0.413 | 0.463 | | | | | | | |


Abbreviations: ECBC=Edgewood Chemical Biological Center; FAL=Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory; IIVS=Institute for *In Vitro* Sciences; 3T3=BALB/c 3T3 fibroblasts; N=Number of substances used to calculate the regression; NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake; R²=Coefficient of determination.


¹Log IC₅₀ in mM; log LD₅₀ in mmol/kg.

²Regression based on a single point per substance (i.e., the geometric mean of the within laboratory replicate IC_{50} values and the reference rat acute oral LD_{50} from **Table 4-2**).

³Regression based on a single point per substance (i.e., the geometric mean of the geometric mean IC_{50} values obtained for each laboratory and the reference rat acute oral LD_{50} from **Table 4-2**).







Points show the geometric means of the laboratory geometric mean IC_{50} values and the reference rat acute oral LD_{50} values (from **Table 4-2**) for 47 reference substances for the 3T3 and 51 reference substances for NHK test methods. Solid lines show the combined-laboratory regressions for each method (see **Table 6-2**).


6.1.2 Comparison of the Combined-Laboratory 3T3 and NHK Regressions to the RC Millimole Regression

The validation study tested 58 RC substances using the 3T3 and NHK NRU test methods (see **Figure 3-1**). The resulting method regressions for each cell type were compared to the RC regressions for the same substances to test the assumption in the *Guidance Document* that the RC millimole regression can be obtained with a basal cytotoxicity test method using a single cell type and endpoint (ICCVAM 2001b). The 47 substances used to calculate these regressions met the following criteria:

- The substance was included in the RC
- All three laboratories reported IC₅₀ values for both the 3T3 and NHK NRU test methods
- There was an associated rat oral reference LD₅₀ value (see **Table 4-2**)


The regression calculated for the 47 substances using the RC IC_{50} and LD_{50} data is shown in **Figure 6-2**. A graphic comparison of the RC regressions and the 3T3 and NHK combinedlaboratory regressions is in **Figure 6-3**. A statistical comparison of slope and intercept (simultaneously) using an F test showed that neither the 3T3 regression (p=0.612) nor the NHK regression (p=0.759) was significantly different from the 47 RC substance regression.

Figure 6-2 Regression for 47 RC Substances Using RC Data



Abbreviations: RC=Registry of Cytotoxicity; R^2 =Coefficient of determination. Points show the IC₅₀ values and the reference rodent (rat and mouse) acute oral LD₅₀ values from the RC for 47 reference substances. The dashed line shows the calculated regression.

Figure 6-3 Regression for 47 RC Substances with the 3T3 and NHK Regressions



Abbreviations: RC=Registry of Cytotoxicity; 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake.

The regression for 47 RC substances using RC data is $\log LD_{50} = 0.640 \log IC_{50} + 0.262 (R^2=0.694)$. The combined-laboratory 3T3 regression for the same 47 substances, is $\log LD_{50} = 0.561 \log IC_{50} + 0.475 (R^2 = 0.579)$ (from **Table 6-2**). The combined-laboratory NHK regression for the same 47 substances, is $\log LD_{50} = 0.471 \log IC_{50} + 0.445 (R^2 = 0.487)$.

6.2 Analysis of Outlier Substances for the RC Millimole Regression

The RC millimole regression and each *in vitro* NRU test method were used to identify outliers among the reference substances tested in the validation study (i.e., those for which the rodent LD_{50} was not accurately predicted by the *in vitro* IC₅₀). The outlier substances were then evaluated to determine if they had common characteristics that could assist in identifying the types of substances that are not suited for use in the 3T3 or NHK NRU test methods for determining starting doses for acute oral toxicity assays.

The RC millimole regression was used to determine the outlier status of reference substances because:

- The RC millimole regression had associated acceptance limits (Halle 1998, 2003): a difference greater than 0.699 (or log 5) for log-observed LD₅₀ (in mmol/kg) from the log-predicted LD₅₀ identifies a substance as an outlier
- The 3T3 and NHK IC₅₀ rat oral LD₅₀ regressions were not significantly different from the RC regressions calculated for the same substances

• Use of the RC millimole regression allows a comparison of the outlier substances determined using RC IC₅₀ values to those determined using the 3T3 and NHK NRU IC₅₀ values.

6.2.1 Identification of Outlier Substances

For each *in vitro* NRU test method, the predicted LD₅₀ values for the reference substances were determined using the geometric mean IC_{50} values of the three geometric mean laboratory values in the RC millimole regression. Outliers were identified using the RC method (Halle 1998): a difference greater than 0.699 (or log 5) for log-observed LD_{50} (in mmol/kg) minus the log-predicted LD_{50} identifies a substance as an outlier (see Appendix J1 for the 3T3 NRU test method and Appendix J2 for the NHK NRU test method for the predicted LD_{50} values). For the best comparison with the RC outlier results, the outlier evaluation for the 3T3 and NHK NRU test methods used same observed LD₅₀ values as those used in the RC database for the 58 reference substances that were included in the RC database (see Table 3-2). For the non-RC substances, the observed values (in Table 3-2) were obtained from other databases such as RTECS® or Hazardous Substances Database (NLM 2002). The outlier analysis included all the reference substances that yielded IC_{50} values from at least one laboratory in the validation study whether the *in vivo* LD₅₀ values were from rats or mice. Thus, 70 substances were used for the 3T3 NRU outlier analysis and 71 substances were used for the NHK NRU outlier analysis. Table 6-3 lists the outlier substances for the RC millimole regression when using the RC IC₅₀ values and the 3T3 and NHK NRU IC₅₀ values.

| Substances Included in the RC Identified as Outliers in: | | | | | | | |
|--|----------------------------|----------------------------|--|--|--|--|--|
| RC ² | 3T3 ³ | NHK ⁴ | | | | | |
| | Acetaminophen (+) | | | | | | |
| | Arsenic III trioxide (–) | Arsenic III trioxide (–) | | | | | |
| | | Aminopterin (–) | | | | | |
| 5-Aminosalicylic acid (+) | | 5-Aminosalicylic acid (+) | | | | | |
| Busulfan (-) | Busulfan (–) | Busulfan (–) | | | | | |
| Caffeine (-) | | Caffeine (-) | | | | | |
| Cycloheximide (-) | Cycloheximide (–) | Cycloheximide (–) | | | | | |
| Dibutyl phthalate (+) | Dibutyl phthalate (+) | Dibutyl phthalate (+) | | | | | |
| | Diethyl phthalate (+) | Diethyl phthalate (+) | | | | | |
| Digoxin (–) | Digoxin (–) | | | | | | |
| Disulfoton (-) | Disulfoton (–) | Disulfoton () | | | | | |
| Epinephrine bitartrate (-) | Epinephrine bitartrate (–) | Epinephrine bitartrate (-) | | | | | |
| Ethanol (+) | Ethanol (+) | Ethanol (+) | | | | | |
| Lindane (-) | Lindane (-) | | | | | | |
| Mercury II chloride (-) | Mercury II chloride (-) | Mercury II chloride (-) | | | | | |
| | | Methanol (+) | | | | | |

Table 6-3Outlier Substances for the RC and the 3T3 and NHK NRU MethodsWhen the RC Millimole Regression is Used1

Table 6-3Outlier Substances for the RC and the 3T3 and NHK NRU MethodsWhen the RC Millimole Regression is Used1

| Substances I | Substances Included in the RC Identified as Outliers in: | | | | | | |
|---------------------------|--|-------------------------|--|--|--|--|--|
| RC ² | 3T3 ³ | NHK ⁴ | | | | | |
| Nicotine (–) | Nicotine (–) | Nicotine (-) | | | | | |
| Paraquat (–) | | Paraquat (–) | | | | | |
| Parathion (–) | Parathion (-) | Parathion (-) | | | | | |
| Phenobarbital (-) | Phenobarbital (-) | Phenobarbital (-) | | | | | |
| Phenylthiourea (-) | Phenylthiourea (-) | Phenylthiourea (-) | | | | | |
| Potassium cyanide (–) | Potassium cyanide (–) | Potassium cyanide (-) | | | | | |
| Propylparaben (+) | Propylparaben (+) | Propylparaben (+) | | | | | |
| | | Sodium oxalate (-) | | | | | |
| Thallium I sulfate (–) | Thallium I sulfate (–) | | | | | | |
| Triethylenemelamine (-) | Triethylenemelamine (-) | Triethylenemelamine (-) | | | | | |
| 1,1,1-Trichloroethane (+) | | | | | | | |
| Verapamil HCl (–) | Verapamil HCl (–) | Verapamil HCl (–) | | | | | |
| | | Xylene (+) | | | | | |
| Outlie | rs That Were Not Included in the RC | C | | | | | |
| | Dichlorvos (–) | Dichlorvos (–) | | | | | |
| | Endosulfan (–) | Endosulfan (-) | | | | | |
| | Fenpropathrin (–) | Fenpropathrin (–) | | | | | |
| | Physostigmine (-) | Physostigmine (-) | | | | | |
| | Sodium hypochlorite (+) | Sodium hypochlorite (+) | | | | | |
| | Sodium selenate (–) | Sodium selenate (-) | | | | | |
| | Strychnine (–) | Strychnine (-) | | | | | |

Abbreviations: RC=Registry of Cytotoxicity; 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake; (–)=Toxicity was underpredicted by the IC_{50} and RC millimole regression (i.e., the LD_{50} value predicted by the IC_{50} was higher than the *in vivo* LD_{50} value); (+)=Toxicity was overpredicted by the IC_{50} and RC millimole regression (i.e., the LD_{50} and RC millimole regression (i.e., the LD_{50} value) regression (i.e., the LD_{50} value predicted by the IC_{50} was lower than the *in vivo* rodent LD_{50} value).

[Note: Empty cells indicate that the substance was not an outlier for that particular IC₅₀ value.]

¹Log LD_{50} (mmol/kg) = 0.435 log IC_{50} (mM) + 0.625. Log LD_{50} (mmol/kg) values for outlier substances were >0.699 from the RC millimole regression.

²Using RC IC₅₀ in the RC millimole regression for the 58 RC substances tested in the validation study.

³Using the 3T3 NRU IC₅₀ in the RC millimole regression for the 70 reference substances that yielded IC₅₀ values from any laboratory in the validation study.

⁴Using the NHK NRU IC₅₀ in the RC millimole regression the RC for the 71 reference substances that yielded IC₅₀ values from any laboratory in the validation study.

Bolded substances have active metabolites in vivo (see Table 3-7).

Substances that showed evidence of insolubility (i.e., precipitates) during testing (see Table 5-11) are identified by italics.

When the RC millimole regression and the RC method of identifying outlier substances were used (Halle 1998, 2003), there were 28 outliers for the 3T3 NRU test method and 31 for the NHK NRU test method. The top part of **Table 6-3** shows a comparison of the 22 RC substances that were identified by the RC as outliers (see **Table 3-2**) and the RC reference substances that were identified as outliers using either the 3T3 or NHK NRU IC₅₀ values with the RC millimole regression. For the 58 RC substances that were tested in the validation

study, 18 of the 22 RC outliers also responded as outliers in both NRU test methods, but some of the substances were outliers only in one of the two NRU test methods. The RC regression outliers, 5-aminosalicylic acid, caffeine, paraquat, and 1,1,1-trichloroethane were not outliers when 3T3 data were used, and the RC outliers, digoxin, lindane, thallium sulfate, and 1,1,1-trichloroethane, were not outliers when the NHK NRU test method was used. In contrast the 3T3 NRU test method identified three substances as outliers that were not identified by the RC: acetaminophen, arsenic trioxide, and diethyl phthalate, and the NHK NRU test method identified six: aminopterin, arsenic trioxide, diethyl phthalate, methanol, sodium oxalate, and xylene. Seven additional substances, that were not included in the RC database, were identified as outliers using the NRU IC₅₀ values in the RC millimole regression: dichlorvos, endosulfan, fenpropathrin, physostigmine, sodium hypochlorite, sodium selenate, and strychnine.

6.2.2 <u>Evaluation of Outlier Substances</u>

A number of physico-chemical and toxicologic characteristics were evaluated for their frequency of occurrence among the 28 and 31 outlier substances in the 3T3 and NHK NRU test methods, respectively, to identify attributes that may have contributed their outlier status. This section provides a summary of these analyses based on the RC millimole regression and outlier criteria. The frequency of outliers versus the total number of reference substances for each physico-chemical and toxicologic category examined is shown in **Appendix L1**.

6.2.2.1 *Physical Characteristics*

A number of physical characteristics were evaluated for their frequency of occurrence in the set of outlier substances versus the complete set of reference substances. The characteristics chosen were those that were assumed to be readily available, or relatively easy to measure, for new substances that may be tested in these NRU assays. The characteristics examined included chemical class, molecular weight, boiling point, IC₅₀, pH, and log K_{ow} (i.e., log octanol:water partition coefficient). Unfortunately, these attributes were not available for all substances. For example, log K_{ow} was available for 50 of the 70 (71%) substances evaluated for the 3T3 NRU test method and for 51 of the 71 (72%) substances evaluated for the NHK NRU test method. Boiling point was available for only 24 of 70 (34%) substances evaluated for the 3T3 NRU test method and for 25 of the 71 (35%) substances evaluated for the NHK NRU test method. For substances with log K_{ow} >3.00, 8/13 (62%) were outliers for both the 3T3 and NHK test methods. For molecular weights >400 g/mole, 4/7 (57%) substances were outliers using the 3T3 NRU test method and 3/7 (43%) were outliers using the NHK NRU test method. For substances with boiling points >200°C, 9/13 (69%) were outliers using the 3T3 NRU test method and 8/13 (62%) were outliers using the NHK NRU test method.

6.2.2.2 Chemical Class

Examination of outliers by chemical class for the RC millimole regression showed that all of the chemical classes that contained at least three reference substances also contained at least one outlier for one test method. Two classes contained 100% outliers for both test methods: organophosphates (3/3) and organic sulfur compounds (5/5). The remaining classes with higher frequencies of outliers included: 2/3 (67%) amines were outliers for both test methods, 7/14 (50%) heterocylics were outliers for the 3T3 NRU and 10/14 (71%) heterocyclics were outliers for the NHK NRU, 2/5 (40%) chlorine compounds were outliers for both test methods, 3/9 (33%) alcohols were outliers for the 3T3 NRU and 4/10 (40%) alcohols were outliers for the NHK

NRU, and 4/14 (29%) carboxylic acids were outliers for the 3T3 NRU and 6/14 (43%) carboxylic acids were outliers for the NHK NRU.

6.2.2.3 *Solubility*

Another attribute that may cause a substance to be an outlier is the lack of solubility in the test system. Because the SMT expected the toxicity of insoluble substances to be underpredicted in the *in vitro* assays, substances that formed precipitates in the tests were noted and compared with the outlier substances. However, insolubility was not consistently associated with the outlier substances for which toxicity was underpredicted. For example, eight of the 22 (36%) underpredicted substances identified by applying the 3T3 results to the RC millimole regression exhibited signs of insolubility in at least one laboratory. NHK results showed that seven of 23 (30%) underpredicted substances exhibited signs of insolubility in at least one laboratory (see **Table 5-11** for substances that had precipitates in the assays). Additionally, there was evidence of insolubility in the 3T3 and NHK NRU test methods of dibutyl phthalate and diethyl phthalate, but toxicity was overpredicted for both substances, rather than underpredicted. This overprediction may be a characteristic of the phthalates, but more substances would have to be tested before a general rule could be adopted.

There were 25 substances that showed evidence of insolubility in the 3T3 test method in at least one laboratory, and 11 (44%) of these were outliers. Of the 24 substances showed evidence of insolubility in at least one NHK laboratory, 11 (46%) were outliers.

6.2.2.4 Metabolism

It was anticipated that the toxicity of substances metabolized *in vivo* to active compounds (see Section 3.3.4.3 and Table 3-7) would be underpredicted *in vitro* by 3T3 and NHK cells, which have little or no metabolic capability (Babich 1991; INVITTOX 1991). Of the 72 reference substances, 19 (26%) are known to have active metabolites *in vivo*, and 10 (45%) of these were classified as outliers for 3T3. Of these 10 substances, which accounted for 36% of the 28 outlier substances, the toxicity of six (60%) was underpredicted, while the toxicity of four (40%) was overpredicted. Among the 31 outliers in the NHK NRU test method, nine (29%) are metabolized to active metabolites. Nine of the 19 substances known to produce active metabolites *in vivo* were discordant for the NHK NRU test method. NHK cells underpredicted the toxicity of five (56%) of these nine substances and overpredicted the other four (44%). These nine outlier substances accounted for 29% of the 31 outliers in the NHK NRU test method. Thus, the fact that a substance has active metabolites that are not expected to be produced in the *in vitro* tests does not necessarily indicate that its toxicity will be underpredicted by *in vitro* basal cytotoxicity test methods.

Similarly, Halle (1998, 2003) noted that the RC substances that required metabolic activation to produce *in vivo* toxicity were not necessarily outliers with respect to their fit to the RC millimole regression. They found that eight (50%) of the 16 substances that required metabolic activation to product toxicity were outliers (see **Table L3-3** in **Appendix L3**).

6.2.2.5 Mechanism of Toxicity

Substances whose mechanisms of toxicity would not be detected in the 3T3 or NHK cells would be expected to fit the RC millimole regression poorly. In particular, toxic mechanisms that include, for example, specific actions on the central nervous system (CNS) or the heart

are not expected to be active in the 3T3 or NHK cells. Neurotoxic mechanisms would include, for example, cholinesterase inhibition, CNS nicotinic receptor blockade or activation, or any activity other than membrane destabilization such as that produced by a solvent, or disturbance of energy utilization such as interruption of oxidative phosphorylation. Representative cardiotoxic mechanisms would include calcium channel blockage and beta-adrenergic receptor activation or blockage.

The 72 reference substances used to validate the 3T3 and NHK NRU test methods included 16 (22%) that had specific CNS toxicity (see **Table 6-4**). Of these 16 substances, 10 (63%) were outliers in both *in vitro* NRU test methods. Three of the six (50%) reference substances that are cardiotoxic were outliers in the 3T3 NRU test method and two (33%) were outliers in the NHK NRU test method. When all the reference substances with mechanisms that are not expected to be active in the 3T3 and NHK cells (i.e., in **Table 6-4**) are summed, 13/22 (59%) are outliers for the 3T3 NRU and 12/22 (55%) are outliers for the NHK NRU. These substances represented 13/28 (46%) and 12/31 (39%) of the total outlier substances for the 3T3 and NHK NRU test methods, respectively. Halle (1998, 2003) reported similar findings for the RC database (i.e., approximately half of the substances expected to be outliers based on their mechanisms of toxicity were outliers) (see **Appendix L3**).

| Table 6-4Substances With Mechanisms of Toxicity Not Expected to Be Active in the 3T3 or NHK Cells in Culture |
|--|
|--|

| Substance | Mechanism of Toxicity ¹ | 3T3 Outlier ² | NHK Outlier ² |
|-------------------|---|--------------------------|--------------------------|
| | Neurotoxic | | |
| Atropine sulfate | Antimuscarinic; anticholinergic action; competitive antagonism of anticholinesterase at cardiac and CNS receptor sites. | No | No |
| Caffeine | Inhibition of phosphodiesterase leading to AMP accumulation; translocation of intracellular Ca ⁺⁺ ; adenosine receptor antagonism; neurotoxic. | No | Yes |
| Carbamazepine | Therapeutically decreases firing of noradrenergic neurons. | No | No |
| Chloral hydrate | Potentiation of GABA _A receptor activity; inhibition of N-methyl-D-aspartate activity; modulation of 5-hydroxytryptamine ₃ receptor-mediated depolarization of the vagas nerve ³ . | No | No |
| Dichlorvos | Inhibition of acetylcholinesterase resulting in acetylcholine accumulation in CNS and effector organs. | Yes | Yes |
| Disulfoton | Inhibition of acetylcholinesterase resulting in acetylcholine accumulation in CNS and effector organs. | Yes | Yes |
| Endosulfan | Affects brain neurotransmitter levels ⁴ . | Yes | Yes |
| Fenpropathrin | Delays closure of sodium channel causing persistent depolarization of membrane. | Yes | Yes |
| Glutethimide | CNS depression; anticholinergic activity. | No | No |
| Haloperidol | Blocks dopamine receptors. | No | No |
| Lindane | CNS depression through inhibition of GABA receptor linked chloride channel at the picrotoxin binding site, leading to blockade of chloride influx into neurons. | Yes | No |
| Nicotine | Cholinergic block causing polarization of CNS and PNS synapses. | Yes | Yes |
| Parathion | Inhibition of acetylcholinesterase resulting in acetylcholine accumulation in CNS and effector organs. | Yes | Yes |
| Phenobarbital | CNS depression through inhibition of GABA synapses; inhibits hepatic NADH cytochrome oxidoreductase. | Yes | Yes |
| Physostigmine | Inhibition of acetylcholinesterase resulting in acetylcholine accumulation in CNS and effector organs. | Yes | Yes |
| Strychnine | Increases glutamic acid in the CNS. | Yes | Yes |
| | Cardiotoxic | | |
| Amitriptyline HCl | Blocks norepinephrine, 5-hydroxytryptamine, and dopamine presynaptic uptake; prevents reuptake of heart norepinephrine. | No | No |
| Digoxin | Impairs ion transport and increases sarcoplasmic calcium by binding to Na ⁺ /K ⁺ ATPase, increasing automaticity of cardiac cells. | Yes | No |

| Table 6-4 | Substances With Mechanisms of Toxicity Not Expected to Be Active in the 3T3 or NHK Cells in Culture |
|-----------|---|
|-----------|---|

| Substance | Mechanism of Toxicity ¹ | 3T3 Outlier ² | NHK Outlier ² |
|------------------------|---|--------------------------|--------------------------|
| Epinephrine bitartrate | Adrenergic receptor stimulation. | Yes | Yes |
| Potassium chloride | Disturbs cardiac membrane potential and electrical activity. | No | No |
| Procainamide HCl | Slows impulse conduction in the heart ⁵ . | No | No |
| Verapamil HCl | Inhibition of transmembrane Ca ⁺⁺ flux in excitatory tissues; alpha-adrenergic blockade. | Yes | Yes |

Abbreviations: NA=Not available or information not found; CNS=Central nervous system; GABA=Gamma aminobutyric

acid; PNS=Peripheral nervous system; NADH=Nicotine adenine dinucleotide (reduced).

¹From Ekwall et al. (1998) or Hazardous Substances Data Bank (NLM 2001, 2002) unless otherwise noted.

²As shown in **Table 6-3**.

³EPA (2000b). ⁴ATSDR (2000a).

⁵Hardman et al. (1996).

6.3 Improving the Prediction of *In Vivo* Rat Oral LD₅₀ Values from *In Vitro* IC₅₀ Data

Because the 3T3 and NHK IC_{50} – rat oral LD_{50} regressions were not significantly different from the RC regression for the same substances, the next step was an attempt to improve the RC millimole regression for the prediction of LD_{50} values from IC_{50} values. Because the validation study provided results similar to the RC, and because the RC database has more than 3.5 times the number of substances tested in the validation study, the RC rat data (282 substances) were used to determine the relationship between IC_{50} and LD_{50} . The RC data were used to develop two new regressions, the RC rat-only millimole regression and the RC rat-only weight regression. For reference, the original RC millimole regression, log LD_{50} (mmol/kg) = 0.435 x log IC_{50} (mM) + 0.625 (Halle 1998, 2003), is shown in **Table 6-5**.

6.3.1 <u>The RC Rat-Only Millimole Regression</u>

The first regression used the RC data for the 282 substances with rat LD_{50} data and the original units of mM for IC_{50} and mmol/kg for LD_{50} (see **Table 6-5** and **Figure 6-9**). Only rat data were used because:

- Rats and mice are not always equally sensitive to all substances
- The majority of acute oral LD₅₀ data used in the RC millimole regression were from studies using rats (282 rat data points versus 65 mouse data points) (Halle 1998, 2003)
- Most acute oral toxicity testing is performed with rats.

The RC rat-only millimole regression is applicable to substances of known molecular weight that are relatively pure.

Table 6-5Linear Regression Analyses to Improve the Prediction of Rodent Acute
Oral LD50 Values from In Vitro NRU IC50 Using the RC Database1

| Data Used | Slope | Intercept | \mathbf{R}^2 |
|--|-------|-----------|--------------------|
| 347 RC substances (282 rat and 65 mouse LD_{50} values) – millimole units ² | 0.435 | 0.625 | 0.452 ³ |
| 282 RC substances with rat LD_{50} data – millimole units ² | 0.439 | 0.621 | 0.452 |
| 282 RC substances with rat LD_{50} data – weight units ⁴ | 0.372 | 2.024 | 0.325 |

Abbreviations: NRU=Neutral red uptake; RC=Registry of Cytotoxicity; R^2 =Coefficient of determination. ¹Slopes of all regressions were significantly different (p <0.05) from zero at p <0.0001.

 ${}^{2}IC_{50}$ in mM; LD₅₀ in mmol/kg.

³Calculated from RC data (i.e., not reported by Halle [1998, 2003]).

 ${}^{4}IC_{50}$ in µg/mL; LD₅₀ in mg/kg.

Table 6-5 shows that the RC millimole regression using only rat acute oral LD_{50} data was essentially identical to the original regression that used both rat and mouse data. The slope changed from 0.435 to 0.439 and the intercept changed from 0.625 to 0.621; these changes were not statistically significantly different.

6.3.2 <u>The RC Rat-Only Weight Regression</u>

The second regression used the same RC rat acute oral LD_{50} data for the 282 substances but was calculated using weight units rather than millimolar units (see **Table 6-5** and **Figure 6**-

4b). Weight units (i.e., mg/kg for the LD_{50} and μ g/mL for the IC₅₀) were selected for the units of measurement because

- Millimole units are not applicable to mixtures and substances with unknown structures or molecular weights.
- They are the most practical, i.e., hazard classification in all regulatory systems is based on LD₅₀ values expressed in mg/kg (see **Table 1-2**).

The RC rat-only weight regression is applicable for use with complex mixtures, substances whose structures or molecular weights are unknown, and substances that are relatively impure (i.e., mixtures that are primarily composed of a named substance).


6.4 Accuracy of the 3T3 and NHK NRU Test Methods for Predicting GHS Acute Oral Toxicity Categories

Based on the correlations/regressions obtained between the 3T3 and NHK NRU IC_{50} values and the rat LD_{50} values, it is clear that these *in vitro* methods are not suitable as replacements for rodent acute oral toxicity tests. The use of *in vitro* methods to reduce animal use for rodent acute oral toxicity assays (i.e., to assist in determining the starting doses for *in vivo* assays) also depends upon their accuracy for the prediction of LD_{50} values. However, this latter (adjunct) use does not require the same precision in LD_{50} prediction as complete replacement would.

The NRU-predicted LD_{50} values were determined using the *in vitro* NRU IC₅₀ values in the RC rat-only regressions presented in **Table 6-5.** The predicted LD_{50} values were used to assign each substance to a predicted GHS acute oral toxicity category (UN 2005). The accuracy of the 3T3 and NHK NRU test methods for predicting GHS acute oral toxicity categories was determined by comparison with categorization based on rat acute oral LD_{50} data. The rationale for evaluating the accuracy of LD_{50} predictions was that the animal savings produced by using these *in vitro* NRU test methods to predict starting doses for rodent acute oral toxicity assays would be greatest when the starting dose is as close as possible to the LD_{50} . This approach was used because regulatory authorities use rodent acute oral toxicity test results for hazard classification and labelling of products to protect handlers and consumers.

The *in vitro* NRU test methods were evaluated for their ability to predict GHS acute oral toxicity categories using the two regressions presented in **Section 6.3**, the RC rat-only millimole regression and the RC rat-only weight regression. The same reference substances were evaluated for each regression. Sixty-seven and 68 substances were evaluated using the 3T3 and NHK NRU test methods, respectively. Of the original 72 reference substances tested, epinephrine bitartrate, colchicine, and propylparaben were excluded because they had no rat acute oral LD₅₀ reference data (see **Table 4-2**). Carbon tetrachloride and methanol were excluded from the 3T3 evaluations because no laboratory attained sufficient toxicity in any test for the calculation of an IC₅₀ (see **Table 5-4**). Carbon tetrachloride was excluded from the NHK evaluations because no laboratory attained sufficient toxicity in any test for the calculation of an IC₅₀ (see **Table 5-4**).





Abbreviations: RC=Registry of Cytotoxicity; R^2 =Coefficient of determination. Regressions calculated using IC₅₀ and rat oral LD₅₀ datapoints for 282 substances from the RC (see **Table 6-5**). For comparison with the NRU test method results and RC rat-only regressions, **Section 6.4.1** provides the accuracy analysis for the RC database used with the RC millimole regression. **Sections 6.4.2** and **6.4.3** provide the accuracy information for the 3T3 and NHK NRU test methods for the RC rat-only millimole regression and RC-rat only weight regression, respectively. A summary of predictivity³ is provided for each predicted toxicity category, along with the percentage of substances whose toxicity was underpredicted or overpredicted.

6.4.1 <u>Prediction of GHS Acute Oral Toxicity Category by the RC IC₅₀ Values Using the RC Millimole Regression</u>

Table 6-6 shows the concordance of the observed (i.e., *in vivo*) and predicted GHS acute oral toxicity categories (UN 2005) for the 347 RC IC₅₀ values in the RC millimole regression, log LD_{50} (mmol/kg) = 0.435 x log IC₅₀ (mM) + 0.625 (Halle 1998, 2003). Accuracy is the agreement of the *in vitro* category predictions with those based on the 347 rodent (282 rat and 65 mouse) oral LD_{50} values used in the RC database (Halle 1998, 2003). Substances for which the *in vitro* toxicity category prediction did not match the *in vivo* category were considered discordant for the GHS acute oral toxicity category predictions.

The overall accuracy of the RC IC₅₀ values for correctly predicting GHS acute oral toxicity classification category using the RC millimole regression was 40% (140/347substances) (**Table 6-6**). Rodent acute oral toxicity was overpredicted for 34% (118/347) and underpredicted for 26% (89/347) of the substances. For this analysis, with respect to the predictions of each GHS category:

- None (0%) of the 12 substances with $LD_{50} < 5 \text{ mg/kg}$ (GHS Category I) was correctly predicted.
- Four (15%) of 26 substances in the 5 < LD₅₀ ≤50 mg/kg category (GHS Category II) were correctly predicted.
- Twenty (29%) of 69 substances in the $50 < LD_{50} \le 300$ mg/kg category (GHS Category III) were correctly predicted.
- Ninety-seven (69%) of 140 substances in the $300 < LD_{50} \le 2000 \text{ mg/kg}$ category (GHS Category IV) were correctly predicted. This toxicity category was also predicted for 106 other substances (52%; 106/203) that did not fall in this category. Thus, the overall predictivity for this category was 48% (97/203 substances predicted for this category matched the *in vivo* category).
- Fourteen (25%) of the 56 substances in the $2000 < LD_{50} \le 5000 \text{ mg/kg}$ category (GHS Category V) were correctly predicted.
- Five (11%) of the 44 substances with LD₅₀ >5000 mg/kg (GHS Unclassified) were correctly predicted.

³ Proportion of correct *in vivo* category matches for all substances with *in vitro* predictions for a particular category. Predictivity is one of the measures of test accuracy (ICCVAM 2003).

| Table 6-6 | Prediction of GHS Acute Oral Toxicity Category by the RC IC ₅₀ Values and the RC Millimole Regression ¹ |
|-----------|---|
| | |

| In Vivo Rodent Oral | | | IC ₅₀ -Predicted G | HS Category (mg/kg) |) ³ | | Total | Accuracy | Toxicity Over- predicted | Toxicity Under- |
|---------------------------|---------------------|-----------------------|-------------------------------|------------------------------|---------------------------|------------------------|-------|----------|--------------------------------|--------------------|
| LD_{50}^{2} (mg/kg) | LD ₅₀ <5 | $5 < LD_{50} \leq 50$ | $50 < LD_{50} \le 300$ | 300 < LD ₅₀ ≤2000 | $2000 < LD_{50} \le 5000$ | LD ₅₀ >5000 | Totai | | | predicted |
| LD ₅₀ < 5 | 0 | 5 | 3 | 4 | 0 | 0 | 12 | 0% | 0% | 100% |
| $5 < LD_{50} \le 50$ | 0 | 4 | 13 | 9 | 0 | 0 | 26 | 15% | 0% | 85% |
| $50 < LD_{50} \le 300$ | 0 | 9 | 20 | 38 | 2 | 0 | 69 | 29% | 13% | 58% |
| $300 < LD_{50} \le 2000$ | 0 | 4 | 24 | 97 | 14 | 1 | 140 | 69% | 20% | 11% |
| $2000 < LD_{50} \le 5000$ | 0 | 1 | 5 | 36 | 14 | 0 | 56 | 25% | 75% | 0% |
| LD ₅₀ >5000 | 0 | 0 | 1 | 19 | 19 | 5 | 44 | 11% | 89% | 0% |
| Total | 0 | 23 | 66 | 203 | 49 | 6 | 347 | 40% | 34% | 26% |
| Predictivity | 0% | 17% | 30% | 48% | 29% | 83% | | | | |
| Category Overpredicted | 0% | 61% | 45% | 27% | 39% | 0% | | | | |
| Category Underpredicted | 0% | 22% | 24% | 25% | 33% | 17% | | | | |

Abbreviations: GHS=Globally Harmonized System of Classification and Labelling of Chemicals (UN 2005); RC=Registry of Cytotoxicity. Shaded cells are those containing the correct predictions; RTECS[®]=Registry of Toxic Effects for Chemical Substances[®]. ¹The RC millimole regression is log LD₅₀ (mmol/kg) = log IC₅₀ (mM) x 0.435 + 0.625. Numbers in table represent numbers of substances.

²Rat (282 values) and mouse (65 values) oral LD₅₀ values, mostly from the 1983/84 RTECS[®] that were converted to mmol/kg for used in the RC (Halle 1998, 2003).

³IC₅₀ values from the RC are geometric mean IC₅₀ values from *in vitro* cytotoxicity assays using multiple cell lines and cytotoxicity endpoints (Halle 1998,

2003). GHS categories were predicted by using the IC_{50} values to calculate predicted LD_{50} values with the RC millimole regression equation. Predicted LD_{50} values in mmol/kg for each substance were converted to mg/kg and used to classify the substance in the appropriate predicted GHS acute oral toxicity category.

The highest accuracy, 69%, for the RC IC₅₀ values in the RC millimole regression were obtained for substances in the $300 < LD_{50} \le 2000$ mg/kg category (GHS Category IV). The lowest accuracy, 0%, was obtained for substances with $LD_{50} < 5$ mg/kg (GHS Category I). Although the 11% accuracy was low for substances with $LD_{50} > 5000$ mg/kg (GHS Unclassified), the highest predictivity, 83%, was obtained for substances in this group. The RC millimole regression generally underpredicted toxicity for substances in the highest toxicity (i.e., lowest LD_{50}) categories and overpredicted for substances in the lowest toxicity (i.e., highest LD_{50}) categories (see **Table 6-6**).

Rodent acute oral toxicity was overpredicted for 34% (118) and underpredicted for 26% (89) of the 347 RC substances. Thus, there was a total of were 207 discordant substances. GHS category was overpredicted for 57% (118/207) of the discordant substances and underpredicted for 43% (89/207) of the discordant substances.

6.4.2 <u>Prediction of GHS Acute Oral Toxicity Category by the 3T3 and NHK NRU Test</u> Methods Using the RC Rat-Only Millimole Regression

Table 6-7 shows the concordance of the observed (i.e., *in vivo*) and predicted GHS acute oral toxicity categories (UN 2005) for each *in vitro* test method using the geometric mean IC₅₀ values (of the three laboratories) in the RC rat-only millimole regression, log LD₅₀ (mmol/kg) = 0.439 x log IC₅₀ (mM) + 0.621. Accuracy is the agreement of the *in vitro* category predictions with those based on the rat acute oral LD₅₀ reference values in **Table 4-**2. Substances for which the *in vitro* toxicity category prediction did not match the *in vivo* category were considered discordant for the GHS acute oral toxicity category predictions.

6.4.2.1 In Vitro – In Vivo Concordance Using the RC Rat-Only Millimole Regression The overall accuracy of the 3T3 NRU test method for correctly predicting GHS acute oral toxicity classification category using the RC rat-only millimole regression was 31% (21/67 substances) (**Table 6-7**). Rat acute oral toxicity was overpredicted for 34% (23) and underpredicted for 34% (23) of the substances. For this analysis, with respect to the predictions of each GHS category:

- None (0%) of the six substances with LD₅₀ <5 mg/kg (GHS Category I) was correctly predicted.
- One (9%) of 11 substances in the 5 < LD₅₀ ≤50 mg/kg category (GHS Category II) was correctly predicted.
- Five (42%) of 12 substances in the 50 < LD₅₀ ≤300 mg/kg category (GHS Category III) were correctly predicted.
- Thirteen (81%) of 16 substances in the $300 < LD_{50} \le 2000$ mg/kg category (GHS Category IV) were correctly predicted. This toxicity category was also predicted for 32 other substances (71%; 32/45) that did not fall in this category. Thus, the overall predictivity for this category was 29% (13/45 substances predicted for this category matched the *in vivo* category).
- None (0%) of the 10 substances in the 2000 < LD₅₀ ≤5000 mg/kg category (GHS Category V) were correctly predicted.
- Two (17%) of the 12 substances with $LD_{50} > 5000 \text{ mg/kg}$ (GHS Unclassified) were correctly predicted.

| Reference Rat Oral | | | 3T3 -Predicted (| GHS Category (mg/kg | ;) | | | Fotal Accuracy | Toxicity | Toxicity Under- predicted |
|---------------------------------------|---------------------|--|------------------------|------------------------------|---------------------------|------------------------|-----------------|----------------|--------------------|---------------------------------|
| LD ₅₀ ² (mg/kg) | LD ₅₀ <5 | $5 < LD_{50} \le 50$ | $50 < LD_{50} \le 300$ | 300 < LD ₅₀ ≤2000 | $2000 < LD_{50} \le 5000$ | LD ₅₀ >5000 | Total | Accuracy | Over- predicted | |
| LD ₅₀ < 5 | 0 | 2 | 0 | 4 | 0 | 0 | 6 ³ | 0% | 0% | 100% |
| $5 < LD_{50} \le 50$ | 0 | 1 | 6 | 3 | 1 | 0 | 114 | 9% | 0% | 91% |
| $50 < LD_{50} \le 300$ | 0 | 0 | 5 | 7 | 0 | 0 | 12 | 42% | 0% | 58% |
| $300 < LD_{50} \le 2000$ | 0 | 1 | 2 | 13 | 0 | 0 | 16 | 81% | 19% | 0% |
| $2000 < LD_{50} \leq 5000$ | 0 | 0 | 0 | 10 | 0 | 0 | 10 ⁵ | 0% | 100% | 0% |
| LD ₅₀ >5000 | 0 | 0 | 0 | 8 | 2 | 2 | 126,7 | 17% | 83% | 0% |
| Total | 0 | 4 | 13 | 45 | 3 | 2 | 67 | 31% | 34% | 34% |
| Predictivity | 0% | 25% | 38% | 29% | 0% | 100% | | | | |
| Category Overpredicted | 0% | 25% | 15% | 40% | 67% | 0% | | | | |
| Category Underpredicted | 0% | 50% | 46% | 31% | 33% | 0% | | | | |
| Reference Rat Oral | | NHK -Predicted Toxicity Category (mg/kg) | | | | | | A | Toxicity Over- | Toxicity Under- |
| LD_{50}^{2} | LD ₅₀ <5 | $5 < LD_{50} \le 50$ | $50 < LD_{50} \le 300$ | $300 < LD_{50} \le 2000$ | $2000 < LD_{50} \le 5000$ | LD ₅₀ >5000 | Total | Accuracy | predicted | predicted |
| LD ₅₀ <5 | 0 | 1 | 2 | 3 | 0 | 0 | 6 ³ | 0% | 0% | 100% |
| $5 < LD_{50} \le 50$ | 0 | 2 | 5 | 3 | 1 | 0 | 11 ⁴ | 18% | 0% | 82% |
| $50 < LD_{50} \le 300$ | 0 | 1 | 6 | 5 | 0 | 0 | 12 | 50% | 8% | 42% |
| $300 < LD_{50} \le 2000$ | 0 | 1 | 2 | 12 | 1 | 0 | 16 | 75% | 19% | 6% |
| $2000 < LD_{50} \le 5000$ | 0 | 0 | 0 | 10 | 0 | 0 | 10 ⁵ | 0% | 100% | 0% |
| LD ₅₀ >5000 | 0 | 0 | 0 | 7 | 6 | 0 | 13 ⁷ | 0% | 100% | 0% |
| Total | 0 | 5 | 15 | 40 | 8 | 0 | 68 | 29% | 40% | 31% |
| Predictivity | 0% | 40% | 40% | 30% | 0% | 0% | | | | |
| Category Overpredicted | 0% | 40% | 13% | 43% | 75% | 0% | | | | |
| Category Underpredicted | 0% | 20% | 47% | 28% | 25% | 0% | | | | |

Table 6-7 Prediction of GHS Acute Oral Toxicity Category by the 3T3 and NHK NRU Test Methods and the RC Rat-Only Millimole Regression¹

Abbreviations: GHS=Globally Harmonized System of Classification and Labelling of Chemicals (UN 2005); 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal

keratinocytes; NRU=Neutral red uptake; RC=Registry of Cytotoxicity. Shaded cells are those containing the correct predictions.

¹The RC rat-only millimole regression is log LD₅₀ (mmol/kg) = log IC₅₀ (mM) x 0.439 + 0.621. Numbers in table represent numbers of substances.

²Reference rat oral LD₅₀ values in mg/kg from **Table 4-2**. ³Epinephrine bitartrate excluded because no rat reference acute oral LD₅₀ was identified (see **Table 4-2**).

⁴Colchine excluded because no rat acute oral LD₅₀ was identified (see **Table 4-2**).

⁵Carbon tetrachloride excluded because no laboratory attained sufficient toxicity for the calculation of an IC₅₀.

⁶Methanol excluded because no laboratory attained sufficient toxicity for the calculation of an IC₅₀.

⁷Propylparaben excluded because no rat acute oral LD₅₀ was identified (see **Table 4-2**).

The overall accuracy of the NHK NRU test method for correctly predicting the GHS acute oral toxicity classification, when the prediction was based on the RC rat-only millimole regression, was 29% (20/68 substances) (see **Table 6-7**). Toxicity was overpredicted for 40% (27) and underpredicted for 31% (21) of the 68 substances. The pattern of concordance between *in vitro* and *in vivo* results for the NHK NRU test method with the RC rat-only millimole regression was similar to that for the 3T3 NRU test method with the exception that none of the substances with a toxicity of $LD_{50} >5000 \text{ mg/kg}$ were correctly predicted. For this analysis, with respect to the predictions of each GHS category:

- None (0%) of the six substances with LD₅₀ <5 mg/kg (GHS Category I) were correctly predicted.
- Two (18%) of 11 substances in the 5< LD₅₀ ≤50 mg/kg category (GHS Category II) were correctly predicted.
- Six (50%) of 12 substances in the 50< LD₅₀ ≤300 mg/kg category (GHS Category III) were correctly predicted.
- 12 (75%) of 16 substances in the 300< LD₅₀ ≤2000 mg/kg category (GHS Category IV) were correctly predicted; however, this category was also predicted for 28 (70%; 28/40) substances that did not match the category. Thus, the overall predictivity for this category was 30% (12/40).
- None (0%) of the 10 substances in the 2000< LD₅₀ ≤5000 mg/kg category (GHS Category V) were correctly predicted.
- None (0%) of the 13 substances with LD₅₀>5000 mg/kg (GHS Unclassified) were correctly predicted.

The RC rat-only millimole regression generally underpredicted toxicity for substances in the highest toxicity (i.e., lowest LD₅₀) categories and overpredicted toxicity for substances in the lowest toxicity (i.e., highest LD₅₀) categories (see **Table 6-7**). Although substances at the very low and high ends of the toxicity range were poorly predicted, those in the middle range (i.e., $300 < LD_{50} \le 2000 \text{ mg/kg}$) were predicted much better, with 75 to 81% accuracy. The pattern of accuracy for the GHS categories was similar to the pattern seen with the RC IC₅₀ and LD₅₀ values and the RC millimole regression (see **Table 6-6**) (i.e., lowest accuracy for very toxic and very nontoxic substances and highest accuracy for substances with 300 < LD₅₀ <2000 mg/kg).

6.4.2.2 Discordant Substances in the Prediction of GHS Acute Oral Toxicity Category by the 3T3 and NHK NRU Test Methods and the RC Rat-Only Millimole Regression Appendix L2 identifies the discordant substances, that is, those for which the *in vitro* predicted GHS acute oral toxicity category did not match the GHS acute oral toxicity category assigned based on the reference rat acute oral LD₅₀ data in Table 4-2. Of the total number of substances used for this evaluation (67 for 3T3, 68 for NHK), the 3T3 test method underpredicted the GHS category for 23 (50%) and overpredicted for 23 (50%) of the 46 discordant substances. The NHK test method underpredicted toxicity for 21 (44%) and overpredicted for 27 (56%) of the 48 discordant substances.

6.4.3 <u>Prediction of GHS Acute Oral Toxicity Category by the 3T3 and NHK NRU Test</u> <u>Methods Using the RC Rat-Only Weight Regression</u>

Table 6-8 shows the concordances of the observed and predicted GHS acute oral toxicity categories for each *in vitro* NRU method using the geometric mean IC₅₀ values from the

three laboratories and the RC rat-only weight regression (**Table 6-5**). The regression formula for the RC rat-only weight regression was $\log LD_{50}$ (mg/kg) = $\log IC_{50}$ (µg/mL) x 0.372 + 2.024. Accuracy is the agreement of the GHS acute oral toxicity category predictions made using the *in vitro* NRU data with those based on the reference rat acute oral LD₅₀ values (**Table 4-2**).

6.4.3.1 In Vitro – In Vivo Concordance Using the RC Rat-Only Weight Regression The overall accuracy of the 3T3 NRU test method with the RC rat-only weight regression was 31% (21/67) (**Table 6-8**). The toxicity was overpredicted for 33% (24) and underpredicted for 36% (22) of the substances. For this analysis, with respect to the predictions of the GHS category:

- None (0%) of the six substances with LD₅₀ <5 mg/kg (GHS Category I) were correctly predicted.
- One (9%) of 11 substances in the 5< LD₅₀ ≤50 mg/kg category (GHS Category II) was correctly predicted.
- Four (33%) of 12 substances in the 50< LD₅₀ ≤300 mg/kg category (GHS Category II) were correctly predicted; however, because 10 other substances were also predicted to be in this category, the overall predictivity was 29% (4/14).
- Twelve (75%) of 16 substances in the 300< LD₅₀ ≤2000 mg/kg category (GHS Category IV) were predicted correctly. Because a total of 40 substances were predicted to be in this category, the overall predictivity was 30% (12/40).
- Four (40%) of 10 substances in the 2000< LD₅₀ ≤5000 mg/kg category (GHS Category V) were correctly predicted; however, because a total of 11 substances were predicted to be in this category, the overall predictivity was 36% (4/11).
- None (0%) of the 12 substances with LD₅₀ >5000 mg/kg (GHS Unclassified) were correctly predicted.

The overall accuracy of the NHK predictions using the RC rat-only weight regression was 31% (21/68) (see **Table 6-8**). The *in vivo* GHS toxicity categories were overpredicted for 37% (22) and underpredicted for 32% (25) of the substances. For this analysis, with respect to the predictions of the GHS category:

- None (0%) of the six substances with $LD_{50} < 5 \text{ mg/kg}$ (GHS Category I) were correctly predicted.
- One (9%) of 11 substances in the 5 < LD₅₀ ≤ 50 mg/kg category (GHS Category II) was correctly predicted.
- Five (42%) of 12 substances in the $50 < LD_{50} \le 300$ mg/kg category (GHS Category III) were correctly predicted; however, because six other substances were also predicted to be in this category, the overall predictivity was 33% (3/9).
- Thirteen (81%) of 16 substances in the $300 < LD_{50} \le 2000 \text{ mg/kg}$ category (GHS Category IV) were predicted correctly; however, because 29 other substances were also predicted to be in this category, the overall predictivity was 31% (13/42).

| Reference Rat Oral | | | 3T3 -Predicted Tox | icity Category (mg/kg | g) | | | Accuracy | Toxicity Over- predicted | Toxicity Under- predicted |
|---|---------------------|--------------------------|----------------------------|------------------------------|-------------------------------|------------------------|-------------------|----------|--------------------------------|---------------------------------|
| LD ₅₀ ² (mg/kg) | LD ₅₀ <5 | 5 < LD ₅₀ ≤50 | 50 < LD ₅₀ ≤300 | 300 < LD ₅₀ ≤2000 | 2000 < LD ₅₀ ≤5000 | LD ₅₀ >5000 | Total | | | |
| LD ₅₀ <5 | 0 | 0 | 2 | 4 | 0 | 0 | 6 ³ | 0% | 0% | 100% |
| $5 < LD_{50} \le 50$ | 0 | 1 | 5 | 5 | 0 | 0 | 114 | 9% | 0% | 91% |
| $50 < LD_{50} \le 300$ | 0 | 0 | 4 | 8 | 0 | 0 | 12 | 33% | 0% | 67% |
| $300 < LD_{50} \le 2000$ | 0 | 1 | 3 | 12 | 0 | 0 | 16 | 75% | 25% | 0% |
| $2000 < LD_{50} \le 5000$ | 0 | 0 | 0 | 6 | 4 | 0 | 10 ⁵ | 40% | 60% | 0% |
| LD ₅₀ >5000 | 0 | 0 | 0 | 5 | 7 | 0 | 12 ^{6,7} | 0% | 100% | 0% |
| Total | 0 | 2 | 14 | 40 | 11 | 0 | 67 | 31% | 33% | 36% |
| Predictivity | 0% | 50% | 29% | 30% | 36% | 0% | | | | |
| Category Overpredicted | 0% | 50% | 21% | 28% | 64% | 0% | | | | |
| Category Underpredicted | 0% | 0% | 50% | 43% | 0% | 0% | | | | |
| | | I | NHK -Predicted To: | xicity Category (mg/k | g) | | | | | |
| Reference Rat Oral LD ₅₀ ² (mg/kg) | LD ₅₀ <5 | $5 < LD_{50} \le 50$ | 50 < LD ₅₀ ≤300 | 300 < LD ₅₀ ≤2000 | 2000 < LD ₅₀ ≤5000 | LD ₅₀ >5000 | Total | Accuracy | Toxicity Over- predicted | Toxicity Under- predicted |
| LD ₅₀ <5 | 0 | 1 | 2 | 3 | 0 | 0 | 6 ³ | 0% | 0% | 100% |
| $5 < LD_{50} \le 50$ | 0 | 1 | 5 | 5 | 0 | 0 | 114 | 9% | 0% | 91% |
| $50 < LD_{50} \le 300$ | 0 | 1 | 5 | 6 | 0 | 0 | 12 | 42% | 8% | 50% |
| $300 < LD_{50} \le 2000$ | 0 | 1 | 2 | 13 | 0 | 0 | 16 | 81% | 19% | 0% |
| $2000 < LD_{50} \le 5000$ | 0 | 0 | 0 | 9 | 1 | 0 | 105 | 10% | 90% | 0% |
| LD ₅₀ >5000 | 0 | 0 | 0 | 6 | 6 | 1 | 13 ⁷ | 8% | 92% | 0% |
| Total | 0 | 4 | 14 | 42 | 7 | 1 | 68 | 31% | 37% | 32% |
| Predictivity | 0% | 25% | 36% | 31% | 14% | 100% | | | | |
| Category Overpredicted | 0% | 50% | 14% | 36% | 86% | 0% | | | | |
| Category Underpredicted | 0% | 25% | 50% | 33% | 0% | 0% | | | | |

Table 6-8 Prediction of GHS Acute Oral Toxicity Category by the 3T3 and NHK NRU Test Methods and the RC Rat-Only Weight Regression¹

Abbreviations: GHS=Globally Harmonized System of Classification and Labelling of Chemicals (UN 2005); 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal

keratinocytes; NRU=Neutral red uptake; RC=Registry of Cytotoxicity.

¹The RC rat-only weight regression is $\log LD_{50}$ (mg/kg) = $\log IC_{50}$ (µg/mL) x 0.372 + 2.024.

²Reference rat oral LD₅₀ values in mg/kg from **Table 4-2**.

³Epinephrine bitartrate excluded because no rat acute oral LD₅₀ was identified (see Table 4-2).

⁴Colchine excluded because no rat acute oral LD₅₀ was identified (see **Table 4-2**).

⁵Carbon tetrachloride excluded because no laboratory attained sufficient toxicity for the calculation of an IC₅₀.

 6 Methanol excluded because no laboratory attained sufficient toxicity for the calculation of an IC₅₀- 7 Propylparaben excluded because no rat acute oral LD_{50} was identified (see **Table 4-2**).

- One (10%) of 10 substances in the 2000 < LD₅₀ ≤5000 mg/kg category (GHS Category V) was correctly predicted.
- One (8%) of 13 substances with LD₅₀ >5000 mg/kg (GHS Unclassified) was correctly predicted.

The RC rat-only weight regression generally underpredicted toxicity for substances in the highest toxicity (i.e., lowest LD₅₀) categories and overpredicted toxicity for substances in the lowest toxicity (i.e., highest LD₅₀) categories (see **Table 6-8**). Although substances at the very low and high ends of the toxicity range were poorly predicted, those in the middle range (i.e., $300 < LD_{50} \leq 2000 \text{ mg/kg}$) were predicted much better, with 75 to 81% accuracy. The pattern of accuracy for the GHS categories was similar to the pattern seen with the RC IC₅₀ and LD₅₀ values and the RC millimole regression (see **Table 6-6**) and with the NRU IC₅₀ and rat oral LD₅₀ values and the RC rat-only millimole regression (see **Table 6-7**) (i.e., lowest accuracy for very toxic and very nontoxic substances and highest accuracy for substances with $300 < LD_{50} \leq 2000 \text{ mg/kg}$).

6.4.3.2 Discordant Substances in the Prediction of GHS Acute Oral Toxicity Category by the 3T3 and NHK NRU Test Methods and the RC Rat-Only Weight Regression

Appendix L2 shows the substances for which the *in vitro* predicted GHS acute oral toxicity category using the RC rat-only weight regression did not match those that were based on the rat acute oral LD₅₀ reference data. The two *in vitro* NRU test methods over- and underpredicted the GHS acute oral toxicity category for similar numbers of substances, compared with the GHS acute oral toxicity categories for the rat acute oral LD₅₀ reference values in **Table 4-2**. The 3T3 NRU test method overpredicted the GHS acute oral toxicity category for 22 (48%) of 46 discordant substances, and underpredicted of 24 (52%) substances. The NHK NRU test method overpredicted the GHS acute oral toxicity category for 25 (53%) of 47 discordant substances, and underpredicted 22 (47%) substances.

6.4.4 <u>Summary of the Regressions Evaluated</u>

Table 6-9 summarizes the regressions evaluated in Section 6.4 for accuracy in predicting the GHS acute oral toxicity categories (UN 2005), and the proportion of over- or underpredictions. Prediction accuracy using the RC IC₅₀ and LD₅₀ values and the RC millimole regression was higher that that for the NRU test methods with the RC rat-only regressions (i.e., 40% for the RC vs. 29% to 31% for the NRU test methods). Prediction accuracy was slightly higher for the 3T3 NRU test method compared with the NHK NRU (i.e., 31% for 3T3 vs. 29% for NHK) using the RC rat-only millimole regression, and the same as the NHK NRU test method (i.e., 31%) using the RC rat-only weight regression. The proportion of discordant substances using the RC IC₅₀ values and the RC millimole regression (60%) was lower than that using the in vitro NRU test methods and the RC rat-only regressions (69% to 71%). The proportion of discordant substances from the 3T3 test method, 69%, was the same whether it was determined with the RC rat-only millimole regression or the RC rat-only weight regression. The proportion of discordant substances for the NHK test method was slightly lower with RC rat-only weight regression than with the RC rat-only millimole regression (69% vs. 71%). The RC IC₅₀ values and the RC millmole regression were expected to perform better than the in vitro NRU methods and the RC rat-only regressions since the IC₅₀ and LD₅₀ values used to evaluate the performance of the RC millimole regression were exactly the same as those used to calculate the linear regression formula. The NRU IC_{50} values and the reference oral LD_{50} values used to evaluate the RC rat-only regressions were different from those used to calculate the RC rat-only regressions.

Table 6-9Comparison of Regressions and In Vitro NRU Test Methods for Their
Performance in Predicting GHS Acute Oral Toxicity Categories

| Regression | N^1 | R ² Statistic | Accuracy | Discordant Substances ² |
|------------------------------------|-------|--------------------------|---------------------------|-------------------------------------|
| RC millimole ³ | 347 | 0.452 | RC IC ₅₀ – 40% | RC IC ₅₀ – 207/347 (60%) |
| RC rat-only millimole ³ | 282 | 0.452 | 3T3-31% NHK-29% | 3T3-46/67(69%) NHK-48/68 (71%) |
| RC rat-only weight ³ | 282 | 0.325 | 3T3-31% NHK-31% | 3T3-46/67 (69%) NHK-47/68 (69%) |

Abbreviations: GHS=Globally Harmonized System of Classification and Labelling of Chemicals (UN 2005); 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake; RC=Registry of Cytotoxicity; R²=Coefficient of determination.

¹Number of substances used in regression.

²Proportion of discordant substances.

³From **Table 6-5**.

The accuracy of the GHS category predictions using the *in vitro* NRU test methods with the RC rat-only regressions obtained for the reference substances from this validations study may or may not be applicable to other substances. A number of reasons may explain the low accuracy for the reference substances. One is the skewness of the substances selected for testing with respect to fit to the RC millimole regression (see **Figure 3-1**). **Table 3-4** shows that 22 (38%) of the 58 RC substances selected for testing were known to poorly fit the RC millimole regression (i.e., the predicted LD₅₀ was outside the RC acceptance interval). Toxicity was underpredicted for 17 (77%) of these outlier substances and overpredicted (i.e., predicted LD₅₀ was lower than measured *in vivo* LD₅₀) for the reference substances that yielded IC₅₀ values were outliers. Other reasons for the low accuracy for GHS acute oral toxicity prediction, such as those discussed in **Section 1.2.3**, include the major differences between cell cultures and whole animals regarding the absorption, distribution (including binding to serum proteins), availability, metabolism, and excretion of reference substances.

6.5 Correlation of NRU Concentration-Response Slope with Rat Lethality Dose-Response Slope

Because the slope calculations available for the NRU concentration-response curve analyses were based on the Hill function, the SMT determined whether the Hill Slope correlated with the rodent dose-mortality slope. If the two were correlated, the Hill Slope from the NRU test methods could be used to estimate the dose-mortality slope, which could, in turn, be used to estimate the most appropriate dose progression for UDP testing in rodents. A more immediate use for the validation study results, however, would be for the computer simulation modeling of animal testing for the UDP and ATC acute oral toxicity methods (described in **Sections 10.2** and **10.3**).

Dose-mortality slope information was available for 22 of the 72 reference substances, as shown in **Table 6-10**. Hill function slopes were available for 20 and 21 of the 22 substances

for the 3T3 and the NHK NRU test methods, respectively. The Hill function slopes were transformed to absolute values because geometric means cannot be calculated for negative numbers, and geometric mean Hill function slopes were calculated for the acceptable NRU tests for each reference substance. When there was more than one dose-mortality slope available for a substance, a geometric mean was calculated from the available values. The absolute values of the geometric mean Hill function slopes are plotted against the geometric mean dose-mortality slopes in **Figure 6-5**. To determine whether there was a relationship between the absolute value of the Hill Slope and the dose-mortality slope, Spearman correlation analyses and least squares linear regression analyses were performed for each method. Both analyses showed that the absolute value of the in vitro Hill function slope was not related to the dose-mortality slope. The Spearman correlation analysis yielded nonsignificant correlations for both in vitro NRU test methods (3T3 r_s=-0.051 with p=0.831, and NHK r_s =-0.142 with p=0.541). Linear regression analyses for the prediction of dosemortality slope by the absolute value of the Hill function slope also showed that the slopes of the regressions were not significantly different from zero (3T3 p=0.774, and NHK p=0.994). Because there was no relationship between Hill function slope and dose-mortality slope, the Hill function slope was not used to predict the dose-mortality slope for the simulation modeling of animal testing for the UDP and ATC acute oral toxicity methods in Sections 10.2 and 10.3.

| Reference Substance | Dose-Mortality Slope ¹ | 3T3 Hill Slope ² | NHK Hill Slope ² |
|----------------------------|-----------------------------------|-----------------------------|-----------------------------|
| Acetylsalicylic acid | 1.45 | 1.658 | 1.906 |
| Boric acid | 7.70 | 1.511 | 1.083 |
| Caffeine | 6.27 | 1.069 | 1.215 |
| Carbon tetrachloride | 2.06 | NA | NA |
| Dichlorvos | 1.24 | 2.240 | 1.383 |
| Dimethylformamide | 1.11 | 1.875 | 3.157 |
| Diquat dibromide | 16.57 | 4.273 | 1.289 |
| Ethanol | 4.57 | 1.725 | 2.049 |
| Ethylene glycol | 38.38 | 2.016 | 2.904 |
| Glycerol | 8.90 | 1.941 | 2.398 |
| Hexachorophene | 12.84 | 1.466 | 2.470 |
| Lactic acid | 4.04 | 4.541 | 2.934 |
| Methanol | 8.53 | NA | 1.173 |
| Nicotine | 3.00 | 11.019 | 0.682 |
| Parathion | 1.31 | 1.551 | 1.467 |
| Potassium cyanide | 14.50 | 1.931 | 1.207 |
| Sodium arsenite | 7.60 | 2.317 | 1.717 |
| Sodium I fluoride | 1.26 | 3.952 | 2.569 |
| Trichloroacetic acid | 20.97 | 1.883 | 1.369 |
| Triethylene melamine | 2.10 | 0.963 | 1.355 |
| Valproic acid | 1.20 | 2.467 | 1.440 |
| Xylene | 9.60 | 1.871 | 2.452 |
| Carbon tetrachloride | 2.06 | NA | NA |

 Table 6-10
 Reference Substances with Dose-Mortality and NRU Hill Slopes

Abbreviations: 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake; NA=Not available.

¹Geometric mean if there was more than one value for each substance (from Appendix H2).

²Geometric mean of absolute values from acceptable *in vitro* NRU tests.




Figure 6-5 Correlation of Dose-Mortality Slope to Hill Function Slope

Abbreviations: 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake. Hill function slopes and dose-mortality slopes for the reference substances shown in **Table 6-10** for (a) the 3T3 data and (b) the NHK data. The solid line indicates the theoretical, one-to-one correspondence of Hill function slope with dose-mortality slope. Spearman's correlation coefficients were $r_s=-0.051$ (p=0.831) for the 3T3 and $r_s=-0.142$ (p=0.541) for the NHK data.

6.6 Strengths and Limitations of the Use of *In Vitro* Cytotoxicity Test Methods with the IC₅₀-LD₅₀ Regressions for Prediction of Rodent Acute Oral Toxicity

6.6.1 *In Vitro* Cytotoxicity Methods

The NRU basal cytotoxicity methods tended to underpredict the toxicity of the most toxic substances and to overpredict the toxicity of the least toxic substances for each regression evaluated. The 3T3 and NHK NRU test methods were best at predicting the toxicity of substances with $300 < LD_{50} \le 2000$ mg/kg. The accuracy of the *in vitro* prediction of this GHS category using the RC rat-only millimole regression and the RC rat-only weight regression was 75-81%. GHS toxicity categories of substances with higher or lower LD₅₀ values were correctly predicted with less than 50% accuracy. The worst accuracy, 0%, was observed for:

- Substances with $LD_{50} \leq 5$ mg/kg in both *in vitro* test methods and regressions
- Substances with 2000< $LD_{50} \leq 5000 \text{ mg/kg}$ using 3T3 with the RC rat-only millimole regression
- Substances with 2000< $LD_{50} \le 5000 \text{ mg/kg}$ or $LD_{50} \ge 5000 \text{ mg/kg}$ using NHK with RC rat-only millimole regression
- Substances with LD₅₀>5000 mg/kg using 3T3 with RC rat-only weight regression

Some substances with low toxicity and low solubility could not be tested in the in vitro NRU test methods because the concentration of dissolved substance was inadequate to obtain an IC_{50} value. None of the laboratories obtained adequate toxicity in any of the 3T3 tests of carbon tetrachloride or methanol, and at least one laboratory failed to achieve adequate toxicity with gibberellic acid or xylene. No laboratory achieved adequate toxicity in any of the NHK experiments with carbon tetrachloride, and at least one laboratory could not achieve adequate toxicity with methanol, 1,1,1-trichloroethane, or xylene. Another limitation of use of the *in vitro* test methods is in the testing of substances that come out of solution by forming a film on the medium surface or plastic well wall (i.e., "film out"), and for substances that etch the laboratory ware plastics (ICCVAM 2006). Substances that etch plastics can be detected by looking for the presence of etched rings in the 96-well plates after exposure. Some substances that produce films in medium also etch plastic. The prediction of rodent acute oral toxicity (and the starting doses for acute oral toxicity tests) by the *in vitro* NRU methods is expected to be poor for substances with mechanisms of toxicity that are not effective in the 3T3 and NHK cells. Such toxic mechanisms include specific, receptor-mediated actions on the CNS or the heart.

The evaluation of the 3T3 and NHK NRU test methods for predicting starting doses for rodent acute oral toxicity testing with its potential to reduce and refine animal use is provided in **Section 10**.

6.6.2 <u>Use of Mole-Based vs. Weight-Based Regressions for the Prediction of Toxicity</u> for Low and High Molecular Weight Substances

The ICCVAM ATWG expressed concern that the RC rat-only weight regression may less accurately predict the toxicity of low and high molecular weight substances than the RC rat-only millimole regression. Using the RC IC_{50} and LD_{50} values for the 282 RC substances with rat oral LD_{50} data, analyses were performed to:

- Determine the difference in the over and under-prediction of rodent acute oral toxicity (i.e., LD₅₀) from IC₅₀ values between low molecular weight substances (i.e., ≤100 g/mole) and substances with molecular weights >100 g/mole
- Determine the difference in the over and under-prediction of rodent acute oral toxicity from IC₅₀ values between high molecular weight substances (i.e., ≥400 g/mole) vs. substances with molecular weights <400 g/mole.
- Compare the RC rat-only millimole regression with the RC rat-only weight regression with respect to the over- and under-prediction of the toxicity of low and high molecular weight substances

This analysis used the RC data rather than the validation studies data because the RC contains data for many more substances. The analysis assumes that the regressions either underpredicted or overpredicted the toxicity of all of the substances evaluated. In other words, there was a difference between the LD_{50} predicted by the regression and the *in vivo* LD_{50} used to calculate the regression even if it was a tiny fraction (i.e., no substances fit the regression exactly). The complete analysis and discussion are presented in **Appendix J7**. Of the 282 RC substances with rat acute oral LD_{50} values, there were 51 with molecular weights ≤ 100 g/mole and 231 with molecular weights >100 g/mole. For the 51 substances with molecular weight ≤ 100 g/mole, the RC rat-only millimole regression underestimated the toxicity of 20/51 (39%) substances and overestimated the toxicity of 24/51 (47%) substances and overestimated the toxicity of 27/51 (53%) substances. Fisher's exact test indicated that there was no difference between the millimole and weight regressions with respect to the under or over-prediction of toxicity for the low molecular weight substances (two-tailed p=0.549) (see **Table 6-11**).

For the 231 substances with molecular weights >100 g/mole, the RC rat-only millimole regression underestimated the toxicity of 108/231 (47%) substances and overestimated the toxicity of 123/231 (53%). The RC rat-only weight regression underestimated the toxicity of 101/231 (44%) substances and overestimated the toxicity of 130/231 (57%). Fisher's exact test indicated that there were no significant differences between the millimole and weight regressions for the under- and over-prediction of toxicity for the 231 substances with molecular weight >100 g/mole (two-tailed p=0.575). Fisher's exact test also showed that there were no significant differences in the under- and over-prediction of the toxicity of the 51 substances with molecular weight \leq 100 g/mole compared to the under- and over-prediction of the toxicity of the 231 with molecular weight >100 g/mole (two-tailed p=0.355 for the RC rat-only millimole regression).

Table 6-11Over- and Under- Prediction of Toxicity for Low and High Molecular
Weight Substances Using RC Rat-Only Weight and Millimole
Regressions

| Comparison | For | Fisher's Exact Test ¹ |
|---|---|-------------------------------------|
| RC rat-only millimole vs. RC rat-only weight regression | Under- and over-prediction of toxicity for 51 substances with molecular weight ≤100 g/mole | 0.549 |
| RC rat-only millimole vs. RC rat-only weight regression | Under- and over-prediction of toxicity for 231 substances with molecular weight >100 g/mole | 0.575 |
| 51 Low molecular weight (≤100 g/mole) substances vs. 231 other substances (>100 g/mole) | RC rat-only millimole regression | 0.355 |
| 51 Low molecular weight (≤100 g/mole) substances vs. 231 other substances (>100 g/mole) | RC rat-only weight regression | 0.756 |
| RC rat-only millimole vs. RC rat-only weight regression | Under- and over-prediction of toxicity for 20 substances with molecular weight ≥400 g/mole | 0.480 |
| RC rat-only millimole vs. RC rat-only weight regression | Under- and over-prediction of toxicity for 262 substances with molecular weight <400 g/mole | NT |
| 20 High molecular weight substances (≥400 g/mole) vs. 262 other substances (<400 g/mole) | RC rat-only millimole regression | 0.362 |
| 20 High molecular weight substances (≥400 g/mole) vs. 262 other substances (<400 g/mole) | RC rat-only weight regression | 0.033 |

Abbreviations: RC=Registry of Cytotoxicity; NT=Not tested because the proportions were the same. Toxicity was underpredicted for 121/262 (46%) substances and overpredicted for 141/262 (54%) substances. ¹P-values.

Of the 282 RC substances with rat acute oral LD_{50} values, there were 20 with molecular weights \geq 400 g/mole and 262 with molecular weights <400 g/mole. The RC rat-only millimole regression underestimated the toxicity of 7/20 (35%) of the \geq 400 g/mole substances and overestimated 13/20 (65%). The RC rat-only weight regression underestimated the toxicity of 4/20 (20%) of the substances and overestimated 16/20 (80%). Fisher's exact test indicated that there were no differences between the millimole and weight regressions for the under- and over-prediction of toxicity for the 20 high molecular weight substances (two-tailed p=0.4801).

For the remaining 262 substances with molecular weights <400 g/mole, both the RC rat-only millimole and the RC rat-only weight regressions underestimated the toxicity of 121/262 (46%) substances and overestimated 141/262 (54%). Thus, there were no statistical differences in the under- and over-esimation of toxicity for the 262 substances with molecular weights <400 g/mole regardless of which regression was used. Fisher's exact test also showed that there was no statistical difference in the under- and over-prediction of the toxicity of substances with high molecular weight (\geq 400 g/mole) compared with the under- and over-prediction the lower molecular weight substances using the RC rat-only millimole regression (two-tailed p=0.362). In contrast the use of the RC rat-only weight regression, resulted in a small but statistically significant difference in the under- and over-prediction of

the toxicity of substances with high molecular weight (>400 g/mole) compared with the under- and over-prediction of the toxicity of substances with lower molecular weight (two-tailed p=0.033). The weight-based regression significantly overestimated the toxicity of the high molecular weight substances (compared with substances with lower molecular weight) while the millimole regression did not.

6.7 Salient Issues of Data Interpretation

One of the most important considerations for the 3T3 and NHK NRU test methods, as for any test method, is the ability to generate good concentration-response results. In addition to technical difficulties with these test methods, such as occasional poor cell growth and the formation of NRU crystals, this validation study yielded non-monotonic concentrationresponse curves for certain substances.

A number of substances produced non-monotonic concentration-response curves in the 3T3 and/or the NHK NRU range finding or definitive tests. Because the *in vitro* NRU test methods, and the calculation of IC_{50} values from the resulting concentration curves, presume that the toxic response is linear, the data from non-linear responses (e.g., biphasic curves), as seen with aminopterin, do not always permit an IC_{50} determination by the standard Hill function analysis. In such cases, the lowest concentration that killed approximately 50% of the cells in the range finding test was used to set the concentration range for the definitive test. The definitive test used more closely spaced concentrations in an attempt to obtain a monotonic concentration-response curve. However, 100% toxicity (or 0%) viability was often unattainable in such definitive tests that exhibited a plateau of toxicity well over 0% viability (e.g., 20%). Care must be used in the calculation of the IC_{50} for curves for which toxicity plateaus to assure that the value reflects the concentration at 50% inhibition of the VC value rather than simply the midpoint of the highest and lowest response.

Because of low toxicity and/or low solubility, some substances did not produce sufficient toxicity for the calculation of an IC_{50} value. Carbon tetrachloride, methanol, xylene, gibberellic acid, lithium carbonate, and 1,1,1-trichloroethane failed to yield acceptable IC_{50} results in at least one laboratory because of insufficient toxicity. All of these substances, with the exception of methanol, produced precipitate in the cell culture medium.

6.8 Comparison of NRU Test Results to Established Performance Standards

The *Guidance Document* method of evaluating *in vitro* basal cytotoxicity assays for predicting starting doses for rodent acute oral toxicity assays provides the existing performance standard (ICCVAM 2001b) for the 3T3 and NHK NRU test methods. The *Guidance Document* recommends testing 10 to 20 reference substances from the RC in an *in vitro* basal cytotoxicity assay for predicting starting doses for rodent acute oral toxicity testing (ICCVAM 2001b). These substances should cover a wide range of toxicity and fit the RC millimole regression as closely as possible. The *Guidance Document* recommends using the IC₅₀ results for the selected reference substances from the candidate method to calculate a new regression line with the LD₅₀ values used by the RC. If the resulting regression is parallel to the RC millimole regression and within the $\pm \log 5$ (i.e., ± 0.699) prediction interval for the RC, candidate assay may be considered effective for predicting starting doses for substances in rodent acute oral toxicity assays.

One goal of the testing in Phases Ib and II of this study was to establish whether the results from the 3T3 and NHK NRU test methods were consistent with the RC millimole regression. As discussed in **Section 3.3.5**, two of the major criteria for selecting the 12 coded substances tested from the 72 reference substances were:

- (a) Two substances must be included from each of the unclassified and classified GHS acute oral toxicity categories, and
- (b) The substances must fit as closely to the RC millimole regression as possible.

Unfortunately, the SMT could not identify 12 substances that fit both criteria because there was only one substance, aminopterin, in the $LD_{50} < 5$ mg/kg category that fit the RC millimole regression. The other substance chosen from that toxicity category was sodium selenate. Because sodium selenate was not included in the RC, there was no indication of how closely it would fit the RC millimole regression, and it was therefore not included in the Phases Ib and II regression analyses. The other 10 substances selected for testing in Phases Ib and II were colchicine, arsenic trioxide, cadmium chloride, sodium fluoride, propranolol, lithium carbonate, potassium chloride, chloramphenicol, 2-propanol, and ethylene glycol.

The geometric mean log IC₅₀ (mM) values from the 3T3 and NHK NRU test methods from each laboratory were used with the oral log rodent LD₅₀ (mmol/kg) values from the RC (see **Appendices J1** and **J2**) for the least squares linear regression analyses (see **Section 5.5.3.3**) for the substances tested in Phases Ib and II. The slopes for all regressions were significantly different from zero at p <0.0001, which indicated that there was a significant relationship between IC₅₀ and LD₅₀. The R² values for the regressions from each laboratory, shown in **Table 6-12**, show that the 3T3 NRU test method produced better-fitting regressions than the corresponding NHK NRU test method (R² = 0.940 to 0.953 vs. 0.577 to 0.621). The relatively low R² values for the NHK NRU test method were attributed to the much lower toxicity of aminopterin in those cells (see **Figures 6-6** to **6-8** and **Tables 5-3** and **5-4**). All test method and laboratory-specific regressions were consistent with the RC millimole regression. **Table 6-12** shows that all joint comparisons of slopes and intercepts with the RC millimole regression were not significant (i.e., p >0.01). The RC millimole regression slope and intercept were used as constants for this comparison.

A graphic comparison of the IC₅₀ regressions with the RC millimole regression as suggested by the *Guidance Document* (ICCVAM 2001b) demonstrated that they were generally within the RC millimole regression acceptance limits (see **Figures 6-6, 6-7,** and **6-8**). According to the *Guidance Document* (ICCVAM 2001b), *in vitro* basal cytotoxicity assays providing such consistency with the RC millimole regression are acceptable for predicting starting doses for rodent acute oral toxicity assays.

As an additional analysis, a regression for the 11 substances tested in Phases Ib and II (the RC-11 millimole regression), was calculated using the log RC IC₅₀ (mM) and log LD₅₀ (mmol/kg) values (see **Table 6-12**). Each of the laboratory regressions for each test method was then compared to the RC-11 regression using an F test for a joint comparison of slope and intercept. None of the regressions were significantly different from the RC-11 regression (p values ranged from 0.755 to 0.933).

| | | 3T3 Regressio | on ¹ | | |
|------------|-----------------------------|----------------------|--------------------------------|--|---|
| Laboratory | Intercept | Slope | R² Statistic | Test Against RC Regression ² | Test Against RC-11 Regression ³ |
| ECBC | 0.793 | 0.584 | 0.940 | 0.040 | 0.829 |
| FAL | 0.709 | 0.598 | 0.953 | 0.024 | 0.909 |
| IIVS | 0.710 | 0.584 | 0.949 | 0.041 | 0.933 |
| | NHK Regression ¹ | | | | |
| Laboratory | Intercept | Slope | R ² Statistic | Test Against RC Regression ² | Test Against RC-11 Regression ³ |
| ECBC | 0.401 | 0.530 | 0.577 | 0.620 | 0.805 |
| FAL | 0.429 | 0.548 | 0.621 | 0.569 | 0.853 |
| IIVS | 0.373 | 0.549 | 0.590 | 0.538 | 0.755 |


Linear Regressions for 11 Substances Tested in Phases Ib and II Table 6-12


Abbreviations: ECBC=Edgewood Chemical Biological Center; FAL=Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory; IIVS=Institute for In Vitro Sciences; RC=Registry of Cytotoxicity; 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; R²=Coefficient of determination.

¹Laboratory and test method regressions were calculated after log transforming the NRU IC₅₀ in mM and the RC LD₅₀ in mmol/kg for the 11 RC substances tested in study Phases Ib and II (shown in **Figures 6-6** through **6-8**). ²Simultaneous comparison of slope and intercept with RC millimole regression: $\log LD_{50}$ (mmol/kg) = 0.435 x $\log IC_{50}$

(mM) + 0.625; R²=0.452; the reported values are p values of the statistic. ³Simultaneous comparison of slope and intercept with RC-11 regression (defined as a regression on the 11 substances): log

 LD_{50} (mmol/kg) = 0.552 x log IC₅₀ (mM) + 0.602; R²=0.971; the reported values are p values of the statistic.





Abbreviations: ECBC=Edgewood Chemical Biological Center; RC=Registry of Cytotoxicity; 3T3=Neutral red uptake using BALB/c 3T3 fibroblasts; NHK= Neutral red uptake using normal human epidermal keratinocytes; R²=Coefficient of determination.

¹Regressions of substances tested in study Phases Ib and II do not include sodium selenate because it was not included in the RC. Regressions were calculated using the NRU IC_{50} values and the RC LD_{50} values. The solid lines show RC millimole regression (bold) and acceptance limits (lighter). The dashed shows the ECBC regressions.





Figure 6-7 In Vitro – In Vivo Regressions¹ for Phases Ib and II for FAL

Abbreviations: FAL=Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory RC=Registry of Cytotoxicity; 3T3=Neutral red uptake using BALB/c 3T3 fibroblasts; NHK=Neutral red uptake using normal human epidermal keratinocytes; R²=Coefficient of determination. ¹Regressions of substances tested in study Phases Ib and II do not include sodium selenate because it was not

Regressions of substances tested in study Phases Ib and II do not include sodium selenate because it was not included in the RC. Regressions were calculated using the NRU IC₅₀ values and the RC LD₅₀ values. The solid lines show RC millimole regression (bold) and acceptance limits (lighter). The dashed shows the FAL regressions.





Abbreviations: IIVS=Institute for *In Vitro* Sciences; RC=Registry of Cytotoxicity; 3T3=Neutral red uptake using BALB/c 3T3 fibroblasts; NHK=Neutral red uptake using normal human epidermal keratinocytes; R²=Coefficient of determination.

¹Regressions of substances tested in study Phases Ib and II do not include sodium selenate because it was not included in the RC. Regressions were calculated using the NRU IC_{50} values and the RC LD_{50} values. The solid lines show RC millimole regression (bold) and acceptance limits (lighter). The dashed shows the IIVS regressions.

6.9 Summary

The millimole regressions developed using the validation study IC_{50} and LD_{50} values were not significantly different from the regressions for the same 47 RC substances using the RC data (F test; p=0.612 for the 3T3 regression and p=0.759 for the NHK regression). Because this validation study provided results similar to the RC, which has more than 3.5 times the number of substances, the 282 RC substances with rat LD_{50} values were used to determine the relationship between the IC_{50} and LD_{50} data. One linear regression was developed using millimole units for the measurement of substances, the RC rat-only millimole regression, and one was developed using weight units (which are more practical in a routine testing situation), the RC rat-only weight regression. The RC rat-only millimole regression is applicable to substances of known molecular weight while the RC rat-only weight regression is applicable for use with complex mixtures, substances whose molecular weight is unknown.

Characteristics that seemed promising for characterizing the RC millimole regression outliers were chemical class, boiling point, molecular weight, and log K_{ow} . Different chemical classes behaved differently with respect to being outliers; ranging from 5/5 (100%) for the organic sulfur compounds for both test methods to 4/14 (29%) for carboxylic acids for the 3T3 NRU. Of the reference substances with boiling points >200°C, 9/13 (69%) were outliers for the 3T3 NRU and 8/13 (62%) were outliers for the NHK NRU. With respect to molecular weights, 4/7 (57%) substances with molecular weight >400 g/mole were outliers using the 3T3 data, and 3/7 (43%) were outliers using the NHK data. When log K_{ow} was used, 8/13 (62%) substances with a log $K_{ow} >3$ were outliers for both test methods.

The lack of fit of individual substances to the RC millimole regression was not consistently related to insolubility or to the fact that the test method systems had little to no metabolic capability. Of the substances that exhibited precipitation, 11/25 (44%) were outliers in the 3T3 NRU assays and 11/24 (46%) were outliers in the NHK NRU assays. However, although the 3T3 and NHK cells have little to no metabolic capability, the toxicity of substances known to produce active metabolites *in vivo* was not underpredicted by these assays. Of the 19 substances known to produce active metabolites *in vivo*, 10 (53%) were outliers in the 3T3 NRU test method; the toxicity of six (60%) was underpredicted while the toxicity of four (40%) overpredicted. These 10 substances accounted for 36% of the 28 outliers identified by the 3T3 NRU test method. Similarly, nine (47%) of the 19 substances known to produce active metabolites in the NHK NRU test method. Of these nine, the NHK NRU test method underpredicted the toxicity of five (56%) and overpredicted four (44%). These nine outliers accounted for 29% of the 31 outliers identified by the NHK NRU test method.

The examination of outliers based on mechanisms of toxicity showed that 10/16 (63%) substances with specific neurotoxic mechanisms were outliers in both the 3T3 and NHK NRU test methods. Three of the six (50%) cardiotoxic substances were outliers in the 3T3 NRU test method and two (33%) were outliers in the NHK NRU test method. When all the reference substances with mechanisms of toxicity that are not expected to be active in the 3T3 and NHK systems (i.e., in **Table 6-3**) were summed, 13/22 (59%) were outliers for the 3T3 NRU and 12/22 (55%) were outliers for the NHK NRU.

The accuracy of the 3T3 and NHK NRU test methods for predicting the GHS acute oral toxicity categories was 31% (21/67) and 29% (20/68), respectively, when used with the RC rat-only millimole regression. The corresponding accuracy with the RC rat-only weight regression was 31% for both methods (21/67 for 3T3, and 21/68 for NHK). Accuracy was highest for substances in the 300< $LD_{50} \leq 2000$ mg/kg range. The accuracies of the regressions, with respect to the GHS categories, were similar for both regressions (millimole and weight) and all three laboratories.

- 0% for substances with $LD_{50} \le 5$ mg/kg (GHS Category I)
- 9% to 18% for substances with $5 \le LD_{50} \le 50 \text{ mg/kg}$ (GHS Category II)
- 33% to 50% for substances with $50 < LD_{50} \le 300 \text{ mg/kg}$ (GHS Category III)
- 75% to 81% for substances with $300 < LD_{50} \le 2000 \text{ mg/kg}$ (GHS Category IV)
- 0% to 40% for substances with 2000 $< LD_{50} \le 5000 \text{ mg/kg}$ (GHS Category V)
- 0% to 17% for substances with $LD_{50} > 5000 \text{ mg/kg}$ (GHS Unclassified)

The overall accuracy for prediction of GHS category prediction using the RC IC₅₀ and LD₅₀ values and the RC millimole regression was higher that that for the NRU test methods with the RC rat-only regressions (i.e., 40% for the RC vs. 29% to 31% for the NRU test methods and RC rat-only regressions). However, the pattern of accuracy for the GHS categories was similar. For all the accuracy analyses, the lowest accuracy was obtained for very toxic and very nontoxic substances and highest accuracy was obtained for substances with $300 < LD_{50} \le 2000 \text{ mg/kg}$.

The accuracy of GHS acute oral toxicity category predictions using the *in vitro* NRU test methods with the RC rat-only regressions obtained for the reference substances may or may not be broadly applicable to substances that might require acute oral toxicity testing. The reasons for the low accuracy obtained in this validation study include: the differences between cell cultures and whole animals regarding the absorption, distribution, availability, metabolism, and excretion of reference substances, and the presence or absence of toxicity targets; the skewness of the selection of substances for testing (with respect to fit to the regression); and the structure of the GHS acute oral toxicity categories.

[This Page Intentionally Left Blank]

| 7.0 | RELI | ABILITY OF THE 3T3 AND NHK NRU TEST METHODS | 7-3 |
|-----|--------|--|------|
| 7.1 | | ence Substances Used to Determine the Reliability of the 3T3 and NRU Test Methods | 7-3 |
| 7.2 | Repro | oducibility Analyses for the 3T3 and NHK NRU Test Methods | 7-5 |
| | 7.2.1 | Comparison of Laboratory-Specific IC ₅₀ -LD ₅₀ Linear Regression | |
| | | Analyses to the Mean Laboratory Regression | 7-5 |
| | 7.2.2 | ANOVA Results for the 3T3 and NHK NRU Test Methods | 7-5 |
| | 7.2.3 | CV Results for the 3T3 and NHK NRU Test Methods | 7-21 |
| | 7.2.4 | Comparison of Maximum to Minimum IC ₅₀ Values Using Laboratory | |
| | | Means | 7-39 |
| | 7.2.5 | Comparison of Maximum: Minimum IC ₅₀ Ratios with the | |
| | | Maximum:Minimum LD ₅₀ Ratios | 7-40 |
| | 7.2.6 | Normalization of Reference Substance IC ₅₀ Values Using SLS | |
| | | Values | 7-42 |
| 7.3 | Histor | rical Positive Control (PC) Data | 7-44 |
| | 7.3.1 | ANOVA and Linear Regression Results for the 3T3 NRU Test Method. | 7-46 |
| | 7.3.2 | ANOVA and Linear Regression Results for the NHK NRU Test | |
| | | Method | 7-48 |
| 7.4 | Labo | ratory Concordance for Solvent Selection | 7-50 |
| 7.5 | Sumn | nary | 7-52 |

[This Page Intentionally Left Blank]

7.0 RELIABILITY OF THE 3T3 AND NHK NRU TEST METHODS

The reliability of the 3T3 and NHK NRU test methods was assessed by determining intraand inter-laboratory reproducibility. Intralaboratory reproducibility is the agreement of results produced when people in the same laboratory perform the method using the same test protocol at different times (ICCVAM 2003). Interlaboratory reproducibility is the agreement of results among different laboratories using the same protocol and reference substances. Interlaboratory reproducibility indicates the extent to which a method can be successfully transferred among laboratories. Repeatability, usually applied to results within a laboratory, is the closeness of agreement between test results obtained when the procedure is performed on the same substance under identical conditions within a given time. This study was not designed to assess intralaboratory repeatability.

The interlaboratory reproducibility of the test results was assessed by comparing the laboratory-specific IC_{50} -LD₅₀ regressions for the 3T3 and NHK NRU test methods to the mean (i.e., across-laboratory mean) laboratory regressions (see Section 7.2.1). This comparison is relevant because the 3T3 and NHK NRU test methods are intended for use with IC_{50} -LD₅₀ regressions to determine starting doses for acute oral toxicity tests. Interlaboratory reproducibility of the 3T3 and NHK NRU test methods was also determined using ANOVA, CV analysis, and comparison of maximum:minimum IC_{50} ratios calculated using laboratory mean values (see Sections 7.2.2, 7.2.3, and 7.2.4, respectively), as discussed in Section 5.5.2.2. Inter- and intra-laboratory reproducibility of the PC (SLS) was determined using ANOVA, CV analysis, and/or linear regression over time (see Section 7.3). The extent of laboratory concordance in selecting the solvent to be used for each test substance (described in Section 2.10) is provided in Section 7.4.

7.1 Reference Substances Used to Determine the Reliability of the 3T3 and NHK NRU Test Methods

The validation study was designed for the purpose of using the IC_{50} results of 72 reference substances (see Table 3-2) to determine the reliability of the IC₅₀ values from the 3T3 and NHK NRU test methods. The number of reference substances used for the reproducibility analysis was not the same as the number of reference substances used for the accuracy analyses in Section 6.4. In the former case, only reference substances for which all three laboratories reported replicate IC₅₀ values were used, while in the latter case, substances with rat acute oral LD₅₀ data only and at least one laboratory reporting replicate IC₅₀ values were used. Table 7-1 lists the reference substances that failed to yield sufficient toxicity for the calculation of an IC_{50} in each laboratory, and the number of remaining reference substances with replicate IC_{50} values. The laboratories obtained acceptable IC_{50} values for 66 to 68 reference substances using the 3T3 NRU test method, and for 69 to 70 substances using the NHK NRU test method. When only reference substances with IC₅₀ values from all three laboratories are considered, 64 and 68 substances were available to evaluate the reliability of the 3T3 and NHK NRU test methods, respectively. The substances that were excluded from the 3T3 reliability analysis were carbon tetrachloride, disulfoton, gibberellic acid, lithium carbonate, methanol, 1,1,1-trichloroethane, valproic acid, and xylene. The substances that were excluded from the NHK reliability analysis were carbon tetrachloride, methanol, 1,1,1trichloroethane, and xylene.

| | 3T3 NRU Test Method | | NHK NRU Test Method | | |
|------------|---|-------|---|------------------|--|
| Laboratory | Reference Substances Lacking IC ₅₀ Results | N^1 | Reference Substances Lacking IC ₅₀ Results | \mathbf{N}^{1} | |
| ECBC | Carbon tetrachloride Methanol 1,1,1-Trichloroethane Xylene | 68 | Carbon tetrachloride Methanol Xylene | 69 | |
| FAL | Carbon tetrachloride Disulfoton Gibberellic acid Lithium carbonate Methanol Xylene | 66 | 1,1,1-Trichloroethane Carbon tetrachloride Xylene | 69 | |
| IIVS | Carbon tetrachloride Lithium carbonate Methanol Valproic acid | 68 | Carbon tetrachloride 1,1,1-Trichloroethane | 70 | |

Table 7-1 Reference Substances Excluded from Reproducibility Analyses Because of Insufficient Cytotoxicity

Abbreviations: 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; NRU= Neutral red uptake; ECBC=Edgewood Chemical Biological Center; FAL=Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory; IIVS=Institute for *In Vitro* Sciences; N=Number of substances. ²Number of substances with replicate IC₅₀ values.

Despite the fact that IC_{50} values were not obtained by all the laboratories for all reference substances, **Table 7-2** shows that the complete range of LD_{50} responses, as defined by the GHS classification for acute oral toxicity in **Table 3-1**, was covered by the reference substances for which replicate IC_{50} values were obtained. The 3T3 NRU IC_{50} values ranged from 0.005 to 38,878 µg/mL, while the NHK values covered a larger range, from 0.00005 to 49,800 µg/mL (see **Tables 5-4** and **5-5**).

| Table 7-2 | Number of Reference Substances Tested vs Number of Reference |
|-----------|--|
| | Substances Yielding IC ₅₀ Values from Each Laboratory, by GHS Acute |
| | Oral Toxicity Category |

| GHS Category ¹ (mg/kg) | Reference Oral LD ₅₀ ² | 3T3 NRU Test Method ³ | NHK NRU Test Method ³ |
|--------------------------------------|---|-------------------------------------|-------------------------------------|
| $LD_{50} \leq 5$ | 7 | 6 | 7 |
| $5 < LD_{50} \le 50$ | 12 | 12 | 12 |
| $50 < LD_{50} \le 300$ | 12 | 12 | 12 |
| $300 < LD_{50} \le 2000$ | 16 | 14 | 16 |
| $2000 < LD_{50} \le 5000$ | 11 | 9 | 9 |
| LD ₅₀ >5000 | 14 | 11 | 12 |

Abbreviations: 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; NRU= Neutral red uptake; GHS=Globally Harmonized System of Classification and Labelling of Chemicals (UN 2005). ¹GHS category for acute oral toxicity.

²Number of reference substances tested in each category. Reference acute oral LD_{50} values from rats and mice were generated after evaluating LD_{50} values located through literature searches and references from toxicity databases such as RTECS[®] (from **Table 4-2**).

³Number of reference substances with IC₅₀ values from all three laboratories.

7.2 Reproducibility Analyses for the 3T3 and NHK NRU Test Methods

The interlaboratory reproducibility of the 3T3 and NHK NRU IC₅₀ values was assessed by comparing the laboratory-specific IC₅₀-LD₅₀ linear regressions for each method to a regression calculated using the mean IC₅₀ values of the laboratories. The interlaboratory reproducibility of the 3T3 and NHK NRU test methods was also assessed using ANOVA, CV analysis, and analysis of the laboratory mean maximum:minimum IC₅₀ ratios, as described in **Section 5.5.2.2.** Intralaboratory reproducibility was assessed using a CV analysis.

7.2.1 <u>Comparison of Laboratory-Specific IC₅₀-LD₅₀ Linear Regression Analyses to the Mean Laboratory Regression</u>

The comparisons of laboratory-specific IC_{50} - LD_{50} linear regressions to the mean laboratory regression for each method were made because the 3T3 and NHK NRU test methods are intended for use with IC_{50} - LD_{50} regressions to determine starting doses for acute oral toxicity tests. Laboratory-specific IC_{50} - LD_{50} linear regressions were generated and displayed graphically for each method using the 64 and 68 reference substances for the 3T3 and NHK NRU test methods, respectively, as indicated in **Section 7.1**. The regressions used the geometric mean IC_{50} values for each substance with the rodent acute oral LD_{50} reference value (**Table 4-2**). To determine whether the laboratory-specific regressions were significantly different from one another, they were compared against the mean laboratory regression for each NRU test method that was calculated using the geometric mean of the laboratory regression for each NRU test method is in **Figure 7-1** with 95% confidence limits, and shows that the laboratory-specific regressions were all within the 95% confidence limits of the mean laboratory regression.

7.2.2 ANOVA Results for the 3T3 and NHK NRU Test Methods

The ANOVA was performed as discussed in Section **5.5.2.2**. Because the sample sizes from this study were small, usually three observations per laboratory, there may be differences that were statistically significant only because there were too few observations within the laboratories to adequately characterize variability or because the within-laboratory variability was small.


7.2.2.1 Differences Among the IC₅₀ Values in Laboratories Using the 3T3 NRU Test Method

The ANOVA results in **Table 7-3** show that there were statistically significant (p < 0.01) differences among the laboratories for 23 of the 64 (36%) reference substances evaluated. The p values from the contrast analyses, post-hoc tests to determine which laboratory was significantly different from the others at p < 0.01 (see **Section 5.5.2.2**), are also provided in **Table 7-3**. The substances for which statistically significant ANOVA and contrast results were obtained are listed in **Table 7-4** along with columns showing the laboratory with significantly differing values from the other two laboratories. Because significant laboratory differences may have resulted from the insolubility or volatility of the test substance, **Table 7-4** also indicates whether any laboratory reported insolubility or volatility during conduct of the test. Insolubility was suggested by the presence of precipitates in either the stock solutions or in cell culture. Volatility was identified by the need for plate sealers to contain volatile contamination of lower concentration wells by higher concentrations. Insolubility and volatility were reported for only six of the 23 chemicals showing significant

interlaboratory variability. In contrast, 22 of the 41 substances that were classified as generating interlaboratory reproducible data exhibited precipitates and/or volatility.

For the 23 substances that yielded significantly different results among laboratories, contrast analyses indicated that the IC_{50} values produced by ECBC and FAL were frequently different from the other laboratories. ECBC tended to report the lowest IC_{50} values (i.e., highest toxicity) among the laboratories while FAL tended to report the highest values of the three laboratories. ECBC reported significantly different results from the other two laboratories for 15 of the 23 substances; for 13 of the 15, ECBC's mean value IC_{50} was the lowest among the laboratories. FAL reported significantly different results from the other two laboratories for 20 of the 23 substances; for 18 of the 20, FAL's IC_{50} value was the highest among the laboratories. IIVS reported significantly different values for 11 of the 26 substances, with no tendency toward highest or lowest IC_{50} values.

Figure 7-1 Mean Laboratory and Laboratory-Specific 3T3 and NHK NRU Regressions



Abbreviations: 3T3=BALB/c 3T3 fibroblasts; NRU=Neutral red uptake; NHK=Normal human epidermal keratinocytes. Solid lines show the mean laboratory linear regressions for the 3T3 NRU (a) and the NHK NRU (b) test methods with dashed curved lines to show the 95% confidence limits of the regression. The regressions were calculated using 64 and 68 reference substances for the 3T3 and NHK NRU test methods, respectively, as described in **Section 7.1**. Regressions used geometric mean IC₅₀ values and reference acute oral LD₅₀ values from **Table 4-2**.

| Reference Substance/Laboratory | Arithmetic Mean IC ₅₀ (mg/mL) ¹ | Maximum: Minimum Mean IC ₅₀ Ratio ² | Arithmetic IntraLab %CV | Arithmetic InterLab %CV | Log Arithmetic Mean IC ₅₀ (mg/mL) ¹ | ANOVA P ³ | Contrast P ⁴ |
|-----------------------------------|---|--|-------------------------------|-------------------------------|--|-------------------------|----------------------------|
| Acetaminophen | 50.1 | 1.6 | | 28 | 1.7 | 0.171 | |
| ECBC | 40.8 | | 22 | | 1.61 | | NA |
| FAL | 66.2 | | 35 | | 1.82 | | NA |
| IIVS | 43.4 | | 26 | | 1.64 | | NA |
| Acetonitrile | 8484 | 1.5 | | 21 | 3.93 | 0.553 | |
| ECBC | 6433 | | 2 | | 3.81 | | NA |
| FAL | 9690 | | 58 | | 3.99 | | NA |
| IIVS | 9330 | | 13 | | 3.97 | | NA |
| Acetylsalicylic acid | 760 | 3.1 | | 56 | 2.88 | < 0.001 | |
| ECBC | 646 | | 10 | | 2.81 | | 0.581 |
| FAL | 1234 | | 24 | | 3.09 | | < 0.001 |
| IIVS | 401 | | 16 | | 2.6 | | < 0.001 |
| 5-Aminosalicylic acid | 1698 | 1.4 | | 19 | 3.23 | 0.054 | |
| ECBC | 1467 | | 14 | | 3.17 | | NA |
| FAL | 2070 | | 16 | | 3.32 | | NA |
| IIVS | 1557 | | 12 | | 3.19 | | NA |
| Aminopterin | 0.007 | 2.4 | | 54 | -2.14 | 0.036 | |
| ECBC | 0.005 | | 20 | | -2.28 | | NA |
| FAL | 0.012 | | 46 | | -1.93 | | NA |
| IIVS | 0.005 | | 23 | | -2.33 | | NA |
| Amitriptyline HCl | 7.23 | 1.3 | | 14 | 0.86 | 0.348 | |
| ECBC | 6.03 | | 23 | | 0.78 | | 0.163 |
| FAL | 7.86 | | 28 | | 0.9 | | 0.469 |
| IIVS | 7.81 | | 18 | | 0.89 | | 0.445 |
| Arsenic trioxide | 2.51 | 3.9 | | 61 | 0.4 | 0.004 | |

| Reference Substance/Laboratory | Arithmetic Mean IC ₅₀ (mg/mL) ¹ | Maximum: Minimum Mean IC ₅₀ Ratio ² | Arithmetic IntraLab %CV | Arithmetic InterLab %CV | Log Arithmetic Mean IC ₅₀ (mg/mL) ¹ | ANOVA P ³ | Contrast P ⁴ |
|-----------------------------------|---|--|-------------------------------|-------------------------------|--|-------------------------|----------------------------|
| ECBC | 2.41 | | 33 | | 0.38 | | 0.527 |
| FAL | 1.04 | | 7 | | 0.02 | | 0.002 |
| IIVS | 4.09 | | 52 | | 0.61 | | 0.006 |
| Atropine sulfate | 85.6 | 2.5 | | 49 | 1.93 | 0.049 | |
| ECBC | 54.1 | | 55 | | 1.73 | | NA |
| FAL | 133 | | 31 | | 2.12 | | NA |
| IIVS | 70 | | 8 | | 1.85 | | NA |
| Boric acid | 2228 | 3.3 | | 69 | 3.35 | 0.01 | |
| ECBC | 1497 | | 32 | | 3.18 | | NA |
| FAL | 3987 | | 17 | | 3.6 | | NA |
| IIVS | 1202 | | 48 | | 3.08 | | NA |
| Busulfan | 135 | 8.0 | | 119 | 2.13 | 0.002 | |
| ECBC | 40 | | 48 | | 1.6 | | 0.012 |
| FAL | 321 | | 56 | | 2.51 | | < 0.001 |
| IIVS | 43.7 | | 4 | | 1.64 | | 0.033 |
| Cadmium chloride | 0.565 | 1.4 | | 39 | -0.25 | 0.124 | |
| ECBC | 0.48 | | 14 | | -0.32 | | NA |
| FAL | 0.4 | | 32 | | -0.4 | | NA |
| IIVS | 0.817 | | 53 | | -0.09 | | NA |
| Caffeine | 161 | 1.4 | | 18 | 2.21 | 0.481 | |
| ECBC | 133 | | 10 | | 2.12 | | NA |
| FAL | 157 | | 52 | | 2.2 | | NA |
| IIVS | 191 | | 7.5 | | 2.28 | | NA |
| Carbamazepine | 109 | 1.8 | | 35 | 2.04 | 0.049 | |
| ECBC | 83 | | 14 | | 1.92 | | NA |

| Reference Substance/Laboratory | Arithmetic Mean IC ₅₀ (mg/mL) ¹ | Maximum: Minimum Mean IC ₅₀ Ratio ² | Arithmetic IntraLab %CV | Arithmetic InterLab %CV | Log Arithmetic Mean IC ₅₀ (mg/mL) ¹ | ANOVA P ³ | Contrast P ⁴ |
|-----------------------------------|---|--|-------------------------------|-------------------------------|--|-------------------------|----------------------------|
| FAL | 152 | | 37 | | 2.18 | | NA |
| IIVS | 91.8 | | 12 | | 1.96 | | NA |
| Carbon tetrachloride | NA | NA | | NA | NA | NA | |
| ECBC | NA | | NA | | NA | | NA |
| FAL | NA | | NA | | NA | | NA |
| IIVS | NA | | NA | | NA | | NA |
| Chloral hydrate | 187 | 1.6 | | 25 | 2.27 | 0.004 | |
| ECBC | 151 | | 10 | | 2.18 | | 0.008 |
| FAL | 241 | | 10 | | 2.38 | | 0.002 |
| IIVS | 170 | | 12 | | 2.23 | | 0.181 |
| Chloramphenicol | 161 | 4.9 | | 67 | 2.21 | < 0.001 | |
| ECBC | 55.3 | | 22 | | 1.74 | | < 0.001 |
| FAL | 273 | | 30 | | 2.44 | | 0.001 |
| IIVS | 156 | | 18 | | 2.19 | | 0.165 |
| Citric acid | 829 | 2.4 | | 41 | 2.92 | 0.002 | |
| ECBC | 473 | | 29 | | 2.68 | | 0.001 |
| FAL | 1148 | | 13 | | 3.06 | | 0.003 |
| IIVS | 865 | | 19 | | 2.94 | | 0.298 |
| Colchicine | 0.047 | 4.7 | | 85 | -1.33 | 0.001 | |
| ECBC | 0.02 | | 11 | | -1.70 | | 0.0028 |
| FAL | 0.093 | | 45 | | -1.03 | | 0.0005 |
| IIVS | 0.028 | | 1 | | -1.55 | | 0.0914 |
| Cupric sulfate pentahydrate | 70.6 | 21.6 | | 85 | 1.85 | < 0.001 | |
| ECBC | 82.7 | | 4 | | 1.92 | | 0.001 |
| FAL | 123 | | 44 | | 2.09 | | < 0.001 |

| Reference Substance/Laboratory | Arithmetic Mean IC ₅₀ (mg/mL) ¹ | Maximum: Minimum Mean IC ₅₀ Ratio ² | Arithmetic IntraLab %CV | Arithmetic InterLab %CV | Log Arithmetic Mean IC ₅₀ (mg/mL) ¹ | ANOVA P ³ | Contrast P ⁴ |
|-----------------------------------|---|--|-------------------------------|-------------------------------|--|-------------------------|----------------------------|
| IIVS | 5.7 | | 31 | | 0.76 | | < 0.001 |
| Cycloheximide | 0.293 | 5.9 | | 104 | -0.53 | 0.021 | |
| ECBC | 0.125 | | 45 | | -0.9 | | NA |
| FAL | 0.647 | | 70 | | -0.19 | | NA |
| IIVS | 0.109 | | 23 | | -0.96 | | NA |
| Dibutyl phthalate | 78.3 | 9.2 | | 124 | 1.89 | < 0.001 | |
| ECBC | 23.5 | | 17 | | 1.37 | | 0.012 |
| FAL | 191 | | 50 | | 2.28 | | < 0.001 |
| IIVS | 20.7 | | 7 | | 1.32 | | 0.005 |
| Dichlorvos | 20.3 | 3.3 | | 57 | 1.31 | 0.002 | |
| ECBC | 9.8 | | 35 | | 0.99 | | 0.001 |
| FAL | 32.8 | | 6 | | 1.52 | | 0.002 |
| IIVS | 18.3 | | 11 | | 1.26 | | 0.823 |
| Diethyl phthalate | 113 | 1.7 | | 28 | 2.05 | 0.127 | |
| ECBC | 85.5 | | 34 | | 1.93 | | 0.092 |
| FAL | 147 | | 26 | | 2.17 | | 0.07 |
| IIVS | 106 | | 24 | | 2.03 | | 0.846 |
| Digoxin | 520 | 2.8 | | 62 | 2.72 | 0.043 | |
| ECBC | 351 | | 39 | | 2.54 | | NA |
| FAL | 892 | | 36 | | 2.95 | | NA |
| IIVS | 317 | | 21 | | 2.5 | | NA |
| Dimethylformamide | 5242 | 1.1 | | 6 | 3.72 | 0.296 | |
| ECBC | 5343 | | 10 | | 3.73 | | NA |
| FAL | 5483 | | 9 | | 3.74 | | NA |
| IIVS | 4900 | | 4 | | 3.69 | | NA |

| Reference Substance/Laboratory | Arithmetic Mean IC ₅₀ (mg/mL) ¹ | Maximum: Minimum Mean IC ₅₀ Ratio ² | Arithmetic IntraLab %CV | Arithmetic InterLab %CV | Log Arithmetic Mean IC ₅₀ (mg/mL) ¹ | ANOVA P ³ | Contrast P ⁴ |
|-----------------------------------|---|--|-------------------------------|-------------------------------|--|-------------------------|----------------------------|
| Diquat dibromide monohydrate | 15.1 | 9.3 | | 120 | 1.18 | 0.017 | |
| ECBC | 3.9 | | 23 | | 0.59 | | NA |
| FAL | 36.1 | | 98 | | 1.56 | | NA |
| IIVS | 5.4 | | 25 | | 0.73 | | NA |
| Disulfoton | 98.6 | 2.3 | | 55 | 1.99 | 0.003 | |
| ECBC | 137 | | 55 | | 2.14 | | NA |
| FAL | NA | | NA | | NA | | NA |
| IIVS | 60.4 | | 87 | | 1.78 | | NA |
| Endosulfan | 8.02 | 4.2 | | 78 | 0.9 | 0.046 | |
| ECBC | 5.3 | | 57 | | 0.72 | | NA |
| FAL | 15.2 | | 78 | | 1.18 | | NA |
| IIVS | 3.6 | | 42 | | 0.56 | | NA |
| Epinephrine bitartrate | 59.4 | 1.2 | | 12 | 1.77 | 0.048 | |
| ECBC | 51.5 | | 12 | | 1.71 | | NA |
| FAL | 63.4 | | 11 | | 1.8 | | NA |
| IIVS | 63.4 | | 3 | | 1.8 | | NA |
| Ethanol | 6731 | 1.6 | | 23 | 3.83 | 0.075 | |
| ECBC | 5360 | | 33 | | 3.73 | | NA |
| FAL | 8420 | | 14 | | 3.93 | | NA |
| IIVS | 6413 | | 5 | | 3.81 | | NA |
| Ethylene glycol | 25292 | 1.7 | | 26 | 4.4 | 0.007 | |
| ECBC | 18325 | | 9 | | 4.26 | | 0.004 |
| FAL | 31650 | | 24 | | 4.50 | | 0.01 |
| IIVS | 25900 | | 12 | | 4.41 | | 0.505 |
| Fenpropathrin | 27.2 | 2.5 | | 49 | 1.43 | 0.301 | |

| Reference Substance/Laboratory | Arithmetic Mean IC ₅₀ (mg/mL) ¹ | Maximum: Minimum Mean IC ₅₀ Ratio ² | Arithmetic IntraLab %CV | Arithmetic InterLab %CV | Log Arithmetic Mean IC ₅₀ (mg/mL) ¹ | ANOVA P ³ | Contrast P ⁴ |
|-----------------------------------|---|--|-------------------------------|-------------------------------|--|-------------------------|----------------------------|
| ECBC | 22.6 | | 11 | | 1.35 | | NA |
| FAL | 42.4 | | 63 | | 1.63 | | NA |
| IIVS | 16.7 | | 12 | | 1.22 | | NA |
| Gibberellic Acid | 7842 | 1.0 | | 3 | 3.89 | 0.621 | |
| ECBC | 8027 | | 11 | | 3.9 | | NA |
| FAL | NA | | NA | | NA | | NA |
| IIVS | 7657 | | 10 | | 3.88 | | NA |
| Glutethimide | 192 | 2.3 | | 43 | 2.28 | < 0.001 | |
| ECBC | 167 | | 4 | | 2.22 | | 0.029 |
| FAL | 284.3 | | 7 | | 2.45 | | < 0.001 |
| IIVS | 125.3 | | 7 | | 2.1 | | < 0.001 |
| Glycerol | 28904 | 1.9 | | 33 | 4.46 | 0.846 | |
| ECBC | 20000 | | 15 | | 4.3 | | NA |
| FAL | 38878 | | 73 | | 4.59 | | NA |
| IIVS | 27833 | | 39 | | 4.44 | | NA |
| Haloperidol | 6.26 | 1.5 | | 24 | 0.8 | 0.006 | |
| ECBC | 5.3 | | 12 | | 0.72 | | 0.03 |
| FAL | 8 | | 8 | | 0.9 | | 0.002 |
| IIVS | 5.5 | | 12 | | 0.74 | | 0.061 |
| Hexachlorophene | 4.48 | 1.7 | | 27 | 0.65 | 0.174 | |
| ECBC | 5 | | 48 | | 0.7 | | NA |
| FAL | 5.3 | | 33 | | 0.72 | | NA |
| IIVS | 3.1 | | 9 | | 0.49 | | NA |
| Lactic acid | 3073 | 1.2 | | 12 | 3.49 | 0.16 | |
| ECBC | 2943 | | 11 | | 3.47 | | NA |

| Reference Substance/Laboratory | Arithmetic Mean IC ₅₀ (mg/mL) ¹ | Maximum: Minimum Mean IC ₅₀ Ratio ² | Arithmetic IntraLab %CV | Arithmetic InterLab %CV | Log Arithmetic Mean IC ₅₀ (mg/mL) ¹ | ANOVA P ³ | Contrast P ⁴ |
|-----------------------------------|---|--|-------------------------------|-------------------------------|--|-------------------------|----------------------------|
| FAL | 3487 | | 16 | | 3.54 | | NA |
| IIVS | 2790 | | 9 | | 3.45 | | NA |
| Lindane | 161 | 2.9 | | 58 | 2.21 | 0.066 | |
| ECBC | 125 | | 95 | | 2.1 | | NA |
| FAL | 266 | | 36 | | 2.43 | | NA |
| IIVS | 90.4 | | 122 | | 1.96 | | NA |
| Lithium carbonate | NA | NA | | NA | NA | NA | NA |
| ECBC | 564 | | 12 | | 2.75 | | NA |
| FAL | NA | | NA | | NA | | NA |
| IIVS | NA | | NA | | NA | | NA |
| Meprobamate | 539 | 2.5 | | 54 | 2.73 | < 0.001 | |
| ECBC | 353 | | 14 | | 2.55 | | NA |
| FAL | 877 | | 15 | | 2.94 | | NA |
| IIVS | 386 | | 2 | | 2.59 | | NA |
| Mercury chloride | 4.32 | 1.7 | | 33 | 0.64 | 0.021 | |
| ECBC | 3.5 | | 5 | | 0.54 | | NA |
| FAL | 6 | | 31 | | 0.78 | | NA |
| IIVS | 3.5 | | 3 | | 0.54 | | NA |
| Methanol | NA | NA | | NA | NA | NA | NA |
| ECBC | NA | | NA | | NA | | NA |
| FAL | NA | | | | NA | | NA |
| IIVS | NA | | | | NA | | NA |
| Nicotine | 378 | 1.7 | | 25 | 2.58 | 0.128 | |
| ECBC | 272 | | 24 | | 2.43 | | NA |
| FAL | 412 | | 33 | | 2.61 | | NA |

| Reference Substance/Laboratory | Arithmetic Mean IC ₅₀ (mg/mL) ¹ | Maximum: Minimum Mean IC ₅₀ Ratio ² | Arithmetic IntraLab %CV | Arithmetic InterLab %CV | Log Arithmetic Mean IC ₅₀ (mg/mL) ¹ | ANOVA P ³ | Contrast P ⁴ |
|-----------------------------------|---|--|-------------------------------|-------------------------------|--|-------------------------|----------------------------|
| IIVS | 450 | | 12 | | 2.65 | | NA |
| Paraquat | 23.3 | 1.2 | | 8 | 1.37 | 1 | |
| ECBC | 21.3 | | 34 | | 1.33 | | NA |
| FAL | 24.9 | | 67 | | 1.4 | | NA |
| IIVS | 23.7 | | 64 | | 1.37 | | NA |
| Parathion | 61.8 | 6.4 | | 111 | 1.79 | 0.014 | |
| ECBC | 22.7 | | 53 | | 1.36 | | NA |
| FAL | 141 | | 70 | | 2.15 | | NA |
| IIVS | 22 | | 22 | | 1.34 | | NA |
| Phenobarbital | 612 | 1.5 | | 21 | 2.79 | 0.232 | |
| ECBC | 634 | | 21 | | 2.8 | | NA |
| FAL | 726 | | 35 | | 2.86 | | NA |
| IIVS | 476 | | 23 | | 2.68 | | NA |
| Phenol | 70.9 | 2.1 | | 41 | | 0.011 | |
| ECBC | 50.2 | | 22 | | 1.7 | | NA |
| FAL | 104 | | 24 | | 2.02 | | NA |
| IIVS | 58.1 | | 12 | | 1.76 | | NA |
| Phenylthiourea | 119 | 7.9 | | 90 | 2.08 | 0.007 | |
| ECBC | 30.1 | | 66 | | 1.48 | | 0.004 |
| FAL | 239 | | 28 | | 2.38 | | 0.006 |
| IIVS | 89 | | 25 | | 1.95 | | 0.718 |
| Physostigmine | 28.8 | 1.9 | | 30 | 1.46 | 0.149 | |
| ECBC | 28.2 | | 53 | | 1.45 | | NA |
| FAL | 37.8 | | 5 | | 1.58 | | NA |
| IIVS | 20.4 | | 33 | | 1.31 | | NA |

| Reference Substance/Laboratory | Arithmetic Mean IC ₅₀ (mg/mL) ¹ | Maximum: Minimum Mean IC ₅₀ Ratio ² | Arithmetic IntraLab %CV | Arithmetic InterLab %CV | Log Arithmetic Mean IC ₅₀ (mg/mL) ¹ | ANOVA P ³ | Contrast P ⁴ |
|-----------------------------------|---|--|-------------------------------|-------------------------------|--|-------------------------|----------------------------|
| Potassium chloride | 3635 | 1.1 | | 7 | 3.56 | 0.846 | |
| ECBC | 3352 | | 14 | | 3.53 | | NA |
| FAL | 3842 | | 31 | | 3.58 | | NA |
| IIVS | 3710 | | 11 | | 3.57 | | NA |
| Potassium cyanide | 64.3 | 10.4 | | 127 | 1.81 | < 0.001 | |
| ECBC | 15.3 | | 25 | | 1.18 | | 0.001 |
| FAL | 159 | | 52 | | 2.2 | | < 0.001 |
| IIVS | 18.9 | | 5 | | 1.28 | | 0.006 |
| Procainamide HCl | 443 | 1.2 | | 11 | 2.65 | 0.007 | |
| ECBC | 400 | | 4 | | 2.6 | | 0.008 |
| FAL | 431 | | 1 | | 2.63 | | 0.396 |
| IIVS | 497 | | 8 | | 2.7 | | 0.003 |
| 2-Propanol | 3563 | 1.6 | | 23 | 3.55 | 0.001 | |
| ECBC | 2610 | | 9 | | 3.42 | | < 0.001 |
| FAL | 3970 | | 4 | | 3.6 | | 0.004 |
| IIVS | 4110 | | 4 | | 3.61 | | 0.002 |
| Propranolol HCl | 14.9 | 1.3 | | 16 | 1.17 | 0.488 | |
| ECBC | 13.6 | | 32 | | 1.13 | | NA |
| FAL | 13.5 | | 51 | | 1.13 | | NA |
| IIVS | 17.6 | | 21 | | 1.25 | | NA |
| Propylparaben | 29.9 | 3.0 | | 64 | 1.48 | 0.001 | |
| ECBC | 20.9 | | 16 | | 1.32 | | 0.045 |
| FAL | 51.8 | | 29 | | 1.71 | | < 0.001 |
| IIVS | 17.1 | | 12 | | 1.23 | | 0.003 |
| Sodium arsenite | 0.873 | 2.8 | | 55 | -0.06 | 0.028 | |

| Reference Substance/Laboratory | Arithmetic Mean IC ₅₀ (mg/mL) ¹ | Maximum: Minimum Mean IC ₅₀ Ratio ² | Arithmetic IntraLab %CV | Arithmetic InterLab %CV | Log Arithmetic Mean IC ₅₀ (mg/mL) ¹ | ANOVA P ³ | Contrast P ⁴ |
|-----------------------------------|---|--|-------------------------------|-------------------------------|--|-------------------------|----------------------------|
| ECBC | 0.5 | | 6 | | -0.3 | | NA |
| FAL | 1.4 | | 57 | | 0.15 | | NA |
| IIVS | 0.7 | | 17 | | -0.15 | | NA |
| Sodium chloride | 4764 | 1.1 | | 3 | 3.68 | 0.759 | |
| ECBC | 4790 | | 5 | | 3.68 | | NA |
| FAL | 4625 | | 13 | | 3.67 | | NA |
| IIVS | 4877 | | 9 | | 3.69 | | NA |
| Sodium dichromate dihydrate | 0.602 | 1.2 | | 9 | -0.22 | 0.822 | |
| ECBC | 0.603 | | 14 | | -0.22 | | NA |
| FAL | 0.657 | | 37 | | -0.18 | | NA |
| IIVS | 0.547 | | 17 | | -0.26 | | NA |
| Sodium fluoride | 79.8 | 1.6 | | 22 | 1.9 | 0.016 | |
| ECBC | 61.3 | | 9 | | 1.79 | | NA |
| FAL | 96.1 | | 18 | | 1.98 | | NA |
| IIVS | 82 | | 7 | | 1.91 | | NA |
| Sodium hypochlorite | 1211 | 2.5 | | 57 | 3.08 | 0.04 | |
| ECBC | 823 | | 13 | | 2.92 | | NA |
| FAL | 805 | | 46 | | 2.91 | | NA |
| IIVS | 2005 | | 44 | | 3.3 | | NA |
| Sodium oxalate | 40.8 | 1.6 | | 23 | 1.61 | 0.643 | |
| ECBC | 42 | | 41 | | 1.62 | | NA |
| FAL | 31 | | 28 | | 1.49 | | NA |
| IIVS | 49.5 | | 53 | | 1.69 | | NA |
| Sodium selenate | 34.5 | 4.3 | | 60 | 1.54 | < 0.001 | |
| ECBC | 12.7 | | 13 | | 1.1 | | < 0.001 |

| Reference Substance/Laboratory | Arithmetic Mean IC ₅₀ (mg/mL) ¹ | Maximum: Minimum Mean IC ₅₀ Ratio ² | Arithmetic IntraLab %CV | Arithmetic InterLab %CV | Log Arithmetic Mean IC ₅₀ (mg/mL) ¹ | ANOVA P ³ | Contrast P ⁴ |
|-----------------------------------|---|--|-------------------------------|-------------------------------|--|-------------------------|----------------------------|
| FAL | 54.2 | | 19 | | 1.73 | | < 0.001 |
| IIVS | 36.5 | | 14 | | 1.56 | | 0.026 |
| Strychnine | 199 | 4.7 | | 83 | 2.3 | < 0.001 | |
| ECBC | 389 | | 21 | | 2.59 | | < 0.001 |
| FAL | 124 | | 16 | | 2.09 | | 0.018 |
| IIVS | 83.5 | | 6 | | 1.92 | | < 0.001 |
| Thallium Sulfate | 7.5 | 4.9 | | 72 | 0.88 | 0.165 | |
| ECBC | 2.8 | | 24 | | 0.45 | | NA |
| FAL | 13.4 | | 78 | | 1.13 | | NA |
| IIVS | 6.3 | | 28 | | 0.8 | | NA |
| Trichloroacetic acid | 928 | 1.6 | | 27 | 2.97 | 0.005 | |
| ECBC | 762 | | 13 | | 2.88 | | 0.022 |
| FAL | 1220 | | 6 | | 3.09 | | 0.002 |
| IIVS | 801 | | 14 | | 2.9 | | 0.069 |
| 1,1,1-Trichloroethane | 15538 | 2.2 | | 52 | 4.19 | < 0.001 | |
| ECBC | NA | | NA | | NA | | NA |
| FAL | 21250 | | 11 | | 4.33 | | NA |
| IIVS | 9827 | | 2 | | 3.99 | | NA |
| Triethylenemelamine | 0.568 | 16.9 | | 135 | -0.25 | < 0.001 | |
| ECBC | 0.086 | | 11 | | -1.07 | | < 0.001 |
| FAL | 1.45 | | 18 | | 0.16 | | < 0.001 |
| IIVS | 0.169 | | 29 | | -0.77 | | 0.002 |
| Triphenyltin hydroxide | 0.022 | 1.7 | | 29 | -1.66 | 0.688 | |
| ECBC | 0.026 | | 17 | | -1.59 | | NA |
| FAL | 0.026 | | 81 | | -1.59 | | NA |

| Reference Substance/Laboratory | Arithmetic Mean IC ₅₀ (mg/mL) ¹ | Maximum: Minimum Mean IC ₅₀ Ratio ² | Arithmetic IntraLab %CV | Arithmetic InterLab %CV | Log Arithmetic Mean IC ₅₀ (mg/mL) ¹ | ANOVA P ³ | Contrast P ⁴ |
|-----------------------------------|---|--|-------------------------------|-------------------------------|--|-------------------------|----------------------------|
| IIVS | 0.015 | | 55 | | -1.83 | | NA |
| Valproic acid | 1177 | 3.3 | | 76 | 3.07 | < 0.001 | |
| ECBC | 547 | | 12 | | 2.74 | | NA |
| FAL | 1807 | | 10 | | 3.26 | | NA |
| IIVS | NA | | NA | | NA | | NA |
| Verapamil HCl | 35.2 | 1.2 | | 10 | 1.55 | 0.23 | |
| ECBC | 32 | | 18 | | 1.51 | | NA |
| FAL | 34.6 | | 5 | | 1.54 | | NA |
| IIVS | 38.9 | | 11 | | 1.59 | | NA |
| Xylene | NA | NA | | NA | NA | NA | NA |
| ECBC | NA | | NA | | NA | | NA |
| FAL | NA | | NA | | NA | | NA |
| IIVS | 724 | | 12 | | 2.86 | | NA |

Abbreviations: 3T3=BALB/c 3T3 fibroblasts; NRU=Neutral red uptake; ECBC=Edgewood Chemical Biological Center;

FAL= Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory; IIVS=Institute for In Vitro

Sciences; NA=No acceptable IC_{50} results reported or calculation was not performed (e.g., for contrast results); CV=Coefficient of variation.

¹Results reported on the same row with chemical names are the means of all the laboratories. Results reported on the same row as laboratories are the laboratory means.

²Maximum laboratory mean IC_{50} divided by minimum laboratory mean IC_{50} .

³p <0.01 indicated statistical significance.

⁴Contrasts were performed if ANOVA was significant (p <0.01) to determine which laboratory was different from the other two laboratories. Significant contrasts were denoted by p <0.01. No contrast tests were performed if only two laboratories reported IC₅₀ values.

| Reference Substance | Signi | ficant Contrast F | Results ¹ | Insoluble/ |
|-----------------------------|-------|-------------------|----------------------|--------------------------|
| iterence Substance | ECBC | FAL | IIVS | Volatile ² |
| Acetylsalicylic acid | | Н | L | |
| Arsenic trioxide | | L | Н | Precipitate |
| Busulfan | | Н | | |
| Chloral hydrate | L | Н | | |
| Chloramphenicol | L | Н | | |
| Citric acid | L | Н | | |
| Colchicine | L | Н | | |
| Cupric sulfate pentahydrate | М | Н | L | |
| Dibutyl phthalate | | Н | L | Precipitate |
| Dichlorvos | L | Н | | Precipitate |
| Ethylene glycol | L | | | |
| Glutethimide | | Н | L | |
| Haloperidol | | Н | | |
| Meprobamate | L | Н | М | |
| Phenylthiourea | L | Н | | |
| Potassium cyanide | L | Н | М | Precipitate /Volatile |
| Procainamide HCl | L | | Н | |
| 2-Propanol | L | М | Н | Volatile |
| Propylparaben | | Н | L | |
| Sodium selenate | L | Н | | |
| Strychnine | Н | | L | Precipitate |
| Trichloroacetic acid | | Н | | |
| Triethylenemelamine | L | Н | | |

Table 7-4Reference Substances with Significant ANOVA Differences Among
Laboratories for the 3T3 NRU Test Method

Abbreviations: ANOVA=Analysis of variance; 3T3=BALB/c 3T3 fibroblasts; NRU=Neutral red uptake; H=Laboratory reported the highest mean IC₅₀; L=Laboratory reported the lowest mean IC₅₀; M=Laboratory reported a mean IC₅₀ between the values of the other two laboratories; ECBC=Edgewood Chemical Biological Center; FAL= Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory; IIVS=Institute for *In Vitro* Sciences.

¹Laboratories significantly different from the other two at p < 0.01.

²From **Table 5-11**. Precipitate reported by at least one laboratory is indicated by "Precipitate". Use of plate sealers by at least one laboratory to prevent volatile contamination of control wells indicated by "Volatility".

7.2.2.2 Differences Among the IC_{50} Values in Laboratories Using the NHK NRU Test Method The ANOVA results in **Table 7-5** indicate that there were statistically significant (p <0.01) laboratory differences for six of the 68 (9%) reference substances evaluated. These substances are listed in **Table 7-6** along with columns showing which laboratory's IC_{50} values were statistically significantly different from the other two (as indicated by the contrast results), and indications of insolubility or volatility during conduct of the assay. Insolubility was reported for three of the six substances, but none of the six substances were volatile.

For the six substances that yielded significantly different IC_{50} values among the laboratories, ECBC reported the highest IC_{50} value for four substances and the lowest for one, FAL reported the lowest values for three substances and the highest for two, and IIVS reported the highest IC_{50} value for one substance and the lowest for two.

7.2.3 <u>CV Results for the 3T3 and NHK NRU Test Methods</u>

CV values were calculated as described in Section **5.5.2.2**. **Tables 7-3** and **7-5** provide the intraand inter-laboratory CV values for the individual reference substances. **Table 7-7** summarizes the CV values for each method and shows that median and mean values were often similar. Median CV values were frequently lower than the corresponding means, which indicated that large individual CV values skewed the CV distributions.

7.2.3.1 Reproducibility of Intralaboratory CV Values

Table 7-7 shows that the intralaboratory CV values and mean intralaboratory CV values were the same, 26%, for both NRU test methods. The median intralaboratory CV values were also similar: 23% and 24% for the 3T3 and the NHK NRU test method, respectively. Of the three laboratories, FAL had the highest mean and median CV values and IIVS had the lowest for both methods.

| Reference Substance/Laboratory | Arithmetic Mean IC ₅₀ (mg/mL) ¹ | Maximum: Minimum Mean IC ₅₀ Ratio ² | Arithmetic IntraLab %CV | Arithmetic InterLab %CV | Log Arithmetic Mean IC ₅₀ (mg/mL) ¹ | ANOVA P ³ | Contrast P ⁴ |
|-----------------------------------|---|--|-------------------------------|-------------------------------|--|-------------------------|----------------------------|
| Acetaminophen | 526 | 1.3 | | 13 | 2.72 | 0.181 | |
| ECBC | 558 | | 15 | | 2.75 | | NA |
| FAL | 447 | | 19 | | 2.65 | | NA |
| IIVS | 571 | | 14 | | 2.76 | | NA |
| Acetonitrile | 10104 | 1.2 | | 8 | 4 | 0.964 | |
| ECBC | 10868 | | 72 | | 4.04 | | NA |
| FAL | 10153 | | 19 | | 4.01 | | NA |
| IIVS | 9290 | | 4 | | 3.97 | | NA |
| Acetylsalicylic acid | 613 | 1.4 | | 15 | 2.79 | 0.060 | |
| ECBC | 631 | | 3 | | 2.8 | | NA |
| FAL | 694 | | 14 | | 2.84 | | NA |
| IIVS | 514 | | 15 | | 2.71 | | NA |
| 5-Aminosalicylic acid | 52.3 | 2.6 | | 47 | 1.72 | 0.044 | |
| ECBC | 29.9 | | 22 | | 1.48 | | NA |
| FAL | 78.2 | | 54 | | 1.89 | | NA |
| IIVS | 48.8 | | 16 | | 1.69 | | NA |
| Aminopterin | 682 | 1.6 | | 27 | 2.83 | 0.025 | |
| ECBC | 889 | | 20 | | 2.95 | | NA |
| FAL | 545 | | 8 | | 2.74 | | NA |
| IIVS | 611 | | 12 | | 2.79 | | NA |
| Amitriptyline HCl | 9.76 | 1.4 | | 19 | 0.99 | 0.365 | |
| ECBC | 10.8 | | 31 | | 1.03 | | NA |
| FAL | 7.57 | | 72 | | 0.88 | | NA |
| IIVS | 10.9 | | 10 | | 1.04 | | NA |
| Arsenic trioxide | 10.4 | 8.2 | | 91 | 1.02 | < 0.001 | |

| Reference Substance/Laboratory | Arithmetic Mean IC ₅₀ (mg/mL) ¹ | Maximum: Minimum Mean IC ₅₀ Ratio ² | Arithmetic IntraLab %CV | Arithmetic InterLab %CV | Log Arithmetic Mean IC ₅₀ (mg/mL) ¹ | ANOVA P ³ | Contrast P ⁴ |
|-----------------------------------|---|--|-------------------------------|-------------------------------|--|-------------------------|----------------------------|
| ECBC | 7.77 | | 33 | | 0.89 | | 0.694 |
| FAL | 2.55 | | 75 | | 0.41 | | < 0.001 |
| IIVS | 20.9 | | 31 | | 1.32 | | 0.0006 |
| Atropine sulfate | 91.9 | 1.3 | | 13 | 1.96 | 0.988 | |
| ECBC | 85.4 | | 12 | | 1.93 | | 0.8903 |
| FAL | 104 | | 85 | | 2.02 | | 0.9069 |
| IIVS | 83.2 | | 25 | | 1.92 | | 0.9832 |
| Boric acid | 473 | 1.2 | | 8 | 2.67 | 0.931 | |
| ECBC | 440 | | 31 | | 2.64 | | 0.9692 |
| FAL | 517 | | 73 | | 2.71 | | 0.7391 |
| IIVS | 464 | | 2 | | 2.67 | | 0.768 |
| Busulfan | 278 | 1.2 | | 11 | 2.44 | 0.659 | |
| ECBC | 253 | | 27 | | 2.4 | | NA |
| FAL | 268 | | 72 | | 2.43 | | NA |
| IIVS | 313 | | 12 | | 2.5 | | NA |
| Cadmium chloride | 1.98 | 1.2 | | 10 | 0.3 | 0.733 | |
| ECBC | 2.2 | | 37 | | 0.34 | | NA |
| FAL | 1.88 | | 65 | | 0.27 | | NA |
| IIVS | 1.86 | | 8 | | 0.27 | | NA |
| Caffeine | 661 | 1.4 | | 21 | 2.82 | 0.296 | |
| ECBC | 817 | | 31 | | 2.91 | | NA |
| FAL | 591 | | 32 | | 2.77 | | NA |
| IIVS | 574 | | 1 | | 2.76 | | NA |
| Carbamazepine | 128 | 4.0 | | 85 | 2.11 | 0.432 | |
| ECBC | 66.1 | | 13 | | 1.82 | | NA |

| Reference Substance/Laboratory | Arithmetic Mean IC ₅₀ (mg/mL) ¹ | Maximum: Minimum Mean IC ₅₀ Ratio ² | Arithmetic IntraLab %CV | Arithmetic InterLab %CV | Log Arithmetic Mean IC ₅₀ (mg/mL) ¹ | ANOVA P ³ | Contrast P ⁴ |
|-----------------------------------|---|--|-------------------------------|-------------------------------|--|-------------------------|----------------------------|
| FAL | 253 | | 129 | | 2.4 | | NA |
| IIVS | 63.9 | | 8 | | 1.81 | | NA |
| Carbon tetrachloride | NA | NA | | NA | NA | NA | |
| ECBC | NA | | NA | | NA | | NA |
| FAL | NA | | NA | | NA | | NA |
| IIVS | NA | | NA | | NA | | NA |
| Chloral hydrate | 137 | 1.4 | | 17 | 2.14 | 0.302 | |
| ECBC | 140 | | 24 | | 2.15 | | NA |
| FAL | 159 | | 32 | | 2.2 | | NA |
| IIVS | 112 | | 2 | | 2.05 | | NA |
| Chloramphenicol | 366 | 1.3 | | 13 | 2.56 | 0.750 | |
| ECBC | 318 | | 45 | | 2.5 | | NA |
| FAL | 414 | | 44 | | 2.62 | | NA |
| IIVS | 367 | | 22 | | 2.56 | | NA |
| Citric acid | 424 | 1.7 | | 25 | 2.63 | 0.006 | |
| ECBC | 526 | | 16 | | 2.72 | | 0.009 |
| FAL | 312 | | 17 | | 2.49 | | 0.002 |
| IIVS | 433 | | 5 | | 2.64 | | 0.483 |
| Colchicine | 0.007 | 1.6 | | 22 | -2.16 | 0.174 | |
| ECBC | 0.005 | | 46 | | -2.28 | | NA |
| FAL | 0.008 | | 10 | | -2.12 | | NA |
| IIVS | 0.008 | | 21 | | -2.09 | | NA |
| Cupric sulfate pentahydrate | 197 | 1.1 | | 4 | 2.29 | 0.374 | |
| ECBC | 190 | | 10 | | 2.28 | | NA |
| FAL | 195 | | 6 | | 2.29 | | NA |

| Reference Substance/Laboratory | Arithmetic Mean IC ₅₀ (mg/mL) ¹ | Maximum: Minimum Mean IC ₅₀ Ratio ² | Arithmetic IntraLab %CV | Arithmetic InterLab %CV | Log Arithmetic Mean IC ₅₀ (mg/mL) ¹ | ANOVA P ³ | Contrast P ⁴ |
|-----------------------------------|---|--|-------------------------------|-------------------------------|--|-------------------------|----------------------------|
| IIVS | 207 | | 3 | | 2.32 | | NA |
| Cycloheximide | 0.082 | 2.3 | | 43 | -1.09 | 0.302 | |
| ECBC | 0.053 | | 22 | | -1.28 | | NA |
| FAL | 0.12 | | 78 | | -0.92 | | NA |
| IIVS | 0.071 | | 19 | | -1.15 | | NA |
| Dibutyl phthalate | 32.6 | 2.2 | | 41 | 1.51 | 0.408 | |
| ECBC | 28.3 | | 27 | | 1.45 | | NA |
| FAL | 47.4 | | 73 | | 1.68 | | NA |
| IIVS | 22 | | 6 | | 1.34 | | NA |
| Dichlorvos | 11.1 | 1.4 | | 20 | 1.05 | 0.181 | |
| ECBC | 8.56 | | 27 | | 0.93 | | NA |
| FAL | 12.4 | | 30 | | 1.09 | | NA |
| IIVS | 12.2 | | 3 | | 1.09 | | NA |
| Diethyl phthalate | 145 | 2.6 | | 44 | 2.16 | 0.049 | |
| ECBC | 174 | | 8 | | 2.24 | | NA |
| FAL | 71.5 | | 94 | | 1.85 | | NA |
| IIVS | 189 | | 18 | | 2.28 | | NA |
| Digoxin | 0.00314 | 107.6 | | 88 | -2.5 | < 0.001 | |
| ECBC | 0.00538 | | 13 | | -2.27 | | < 0.001 |
| FAL | 0.00005 | | 36 | | -4.29 | | < 0.001 |
| IIVS | 0.00398 | | 7 | | -2.4 | | < 0.001 |
| Dimethylformamide | 7856 | 1.5 | | 19 | 3.9 | < 0.001 | |
| ECBC | 9353 | | 2 | | 3.97 | | < 0.001 |
| FAL | 7817 | | 1 | | 3.89 | | 0.508 |
| IIVS | 6397 | | 3 | | 3.81 | | < 0.001 |

| Reference Substance/Laboratory | Arithmetic Mean IC ₅₀ (mg/mL) ¹ | Maximum: Minimum Mean IC ₅₀ Ratio ² | Arithmetic IntraLab %CV | Arithmetic InterLab %CV | Log Arithmetic Mean IC ₅₀ (mg/mL) ¹ | ANOVA P ³ | Contrast P ⁴ |
|-----------------------------------|---|--|-------------------------------|-------------------------------|--|-------------------------|----------------------------|
| Diquat dibromide monohydrate | 4.73 | 1.9 | | 37 | 0.67 | 0.217 | |
| ECBC | 3.59 | | 23 | | 0.56 | | NA |
| FAL | 6.77 | | 55 | | 0.83 | | NA |
| IIVS | 3.84 | | 8 | | 0.58 | | NA |
| Disulfoton | 378 | 5.8 | | 99 | 2.58 | < 0.001 | |
| ECBC | 140 | | 19 | | 2.15 | | 0.002 |
| FAL | 808 | | 26 | | 2.91 | | < 0.001 |
| IIVS | 186 | | 32 | | 2.27 | | 0.018 |
| Endosulfan | 2.35 | 2.4 | | 43 | 0.37 | 0.029 | |
| ECBC | 3.44 | | 17 | | 0.54 | | NA |
| FAL | 1.42 | | 50 | | 0.15 | | NA |
| IIVS | 2.19 | | 20 | | 0.34 | | NA |
| Epinephrine bitartrate | 90.6 | 1.5 | | 24 | 1.96 | 0.119 | |
| ECBC | 115 | | 9 | | 2.06 | | NA |
| FAL | 81.7 | | 35 | | 1.91 | | NA |
| IIVS | 75 | | 16 | | 1.88 | | NA |
| Ethanol | 10184 | 1.4 | | 18 | 4.01 | 0.035 | |
| ECBC | 8290 | | 5 | | 3.92 | | NA |
| FAL | 12013 | | 19 | | 4.08 | | NA |
| IIVS | 10250 | | 9 | | 4.01 | | NA |
| Ethylene glycol | 42600 | 1.3 | | 15 | 4.63 | 0.063 | |
| ECBC | 38000 | | 12 | | 4.58 | | NA |
| FAL | 49800 | | 9 | | 4.7 | | NA |
| IIVS | 40000 | | 13 | | 4.6 | | NA |
| Fenpropathrin | 2.6 | 2.0 | | 39 | 0.41 | 0.031 | |

| Reference Substance/Laboratory | Arithmetic Mean IC ₅₀ (mg/mL) ¹ | Maximum: Minimum Mean IC ₅₀ Ratio ² | Arithmetic IntraLab %CV | Arithmetic InterLab %CV | Log Arithmetic Mean IC ₅₀ (mg/mL) ¹ | ANOVA P ³ | Contrast P ⁴ |
|-----------------------------------|---|--|-------------------------------|-------------------------------|--|-------------------------|----------------------------|
| ECBC | 3.73 | | 27 | | 0.57 | | NA |
| FAL | 2.23 | | 28 | | 0.35 | | NA |
| IIVS | 1.82 | | 17 | | 0.26 | | NA |
| Gibberellic Acid | 2866 | 1.0 | | 2 | 3.46 | 0.862 | |
| ECBC | 2850 | | 14 | | 3.45 | | NA |
| FAL | 2940 | | 9 | | 3.47 | | NA |
| IIVS | 2807 | | 4 | | 3.45 | | NA |
| Glutethimide | 177 | 1.1 | | 5 | 2.25 | 0.968 | |
| ECBC | 187 | | 34 | | 2.27 | | NA |
| FAL | 170 | | 14 | | 2.23 | | NA |
| IIVS | 176 | | 16 | | 2.24 | | NA |
| Glycerol | 27108 | 1.9 | | 31 | 4.43 | 0.200 | |
| ECBC | 34267 | | 45 | | 4.53 | | NA |
| FAL | 18023 | | 46 | | 4.26 | | NA |
| IIVS | 29033 | | 16 | | 4.46 | | NA |
| Haloperidol | 3.57 | 1.1 | | 7 | 0.55 | 0.935 | |
| ECBC | 3.69 | | 27 | | 0.57 | | NA |
| FAL | 3.72 | | 49 | | 0.57 | | NA |
| IIVS | 3.29 | | 35 | | 0.52 | | NA |
| Hexachlorophene | 0.031 | 2.2 | | 41 | -1.5 | 0.097 | |
| ECBC | 0.027 | | 16 | | -1.57 | | NA |
| FAL | 0.046 | | 44 | | -1.34 | | NA |
| IIVS | 0.021 | | 11 | | -1.67 | | NA |
| Lactic acid | 1308 | 1.0 | | 1 | 3.12 | 0.904 | |
| ECBC | 1290 | | 4 | | 3.11 | | NA |

| Reference Substance/Laboratory | Arithmetic Mean IC ₅₀ (mg/mL) ¹ | Maximum: Minimum Mean IC ₅₀ Ratio ² | Arithmetic IntraLab %CV | Arithmetic InterLab %CV | Log Arithmetic Mean IC ₅₀ (mg/mL) ¹ | ANOVA P ³ | Contrast P ⁴ |
|-----------------------------------|---|--|-------------------------------|-------------------------------|--|-------------------------|----------------------------|
| FAL | 1320 | | 5 | | 3.12 | | NA |
| IIVS | 1313 | | 11 | | 3.12 | | NA |
| Lindane | 19.3 | 1.5 | | 20 | 1.29 | 0.203 | |
| ECBC | 19.1 | | 17 | | 1.28 | | NA |
| FAL | 23.2 | | 31 | | 1.37 | | NA |
| IIVS | 15.6 | | 15 | | 1.19 | | NA |
| Lithium carbonate | 477 | 1.3 | | 13 | 2.68 | 0.295 | |
| ECBC | 411 | | 29 | | 2.61 | | NA |
| FAL | 486 | | 20 | | 2.69 | | NA |
| IIVS | 535 | | 6 | | 2.73 | | NA |
| Meprobamate | 516 | 4.7 | | 61 | 2.71 | 0.027 | |
| ECBC | 761 | | 15 | | 2.88 | | NA |
| FAL | 163 | | 116 | | 2.21 | | NA |
| IIVS | 624 | | 14 | | 2.8 | | NA |
| Mercury chloride | 5.87 | 1.3 | | 15 | 0.77 | 0.120 | |
| ECBC | 6.87 | | 15 | | 0.84 | | NA |
| FAL | 5.4 | | 19 | | 0.73 | | NA |
| IIVS | 5.35 | | 2 | | 0.73 | | NA |
| Methanol | 1616 | 1.9 | | 42 | 3.21 | 0.007 | |
| ECBC | NA | | NA | | NA | | NA |
| FAL | 1133 | | 19 | | 3.05 | | NA |
| IIVS | 2100 | | 11 | | 3.32 | | NA |
| Nicotine | 113 | 1.4 | | 17 | 2.05 | 0.700 | |
| ECBC | 94.3 | | 26 | | 1.97 | | NA |
| FAL | 134 | | 59 | | 2.13 | | NA |

| Reference Substance/Laboratory | Arithmetic Mean IC ₅₀ (mg/mL) ¹ | Maximum: Minimum Mean IC ₅₀ Ratio ² | Arithmetic IntraLab %CV | Arithmetic InterLab %CV | Log Arithmetic Mean IC ₅₀ (mg/mL) ¹ | ANOVA P ³ | Contrast P ⁴ |
|-----------------------------------|---|--|-------------------------------|-------------------------------|--|-------------------------|----------------------------|
| IIVS | 112 | | 25 | | 2.05 | | NA |
| Paraquat | 66.1 | 2.0 | | 40 | 1.82 | 0.047 | |
| ECBC | 48.3 | | 13 | | 1.68 | | NA |
| FAL | 96.6 | | 39 | | 1.98 | | NA |
| IIVS | 53.4 | | 10 | | 1.73 | | NA |
| Parathion | 31.4 | 1.2 | | 8 | 1.5 | 0.845 | |
| ECBC | 34 | | 30 | | 1.53 | | NA |
| FAL | 31.2 | | 38 | | 1.49 | | NA |
| IIVS | 29 | | 29 | | 1.46 | | NA |
| Phenobarbital | 478 | 1.9 | | 39 | 2.68 | 0.027 | |
| ECBC | 693 | | 26 | | 2.84 | | NA |
| FAL | 360 | | 27 | | 2.56 | | NA |
| IIVS | 381 | | 18 | | 2.58 | | NA |
| Phenol | 77.7 | 1.6 | | 22 | 1.89 | 0.094 | |
| ECBC | 59.1 | | 36 | | 1.77 | | NA |
| FAL | 93.2 | | 6 | | 1.97 | | NA |
| IIVS | 80.8 | | 6 | | 1.91 | | NA |
| Phenylthiourea | 346 | 1.5 | | 19 | 2.54 | 0.133 | |
| ECBC | 363 | | 16 | | 2.56 | | NA |
| FAL | 401 | | 21 | | 2.6 | | NA |
| IIVS | 272 | | 26 | | 2.44 | | NA |
| Physostigmine | 172 | 1.5 | | 22 | 2.24 | 0.623 | |
| ECBC | 164 | | 3 | | 2.21 | | NA |
| FAL | 213 | | 112 | | 2.33 | | NA |
| IIVS | 139 | | 6 | | 2.14 | | NA |

| Reference Substance/Laboratory | Arithmetic Mean IC ₅₀ (mg/mL) ¹ | Maximum: Minimum Mean IC ₅₀ Ratio ² | Arithmetic IntraLab %CV | Arithmetic InterLab %CV | Log Arithmetic Mean IC ₅₀ (mg/mL) ¹ | ANOVA P ³ | Contrast P ⁴ |
|-----------------------------------|---|--|-------------------------------|-------------------------------|--|-------------------------|----------------------------|
| Potassium chloride | 2279 | 1.3 | | 13 | 3.36 | 0.396 | |
| ECBC | 2560 | | 17 | | 3.41 | | NA |
| FAL | 2287 | | 28 | | 3.36 | | NA |
| IIVS | 1990 | | 8 | | 3.3 | | NA |
| Potassium cyanide | 45.1 | 5.3 | | 86 | 1.65 | 0.340 | |
| ECBC | 29.3 | | 24 | | 1.47 | | NA |
| FAL | 89 | | 112 | | 1.95 | | NA |
| IIVS | 16.9 | | 13 | | 1.23 | | NA |
| Procainamide HCl | 1764 | 1.4 | | 16 | 3.25 | 0.053 | |
| ECBC | 1480 | | 14 | | 3.17 | | NA |
| FAL | 1787 | | 12 | | 3.25 | | NA |
| IIVS | 2027 | | 11 | | 3.31 | | NA |
| 2-Propanol | 5541 | 1.7 | | 26 | 3.74 | 0.033 | |
| ECBC | 5263 | | 11 | | 3.72 | | NA |
| FAL | 4273 | | 27 | | 3.63 | | NA |
| IIVS | 7087 | | 7 | | 3.85 | | NA |
| Propranolol HCl | 36.9 | 1.5 | | 21 | 1.57 | 0.003 | |
| ECBC | 38.27 | | 12 | | 1.58 | | 0.325 |
| FAL | 43.8 | | 6 | | 1.64 | | 0.006 |
| IIVS | 28.6 | | 11 | | 1.46 | | 0.001 |
| Propylparaben | 16.8 | 1.3 | | 16 | 1.23 | 0.066 | |
| ECBC | 18.1 | | 13 | | 1.26 | | NA |
| FAL | 18.6 | | 15 | | 1.27 | | NA |
| IIVS | 13.8 | | 9 | | 1.14 | | NA |
| Sodium arsenite | 0.532 | 2.4 | | 44 | -0.27 | 0.061 | |

| Reference Substance/Laboratory | Arithmetic Mean IC ₅₀ (mg/mL) ¹ | Maximum: Minimum Mean IC ₅₀ Ratio ² | Arithmetic IntraLab %CV | Arithmetic InterLab %CV | Log Arithmetic Mean IC ₅₀ (mg/mL) ¹ | ANOVA P ³ | Contrast P ⁴ |
|-----------------------------------|---|--|-------------------------------|-------------------------------|--|-------------------------|----------------------------|
| ECBC | 0.79 | | 32 | | -0.1 | | NA |
| FAL | 0.336 | | 56 | | -0.47 | | NA |
| IIVS | 0.47 | | 14 | | -0.33 | | NA |
| Sodium chloride | 2724 | 3.2 | | 51 | 3.44 | 0.045 | |
| ECBC | 3583 | | 7 | | 3.55 | | NA |
| FAL | 1118 | | 124 | | 3.05 | | NA |
| IIVS | 3470 | | 9 | | 3.54 | | NA |
| Sodium dichromate dihydrate | 0.737 | 1.5 | | 19 | -0.13 | 0.258 | |
| ECBC | 0.784 | | 14 | | -0.11 | | NA |
| FAL | 0.851 | | 36 | | -0.07 | | NA |
| IIVS | 0.576 | | 17 | | -0.24 | | NA |
| Sodium fluoride | 47.4 | 1.4 | | 15 | 1.68 | 0.313 | |
| ECBC | 48.7 | | 14 | | 1.69 | | NA |
| FAL | 39.7 | | 24 | | 1.6 | | NA |
| IIVS | 53.7 | | 13 | | 1.73 | | NA |
| Sodium hypochlorite | 1580 | 1.5 | | 20 | 3.2 | 0.313 | |
| ECBC | 1863 | | 31 | | 3.27 | | NA |
| FAL | 1243 | | 46 | | 3.09 | | NA |
| IIVS | 1633 | | 11 | | 3.21 | | NA |
| Sodium oxalate | 355 | 1.0 | | 1 | 2.55 | 0.926 | |
| ECBC | 355 | | 15 | | 2.55 | | NA |
| FAL | 350 | | 42 | | 2.54 | | NA |
| IIVS | 360 | | 26 | | 2.56 | | NA |
| Sodium selenate | 11.2 | 2.2 | | 40 | 1.05 | 0.134 | |
| ECBC | 7.47 | | 12 | | 0.87 | | NA |

| Reference Substance/Laboratory | Arithmetic Mean IC ₅₀ (mg/mL) ¹ | Maximum: Minimum Mean IC ₅₀ Ratio ² | Arithmetic IntraLab %CV | Arithmetic InterLab %CV | Log Arithmetic Mean IC ₅₀ (mg/mL) ¹ | ANOVA P ³ | Contrast P ⁴ |
|-----------------------------------|---|--|-------------------------------|-------------------------------|--|-------------------------|----------------------------|
| FAL | 16.1 | | 59 | | 1.21 | | NA |
| IIVS | 10 | | 13 | | 1 | | NA |
| Strychnine | 69.3 | 1.9 | | 39 | 1.84 | 0.364 | |
| ECBC | 100 | | 76 | | 2 | | NA |
| FAL | 52.5 | | 53 | | 1.72 | | NA |
| IIVS | 55.1 | | 6 | | 1.74 | | NA |
| Thallium Sulfate | 0.16 | 1.6 | | 23 | -0.8 | 0.405 | |
| ECBC | 0.198 | | 51 | | -0.7 | | NA |
| FAL | 0.153 | | 20 | | -0.82 | | NA |
| IIVS | 0.127 | | 16 | | -0.9 | | NA |
| Trichloroacetic acid | 427 | 1.6 | | 24 | 2.63 | 0.134 | |
| ECBC | 348 | | 18 | | 2.54 | | NA |
| FAL | 541 | | 28 | | 2.73 | | NA |
| IIVS | 394 | | 13 | | 2.6 | | NA |
| 1,1,1-Trichloroethane | NA | NA | | NA | NA | NA | |
| ECBC | 8137 | | 7 | | 3.91 | | NA |
| FAL | NA | | NA | | NA | | NA |
| IIVS | NA | | NA | | NA | | NA |
| Triethylenemelamine | 1.95 | 1.3 | | 12 | 0.29 | 0.562 | |
| ECBC | 1.69 | | 57 | | 0.23 | | NA |
| FAL | 2.03 | | 23 | | 0.31 | | NA |
| IIVS | 2.13 | | 23 | | 0.33 | | NA |
| Triphenyltin hydroxide | 0.013 | 3.0 | | 55 | -1.89 | 0.088 | |
| ECBC | 0.021 | | 32 | | -1.68 | | NA |
| FAL | 0.007 | | 106 | | -2.15 | | NA |

| Reference Substance/Laboratory | Arithmetic Mean IC ₅₀ (mg/mL) ¹ | Maximum: Minimum Mean IC ₅₀ Ratio ² | Arithmetic IntraLab %CV | Arithmetic InterLab %CV | Log Arithmetic Mean IC ₅₀ (mg/mL) ¹ | ANOVA P ³ | Contrast P ⁴ |
|-----------------------------------|---|--|-------------------------------|-------------------------------|--|-------------------------|----------------------------|
| IIVS | 0.011 | | 32 | | -1.96 | | NA |
| Valproic acid | 533 | 1.6 | | 28 | 2.73 | 0.081 | |
| ECBC | 468 | | 25 | | 2.67 | | 0.331 |
| FAL | 702 | | 23 | | 2.85 | | 0.032 |
| IIVS | 430 | | 17 | | 2.63 | | 0.135 |
| Verapamil HCl | 68.7 | 1.3 | | 14 | 1.84 | 0.624 | |
| ECBC | 60.5 | | 22 | | 1.78 | | NA |
| FAL | 79.4 | | 42 | | 1.9 | | NA |
| IIVS | 66.2 | | 8 | | 1.82 | | NA |
| Xylene | NA | NA | | NA | NA | NA | |
| ECBC | NA | | NA | | NA | | NA |
| FAL | NA | | NA | | NA | | NA |
| IIVS | 486 | | 38 | | 2.69 | | NA |

Abbreviations: NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake; ECBC=Edgewood Chemical Biological Center; FAL=

Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory; IIVS=Institute for In Vitro Sciences; NA=No acceptable

IC₅₀ results reported or calculation was not performed (e.g., for contrast results); CV=Coefficient of variation.

¹Results reported on the same row with chemical names are the means of all the laboratories. Results reported on the same row as laboratories are the laboratory means.

²Maximum laboratory mean IC_{50} divided by minimum laboratory mean IC_{50} .

³p <0.01 indicated statistical significance.

⁴Contrasts were performed if ANOVA was significant (p <0.01) to determine which laboratory was different from the other two laboratories. Significant contrasts were denoted by p < 0.01. No contrast tests were performed if only two laboratories reported IC₅₀ values.

Table 7-6Reference Substances with Significant ANOVA Differences Among
Laboratories for the NHK NRU Test Method

| Reference Substance | Signifi | Solubility/ | | |
|---------------------|---------|-------------|------|-------------------------|
| Kenerence Substance | ECBC | FAL | IIVS | Volatility ² |
| Arsenic trioxide | | L | Н | Precipitate |
| Citric acid | Н | L | | Precipitate |
| Digoxin | Н | L | | |
| Dimethylformamide | Н | | L | |
| Disulfoton | L | Н | | Precipitate |
| Propranolol HCl | | Н | L | |

Abbreviations: ANOVA=Analysis of variance; NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake; H=Laboratory reported the highest mean IC₅₀; L=Laboratory reported the lowest mean IC₅₀; ECBC=Edgewood Chemical Biological Center; FAL= Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory; IIVS=Institute for *In Vitro* Sciences.

¹Laboratories significantly different from the other two at p < 0.01

²From **Table 5-11**. Precipitate reported by at least one laboratory.

7.2.3.2 Reproducibility of Interlaboratory CV Values

The mean and median interlaboratory CV for the reference substances were lower in the NHK NRU test method (mean=28%; median=21% vs. mean=47%; median=37% for 3T3 (see **Table 7-7**).

| CV | 3T3 NRU Test Method | | | | NHK NRU Test Method | | | |
|--------------------|---------------------|------|--------|--------|---------------------|------|--------|--------|
| C V | Ν | Mean | Median | Range | Ν | Mean | Median | Range |
| Intralaboratory CV | 198 | 26% | 23% | 1-122% | 204 | 26% | 24% | 1-129% |
| ECBC | 64 | 23% | 17% | 2-95% | 68 | 23% | 20% | 2-76% |
| FAL | 64 | 33% | 31% | 1-98% | 68 | 43% | 34% | 1-129% |
| IIVS | 64 | 21% | 14% | 1-122% | 68 | 13% | 13% | 1-35% |
| Interlaboratory CV | 64 | 47% | 37% | 3-135% | 68 | 28% | 21% | 1-91% |

Table 7-7 Summary of CV Results for the 3T3 and NHK NRU Test Methods

Abbreviations: CV=Coefficient of variation; 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake; N=number of values; ECBC=Edgewood Chemical Biological Center; FAL= Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory; IIVS=Institute for *In Vitro* Sciences. Note: For the 3T3 method, the following substances were excluded because all laboratories did not obtain sufficient IC₅₀ data: carbon tetrachloride; disulfoton; gibberellic acid; lithium carbonate; methanol; 1,1,1-trichloroethane; valproic acid; and xylene. For the NHK method, the following substances were excluded because all laboratories did not obtain sufficient IC₅₀ data: carbon tetrachloride; methanol; 1,1,1-trichloroethane; and xylene.

7.2.3.3 Variation of CV with Chemical Property

To identify chemical characteristics that may be associated with high or low CV values, their associations were assessed for chemical class along with the following chemical attributes: physical state (i.e., solid or liquid), solubility, volatility, molecular weight, log K_{ow} , IC₅₀, and boiling point. The CVs were also examined with respect to their association with the GHS acute oral toxicity class (UN 2005). For categorical characteristics such as physical form, solubility (i.e., precipitate/no precipitate), volatile/not volatile, and chemical class, the mean

CV values and ranges for the groups were compared to one another and to the overall mean CV and CV range for each method. No statistical analyses were performed for these comparisons. Spearman correlation analyses were performed for chemical characteristics measured by continuous variables, such as molecular weight, log K_{ow}, and IC₅₀, and boiling point.

7.2.3.4 Results of Intralaboratory CV Analysis

The intralaboratory CV analysis (see **Table 7-8**) uses one mean intralaboratory CV for each reference substance that was calculated from the intralaboratory CV values from each laboratory. There seemed to be little difference in CV values among the categorical physical/chemical/toxicological attributes. The mean intralaboratory CV values for solids and liquids were similar (26 vs. 23% for 3T3; 27 vs. 24% for NHK). The mean intralaboratory CV values for reference substances for which precipitates were observed were similar to values for substances with no precipitates were observed (32 vs. 23% for 3T3; 24 vs. 27% for NHK). The mean intralaboratory CV values for substances with no precipitates for substances that exhibited volatility were similar to those that did not (31 vs. 25% for 3T3; 27 vs. 26% for NHK). Similarly, the substances grouped by GHS acute oral toxicity category (UN 2005) had mean intralaboratory CV values (26% for both test methods). However, the mean intralaboratory CV values for both NRU test methods tended to increase with decreasing LD₅₀.

Mean intralaboratory CV values were calculated for the chemical classes that contained at least three of the reference substances included in the reproducibility analyses (i.e., 64 substances for 3T3 and 68 substances for NHK). Reference substances in the amide chemical class had unusually low mean intralaboratory CV values for both the 3T3 (13%) and the NHK (10%) NRU test method compared with the overall mean CV (26% for both test methods), but there were only three substances in this chemical class (acetaminophen, dimethylformamide, procainamide HCl). Organic sulfur compounds had a high mean intralaboratory CV for the 3T3 test method (46%), but not for the NHK NRU test method (29%) compared with the overall mean intralaboratory CV for both test methods (26%). The intralaboratory CV values for the remaining chemical classes were unremarkable compared with the overall mean intralaboratory CV values.

For the characteristics amenable to correlation analysis, none of the Spearman correlation coefficients were large (absolute value of $r_s < 0.6$), but several were statistically significantly different from zero (p <0.05). Molecular weight (p=0.016), IC₅₀ (p=0.002), and boiling point (p=0.009) exhibited statistically significant correlations to intralaboratory CV for the 3T3 test NRU method. The higher molecular weight substances had higher intralaboratory CV values and the substances with lower IC₅₀ values had higher intralaboratory CV values. The finding that substances with higher boiling points had higher CV values was consistent with the categorical analysis of volatility. The substances that exhibited volatile characteristics (i.e., cross contamination of VC wells) in the 3T3 NRU test method had slightly higher mean intralaboratory CV values (31%) than the substances that did not exhibit volatile characteristics (25%).

| Class/Attribute | | 3T3 NRU Tes | st Method | | NHK NRU Test Method | | | |
|--|-----------------|----------------|-----------|-----------------|---------------------|---------|--|--|
| | N ¹ | Range | Mean | N^1 | Range | Mean | | |
| All chemicals | 64 | 1-122% | 26% | 68 | 1-129% | 26% | | |
| Chemical form | | | | | | | | |
| Solid | 51 | 4-84 | 26 | 53 | 6-57 | 27 | | |
| Liquid | 13 | 6-48 | 23 | 15 | 2-40 | 24 | | |
| Solubility | | | | | | | | |
| Precipitate ² | 18 | 11-84 | 32 | 19 | 2-47 | 24 | | |
| No precipitate | 46 | 4-55 | 23 | 49 | 7-57 | 27 | | |
| Volatility ³ | | | | | | | | |
| Volatile | 10 | 6-84 | 31 | 9 | 11-50 | 27 | | |
| Nonvolatile | 54 | 4-55 | 25 | 59 ² | 2-57 | 26 | | |
| Chemical Class | | | | | | | | |
| Alcohol | 9 | 6-42 | 22 | 9 | 10-37 | 22 | | |
| Amide | 3 | 4-28 | 13 | 3 | 2-16 | 10 | | |
| Amine | 3 | 9-35 | 18 | 3 | 10-24 | 18 | | |
| Carboxylic acid | 13 | 4-41 | 18 | 14 | 2-48 | 23 | | |
| Heterocyclic | 14 | 6-59 | 31 | 14 | 13-50 | 32 | | |
| Organophosphorous | 2 | NA | NA | 3 | 20-32 | 26 | | |
| Organic sulfur | 4 | 36-59 | 46 | 5 | 21-27 | 29 | | |
| Phenol | 5 | 14-30 | 20 | 5 | 11-31 | 19 | | |
| Polycyclic | 4 | 19-35 | 27 | 5 | 9-38 | 20 | | |
| Inorganic | 14 | 9-43 | 25 | 15 | 6-50 | 29 | | |
| Inorganic chlorine | 5 | 9-33 | 19 | 5 | 12-50 | 32 | | |
| Inorganic sodium | 6 | 9-34 | 20 | 6 | 17-47 | 30 | | |
| GHS Acute Oral | | | | | | | | |
| Toxicity Class | | | | | | | | |
| $LD_{50} \leq 5 \text{ mg/kg}$ | 6 | 9-46 | 27 | 7 | 20-40 | 30 | | |
| $5 < LD_{50} \le 50$ | 12 | 13-59 | 32 | 12 | 12-50 | 31 | | |
| $50 < LD_{50} \le 300$ | 12 | 11-84 | 33 | 12 | 17-37 | 25 | | |
| $300 < LD_{50} \le 2000$ | 14 | 4-51 | 22 | 16 | 6-57 | 25 | | |
| $2000 < LD_{50} \le 5000$ | 9 | 9-32 | 20 | 9 | 7-50 | 30 | | |
| LD ₅₀ >5000 | 11 | 6-42 | 20 | 12 | 2-40 | 19 | | |
| Correlations | Ν | r _s | P value | Ν | r _s | P value | | |
| Molecular weight | 64 | 0.301 | 0.016 | 68 | 0.181 | 0.140 | | |
| Log K _{ow} | 45 ⁴ | 0.121 | 0.430 | 48^{4} | 0.310 | 0.032 | | |
| IC ₅₀ | 64 | -0.382 | 0.002 | 68 | -0.346 | 0.004 | | |
| Boiling point bbreviations: CV=Coeffici | 24 ⁵ | 0.520 | 0.009 | 24 ⁵ | 0.226 | 0.289 | | |

Table 7-8Intralaboratory CV Values by Chemical Characteristics for the 3T3 and
NHK NRU Test Methods

Abbreviations: CV=Coefficient of variation; 3T3=BALB/c 3T3 fibroblasts; GHS=Globally Harmonized System of Classification and Labelling of Chemicals (UN 2005); NA=Not applicable because class had less than three observations; NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake; N=Number of values; r_s=Spearman correlation coefficient; K_{ow}=Octanol:water partition coefficient.

¹One intralaboratory CV for each chemical was calculated by averaging the CV values for each reference substance. ²Identified by laboratory reports of precipitate in the stock reference substance solutions or in cell culture (see **Table 5-11**).

³Identified by laboratory reports of using plate sealers to avoid contamination of the VC wells (see **Table 5-11**).

⁴Number of reference substances with CV values and log K_{ow} data.

⁵Number of reference substances with CV values and boiling point data.

Among the IC₅₀ values obtained using the NHK NRU test method, two of the characteristics amenable to correlation analysis were statistically significantly different from zero, although the correlation coefficients did not have large magnitudes (absolute value of $r_s < 0.4$). The log

 K_{ow} (p=0.032) and IC₅₀ (p=0.004) exhibited statistically significant correlations (p <0.05) to the intralaboratory CV. Log K_{ow} was positively correlated (i.e., higher log K_{ow} values were associated with higher mean intralaboratory CV), but the IC₅₀ was negatively correlated (i.e., higher log IC₅₀ values were associated with lower mean intralaboratory CV) to mean intralaboratory CV.

7.2.3.5 *Results of the Interlaboratory CV Analysis*

Table 7-9 shows the analysis of the interlaboratory CV values. There seemed to be little difference in interlaboratory CV values for most of the categorical physical/chemical characteristics. The mean interlaboratory CV values for solids and liquids were similar (48% for solids vs. 42% for liquids for 3T3, and 28% for solids vs. 21% for liquids for NHK), as were the values for substances for which precipitates were observed versus no precipitates (58% vs. 43% for 3T3, and 24% vs. 28% for NHK), and the values for substances that exhibited volatile characteristics (51% for volatile substances vs. 46% for nonvolatile substances for NHK).

Mean interlaboratory CV values were calculated for the chemical classes that contained at least three of the reference substances included in the reproducibility analyses (i.e., 64 substances for 3T3 and 68 substances for NHK). Reference substances in the amide chemical class had low mean interlaboratory CV values for both the 3T3 (15%) and the NHK (16%) NRU test methods compared with the overall mean interlaboratory CV (47% and 28%, respectively). Substances in the amine class also had low mean interlaboratory CV values for the 3T3 NRU (13%), but not for the NHK NRU (20%). Organic sulfur compounds had unusually high mean interlaboratory CV values for the 3T3 test method (100%), but not for the NHK NRU (36%) compared with the overall mean interlaboratory CV (47% and 28%, respectively). Because of the low number of reference substances in these classes, these results were deemed to not be significant.

Mean interlaboratory CV values tended to be large for chemicals in the most toxic GHS acute oral toxicity categories, especially with the 3T3 NRU test method. The mean interlaboratory CV for reference substances in the $LD_{50} \le 5 \text{ mg/kg}$ (72%) and $5 < LD_{50} \le 50 \text{ mg/kg}$ (78%) classes were larger than the mean overall interlaboratory CV (47%,). For the NHK NRU test method, the mean interlaboratory CV for chemicals in the $5 < LD_{50} \le 5 \text{ mg/kg}$ (37%) and $5 < LD_{50} \le 50 \text{ mg/kg}$ (41%) classes were larger than the mean overall interlaboratory CV (28%).

For the characteristics amenable to correlation analysis, none of the correlation coefficients were large (absolute value of $r_s < 0.6$), but IC₅₀ (p=0.015) and boiling point (p=0.007) exhibited statistically significant correlations (p <0.05) to interlaboratory CV in the 3T3 test NRU method. There was a negative correlation between interlaboratory CV and IC₅₀, but the correlation between boiling point and interlaboratory CV was positive. The positive correlation of CV with boiling point was largely consistent with the categorical analysis of volatility. The substances that exhibited volatile characteristics in the 3T3 NRU test method had slightly higher mean CV values than substances that did not exhibit volatile characteristics (51% vs. 46%). Only the IC₅₀ was significantly correlated (p=0.014) to

interlaboratory CV with a negative correlation (r_s =-0.271) when the NHK NRU test method was used.

| | 3 | 3T3 NRU Test M | Aethod | | NHK NRU Test Method | | | |
|--------------------------------|-----------------|----------------|---------|-----------------|---------------------|---------|--|--|
| Class/Attribute | N Range | | Mean | Ν | Range | Mean | | |
| All chemicals | 64 ¹ | 3-135% | 47% | 68 ¹ | 1-91% | 28% | | |
| Chemical Form | | | | | | | | |
| Solids | 51 | 3-135 | 48 | 53 | 1-91 | 28 | | |
| Liquids | 13 | 6-124 | 42 | 15 | 1-44 | 21 | | |
| Solubility | | | | | | | | |
| Precipitate ² | 18 | 7-127 | 58 | 19 | 1-91 | 24 | | |
| No precipitate | 46 | 3-135 | 43 | 49 | 1-88 | 28 | | |
| Volatility | | | | | | | | |
| Volatile ³ | 10 | 21-127 | 51 | 9 | 8-86 | 32 | | |
| Nonvolatile | 54 | 3-135 | 46 | 59 | 1-91 | 26 | | |
| Chemical Class | | | | | | | | |
| Alcohol | 9 | 12-119 | 38 | 9 | 11-31 | 20 | | |
| Amide | 3 | 6-28 | 15 | 3 | 13-19 | 16 | | |
| Amine | 3 | 10-16 | 13 | 3 | 14-24 | 20 | | |
| Carboxylic acid | 13 | 6-124 | 38 | 14 | 1-61 | 26 | | |
| Heterocyclic | 14 | 8-135 | 57 | 14 | 5-85 | 32 | | |
| Organic sulfur | 4 | 78-119 | 100 | 5 | 8-99 | 36 | | |
| Organophosphorous | 2 | NA | NA | 3 | 8-99 | 42 | | |
| Phenol | 5 | 19-64 | 41 | 5 | 15-47 | 28 | | |
| Polycyclic | 4 | 14-85 | 44 | 5 | 2-88 | 30 | | |
| Inorganic | 14 | 3-127 | 50 | 15 | 4-91 | 30 | | |
| Inorganic chlorine | 5 | 3-127 | 45 | 5 | 10-86 | 35 | | |
| Inorganic sodium | 6 | 3-60 | 34 | 6 | 15-51 | 32 | | |
| GHS Acute Oral | | | | | | | | |
| Toxicity Class | | | | | | | | |
| $LD_{50} \leq 5 \text{ mg/kg}$ | 6 | 12-135 | 72 | 7 | 12-99 | 37 | | |
| $5 < LD_{50} \le 50$ | 12 | 33-127 | 78 | 12 | 8-91 | 41 | | |
| $50 < LD_{50} \le 300$ | 12 | 8-120 | 37 | 12 | 10-41 | 26 | | |
| $300 < LD_{50} \le 2000$ | 14 | 11-85 | 35 | 16 | 1-61 | 20 | | |
| $2000 < LD_{50} \le 5000$ | 9 | 3-69 | 29 | 9 | 1-85 | 27 | | |
| LD ₅₀ >5000 | 11 | 6-124 | 41 | 12 | 2-44 | 23 | | |
| Correlations | Ν | rs | P value | Ν | r _s | P value | | |
| Molecular weight | 64 | 0.245 | 0.051 | 68 | 0.169 | 0.168 | | |
| Log K _{ow} | 45 ⁴ | 0.151 | 0.324 | 48^{4} | 0.210 | 0.151 | | |
| IC ₅₀ | 64 | -0.304 | 0.015 | 68 | -0.297 | 0.014 | | |
| Boiling point | 22^{5} | 0.563 | 0.007 | 25^{5} | -0.051 | 0.809 | | |

Table 7-9Interlaboratory 3T3 and NHK NRU Test Method CV Values Sorted by
Chemical Characteristics

Abbreviations: CV=Coefficient of variation; 3T3=BALB/c 3T3 fibroblasts; GHS=Globally Harmonized System of Classification and Labelling of Chemicals (UN 2005); NA=Not applicable because class had less than three observations; NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake; N=Number of values; r_s=Spearman correlation coefficient; K_{ow}=Octanol:water partition coefficient.

¹One intralaboratory CV for each chemical was calculated by averaging the CV values for each reference substance.

²Identified by laboratory reports of precipitate in the stock reference substance solutions or in cell culture (see **Table 5-11**).


³Identified by laboratory reports of using plate sealers to avoid contamination of the VC wells (see Table 5-11).

⁴Number of reference substances with CV values and log K_{ow} data.

⁵Number of reference substances with CV values and boiling point data.


7.2.4 Comparison of Maximum to Minimum IC_{50} Values Using Laboratory Means Interlaboratory reproducibility was also compared by calculating maximum to minimum mean IC_{50} values using the laboratory means from each method, so that the reproducibility of the IC_{50} values could be compared with the reproducibility of the reference LD_{50} values derived in **Section 4.2**. The **Figure 7-2** frequency histogram for the 3T3 NRU test method maximum:minimum mean IC_{50} values shows that approximately half (37) of the 64 reference substances produced ratios less than 2.5-fold of each other, and only nine chemicals had ratios greater than 5.5-fold, including one substance (cupric sulfate pentahydrate) that had a ratio of 22.


Figure 7-2 Frequency of Maximum: Minimum 3T3 NRU IC₅₀ Ratios



Abbreviations: 3T3=BALB/c 3T3 fibroblasts; NRU=Neutral red uptake. Bars show the number of substances with maximum:minimum 3T3 NRU IC₅₀ ratios within ±0.5 units of the bar label (e.g., the first bar indicates that there were 14 reference substances for which the laboratory mean maximum:minimum 3T3 NRU IC₅₀ ratios were 0.5 to1.4). The analysis includes 64 reference substances. Carbon tetrachloride, disulfoton, gibberellic acid, lithium carbonate, methanol, 1,1,1-trichloroethane, valproic acid, and xylene were excluded because not all laboratories obtained IC₅₀ values.

The **Figure 7-3** frequency histogram for the maximum:minimum mean IC_{50} values for the NHK NRU test method shows that ratios of 58 of the 68 chemicals were less than 2.5-fold of one another. The highest ratio of 108 for digoxin is not shown in the figure. Comparison of **Figures 7-2** and **7-3** shows that the interlaboratory reproducibility of the NHK NRU test method was better than that for the 3T3 NRU test method based on the distribution of the low maximum:minimum IC_{50} ratios.







Abbreviations: NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake. Bars show the number of substances with maximum:minimum NHK NRU IC₅₀ ratios within ±0.5 units of the bar label (e.g., the first bar indicates that there were 30 reference substances for which the laboratory mean maximim:minimum NHK NRU IC₅₀ ratios were 0.5 to 1.4). The analysis includes 68 reference substances. Carbon tetrachloride, methanol, 1,1,1-trichloroethane, and xylene were excluded because not all laboratories obtained IC₅₀ values. The maximum:minimum IC₅₀ for digoxin of 108 was excluded from this figure.

7.2.5 <u>Comparison of the Maximum:Minimum IC₅₀ Ratios with the Maximum:Minimum LD₅₀ Ratios</u>

To compare the reproducibility of the NRU IC₅₀ values with that of the LD₅₀ values, the maximum:minimum IC₅₀ ratios for each method (shown in **Tables 7-3** and **7-5**) were compared with the maximum:minimum LD₅₀ ratios reported in **Table 4-2**. This analysis excluded reference substances for which fewer than three laboratories reported IC₅₀ values, and reference substances for which fewer than two acceptable acute oral LD₅₀ values were identified. As a result, there were 53 substances analysed for the 3T3 NRU test method and 57 for the NHK NRU test method. The following substances were excluded from both analyses because fewer than two acceptable LD₅₀ values could be identified: aminopterin; colchicine; digoxin; epinephrine bitartrate; gluthethimide; phenylthiourea; physostigmine; procainamide HCl, propranolol HCl; propylparaben; and thallium sulfate. Carbon tetrachloride, disulfoton, gibberellic acid, lithium carbonate, methanol, 1,1,1-trichloroethane, valproic acid, and xylene, were excluded from the 3T3 analysis, and carbon tetrachloride, methanol, 1,1,1-trichloroethane, and xylene, were excluded from the NHK analysis, because fewer than three laboratories reported IC₅₀ values.

Figure 7-4 shows that the maximum:minimum LD_{50} ratios tend to be larger than either the 3T3 NRU IC₅₀ or NHK NRU IC₅₀ ratios because there are more points below the theoretical one-to-one correspondence line than above the line. The difference between the LD_{50} maximum:minimum values and the NRU IC₅₀ maximum:minimum values is more striking for the NHK since there are fewer points above the line for the NHK graph (**Figure 7-4b**) than for the 3T3 graph (**Figure 7-4a**).





Abbreviations: 3T3=BALB/c 3T3 fibroblasts; NRU=Neutral red uptake; NHK=Normal human epidermal keratinocytes. Comparison of maximum:minimum ratios of IC₅₀ and LD₅₀ for 53 reference substances for the 3T3 NRU test method (a) and 57 reference substances for the NHK NRU test method (b). Solid lines show the theoretical one to one correspondence of maximum:minimum IC₅₀ to maximum:minimum LD₅₀.

7.2.6 Normalization of Reference Substance IC₅₀ Values Using SLS IC₅₀ Values As an alternate analysis for reproducibility, IC₅₀ values for reference substances were normalized to those of the corresponding SLS IC₅₀values. This approach was tested using five reference substances for each test method to determine whether such normalization would reduce the variability, measured using CV values, of the results. The reference substances selected for this evaluation were those for which the ANOVA indicated statistically significant differences among the laboratories. Because there were a number of reference substances that met this criterion for the 3T3 NRU test method, the substances were selected so as to cover a wide range of rodent acute oral toxicity. One reference substance was selected from each GHS category with the exception of the $50 \le LD_{50} \le 300$ mg/kg category. There was no substance represented by this category because there were six acute oral toxicity categories and only five substances were used for this assessment. The reference substances, shown in Table 7-10, were busulfan, chloramphenicol, meprobamate, propylparaben, and triethylenemelamine. Because there were only six reference substances with significant ANOVAs in the NHK NRU test method, the last five reference substances in Table 7-5 (citric acid, digoxin, dimethylformamide, disulfoton, and propranolol HCl) were selected for this analysis.

Millimolar units were used for the IC_{50} values in this analysis since the mole is the most appropriate unit for measuring and comparing biological activity. The IC_{50} value (in mM) for each reference substance was normalized to the corresponding SLS IC_{50} value (in mM) by dividing the SLS IC_{50} by the reference substance IC_{50} . Intra- and inter-laboratory CV values were calculated for both the IC_{50} values and for the SLS IC_{50} :reference substance IC_{50} ratios to determine whether this type of normalization would reduce the interlaboratory CV values.

Table 7-10 shows that the mean intralaboratory CV of the IC_{50} values for the five substances used in the 3T3 evaluation was 22% and the interlaboratory CV was 88%. Normalizing the reference substance IC_{50} values to the SLS IC_{50} yielded a slightly higher intralaboratory CV of 25% and a lower interlaboratory CV of 65%. The mean intralaboratory CV of the IC_{50} values for the five substances used in the NHK evaluation was 14% and the interlaboratory CV was 50%. Normalizing the reference substance IC_{50} values to the SLS IC_{50} yielded a slightly higher intralaboratory CV of 16% and a higher interlaboratory CV of 61%. When the normalization ratios are examined for each chemical-by-laboratory combination (**Table 7-10**), nine CVs increased, five decreased, and one remained the same for the 3T3 NRU test method, and eight increased, six decreased, and one remained the same for the NHK NRU test method. Thus, for the reference substances used in this analysis, normalizing the reference substances used in this analysis, normalizing the reference substance IC₅₀ did not reduce the overall variability of the measurements, as measured by the CV values.

| Reference Substance | IC ₅₀ (mM) ¹ | IntraLab CV ² (%) | InterLab CV ³ (%) | SLS IC ₅₀ : Substance IC ₅₀ ⁴ | IntraLab CV SLS IC ₅₀ : Substance IC ₅₀ ⁵ (%) | InterLab CV SLS IC ₅₀ : Substance IC ₅₀ ⁶ (%) |
|--------------------------|---------------------------------------|---------------------------------|---------------------------------|--|---|--|
| | | 3T3 | NRU Test M | ethod | | |
| Busulfan | 0.548 | | 119 | 0.677 | | 74 |
| ECBC | 0.163 | 48 | | 1.05 | 70 | |
| FAL | 1.30 | 56 | | 0.109 | 53 | |
| IIVS | 0.177 | 4 | | 0.877 | 9 | |
| Chloramphenicol | 0.498 | | 67 | 0.725 | | 29 |
| ECBC | 0.171 | 22 | | 0.847 | 30 | |
| FAL | 0.845 | 30 | | 0.844 | 22 | |
| IIVS | 0.483 | 18 | | 0.483 | 21 | |
| Meprobamate | 2.47 | | 54 | 0.071 | | 39 |
| ECBC | 1.62 | 14 | | 0.085 | 23 | |
| FAL | 4.02 | 15 | | 0.039 | 29 | |
| IIVS | 1.77 | 2 | | 0.088 | 3 | |
| Propylparaben | 0.166 | | 64 | 1.16 | | 49 |
| ECBC | 0.116 | 16 | | 1.29 | 20 | |
| FAL | 0.287 | 29 | | 0.535 | 22 | |
| IIVS | 0.0949 | 12 | | 1.65 | 9 | |
| Triethylene- melamine | 0.00278 | | 135 | 191 | | 87 |
| ECBC | 0.000421 | 11 | 155 | 354 | 11 | 0, |
| FAL | 0.00710 | 18 | | 21.4 | 24 | |
| IIVS | 0.000827 | 29 | | 197 | 23 | |
| Mean | 0.000027 | 22 | 88 | 177 | 25 | 65 |
| Wittan | | | NRU Test M | [ethod | 20 | 05 |
| Citric Acid | 2.21 | | 25 | 0.00587 | | 26 |
| ECBC | 2.74 | 16 | 25 | 0.0053 | 14 | 20 |
| FAL | 1.62 | 10 | | 0.0076 | 28 | |
| IIVS | 2.25 | 5 | | 0.0047 | 16 | |
| Digoxin | 4.02E-06 | 5 | 88 | 62378 | 10 | 168 |
| ECBC | 6.89E-06 | 13 | 00 | 1264 | 10 | 100 |
| FAL | 6.53E-08 | 36 | | 183479 | 44 | |
| IIVS | 5.10E-06 | 7 | | 2389 | 26 | |
| Dimethylform- amide | 107 | | 19 | 0.00011 | 20 | 31 |
| ECBC | 128 | 2 | 17 | 0.00007 | 7 | 51 |
| FAL | 107 | 1 | | 0.00013 | 1 | |
| IIVS | 87.5 | 3 | | 0.00013 | 19 | |
| Disulfoton | 1.38 | 5 | 99 | 0.00013 | 17 | 61 |
| ECBC | 0.509 | 19 | 27 | 0.0140 | 6 | 01 |
| FAL | 2.94 | 26 | | 0.022 | 5 | |
| IIVS | 0.679 | 32 | | 0.003 | 20 | |
| Propranolol HCl | 0.079 | 52 | 21 | 0.013 | 20 | 20 |
| ECBC | 0.125 | 12 | ∠1 | | 15 | 20 |
| EUDU | 0.129 | 12 | | 0.081 | 13 | |

Table 7-10CV Values for 3T3 and NHK NRU Test Method IC50 Values and
Normalized IC50 Values

Table 7-10CV Values for 3T3 and NHK NRU Test Method IC50 Values and
Normalized IC50 Values

| Reference Substance | IC ₅₀ (mM) ¹ | IntraLab CV ² (%) | InterLab CV ³ (%) | SLS IC ₅₀ : Substance IC ₅₀ ⁴ | IntraLab CV SLS IC ₅₀ : Substance IC ₅₀ ⁵ (%) | InterLab CV SLS IC ₅₀ : Substance IC ₅₀ ⁶ (%) |
|------------------------|---------------------------------------|---------------------------------|---------------------------------|--|---|--|
| FAL | 0.148 | 6 | | 0.087 | 25 | |
| IIVS | 0.0967 | 11 | | 0.116 | 9 | |
| Mean | | 14 | 50 | | 16 | 61 |

Abbreviations: 3T3=BALB/c 3T3 fibroblasts; ECBC=Edgewood Chemical Biological Center; FAL= Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory; IIVS=Institute for *In Vitro* Sciences; NA=No acceptable IC₅₀ results reported or calculation was not performed (e.g., for contrast results); CV=Coefficient of variation. ¹Results reported on the same row with reference substance names are the arithmetic means of all the laboratories. Results reported on the same row as laboratories are the arithmetic laboratory means.

 2 CV for IC₅₀ values from the acceptable tests within each laboratory.

³CV calculated using the arithmetic mean IC₅₀ values from each laboratory.

⁴Concurrent SLS IC_{50} in mM divided by the reference substance IC_{50} . Results reported on the same row with reference substance names are the arithmetic means of all the laboratories. Results reported on the same row as laboratories are the arithmetic laboratory means.

 5 CV for SLS IC₅₀:reference substance IC₅₀ values within each laboratory.

³CV calculated using the mean SLS IC₅₀:reference substance IC₅₀ values from each laboratory.

7.3 Historical Positive Control (PC) Data

The reproducibility of the PC (SLS) data was assessed by CV analysis, ANOVA, and linear regression over time, as described in **Section 5.5.4.2**. To obtain an assessment of the true variation of SLS IC₅₀ values, the reproducibility analyses also included IC₅₀ values from SLS tests that failed the test acceptance criterion for the IC₅₀ acceptance limits determined for each study phase. Therefore, the values used for this analysis included some that were not included in **Table 5-3**. These additional SLS tests, however, passed all other test acceptance criteria. If more than one SLS test was performed in a single day (for each method and laboratory), the IC₅₀ values were averaged to determine a single IC₅₀ for the day so that the multiple results from that day would not overly influence the average.

Figure 7-5 shows the average SLS IC_{50} values for each method, laboratory, and study phase. The SLS IC_{50} for the 3T3 test method (**Figure 7-5a**) was relatively consistent over the entire period of the study (approximately 2.5 years). The intralaboratory CV values for the individual study phases ranged from 5% to 24% (**Figure 7-5a**). With the exception of the Phase Ib CV at FAL, the CV values for each laboratory and phase were less than 20%. The interlaboratory CV values were even smaller, 6% in Phases Ia and Ib, 10% in Phase II, and 2% in Phase III.

Figure 7-5b shows that the SLS IC₅₀ for the NHK NRU test method tended to vary with time, but, with the exception of the values from FAL, there appeared to be no consistent trend. The IC₅₀ values from FAL, which changed their cell culture methods after Phase Ib (see **Section 5.3.3.1**), tended to decrease over time. Although the change in cell culture methods reduced the magnitude of the IC₅₀, the variability (as evidenced by the intralaboratory CV values shown in **Figure 7-5b**) remained relatively high (CV \geq 34% for all FAL study phases).




Figure 7-5 SLS IC₅₀ for Each Laboratory and Study Phase

b NHK NRU Test Method 39% 10 8 IC₅₀ (µg/mL) 35% 2<u>4%</u> **ECBC** 6 51% 29% 34% FAL 12% 22% IIVS 23% 16% 11% 43% 4 T Т Т 2 Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν N Ν 5 5 12 6 10 5 11 15 31 34 19 12 0 Phase Ia Phase Ib Phase II Phase III

Abbreviations: 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake; ECBC=Edgewood Chemical Biological Center; FAL= Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory; IIVS=Institute for *In Vitro* Sciences; N=Number of values. Note: Bars show mean SLS IC₅₀ values. Error bars show standard deviation. Percent values above error bars are intralaboratory CVs.

The CV values for all the laboratories and study phases show that the SLS IC_{50} values in the NHK NRU test method are more variable within laboratories than the corresponding 3T3 SLS IC_{50} values. The CV values for the SLS IC_{50} for the NHK NRU test method ranged from 11 to 51%, with nine of the 12 values greater than 20%. The interlaboratory CV values, which were also greater than those for the 3T3 NRU test method, were 39% in Phase Ia, 21% in Phase Ib, 31% in Phase II, and 8% in Phase III.

7.3.1 ANOVA and Linear Regression Results for the 3T3 NRU Test Method

7.3.1.1 Variation of SLS IC₅₀ Values with Time

Table 7-11 shows the SLS ANOVA results from the 3T3 test method. When the IC₅₀ values in each laboratory were compared, there were no statistically significant differences (p < 0.01) among study phases for any laboratory. **Table 7-12** shows that the slopes of the linear regressions of the IC₅₀ values over time (expressed as index values) were significantly different from zero for ECBC and FAL (p=0.001 and 0.012, respectively), but, because the slopes were so small (0.000204 and -0.000324), and in different directions, these differences were considered to be unimportant, regardless of the statistical conclusions. The slope of the IIVS regression of SLS IC₅₀ over time was not significantly different from zero (p=0.651; **Table 7-12**), which was consistent with the ANOVA analysis (**Table 7-11**), and showed that SLS IC₅₀ from IIVS did not vary with study phase (p=0.854). The ANOVA analysis, with study phase as the factor (with laboratories combined), showed that the 3T3 NRU IC₅₀ values from all the laboratories were consistent over time (p=0.304).

7.3.1.2 Comparison of SLS IC₅₀ Values Among the Laboratories

When all study phases from each laboratory were combined, ANOVA, with laboratory as the factor, showed that the SLS IC₅₀ values in the 3T3 NRU test method differed significantly among the laboratories (p < 0.006) (Table 7-11). However, as can be seen in Figure 7-5a, the individual laboratory SDs overlap one another.

| Study Phase/ | | ECBC | | | | FAL | | | | IIVS | | |
|---------------------|-----------------------------------|----------------|----------|-----------------------|-----------------------------------|-------|----|-----------------------|-----------------------------------|-------|----|-----------------------|
| Laboratory | Log Mean IC ₅₀ (mM) | SD | N | P ¹ | Log Mean IC ₅₀ (mM) | SD | Ν | P ¹ | Log Mean IC ₅₀ (mM) | SD | Ν | P ¹ |
| Test for difference | es between phases w | vithin each la | iborator | ry | | | | | | | | |
| Phase Ia | -0.876 | 0.042 | 6 | 0.031 | -0.811 | 0.046 | 9 | 0.015 | -0.850 | 0.034 | 7 | 0.854 |
| Phase Ib | -0.864 | 0.066 | 6 | | -0.846 | 0.065 | 8 | | -0.838 | 0.025 | 5 | |
| Phase II | -0.848 | 0.027 | 16 | | -0.796 | 0.057 | 19 | | -0.854 | 0.025 | 8 | |
| Phase III | -0.842 | 0.036 | 36 | | -0.851 | 0.066 | 27 | | -0.844 | 0.041 | 23 | |
| Test for difference | es between laborato | ries (phases | combin | ed) | | | | | | | | |
| All Phases | -0.849 | 0.039 | 64 | 0.006 | -0.826 | 0.062 | 63 | | -0.847 | 0.035 | 44 | |
| Test for difference | es between phases (l | laboratories | combin | ed) | | | | | | | | |
| Phase Ia | -0.839 | 0.049 | 22 | 0.304 | | | | | | | | |
| Phase Ib | -0.850 | 0.056 | 19 | | | | | | | | | |
| Phase II | -0.831 | 0.047 | 34 | | | | | | | | | |
| Phase III | 0.845 | 0.045 | 86 | | | | | | | | | |

Table 7-11ANOVA Results for the SLS IC50 Values in the 3T3 NRU Test Method

Abbreviations: ANOVA=Analysis of variance; SLS=Sodium lauryl sulfate; 3T3=BALB/c 3T3 fibroblasts; NRU=Neutral red uptake; N=Number of values; SD=Standard deviation; ECBC=Edgewood Chemical Biological Center; FAL=Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory; IIVS=Institute for *In Vitro* Sciences. ¹Statistically significant at p <0.01.

| Laboratory | Slope | P-value (Slope) ² | Intercept | | | | | | | |
|---------------------|-----------|------------------------------|-----------|--|--|--|--|--|--|--|
| 3T3 NRU Test Method | | | | | | | | | | |
| ECBC | 0.000204 | 0.001 | -0.874 | | | | | | | |
| FAL | -0.000324 | 0.012 | -0.796 | | | | | | | |
| IIVS | 0.0000304 | 0.651 | -0.850 | | | | | | | |
| | NHK NRU T | Test Method | | | | | | | | |
| ECBC | -0.000559 | 0.002 | -1.901 | | | | | | | |
| FAL | -0.00112 | < 0.001 | -1.737 | | | | | | | |
| IIVS | -0.000445 | 0.002 | -1.885 | | | | | | | |

Table 7-12Linear Regression Analysis of SLS IC50 Values Over Time1

Abbreviations: SLS=Sodium lauryl sulfate; 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake; N=Number of values; ECBC=Edgewood Chemical Biological Center; FAL=Fund for the

Replacement of Animals in Medical Experiments Alternatives Laboratory;

IIVS=Institute for In Vitro Sciences.

¹Time was expressed as index values. The index value of each test reflected the order of testing without respect to the time lapsing between tests.

²Statistically significant from zero at p < 0.05.

7.3.2 ANOVA and Linear Regression Results for the NHK NRU Test Method

7.3.2.1 Variation of SLS IC₅₀ Values with Time

Table 7-13 shows the ANOVA results for the NHK NRU test method. When the IC₅₀ values within each laboratory were compared by study phase, the values were statistically different (p < 0.01) at each laboratory. The IC₅₀ values from the various study phases were also significantly different from one another when the laboratory data were combined (p < 0.001). The change in cell culture methods at FAL after Phase Ib (see Section 5.3.3.1) contributed to this difference. Table 7-13 shows that FAL had clearly the lowest log mean SLS IC₅₀ for Phases Ia and Ib. Linear regression analyses showed that the IC₅₀ slopes over time (expressed as an index values) were statistically significantly less than zero for each laboratory (see Table 7-12). Because the slopes were so small (-0.000559, -0.00112, and -0.000445), and negative, their statistical significance was considered to be irrelevant.

7.3.2.2 Comparison of SLS IC₅₀ Values Among the Laboratories

The ANOVA results, with laboratory as a factor (**Table 7-13**), showed that the SLS IC₅₀ was statistically significantly different among the laboratories when the data from the study phases were pooled (p < 0.001). **Figure 7-5b** shows that the SLS data from ECBC and IIVS were rather similar to one another for Phases Ia, Ib, and III. The SLS IC₅₀ data from FAL are different from the other two laboratories for Phases Ia, Ib, and II, but the SDs for Phase III show that the data from all laboratories produced similar values.

| Study Dhase/ | | ECB | С | | | FAI | | | | IIVS | 5 | |
|----------------------------|-----------------------------------|-------------|------------|-----------------------|-----------------------------------|-------|----|-----------------------|-----------------------------------|-------|----|-----------------------|
| Study Phase/ Laboratory | Log Mean IC ₅₀ (mM) | SD | Ν | P ¹ | Log Mean IC ₅₀ (mM) | SD | Ν | P ¹ | Log Mean IC ₅₀ (mM) | SD | Ν | P ¹ |
| Test for different | ces between pha | ises within | each labo | oratory | | | | | | | | |
| Phase Ia | -1.867 | 0.135 | 5 | 0.001 | -1.656 | 0.125 | 5 | < 0.001 | -1.904 | 0.060 | 12 | < 0.001 |
| Phase Ib | -1.936 | 0.092 | 6 | | -1.829 | 0.141 | 10 | | -1.965 | 0.046 | 5 | |
| Phase II | -2.007 | 0.109 | 11 | | -1.982 | 0.173 | 15 | | -1.863 | 0.058 | 12 | |
| Phase III | -1.990 | 0.098 | 31 | | -1.941 | 0.113 | 34 | | -1.972 | 0.070 | 19 | |
| Test for different | ces between lab | oratories (| phases co | mbined) | | | | | | | | |
| All Phases | -1.971 | 0.113 | 53 | < 0.001 | -1.879 | 0.175 | 64 | | -1.924 | 0.073 | 48 | |
| Test for different | ces between pha | ises (labor | atories co | mbined) | | | | | | | | |
| Phase Ia | -1.833 | 0.143 | 22 | < 0.001 | | | | | | | | |
| Phase Ib | -1.891 | 0.125 | 21 | | | | | | | | | |
| Phase II | -1.964 | 0.139 | 38 | | | | | | | | | |
| Phase III | -1.971 | 0.100 | 84 | | | | | | | | | |

Table 7-13ANOVA Results for the SLS IC50 Values in the NHK NRU Test Method

Abbreviations: ANOVA=Analysis of variance; SLS=Sodium lauryl sulfate; NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake; N=Number of values; SD=Standard deviation; ECBC=Edgewood Chemical Biological Center; FAL=Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory; IIVS=Institute for *In Vitro* Sciences.

¹Statistically significant at p <0.01.

7.4 Laboratory Concordance for Solvent Selection

The solvents used for the reference substances are shown in **Table 7-14**. For Phases Ib and II, the SMT based their selection of solvents on the results provided by BioReliance (see **Table 5-9**) using the solubility protocol in **Appendix G2**. Despite the fact that the solubility of an individual substance might be different in 3T3 and NHK growth media, the SMT selected the same solvent (i.e., medium or DMSO) for both test methods, rather than having different solvents for each method.

BioReliance occasionally achieved higher solubility values for the Phase I and II substances than the three cytotoxicity laboratories (e.g., see the results for arsenic trioxide, aminopterin, and chloramphenicol in **Table 5-10**). The laboratories were using the solubility protocols in **Appendices C3** through **C6** (for Phases Ib and II), which were somewhat different from the protocol used by BioReliance. Although all the laboratories used the same protocols, they did not always obtain similar results with respect to the solvent to be used (e.g., see the results for aminopterin, cadmium chloride, and chloramphenicol in **Table 5-10**). In an attempt to avoid the selection of a solvent for which one or more laboratories could not achieve the desired solubility, the SMT used the solubility data from all the laboratories to determine the solvents to be used for each chemical tested in Phase III. **Table 7-14** shows that cell culture medium was used as the solvent for 38 substances and DMSO was used for 34 substances.

Five of the substances were insoluble in medium and DMSO in at least one testing laboratory. Arsenic trioxide was insoluble at all laboratories. IIVS also found sodium oxalate, strychnine, and triethylenemelamine insoluble in media and DMSO, and FAL found thallium sulfate insoluble in both solvents. Therefore, the SMT used the results from the laboratories that did achieve solubility to select the solvents to be used for testing these substances.

The testing laboratories selected the same solvent for 55 of the 72 reference substances (76%). Excluding the five substances that were found to be insoluble in both solvents by at least one laboratory, there were 12 substances on which the laboratories disagreed: acetaminophen, acetylsalicylic acid, carbamazepine, carbon tetrachloride, chloramphenicol, dichlorvos, meprobamate, methanol, phenobarbital, phenylthiourea, physostigmine, and valproic acid. Each laboratory reported relatively low solubility, ≤ 2 mg/mL, in medium for these substances. Because 2 mg/mL in medium is the departure point for the selection of medium or DMSO, small variations in solubility lead the laboratories to select different solvents. The solubility of acetaminophen, for example was reported as 2 mg/mL in culture media by ECBC and FAL, but <2 mg/mL by IIVS. IIVS found it soluble in 200 mg/mL DMSO and selected DMSO as the solvent. ECBC and FAL selected culture media as the solvent. The SMT selected DMSO as the solvent for acetaminophen to be used by all laboratories so that they would all be assured of obtaining usable test results.

| Reference Substance | Solvent Used for Testing ¹ | ECBC | FAL | IIVS |
|---------------------------------|--|--------|--------|--------|
| Acetaminophen | DMSO | Medium | Medium | DMSO |
| Acetonitrile | Medium | Medium | Medium | Medium |
| Acetylsalicylic acid | DMSO | Medium | DMSO | Medium |
| Aminopterin | DMSO | DMSO | DMSO | DMSO |
| 5-Aminosalicylic acid | Medium | Medium | Medium | Medium |
| Amitriptyline HCl | DMSO | DMSO | DMSO | DMSO |
| Arsenic III trioxide | Medium | ID | ID | ID |
| Atropine sulfate | Medium | Medium | Medium | Medium |
| Boric aid | Medium | Medium | Medium | Medium |
| Busulfan | DMSO | DMSO | DMSO | DMSO |
| Cadmium II chloride | DMSO | DMSO | DMSO | DMSO |
| Caffeine | Medium | Medium | Medium | Medium |
| Carbamazepine | DMSO | Medium | DMSO | DMSO |
| Carbon tetrachloride | DMSO | Medium | DMSO | Medium |
| Chloral hydrate | Medium | Medium | Medium | Medium |
| Chloramphenicol | DMSO | DMSO | DMSO | Medium |
| Citric acid | Medium | Medium | Medium | Medium |
| Colchicine | Medium | Medium | Medium | Medium |
| Cupric sulfate pentahydrate | Medium | Medium | Medium | Medium |
| Cycloheximide | Medium | Medium | Medium | Medium |
| Dibutyl phthalate | DMSO | DMSO | DMSO | DMSO |
| Dichlorvos | DMSO | Medium | DMSO | Medium |
| Diethyl phthalate | DMSO | DMSO | DMSO | DMSO |
| Digoxin | DMSO | DMSO | DMSO | DMSO |
| Dimethylformamide | Medium | Medium | Medium | Medium |
| Diquat dibromide monohydrate | Medium | Medium | Medium | Medium |
| Disulfoton | DMSO | DMSO | DMSO | DMSO |
| Endosulfan | DMSO | DMSO | DMSO | DMSO |
| Epinephrine bitartrate | Medium | Medium | Medium | Medium |
| Ethanol | Medium | Medium | Medium | Medium |
| Ethylene glycol | Medium | Medium | Medium | Medium |
| Fenpropathrin | DMSO | DMSO | DMSO | DMSO |
| Gibberellic acid | Medium | Medium | Medium | Medium |
| Glutethimide | DMSO | DMSO | DMSO | DMSO |
| Glycerol | Medium | Medium | Medium | Medium |
| Haloperidol | DMSO | DMSO | DMSO | DMSO |
| Hexachlorophene | DMSO | DMSO | DMSO | DMSO |
| Lactic acid | Medium | Medium | Medium | Medium |
| Lindane | DMSO | DMSO | DMSO | DMSO |
| Lithium I carbonate | Medium | Medium | Medium | Medium |
| Meprobamate | DMSO | Medium | Medium | DMSO |
| Mercury II chloride | DMSO | DMSO | DMSO | DMSO |
| Methanol | DMSO | Medium | Medium | DMSO |
| Nicotine | Medium | Medium | Medium | Medium |
| Paraquat | Medium | Medium | Medium | Medium |
| Parathion | DMSO | DMSO | DMSO | DMSO |
| Phenobarbital | DMSO | Medium | DMSO | DMSO |
| Phenol | Medium | Medium | Medium | Medium |
| Phenylthiourea | DMSO | DMSO | Medium | DMSO |

Table 7-14Solvent Determinations by Laboratory

| Reference Substance | Solvent Used for Testing ¹ | ECBC | FAL | IIVS |
|-----------------------------|--|--------|--------|--------|
| Physostigmine | DMSO | Medium | DMSO | DMSO |
| Potassium I chloride | Medium | Medium | Medium | Medium |
| Potassium cyanide | Medium | Medium | Medium | Medium |
| Procainamide HCl | Medium | Medium | Medium | Medium |
| 2-Propanol | Medium | Medium | Medium | Medium |
| Propranolol HCl | DMSO | Medium | Medium | Medium |
| Propylparaben | DMSO | DMSO | DMSO | DMSO |
| Sodium arsenite | Medium | Medium | Medium | Medium |
| Sodium chloride | Medium | Medium | Medium | Medium |
| Sodium dichromate dihydrate | Medium | Medium | Medium | Medium |
| Sodium fluoride | Medium | Medium | Medium | Medium |
| Sodium hypochlorite | Medium | Medium | Medium | Medium |
| Sodium oxalate | Medium | Medium | Medium | ID |
| Sodium selenate | Medium | Medium | Medium | Medium |
| Strychnine | Medium | Medium | Medium | ID |
| Thallium I sulfate | Medium | Medium | ID | Medium |
| Trichloroacetic acid | Medium | Medium | Medium | Medium |
| 1,1,1-Trichloroethane | Medium | Medium | Medium | Medium |
| Triethylenemelamine | DMSO | Medium | DMSO | ID |
| Triphenyltin hydroxide | DMSO | DMSO | DMSO | DMSO |
| Valproic acid | DMSO | Medium | DMSO | DMSO |
| Verapamil HCl | DMSO | DMSO | DMSO | DMSO |
| Xylene | DMSO | DMSO | DMSO | DMSO |
| DMSO Total | 34 | 22 | 29 | 28 |
| Medium Total | 38 | 49 | 41 | 40 |

Abbreviations: DMSO=Dimethyl sulfoxide; ECBC=Edgewood Chemical Biological Center; FAL= Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory; IIVS=Institute for *In Vitro* Sciences; ID=Insufficient data to select solvent; Medium=Cell culture medium.

¹Solvents selected by the SMT for use by all laboratories.

7.5 Summary

Intra- and inter-laboratory reproducibility were assessed by comparing the laboratoryspecific IC_{50} - LD_{50} regressions to the mean, across-laboratory regression for each method, ANOVA, CV analysis, and comparison of maximum:minimum mean laboratory IC_{50} values. ANOVA permitted statistical comparisons of laboratories and experimental averages, while controlling for other factors. CV analysis compared the relative magnitudes of variability on a standardized scale. Reproducibility was evaluated using the results from the reference substances that yielded IC_{50} values from all three laboratories: 64 and 68 reference substances in the 3T3 and the NHK NRU test methods, respectively. The analysis of intralaboratory reproducibility, by evaluating the similarity of the laboratory specific IC_{50} - LD_{50} regressions, showed that the laboratory regressions for both NRU test methods were within the 95% confidence limits of the laboratory mean regressions.

The ANOVA showed significant interlaboratory differences for 23 substances in the 3T3 NRU test method and six in the NHK NRU test method. Intralaboratory CV values ranged from 1-122% in the 3T3 test method and 1-129% in the NHK NRU test method. Mean interlaboratory CV values were 26% for both NRU test methods, but NHK had a lower mean

interlaboratory CV (28% vs 47% for 3T3 NRU). Interlaboratory CV values ranged from 3-135% in the 3T3 NRU test method and 1-91% in the NHK NRU test method. FAL had the highest mean intralaboratory CV in both NRU test methods (33% in 3T3, 43% in NHK).

An analysis to determine the relationship between the chemical attributes and interlaboratory CV indicated that chemical structure, physical form, solubility, and volatility had little effect on CV. The CV seemed to be related, however, to GHS acute toxicity category, IC₅₀, and boiling point. Mean interlaboratory CV values were larger for substances in the most toxic GHS categories than for substances in the other toxicity categories, especially with the 3T3 NRU test method. The mean interlaboratory CV for substances in the LD₅₀ \leq 5 mg/kg (72%) and 5< LD₅₀ \leq 50 mg/kg (78%) classes were larger than the mean overall interlaboratory CV (47%) with the 3T3 NRU test method. The mean interlaboratory NHK CV was 37% for substances with LD₅₀ \leq 5 mg/kg, and 41% for substances with 5< LD₅₀ \leq 50 mg/kg, while the mean overall interlaboratory CV was 28%. A Spearman correlation analysis showed that the IC₅₀ was inversely correlated to interlaboratory CV for both the 3T3 (p=0.015) and NHK (p=0.014) test methods, and that boiling point was positively correlated to interlaboratory CV (p=0.007) (i.e., higher boiling points were associated with higher CV values) for the 3T3 but not the NHK NRU test method (p=0.809).

The ANOVA results for the PC IC₅₀ in the 3T3 NRU test method showed that there were significant differences among laboratories (p=0.006) but not among study phases within laboratories (p >0.01). However, interlaboratory CV values, which ranged from 2% to 10% for the different study phases, were small and the intralaboratory CV values ranged from 5% to 24%. The SLS IC₅₀ values from the NHK NRU test method were more variable than those from the 3T3 NRU test method. The ANOVA results for SLS in the NHK NRU test method indicated that there were significant differences among laboratories (p <0.001) and among study phases within laboratories (p ≤0.001). A change in cell culture methods at FAL after Phase Ib decreased the SLS IC₅₀ in subsequent phases, but FAL's CV values still tended to be higher than in the other laboratories. Intralaboratory CV values for the NHK SLS IC₅₀ during the various study phases ranged from 11% to 51% and interlaboratory CV values for SLS in the NHK NRU test method ranged from 8% in Phase III to 39% in Phase Ia.

Cell culture medium was used as the solvent for 38 substances and DMSO was used for 34 substances. Concordance among all three laboratories in selecting the solvent for the reference substances was 76% (55/72).

[This Page Intentionally Left Blank]

| 8.0 | 3T3 A | ND NHK NRU TEST METHOD DATA QUALITY | |
|-----|--------|--|------|
| 8.1 | Comp | liance with Good Laboratory Practice Regulations | |
| | 8.1.1 | Guidelines Followed for Cytotoxicity Testing | 8-3 |
| | 8.1.2 | Quality Assurance (QA) for NRU Cytotoxicity Test Data | |
| | 8.1.3 | Guidelines Followed for Rodent Acute Oral LD ₅₀ Data Collection | |
| 8.2 | Resul | ts of Data Quality Audits | |
| | 8.2.1 | QA Statements | |
| | | QA Statements from the Laboratories | |
| 8.3 | Effect | t of Deviations or Non-compliance with GLPs | |
| | 8.3.1 | Laboratory Error Rates | |
| | 8.3.2 | • | |
| | 8.3.3 | Intralaboratory Reproducibility | |
| | 8.3.4 | | |
| 8.4 | Avail | ability of Laboratory Notebooks | |
| 8.5 | Sumn | nary | 8-13 |

[This Page Intentionally Left Blank]

8.0 3T3 AND NHK NRU TEST METHOD DATA QUALITY

This section of the BRD presents the extent of adherence to GLP regulations for generation of the validation study data. Data quality is described, along with deviations from the regulations and their effect (if any) on the quality of the data. Statistical analyses are provided to compare the data generation, collection, and reporting by the two GLP compliant laboratories and the one non-GLP compliant laboratory, as well as for the GLP-compliant laboratory that distributed the reference substances and performed solubility studies. Discussions of various quality assurance aspects of the study are included.

8.1 Compliance With Good Laboratory Practice Regulations

8.1.1 <u>Guidelines Followed for Cytotoxicity Testing</u>

8.1.1.1 *Good Laboratory Practices*

The SOW provided the following definition of U.S. Regulatory agency GLPs to each laboratory:

"Regulations governing the conduct, procedures, and operations of toxicology laboratories; regulations to assure the quality and integrity of the data and to address such matters as organization and personnel, facilities, equipment, facility operations, test and control articles, and validation study protocol, and conduct (U.S. Food and Drug Administration, Title 21 CFR Part 58; U.S. Environmental Protection Agency, Title 40 CFR Part 160)."

IIVS, ECBC, and BioReliance performed testing under GLP guidelines. The details of GLP compliance and training are addressed in **Section 11.2**.

8.1.1.2 Spirit of GLP

The SMT determined a definition for "spirit of GLP" and provided the following to the laboratories:

"Laboratories that are non GLP-compliant shall adhere to GLP principles and other method parameters as put forth in this Statement of Work and the Test Method Protocols (provided by NIEHS/NICEATM); documentation and accountability shall be equal to GLP requirements; laboratories must make assurances that they are equal in performance criteria and that there is parity amongst the laboratories."

FAL performed testing in the "spirit of GLP" (see Section 11.2.2.1) by following the international GLP standards referenced in the ECVAM Workshop 37 Report (Cooper-Hannan 1999) and the OECD Principles of GLP (OECD 1998). The laboratory did not have their data and test procedures reviewed by an independent, quality assurance (QA) auditor. The SOW directed FAL to, at a minimum, routinely document their equipment monitoring and record keeping (see **Table 8-1**), and to archive all documents. The FAL already had most of the requested procedures and guidelines in place for routine laboratory procedures before initiation of this study. The various general laboratory-related activities were documented in workbooks and logbooks, and the information was made available to the SMT.

| Daily | Per Use | Periodic |
|---|---|---|
| Temperatures Laboratory (ambient), incubators, water baths, refrigerators, freezers | Cryogenic Storage Unit Liquid N ₂ volume | Laboratory Supplies ¹ Lot numbers and expiration dates for stock media formulations and components, NRU reagents, tissue culture plasticware |
| Humidity/CO ₂ Cell culture incubators | Equipment Calibration Balances, pH meters, cell counters | Cells Quantity, and cryogenic storage conditions, for 3T3 and NHK cells |
| Visual Observations Cell Culture Growth | Reagents Lot numbers and expiration dates of medium/supplements | Equipment Calibration Incubators, laminar flow hoods, autoclaves, micropipettors, spectrophotometer plate readers, computers (software) |

Table 8-1SMT-Recommended Documentation for FAL

Abbreviations: SMT=Study Management Team; FAL=Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory; NRU=Neutral red uptake; 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes.

¹Documentation for laboratory supplies begins when supplies are purchased and received by the laboratory

8.1.1.3 Good Cell Culture Practices (GCCP)

The SMT provided guidance in the SOW for implementing GLPs in a cell culture laboratory environment. The initial assumption by the SMT was that each laboratory had the basic cell culture skills and knowledge (e.g., as described in Freshney 2000) to reliably perform the *in vitro* NRU cytotoxicity test methods. Reviews of historical laboratory documents, and scientific and professional exchanges with the laboratory personnel, assured the SMT that each laboratory had demonstrated, through previous validation studies and other experience, that the personnel were capable of providing quality scientific data through the use of good cell culture practices. A comparison of the SOW and the *in vitro* NRU cytotoxicity protocols showed that the guidelines developed for the NICEATM/ECVAM study were harmonious with the guidelines in the ECVAM Good Cell Culture Practices Reports (Hartung 2002; Coecke et al. 2005), and the OECD document on GLPs and *in vitro* studies (OECD 2004a).

8.1.2 Quality Assurance (QA) for NRU Cytotoxicity Test Data

8.1.2.1 *Coded Reference Substances*

BioReliance acquired 73 high purity chemicals (72 reference substances and one positive control substance) from reputable commercial sources. Sixty-four of the reference substances were \geq 99% pure, and seven were between 90 and 99% pure. Lactic acid had the lowest purity, 89% (See **Appendix F1**). The substances were coded with unique identification numbers and provided to the testing laboratories in a blinded fashion. Procurement of chemicals and their preparation for distribution was performed under GLP guidelines and the SOW provided by the SMT (see **Appendix G**). **Section 3.4** provides detailed information on the acquisition and distribution of reference substances.

8.1.2.2 Solubility Testing and Data Review

All laboratories performed solubility tests on all reference substances using the solvents and procedures specified in the protocols provided by the SMT, and submitted solubility data to the SMT in the form of hard copy printouts and electronic worksheets. The Study Directors reviewed all laboratory procedures and all data produced at their respective laboratories, and the QA designee in each GLP-compliant laboratory reviewed all data in their laboratory. The SMT Project Coordinators served as informal QA reviewers for FAL (i.e., reviewed all the raw data sheets). The errors and omissions detected were reported to FAL, and corrections were requested. The SMT reviewed all solubility data and NRU assay data produced by all of the laboratories.

The SMT reviews of the submitted data in Phases Ia and Ib revealed that, even after data review by the Study Directors, the data files contained an unacceptably high frequency of errors (see **Section 2.6.2.5**). The laboratories were alerted to the problem and personnel from all laboratories attended a weeklong training session at the IIVS laboratories in Gaithersburg, Maryland to enhance harmonization among the laboratories. Errors continued to be found in data files submitted for Phase III after the training, albeit less frequently; however, such errors generally resulted from the rush to rapidly complete the data files for submission to the SMT shortly after the conclusion of each test. The formal QA reviews of the files occurred later in each phase of the study.

The most common errors included typographical mistakes, transcriptional and data entry errors in the Microsoft[®] EXCEL[®] and the GraphPad PRISM[®] 3.0 templates, and incorrect labeling of files. The SMT reviewed every electronic file and hard copy printout throughout the study and alerted the Study Directors of the affected laboratories when errors were found. All data files were checked for consistency within the documents, and for compliance with the protocols. The SMT also documented errors on the hard copy printouts in the form of handwritten notations to the files (at NICEATM) and added these notations to the electronic data summary files compiled for data management. Files that were revised and/or corrected by the Study Director were resubmitted to the SMT and identified as corrected files.

8.1.2.3 NRU Cytotoxicity Test Tallies

The Study Directors periodically received individualized test tallies specific to their laboratories from NICEATM that detailed:

- The number of range finder tests performed by the laboratory
- The number of definitive tests performed, and the pass/fail status of each
- The number of PC tests performed, and the pass/fail status of each
- The number of acceptable tests completed
- The test completion status for each chemical (i.e., whether one range finder test had been completed, and the number of acceptable definitive tests had been completed)

The laboratories compared the NICEATM tallies to their own records to verify their consistency and accuracy. Discrepancies were resolved through direct communication between the Study Director and the SMT.

8.1.3 <u>Guidelines Followed for Rodent Acute Oral LD₅₀ Data Collection</u>

For the purposes of this validation study, the *in vitro* NRU test methods were proposed for predicting starting doses for rodent acute oral toxicity test methods, rather than as replacement tests for the *in vivo* test method. No *in vivo* tests were performed for this validation study. All *in vivo* data (i.e., rat and mouse LD₅₀ values) were collected by NICEATM through reviews of the literature and from publicly available databases. All relevant data and pertinent information were gathered and stored in an Excel[®] spreadsheet.

8.1.3.1 Rodent Acute Oral LD_{50} Values Used in the Registry of Cytotoxicity (RC) The RC is a database of acute oral LD_{50} values for rats and mice obtained primarily from the 1983/84 RTECS[®] database compiled by NIOSH, and IC₅₀ values from *in vitro* cytotoxicity assays using multiple cell lines and cytotoxicity endpoints for chemicals with known molecular weights (Halle 1998, 2003). Collection and reporting methods used for generating the data in RTECS[®] were not a part of the data collection hierarchy employed by NIOSH, and the data in this database were not evaluated for quality and accuracy. Many of the values come from secondary sources with no citation to the original report. GLP guidelines were not used to determine acceptable data for the database. The only criterion used by NIOSH for reporting acute oral toxicity data in RTECS[®] was that the LD₅₀ value was the most toxic LD₅₀ value for a chemical that could be found in the literature, regardless of the number of other values available, or their distribution.

8.1.3.2 Rodent Acute Oral LD_{50} Values Collected by NICEATM from Other Sources One critical aspect of the validation study design was the establishment of a rat acute oral LD_{50} reference value for each of the 72 reference substances (see **Section 4**). These reference values were used to evaluate the extent to which the two *in vitro* NRU test methods could predict rat acute oral LD_{50} values. Primary rat acute oral LD_{50} studies were located through searching electronic databases, published articles, and secondary references. Rat data were not available for three of the reference substances and mouse acute oral LD_{50} values were used. Only seven of the 455 LD_{50} values collected from the literature were produced under GLP guidelines.

8.2 Results of Data Quality Audits

The QA unit or designee in each GLP laboratory provided a systematic and critical comparison of the data provided in the laboratory's study reports to the raw data in the laboratory records. The SOW provided to each laboratory contained the following guidance regarding QA statements:

"The Final Reports for all phases of the Validation Study shall be audited by the Quality Assurance unit of the Testing Facility for GLP compliance and a QA Statement shall be provided by the Testing Facility. Each Final Report shall identify: 1) the phases and data inspected, 2) dates of inspection, and 3) dates findings were reported to the Study Director and Testing Facility management. The QA Statement shall identify whether the methods and results described in the Final Report accurately reflect the raw data produced during the Validation Study."

8.2.1 <u>QA Statements</u>

The QA statements from the GLP-compliant laboratories addressed the reviews of:

- Protocols
- Laboratory standard operating procedures (SOPs)

- Laboratory operations, in general
- 3T3 and NHK NRU experiment data
- The report submitted to the SMT

The QA statements from the GLP laboratories affirm that the methods described in the protocols are the methods that the laboratory personnel used, and that the data reported to the SMT accurately reflect the raw data obtained by the laboratory. See **Section 8.2.2** for information about the QA statements for the non-GLP laboratory.

8.2.2 <u>QA Statements from the Laboratories</u>

8.2.2.1 BioReliance QA Statements

The Study Director/Laboratory Director provided the following statement in all of the final reports:

"The solubility studies, acquisition, preparation, and distribution of the test chemicals were conducted in compliance with GLP. Although not audited (per SOW), the work described in this report for Phase X (i.e., Ia, Ib, and II) fully and accurately reflects to the best of my knowledge the raw data generated in the study."

8.2.2.2 FAL QA Statements

The Study Director for FAL performed the final review of all data and reports before sending them to the SMT, and provided the following two statements in the final reports provided to the SMT.

- "The laboratory worked under the principles of GLP whilst not being a GLP-compliant laboratory."
- "The report accurately reflects the work undertaken and the results obtained at the FRAME Alternatives Laboratory."

Formal QA statements were not provided to FAL because the SMT performed informal QA reviews.

8.2.2.3 ECBC QA Statements

The QA statements reported the particular study phase and laboratory procedures that were examined for GLP compliance. In addition, the laboratory's statement noted that the scope of work, associated protocols, and quality control (QC) acceptance criteria were updated or changed during the study, which made the assessment of the procedures and data for conformance to the SOPs more difficult. However, compliance with the requirements and intent of GLP guidelines was continually assessed during the review of the SOPs and the observance of operations. The QA reviews found the ECBC protocols to be in compliance with the NICEATM/ECVAM study protocols. The aspects of the studies inspected by the QA designee were:

- Review of protocols and laboratory SOPs
- Review of waste handling procedures
- Review of laboratory operations
- Certification of new personnel
- Review of data
- Review of the final report for each testing phase

The QA designee also observed the preparation of reference substances, 96-well plate configuration, application of reference substance, annotation to the workbook, and appropriate sterile technique while performing the testing. The number of inspections of laboratory operations was reduced in the latter phases of the study because the same personnel conducted the testing throughout the entire study.

ECBC Review Dates of the Study Phases

- Phase Ia: July 2002 through May 2003
- Phase Ib: July 2002 through January 2003
- Phase II: May 2003 through February 2004
- Phase III: November 2003 through March 2005

8.2.2.4 *IIVS QA Statements*

Because the IIVS QA unit is small, it carried out reviews of different aspects of the procedures at different times. The IIVS QA Statement reads:

"This study has been divided into a series of in-process phases. Using a random sampling approach, Quality Assurance monitors each of these phases over a series of studies. Procedures, documentation, equipment records, etc., are examined to assure that the study is performed in accordance with the U.S. FDA Good Laboratory Practice regulations (21 CFR 58), the U.S. EPA GLP Standards (40 CFR 792 and 40 CFR 160) and the OECD Principles of Good Laboratory Practice and to assure that the study is conducted according to the protocol and relevant Standard Operating Procedures."

The aspects of the studies inspected by the QA designee were as follows:

- Protocol and initial paperwork
- Reading of the plates (definitive test)
- Dilution of the test articles (definitive test)
- Treatment of the cells
- Termination of treatment and addition of the NR dye (definitive test)
- Cell concentration determination and seeding of the plates (third definitive test)
- Termination of treatment and addition of the NR dye
- Washing the cells
- Draft report and data
- Final report

IIVS Review Dates of Various Aspects of the Test Phases

- Phase Ia: August 2002 Final Report Review: October 2005
- Phase Ib: January 2003
- Final Report Review: October 2005
- Phase II: July-August 2003 Final Report Review: October 2005
- Phase III: January-November 2004 Final Report Review: October 2005

8.2.2.5 Other QA Information

•

•

Data generated by the laboratories and reviewed by their respective Study Directors were submitted to the SMT. Often, the data were provided electronically within days of the end of testing. The SMT was active as a secondary QA reviewer of all information provided by the Study Directors. If the SMT found discrepancies, the Project Coordinators corresponded with the appropriate Study Director to identify and rectify the error. The Study Director made corrections/adjustments to the discrepancies in data reporting and presented the changes to the SMT. The SMT did not initiate any external data quality audits.

The quality of the reference substances was assured in the form of certificates of analysis provided by the chemical manufacturer to BioReliance at the time of purchase. The SMT and the laboratories obtained certificates of analysis from CAMBREX for Clonetics[®] NHK culture medium and supplements. In addition, the SMT obtained QC data directly from CAMBREX technical departments concerning the NHK medium's ability to support keratinocyte growth.

8.3 Effect of Deviations or Non-compliance with GLPs

Rates for several types of errors (i.e., documentation, testing methods, and data management) were determined by the SMT. Many of the errors (particularly in Phases Ia and Ib) were the result of minor mistakes (e.g., typographical, mislabeling) and did not affect the quality of the data.

8.3.1 <u>Laboratory Error Rates</u>

The SMT was concerned about the number of errors that were seen in documentation and testing methods during Phases Ia and Ib, and compiled the detected errors from each laboratory. The types of errors found included errors in documentation (e.g., reference substance identification did not match on all associated data sheets; IC₂₀ and IC₈₀ values were transposed in the EXCEL[®] template; a test acceptance criterion flag in a data sheet was incorrect) and in testing (e.g., wrong dilution scheme was used for the PC; wrong SLS IC₅₀ was used as the PC IC₅₀). Error rates were compiled as the number of tests with errors per total number of tests. As shown in **Table 2-3**, FAL had the highest error rates: 93% for the 3T3 NRU test method and 41% for the NHK NRU test method. The highest error rates in the other laboratories were 10% for the 3T3 NRU test method and 23% for the NHK NRU test method (both ECBC).

There were relatively few errors detected in the Phase III data files. The SMT did not compile the typographical and transcriptional errors found, but reported them directly to the appropriate Study Director so that the data sheets could be immediately corrected. The SMT did not detect errors in the raw optical density data from the 96-well plates provided in each data file. The laboratories and the SMT corrected typographical and transcriptional errors (e.g., incorrect logIC₅₀ value entered) in the EXCEL[®] templates. The EXCEL[®] template formulas were used for the statistical analyses.

An assessment of error rates was performed specifically for Phase III for one particular clerical error – the transfer of the final results (e.g., ICx values) from the GraphPad PRISM[®] 3.0 template to the Microsoft[®] EXCEL[®] template. It was often necessary for the SMT to revise the EXCEL[®] data files provided by the laboratories because the incorrect values had been transferred to EXCEL[®]. **Table 8-2** summarizes the Phase III error rates resulting from the transfer of data from PRISM[®] to EXCEL[®].

| Laboratory | Number of Errors Detected | Number of Definitive Tests | Percentage of Tests with Detected Errors |
|------------|------------------------------|-------------------------------|---|
| ECBC | 49 | 402 | 12 |
| FAL | 171 | 513 | 33 |
| IIVS | 25 | 419 | 6 |

Table 8-2 Phase III Error Rates in the Transfer of Data to the EXCEL[®] Template

Abbreviations: ECBC=Edgewood Chemical Biological Center; FAL=Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory; IIVS=Institute for *In Vitro* Sciences.

8.3.2 Failure Rates for Definitive and PC Tests

Table 8-3 presents the test failure (i.e., did not meet test acceptance criteria) rates experienced in Phase III. Approximately 25% of all 3T3 definitive tests and 18% of all NHK definitive tests failed. If a definitive test (see Section 2.3.2.2 for the definition of a definitive test) failed, the laboratory repeated the test and attempted to obtain three acceptable definitive tests for each reference substance in each cell type (see Section 2.5 for criteria for repeating tests). The PC tests failed 0 to 18% of the time with a combined average failure rate of 8% for both cell types. FAL had the highest individual laboratory test failure rates for 3T3 definitive tests (30%), NHK definitive tests (32%), and NHK PC tests (18%). ECBC had the highest failure rate for 3T3 PC tests (11%). IIVS had no PC test failures.

| Track Traces | 3T3 N | NRU T | est Me | thod | NHK NRU Test Method | | | | Total |
|---|-------|-------|--------|-------|---------------------|-----|------|-------|-------|
| Test Type | ECBC | FAL | IIVS | Total | ECBC | FAL | IIVS | Total | Totai |
| Definitive Tests - Acceptable | 169 | 177 | 176 | 522 | 173 | 175 | 174 | 522 | 1044 |
| Definitive Tests - Total | 215 | 257 | 225 | 697 | 187 | 256 | 194 | 637 | 1334 |
| % Failed Definitive Tests | 21 | 30 | 22 | 25 | 8 | 32 | 10 | 18 | 22 |
| PC Tests - Acceptable | 66 | 40 | 16 | 122 | 58 | 37 | 20 | 115 | 237 |
| PC Tests - Total | 74 | 42 | 17 | 133 | 59 | 45 | 20 | 124 | 257 |
| % Failed PC Tests | 11 | 5 | 6 | 8 | 2 | 18 | 0 | 7 | 8 |
| Definitive Tests Failed Only Because PC Tests Failed | 14 | 6 | 14 | 34 | 0 | 22 | 0 | 22 | 56 |
| % Definitive Tests Failed Only Because PC Tests Failed | 7 | 2 | 6 | 5 | 0 | 9 | 0 | 4 | 4 |

Table 8-3 Definitive Test and Positive Control (PC) Test Failure Rates in Phase III

Abbreviations: ECBC=Edgewood Chemical Biological Center; FAL=Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory; IIVS=Institute for *In Vitro* Sciences; NRU=Neutral red uptake; 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes.

The Phase III guidelines required each laboratory to provide three acceptable definitive tests for each substance for both cell types ($3 \times 60 \times 2 = 360$ definitive tests). PC tests were run concurrently with the definitive tests, and more than one reference substance was usually tested in conjunction with each PC test. Because of test failures, each laboratory performed additional testing to obtain the three acceptable definitive tests required for each substance.

Table 8-4 presents the success rates for each laboratory for Phase III testing and a total for all the laboratories combined.

| Table 8-4 | Combined Definitive and Positive Control (PC) Test Success Rates for the |
|-----------|--|
| | 3T3 and NHK Methods in Phase III |

| Test Type | ECBC | FAL | IIVS | Total |
|--|---------|---------|---------|-----------|
| Acceptable Definitive Tests/ Total Definitive Tests | 342/402 | 352/513 | 350/419 | 1044/1334 |
| % Acceptable Definitive Tests | 85% | 69% | 84% | 78% |
| Acceptable PC Tests/Total PC Tests | 124/133 | 77/87 | 36/37 | 237/257 |
| % Acceptable PC Tests | 93% | 89% | 97% | 92% |

Abbreviations: ECBC=Edgewood Chemical Biological Center; FAL=Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory; IIVS=Institute for *In Vitro* Sciences; NRU=Neutral red uptake; 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes.

8.3.3 Intralaboratory Reproducibility

CV values for each method were determined for each reference substance in each laboratory using the IC_{50} values from the acceptable definitive tests, as described in **Section 5.5.2**. **Table 8-5** presents the average CV values for the substances tested in each of the study phases, and for the entire study.

| Table 8-5CV Values for Definitive Television | ests |
|--|------|
|--|------|

| | | Phases I & II | | Phase III | | All Phases | |
|--------------|------|--------------------------------------|-----------------|--------------------------------------|-----------------|--------------------------------------|-----------------|
| Cell Type | Labs | Number of Reference Substances | Average % CV | Number of Reference Substances | Average % CV | Number of Reference Substances | Average % CV |
| | ECBC | 12 | 17 | 57 | 24 | 69 | 23 |
| 3T3 | FAL | 11 | 28 | 55 | 33 | 66 | 33 |
| | IIVS | 11 | 20 | 56 | 22 | 68 | 21 |
| | | | | | | | |
| | ECBC | 12 | 24 | 57 | 22 | 69 | 23 |
| NHK | FAL | 12 | 31 | 57 | 45 | 69 | 42 |
| | IIVS | 12 | 14 | 58 | 14 | 70 | 14 |

Abbreviations: ECBC=Edgewood Chemical Biological Center; FAL=Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory; IIVS=Institute for *In Vitro* Sciences; 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; CV=Coefficient of variation.

8.3.4 <u>Prediction of GHS Acute Oral Toxicity Categories</u>

Predicted LD₅₀ values were determined using the *in vitro* NRU IC₅₀ values in the IC₅₀-LD₅₀ regressions presented in Table 6-5. The predicted LD₅₀ values were used to assign each substance to a predicted GHS acute oral toxicity category (UN 2005). The accuracy of the 3T3 and NHK NRU test methods for predicting GHS categories was determined by comparison with categorization based on *in vivo* rat oral LD₅₀ values (in mg/kg) in Table 4-2. Using the RC rat-only millimole regression, the accuracy of the predictions and the extent of underprediction or overprediction are shown for each laboratory in Table 8-6. The laboratories generally agreed with each other in their predictions. Although FAL had the highest error rates and CV values, their predictions of GHS categories were consistent with the other laboratories. The laboratories determined category matches for 25 to 30% of the reference substances for the 3T3 NRU test method and 29 to 31% of the reference substances for the NHK NRU test method. For the 3T3 NRU test method, toxicity was overpredicted for 38% of the reference substances and underpredicted for 33 to 38% of them. For the NHK NRU test method, toxicity was overpredicted for 35 to 38% of the reference substances and underpredicted for 32 to 34% of them. (See Appendix J for additional laboratory comparisons for the other *in vitro* - *in vivo* regressions evaluated in Section 6.)

8.4 Availability of Laboratory Notebooks

All laboratories maintained laboratory notebooks using a template provided by IIVS, and provided copies of the notebooks to the SMT (archived at NICEATM) after completion of each testing phase. The notebooks contained information from all aspects of testing including, but not limited to:

- Environmental conditions
- Reagent identification
- Preparation of 96-well plates
- Preparation of reference substances
- Treatment of cell cultures
- Visual observations of cell cultures
- NRU assays
- Data analysis

| | Labs | Total Reference Substances | Category Match | Toxicity Overpredicted | Toxicity Underpredicted |
|-----|------|----------------------------------|-------------------|---------------------------|----------------------------|
| | ECBC | 64 | 30% | 38% | 33% |
| 3Т3 | FAL | 64 | 25% | 38% | 38% |
| | IIVS | 64 | 27% | 38% | 36% |
| | | | | | |
| | ECBC | 68 | 31% | 35% | 34% |
| NHK | FAL | 68 | 29% | 38% | 32% |
| | IIVS | 68 | 31% | 37% | 32% |

Table 8-6 GHS Acute Oral Toxicity Category Predictions by Laboratory¹

Abbreviations: ECBC=Edgewood Chemical Biological Center; FAL=Fund for the Replacement of Animals in Medical Experiments Alternatives Laboratory; IIVS=Institute for *In Vitro* Sciences; 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; GHS=Globally Harmonized System for Classification and Labelling of Chemicals (UN 2005).

¹3T3 and NHK NRU test method IC₅₀ data (geometric mean of within laboratory replicates) used with the RC rat-only millimole regression, log LD₅₀ (mmol/kg) = 0.439 x log IC₅₀ (mM) + 0.621, to assign GHS category. *In vivo* category was based on reference rodent oral LD₅₀ values (mg/kg) in **Table 4-2**. For each method, the reference substances evaluated were those for which all three laboratories obtained IC₅₀ values.

8.5 Summary

- The determinations of test method and data collection errors showed that FAL consistently had the highest error levels; however, the laboratory's GHS acute oral toxicity category predictions were comparable to the other laboratories' results.
- The laboratories reported no significant deviations from the protocols, and deviations that did occur during the testing phases were generally quickly acknowledged and addressed by the Study Directors. If a deviation occurred that would affect the data (e.g., improper concentration of DMSO solvent), the Study Director would reject the test, notify the SMT, and perform an additional test. Improper transfer of data to either the EXCEL[®] or PRISM[®] templates, which would affect the data summaries and analyses, were recognized, documented, and rectified by the Study Director and/or the SMT.
- The SMT reviewed all data sheets to ensure that data were not inadvertently attributed to the incorrect data summary files, and that the correct data were used in all statistical analyses.
- An electronic copy of all data for this validation study can be obtained from NICEATM upon request by mail, fax, or e-mail to Dr. William S. Stokes, NICEATM, NIEHS, P. O. Box 12233, MD EC-17, Research Triangle Park, NC, 27709, (phone) 919-541-2384, (fax) 919-541-0947, (e-mail) niceatm@niehs.nih.gov.

[This Page Intentionally Left Blank]

| 9.0 | - | ER SCIENTIFIC REPORTS AND REVIEWS OF <i>IN VITRO</i> | |
|-----|-------|---|------|
| | - | OTOXICITY TEST METHODS AND THEIR ABILITY TO DICT <i>IN VIVO</i> ACUTE TOXICITY AND OTHER TOXIC | |
| | | CCTS | 9-3 |
| 9.1 | Relev | ant Studies | 9-3 |
| | 9.1.1 | | |
| | 9.1.2 | Use of In Vitro Cytotoxicity Data to Reduce the Use of Animals in | |
| | | Acute Oral Toxicity Testing | 9-7 |
| | 9.1.3 | Other Evaluations of 3T3 or NHK NRU Methods | 9-10 |
| 9.2 | Indep | endent Scientific Reviews | 9-13 |
| | 9.2.1 | In Vitro Acute Toxicity Testing for the Classification and Labeling of | |
| | | Chemicals | 9-13 |
| | 9.2.2 | Use of <i>In Vitro</i> Cytotoxicity Data for Estimation of Starting Doses for Acute Oral Toxicity Testing | 9-14 |
| | 9.2.3 | | |
| 9.3 | Studi | es Using In Vitro Cytotoxicity Methods with Established | |
| | | rmance Standards | 9-18 |
| | 9.3.1 | | 9-18 |
| | 9.3.2 | | |
| | 9.3.3 | A-Cute-Tox Project: Optimization and Pre-Validation of an In Vitro | |
| | | Test Strategy for Predicting Human Acute Toxicity (Clemedson 2005) | 9-19 |
| 9.4 | Summ | nary | 9-20 |

[This Page Intentionally Left Blank]

9.0 OTHER SCIENTIFIC REPORTS AND REVIEWS OF *IN VITRO* CYTOTOXICITY TEST METHODS AND THEIR ABILITY TO PREDICT *IN VIVO* ACUTE TOXICITY AND OTHER TOXIC EFFECTS

In vitro cytotoxicity methods based on NRU have been evaluated for a number of uses. This section reviews studies that used *in vitro* NRU cytotoxicity methods to:

- Predict acute rodent oral toxicity
- Predict starting doses for acute systemic toxicity tests
- Predict other *in vivo* toxicity endpoints, including phototoxicity and eye irritation.

Section 9.1 describes studies that evaluated *in vitro* cytotoxicity test methods that measured NRU for its ability to predict acute systemic toxicity in rodents, and other *in vivo* endpoints. Also reviewed are studies that evaluated the use of *in vitro* cytotoxicity results to reduce animal use in acute toxicity testing. **Section 9.2** reviews independent evaluations of the use of *in vitro* cytotoxicity methods to predict acute oral toxicity, and to determine starting doses for acute systemic toxicity assays. Also discussed is a 3T3 NRU test method that has been validated and accepted for regulatory use for detecting phototoxic potential using a protocol similar to that used in the NICEATM/ECVAM validation study. The conclusions of these reports will be compared to the conclusions reached in this study, wherever possible. **Section 9.3** reviews published studies that used the *Guidance Document* approach (ICCVAM 2001b), which established the current test method performance standard.

9.1 Relevant Studies

9.1.1 <u>Correlation of NRU Cytotoxicity Values with Rodent Lethality</u>

This section reviews five published *in vitro* cytotoxicity studies that correlated cytotoxicity values (i.e., IC_{20} or IC_{50}) from NRU cytotoxicity test methods that used various cell types, to rat and/or mouse acute LD_{50} values from various exposure routes. In these sections, *italics* are used to identify reference substances tested in the reviewed studies that were also tested in the NICEATM/ECVAM validation study. **Table 9-1** characterizes the substances tested in the reviewed studies by providing the ranges of their rat oral LD_{50} values. Also shown for comparison are the mouse and/or rat oral LD_{50} ranges for the NICEATM/ECVAM validation study and the RC. The table shows that the substances tested by Peloux et al. (1992), Fautrel et al. (1993), and Rasmussen (1999), covered a wide range of rat acute LD_{50} values. The substances used by Roguet et al. (1993) and Creppy et al. (2004) covered a much smaller range. **Table 9-2** characterizes the test substances by chemical class based on NLM Medical Subject Heading (MeSH[®]) descriptors.

Table 9-1Rat Acute Oral LD50 Ranges for Test Substances Used in Previous In
Vitro NRU Cytotoxicity Studies and the NICEATM/ECVAM Study1

| Study/Database | Ν | Rat Acute Oral LD₅₀ Range (mg/kg)² |
|---------------------------------------|-----|---|
| Peloux et al. (1992) | 30 | 2 - 14500 |
| Fautrel et al. (1993) | 31 | 2 - 14500 |
| Roguet et al. (1993) | 28 | 0.04 - 176 |
| Rasmussen (1999) | 20 | 1 - 10298 |
| Creppy et al. (2004) | 2 | $48 - 924^5$ |
| NICEATM/ECVAM Validation ³ | 72 | 2 - 19770 |
| RC^4 | 347 | 1 - 31015 |

Abbreviations: N=Number of substances in the study/database; RC=Registry of Cytotoxicity. ¹Studies reviewed in Section 9.1.1.

²Values cited in the studies or from references provided by the studies.

³Current study summarized in this BRD.

⁴The RC includes both rat and mouse LD₅₀ values.

⁵Upper limit of range is an LD_{50} calculated from the *in vitro* NRU IC₅₀ because there was no *in vivo* value available for that substance.

Table 9-2Chemical Classes Represented by the Substances Used in Published
Studies for Correlation of In Vitro NRU Cytotoxicity with Rodent Acute
Lethality

| Chemical Class ¹ | Study ² | Chemical Class ¹ | Study ² | Chemical Class ¹ | Study ² |
|-----------------------------|--------------------|-----------------------------|--------------------|-----------------------------|--------------------|
| Alcohols | 1, 2, 3, 4 | Fluorine | 3, 4 | Nitriles | 1, 2 |
| Amides | 1, 2, 3 | Heterocyclics | 1, 2, 3, 4, 5 | Nitrogen | 3, 4 |
| Amines | 1, 2 | Hydrocarbons | 1, 2, 3, 4, 5 | Organophosphates | 3, 4 |
| Arsenicals | 3, 4 | Iron | 3 | Phenols | 3, 4 |
| Carboxylic Acids | 1, 2, 3, 4 | Lactones | 1, 2 | Polycyclics | 3 |
| Chlorine | 3, 4 | Lithium | 1, 2, 3, 4 | Potassium | 3, 4 |
| Copper | 3, 4 | Mercury | 3, 4 | Sodium | 3, 4 |
| Ethers | 1, 2 | Metals | 3, 4 | Sulfur | 1, 2, 3, 4 |

Study references: 1=Peloux et al. (1992) (24/25 substances were organic compounds); 2=Fautrel et al. (1993) (30/31 substances were organic compounds); 3=Roguet et al. (1993) (22/30 substances were organic compounds); 4=Rasmussen (1993) (13/20 substances were organic compounds); 5=Creppy et al. (2004) (2/2 substances were organic compounds).

¹Classification by NLM Medical Subject Heading (MeSH[®]) descriptors.

²Studies reviewed in Section 9.1.1.

9.1.1.1 Peloux et al. (1992)

The authors used several different *in vitro* cytotoxicity methods with primary rat hepatocytes to determine the correlation with rat/mouse intraperitoneal (i.p.) or intravenous (i.v.) LD_{50} values for the 25 substances tested. The *in vitro* cytotoxicity methods, which used 20-hour test substance exposure durations, assessed the following endpoints: NRU, total protein content, LDH release, MTT reduction. MTT is metabolized by mitochondrial succinate dehydrogenase of viable cells to yield a purple formazan reaction product. The IC₅₀ values

obtained using the four endpoints were highly correlated (r = 0.973 to 0.999) to each other. When performing the IC₅₀-LD₅₀ regressions, Peloux et al. (1992) used the lowest reported published LD₅₀ value for acute rat or mouse studies that administered the test substances using the i.p. or i.v. routes. The IC₅₀ values obtained using NRU as the endpoint had the highest correlation coefficient, r = 0.877, to the rat/mouse i.p./i.v. LD₅₀ values. The total protein assay yielded r = 0.872, the MTT reduction assay yielded r = 0.808, and the LDH release assay yielded r = 0.789.

Peloux et al. (1992) followed the recommendations of Fry et al. (1988, 1990) and used parenteral LD₅₀ values rather than oral LD₅₀ values for comparison with *in vitro* values. Fry et al. (1988, 1990) recommended the use of the i.p./i.v. LD₅₀ values for comparisons because they proposed that cells *in vivo* receive a more direct test substance exposure via these routes than through the oral route. They had posited that *in vitro* cell cultures would mirror this (direct) toxicity because they also receive direct exposure to test substances via the cell culture medium. The authors also noted that the oral route of exposure presents confounding variables such as, 1) only a fraction of a test substance would be available in the systemic circulation due to limited absorption or pre-systemic metabolism, and 2), the level of the substance in the systemic circulation decreases due to elimination mechanisms (e.g., metabolism, excretion). Fry et al. (1990) had reported a correlation of only r = 0.49 for *in vivo/in vitro* comparisons of oral LD₅₀ and IC₅₀ values¹.

9.1.1.2 Fautrel et al. (1993)

Six laboratories tested the cytotoxicity of 31 substances in primary rat hepatocyte cultures using a 24-hour exposure followed by measurement of NRU. The investigators performed linear regression analyses for the prediction of rat i.v., i.p., and oral LD₅₀ values from the NRU IC₅₀ values. The regressions for the various *in vivo* administration routes did not use the same substances because LD₅₀ values were not available for all of the tested substances in all of the routes. Oral, i.v., and i.p. LD₅₀ values were available for 27, 24, and 18 substances, respectively, and IC₅₀ values were obtained for 15, 14, and 11 of these substances, respectively. The regression for the i.v. data was statistically significant (r = 0.88, n = 11), but the i.p. (r = 0.48, n = 14) and oral regressions (r = 0.17, n = 15) were not. The finding that the i.v. LD₅₀ values corresponded more closely with the *in vitro* cytotoxicity data than did the oral LD₅₀ was thought to be the result of having fewer pharmacokinetic variables (i.e., absorption, distribution, etc.) to consider following i.v. administration.

9.1.1.3 Roguet et al. (1993)

Roguet et al. (1993) tested the cytotoxicity of 28 MEIC substances in primary rat hepatocytes exposed for 21 hours, followed by the measurement of NRU. A correlation of the NRU IC₅₀ values to oral LD₅₀ values obtained from the unpublished data of B. Ekwall et al. (personal communication) yielded a statistically significant linear correlation (p < 0.001) with r = 0.80 when the *in vivo* and *in vitro* data were in molar units. [NOTE: The LD₅₀ values subsequently published by Ekwall et al. (1998) were from the 1997 edition of RTECS[®].] The authors reported that the toxicities of thioridazine, malathion, and *copper sulfate* were overestimated, and the toxicity of *potassium cyanide* was underestimated by the correlation, but their criteria for over- and under- estimation were not provided.

¹ ID₅₀: index of cytotoxicity; concentrations (μ g/mL) producing a 50% reduction in protein value.

The in vivo toxicity of potassium cyanide was also underpredicted in the

NICEATM/ECVAM validation study. **Table 6-3** shows that *potassium cyanide* was an outlier for which toxicity was underpredicted when using the IC₅₀ values from both the 3T3 and NHK NRU test methods in the RC millimole regression (log LD₅₀ mmol/kg = 0.435 log IC₅₀ mM + 0.625). The GHS category predictions using both NRU test methods and the RC rat-only millimole regression (log LD₅₀ mmol/kg = 0.439 log IC₅₀ mM + 0.621), and the RC rat-only weight regression (i.e., log LD₅₀=0.372 log IC₅₀ + 2.024), were also higher (i.e., less toxic) than the *in vivo* category (see **Appendix L2**).

9.1.1.4 Rasmussen (1999)

Twenty MEIC substances were tested for cytotoxicity using NRU release from 3T3 cells following 24-hr exposure, with and without the addition of a Aroclor-induced rat liver microsomal preparation (S9 mix). Similar to the present validation study, Rasmussen (1999) observed that *xylene* was non-toxic to the cells, even though it was dissolved in ethanol instead of DMSO. In the presence of S9, the cytotoxicities of malathion, 2,4-dichlorophenoxyacetic acid, *propranolol*, thioridazine, *lithium* sulfate, *copper sulfate*, and *thallium sulfate*, were significantly decreased (p <0.05), while the cytotoxicities of 1,1,1-trichloroethane, phenol, nicotine, and paraquat were significantly increased (p <0.05).

Because the NICEATM/ECVAM validation study used cells with little or no xenobiotic metabolizing capability, it could be expected that these systems would overpredict the toxicity of substances that would be inactivated by the addition of a metabolizing system, or to underpredict the toxicity of substances that are metabolized to more toxic substances. None of the four substances in common for which toxicity was decreased by the addition of S9 were overpredicted in the NICEATM/ECVAM study. However, the toxicities of two of the four substances in common for which toxicity was increased by the addition of S9, were underpredicted in the NICEATM/ECVAM study. **Table 6-3** shows that *nicotine* was an outlier whose toxicity was underpredicted when using the 3T3 and NHK IC₅₀ values in the RC millimole regression (log LD₅₀ mmol/kg = 0.435 log IC₅₀ mM + 0.625). *Paraquat* was an outlier whose toxicity was underpredicted when using the NHK IC₅₀ value in the RC millimole regression. The GHS category predictions for both substances using both NRU test methods with the RC rat-only millimole regression (log LD₅₀ mg/kg = 0.357 log IC₅₀ μ g/mL + 2.194) were also higher than the *in vivo* category (see **Appendix L2**).

Although both the IC₂₀ and IC₅₀ values were determined in the Rasmussen (1999) study, only the IC₂₀ values were used for correlations with the rat acute oral LD₅₀ values from RTECS[®]. The units of the LD₅₀ values were not reported, but the correlations were assumed to be in molar units because the IC₂₀ and IC₅₀ values were reported in μ M units. Significant correlations (p <0.001) between IC₂₀ and LD₅₀ values were obtained with and without rat liver microsomes. The correlation of IC₂₀ with LD₅₀ was slightly higher with the S9 mix (r = 0.72 vs. 0.68 for oral LD₅₀ values, and 0.82 vs. 0.78 for i.p. LD₅₀ values).

Although the presence of S9 increased the cytotoxicity of some substances to the 3T3 cells, it decreased the toxicity of others, and yielded only a small improvement in the correlation to *in vivo* data. Rasmussen (1999) concluded that the toxicity of the S9 mix (0.32 mg protein/mL), itself, was insignificant because it reduced cell survival by less than 10% compared with cells

without S9. However, others have shown that S9 microsomal mixes could produce significant cytotoxic effects. Kohn (1993) showed that an S9 mix containing 0.07 mg protein/mL was cytotoxic to all types of murine neurons in culture when the cells were exposed for four days or longer. Non-neuronal cells tolerated higher concentration exposures of S9, but exhibited cytoplasmic inclusions when exposed to S9 at 0.35 mg protein/mL. Dal Negro et al. (2006) reported 100% cell death of human monocyte-derived U-937 cells when the S9 fraction (1 mg protein/mL) and co-factors were applied to the cells for a 72-hour incubation. Both of these studies used longer exposure durations, and/or higher protein concentrations, than the Rasmussen (1999) study.

9.1.1.5 *Creppy et al. (2004)*

Creppy et al. (2004) used a 48-hour NRU assay to determine the cytotoxicity of ochratoxin A (OTA) and fumonisin B1 (FB1) on cultured C6 glioma (rat brain), Caco-2 (human intestinal), and Vero (green monkey kidney) cells. The IC_{50} determined in the NRU assay was used in the RC millimole regression to predict rodent acute oral LD_{50} values. The predicted LD_{50} for OTA using the C6 glioma cells was similar to mouse LD_{50} values generated from four *in vivo* mouse studies, but the LD_{50} values predicted by the other cell lines were about 50 times greater. The authors found the relative insensitivity of the Vero cells surprising because OTA is a kidney toxin. There were no available *in vivo* rodent oral LD_{50} values with which to compare the predicted LD_{50} of FB1, which ranged from 671 to 924 mg/kg for the three cell types tested.

9.1.2 <u>Use of *In Vitro* Cytotoxicity Data to Reduce the Use of Animals in Acute Oral</u> <u>Toxicity Testing</u>

9.1.2.1 Halle et al. (1997): Animal Savings with the ATC Method Using Cytotoxicity Data This study assessed the animal savings that would be produced by using IC_{50} data in an IC_{50} - LD_{50} regression to determine a starting dose for ATC testing. No cytotoxicity testing was performed for this study. Instead, the authors used the IC_{50} values from the RC database and the RC millimole regression to predict the LD_{50} for 347 RC substances. The predicted LD_{50} values were then used to determine the starting doses for simulated ATC testing.

At the time of the Halle et al. (1997) study, the ATC method (1996 version from OECD) was designed to classify substances using three classes of acute oral toxicity and an unclassified group, as defined by the acute oral toxicity classification system of the EU (see **Table 9-3**). As a result, the fixed doses for the ATC testing were 25, 200, and 2000 mg/kg. The authors used the LD_{50} predicted by the RC IC_{50} and the RC millimole regression for the 347 RC substances as a starting point to estimate the number of ATC dose steps, and number of animals, that would be needed to classify the substances in the EU category associated with the rodent oral LD_{50} (i.e., rat or mouse values from RTECS[®]). The method required the simulated ATC testing for each substance to start at the fixed ATC dose nearest to the predicted LD_{50} . The outcome of the simulated testing of three animals per fixed dose was determined by the *in vivo* LD_{50} . If the test dose was lower than the *in vivo* LD_{50} , animals were assumed to live and, if the test dose was higher than the LD_{50} , the animals were assumed to die. Testing of the substance would proceed with higher (when the animals lived) or lower fixed doses (when the animals died) until the substance was placed into the EU toxicity category indicated by the *in vivo* rodent oral LD_{50} .

| Category | LD ₅₀ (mg/kg) |
|--------------|--------------------------|
| 1 | $LD_{50} \leq 25$ |
| 2 | $25 < LD_{50} \leq 200$ |
| 3 | $200 < LD_{50} \le 2000$ |
| Unclassified | LD ₅₀ >2000 |

Table 9-3EU1 Classes of Acute Oral Toxicity

Abbreviations: EU=European Union ¹Anon (1993)

The method of Halle et al. (1997) can be illustrated with digoxin, which has an *in vivo* mouse LD_{50} of 18 mg/kg (from RTECS[®]). The predicted LD_{50} of 414 mg/kg was calculated using the RC IC₅₀ in the RC millimole regression (log LD_{50} [mmol/kg] = 0.435 x log IC₅₀ (mM) + 0.625). Simulated ATC testing would start at the nearest fixed dose, 200 mg/kg. The three animals tested were assumed to die, and then three more animals would be tested at 25 mg/kg. The animals tested at 25 mg/kg were assumed to die and digoxin would be classified in category 1 for $LD_{50} \le 25$ mg/kg. Thus, the classification of digoxin using the 4-category system required six animals.

Using such simulations of ATC testing, Halle et al. (1997) estimated that 2139 animals would be used to test the 347 substances:

- Three hundred twenty-eight would require testing with two doses using three test animals each.
- Nineteen would require testing with three doses using three animals each.

Halle et al. (1997) cited Schlede et al. (1995) in reporting that the average number of animals required to classify substances using the ATC method was 9.11 animals per test. Using this average, ATC testing of the 347 RC substances would require 3161 animals. Thus, Halle et al. (1997) estimated that there would be a 32% reduction ([3161-2139]/3161) in the number of test animals used when the LD₅₀ prediction from the RC millimole regression was used with the 1996 version of the ATC method, in lieu of the standardanimal classification procedure (Halle et al. 1997).

The simulated average animal savings for the ATC in the NICEATM/ECVAM validation study at dose-response slopes of 2.0 and 8.3 was 4.8% to 10.2% (0.51 to 1.09 animals) for the 3T3 (67 reference substances) and NHK (68 reference substances) NRU test methods (see **Section 10.3.3.2**), depending on the regression evaluated. This is considerably lower than the average savings of 32% estimated by Halle et al. (1997). However, there are a number of differences between the evaluation performed by Halle et al. (1997) and the NICEATM/ECVAM study that contribute to the difference in calculated animal savings:

• The NICEATM/ECVAM study used six GHS acute toxicity categories for classification whereas Halle et al. (1997) used the EU toxicity classification scheme, which had only four toxicity categories. The accuracy of category prediction by any method would be higher with fewer categories.

- The NICEATM/ECVAM study used experimentally derived *in vitro* cytotoxicity data from a standardized protocol to estimate starting doses (using two regressions based on the RC substances with rat LD₅₀ data), whereas Halle et al. (1997) used IC₅₀ data from the RC database.
- The reference substances tested in the NICEATM/ECVAM study poorly fit the RC millimole regression. Nearly half of the reference substances evaluated were outliers (28/70 [40%] in the 3T3 NRU test method, and 31/71 [44%] in the NHK NRU test method) (see **Table 6-3**). The RC database had 95/347 (27.4%) substances outside of the prediction intervals.
- The NICEATM/ECVAM study used computer simulations of ATC testing, which incorporated assumptions about mortality distributions, to determine animals used, whereas Halle et al. (1997) used simplified assumptions (i.e., all animals lived when test dose was less than the *in vivo* LD₅₀ and all animals died when test dose was greater than the *in vivo* LD₅₀).
- The NICEATM/ECVAM study determined animal savings by comparing animal use with starting doses determined by the *in vitro* data, to animals used at the default starting dose of 300 mg/kg. Halle et al. (1997) used the average animal use for the ATC for comparison to animal use with simulated testing.

9.1.2.2 Spielmann et al. (1999): Animal Savings Using Cytotoxicity Data with the UDP Spielmann et al. (1999) recommended an *in vitro* cytotoxicity procedure as a range finding test for the *in vivo* toxicity test to reduce the number of animals used in acute toxicity tests. The authors identified nine substances in both the RC database and an evaluation of acute toxicity methods by Lipnick et al. (1995). They then compared the LD₅₀ values from Lipnick et al. (1995) to LD₅₀ predictions calculated when using the RC IC₅₀ values in the RC millimole regression formula (log LD₅₀ [mmol/kg] = 0.435 x log IC₅₀ [mM] + 0.625). For seven of the nine substances, the LD₅₀ prediction was within an order of magnitude of the experimental LD₅₀ reported by Lipnick et al. (1995). Spielmann et al. (1999) concluded that the RC millimole regression provided an adequate prediction of LD₅₀, and that *in vitro* cytotoxicity data could be used to predict starting doses for the UDP. The authors recommended using the IC₅₀, with the RC millimole regression, to calculate a starting dose (i.e., an estimated LD₅₀) for the UDP, FDP, or ATC method whenever an IC₅₀ was available.

If no IC₅₀ was available, Spielmann et al. (1997) recommended determining cytotoxicity using a standard cell line and specific cytotoxic endpoint (e.g., NRU, total protein, MTT reduction). They recommended testing 10 to 20 RC substances to demonstrate that the *in vitro* cytotoxicity test methods provide results that are consistent with the RC millimole regression. The resulting IC₅₀ values would then be used to calculate a new regression (using the LD₅₀ values reported in the RC), which would be compared to the RC millimole regression. If the new regression fit into the acceptance interval ($\pm \log 5$ of the fitted regression line) of the RC millimole regression, the RC millimole regression would be used to predict starting doses for the UDP. If the new regression is parallel to the RC millimole regression, but outside the $\pm \log 5$ acceptance interval, then the new regression would be used for the prediction of the starting dose.

Spielmann et al. (1999) contended that the RC millimole regression provides a sufficient prediction of LD_{50} values from IC_{50} values for substances that do not require metabolic

activation and are not very toxic (i.e., $LD_{50} > 200 \text{ mg/kg}$). The authors acknowledged that the fit of substances with $LD_{50} < 200 \text{ mg/kg}$ to the RC millimole regression is not good, and attributed the poor fit of these substances to the need for metabolic activation to a more toxic substance. They suggested that the prediction of starting doses using cytotoxicity data can be used with the UDP and ATC methods, but not with the FDP because dosing is not sequential (which contradicted a claim made earlier in the paper that the approach could be used with the FDP). They did not estimate the number of animals that might be saved with this approach, but did recommend that the approach be validated experimentally using several established cell lines with a limited number of representative substances from the RC.

9.1.2.3 EPA (2004): U.S. EPA HPV Challenge Program Submission

In response to the EPA HPV Chemical Challenge Program, PPG Industries, Inc., the manufacturer of Propanoic acid, 2-hydroxy-, compound with 3-[2-(dimethylamino)ethyl] 1-(2-ethylhexyl) (4-methyl-1,3-phenylene)bis[carbamate] (1:1) [CASRN 68227-46-3], and the sponsor of this compound, submitted data to the EPA. This is an isolated intermediate used to produce a resin component of paint products. PPG provided the following types of data in their submission to the EPA: physical-chemical, environmental fate and pathway, ecotoxicity, and toxicology. The acute mammalian toxicology data were generated using both *in vitro* and *in vivo* methods.

An *in vitro* NRU cytotoxicity test was conducted with 3T3 cells to estimate a starting dose for the in vivo acute UDP oral toxicity test (OECD 2001a) (see Appendix M1 for the OECD UDP test guideline). The use of this in vitro NRU test method was intended to minimize the number of animals used for *in vivo* testing. The estimated LD₅₀ of the compound as determined by the NRU assay was 489 mg/kg. Therefore, the starting dose for the UDP study was set at 175 mg/kg, which is the first default dose below the estimated LD₅₀ value; this is also the default starting dose for the UDP, and is used when no information on which to base a starting dose is available. A total of fifteen female rats received the compound at 175, 550, or 2000 mg/kg. Five of nine rats treated at 2000 mg/kg died prematurely on Days 2 and 3, and by Day 15, 2/4 surviving animals at this dose had lost up to 25% of their Day 1 body weights. The LD₅₀ was estimated to be 2000 mg/kg, with a 95% confidence interval of 1123-5700 mg/kg. Thus, the in vitro NRU test method overpredicted the toxicity of the compound by estimating an LD₅₀ value that was lower than that determined in the UDP test. The report authors reported that a greater than predicted number of animals was used for the UDP testing because the estimated LD_{50} , 489 mg/kg and, consequently, the starting dose, was much lower than the *in vivo* LD₅₀ of 2000 mg/kg. However, because the UDP started with the default starting dose of 175 mg/kg, the claim that more animals were used is incorrect, because animal use with the default starting dose is the baseline against which other animal use should be compared.

9.1.3 Other Evaluations of 3T3 or NHK NRU Test Methods

This section briefly reviews five studies that evaluated NRU test methods for purposes other than the prediction of starting doses for acute oral toxicity assays. NRU test methods using either 3T3 or NHK cells have been evaluated for use as alternatives to the Draize eye irritation test, to measure phototoxicity, and to predict acute lethality in humans. Except for the 3T3 NRU phototoxicity assay, NRU methods have not been scientifically validated by an independent review for any of these purposes or accepted for regulatory use. The use of the

validated 3T3 NRU test method to determine phototoxic potential is addressed in **Section 9.2**.

The *in vitro* NRU protocols evaluated in the five reviewed studies are similar to those used in the NICEATM/ECVAM validation study, all of which were based on the method of Borenfreund and Puerner (1985). The major difference is that most studies used a 24-hour test substance exposure duration for the 3T3 NRU test method, while the NICEATM/ECVAM 3T3 study used a 48-hour exposure duration. The major difference between the NHK protocols used in the reviewed studies and the protocol used in the NICEATM/ECVAM study is that the cell culture medium was changed at the time of test substance application in the NICEATM/ECVAM study.

9.1.3.1 Draize Eye Irritation

Triglia et al. (1989)

Four laboratories collaborated in an interlaboratory validation study to test the NHK NRU assay marketed by Clonetics[®] Corporation² for its intra- and inter-laboratory reproducibility and ability to predict *in vivo* ocular irritancy. Each laboratory tested 11 blind-coded surfactant-based substances and compared the IC₅₀ values to *in vivo* Draize ocular irritancy scores.

The test exhibited the following performance characteristics for the comparison of *in vitro* and *in vivo* data:

- Specificity (percentage of non-irritants correctly detected) = 93%
- Sensitivity (percentage of true irritants correctly detected) = 80%
- Predictive values (probability that an unknown agent will be properly classified)
 - \circ Positive predictive value = 90%
 - \circ Negative predictive value = 87%

The authors reported that there was excellent correlation among the laboratories, and good correlation between the *in vitro* IC_{50} values and *in vivo* Draize scores (Spearman Rank correlation coefficients between *in vivo* and *in vitro* data for the laboratories ranged from 0.67-0.76). The authors also concluded that the NRU test could not replace the Draize test, but may be an effective screening tool for use in a battery of *in vitro* alternatives

Sina et al. (1995)

Sina et al (1995) evaluated the NHK NRU test method along with six other *in vitro* methods to determine whether they could be used as complimentary tests in a battery approach to estimate ocular irritation. The NRU data correlated poorly with Draize ocular scores for the 33 pharmaceutical intermediates tested. The Spearman correlation coefficient for the IC₅₀ and maximum average Draize score (MAS) was -0.10, and the Pearson correlation coefficient was -0.04.

² Clonetics[®] Corporation sponsored this study. It was not clear in the publication if Clonetics[®] Corporation participated as one of the testing laboratories.

Brantom et al. (1997)

This study examined the potential of 10 alternative methods to predict the eye irritation potential of cosmetic ingredients. Four laboratories tested 55 coded substances (23 single ingredients and 32 formulations) using the 3T3 NRU test method, and used the resulting IC_{50} values to predict modified maximum average scores (MMAS) for the Draize test.

An endpoint was generated for each test by interpolation from a plot of percent cell survival versus test substance concentration. A prediction model was developed from data of 30 single ingredients (29 surfactants and one substance not classified by the authors) to equate the IC_{50} value to an MMAS.

The interlaboratory CV for the IC₅₀ values was $37.3 \pm 29.8\%$ (7.5 ± 6.8, log transformed). Most of the mean IC₅₀ values from a single laboratory differed by plus or minus an order of magnitude from the means of all the laboratories for each substance, which the authors interpreted as "no significant outliers". Correlations of NRU-predicted MMAS scores with *in vivo* MMAS scores yielded Pearson's r values ranging from 0.25 to 0.32 for the four laboratories.

Although the authors concluded the interlaboratory reproducibility was good, the IC₅₀ values did not predict the MMAS. The r values for the *in vitro/in vivo* correlations were low (0.246 to 0.316) and the tests all underpredicted irritants and overpredicted non-irritants. Four substances were outside of the 95% confidence intervals and the authors concluded that the 3T3 NRU test method had wide applicability to test the remaining 51 coded substances according to the limitations in the prediction model, but that it was not effective as a standalone replacement for the Draize test across the entire irritation scale. The authors did not identify the test substances.

Harbell et al. (1997)

This publication reported the results of the evaluation of 12 *in vitro* cytotoxicity assays to predict ocular irritation. Data were voluntarily submitted to the U.S. Interagency Regulatory Alternatives Group (IRAG), composed of members from CPSC, EPA, and FDA. The NHK NRU test method was one of the tests evaluated by six laboratories testing surfactants and surfactant-containing formulations (the 3T3 NRU test method was not tested). Two laboratories submitted results for the same test substances, but the other four submitted data for various sets of substances and formulations.

The correlation of results from the two laboratories that independently tested the same substances was r=0.99. Correlations between the IC₅₀ data and *in vivo* maximum average Draize score (MAS) ranged from -0.92 to -0.54. The IRAG concluded that the assays were suitable as a screening and adjunct assay to assess eye irritation over the range of toxicities found in personal care and household products, and recommended that its use be limited to water-soluble materials. Although the method was also evaluated for surfactants, IRAG recommended that the evaluation continue for its performance in predicting eye irritation for various product classes (e.g., fabric softeners, shampoos). In addition, the substance's physical form should be considered because the *in vitro* toxicity of a solution of the test substance will not necessarily predict toxicity of the parent, solid substance *in vivo*.

9.1.3.2 Predicting Human Lethal Blood Concentrations (LC) Seibert et al. (1992)

This single laboratory study was designed to evaluate various aspects of cellular toxicity in four *in vitro* test systems for their relevance and reliability with respect to acute systemic toxicity, in particular, human LC. The 3T3 NRU test method was one of four methods evaluated with 10 MEIC substances.

The authors stated that final conclusions on the relevance of the *in vitro* systems for *in vivo* data could not be determined because the variations in LC were unknown so that limits for over or underprediction of human *in vivo* toxicity using experimental models could not be defined. In addition, the ability of *in vitro* toxicity to predict *in vivo* toxicity may depend on toxicokinetic factors that were not considered in the *in vitro* systems.

9.2 Independent Scientific Reviews

This section summarizes independent scientific reviews of the use of *in vitro* cytotoxicity methods for the prediction of rodent acute oral toxicity, and for the reduction of animal use in acute toxicity testing. The conclusions of these reviews are compared to the conclusions of the current study. Also discussed is the 3T3 NRU phototoxicity method, because it is similar to the 3T3 NRU test method used in the current validation study and has been validated by ECVAM and is the subject of OECD Test Guideline 432 (OECD 2004).

9.2.1 *In Vitro* Acute Toxicity Testing for the Classification and Labelling of Chemicals

9.2.1.1 Seibert et al. (1996): ECVAM Workshop 16

ECVAM sponsored a workshop in 1994 to review the current status of various *in vitro* methods and to determine their potential uses for reducing, refining, and/or replacing the use of laboratory animals for acute systemic toxicity testing. The workshop participants reviewed various types of toxicity, *in vitro* cytotoxicity testing schemes and strategies, inclusion of biokinetic parameters, biotransformation, biodistribution *in vitro* and *in vivo*, and a proposed acute toxicity testing scheme for the classification of substances.

The workshop participants agreed that some studies showed good correlations between *in vitro* cytotoxicity data and LD_{50} values. They also acknowledged that *in vitro* basal cytotoxicity tests could not address all the different of mechanisms of acute systemic toxicity. Additional approaches to replacing animals would have to incorporate the three main types of cellular level toxic effects that can lead to in acute systemic toxicity (i.e., basal cytotoxicity, selective toxicity, and cell-specific function toxicity). The participants determined that it is also important that any alternative method take into account the active concentration and meaningful dose of a test substance in an *in vitro* cell culture system. Quantitative comparisons of test substance concentrations must be made to evaluate the effects of the test substances regarding the three types of cytotoxicity.

The biokinetics of a test substance (determined by its absorption, distribution, metabolism, and elimination) must be considered when making predictions of *in vivo* toxicity using *in vitro* toxicity data. Various methods can be used to convert *in vitro* effective concentrations of a test substance to equivalent body doses. Test substance factors, such as physicochemical characteristics (e.g., pKa, lipophilicity, volatility), estimates of protein binding, and *in vitro*

characteristics (e.g., cell concentration, cell protein concentration, ratio of cell/medium volumes, medium albumin concentration), are needed for such conversions.

An *in vitro* tiered testing scheme was proposed by the workshop participants for using *in vitro* methods to determine the acute oral toxicity of a substance:

- Stage 1: Basal cytotoxicity test
- Stage 2: Hepatocyte-specific cytotoxicity test to assess the role of biotransformation in producing toxicity
- Stage 3: Test system that evaluates non-hepatocyte-specific selective cytotoxicity (i.e., effects on cell-specific functions)

This testing scheme was proposed as an approach to classify substances by their *in vitro* toxicity. The lowest IC_{50} value determined at any of the testing stages would be used to classify a substance (i.e., very toxic, toxic, harmful, and no label). The workshop participants recommended that a feasibility study be conducted to determine the practicability, relevance, and reliability of this tiered testing scheme. As noted in the NICEATM/ECVAM study (see **Section 6.4**), the *in vitro* basal cytotoxicity tests are not suitable as replacements for rodent acute oral toxicity tests and could only be used as an adjunct test, and not a stand-alone test, for classifying substances for acute oral toxicity. However, *in vitro* tests could be used to identify starting doses for acute toxicity testing to reduce the number of animals used.

- 9.2.2 <u>Use of *In Vitro* Cytotoxicity Data for Estimation of Starting Doses for Acute Oral</u> <u>Toxicity Testing</u>
- 9.2.2.1 ICCVAM (2001a): Estimation of Animal Savings Using Cytotoxicity Data with the ATC Method

Participants at Workshop 2000 examined the influence of starting dose on animal use in the ATC method (ICCVAM 2001a; Section 2.2.3, pp.12-14; no testing was performed at the Workshop). The participants made inferences from the 1996 version of the ATC method that was based on the EU toxicity classification system (**Table 9-1**). The fixed doses for testing were 25, 200, and 2000 mg/kg. Normally, classification of a substance requires testing three animals in two to four dosing steps (i.e., six to 12 animals). The number of dosing steps increases with increasing distance between the true toxicity class and the starting dose. They estimated that one to three dosing steps could be avoided (i.e., three to nine animals saved) if the optimum starting dose could be predicted by *in vitro* cytotoxicity testing.

The predicted savings of one to three dosing steps was made under ideal conditions. The Workshop 2000 report (ICCVAM 2001a) provides a biometric analysis at a dose-mortality slope of 2.0 that shows that the greatest animal savings would occur for substances with very high and very low toxicity. Three animals are needed to classify a substance in the <25 mg/kg class if the true LD₅₀ is 1 mg/kg and 25 mg/kg is the starting dose, but six animals are needed if the test starts from the default starting dose of 200 mg/kg (i.e., an animal savings of 50%). For a substance with a true LD₅₀ of 10000 mg/kg, 11.3 animals on average are needed when the default starting dose is used, but only 7.7 animals would be needed at the 2000 mg/kg starting dose (i.e., an animal savings of 31%). For substances with a true LD₅₀ of 2000 mg/kg, no animals would be saved by starting at the 2000 mg/kg dose (compared to starting at the default starting dose of 200 mg/kg).

Although these analyses were performed assuming the 1996 ATC method used starting doses of 25, 200, 2000 mg/kg, the Workshop 2000 participants noted that the animal savings that would be produced by improving the starting dose would not be significantly different for the current ATC method that uses GHS doses of 5, 50, 300, and 2000 mg/kg (or up to 5000 mg/kg) (OECD 2001c; see **Appendix M** for the current ATC test guideline). The Workshop 2000 participants did not predict the animal savings when *in vitro* cytotoxicity methods are used to estimate starting doses for the ATC, other than the biometric analysis described above.

The NICEATM/ECVAM study yielded patterns of animal savings with the ATC that were similar to those discussed at the 2000 Workshop (i.e., animal savings were greater for substances with a lower or higher LD_{50} than the default starting dose; see **Section 10.3.3.3**). Depending on the NRU test method and regression evaluated, the average animal savings per test (for the 67 or 68 reference substances evaluated) predicted by the NICEATM/ECVAM 7validation study at a dose-mortality slope of 2.0 were:

- 22.6 to 30.4 % (2.21 to 2.96 animals) for substances in the $LD_{50} \le 5$ mg/kg category
- 10.2 to 13.0 % (1.17 to 1.51 animals) for substances in the 5< $LD_{50} \le 50$ mg/kg category
- 3.8 to 4.3 % (0.42 to 0.47 animals) for substances in the 50< $LD_{50} \leq$ 300 mg/kg category
- -9.5 to -6.1% (-0.93 to -0.60 animals) for substances in the 300< LD₅₀ \leq 2000 mg/kg category
- -0.03 to 12.7% (-0.30 to 1.43 animals) for substances in the 2000< $LD_{50} \leq 5000 \text{ mg/kg}$ category
- 17.1 to 25.5% (2.03 to 3.02 animals) for substances with $LD_{50} > 5000 \text{ mg/kg}$

The major differences between the evaluation reviewed by the Workshop 2000 participants and the NICEATM/ECVAM study were:

- The NICEATM/ECVAM study used the GHS toxicity categories for classification whereas the Workshop participants used the EU classification scheme, which has fewer toxicity categories. The accuracy of category prediction is higher with fewer categories.
- The NICEATM/ECVAM study used *in vitro* cytotoxicity data to estimate starting doses using two regressions based on the RC substances with rat LD₅₀ data, whereas the Workshop 2000 participants used the fixed ATC doses as starting doses.
- The NICEATM/ECVAM study used computer simulations of ATC testing for individual substances whereas Workshop 2000 participants used an evaluation that estimated animal use based on fixed *in vivo* LD₅₀ values and the fixed ATC doses.

9.2.2.2 ICCVAM (2001a): Estimation of Animal Savings Using Cytotoxicity Data with the UDP

Workshop 2000 participants examined the effect of starting dose on animal usage in the UDP assay by making inferences from the computer simulations of animal use shown in the peerreview BRD for the UDP (ICCVAM 2000). When the rule that requires testing to stop when four animals have been tested after the first reversal is used, and no other stopping rules are considered, the animal use is relatively insensitive to the slope of the dose-mortality curve. The number of animals required when the starting dose equals the true LD_{50} is approximately six. However, approximately nine animals are required when the starting dose is 1% of the true LD_{50} . Thus, animal use is 30% less when the starting dose is the true LD_{50} compared to a starting dose that is 1% of the true LD_{50} (ICCVAM 2001a, section 2.2.4, pg. 16). When UDP testing stops based on the likelihood-ratio stopping rule, the animal use depends principally on the slope of the dose-mortality curve. The Workshop 2000 participants estimated that 25 to 40% of the animals would be saved when the starting dose is equal to the true LD_{50} , compared to the savings at a starting dose 1% of the true LD_{50} .

According to the UDP BRD (ICCVAM 2000) used by the Workshop participants, UDP simulations at a mortality-response slope of 2.0 showed that an average of 12.4 animals per test were used when the starting dose was 1% of the true LD₅₀, but an average of 8.7 animals was used when the starting dose was the true LD₅₀ (i.e., a 30% reduction). At a slope of 8.3, an average of 11 animals per test were used when the starting dose was 1% of the true LD₅₀, but an average of only six animals were used when the starting dose was the true LD₅₀, but an average of only six animals were used when the starting dose was the true LD₅₀ (i.e., a 46% reduction). The animal savings predicted by Workshop 2000 participants was 25 to 40% based on starting at the true LD₅₀ in comparison to starting at a dose that is 1% of the true LD₅₀.

Depending on the regression evaluated, the average animal savings predicted in the NICEATM/ECVAM validation study at dose-response slopes of 2.0 and 8.3 were 5.8 to 7.8% (0.49 to 0.66 animals) using the 3T3 (67 reference substances) and NHK (68 reference substances) NRU test methods (see **Section 10.2.3**). When averaged for the reference substances in each GHS category, the highest mean animal savings at a mortality-response slope of 2.0 was obtained for reference substances in the $2000 < LD_{50} \le 5000$ mg/kg and $LD_{50} > 5000$ mg/kg categories. Animal savings were 11.3 to 16.7% (1.28 to 1.65 animals) using the 3T3 and NHK NRU test methods for the two regressions evaluated. The average animal savings for the substances in these categories at a dose-mortality slope of 8.3 were 12.1 to 21.0% (1.11 to 1.63 animals) for both methods and regressions. The major differences between the evaluation performed by the Workshop 2000 participants and the NICEATM/ECVAM study were that:

- The default starting dose used for the NICEATM/ECVAM simulations was 175 mg/kg (see Section 10.2.2), rather than 1% of the true LD₅₀ assumed by the Workshop 2000 participants.
- The NRU IC₅₀ was used in two regressions of *in vitro* data against *in vivo* data to estimate starting doses. This estimation was not always close to the true LD₅₀, which was the value used by the Workshop 2000 participants. For example, LD₅₀ values predicted by the NICEATM/ECVAM study for phenylthiourea were approximately 540 mg/kg by the 3T3 IC₅₀ and

approximately 904 mg/kg by the NHK IC_{50} using the RC rat-only millimole regression. The true *in vivo* LD_{50} for phenylthiourea is 3 mg/kg. Workshop 2000 participants used a best-case scenario when they assumed that *in vitro* cytotoxicity precisely predicted the true LD_{50} .

9.2.3 Validation of the 3T3 NRU Assay for Phototoxicity

An NRU assay using 3T3 cells was validated by ECVAM, and accepted for regulatory use, to detect the phototoxic potential of test substances. The 3T3 NRU test for phototoxicity requires a 60-minute exposure to the test substance, a 50-minute exposure to ultraviolet (UVA, 315-400 nm) light, followed by removal of test substance and incubation for another 24 hours in fresh medium (Spielmann et al. 1998). NR medium is then added, and NRU is measured after a 3-hour incubation. Phototoxic potential is assessed by comparing the differences in cytotoxicity between test plates containing the test substance that have not been exposed to UVA and comparable test plates exposed to UVA.

Two different models, employing the Photoinhibition Factor (PIF) and the Mean Photo Effect (MPE), were validated for the prediction of *in vivo* phototoxic potential. The accuracy of the models for classifying the phototoxic potential of the 30 substances tested in nine laboratories was 88% for the PIF, and 92% for the MPE, when compared with *in vivo* classifications. Interlaboratory variability for classification (i.e., phototoxic vs. non-phototoxic) was assessed using a bootstrapping approach. For each substance, the classification based on a single experiment was compared to the classification based on the mean PIF or mean MPE. The interlaboratory variability for classification was 0 to 18.8% using PIF and 0 to 20% using MPE.

The ECVAM Scientific Advisory Committee confirmed the scientific validity of the method in 1997 (ECVAM 1997) and its regulatory acceptance was noted in Annex V of Council Directive 67/548/EEC part B.41 on phototoxicity, in 2000. An OECD Test Guideline, 432, was finalized in 2004 (OECD 2004). The 3T3 NRU phototoxicity test is used in a tiered testing approach to determine the phototoxic potential of test substances.

The performance of the 3T3 NRU phototoxicity assay could not be compared with the performance of the 3T3 NRU test method used in this validation study because different classification schemes were used (i.e., a two-category classification for the phototoxicity vs. a six-class scheme for acute oral toxicity). The ECVAM measurements of interlaboratory variability also used different techniques and were not comparable to those used for the NICEATM/ECVAM study.

9.2.3.1 NHK NRU Phototoxicity Assay

FAL participated in the European Union/European Cosmetic, Toiletry and Perfumery Association (EU/COLIPA) study (30 substances tested using NHK and 3T3 cells) and the ECVAM/COLIPA study (20 substances tested using NHK cells) (Clothier et al. 1999). The studies showed that the NHK NRU test method could be used to predict phototoxic potential. The accuracy for predicting *in vivo* results was similar to that of the 3T3 NRU phototoxicity test (see **Table 9-4**). The NHK NRU phototoxicity test uses the same test substance exposure duration (approximately 2 hours) as the 3T3 NRU test method, but the duration of culture after UV exposure is 72 hours rather than 24 hours. NRU was measured after a 45-minute incubation with NR. Although the NHK NRU phototoxicity method achieved good concordance with *in vivo* phototoxicity, it has not yet been validated for regulatory use.

Table 9-4Correct Identification of In Vivo Phototoxicants by the NHK NRU
Phototoxicity Assay

| Study | 3T3 NRU Phototoxicity Method | NHK NRU Phototoxicity Method |
|--------------------------------------|---------------------------------|---|
| EU/COLIPA (Spielmann et al. 1998) | $29/30(97\%)^1$ | $28/30(93\%)^1$ |
| ECVAM/COLIPA | NA | $\frac{18/20}{19/20} \frac{(90\%)^1}{(95\%)^2}$ |
| Combined Study Data | $45/45 (100\%)^2$ | $44/45(98\%)^2$ |

Abbreviations: 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake; EU=European Union; ECVAM=European Centre for the Validation of Alternative Methods; COLIPA=The European Cosmetic Toiletry and Perfumery Association; NA=not available.

¹Mean Photo Effect (MPF) prediction model.

²Photoinhibition Factor (PIF) prediction model.

Standards

9.3 Studies Using *In Vitro* Cytotoxicity Methods with Established Performance

The procedure provided in the *Guidance Document* for evaluating basal cytotoxicity assays for use in predicting starting doses for acute oral toxicity assays provides the existing performance standards for the 3T3 and NHK NRU test methods (ICCVAM 2001b).

9.3.1 *Guidance Document* (ICCVAM 2001b)

In addition to guidance for evaluating *in vitro* basal cytotoxicity methods for use in predicting starting doses for rodent acute oral toxicity assays, the *Guidance Document* provided results from testing 11 reference substances using the recommended 3T3 and NHK NRU protocols (ICCVAM 2001b). The 11 substances were chosen from the RC database so as to have a close fit to the RC millimole regression and to cover a wide range of cytotoxicity. The major differences between the *Guidance Document* protocols and the protocols used in this validation study are the reduced NR concentrations (from 50 µg/mL to 25 µg/mL in the 3T3 NRU test method, and from 50 µg/mL to 33 µg/mL in the NHK NRU test method, the increased duration of test substance exposure in the 3T3 NRU test method, from 24 to 48 hours, and the lack of a refeeding step in the NHK NRU test method just prior to substance application (see **Sections 2.6** and **2.7** for further detail). Despite these differences, the *Guidance Document* shows that the test results for the 11 substances in both the 3T3 and NHK NRU test methods were similar to the results in the RC database. The calculated regressions for the 11 *Guidance Document* substances were:

- $\log LD_{50} = 0.506 \log IC_{50} + 0.475 (R^2 = 0.985)$ for the 3T3 NRU test method
- $\log LD_{50} = 0.498 \log IC_{50} + 0.551 (R^2 = 0.936)$ for the NHK NRU test method
- $\log LD_{50} = 0.435 \log IC_{50} + 0.625$ for the RC millimole regression

The 3T3 and NHK NRU regressions were compared with the RC millimole regression (347 substances) to show that the regression lines, as well as all 11 substance data points, were

within the acceptance interval (± 0.5 log around the regression) of the RC millimole regression (see *Guidance Document* Figures 3 and 4, p.13 [ICCVAM 2001b]).

9.3.2 King and Jones (2003)

This study also tested the 11 substances recommend in the *Guidance Document* using the recommended 3T3 NRU protocol. The IC_{50} - LD_{50} regression obtained was comparable to the RC millimole regression and to the 11 substance regression provided in the *Guidance Document* (ICCVAM 2001b). The regression was log $LD_{50} = 0.552 \log IC_{50} + 0.503$ (R²=0.929) and the RC millimole regression was log $LD_{50} = 0.435 \log IC_{50} + 0.625$. The 11-substance regression fit within the acceptance interval (± 0.5 log) of the RC millimole regression.

King and Jones (2003) also showed that a 3T3 NRU test method that was adapted for high throughput testing by using three test sample concentrations yielded approximately the same IC_{50} as an eight concentration-response. A regression used to compare the IC_{50} values using the two different concentration-response approaches yielded R²=0.945.

9.3.3 <u>A-Cute-Tox Project: Optimization and Pre-Validation of an *In Vitro* Test Strategy for Predicting Human Acute Toxicity (Clemedson 2005)</u>

The A-Cute-Tox Project is an Integrated Project under the EU 6th framework program that started in January 2005, with a termination date of January 2010. It was initiated in response to the REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) Directive and the 7th amendment of the Cosmetics Directive, which calls for the broad replacement of animal experiments for finished products by 2003, and for ingredients by 2009. The project is an extension of the NICEATM/ECVAM validation study and the EDIT program, which is the continuation of the MEIC program. The partnership is made up of the EDIT Consortium, ECVAM, and 35 other European toxicity research group partners.

The aim of the project is to develop a simple and robust *in vitro* testing strategy for prediction of human acute oral toxicity, which could replace the animal acute oral toxicity tests currently used for regulatory purposes. The objectives of A-Cute-Tox are:

- Compilation, critical evaluation, and generation of high quality *in vitro* and *in vivo* data for comparative analysis.
- Identifying factors (e.g., kinetics, metabolism, and organ specificity) that influence the correlation between *in vitro* toxicity (concentration) and *in vivo* toxicity (dosage), and to define an algorithm that accounts for these effects.
- Explore innovative tools and cellular systems to identify new toxicity endpoints and strategies to better anticipate animal and human toxicity.
- To design a simple, robust and reliable *in vitro* test strategy associated with the prediction model for acute toxicity that is amenable to high-throughput testing.

The project has been divided into the following workpackages that will be implemented by various configurations of research partners:

• <u>WP1</u>: Generation of a "high quality" *in vivo* database (through literature searches and historical data) and establishment of a depository list of reference substances

- <u>WP2</u>: Generation of a "high quality" *in vitro* database (including data from the NICEATM/ECVAM study, EDIT studies, and MEIC studies)
- <u>WP3</u>: Iterative amendment of the testing strategy
- <u>WP4</u>: New end-points and new cell systems
- <u>WP5</u>: Alerts and correctors in toxicity screening (I): Role of absorption, distribution, and excretion
- <u>WP6</u>: Alerts and correctors in toxicity screening (II): Role of metabolism
- <u>WP7</u>: Alerts and correctors in toxicity screening (III): Role of target organ toxicity (i.e., neuro-, nephro-, hepato-toxicity)
- <u>WP8</u>: Technical optimisation of the amended test strategy
- <u>WP9</u>: Pre-validation of the test strategy

A-Cute-Tox aims to extend the NICEATM/ECVAM and MEIC/EDIT approaches toward a full replacement test strategy by improving the prediction of acute oral toxicity using *in vitro* methods, and then validating the testing procedure.

9.4 Summary

- *In vitro* NRU cytotoxicity test methods using various cell types have been evaluated for their correlation with rodent lethality endpoints (e.g., rat/mouse i.v., i.p., and oral toxicity). Peloux et al. (1992) and Fautrel et al. (1993) showed good correlations (r=0.877 and 0.88, respectively) of *in vitro* cytotoxicity with rodent i.p./i.v. and i.v. toxicity data, respectively.
- 3T3 and NHK NRU test methods have been evaluated for purposes other than the prediction of starting doses for acute toxicity studies (e.g., ocular irritancy; human LC values, *in vivo* phototoxicity).
- A 3T3 NRU test method has been validated by ECVAM for the identification of *in vivo* phototoxic potential.
- No *in vitro* test methods have been validated for the prediction of acute oral • toxicity. Estimations of animal savings using in vitro cytotoxicity data to estimate starting doses for the UDP did not use actual in vitro cytotoxicity data. Instead, animal savings were estimated by assuming that the in vivo starting dose equals the true LD_{50} , which is an approach that assumes that cytotoxicity data can perfectly predict in vivo lethality. These theoretical predictions of animal savings in the UDP ranged from 25 to 40% (ICCVAM 2001a), as compared with the average animal savings of 5.3 to 7.8% predicted using computer simulation modeling of the UDP for the reference substances tested in the NICEATM/ECVAM study. Halle et al. (1997) used the in vitro cytotoxicity data in the RC to determine that an animal savings of 32% can be attained for the ATC method by using the LD₅₀ predicted by the RC regression as the starting dose. For the reference substances tested in the NICEATM/ECVAM validation study, most of which were a poor fit to the RC millimole regression, the average animal savings for the ATC, as determined by computer simulation modeling, was 4.8 to 10.2%.

| 10.0 | ANIMAL WELFARE CONSIDERATIONS (REFINEMENT, REDUCTION, AND REPLACEMENT) | 10-3 |
|------|--|-------|
| 10.1 | Use of 3T3 and NHK NRU Test Methods to Predict Starting Doses for Rodent Acute Oral Toxicity Assays | 10-4 |
| 10.2 | Reduction and Refinement of Animal Use for the UDP | 10-4 |
| | 10.2.1 In Vivo Testing Using the UDP | |
| | 10.2.2 Computer Simulation Modeling of the UDP | 10-6 |
| | 10.2.3 Animal Savings in the UDP When Using 3T3- and NHK-Based | |
| | Starting Doses | 10-7 |
| | 10.2.4 Refinement of Animal Use for the UDP When Using 3T3- and NHK- | |
| | Based Starting Doses | 10-15 |
| | 10.2.5 Accuracy of UDP Outcomes Using the IC ₅₀ -Based Starting Doses | 10-16 |
| 10.3 | Reduction and Refinement of Animal Use in the ATC Method | 10-16 |
| | 10.3.1 In Vivo Testing Using the ATC Method | 10-16 |
| | 10.3.2 Computer Simulation Modeling of the ATC Method | |
| | 10.3.3 Animal Savings for the ATC Method When Using 3T3- and NHK- | |
| | Based Starting Doses | 10-18 |
| | 10.3.4 Refinement of Animal Use in the ATC Method When Using 3T3- and | |
| | NHK-Based Starting Doses | 10-26 |
| | 10.3.5 Accuracy of the ATC Method Outcomes Using the IC ₅₀ -Based | |
| | Starting Doses | 10-27 |
| 10.4 | The Impact of Accuracy on Animal Savings | 10-28 |
| 10.5 | The Impact of Prevalence on Animal Savings | 10-30 |
| 10.6 | Summary | 10-31 |

[This Page Intentionally Left Blank]

10.0 ANIMAL WELFARE CONSIDERATIONS (REFINEMENT, REDUCTION, AND REPLACEMENT)

As demonstrated in **Section 6**, *in vitro* basal cytotoxicity methods cannot be used as replacement assays¹ for rodent acute oral toxicity test methods for hazard classification. However, as described in this section, these methods can be used to reduce² and refine³ animal use in the UDP or ATC acute oral toxicity assays, as shown by the computer simulations of such testing. Although the use of *in vitro* cytotoxicity data to determine starting doses for the FDP may reduce the use of animals for the FDP, even though death is not the primary endpoint, such an evaluation will not be provided in this document.

The test guidelines recommend using information on structurally-related substances and the results of any other toxicity tests (EPA 2002b) for the test substance, including *in vitro* cytotoxicity results, to approximate the LD₅₀ and the slope of the dose-mortality curve (OECD 2001a; OECD 2001d; EPA 2002a). However, for the purposes of the reduction and refinement evaluation conducted in this section, it was assumed that no information other than 3T3 and NHK NRU IC₅₀ data would be available. To determine the extent of animal reduction or refinement that would occur in the UDP and the ATC method when using a starting dose based on 3T3 or NHK NRU IC₅₀ values rather than the default starting dose, computer models were used to simulate the *in vivo* testing of the reference substances used in the validation study.

Section 10.1 lists the regressions that were used with IC₅₀ data from the 3T3 and NHK NRU test methods to determine starting doses for the UDP and the ATC. Sections 10.2.1 and **10.3.1** summarize the animal testing procedures in the current test guidelines for the UDP and the ATC, respectively. The procedures for using computer simulation of the animal testing of the reference substances are described in Sections 10.2.2 and 10.3.2. The computer simulations were used to determine the numbers of animals used and the numbers of animals that "died" for each test. The modeling was performed using five different dose-mortality slopes⁴ (i.e., 8.3, 4.0, 2.0, 0.8, and 0.5) because such slope information was not available for all of the reference substances used. To simplify the presentation of results, the animal use figures provided in Sections 10.2.3, 10.2.4, 10.3.3, and 10.3.4 include the data for only two of the slopes, 8.3 and 2.0. The slope of 2.0 is the default used for the calculation of LD_{50} by the UDP method (OECD 2001a; EPA 2002a) and the slope of 8.3 is shown to represent substances, such as pesticides, with higher slopes. The results for the other three slopes were calculated, and are provided in Appendices N and Q. The numbers of animals used are summarized to show the mean number of animals tested when the default starting dose is used and the mean number of animals used when the starting dose was determined from the 3T3 or NHK NRU IC₅₀ values. The difference in animal use between the default starting doses and the IC₅₀-based starting doses is referred to as the animal savings. Differences were

¹ Replacement alternative: a new or modified test method that replaces animals with nonanimal systems or one animal species with a phylogenetically lower one (e.g., a mammal with an invertebrate).

² Reduction alternative: a new or modified test method that reduces the number of animals required.

³ Refinement alternative: a new or modified test method that refines procedures to lessen or eliminate pain or distress in animals or enhances animal well-being.

⁴ The dose-mortality slope is the slope of the dose-response curve for mortality.

tested for statistical significance (at p <0.05) using a one-sided Wilcoxon signed ranked test based on the number of substances evaluated. **Sections 10.2** and **10.3** summarize mean animal use by the total number of substances tested and by the number of substances in each GHS category. **Sections 10.2.4** and **10.3.4** provide the mean number of animal deaths compared to the mean number of animals used for each default and IC₅₀-based starting dose to determine whether the IC₅₀-based starting doses lead to a reduction in the number of animals used and the number that die (i.e., refinement). **Sections 10.2.5** and **10.3.5** discuss concordance for the reference substance outcomes of simulated testing using the IC₅₀-based starting doses, with the outcomes of the default starting doses. Sections 10.4 and 10.5 discuss the impact of accuracy and the impact of prevalence (i.e., the number of substances to be tested in each GHS category) on animal savings.

10.1 Use of the 3T3 and NHK NRU Test Methods to Predict Starting Doses for Rodent Acute Oral Toxicity Assays

The IC₅₀ values developed from the 3T3 and NHK NRU test methods were used to predict starting doses for rodent acute oral toxicity tests using the following linear regressions of IC₅₀-LD₅₀ values (from **Section 6.3**):

- The RC rat-only millimole regression: log LD₅₀ (mmol/kg) = 0.439 log IC₅₀ (mM) + 0.621
- The RC rat-only weight regression: $\log LD_{50} (mg/kg) = 0.372 \log IC_{50} (\mu g/mL) + 2.024$

The IC_{50} values from each *in vitro* NRU test method were evaluated with each regression and simulated acute oral toxicity test method,. The criteria for the use of a reference substance for this evaluation were that it must have:

- Replicate IC₅₀ values from at least one laboratory
- A rat acute oral LD₅₀ reference value (from **Table 4-2**)

Sixty-seven and 68 reference substances were evaluated for the 3T3 and the NHK NRU test methods, respectively. Of the 72 reference substances tested, epinephrine bitartrate, colchicine, and propylparaben were excluded because they did not have associated rat oral LD_{50} data. Carbon tetrachloride and methanol were excluded from the 3T3 evaluations, and carbon tetrachloride was excluded from the NHK evaluations, because none of the laboratories achieved sufficient toxicity in any test for the calculation of an IC₅₀.

10.2 Reduction and Refinement of Animal Use for the UDP

10.2.1 *In Vivo* Testing Using the UDP

This section describes the general dosing procedure for the UDP (OECD 2001a; EPA 2002a). Although doses, interval between doses, and dose progression, may be adjusted as necessary, the procedures described reflect the default guidance. Guidance on the types of animals that can be used, animal housing, clinical observations, etc., are outside the scope of the current discussion and are provided in the test guidelines (see **Appendices M1** and **M2**).

10.2.1.1 Main Test

The UDP is based on a staircase design in which single animals are dosed, in sequence, at 48-hour intervals. The effect on the first animal determines the dose of the next animal. If the first animal dies or is in a moribund state within 48 hours after dosing, the dose administered

to the next animal is lowered by dividing the original dose by one-half log (i.e., 3.2, which is the default dose progression). If the first animal survives, the dose administered to the next animal is increased by one-half log times the original dose. A dose progression of one-half log unit corresponds to a dose-mortality slope of 2.0. The default dose progression can be adjusted if the analyst has prior information upon which to estimate a slope.

The starting dose recommended by the guideline is one dose progression step below the analyst's best estimate of the LD_{50} , because, in the UDP test method, the LD_{50} estimate tends to move toward the starting dose. A default starting dose of 175 mg/kg is used if there is no information on which to base a starting dose. The default dosing scheme, using the dose progression of 3.2, is 1.75, 5.5, 17.5, 55, 175, 550, 1750, and 5000 mg/kg (EPA 2002a) or 1.75, 5.5, 17.5, 55, 175, 550, and 2000 mg/kg (OECD 2001a). The difference between the two reflects the different maximum doses emphasized in the different guidelines. Dosing single animals, upward or downward, in sequence proceeds until the first of three conditions, referred to as stopping rules, is met:

- Three consecutive animals survive at the upper dose limit (2000 or 5000 mg/kg)
- Five reversals⁵ occur in any six consecutive animals tested
- Four or more animals have followed the first reversal, and the likelihoodratios specified by the guideline exceed the critical value. For a wide variety of LD₅₀ values and dose-mortality slopes, this rule is satisfied with four to six animals after the first reversal. Three likelihood values are calculated: a likelihood at an LD₅₀ point estimate (called the rough estimate or doseaveraging estimate); a likelihood at a value below the point estimate (the point estimate divided by 2.5); and a likelihood at a value above the point estimate (the point estimate multiplied by 2.5). The ratios of the likelihoods are examined to determine whether they exceed a critical value.

If none of these conditions is met, the dosing stops after 15 animals have been used.

10.2.1.2 Limit Test

The UDP guidelines include a limit test using three to five animals dosed sequentially at 2000 mg/kg (OECD 2001a) or 5000 mg/kg (EPA 2002a). The EPA guideline for testing at a limit dose calls for proceeding to the main test if the first animal dosed at 5000 mg/kg dies (EPA 2002a). If the first animal lives, two more animals are dosed, in sequence, with 5000 mg/kg. If both animals live, then testing is terminated, and the substance is designated as having an $LD_{50} >5000$ mg/kg. If one or both animals die, then two more animals are dosed in sequence. As soon as a total of three animals survive, the test is terminated, with the conclusion that $LD_{50} >5000$ mg/kg. However, the main test is conducted if three animals die.

⁵ Reversal: a situation where a nonresponse (i.e., animal lives) is observed at some dose, and a response is observed at the next dose tested (i.e. animal dies), or vice versa. Reversal is created by a pair of responses. (See **Appendices M1** and **M2**)

The OECD guideline for testing at a limit dose calls for proceeding to the main test if the first animal dosed at 2000 mg/kg dies (OECD 2001a). If the animal lives, four more animals are sequentially dosed. The main test is performed if three animals die. If three or more animals survive, testing is terminated with the conclusion that the $LD_{50} > 2000 \text{ mg/kg}$.

10.2.2 <u>Computer Simulation Modeling of the UDP</u>

Ten thousand UDP testing simulations were run for each substance, *in vitro* NRU test method, and dose-mortality slope. Because the analysis assumed there was no information upon which to estimate a dose-mortality slope, the modeling used the default dose progression factor of 3.2, and 5000 mg/kg as the upper limit dose because this upper limit is emphasized in the EPA guideline (EPA 2002a)⁶. If the starting dose estimated from the *in vitro* IC₅₀ value was \geq 4000 mg/kg, then the limit test, rather than the main test, was performed. If, during the dose progression, the next highest dose to be administered was approximately 4000 mg/kg or greater, then the limit dose of 5000 mg/kg was administered. If a dose one step below the IC₅₀-estimated LD₅₀ was used as the starting dose, the other doses administered corresponded to the default doses specified in the guidelines (OECD 2001a; EPA 2002a). The simulation modeling procedures also used a lower limit of 1 mg/kg. Thus, a dose of 1 mg/kg was administered if the dose progression fell below 1 mg/kg. To estimate animal use by the default method, a starting dose corresponded to the doses specified in the guidelines (OECD 2001a; EPA 2002a).

The simulation was performed using SAS[®] version 8 (SAS 1999) and implemented the distributional assumptions underlying the dose-mortality relationship. The lowest dose at which an animal dies in response to the administration of a toxic substance varies from animal to animal. For an entire population of animals, mortality is assumed to have a log-normal distribution, with the mean equal to the log of the true LD₅₀. Sigma (σ), the variability of the simulated population, is the inverse of the slope of the dose-mortality curve. Because of a lack of information concerning the actual dose-mortality curves, the simulations assumed several different values of the slope, but no corresponding changes were made in the dose progression. Dose-mortality slopes of 0.5, 0.8, 2.0, 4.0, and 8.3 were used because these were used in the simulation modeling used to evaluate the current version of the UDP guidelines (ICCVAM 2001c).

To model the variability of the IC_{50} values within and among laboratories, the values for each reference substance were log-transformed to normalize their distribution. The mean and variance of these log-transformed values were used to generate a log-normal distribution from which an IC_{50} value was randomly selected. This IC_{50} value was used with the regressions to determine starting doses using two different methods. One method used the LD_{50} estimated from the IC_{50} and the regression as the starting dose, while the other used the closest default dose that was lower than the estimated LD_{50} . The latter method is recommended by the EPA and OECD test guidelines (EPA 2002a; OECD 2001a), and the results from that simulation are presented in **Section 10.2**. The UDP is only usable for regulatory purposes if the starting dose is set below the expected LD_{50} . **Appendix Q** contains

 $^{^{6}}$ The results from UDP simulations for a limit dose of 2000 mg/kg will be presented in a future addendum to this document.

the results obtained when the LD_{50} that was estimated by the IC₅₀ and the regression was used as the starting dose.

The simulation procedure used the following steps for each reference substance:

- 1. The LD_{50} value (in mg/kg) from **Table 4-2** was entered as the true LD_{50} value and the choices of assumed slope were entered as the true slopes for the dose-mortality curve.
- 2. An IC₅₀ value was selected from a distribution identified by the mean and variance of the IC₅₀ values for each chemical to reflect the variation in IC₅₀ values produced by the different laboratories (see **Tables 5-4** and **5-5** for mean IC₅₀ values and standard deviations for the 3T3 and NHK NRU test methods, respectively).
- 3. The IC_{50} value from Step 2 was used in the regression model being evaluated to predict a LD_{50} value, which was used to determine the starting dose.
- 4. The dosing simulation was run three times: once with the default starting dose of 175 mg/kg, once at the next default dose below the LD₅₀ estimated by the regression being evaluated, and once at a dose equal to that of the LD₅₀ estimated by the regression being evaluated.
- 5. For each simulated trial, the animals are dosed sequentially; therefore for each animal (*i*) there is a corresponding dose (*i*) that is administered to the animal. For the first animal in each trial, it is the starting dose for that trial. For each subsequent animal, the dose is dependent on the previous dose and the previous animal's response, as described in **Section 10.2.1**. For animal (*i*), the probability of a response is computed with the cumulative log-normal distribution at the dose administered. That is,

 $P(response) = P(x < \log[dose(i)])$ where $x \sim N(\mu, \sigma)$, where μ is the log of the true LD₅₀ value, and σ is the inverse of the assumed slope of the dose-mortality curve. One observation is then sampled from a binomial distribution with this calculated probability of success to determine whether the animal lives or dies.

6. Dosing simulation is stopped as soon as one of the stopping rules is satisfied.

Steps 2-6 were repeated 10,000 times in order to compute an average animal use for each method evaluated.

10.2.3 Animal Savings in the UDP When Using 3T3- and NHK-Based Starting Doses

10.2.3.1 *The Effect of the Dose-Mortality Slope on Animal Use*

As described in **Section 10.2.2**, the simulation modeling of animal use for the UDP assumed five different dose-mortality slopes in order to assess animal use under various conditions of population variability. **Table 10-1** shows that the number of animals used for the UDP decreases with increasing slope for both the default starting dose and the IC₅₀-determined starting dose when based on the RC rat-only millimole regression. The IC₅₀-determined starting dose was the next default dose lower than the regression-estimated LD₅₀. For example, because the LD₅₀ predicted for cadmium chloride by the 3T3 NRU IC₅₀ with the RC rat-only millimole regression was 1.75 mg/kg (i.e., the next default dose below the predicted LD₅₀). This approach is consistent with the UDP

guidelines (OECD 2001a; EPA 2002a) as a means of reducing the number of animals that might experience pain and suffering from a treatment. This approach also overcomes the nonconservative bias of the UDP, which tends to yield an LD_{50} close to the starting dose.

Table 10-1 shows that, for each dose-mortality slope, the mean number of animals saved was statistically significant (p<0.05) when compared to mean number of animals needed when the default starting dose was used. When expressed as a percentage of the number of animals used when the default starting dose is used, animal savings also generally increased with increasing slope of the dose-response. The animal savings is the same at all slopes tested, but fewer animals are used at the steeper slopes, which increases the relative percentages of animals saved.

| Dose-Mortality Slope | With Default Starting Dose ^{1,3} | With IC ₅₀ -Based Starting Dose ^{1,4} | Animals Saved ⁵ | | | | |
|----------------------|--|--|----------------------------|--|--|--|--|
| 3T3 NRU Test Method | | | | | | | |
| 0.5 | 10.01 ± 0.10 | 9.48 ±0.11 | 0.53* (5.3%) | | | | |
| 0.8 | 9.95 ±0.13 | 9.34 ±0.14 | 0.61* (6.1%) | | | | |
| 2.0 | 9.35 ±0.16 | 8.80 ±0.17 | 0.54* (5.8%) | | | | |
| 4.0 | 8.68±0.18 | 8.15 ±0.19 | 0.52* (6.0%) | | | | |
| 8.3 | 7.95 ±0.18 | 7.42 ± 0.20 | 0.53* (6.6%) | | | | |
| | NHK NRU Te | st Method | | | | | |
| 0.5 | 10.01 ±0.09 | 9.53 ±0.12 | 0.49* (4.9%) | | | | |
| 0.8 | 9.96 ±0.13 | 9.41 ±0.15 | 0.55* (5.5%) | | | | |
| 2.0 | 9.36 ±0.16 | 8.86 ±0.18 | 0.50* (5.3%) | | | | |
| 4.0 | 8.66 ±0.17 | 8.18 ±0.20 | 0.48* (5.6%) | | | | |
| 8.3 | 7.92 ±0.18 | 7.43 ±0.20 | 0.49* (6.2%) | | | | |

Table 10-1Change in Animal Use¹ with Dose-Mortality Slope for the UDP²

Abbreviations: UDP=Up-and-Down Procedure; 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; RC=Registry of Cytotoxicity.

*Statistically significant (p<0.05) by a one-sided Wilcoxon signed rank test. Percentage difference is shown in parentheses. ¹Mean numbers of animals \pm standard errors for 10,000 simulations for each of the 67 substances in the 3T3 NRU test method and 68 substances in the NHK NRU test method. Although the simulations used whole animals, averaging the results over a large number of simulations produced fractional numbers. Upper limit dose =5000 mg/kg. ²OECD (2001a); EPA (2002a).

³Default starting dose = 175 mg/kg.

⁴The starting dose = next lower default dose to the predicted LD_{50} , which was calculated from the IC_{50} value in the RC ratonly millimole regression: log LD_{50} (mmol/kg) = 0.439 log IC_{50} (mM) + 0.621. The IC_{50} value for each reference substance was randomly selected from the distribution of values obtained during the testing with each method.

⁵Difference between mean animal use with the default starting dose and mean animal use with the IC₅₀-based starting dose.

To simplify the presentation of animal savings and the comparison of the various regressions and starting doses, the results of subsequent analyses presented in **Section 10.2.3** are limited to the dose-mortality slopes of 2.0 and 8.3. The slope of 2.0 is the default used for the calculation of LD_{50} by the UDP method (OECD 2001a; EPA 2002a) and the slope of 8.3 is shown to represent substances, such as pesticides, with higher slopes. Animal savings results for the other dose-mortality slopes were calculated, and are presented in **Appendices N1-N3**. Although using the next lower default dose to the *in vitro*-determined LD_{50} value overcomes the bias of the UDP toward the starting dose (OECD 2001a, EPA 2002a) and is the appropriate approach for regulatory use, animal savings results using the estimated LD_{50} as the starting dose were also calculated (see **Appendix Q**).

10.2.3.2 Mean Animal Use for UDP Simulations – Comparison of Regressions and Predictions from the 3T3 and NHK NRU Test Methods

Table 10-2 shows the mean animal use for the simulated UDP testing of the reference substances described in **Section 10.1**. Mean animal use is shown for the default starting dose and for starting doses that were one default dose lower than the LD₅₀ predicted from the *in vitro* NRU methods and the regressions evaluated in **Section 6.4** for the prediction of GHS category. The difference in animal use between the two starting doses is the mean animal savings produced by using the starting dose based on the *in vitro* NRU methods. All differences (i.e., mean animal savings) were statistically significant (p <0.05) by a one-sided Wilcoxon signed rank test. Mean animal savings ranged from 0.49 to 0.66 (6.2% to 7.0%) animals per test depending upon the *in vitro* NRU test method, regression, and dose-mortality slope. The lowest mean animal savings were obtained for the RC rat-only millimole regression (0.49 [6.2%] to 0.54 [5.8%] animals for the different test methods and dose-mortality slopes), and the greatest mean animal savings were obtained with the RC rat-only weight regression (0.54 [6.8%] to 0.66 [7.0%] animals per test).

The animal savings using the *in vitro* NRU test methods with the RC rat-only regressions apply only to the reference substances evaluated in this validation study, and are based on substances pre-selected for their known *in vivo* toxicities and may not be broadly applicable to other substances. **Table 3-4** shows that 22 (38%) of the 58 RC substances selected for testing were known to have a poor fit to the RC millimole regression (i.e., the *in vivo* LD₅₀ was outside the RC acceptance interval for the predicted LD₅₀). **Table 6-3** shows that 40% (28/70 for the 3T3) and 44% (31/71 for the NHK) of the reference substances that produced IC₅₀ values were outliers. The RC rat-only millimole regression evaluated here is very similar to the RC millimole regression (see **Table 6-5**). Substances with better fits to the regression are more likely to yield greater animal savings.

10.2.3.3 Animal Savings in the UDP by GHS Acute Oral Toxicity Category Using 3T3- and NHK-Based Starting Doses

Tables 10-3 and **10-4** show mean animal use and mean animal savings for the UDP when the default starting dose and the IC_{50} -predicted starting doses were used, and when the reference substances are grouped by GHS category (UN 2005). The data come from the same analyses as the data provided in **Table 10-2**. The IC_{50} -predicted starting doses were based on the:

- RC rat-only millimole regression (Table 10-3)
- RC rat-only weight regression (**Table 10-4**)

Table 10-2Mean Animal Use1 in the UDP2 Using Starting Doses Based on the 3T3 and NHK NRU Test
Methods with the Different Regressions

| Assay/Regression | With Default Starting Dose ³ | With IC ₅₀ - Based Starting Dose ⁴ | Animals Saved ⁵ | With Default Starting Dose ³ | With IC ₅₀ - Based Starting Dose ⁵ | Animals Saved ⁵ | |
|------------------------------------|--|---|-------------------------------|--|---|-------------------------------|--|
| 3T3 NRU Test Method | Dose-mortality Slope = 2.0 | | | Dose-mortality Slope = 8.3 | | | |
| RC rat-only millimole ⁶ | 9.35 ±0.16 | 8.80 ± 0.17 | 0.54* (5.8%) | $7.95\pm\!0.18$ | 7.42 ± 0.20 | 0.53* (6.6%) | |
| RC rat-only weight ⁷ | $9.36\pm\!\!0.16$ | 8.70 ±0.16 | 0.66* (7.0%) | 7.94 ±0.18 | 7.32 ± 0.19 | 0.62* (7.8%) | |
| NHK NRU Test Method | Dose | e-mortality Slope | e = 2.0 | Dos | e-mortality Slop | e = 8.3 | |
| RC rat-only millimole ⁶ | $9.36\pm\!\!0.16$ | $8.86\pm\!\!0.18$ | 0.50* (5.3%) | $7.92\pm\!\!0.18$ | 7.43 ± 0.20 | 0.49* (6.2%) | |
| RC rat-only weight ⁷ | $9.36\pm\!\!0.16$ | $8.80\pm\!\!0.17$ | 0.56* (6.0%) | $7.92\pm\!\!0.18$ | 7.38 ± 0.20 | 0.54* (6.8%) | |

Abbreviations: 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; RC=Registry of Cytotoxicity; UDP=Up-and-Down Procedure. *Statistically significant (p <0.05) by a one-sided Wilcoxon signed rank test. Percentage difference is shown in parentheses.

¹Mean numbers of animals \pm standard errors for 10,000 simulations for each of the 67 substances in the 3T3 NRU test method and 68 substances in the NHK NRU test method. Although the simulations used whole animals, averaging the results over a large number of simulations produced fractional numbers. Upper limit dose =5000 mg/kg.

²OECD (2001a); EPA (2002a).

³Default starting dose =175 mg/kg.

⁴The starting dose = one default dose lower than the predicted acute oral LD_{50} calculated using the IC_{50} value in the specified regression. The IC_{50} value for each reference substance was randomly selected from the distribution of values obtained during the *in vitro* testing with each test method.

⁵Difference between mean animal use with default starting dose and mean animal use with the IC₅₀-based starting dose.

 $^{6}\log \text{LD}_{50} \text{ (mmol/kg)} = 0.439 \log \text{IC}_{50} \text{ (mM)} + 0.621.$

 $^{7}\log LD_{50} (mg/kg) = 0.372 \log IC_{50} (\mu g/mL) + 2.024.$

These analyses showed that:

- For each *in vitro* NRU test method and regression, animal savings were statistically significant for substances in the $2000 < LD_{50} \le 5000 \text{ mg/kg}$ and $LD_{50} > 5000 \text{ mg/kg}$ toxicity categories.
- For substances with $5 < LD_{50} \le 50$ mg/kg and $50 < LD_{50} \le 300$ mg/kg, both *in vitro* NRU test methods with each regression used slightly more animals than the default-starting dose, but the differences were not statistically significant.

Animal Savings for the UDP by GHS Acute Oral Toxicity Category Using 3T3- and NHK-Based Starting Doses with the RC Rat-Only Millimole Regression

Table 10-3 shows the animal savings by GHS category when the IC_{50} values are used with the RC rat-only millimole regression. Mean animal savings were statistically significant (p <0.05) by a one-tailed Wilcoxon signed rank test for the following GHS toxicity categories, test methods, and dose-mortality slopes:

- The use of the NHK NRU test method at both dose-mortality slopes for substances with $300 < LD_{50} \le 2000 \text{ mg/kg}$ that produced savings of 0.49 (6.5%) to 0.52 (6.1%) animals per test.
- The use of the 3T3 NRU test method at the 8.3 dose-mortality slope for substances with $300 < LD_{50} \le 2000 \text{ mg/kg}$ that produced a saving of 0.31 (4.1%) animals per test.
- The use of both *in vitro* NRU test methods at both dose-mortality slopes for substances with 2000 < LD₅₀ ≤5000 mg/kg that produced savings of 1.11 (12.1%) to 1.28 (11.9%) animals per test.
- The use of both *in vitro* NRU test methods and both dose-mortality slopes for substances with an LD₅₀ >5000 mg/kg that produced savings of 1.47 (14.8%) to 1.58 (20.3%) animals per test.

The mean animal savings for the 3T3 and NHK NRU test methods were similar for most toxicity categories at both dose-mortality slopes, with the mean savings with the 3T3 slightly higher than with the NHK. For the dose-mortality slope of 2.0, the mean animal savings with the 3T3 NRU test method ranged from -0.42 (-5.5%) to 1.58 (16.0%) animals per test for the various toxicity categories, and savings for the NHK NRU test method ranged from -0.34 (-3.5%) to 1.47 (14.8%) animals per test. For the dose-mortality slope of 8.3, animal savings for the 3T3 NRU test method ranged from -0.29 (-4.3%) to 1.58 (20.3%) animals per test and savings for the NHK NRU test method ranged from -0.33 (-3.9%) to 1.47 (19.2%) animals per test. Animal savings were also obtained for highly toxic substances (LD₅₀ \leq 5 mg/kg) with both the 3T3 (0.96 [9.9%] to 1.14 [10.0%] animals per test) and NHK (0.71 [7.3%] to 0.75 [6.7%] animals per test) NRU test methods, but the savings were not statistically significant.

No mean animal savings (\leq -0.28 animal per test) were observed for substances with 50 LD₅₀ \leq 300 mg/kg by either the 3T3 or the NHK NRU test method. This category includes the default starting dose of 175 mg/kg. Animal savings were not expected for this category because savings were determined by comparing animal use with the IC₅₀-based starting dose with animal use at the default starting dose. No animal savings (-0.07 to -0.34 animals per test) were observed for substances with 5< LD₅₀ \leq 50 mg/kg for either NRU test method. None of these differences in animal use was statistically significant.

Table 10-3Animal Use1 for the UDP2 by GHS Acute Oral Toxicity Category3 Using Starting Doses Based on the 3T3
and NHK NRU Test Methods with the RC Rat-Only Millimole Regression4

| | | Dose-mortality Slope = 2.0 | | | Dose-mortality Slope = 8.3 | | |
|--|--------------------------------------|---|---|-------------------------------|---|---|-------------------------------|
| GHS Acute Oral Toxicity Category ³ | Number of Reference Substances | With Default Starting Dose ⁵ | With IC ₅₀ - Based Starting Dose ⁶ | Animals Saved ⁷ | With Default Starting Dose ⁵ | With IC ₅₀ - Based Starting Dose ⁶ | Animals Saved ⁷ |
| | | | | 3T3 NRU T | est Method | | |
| $LD_{50} \leq 5 \text{ mg/kg}$ | 6 | 11.32 ± 0.20 | 10.19 ± 0.70 | 1.14 (10.0%) | $9.70\pm\!\!0.28$ | 8.74 ± 0.43 | 0.96 (9.9%) |
| $5 < LD_{50} \leq 50 \text{ mg/kg}$ | 11 | 9.68 ±0.23 | 9.74 ± 0.45 | -0.07 (-0.7%) | 8.46 ± 0.28 | $8.54\pm\!\!0.47$ | -0.08 (-1.0%) |
| $50 < LD_{50} \le 300 \text{ mg/kg}$ | 12 | 7.76 ±0.10 | 8.18 ± 0.21 | -0.42 (-5.5%) | 6.61 ±0.19 | 6.90 ± 0.19 | -0.29 (-4.3%) |
| $300 < LD_{50} \le 2000 \text{ mg/kg}$ | 16 | 8.53 ±0.21 | 8.14 ± 0.21 | 0.38 (4.5%) | 7.46 ± 0.24 | 7.15 ±0.19 | 0.31* (4.1%) |
| $2000 < LD_{50} \le 5000 \text{ mg/kg}$ | 10 | 10.73 ± 0.10 | 9.46 ± 0.15 | 1.28* (11.9%) | 9.17 ±0.23 | 7.96 ± 0.31 | 1.21* (13.2%) |
| LD ₅₀ >5000 mg/kg | 12 | 9.87 ± 0.34 | 8.29 ± 0.49 | 1.58* (16.0%) | 7.76 ± 0.59 | 6.18 ± 0.69 | 1.58* (20.3%) |
| | | | | NHK NRU 7 | Fest Method | | |
| $LD_{50} \leq 5 \text{ mg/kg}$ | 6 | 11.21 ±0.24 | 10.47 ± 0.71 | 0.75 (6.7%) | 9.66 ±0.27 | 8.95 ± 0.52 | 0.71 (7.3%) |
| $5 < LD_{50} \le 50 \text{ mg/kg}$ | 11 | 9.65 ±0.16 | 9.99 ±0. 45 | -0.34 (-3.5%) | 8.43 ± 0.26 | 8.77 ± 0.49 | -0.33 (-3.9%) |
| $50 < LD_{50} \le 300 \text{ mg/kg}$ | 12 | 7.78 ±0.11 | 8.12 ±0.21 | -0.34 (-4.4%) | 6.57 ± 0.19 | 6.85 ±0.19 | -0.28 (-4.2%) |
| $300 < LD_{50} \le 2000 \text{ mg/kg}$ | 16 | 8.55 ±0.22 | 8.03 ±0.23 | 0.52* (6.1%) | 7.49 ±0.25 | 7.00 ± 0.20 | 0.49* (6.5%) |
| $2000 < LD_{50} \le 5000 \text{ mg/kg}$ | 10 | 10.75 ± 0.08 | 9.54 ± 0.20 | 1.21* (11.3%) | 9.17 ±0.23 | 8.06 ± 0.29 | 1.11* (12.1%) |
| LD ₅₀ >5000 mg/kg | 13 | 9.87 ± 0.32 | 8.41 ± 0.44 | 1.47* (14.8%) | 7.66 ± 0.59 | 6.18 ± 0.69 | 1.47* (19.2%) |

Abbreviations: 3T3=BALB/c 3T3 fibroblasts; GHS=Globally Harmonized System of Classification and Labelling of Chemicals (UN 2005); NHK=Normal human epidermal keratinocytes; RC=Registry of Cytotoxicity; UDP=Up-and-Down Procedure.

*Statistically significant (p<0.05) by a one-sided Wilcoxon signed rank test. Percentage difference shown in parentheses.

¹Mean numbers of animals used ±standard errors for 10,000 simulations for each substance with an upper limit dose of 5000 mg/kg. Although the simulations used whole animals, averaging the results over a large number of simulations produced fractional numbers. Results are provided for 67 substances in the 3T3 NRU test method and 68 substances in the NHK NRU test method. Substances were categorized using the rat acute oral LD₅₀ reference values in mg/kg from **Table 4-2**. ²OECD (2001a); EPA (2002a).

³UN (2005).

⁴The RC rat-only millimole regression is $\log LD_{50} \text{ (mmol/kg)} = 0.439 \log IC_{50} \text{ (mM)} + 0.621.$

⁵Default starting dose = 175 mg/kg.

⁶The starting dose was one default dose lower than the predicted LD_{50} calculated using the IC₅₀ value for each reference substance in the RC rat-only millimole regression. The IC₅₀ value for each reference substance was randomly selected from the distribution of values obtained during the testing with each method.

⁷Difference between mean animal use with the default starting dose and mean animal use with the predicted starting dose.

The animal savings from the future use of these *in vitro* NRU test methods with the RC ratonly millimole regression will depend on the proportion of test substances that will fall into each of the GHS categories.

<u>Animal Savings for the UDP by GHS Category Using 3T3- and NHK-Based Starting Doses</u> with the RC Rat-Only Weight Regression

Table 10-4 shows the mean animal savings by GHS acute oral toxicity category when the IC_{50} values are used with the RC rat-only weight regression. A comparison of mean animal savings, by category, with the RC rat-only millimole regression, indicates that, in most cases, animal savings were slightly higher for the RC rat-only weight regression than for the millimole regression. In the RC rat-only weight regression, the mean differences between animal use for the default starting dose and mean animal use with the IC_{50} -determined starting dose were statistically significant (p <0.05) by a one-sided Wilcoxon signed rank test for the following GHS categories, NRU test methods, and dose-mortality slopes:

- The use of the 3T3 NRU test method at the 8.3 mortality-slope for substances with $300 < LD_{50} \le 2000$ mg/kg that produced a savings of 0.28 (3.8%) animals per test.
- The use of both *in vitro* NRU test methods at both dose mortality slopes for substances with 2000< LD₅₀ ≤5000 mg/kg that produced savings of 1.28 (14.0%) to 1.64 (15.2%) animals per test.
- The use of both *in vitro* NRU test methods at both dose-mortality slopes for substances with LD₅₀ >5000 mg/kg that produced savings of 1.53 (20.0%) to 1.65 (16.7%) animals per test.

For the dose-mortality slope of 2.0, the mean animal savings (for the various GHS categories) with the 3T3 NRU test method ranged from -0.25 (-3.3%) to 1.65 (16.7%) animals per test, and from -0.24 (-3.1%) to 1.54 (15.6%) animals per test using the NHK NRU test method. At the dose-mortality slope of 8.3, animal savings with the 3T3 NRU test method ranged from -0.18 (-2.7%) to 1.63 (21.0%) animals per test, and savings for the NHK NRU test method ranged from -0.18 (-2.7%) to 1.53 (20.0%) animals per test. Animal savings were also obtained for highly toxic substances (LD₅₀ \leq 5 mg/kg) with both the 3T3 (0.78 [8.0%] to 0.90 [8.0%] animals per test) and NHK (0.69 [7.1%] to 0.72 [6.4%] animals per test) NRU test methods, but these savings were not statistically significant.

There were no mean animal savings (\leq -0.18 animals per test) for substances with 50 < LD₅₀ \leq 300 mg/kg with either *in vitro* NRU test method. This category includes the default starting dose of 175 mg/kg. Animal savings were not expected for this category because savings were determined by comparing animal use at the IC₅₀-based starting dose with animal use at the default starting dose. For the NHK NRU test method, there were no animal savings (-0.07 to -0.13 animals per test) when used for substances with 5 < LD₅₀ \leq 50 mg/kg. None of these small changes in animal use were statistically significant.

The animal savings from testing new substances with these *in vitro* NRU test methods using the RC rat-only weight regression will depend on the proportion of test substances that fall into each of the GHS categories.

| Table 10-4 | Animal Use ¹ for the UDP ² by GHS Acute Oral Toxicity Category ³ Using Starting Doses Based on the 3T3 |
|------------|---|
| | and NHK NRU Test Methods with the RC Rat-Only Weight Regression ⁴ |

| | | Dose-mortality Slope = 2.0 | | | Dose-mortality Slope = 8.3 | | | |
|--|--------------------------------------|--|--|-------------------------------|---|---|-------------------------------|--|
| GHS Acute Oral Toxicity Category ³ | Number of Reference Substances | With Default Starting Dose ⁵ | With IC ₅₀ - Based Starting Dose | Animals Saved ⁷ | With Default Starting Dose ⁵ | With IC ₅₀ - Based Starting Dose | Animals Saved ⁷ | |
| | | | | 3T3 NRU ' | Test Method | | | |
| $LD_{50} \leq 5 \text{ mg/kg}$ | 6 | 11.29 ±0.20 | 10.38 ± 0.62 | 0.90 (8.0%) | 9.70 ± 0.28 | 8.92 ± 0.37 | 0.78 (8.0%) | |
| $5 < LD_{50} \le 50 \text{ mg/kg}$ | 11 | 9.71 ±0.22 | 9.58 ± 0.42 | 0.13 (1.3%) | 8.47 ± 0.28 | 8.41 ±0.44 | 0.06 (0.8%) | |
| $50 < LD_{50} \le 300 \text{ mg/kg}$ | 12 | 7.74 ± 0.10 | 7.99 ±0.18 | -0.25 (-3.3%) | 6.58 ±0.19 | 6.76 ± 0.18 | -0.18 (-2.7%) | |
| $300 < LD_{50} \le 2000 \text{ mg/kg}$ | 16 | 8.52 ±0.21 | 8.16 ±0.19 | 0.35 (4.1%) | 7.46 ± 0.24 | 7.17 ±0.16 | 0.28* (3.8%) | |
| $2000 < LD_{50} \le 5000 \text{ mg/kg}$ | 10 | 10.78 ± 0.11 | 9.14 ±0.24 | 1.64* (15.2%) | 9.20 ± 0.24 | 7.61 ±0.37 | 1.59* (17.3%) | |
| LD ₅₀ >5000 mg/kg | 12 | 9.87 ± 0.34 | 8.23 ± 0.48 | 1.65* (16.7%) | 7.76 ±0.59 | 6.14 ±0.69 | 1.63* (21.0%) | |
| | | | | NHK NRU | Test Method | | | |
| $LD_{50} \leq 5 \text{ mg/kg}$ | 6 | 11.21 ±0.24 | 10.49 ± 0.71 | 0.72 (6.4%) | 9.66 ±0.27 | 8.97 ± 0.52 | 0.69 (7.1%) | |
| $5 < LD_{50} \le 50 \text{ mg/kg}$ | 11 | 9.70 ±0.18 | 9.78 ±0.41 | -0.07 (-0.8%) | 8.45 ±0.27 | 8.59 ±0.44 | -0.13 (-1.6%) | |
| $50 < LD_{50} \le 300 \text{ mg/kg}$ | 12 | 7.75 ±0.11 | 7.99 ±0.21 | -0.24 (-3.1%) | 6.58 ±0.19 | 6.76 ±0.18 | -0.18 (-2.7%) | |
| $300 < LD_{50} \le 2000 \text{ mg/kg}$ | 16 | 8.54 ±0.21 | 8.20 ± 0.22 | 0.34 (3.9%) | 7.48 ±0.23 | 7.17 ±0.16 | 0.31 (4.1%) | |
| 2000 < LD ₅₀ ≤5000 mg/kg | 10 | 10.77 ± 0.08 | 9.40 ±0.25 | 1.38*(12.8%) | 9.18 ±0.23 | 7.90 ±0.33 | 1.28* (14.0%) | |
| LD ₅₀ >5000 mg/kg | 13 | 9.88 ±0.32 | 8.34 ± 0.44 | 1.54*(15.6%) | 7.66 ±0.56 | 6.12 ±0.63 | 1.53* (20.0%) | |

Abbreviations: 3T3=BALB/c 3T3 fibroblasts; GHS=Globally Harmonized System of Classification and Labelling of Chemicals (UN 2005); NHK=Normal human epidermal keratinocytes; RC=Registry of Cytotoxicity; UDP=Up-and-Down Procedure.

*Statistically significant (p <0.05) by a one-sided Wilcoxon signed rank test. Percent difference is shown in parentheses.

¹Mean number of animals used \pm standard errors for 10,000 simulations for each substance with a limit dose of 5000 mg/kg. Although the simulations used whole animals, averaging the results over a large number of simulations produced fractional numbers. Results are provided for 67 substances for the 3T3 NRU test method and 68 substances for the NHK NRU test method categorized using the rat acute oral LD₅₀ reference values in mg/kg from **Table 4-2**. ²OECD (2001a); EPA (2002a).

³UN (2005).

⁴The RC rat-only weight regression is log LD_{50} (mg/kg) = 0.372 log IC_{50} (µg/mL) + 2.024

⁵Default starting dose = 175 mg/kg.

⁶The starting dose was one default dose lower than the predicted LD_{50} calculated using the IC_{50} values for each reference substance in the RC rat-only weight regression. The IC_{50} value for each reference substance was randomly selected from the distribution of values obtained during the testing with each method.

⁷Difference between mean animal use with the default starting dose and mean animal use with the predicted starting dose.

10.2.4 <u>Refinement of Animal Use for the UDP When Using 3T3- and NHK-Based</u> <u>Starting Doses</u>

A procedure refines animal use when it lessens or eliminates pain or distress in animals or enhances animal well-being (ICCVAM 2003). This section evaluates whether the use of 3T3and NHK-based starting doses refines animal use by reducing the number of animals that die and experience accompanying pain and distress during UDP testing, compared to the number of animals that die when the default starting dose of 175 mg/kg is used. **Table 10-5** reports the results for the UDP simulation modeling using the 5000 mg/kg limit dose. For every regression evaluated, the mean number of deaths when using the IC₅₀-based starting doses were essentially equal to the mean number of deaths when using the default starting dose. The percentage of deaths, however, was slightly higher for the IC₅₀-based starting doses than for the default starting dose because the total number of animals used was lower for the IC₅₀based starting doses. Thus, fewer animals were used when using an IC₅₀-based starting dose compared with use of the default starting dose, but the same numbers of animals died.

Table 10-5Animal Deaths1 in the UDP2 Using Starting Doses Based on the 3T3 and
NHK NRU Test Methods

| Assay/Regression | With Default Starting Dose ³ | | | With IC ₅₀ -Based Starting Dose ⁴ | | |
|------------------------------------|---|------|----------------------|---|------|----------|
| | Used | Dead | % Deaths | Used | Dead | % Deaths |
| 3T3 NRU Test Method | | Ι | Dose-Mortalit | y Slope = 2.0 | 1 | |
| RC rat-only millimole ⁵ | 9.35 | 4.11 | 44.0% | 8.80 | 4.09 | 46.5% |
| RC rat-only weight ⁶ | 9.36 | 4.11 | 43.9% | 8.70 | 4.05 | 46.6% |
| | Dose-Mortality Slope = 8.3 | | | | | |
| RC rat-only millimole ⁵ | 7.95 | 3.44 | 43.3% | 7.42 | 3.43 | 46.2% |
| RC rat-only weight ⁶ | 7.94 | 3.43 | 43.2% | 7.32 | 3.39 | 46.3% |
| NHK NRU Test Method | | I | Dose-Mortalit | y Slope = 2.0 | 1 | |
| RC rat-only millimole ⁵ | 9.36 | 4.08 | 43.6% | 8.86 | 4.07 | 45.9% |
| RC rat-only weight ⁶ | 9.36 | 4.08 | 43.6% | 8.80 | 4.02 | 45.7% |
| | Dose-Mortality Slope = 8.3 | | | | | |
| RC rat-only millimole ⁵ | 7.92 | 3.39 | 42.8% | 7.43 | 3.39 | 45.6% |
| RC rat-only weight ⁶ | 7.92 | 3.39 | 42.8% | 7.38 | 3.35 | 45.4% |

Abbreviations: 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; RC=Registry of Cytotoxicity; UDP=Up-and-Down Procedure.

¹Numbers are mean numbers of animals used for 10,000 simulations for each substance. Although the simulations used whole animals, averaging the results over a large number of simulations produced fractional numbers. Upper limit dose = 5000 mg/kg. Results are provided for 67 substances in the 3T3 NRU test method and 68 substances in the NHK NRU test methods.

²OECD (2001a); EPA (2002a).

³Default starting dose = 175 mg/kg.

⁴The starting dose was one default dose lower than the predicted LD_{50} calculated using the IC_{50} value in the regression specified. The IC_{50} value for each reference substance was randomly selected from the distribution of values obtained during the testing with each method.

 $^{5}\log LD_{50}$ (mmol/kg) = 0.439 log IC₅₀ (mM) + 0.621.

 6 log LD₅₀ (mg/kg) = 0.372 log IC₅₀ (µg/mL) + 2.024.

10.2.5 Accuracy of UDP Outcomes Using the IC₅₀-Based Starting Doses

For each of the reference substances, the outcome of the simulated UDP testing, the simulated LD_{50} was used to classify the substance into a GHS acute oral toxicity category. The accuracy of GHS toxicity category assignments using the IC₅₀-based starting doses was determined by calculating the proportion of reference substances for which the GHS acute oral toxicity category obtained using the IC₅₀-based starting dose matched the categories obtained using the default starting dose.

The concordance between the GHS categories determined using the 3T3 and NHK NRU test methods with the RC rat-only millimole regression, and those determined using the UDP default starting dose, was 96% for 3T3 and 97% for NHK (see **Appendix N1**). The discordant reference substances were acetaminophen and sodium dichromate dihydrate in the 3T3 NRU test method, and acetaminophen, caffeine, and sodium dichromate dihydrate in the NHK NRU test method. The use of the IC₅₀-based starting dose from both *in vitro* NRU test methods resulted in a higher GHS category (i.e., higher simulated LD₅₀) for acetaminophen (simulated LD₅₀ = 2047 vs. 1765 mg/kg for 3T3, and LD₅₀ = 2174 vs. 1755 mg/kg for NHK), and a lower GHS category for sodium dichromate dihydrate (simulated LD₅₀ = 44 vs. 52 mg/kg for 3T3 and LD₅₀ = 45 vs. 52 mg/kg for NHK) than when using the default starting dose. The NHK-based starting dose resulted in a lower GHS category for caffeine (simulated LD₅₀ = 280 vs. 357 mg/kg).

The concordance of GHS acute toxicity category predictions with those determined using the default starting dose was 97% for the 3T3 and NHK NRU test methods when the RC rat-only weight regression was used (see **Appendix N2**). The discordant reference substances were caffeine and sodium dichromate dihydrate. The simulated LD₅₀ outcome for caffeine was lowered from 338 mg/kg for the default starting dose to 272 mg/kg for the 3T3-based starting dose, and from 339 mg/kg to 270 mg/kg for the NHK-based starting dose. The simulated LD₅₀ outcome for sodium dichromate dihydrate was lowered from 51 mg/kg for the default starting dose to 48 mg/kg for the 3T3-based starting dose, and from 51 mg/kg to 49 mg/kg for the NHK-based starting dose.

Thus, the use of the IC_{50} -based starting doses did not significantly alter the outcome of the simulated UDP tests compared with the outcome obtained using the default starting doses.

10.3 Reduction and Refinement of Animal Use in the ATC Method

10.3.1 *In Vivo* Testing Using the ATC Method

This section describes the general dosing procedure for the conduct of the ATC procedure (OECD 2001d). The ATC is used to assign a test substance to the appropriate GHS category for classification and labeling. This is done by estimating the range of the LD_{50} values for the test substance, rather than calculating a point estimate of the LD_{50} . The time between administration of test substance doses is determined by the onset, duration, and severity of toxic signs. Guidance on the types of animals to use, animal housing, clinical observations, etc., which are outside the scope of the current discussion, are provided in the test guideline (See **Appendix M3**).

10.3.1.1 Main Test

The ATC method uses a stepwise administration of test substances to three animals at a time, at one of a number of fixed doses: 5, 50, 300, and 2000 mg/kg (and 5000 mg/kg, if necessary). The starting dose is selected so that at least some of the animals die at that dose. If no information on which to base a starting dose is available, a default starting dose of 300 mg/kg is used. The next step is determined by the starting dose and the outcome of the three animals tested at the starting dose and may be a decision to stop testing, test additional animals at the same dose, test at the next higher dose, or test at the next lower dose. For example, if two to three animals die or are in a moribund state after receiving the 300 mg/kg starting dose, the next step is to administer 50 mg/kg to three more animals. However, if no, or one, animal dies at 300 mg/kg, three additional animals are tested at that dose. Most substances require two to four dosing steps before they can be classified, and testing can be stopped. See **Appendix M3** for the outcome-based testing sequence for each starting dose.

10.3.1.2 Limit Test

For test substances that are likely to be nontoxic, the ATC guideline includes a limit test in which six animals (three animals per step [see **Appendix M3**]) are tested at the limit dose of 2000 mg/kg or three animals are tested at a limit dose of 5000 mg/kg (OECD 2001d).

10.3.2 Computer Simulation Modeling of the ATC Method

The simulation for the ATC method was performed using MATLAB[®] (The MathWorks, Inc. 1996-2004) computational software, which is functionally comparable with SAS[®] version 8. Two thousand simulations of ATC testing were run for each substance, *in vitro* NRU test method, and dose-mortality slope, using an upper limit dose of 2000 mg/kg⁷. The simulation implements the distributional assumptions underlying the dose-mortality response. The lowest dose at which an animal dies in response to the administration of a toxic substance varies from animal to animal. For an entire population of animals, mortality is assumed to have a log-normal distribution with the mean equal to the log of the true LD₅₀. Sigma (σ), the variability of the simulated population, is the inverse of the slope of the dose-mortality curve. For any given dose, the probability that an animal will die is computed by the cumulative log-normal distribution:

Probability (death) =
$$\frac{1}{\sigma\sqrt{2\pi}} \int_{-\infty}^{\log dose} e^{\frac{-(t-\log trueLD_{50})^2}{2\sigma^2}} dt$$

Because of a lack of information regarding the real dose-mortality curves, the simulations assumed several different values of the slope (i.e., the inverse of σ). Dose-mortality slopes of 0.5, 0.8, 2.0, 4.0, and 8.3 were chosen, so as to be comparable to the slopes chosen for simulation modeling of the UDP (see Section 10.2.2).

To model the variability of the IC_{50} values within and among laboratories, the values for each substance were log-transformed to normalize their distribution. The mean and variance of

⁷ The results from ATC simulations for a limit dose of 5000 mg/kg will be presented in a future addendum to this document.

these log-transformed values were used to generate a log-normal distribution from which to randomly select an IC_{50} value.

The simulation procedure used the following steps for each substance:

- 1. The rodent acute oral LD_{50} value (in mg/kg) from **Table 4-2** was entered as the true LD_{50} value and the choices of assumed slope were entered as the true slope for the dose-mortality curve.
- 2. An IC_{50} value was selected from a distribution identified by the mean and variance of the IC_{50} values computed from the data to reflect that different laboratories produce different IC_{50} values in different situations (see **Tables 5-4** and **5-5** for mean IC_{50} values and standard deviations for the 3T3 and NHK NRU test methods, respectively).
- 3. The IC_{50} value from Step 2 was used in the regression model being evaluated to compute a predicted LD_{50} value for determining the starting dose.
- 4. The dosing simulation (of 2000 iterations) was run twice: once with the default starting dose of 300 mg/kg and once with a starting dose equal to the next fixed dose below the predicted LD_{50} , which was estimated by the regression being evaluated (i.e., the IC₅₀-based starting dose). If the IC₅₀-based starting dose was greater than the 2000 mg/kg limit dose, then testing proceeded using the 2000 mg/kg limit test rather than the main test.
- 5. For every dose group of three animals, one observation was sampled from a binomial distribution with the probability of death calculated by the probability equation for a population of three. The sampled value, referred to as N1, indicates the number of animals, 0, 1, 2, or 3, in the dosing group that die.
- 6. If $N1 \le 1$, step 4 is repeated with the same dose. The resulting sampled value from the binomial distribution is referred to as N2.
- If N2 ≤1 and the dose is the highest dose tested, or the dose has already been decreased, a toxicity category is assigned and testing is terminated. If the dose is not the highest dose tested, or if the dose has not been decreased, the next higher fixed dose is administered and step 4 is repeated.
- 8. If N1 >1 or N2 >2, and the dose is the lowest dose tested, or if the dose has already been increased, a toxicity category is assigned and testing is terminated. If the dose is not the lowest dose tested, or if the dose has not already been increased, the next lower fixed dose is administered and step 4 is repeated.

10.3.3 <u>Animal Savings for the ATC Method When Using 3T3- and NHK-Based Starting</u> <u>Doses</u>

10.3.3.1 The Effect of the Dose-Mortality Slope on Animal Use

As described in Section 10.3.2, the simulation modeling of animal use for the ATC used five different dose-mortality slopes to assess animal use under various conditions of population variability. Table 10-6 shows how mean animal use for the simulated ATC changes with dose-mortality slope for both the default starting dose of 300 mg/kg and a starting dose that was one fixed dose lower than that predicted by the 3T3 and NHK NRU IC₅₀ values with the RC rat-only millimole regression. The mean number of animals used for the ATC method

decreased slightly with increasing slope for both the default starting dose and the IC_{50} -based starting dose.

The mean numbers of animals saved at all dose-mortality slopes were statistically significant (p < 0.05 by one-sided Wilcoxon signed rank tests) when compared with mean animal use with the default dose, and tended to decrease with increasing slope. To simplify the presentation of animal savings and comparisons of the various regressions and starting doses, subsequent results in **Section 10.3.3** are shown only for dose-mortality slopes of 2.0 and 8.3. As stated earlier, these slopes are shown here because the slope of 2.0 is the default used for the calculation of LD_{50} by the UDP method (OECD 2001a; EPA 2002a) and the slope of 8.3 is shown to represent substances, such as pesticides, with higher slopes. Results for the other dose-mortality slopes were computed, and are presented in **Appendices N3** and **N4**.

| Dose-Mortality Slope | e-Mortality Slope With Default Starting Dose ^{1,3} | | Animals Saved ⁵ | | | | | |
|----------------------|---|-------------|----------------------------|--|--|--|--|--|
| 3T3 NRU Test Method | | | | | | | | |
| 0.5 | 11.25 ±0.05 | 10.56 ±0.17 | 0.69* (6.1%) | | | | | |
| 0.8 | 11.10 ± 0.07 | 10.46 ±0.19 | 0.64* (5.8%) | | | | | |
| 2.0 | 10.89 ± 0.12 | 10.27 ±0.24 | 0.62* (5.7%) | | | | | |
| 4.0 | 10.73 ±0.15 | 10.15 ±0.26 | 0.58* (5.4%) | | | | | |
| 8.3 | 10.64 ± 0.17 | 10.13 ±0.27 | 0.51* (4.8%) | | | | | |
| | NHK NRU Test | Method | | | | | | |
| 0.5 | 11.25 ± 0.05 | 10.43 ±0.16 | 0.82* (7.3%) | | | | | |
| 0.8 | 11.10 ± 0.07 | 10.31 ±0.18 | 0.79* (7.1%) | | | | | |
| 2.0 | 10.91 ±0.11 | 10.11 ±0.24 | 0.80* (7.3%) | | | | | |
| 4.0 | 10.75 ± 0.15 | 9.98 ±0.27 | 0.77* (7.1%) | | | | | |
| 8.3 | 10.67 ± 0.17 | 9.96 ±0.29 | 0.70* (6.6%) | | | | | |

Table 10-6 Change in Animal Use¹ with Dose-Mortality Slope in the ATC Method²

Abbreviations: 3T3=BALB/c 3T3 fibroblasts; ATC=Acute Toxic Class method; NHK=Normal human epidermal keratinocytes; RC=Registry of Cytotoxicity.

*Statistically significant (p <0.05) by a one-sided Wilcoxon rank test. Percent difference is shown in parentheses. ¹Mean numbers of animals used \pm standard errors for 2000 simulations each for 67 substances in the 3T3 NRU test method and 68 substances in the NHK NRU test method. Although the simulations used whole animals, averaging the results over a large number of simulations produced fractional numbers. Upper limit dose = 2000 mg/kg.

²OECD (2001d).

³Default starting dose = 300 mg/kg.

⁴Next fixed dose lower than the predicted LD_{50} calculated using the IC_{50} value for each reference substance in the RC ratonly millimole regression: log LD_{50} (mmol/kg) = 0.439 log IC_{50} (mM) + 0.621. The IC_{50} value for each reference substance was randomly selected from the distribution of values obtained during the testing with each method.

⁵Difference between mean animal use with the default starting dose and mean animal use with the IC₅₀-based starting dose.

10.3.3.2 Mean Animal Use for ATC Simulations – Comparison of Regressions and Predictions from the 3T3 and NHK NRU Test Methods

Table 10-7 shows the mean animal use for testing the reference substances using the simulated ATC method, when the starting dose was the default starting dose and when the starting dose was one fixed dose lower than that determined by the 3T3 and NHK-predicted LD₅₀, and the regressions evaluated in **Section 6.4** for prediction of GHS category. The mean difference in animal use between the two starting doses is the mean animal savings. All mean animal savings were statistically significant (p <0.05 using one-sided Wilcoxon signed rank tests), and ranged from 0.51 (4.8%) to 1.09 (10.2%) animals per test depending upon the NRU test method, regression, and dose-mortality slope. The lowest mean animal savings were obtained for the RC rat-only millimole regression (0.51 [4.8%] to 0.80 [7.3%] animals per test), and the highest were obtained with the RC rat-only weight regression (0.91 [8.6%] to 1.09 [10.2%] animals per test).

The animal savings obtained using the *in vitro* NRU test methods with the RC rat-only regressions apply only to the reference substances evaluated in this validation study, and are based on substances pre-selected for their known *in vivo* toxicities and may not be broadly applicable to other substances. **Table 3-4** shows that 22 (38%) of the 58 RC substances selected for testing were known to have a poor fit to the RC millimole regression (i.e., the predicted LD₅₀ was outside the RC acceptance interval). **Table 6-3** shows that 40% (28/70 in the 3T3) and 44% (31/71 in the NHK) of the reference substances that yielded IC₅₀ values were outliers. Substances that better fit the regression are likely to yield greater animal savings.

Table 10-7Animal Use1 for the ATC2 Method Using Starting Doses Based on the 3T3 and NHK NRU Test Methods with
the Different Regressions

| Method/Regression | With Default Starting Dose ³ | With IC ₅₀ - Based Starting Dose ⁴ | Animals Saved ⁵ | With Default Starting Dose ³ | With IC ₅₀ - Based Starting Dose ⁵ | Animals Saved ⁵ |
|------------------------------------|--|---|-------------------------------|--|---|-------------------------------|
| 3T3 NRU Test Method | Dose | -Mortality Slope = 2.0 | Dose-Mortality Slope = 8.3 | | | |
| RC rat-only millimole ⁶ | 10.89 ± 0.12 | 10.27 ± 24 | 0.62* (5.7%) | 10.64 ±0.17 | 10.13 ±0.27 | 0.51* (4.8%) |
| RC rat-only weight ⁷ | 10.89 ± 0.12 | 9.85 ±0.24 | 1.04* (9.6%) | 10.64 ±0.17 | 9.55 ±0.29 | 1.09* (10.2%) |
| NHK NRU Test Method | Dose | Mortality Slope = 2.0 | | Dose | e-Mortality Slope = 8 | 3.3 |
| RC rat-only millimole ⁶ | 10.91 ± 0.11 | 10.11 ±0.24 | 0.80* (7.3%) | 10.67 ± 0.17 | 9.96 ±0.29 | 0.70* (6.6%) |
| RC rat-only weight ⁷ | 10.91 ±0.11 | 9.95 ±0.24 | 0.96* (8.8%) | 10.67 ±0.17 | 9.75 ±0.30 | 0.91* (8.6%) |

Abbreviations: 3T3=BALB/c 3T3 fibroblasts; ATC=Acute Toxic Class method; NHK=Normal human epidermal keratinocytes; RC=Registry of Cytotoxicity. *Statistically significant (p<0.05) using a one-sided Wilcoxon signed rank test. Percentage difference is shown in parentheses.

¹Mean numbers of animals used \pm standard errors for 2000 simulations each for 67 substances in the 3T3 NRU test method and 68 substances in the NHK NRU test method. Upper limit dose =2000 mg/kg.

²OECD (2001d).

³Default starting dose = 300 mg/kg.

⁴Starting dose was one fixed dose lower than the predicted LD_{50} calculated using the IC_{50} value for each reference substance in the regression specified. The IC_{50} value for each reference substance was randomly selected from the distribution of values obtained during the testing with each test method.

⁵Difference between mean animal use with the default starting dose and mean animal use with the IC₅₀-based starting dose.

 $^{6}\log LD_{50} \text{ (mmol/kg)} = 0.439 \log IC_{50} \text{ (mM)} + 0.621.$

 7 log LD₅₀ (mg/kg) = 0.372 log IC₅₀ (µg/mL) + 2.024.

10.3.3.3 Animal Savings in the ATC Method by GHS Acute Oral Toxicity Category Using the 3T3- and NHK -Based Starting Doses

Tables 10-8 and **10-9** show mean animal use and mean animal savings for the ATC when used with the *in vitro* NRU test methods, organized by GHS category (UN 2005), and when based on the:

- RC rat-only millimole regression (Table 10-8)
- RC rat-only weight regression (**Table 10-9**)

The following data come from the same analyses as the data provided in Table 10-7.

The analyses showed that:

- For each *in vitro* NRU test method and regression, the highest mean animal savings were generally in the $LD_{50} \le 5 \text{ mg/kg}$ and $LD_{50} \ge 5000 \text{ mg/kg}$ toxicity categories.
- For each NRU test method and regression, the lowest mean animal savings were in the 300 < LD₅₀ ≤2000 mg/kg toxicity category.

<u>Animal Savings in the ATC Method by GHS Category Using the 3T3- and NHK-Based</u> <u>Starting Doses with the RC Rat-Only Millimole Regression</u>

Table 10-8 shows the mean animal savings in the ATC method by GHS category for the *in vitro* NRU test methods used with the RC rat-only millimole regression. Mean differences between animal use for the default starting dose and with the IC₅₀-determined starting dose were statistically significant (p < 0.05) by a one-sided Wilcoxon signed rank test for the following GHS toxicity categories, NRU test methods, and dose-mortality slopes:

- The use of both *in vitro* NRU test methods at both dose-mortality slopes for substances with 5 < LD₅₀ ≤50 mg/kg produced savings of 1.15 (9.8%) to 1.33 (11.4%) animals per test
- The use of the 3T3 NRU test method at both dose-mortality slopes for substances with $300 < LD_{50} \le 2000 \text{ mg/kg}$ used more animals per test (i.e., produced savings of -0.92 [-9.5%] to -1.30 [-14.0%] animals per test)
- The use of both *in vitro* NRU test methods at both dose-mortality slopes for substances with LD₅₀ >5000 mg/kg produced savings of 2.03 (17.1%) to 2.66 (22.2%) animals per test

At the dose-mortality slope of 2.0, the mean animal savings with the 3T3 NRU test method ranged from -0.92 (-9.5%) to 2.68 (27.4%) animals per test, and the animal savings with the NHK NRU test method ranged from -0.60 (-6.1%) to 2.96 (30.4%) animals per test. At the dose-mortality slope of 8.3, the mean animal savings with the 3T3 NRU test method ranged from -1.30 (-14.0%) to 2.70 (29.7%) animals per test, and the animal savings with the NHK NRU test method ranged from -0.85 (-9.2%) to 2.99 (33.0%) animals per test.

Table 10-8Animal Savings1 for the ATC2 Method by GHS Acute Oral Toxicity Category3 Using Starting Doses Based
on the 3T3 and NHK NRU Test Methods with the RC Rat-Only Millimole Regression4

| | | Dos | Dose-Mortality Slope = 2.0 | | | -Mortality Slope | e = 8.3 |
|--|--------------------------------------|---|---|----------------------------|--|--|-------------------------------|
| GHS Acute Oral Toxicity Category ³ | Number of Reference Substances | With Default Starting Dose ⁵ | With IC ₅₀ - Based Starting Dose ⁶ | Animals Saved ⁷ | With Default Starting Dose ⁵ | WithIC ₅₀ - Based Starting Dose ⁶ | Animals Saved ⁷ |
| | | | | 3T3 NRU 1 | Fest Method | | |
| $LD_{50} \leq 5 \text{ mg/kg}$ | 6 | 9.77 ±0.17 | 7.09 ± 1.09 | 2.68 (27.4%) | $9.08\pm\!\!0.08$ | 6.38 ± 1.09 | 2.70 (29.7%) |
| $5 < LD_{50} \le 50 \text{ mg/kg}$ | 11 | 11.56 ± 0.21 | 10.39 ± 0.52 | 1.17* (10.2%) | 11.75 ±0.16 | 10.60 ± 0.43 | 1.15* (9.8%) |
| $50 < LD_{50} \le 300 \text{ mg/kg}$ | 12 | 10.81 ±0.20 | 10.39 ± 0.17 | 0.42 (3.9%) | 9.42 ±0.26 | 9.27 ±0.11 | 0.15 (1.6%) |
| $300 < LD_{50} \le 2000 \text{ mg/kg}$ | 16 | 9.75 ±0.07 | 10.67 ± 0.48 | -0.92* (-9.5%) | 9.26 ± 0.10 | 10.56 ± 0.62 | -1.30* (-14.0%) |
| $2000 < LD_{50} \le 5000 \text{ mg/kg}$ | 10 | 11.22 ± 0.08 | 11.14 ± 0.08 | 0.08 (0.7%) | 11.88 ± 0.10 | 11.77 ±0.10 | 0.11 (0.9%) |
| LD ₅₀ >5000 mg/kg | 12 | 11.85 ± 0.04 | 9.82 ± 0.78 | 2.03* (17.1%) | 12.00 ± 0.000 | 9.81 ±0.84 | 2.19* (18.3%) |
| | | | | NHK NRU | Test Method | | |
| LD ₅₀ ≤5 mg/kg | 6 | 9.74 ±0.16 | 6.78 ± 1.31 | 2.96 (30.4%) | 9.09 ± 0.08 | 6.09 ± 1.23 | 2.99 (33.0%) |
| $5 < LD_{50} \le 50 \text{ mg/kg}$ | 11 | 11.56 ±0.21 | 10.38 ± 0.35 | 1.18* (10.2%) | 11.76 ±0.17 | 10.42 ± 0.45 | 1.33* (11.4%) |
| $50 < LD_{50} \le 300 \text{ mg/kg}$ | 12 | 10.83 ± 0.21 | $10.39\pm\!\!0.29$ | 0.44 (4.0%) | 9.44 ±0.26 | 9.63 ±0.49 | -0.20 (-2.1%) |
| $300 < LD_{50} \le 2000 \text{ mg/kg}$ | 16 | 9.77 ±0.06 | 10.37 ± 0.49 | -0.60 (-6.1%) | 9.26 ±0.10 | 10.11 ±0.63 | -0.85 (-9.2%) |
| $2000 < LD_{50} \le 5000 \text{ mg/kg}$ | 10 | 11.22 ± 0.08 | 11.25 ±0.12 | -0.03 (-0.3%) | 11.87 ±0.10 | 11.89 ± 0.15 | -0.02 (-0.2%) |
| LD ₅₀ >5000 mg/kg | 13 | 11.86 ± 0.03 | 9.43 ± 0.73 | 2.43* (20.5%) | 12.00 ± 0.000 | 9.34 ± 0.80 | 2.66* (22.2%) |

Abbreviations: 3T3=BALB/c 3T3 fibroblasts; ATC=Acute Toxic Class method; GHS=Globally Harmonized System of Classification and Labelling of Chemicals (UN 2005); NHK=Normal human epidermal keratinocytes; RC=Registry of Cytotoxicity.

*Statistically significant (p < 0.05) by a one-sided Wilcoxon signed rank test. Percentage difference is shown in parentheses.

¹Mean number of animals used \pm standard errors for 2000 simulations for each substance with an upper limit dose of 2000 mg/kg. Results are provided for 67 substances in the 3T3 NRU test method and 68 substances in the NHK NRU test method categorized using the rat acute oral LD₅₀ reference values in mg/kg from **Table 4-2**. Although the simulations used whole animals, averaging the results over a large number of simulations produced fractional numbers. ²OECD (2001d).

³GHS for acute oral toxicity (UN 2005).

⁴The RC rat-only millimole regression is $\log LD_{50} \text{ (mmol/kg)} = 0.439 \log IC_{50} \text{ (mM)} + 0.621.$

⁵Default starting dose =300 mg/kg.

 6 The starting dose was the next fixed dose lower than the predicted LD₅₀ using the IC₅₀ for each reference substance in the RC rat-only millimole regression. The IC₅₀ value for each reference substance was randomly selected from the distribution of values obtained during the testing with each method.

⁷Difference between mean animal use with the default starting dose and mean animal use with the IC₅₀-based starting dose.

At both the 2.0 and 8.3 dose-mortality slopes, the mean animal savings using the 3T3 NRU test method were lower than the corresponding savings using the NHK NRU test method, for substances in at least four of the six toxicity categories: $LD_{50} \le 5 \text{ mg/kg}$; $5 < LD_{50} \le 50 \text{ mg/kg}$; $300 < LD_{50} \le 2000 \text{ mg/kg}$; and $LD_{50} > 5000 \text{ mg/kg}$. The mean animal savings per test were higher with the 3T3 NRU test method than the NHK NRU test method for substances in the $2000 < LD_{50} \le 5000 \text{ mg/kg}$ category at both dose-mortality slopes. For substances in the $50 < LD_{50} \le 300 \text{ mg/kg}$ category, the mean animal savings using the 3T3 NRU test method was greater than the savings using the NHK NRU test method, when the dose-mortality slope equaled 8.3. When the 3T3 NRU test method was used, the highest mean animal savings occurred when testing substances in the $LD_{50} \le 5 \text{ mg/kg}$ category (2.68 [27.4%] animals per test at dose-mortality slope = 2.0, and 2.70 [29.7%] at dose-mortality slope = 8.3). When the NHK NRU test method was used, the highest mean animal savings occurred when testing substances in the substances in the LD₅₀ $\le 5 \text{ mg/kg}$ category (2.96 [30.4%] animals per test at dose-mortality slope = 2.0, and 2.99 [33.0%] animals per dose at dose-mortality slope = 8.3). However, the animal savings were not statistically significant with either *in vitro* NRU test method.

The smallest mean animal savings (≤ 0.44) in both *in vitro* NRU test methods were observed for substances with LD₅₀ values between 50 and 5000 mg/kg. Because the default starting dose was 300 mg/kg, little change in mean animal use was expected for substances in the 50 < LD₅₀ \leq 300 mg/kg and 300 < LD₅₀ \leq 2000 mg/kg categories. The mean animal savings from both *in vitro* NRU test methods and both dose-mortality slopes for the substances in the 50 < LD₅₀ \leq 300 mg/kg category were -0.20 to 0.44 animals per test. There were no animal savings for substances in the 300 < LD₅₀ \leq 2000 mg/kg category using either NRU test method or dose-mortality slope. In fact, significantly animals were used when the starting doses were based on the 3T3 NRU IC₅₀ than using the default starting dose (-0.92 to -1.30 animals per test). More animals were also used when the starting doses were based on the NHK NRU IC₅₀ (-0.85 to -0.60 animals/test), but the difference was not statistically significant.

The animal savings in the various GHS acute oral toxicity categories using the *in vitro* NRU test methods with the RC rat-only millimole regression applies only to the reference substances evaluated in this validation study, and may not be broadly applicable to other substances. The animal savings for future testing using the *in vitro* NRU test methods with the RC rat-only millimole regression will depend on the prevalence of test substances in each of the GHS acute oral toxicity categories.

Animal Savings with the ATC Method by GHS Category Using 3T3- and NHK-Based Starting Doses with the RC Rat-Only Weight Regression

Table 10-9 shows the animal savings for the simulated ATC method by GHS category for the *in vitro* NRU methods used with the RC rat-only weight regression. Mean animal savings were statistically significant (p < 0.05) by a one-tailed Wilcoxon signed rank test for the following GHS toxicity categories, NRU test methods, and dose-mortality slopes.

• The use of both *in vitro* NRU test methods at both dose-mortality slopes for substances with 5 < LD₅₀ ≤50 mg/kg produced savings of 1.25 (10.8%) to 1.51 (13.0%) animals per test.

Table 10-9Animal Savings1 for the ATC2 Method by GHS Acute Oral Toxicity Category3 Using Starting DosesBased on the 3T3 and NHK NRU Test Methods with the RC Rat-Only Weight Regression4

| | | Dose-Mortality Slope = 2.0 | | Dose-Mortality Slope = 8.3 | | | |
|--|--------------------------------------|--|---|-------------------------------|--|---|-------------------------------|
| GHS Acute Oral Toxicity Category ³ | Number of Reference Substances | With Default Starting Dose ⁵ | With IC ₅₀ - Based Starting Dose ⁶ | Animals Saved ⁷ | With Default Starting Dose ⁵ | With IC ₅₀ - Based Starting Dose ⁶ | Animals Saved ⁷ |
| | | | | 3T3 NRU T | est Method | | |
| $LD_{50} \leq 5 \text{ mg/kg}$ | 6 | 9.77 ±0.17 | 7.56 ± 1.03 | 2.21 (22.6%) | 9.08 ± 0.08 | $6.85\pm\!\!0.99$ | 2.24 (24.6%) |
| $5 < LD_{50} \le 50 \text{ mg/kg}$ | 11 | 11.56 ± 0.21 | 10.06 ± 0.38 | 1.51* (13.0%) | 11.75 ± 0.16 | 10.27 ± 0.33 | 1.48* (12.6%) |
| $50 < LD_{50} \le 300 \text{ mg/kg}$ | 12 | 10.81 ± 0.20 | 10.35 ± 0.18 | 0.47* (4.3%) | 9.42 ± 0.26 | 9.20 ± 0.10 | 0.22 (2.4%) |
| $300 < LD_{50} \le 2000 \text{ mg/kg}$ | 16 | 9.75 ± 0.07 | 10.67 ± 0.50 | -0.93* (-9.5%) | 9.26 ± 0.10 | 10.65 ± 0.66 | -1.39 (-15.0%) |
| $2000 < LD_{50} \le 5000 \text{ mg/kg}$ | 10 | 11.22 ± 0.08 | 9.80 ± 0.51 | 1.43* (12.7%) | 11.88 ± 0.10 | 9.44 ± 0.88 | 2.43 (20.5%) |
| LD ₅₀ >5000 mg/kg | 12 | 11.85 ± 0.04 | 8.83 ± 0.83 | 3.02* (25.5%) | 12.00 ± 0.00 | $8.67\pm\!\!0.91$ | 3.33* (27.7%) |
| | | NHK NRU Test Method | | | | | |
| $LD_{50} \leq 5 \text{ mg/kg}$ | 6 | 9.74 ±0.16 | 6.87 ± 1.28 | 2.87 (29.4%) | 9.09 ± 0.08 | 6.18 ± 1.20 | 2.91 (32.0%) |
| $5 < LD_{50} \le 50 \text{ mg/kg}$ | 11 | 11.56 ± 0.21 | 10.31 ±0.19 | 1.25* (10.8%) | 11.76 ±0.17 | 10.40 ± 0.33 | 1.36* (11.5%) |
| $50 < LD_{50} \le 300 \text{ mg/kg}$ | 12 | 10.83 ±0.21 | 10.41 ±0.28 | 0.42 (3.8%) | 9.44 ±0.26 | 9.63 ± 0.49 | -0.20 (-2.1%) |
| $300 < LD_{50} \le 2000 \text{ mg/kg}$ | 16 | 9.77 ±0.62 | 10.46 ± 0.50 | -0.69 (-7.1%) | 9.26 ±0.10 | 10.23 ± 0.65 | -0.97 (-10.4%) |
| $2000 < LD_{50} \le 5000 \text{ mg/kg}$ | 10 | 11.22 ± 0.09 | 10.69 ± 0.37 | 0.53 (4.7%) | 11.87 ± 0.10 | 11.03 ± 0.60 | 0.84 (7.1%) |
| LD ₅₀ >5000 mg/kg | 13 | 11.86 ± 0.03 | 8.91 ±0.78 | 2.94* (24.8%) | 12.00 ± 0.00 | 8.75 ± 0.85 | 3.25* (27.1%) |

Abbreviations: 3T3=BALB/c 3T3 fibroblasts; ATC=Acute Toxic Class method; GHS=Globally Harmonized System of Classification and Labelling of Chemicals (UN 2005); NHK=Normal human epidermal keratinocytes; RC=Registry of Cytotoxicity.

*Statistically significant (p < 0.05) by a one-sided Wilcoxon signed rank test. Percentage difference is shown in parentheses.

¹Mean number of animals used \pm standard errors for 2000 simulations for each substance with an upper limit dose of 2000 mg/kg. Although the simulations used whole animals, averaging the results over a large number of simulations produced fractional numbers. Results are provided for 67 substances in the 3T3 NRU test method and 68 substances in the NHK NRU test method categorized using the rat acute oral reference LD₅₀ values in mg/kg from **Table 4-2**.

²OECD (2001d). ³GHS for acute oral toxicity (UN 2005).

⁴From **Table 6-2**; $\log LD_{50} (mg/kg) = 0.372 \log IC_{50} (\mu g/mL) + 2.024$

⁵Default starting dose = 300 mg/kg.

⁶The starting dose was one fixed dose lower than the predicted LD_{50} calculated using the IC_{50} for each reference substance in the RC rat-only weight regression. The IC_{50} value for each reference substance was randomly selected from the distribution of values obtained during the testing with each method.

⁷Difference between mean animal use with the default starting dose and mean animal use with the IC₅₀-based starting dose.

- The use of the 3T3 NRU test method at the 2.0 dose-mortality slope for substances with $50 < LD_{50} \le 300$ mg/kg produced savings of 0.47 (4.3%) animals per test.
- The use of the 3T3 NRU test method at the 2.0 dose-mortality slope for substances with $300 < LD_{50} \le 2000 \text{ mg/kg}$ produced savings of -0.93 (-9.5%) animals per test (i.e., used more animals per test than the default starting dose).
- The use of the 3T3 NRU test method at the 2.0 dose-mortality slope for substances with $2000 < LD_{50} \le 5000$ mg/kg produced savings of 1.43 (12.7%) animals per test.
- The use of both *in vitro* NRU test methods at both dose-mortality slopes for substances with LD₅₀ >5000 mg/kg produced savings of 2.94 (24.8%) to 3.33 (27.7%) animals per test.

The mean animal savings with the 3T3 and NHK NRU test methods were similar for most acute oral toxicity categories at both dose-mortality slopes; the mean savings for the 3T3 NRU test method was slightly higher than for the NHK NRU test method for most toxicity categories. At the dose-mortality slope of 2.0, the mean animal savings for the 3T3 NRU test method (for the various toxicity categories) ranged from -0.93 (-9.5%) to 3.02 (25.5%) animals per test, and savings for the NHK NRU test method ranged from -0.69 (-7.1%) to 2.94 (24.8%) animals per test. At the dose-mortality slope of 8.3, animal savings with the 3T3 NRU test method ranged from -1.39 (-15.0%) to 3.33 (27.7%) animals per test, and savings with the NHK NRU test method ranged from -0.97 (-10.4%) to 3.25 (27.1%) animals per test.

There were no mean animal savings (\leq -0.69 animals) for substances with 300 < LD₅₀ \leq 2000 when either *in vitro* NRU test method was used. The mean animal savings for the substances in the 50 < LD₅₀ \leq 300 mg/kg category using both *in vitro* NRU test methods and dosemortality slopes were also relatively small (-0.20 to 0.47 animals per test). Because the default starting dose was 300 mg/kg, little change in mean animal use was expected for substances in the 50< LD₅₀ \leq 300 mg/kg and 300 < LD₅₀ \leq 2000 mg/kg categories. The highest mean animal savings (\leq -0.69 animals) occurred for substances with LD50 >5000 mg/kg when either *in vitro* NRU test method was used. For both test methods and dose-mortality slopes, the mean animal savings for substances in this category were 2.94 (24.8%) to 3.33 (27.7%) animals per test and were statistically significant. Mean animal savings were also high (2.21 [22.6%] to 2.91 [32.0%] animals per test) for substances with LD₅₀ \leq 5 mg/kg, but these savings were not statistically significant.

The animal savings in the various GHS categories using the two *in vitro NRU* test methods with the RC rat-only weight regression applies only to the reference substances evaluated in this validation study, and may not be broadly applicable to other substances.

10.3.4 <u>Refinement of Animal Use in the ATC Method When Using 3T3- and NHK-Based</u> <u>Starting Doses</u>

A procedure refines animal use when it lessens or eliminates pain or distress in animals, or enhances animal well-being (ICCVAM 2003). This section evaluates whether the use of 3T3- and NHK-based starting doses refines animal use by reducing the number of animals that die

when the IC_{50} -predicted starting doses are used, compared to the number of animals that die when using the default ATC starting dose of 300 mg/kg. **Table 10-10** reports the results for the ATC simulation modeling using the 2000 mg/kg limit dose. For every regression evaluated, the mean number of deaths when using the 3T3- and NHK-based starting doses was less than the mean number of deaths when using the default starting dose, by approximately 0.4 to 0.5 deaths per test. For the RC rat-only millimole regression and the RC rat-only weight regression, the percentage of deaths (compared with the numbers of animals used) was also slightly lower with the *in vitro*-based starting dose compared with the default starting dose. In general, fewer animals were used with the *in vitro*-based starting dose, and fewer animals died.

| Method/Regression | Default Starting Dose ³ | | | IC ₅₀ - Based Starting Dose ⁴ | | |
|------------------------------------|------------------------------------|------|----------|---|------|----------|
| | Used | Dead | % Deaths | Used | Dead | % Deaths |
| 3T3 NRU Test Method | Dose-Mortality Slope = 2.0 | | | | | |
| RC rat-only millimole ⁵ | 10.89 | 3.77 | 34.6% | 10.27 | 3.31 | 32.2% |
| RC rat-only weight ⁶ | 10.89 | 3.77 | 34.6% | 9.85 | 3.27 | 33.2% |
| | Dose-Mortality Slope = 8.3 | | | | | |
| RC rat-only millimole ⁵ | 10.64 | 3.20 | 30.1% | 10.13 | 2.77 | 27.3% |
| RC rat-only weight ⁶ | 10.64 | 3.20 | 30.1% | 9.55 | 2.73 | 28.6% |
| NHK NRU Test Method | Dose-Mortality Slope = 2.0 | | | | | |
| RC rat-only millimole ⁵ | 10.91 | 3.72 | 34.1% | 10.11 | 3.19 | 31.6% |
| RC rat-only weight ⁶ | 10.91 | 3.72 | 34.1% | 9.95 | 3.21 | 32.3% |
| | Dose-Mortality Slope = 8.3 | | | | | |
| RC rat-only millimole ⁵ | 10.67 | 3.15 | 29.5% | 9.96 | 2.67 | 26.8% |
| RC rat-only weight ⁶ | 10.67 | 3.15 | 29.5% | 9.75 | 2.67 | 27.4% |

Table 10-10Animal Deaths1 for the ATC2 Method Using Starting Doses Based on the
3T3 and NHK NRU Test Methods

Abbreviations: 3T3=BALB/c 3T3 fibroblasts; ATC=Acute Toxic Class method; NHK=Normal human epidermal keratinocytes; RC=Registry of Cytotoxicity.

¹Mean numbers of animals used for 2000 simulations for each of 67 substances in the 3T3 NRU test method and 68 substances in the NHK NRU test method. Although the simulations used whole animals, averaging the results over a large number of simulations produced fractional numbers. Upper limit dose =2000 mg/kg.

²OECD (2001d). ³Default starting dose =300 mg/kg.

⁴The starting dose was one fixed dose lower than the predicted LD_{50} calculated by using the IC₅₀ for each reference substance in the regression evaluated. The IC₅₀ value for each reference substance was randomly selected from the

distribution of values obtained during the testing with each method.

 $^{5}\log LD_{50} \text{ (mmol/kg)} = 0.439 \log IC_{50} \text{ (mM)} + 0.621.$

 $^{6}\log LD_{50} (mg/kg) = 0.372 \log IC_{50} (\mu g/mL) + 2.024.$

10.3.5 <u>Accuracy of the ATC Method Outcomes Using the IC_{50} -Based Starting Doses</u> The accuracy of the outcome of the simulated ATC testing (i.e., the simulated GHS acute oral toxicity category) using the IC_{50} -based starting dose was determined by calculating the proportion of reference substances for which the simulated GHS category for the IC_{50} -based starting dose matched the simulated GHS category for the default starting dose. When the RC rat-only millimole regression with the 3T3 and NHK NRU test methods was used, the concordance of simulated GHS categories for the IC₅₀-based starting doses with those for the default starting dose was 99% for both *in vitro* NRU test methods (see **Appendix N3**). The discordant reference substance in the 3T3 NRU test method was caffeine. The simulated GHS category using the 3T3-based starting dose was $300 < LD_{50} \le 300$ mg/kg, and the simulated GHS category using the default starting dose was $300 < LD_{50} \le 2000$ mg/kg.

The discordant reference substance in the NHK NRU test method was sodium dichromate dihydrate. The simulated GHS acute oral toxicity category using the NHK-based starting dose was $5 < LD_{50} \le 50$ mg/kg and the simulated GHS category using the default starting dose was $50 < LD_{50} \le 300$ mg/kg. Both discordant substances were predicted to have a starting dose one category below the actual category.

When the RC rat-only weight regression was used with the 3T3 and NHK NRU test methods, the concordance of simulated GHS acute toxicity category predictions with those determined using the default starting dose was 99% and 97% for the 3T3 and the NHK NRU test methods, respectively (see **Appendix N4**). The discordant reference substance in the 3T3 NRU test method was caffeine. The simulated GHS acute oral toxicity category for caffeine using the 3T3-based starting dose was $50 < LD_{50} \le 300$ mg/kg and that using the default starting dose was $300 < LD_{50} \le 2000$ mg/kg. The discordant reference substances in the NHK NRU test method were caffeine and sodium dichromate dihydrate. The simulated GHS acute oral toxicity category for caffeine using the simulated GHS category using the default starting dose was $300 < LD_{50} \le 2000$ mg/kg. The discordant reference substances in the NHK NRU test method were caffeine using the NHK-based starting dose was $50 < LD_{50} \le 300$ mg/kg and the simulated GHS category using the default starting dose was $300 < LD_{50} \le 2000$ mg/kg. The simulated GHS acute oral toxicity category for sodium dichromate dihydrate using the NHK-based starting dose was $50 < LD_{50} \le 2000$ mg/kg. The simulated GHS acute oral toxicity category for sodium dichromate dihydrate using the NHK-based starting dose was $50 < LD_{50} \le 2000$ mg/kg. Similar to what was seen with the RC millimole regression, the predicted starting doses for the discordant substances were one GHS category below the actual category.

Thus, the use of the IC_{50} -based starting doses did not significantly alter the outcomes of the simulated ATC tests compared with the outcome based on the default starting dose.

10.4 The Impact of Accuracy on Animal Savings

Two types of accuracy analyses were performed for the NICEATM/ECVAM validation study. The first analyses determined the accuracy of using the NRU IC₅₀ values with an IC₅₀-LD₅₀ regression to predict LD₅₀ values. It calculated the concordance for GHS acute oral toxicity category by comparing the GHS categorization yielded by the NRU-predicted LD₅₀ values (using the *in vitro* NRU IC₅₀ values in the regressions presented in **Table 6-5**) with the GHS categorization based on rat acute oral LD₅₀ data (see **Section 6.4**). The second analysis determined the accuracy of the simulation outcomes using the IC₅₀-based starting doses (see **Sections 10.2.5** and **10.3.5**). It calculated the concordance for the GHS acute oral toxicity category outcomes obtained using the IC₅₀-based starting doses with the GHS category outcomes obtained using the default starting dose. The magnitude of animal savings did not correlate with either determination of accuracy and the accuracy determinations for IC₅₀based predictions and IC₅₀-based outcomes for GHS category did not correlate with one another. Animal savings did not correlate with the accuracy of the GHS acute oral toxicity category predictions based on the LD₅₀ values calculated using the IC₅₀ values in the RC rat-only regressions (see **Sections 6.4.2** and **6.4.3**). Substances in categories with the lowest accuracy produced the highest animal savings. For example, using the RC rat-only millimole regression with the *in vitro* NRU IC₅₀ values yielded very low accuracy (0 to 17%) for GHS acute oral toxicity category prediction for substances with LD₅₀ >5000 mg/kg (see **Table 6-**7), but the highest animal savings of 14.8 to 20.3% occurred in this category (see **Table 10-**3). Animal savings were small, 4.5 to 6.5%, for substances with $300 \le LD_{50} \le 2000$ mg/kg, but the accuracy of 75-81% for GHS acute oral toxicity category prediction of GHS acute oral toxicity category based on the LD₅₀ values calculated using IC₅₀ values in the RC rat-only regressions is because two different standards are used for comparison in the two analyses:

- GHS acute oral toxicity category predictions using IC₅₀ values in the RC ratonly regressions are compared with the GHS categories derived from the *in vivo* reference LD₅₀
- The number of animals used (to determine animal savings) was compared with the animal use at the default starting dose of 175 mg/kg for the UDP or 300 mg/kg for the ATC

Despite the relatively poor GHS accuracy for the low toxicity chemicals (the toxicity of almost all were overpredicted by one GHS category), animal savings were greatest due to the fact that testing goes to the limit dose faster.

The accuracy of the simulated GHS toxicity category assignments using the IC₅₀-based starting doses for UDP and ATC test simulations was determined by calculating the proportion of reference substances for which the GHS acute oral toxicity category obtained using the IC₅₀-based starting dose matched the categories obtained using the default starting dose (see Sections 10.2.5 and 10.3.5). The accuracy of these GHS toxicity category assignments based on the simulation outcomes does not correlate with animal savings using the IC₅₀ values in the RC rat-only regressions (see Sections 6.4.2 and 6.4.3). For example, the accuracy of GHS acute oral toxicity category outcomes for the ATC test method when using the RC rat-only millimole regression was 100% for the 3T3 NRU test method for substances with $300 \le LD_{50} \le 2000$ mg/kg (see Appendix N3). In contrast, the animal savings for those substances was negative at -6.1 to -14.0% (i.e., more animals were used compared with the default starting dose) (see Table 10-8). The reason the outcome-based GHS acute oral toxicity category predictions is unrelated to animal savings is that two different parameters are being measured in the two analyses:

- The accuracy of the simulatedGHS acute oral toxicity outcomes using the IC_{50} -based starting doses measured outcome (i.e., simulated GHS category based on the simulated LD_{50} outcome for the UDP and simulated GHS category for the ATC)
- The animal savings analysis measured the number of animals used at the IC_{50} -based starting dose and the default starting dose of 175 mg/kg for the UDP or 300 mg/kg for the ATC

Thus, the measurements for the two analyses are different: outcome (i.e., GHS category) and number of animals used to achieve the outcome.

In addition, accuracy of the GHS toxicity category assignments based on the simulation outcomes does not correlate with the accuracy of the GHS acute oral toxicity category predictions using the IC_{50} values in the RC rat-only regressions (see **Section 6.4.2** and **6.4.3**). For example, the overall accuracy of GHS acute oral toxicity category outcomes for the ATC test method when using the RC rat-only millimole regression was 99% for both *in vitro* NRU test methods (see **Section 10.3.5** and **Appendix N3**). In contrast, the overall accuracy of GHS acute oral toxicity category predictions using the using the IC_{50} values in the RC rat-only millimole regression was 31% for the 3T3 NRU test method and 29% for the NHK NRU test method (see **Table 6-7**). The reason the simulated outcome-based GHS acute oral toxicity category predictions differed from the accuracy of the GHS acute oral toxicity category predictions differed from the accuracy of the GHS acute oral toxicity category predictions differed from the accuracy of the GHS acute oral toxicity category predictions differed from the accuracy of the GHS acute oral toxicity category predictions differed from the accuracy of the GHS acute oral toxicity category predictions differed from the accuracy of the GHS acute oral toxicity category predictions differed from the accuracy of the GHS acute oral toxicity category predictions based on the calculation of LD_{50} using the IC_{50} in the IC_{50} - LD_{50} regression is because two different standards are used for comparison in the two analyses:

- Simulated GHS acute oral toxicity outcomes for the IC₅₀-based starting doses were compared with the simulated GHS category outcomes using the default starting doses
- GHS acute oral toxicity category predictions using the IC₅₀ values in the RC rat-only regressions were compared with the GHS category derived from the *in vivo* reference LD₅₀

Thus, despite that the IC_{50} values and IC_{50} - LD_{50} regressions predicted GHS acute oral toxicity categories poorly, the GHS acute oral toxicity category outcomes using the IC_{50} -based starting doses were practically the same as the GHS acute oral toxicity category outcomes using the default starting dose.

10.5 The Impact of Prevalence on Animal Savings

As stated several times in this section, the animal savings for substances tested in the futureusing the 3T3 and NHK NRU test methods to determine the staring dose for rodent acute oral toxicity test methods will depend on the proportion of test substances that fall into each of the GHS acute toxicity hazard categories. Although the prevalence of substances among the different categories will depend, to a large extent, on the mandate of a particular regulatory agency, Spielmann et al. (1999) indicated that 76% (845/1115) of the industrial substances submitted to the Federal Institute for Health Protection of Consumers and Veterinary Medicine in Berlin, Germany, since 1982 had LD₅₀ >2000 mg/kg. The extent to which these substances represent the population of substances in commerce is not known. However, if the results of the validation study are broadly applicable to substances to be tested in the future, and if such substances are relatively nontoxic, the selection of starting doses using the *in vitro* NRU test methods may save a considerable number of animals since animal savings for the validation study were highest for the least toxic substances.

10.6 Summary

Computer simulation modeling of UDP testing using the default dose progression shows that, for the subset of reference substances evaluated, the prediction of starting doses using the 3T3 and NHK NRU test methods with the RC rat-only millimole regression resulted in a statistically significant (p < 0.05) decrease in the number of animals used by an average of 0.49 (6.2%) to 0.54 (5.8%) animals per test, depending upon the *in vitro* NRU test method and the dose-mortality slope (2.0 or 8.3) used. The mean animal savings improved slightly, to 0.54 (6.8%) to 0.66 (7.0%) animals per test, when the RC rat-only weight regression was used.

When reference substances were grouped by GHS category, there were no mean animal savings by simulated UDP testing for substances with $50 < LD_{50} \le 300$ mg/kg. The highest, and statistically significant, animal savings were observed with both *in vitro* NRU test methods when testing substances with $2000 < LD_{50} \le 5000$ mg/kg and $LD_{50} > 5000$ mg/kg. When using the RC rat-only millimole regression, animal savings for these categories ranged from 1.28 (11.9%) to 1.58 (20.3%) animals per test. The use of the RC rat-only weight regression improved animal savings slightly for the substances in these toxicity categories to 1.28 (14.0%) to 1.65 (16.7%) animals per test. Although the use of IC₅₀ values to estimate starting doses for the simulated UDP deceased the number of animals used per test, it did not change the number of animals that would have died during the procedures.

Computer simulation modeling of ATC testing showed that, for the reference substances tested in this validation study, the prediction of starting doses using the 3T3 and NHK NRU test methods with the RC rat-only millimole regression resulted in a statistically significant (p < 0.05) decrease in the number of animals for ATC testing by an average of 0.51 (4.8%) to 0.80 (7.3%) animals per test, depending upon the *in vitro* NRU test method and the dose-mortality slope (2.0 or 8.3) used. Animal savings improved to a mean of 0.91 (8.6%) to 1.09 (10.2%) animals per test when the RC rat-only weight regression was used.

When test substances were grouped by GHS category, the mean animal savings for ATC testing using the RC rat-only millimole regression were statistically significant with the 3T3 NRU test method at both dose-mortality slopes for substances with $5 < LD_{50} \le 50 \text{ mg/kg}$ (1.15 [9.8%] to 1.17 [10.2%] animals per test), and for substances with LD₅₀ >5000 mg/kg (2.03 [17.1%] to 2.19 [18.3%] animals per test). Significantly more animals were needed when the 3T3-based starting doses were used, than the default starting dose for reference substances with $300 \le LD_{50} \le 2000 \text{ mg/kg}$ (i.e., the animal savings were negative: -0.92 [-9.5%] to -1.30 [-14.0%] animals). The mean animal savings with the NHK NRU test method and the RC rat-only millimole regression were statistically significant at both dose-mortality slopes for substances with $5 < LD_{50} \le 50 \text{ mg/kg} (1.18 [10.2\%] \text{ to } 1.33 [11.4\%] \text{ animals per}$ test), and for substances with $LD_{50} > 5000 \text{ mg/kg}$ (2.43 [20.5%] to 2.66 [22.2%] animals per test). When the RC rat-only weight regression was used, statistically significant savings in animals used were observed with both *in vitro* NRU test methods and dose-mortality slopes for substances with $5 \leq LD_{50} \leq 50 \text{ mg/kg}$ (1.25 [10.8%] to 1.51 [13.0%] animals per test), and for substances with $LD_{50} > 5000 \text{ mg/kg}$ (2.94 [24.8%] to 3.33 [27.7%] animals per test). The use of IC₅₀ values to estimate starting doses for the ATC refined animal use by producing

approximately 0.5 to 0.6 fewer mean animal deaths per test than when the default starting dose of 300 mg/kg was used.

The use of the IC_{50} -based starting doses did not significantly alter the GHS category outcomes of the simulated UDP or ATC when compared with the outcomes based on the default starting dose. The concordance for GHS acute oral toxicity category for the IC_{50} -based starting dose with the default starting dose was 97 to 99% for both *in vitro* NRU methods and IC_{50} -LD₅₀ regressions evaluated.

The magnitude of animal savings did not correlate with the accuracy of GHS categorization yielded by the NRU-predicted LD_{50} values (using the *in vitro* NRU IC₅₀ values in the IC₅₀-LD₅₀ regressions) or with the accuracy of GHS category outcomes since the accuracy and animals savings analyses used different standards for comparison.

The specific animal savings using the 3T3 and NHK NRU test methods with the RC rat-only regressions apply only to the reference substances evaluated in this validation study, and may not be broadly applicable to other substances. Spielmann et al. (1999) indicated that 76% (845/1115) of the industrial substances submitted to the Federal Institute for Health Protection of Consumers and Veterinary Medicine in Berlin, Germany, since 1982 had LD₅₀ >2000 mg/kg. The extent to which these substances represent the population of substances in commerce is not known. However, if the results of the validation study are broadly applicable to substances to be tested in the future, and if such substances are relatively nontoxic, the selection of starting doses using the *in vitro* NRU test methods may save a considerable number of animals since animal savings for the validation study were highest for the least toxic substances.

| 11.0 | PRACTICAL CONSIDERATIONS | |
|-------------|--|--|
| | Transferability of the 3T3 and NHK NRU Test Methods | |
| | Facilities and Major Fixed Equipment. | |
| | Availability of Other Necessary Equipment and Supplies | |
| 11.1.3 | Problems Specific to the NHK Test Method | |
| 11.2 | 3T3 and NHK NRU Test Method Training Considerations | |
| 11.2.1 | Required Training and Expertise | |
| 11.2.2 | Training Requirements to Demonstrate Proficiency | |
| | Personnel Needed to Perform the In Vitro NRU Test Methods | |
| 11.3 | Cost Considerations | |
| 11.3.1 | 3T3 and NHK NRU Test Methods | |
| | Rodent Acute Oral Toxicity Testing | |
| 11.4 | Time Considerations for Performing the 3T3 and NHK NRU Tests The 3T3 NRU Test Method | |
| | The NHK NRU Test Method | |
| | Prequalification of NHK Medium | |
| | | |
| | <i>In Vivo</i> Testing The Limit Test | |
| 11.4.3 | | |
| 11.5 | Summary | |

[This Page Intentionally Left Blank]

11.0 PRACTICAL CONSIDERATIONS

The 3T3 and NHK NRU test methods are proposed as adjuncts, rather than replacements for, *in vivo* acute oral toxicity assays. Data from these *in vitro* basal cytotoxicity test methods are used with a linear regression model to predict the rat acute oral LD_{50} of the test substance, which is then used to determine the starting dose for subsequent rat acute oral toxicity tests, as described in **Sections 10.2.2** and **10.3.2**. This section discusses practical issues involved in using these two *in vitro* NRU test methods for predicting starting doses for rat acute oral toxicity tests. Practical issues that need to be considered with respect to the implementation of these cell culture methods include the need for, and availability of, specialized equipment, personnel training and expertise requirements, cost considerations, and time expenditures.

11.1 Transferability of the 3T3 and NHK NRU Test Methods

Transferability of a test method is defined as the ability of a method or procedure to be accurately and reliably performed in different, competent laboratories (ICCVAM 2003). Accuracy and reliability of these NRU test methods are discussed in **Sections 6** and 7, respectively.

Protocols for the 3T3 and NHK NRU test methods, including solubility testing, and prequalification of keratinocyte growth medium, have been optimized and are available on the ICCVAM/NICEATM website (http://iccvam.niehs.nih.gov/methods/invitro.htm). The protocols were designed with GLP-compliance in mind and can be easily implemented or adapted by scientists with the appropriate technical experience.

Although the *in vitro* and *in vivo* test methods require some similar, general laboratory skills (e.g., preparation of solutions and test substance doses, record keeping), *in vitro* testing requires skills specific to cell culture systems (e.g., aseptic techniques, microscopic evaluation of cell cultures, propagation of cells in medium) but not to the maintenance, handling, or treatment of rodents.

11.1.1 Facilities and Major Fixed Equipment

The following lists of facility requirements, equipment and supplies, and training and expertise are common to most *in vitro* mammalian cell culture laboratories. Required equipment and supplies are also described in detail in the validation study 3T3 and NHK protocols (**Appendices B** and **C**), the *Guidance Document* (ICCVAM 2001b), and Hartung et al. (2002).

11.1.1.1 Facility Requirements

The testing facility should be appropriate for operating a scientific laboratory (e.g., laboratory space, air handling procedures, access to utilities, shipping/receiving department [for appropriate receipt and handling of cell culture materials], etc.). Each facility should provide:

- Adequate facilities, equipment, and supplies
- Proper health and safety guidelines
- Satisfactory quality assurance procedures

Each facility should conform to all appropriate statutes (i.e., local, state, provincial, federal, national, international) concerning safety guidelines (e.g., general workplace safety

guidelines, chemical handling and disposal guidelines, biohazard guidelines). Hartung et al. (2002) provides recommended safety guidelines for working with potentially infectious materials (e.g., HIV, hepatitis B, hepatitis C) and human materials (e.g., cells, tissues, fluids).

11.1.1.2 Cell Culture Laboratory

The testing facility should have a designated cell culture laboratory to ensure that *in vitro* cytotoxicity assays are performed under clean and proper aseptic conditions. The dedicated laboratory should be located such that through traffic is minimal to reduce possible disturbances that can lead to contamination which could compromise the cell culture assays. The room temperature of the laboratory should be regulated, monitored, and documented. Access to the laboratory and its supplies and test chemicals should be restricted to appropriate personnel.

11.1.1.3 Major Equipment

Each testing facility should have at a minimum the following equipment:

- Incubator $(37^{\circ}C \pm 1^{\circ}C, 90\% \pm 10\% \text{ humidity}, 5.0\% \pm 1\% \text{ CO}_2/\text{air})$
- Laminar flow clean bench/cabinet (standard: "biological hazard")
- Inverted phase contrast microscope
- 96-well plate spectrophotometric plate reader equipped with 540 nm ± 10 nm filter (if testing in 96-well plates)
- Autoclave
- Refrigerator
- Freezer (-70°C)
- Cryogenic (liquid nitrogen) freezer/storage unit
- Computer

Equipment maintenance and calibration should be routinely performed and documented according to GLP guidelines and testing facility SOPs.

11.1.2 <u>Availability of Other Necessary Equipment and Supplies</u>

11.1.2.1 General Equipment

Each testing facility should have at a minimum the following equipment:

- Low speed centrifuge
- Adjustable temperature waterbath
- Pipettors
- Balance
- pH meter
- Cell counting system
- Water bath sonicator
- Magnetic stirrer
- Vortex mixer
- Antistatic bar ionizer (for reduction of static on tissue culture plates)

Equipment maintenance and calibration should be routinely performed and documented as per GLP guidelines and testing facility SOPs. The types of equipment listed in this section are available from scientific and laboratory supply companies (e.g., Thomas Scientific - http://www.thomassci.com/index.jsp; Fisher Scientific - https://www.fishersci.com/).

11.1.2.2 *Cell Culture Materials and Supplies*

The following supplies are needed for the *in vitro* NRU test methods. Specific product and private company names are provided either as an identification of actual materials/brands used in the validation study or as examples. Mention of these names does not imply endorsement of the product or company.

- Tissue culture plasticware (flasks [e.g., 25 cm², 75-80 cm²], 96-well plates, disposable pipettes)
- Laboratory glassware (e.g., flasks, bottles, graduated cylinders)
- Adhesive film plate sealers (e.g., Excel Scientific SealPlateTM)
- Sterile filtration systems (e.g., vacuum filtration units with 0.22 μ m and 0.45 μ m sterile filters)
- Culture medium and supplements (e.g., DMEM; prequalified NHK medium)
- NCS (bovine)
- Balanced salt solutions (e.g., HBSS, D-PBS)

Cell culture supplies are generally available through the major scientific and laboratory supply companies and through specialty companies (e.g., GIBCO, SIGMA-Aldrich, CAMBREX/Biowhittaker, Becton Dickinson). Compositions of culture media, supplements/additives, salt solutions, NRU assay chemicals, and the volumes of each needed for each test method, should be defined. All tissue culture flasks and dishes needed to assure proper cell propagation should be identified.

11.1.2.3 Cell Cultures

3T3 Mouse Fibroblasts: BALB/c 3T3 cells, clone 31, can be obtained from national/international cell culture repositories (e.g., American Type Culture Collection [ATCC], Manassas, VA, product # CCL-163).

NHKs: These non-transformed keratinocyte cells from cryopreserved primary or secondary cells can be obtained from national/international cell culture repositories (e.g., CAMBREX Bio Science, 8830 Biggs Ford Road, Walkersville, MD), or isolated from donated tissue using proper collection, preparation, and propagation techniques. It may be difficult, at times, to obtain adequate supplies of keratinocytes; the preparation of a pool of cells depends on the availability of tissue donors. It is recommended that testing laboratories procure of a commercially available stock pool of cells and store them indefinitely in a cryogenic freezer.

All cell stock and cultures used for testing must be certified as free of contamination by mycoplasma and bacteria.

11.1.3 Problems Specific to the NHK NRU Test Method

FAL had difficulty obtaining an adequate supply of NHK medium during the validation study. Communication between the UK distributor and the laboratory was uneven and the SMT attempted to resolve the supply issue on several occasions. The other laboratories periodically had difficulties in obtaining NHK medium and supplements that adequately supported keratinocyte growth. Although the purchased medium and supplements met the manufacturer's QA/QC standards, certain lots of the medium and supplements did not support the growth of NHK cells to the extent needed in the test protocol. To deal with these problems, an NHK medium prequalification protocol was incorporated into the study to

avoid unnecessarily repeating studies because of medium and supplements that did not adequately support cell growth. These experiences illustrate the need for multiple sources of keratinocyte cell culture medium. They also suggest that the NHK results could be more variable than the 3T3 results because of the batch-to-batch differences in NHK growth medium and supplements.

11.2 3T3 and NHK NRU Test Method Training Considerations

The ECVAM Good Cell Culture Practice Task Force Report 1 (Hartung et al. 2002) encouraged the establishment of practices and principles that will reduce uncertainty in the development and application of *in vitro* test methods. Training in good cell culture practices, in conjunction with good laboratory practices, are essential for all *in vitro* cytotoxicity testing and should be employed to ensure that data produced from the 3T3 and NHK NRU test methods are reproducible, credible, and acceptable.

In vitro cytotoxicity test methods require personnel trained specifically in sterile tissue/cell culture techniques and general laboratory procedures. Personnel should have mandatory training in good cell culture practices, in the specialized culture procedures needed for these assays, and in safety and handling practices appropriate to the types of substances that may be tested in the laboratory (Hartung et al. 2002).

The facility management should establish scientific guidelines and procedures, train and supervise professional and technical staff, and evaluate results and performance within their discipline area relative to the testing requirements. Performance of the tests requires a moderate degree of technical capability and a high degree of skill in monitoring and maintaining appropriate cell growth conditions, troubleshooting the potential and real problems in culture systems, and analyzing and interpreting *in vitro* cytotoxicity data. Each individual engaged in the conduct of a study, or responsible for its supervision, shall have education, training, and experience, or combination thereof, to enable that individual to perform the assigned duties. The NRU test methods do not require that personnel be trained to perform *in vivo* testing.

11.2.1 <u>Required Training and Expertise</u>

Personnel performing *in vitro* testing should have training in basic cell culture aspects such as: sterile technique, handling culture media, feeding cultures, cell counting, subculture (trypsinization), detection and elimination of contamination, cell growth and measurement of growth curves, viability assays, and storage and freezing/thawing of cells. Additionally, training is encouraged for special culture procedures such as primary cell and tissue cultures, toxicity testing, and viability assays. Laboratory personnel should be trained in the application of GLP requirements (see **Section 8.1.1**), and in the safe storage, handling, and disposal of toxic substances.

11.2.1.1 Specific Training and Expertise Needed

Personnel performing the *in vitro* cytotoxicity test methods should be well experienced in general cell culture techniques and should be able to:

- Work with cryogenic freezing apparatus
- Pipette solutions with large volume pipettors and multi-channel pipettors

- Establish cells in culture vessels under aseptic conditions and monitor growth; recognize normal and abnormal cell growth characteristics; and document observations of cell cultures throughout all aspects of the procedure
- Perform the *in vitro* assays by following the protocols to grow the cells, count, transfer, and feed the cells, treat the cells with test substances, perform application of adhesive plate sealers to culture plates for control of volatile substances, perform the NRU assay, perform optical density measurements, transfer data to electronic templates
- Operate equipment necessary for maintaining cell culture laboratories (e.g., incubators, biohazard hoods, spectrophotometric microtiter plate readers)

11.2.1.2 General Laboratory Expertise Needed

Personnel should also be able to understand and perform basic laboratory techniques and laboratory management:

- Prepare cell culture solutions (e.g., culture medium, NRU solutions), measure pH, know proper storage conditions, and maintain proper documentation
- Prepare test substances for application to cell cultures, follow solubility protocols to adequately prepare test chemicals in solution, recognize solubility issues (e.g., insolubility nature of chemical, precipitation), and implement procedures for dissolving the test chemicals
- Monitor and control laboratory environment (e.g., temperature, humidity, lighting, traffic), maintain equipment to support cell cultures (e.g., temperature, humidity, gas flow, calibrations)

11.2.2 <u>Training Requirements to Demonstrate Proficiency</u>

Laboratories establish their own criteria for proficiency but, over the course of training, laboratory personnel should be able to understand the protocol, perform the protocol with guidance from an experienced supervisor/trainer and, eventually, perform the protocol with minimal or no supervision. An experienced supervisor determines when a technician is adequately trained because there are no standardized criteria or tasks that can be used to accurately measure competence. After the technician demonstrates competence in executing all the aspects of the test protocols(s), it is appropriate to perform routine assessments of technical competence using a benchmark, coded control test substance (e.g., SLS). It is essential that the laboratory staff be certified as proficient in using the test methods to test unknowns.

The laboratories in the validation study were selected because of their experience in performing *in vitro* cytotoxicity assays but were required to develop additional skills through Phases I and II (e.g., data collection and transfer to Excel[®] and PRISM[®] templates). Inexperienced laboratory personnel were trained by having them perform "training" assays using SLS. In the early phases of the validation study, the laboratories continued training by testing coded reference substances of various toxicities, and performing solubility testing on substances of varying solubilities. These procedures helped improve proficiency among the laboratories for the final phase of the validation study.

11.2.2.1 Proficiency With GLP-Compliance

Results from these test methods will be submitted to regulatory agencies that will, for the most part, require GLPs. Laboratories should work toward attaining GLP compliance. GLP compliance in each laboratory is determined by its independent QA unit. ECBC and IIVS conducted this validation study in compliance with GLP (see Section 8.1.1). Their respective QA units (as per GLPs) reviewed the various aspects of the study and issued QA statements that addressed whether the test methods and the results described in the Final Report accurately followed the test protocol and reflected the raw data produced during the study, and provided assurance that all testing was done under according to GLP. FAL (which was non-GLP-adherent) followed the GLP standards referenced in Section 8.1.1 as guidelines for conducting this study. FAL had no QA unit to judge GLP compliance.

11.2.3 <u>Personnel Needed to Perform the In Vitro NRU Test Methods</u>

The facility management will be responsible for determining which qualified personel meet the criteria (e.g., scientific knowledge, specialized training) for the following positions needed for adequate performance of the *in vitro* NRU test methods and oversight of the testing.

- Study Director: the individual with the overall responsibility for the technical conduct of the testing (e.g., is familiar with the test procedures, provides SOPs and ensures GLP compliance, analyzes and interprets the data, determines test acceptance, oversees recordkeeping procedures, and produces the test reports.
- Quality Assurance Officer: monitors the testing to assure conformance with GLP requirements; must be independent of the Study Director.
- Laboratory Technician(s): individuals trained in sterile tissue/cell culture techniques and general laboratory procedures and who are capable of performing the test methods according to GLPs.

11.3 Cost Considerations

11.3.1 <u>3T3 and NHK NRU Test Methods</u>

11.3.1.1 Equipment Costs

Major instruments and equipment needed to implement the *in vitro* cytotoxicity test methods are described in **Section 11.1.1**. Ranges of costs for some of the equipment were obtained from on-line catalogues for two major scientific equipment and supplies companies (Thomas Scientific - http://www.thomassci.com/index.jsp; Fisher Scientific -

https://www.fishersci.com/). These prices are for equipment that will meet the minimum needs of the NRU test methods (see **Table 11-1**). These costs were researched in August 2006.

11.3.1.2 Costs for Cell Cultures and Supplies

Supplies such as cell culture chemicals, the reagents used to measure NRU, and cell culture plasticware are available from numerous suppliers, and are not cost prohibitive.

| Equipment | Range of Costs ¹ | |
|---|-----------------------------|--|
| Class II Biological Safety Cabinet | \$7,300 - \$12,200 | |
| CO ₂ Incubator | \$5,100 - \$16,400 | |
| Spectrophotometer Microplate Reader | \$5,000 - \$7,500 | |
| Freezer (capable of -70°C) | \$8,000 - \$15,300 | |
| Refrigerator | \$1,300 - \$9,800 | |
| Centrifuge (benchtop model) | \$2,100 - \$8,500 | |
| Microscope (inverse phase contrast) | \$3,000 - \$14,500 | |
| Coulter Counter ^{2, 3} | \$3,000 - \$9,000 | |
| Autoclave (benchtop model) ² | \$3,500 - \$15,400 | |
| Cryogenic (liquid nitrogen) Storage | \$1,000 - \$3,700 | |

Table 11-1Costs for Major Laboratory Equipment

¹From on-line scientific equipment catalogues (Thomas Scientific - http://www.thomassci.com/index.jsp; Fisher Scientific - https://www.fishersci.com/). [searched August 2006]

²May be useful, but not required for performing the tests.

³Other automatic cell counters may be used.

The 3T3 NRU test method is generally less expensive to perform than the NHK NRU test method. One vial of the immortalized 3T3 cells (~\$200 [ATCC]) can be propagated indefinitely by passaging cells and periodically cryopreserving batches of cells. The NHK NRU test method requires a fresh sample of primary cells for each test run (~\$380 per vial [CAMBREX]). Because primary NHK cells are passaged only once after initiating the culture, there are no cells available to cryopreserve a stock batch of cells. The DMEM medium used for the 3T3 cells is less expensive, more "generic", and more readily available than keratinocyte-specific NHK medium. (See **Table 11-2.**)

11.3.1.3 Commercial Testing

The following price quotes are provided as examples of test costs and were acquired from commercial laboratories through Internet contact or through personal communication. Use of information from these specific laboratories does not imply endorsement of them.

A representative of MB Research Laboratories (Spinnerstown, PA, http://www.mbresearch.com/) provided a quote (personal communication, 2005) for an *in vitro* 24-hr cytotoxicity test (but not a 48-hour test period) of \$1050 (USP standards¹) or \$1950 (ISO standards¹) for a set of three test chemicals. The lead laboratory for the NICEATM/ECVAM study, IIVS (Gaithersburg, MD, http://www.iivs.org/) provides

¹ USP=United States Pharmacopeia; ISO=International Standards Organization. These organizations provide international standard testing requirements for products that require high quality for public use.

commercial laboratory GLP-compliant testing using this study's protocols (48-hour test period) at a cost of \$1120 - \$1850 per chemical/sample for one cell type (personal communication 2005) (see **Table 11-2**).

| Table 11-2 | Costs for Cell Culture Materials and Commercial Laboratory In Vitro |
|-------------------|---|
| | Cytotoxicity Testing |

| Item | Cost (approximate) | Number of Tests Possible | Other |
|---|---|--|---|
| 3T3 Cells | ~\$200/vial ¹ | indefinite | One vial can produce an indefinite supply of cells by propagating the cells in culture and periodically freezing a pool of cells. |
| NHK Cells | ~\$380/vial ² | ~5 (96-well plates) | Since cells are passaged only once beyond cryopreservation, new vials should be thawed as needed to maintain continuous testing. |
| Dulbeccos' Minimum Essential Medium (D- MEM) with supplements | ~\$20/500mL ³ | ~15 (96-well plates) | Establish cells in culture (~20 mL/vial of cells; 60 mL/3 vials), seed cells in 96-well plates (12 mL/plate; 180 mL/15 plates); prepare stock solution and eight concentration dilutions (~20 mL/chemical; 300 mL/15 plates). |
| NHK Medium with supplements | ~\$80/500 mL ² | ~15 (96-well plates) | Same as DMEM (above) |
| Commercial Laboratory Testing (MB Research Laboratories [GLP- compliant]) | \$1050/\$1950 (USP/ISO) per 3 test materials ⁴ | 1 test/material | <i>in vitro</i> NRU cytotoxicity test (24-hour test period) |
| Commercial Laboratory Testing (Institute for <i>In Vitro</i> Sciences [GLP- compliant]) | \$1120 (GLP) per test material (minimum of 5 materials tested simultaneously) ⁴ | 1 range finder, 2 definitive tests per test material | <i>in vitro</i> NRU cytotoxicity test (48-hour test period) |
| Commercial Laboratory Testing (Institute for <i>In Vitro</i> Sciences) | \$1850 (GLP) per single test material (tested individually) ⁴ | 1 range finder, 2 definitive tests per test material | <i>in vitro</i> NRU cytotoxicity test (48-hour test period) |

Abbreviations: 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake; USP/ISO= United States Pharmacopeia/International Standards Organization GLP=Good Laboratory Practices

¹Catalogue price from American Type Culture Collection (ATCC) (http://www.atcc.org/)

²Catalogue price from CAMBREX (http://www.cambrex.com/Welcome.asp)

³Catalogue price from INVITROGEN (http://www.invitrogen.com/content.cfm?pageid=1)

⁴Personal communication (Raabe 2005)

11.3.2 Rodent Acute Oral Toxicity Testing

As stated in **Section 11.3.1.3**, presentation of price quotes from commercial laboratories provides examples of test costs and does not imply an endorsement of that laboratory. **Table 11-3** provides some commercial prices for acute oral systemic toxicity testing. MB Research Laboratories performs the UDP test at a cost of \$750 for three rats and charges \$250 for each additional rat needed. In the best-case scenario, the UDP test needs only three rats (\$750). In the worst-case scenario, this test would need an additional 12 rats (15 maximum for the test); the total cost of the test would be \$3,750. In this costing strategy, \$250 is saved for each rat not used by an accurate prediction of the starting dose by the 3T3 or NHK NRU test method. Because the *in vitro* cytotoxicity test costs from \$350 to \$1850 per chemical, there is no net savings in animal costs if fewer than two to six animals are saved.

| Test | GLP-Compliant | Non GLP- Compliant | Company |
|--|---|-----------------------|---|
| Acute Oral Toxicity UDP: Limit Test - 2000 mg/kg | \$1200 | \$1000 | Product Safety Laboratories |
| Acute Oral Toxicity UDP: Limit Test - 5000 mg/kg | \$800 | \$650 | Product Safety Laboratories |
| Acute Oral Toxicity UDP: LD ₅₀ | \$2700 | \$2200 | Product Safety Laboratories ¹ |
| Acute Oral Rat Toxicity: single dose ² | \$950 | NA | Bio Research Laboratories |
| Acute Oral Rat Toxicity: two doses ² | \$1500 | NA | Bio Research Laboratories |
| Acute Oral Rat Toxicity: LD ₅₀ | \$3000 | NA | Bio Research Laboratories |
| Acute Oral Toxicity – UDP | \$730 for the first 3 animals; \$250 each additional animal | NA | MB Research Laboratories ¹ |

Table 11-3 Commercial Prices for Conducting In Vivo Acute Rat Toxicity Testing

Abbreviations: UDP=Up-and-Down Procedure; GLP=Good Laboratory Practices; NA=Not available. ¹Personal communication (Wnorowski 2005).

²Washington State Biological Testing Methods #80-12 For the Designation of Dangerous Waste; Part B: Acute Oral Rat Toxicity Test [http://www.ecy.wa.gov/pubs/80012.pdf]. This test method is an adaptation of the EPA Health Affects Test Guidelines OPPTS 870.110 Acute Oral Toxicity and American Society for Testing and Materials (ASTM) methods E 1163-90 (Standard test method for estimating acute oral toxicity in rats) and E 1372-90 (Standard test method for conducting a 90day oral toxicity study in rats).

The President of Product Safety Laboratories, Gary Wnorowski, (Dayton, NJ, http://www.productsafetylabs.com/), provided a cost quote of \$2700 for determination of a rat LD₅₀ value using the UDP test; the cost is independent of the number of rats that are needed. Each test dose is administered ~24-48 hours after the previous dose and each animal test generally does not exceed four days. The time involved in providing the LD₅₀ value is approximately three months (initiation of the test to provision of the final report). Having the estimated LD₅₀ value would not affect the cost of the *in vivo* test but could reduce the number of animals needed.

Bio Research Laboratories performs the rat acute oral toxicity test using a test method that determines lethality and signs of acute toxicity from a waste sample administered in a single dose, by gavage, to a limited number of rats. The bioassay determines if the test sample

produces an LD_{50} either greater than or less than a regulatory threshold corresponding to a hazardous waste designation (i.e., 5000, 500, 50 mg/kg). A minimum of 10 rats is used at the tested dose for the regulatory threshold value that is relevant to the test sponsor. In this testing scenario, knowledge of the estimated LD_{50} would not reduce animal use or test costs if a single predetermined dose is tested.

11.4 Time Considerations for Performing the 3T3 and NHK NRU Tests

11.4.1 <u>The 3T3 NRU Test Method</u>

Approximately one week is needed to thaw cryopreserved 3T3 cells, propagate them, and passage them at least two times before subculturing them into the 96-well test plates. After subculture into 96-well plates, the cells are incubated another 24 hours to reach the proper confluence, and then exposed to test chemical for 48 hours. The initial 3T3 NRU test (range finder or definitive test) takes approximately 10 days. However, after the cells are established in culture, they can be passaged for approximately two months before having to go back to the cryopreserved cells to start a new culture. A 3T3 NRU test can be completed in less than four consecutive days when started from an established stock culture. Multiple substances can be tested at the same time, and different tests can overlap each other; thus, many substances can be tested in a relatively short time.

11.4.2 <u>The NHK NRU Test Method</u>

Approximately one week is needed to thaw cryopreserved NHK cells, propagate them, and passage them into the 96-well test plates. After subculture into 96-well plates, the cells are incubated another 48-72 hours to reach the proper confluence and then exposed to test chemical for 48 hours. The entire NHK NRU test (range finder or definitive test) requires approximately 11-12 days. Cells can be seeded at different densities from one starter vial in the culture flasks so that passaging the cultures can take place on different days. Once the cells are established in culture, they are passaged once to the 96-well test plates and an NHK NRU test can usually be completed in five to six consecutive days. Multiple substances can be tested at the same time, and different tests can overlap each other; thus, many substances can be tested in a relatively short time.

11.4.3 Prequalification of NHK Medium

The protocol for the prequalification of NHK medium requires nearly identical steps, and similar time-line (i.e., 11-12 days), as required for the NHK rangefinder and definitive tests. **Table 11-2** provides an estimate of how many tests could be performed using one 500 mL bottle of medium with supplements (~15 tests in 96-well plates).

11.4.4 In Vivo Testing

According to guidelines for acute oral toxicity testing, single animals or groups of animals are dosed in sequence, usually at 2-4 day intervals, and observations are generally made for up to 14 days (for animals that are not moribund) for the main test and limit dose test (EPA 2002a; OECD 2001a; OECD 2001b, OECD 2001c). The addition of 3T3 or NHK NRU testing to estimate a starting dose prior to the implementation of the UDP main test or limit dose test would take 10-12 days, but could save up to 14 days of observation for every animal not used.

11.4.5 <u>The Limit Test</u>

The *in vitro* NRU test methods can provide a savings of time when used to determine if an *in vivo* acute oral toxicity limit test can be employed as the initial test for a substance with unknown *in vivo* toxicity. If the IC₅₀ value from an *in vitro* NRU test could accurately predict an LD₅₀ that is greater than, or equal to, the limit dose (i.e., 2000 mg/kg or 5000 mg/kg), the *in vivo* test could start at the limit test dose. This approach has the potential to eliminate the need to do the main test and could result in a net savings of six days for the UDP test method and about one day for the ATC test method. **Table 11-4** illustrates the following:

- Time needed to perform the 3T3 and NHK NRU test
- Time needed to reach the limit test starting dose when initiating the *in vivo* main test using the default starting doses (UDP and ATC)

The times presented in **Table 11-4** use the following assumptions:

- 3T3 cells reach \leq 50% confluence in approximately 24 hours
- NHK cells reach >20% confluence in approximately 48 hours
- Animals show no evident toxicity 48 hours post-dosing, and additional animals are dosed at the next higher default dose
- Limit test dose = 5000 mg/kg for the UDP and 2000 mg/kg for the ATC method

| Time | 3T3 NRU Test Method | NHK NRU Test Method | UDP (5000 mg/kg upper limit) | ATC (2000 mg/kg upper limit) |
|-------|--|--|---|---|
| Day 1 | Seed cells in 96-well plate Incubate for 24 ±2 hr | Seed cells in 96-well plate Incubate for approximately 48 to 72 hr | Dose 1 animal at default dose (175 mg/kg) Observe for 48 hr | Dose 3 animals at default dose (300 mg/kg) Observe for 48 hr |
| Day 2 | Apply test substance Incubate for 48 ±0.5 hr | Incubate | Observe | Observe |
| Day 3 | Incubate | Apply test substance Incubate for 48 ±0.5 hr | No death Dose 1 animal at next default dose (550 mg/kg) Observe 48 hr | 0 – 1 animal dies Dose 3 animals at default dose (300 mg/kg) Observe 48 hr |
| Day 4 | NRU: 3 ± 0.1 hr Elute NR: 0.33 to 0.75 hr OD ₅₄₀ measurement Calculate IC ₅₀ Estimate LD ₅₀ and Starting Dose* | Incubate | Observe | Observe |
| Day 5 | | NRU: 3 ± 0.1 hr Elute NR: 0.33 to 0.75 hr OD ₅₄₀ measurement Calculate IC ₅₀ Estimate LD ₅₀ and Starting Dose* | No death Dose 1 animal at next default dose (1750 mg/kg) Observe 48 hr | 0 – 1 animal dies Dose 3 animals at next default dose (2000 mg/kg) Starting Point for the Limit Test |
| Day 6 | | | Observe | |
| Day 7 | ne: 3T3=BALB/c 3T3 fibroblaste | ; NHK=Normal human epidermal | No death Dose 1 animal at next default dose (5000 mg/kg) Starting Point for the Limit Test keratinocytes: NRU=Neutral | red untake: UDP=Un_and |

Table 11-4 Comparison of Time Needed for In Vitro and In Vivo Testing

Abbreviations: 3T3=BALB/c 3T3 fibroblasts; NHK=Normal human epidermal keratinocytes; NRU=Neutral red uptake; UDP=Up-and-Down Procedure; ATC=Acute Toxic Class method; hr=Hour; NR=Neutral red; OD₅₄₀=Optical density at 540 nm.

11.5 Summary

• All equipment and supplies should be readily commercially available. During the validation study, direct communication with the NHK medium supplier insured that specific lots of medium were available to the laboratories. The test methods are expected to be transferable to laboratories experienced with mammalian cell culture methods.

- Much of the training and expertise needed to perform the 3T3 and NHK NRU test methods are common to mammalian cell culture procedures. Additional technical training would not be extensive because these test methods are similar to other *in vitro* mammalian cell culture assays, and no extraordinary techniques are necessary. GLP training should be provided to technicians to ensure proper adherence to protocols and documentation procedures.
- Prices for commercial testing for one chemical are \$1,120 to \$1,850 (**Table 11-2**) for *in vitro* cytotoxicity testing in the 3T3 and NHK test methods, respectively, to determine the IC₅₀ (Raabe 2005, personal communication). In contrast, the *in vivo* rat acute oral testing for LD₅₀ determination could cost from \$750 \$3,750 (**Table 11-3**), depending on the test method used and the toxicity of the test substance. Comparison of costs of *in vitro* testing to *in vivo* testing is difficult because the *in vitro* NRU test methods are not replacements for the animal testing, and animal testing would be performed regardless of the responses of the 3T3 or NHK cells. The use of these *in vitro* NRU test methods may not reduce the overall cost of the *in vivo* rat acute oral toxicity test, but has the potential to reduce the number of animals needed for a study.

[This Page Intentionally Left Blank]

12.0 REFERENCES

Adegunloye BI, Sofola OA. 1997. Differential responses of rat aorta and mesenteric artery to norepinephrine and serotonin *in vitro*. Pharmacology 55:25-31.

Ames A III. 2000. CNS energy metabolism as related to function. Brain Res Rev 34:42-68.

Anon. 1993. Annexes I, II, III, and IV to Commission Directive 93/21/EEC of 27 April 1993 adapting to technical progress for the 18th time Council Directive 67/548/EEC on the approximation of laws, regulations and administrative provisions relating to the classification, packaging and labeling of dangerous substances. Official Journal of the European Communities L110A, 1-86.

ASTM. 1999. American Society of Testing and Materials (ASTM) Standard E691-99, Standard Practice for Conducting an Interlaboratory Study to Determine the Precision of a Test Method. American National Standards Institute. Washington, D.C. Available: <u>http://www.ansi.org/</u> [accessed 01 November 2006].

ATSDR. 1999a. Toxicological Profile for Cadmium. Update PB/99/166621. U.S. Dept. of Health and Human Services. Atlanta, GA:Agency for Toxic Substances and Disease Registry. Available: <u>http://www.atsdr.cdc.gov/toxpro2.html</u> [accessed 01 November 2006].

ATSDR. 1999b. Toxicological Profile for Diethyl phthalate. PB/95/264214/AS. U.S. Dept. of Health and Human Services. Atlanta, GA:Agency for Toxic Substances and Disease Registry. Available: <u>http://www.atsdr.cdc.gov/toxpro2.html</u> [accessed 01 November 2006].

ATSDR. 2000a. Toxicological Profile for Endosulfan. Update. PB/2000/108023. U.S. Dept. of Health and Human Services. Atlanta, GA:Agency for Toxic Substances and Disease Registry. Available: <u>http://www.atsdr.cdc.gov/toxpro2.html</u> [accessed 01 November 2006].

ATSDR. 2000b. Toxicological Profile for Chromium. Update. PB/2000/108022. U.S. Dept. of Health and Human Services. Atlanta, GA:Agency for Toxic Substances and Disease Registry.Available: <u>http://www.atsdr.cdc.gov/toxpro2.html</u> [accessed 01 November 2006].

ATSDR. 2001. Toxicological Profile for Di-n-butyl phthalate. Update. PB/2001/109104/AS. U.S. Dept. of Health and Human Services. Atlanta, GA:Agency for Toxic Substances and Disease Registry. Available: <u>http://www.atsdr.cdc.gov/toxpro2.html</u> [accessed 01 November 2006].

ATSDR. 2004a. Toxicological Profile for Pyrethrins and Pyrethroids. Update. PB2004-100004. U.S. Dept. of Health and Human Services. Atlanta, GA:Agency for Toxic Substances and Disease Registry. Available: <u>http://www.atsdr.cdc.gov/toxpro2.html</u> [accessed 01 November 2006].

ATSDR. 2004b. Toxicological Profile for Selenium. Update. PB2004-100005. U.S. Dept. of Health and Human Services. Atlanta, GA:Agency for Toxic Substances and Disease Registry. Available: <u>http://www.atsdr.cdc.gov/toxpro2.html</u> [accessed 01 November 2006].

Babich H, Martin-Alguacil N, Raul C, Rosenberg DW, Borenfreund E. 1991. Response of human cell cultures to cytotoxicants requiring metabolic activation. In: Alternative Methods in Toxicology (Goldberg AM, ed.), Vol. 8. New York:Mary Ann Liebert, Inc., 263-276.

Balls M, Botham PA, Bruner LH, Spielmann H. 1995. The EC/HO international validation study on alternatives to the Draize eye irritation test for classification and labelling of chemicals. Toxicol *In Vitro* 9:871-929.

Bernson V, Bondesson I, Ekwall B, Stenberg K, Walum E. 1987. A Multicentre evaluation study of *in vitro* cytotoxicity. Altern Lab Anim 14:144-146.

Bliss CI. 1938. The determination of the dosage-mortality curve from small numbers. Q J Pharm Pharmacol 11:192-214.

Bondesson I, Ekwall B, Hellberg S, Romert L, Stenberg K, Walum E. 1989. MEIC - A new international multicenter project to evaluate the relevance to human toxicity of *in vitro* cytotoxicity tests. Cell Biol Toxicol 5:331-347.

Borenfreund E, Puerner J. 1984. A simple quantitative procedure using monolayer cultures for cytotoxicity assays (HTD/ NR-90). J Tissue Culture Meth 9:7-9.

Borenfreund E, Puerner JA. 1985. Toxicity determination *in vitro* by morphological alterations and neutral red absorption. Toxicol Lett 24:119-124.

Botham PA. 2004. The validation of *in vitro* methods for skin irritation. Toxicol Lett 149:387-390.

Brantom PG, Bruner LH, Chamberlain M, De Silva O, Dupuis J, Earl LK, et al. 1997. A summary report of the COLIPA international validation study on alternatives to the Draize rabbit eye irritation test. Toxicol *In Vitro* 11:141-179.

Calabrese EJ. 2005. Cancer biology and hormesis: human tumor cell lines commonly display hormetic (biphasic) dose responses. Crit Rev Toxicol 35:463-582.

Canadian Centre for Occupational Health and Safety. 2005. IPCS INTOX Database. Available: <u>http://www.intox.org/databank/index.htm</u> [accessed 01 November 2006].

Casarett LJ, Klaassen CD, Doull J, eds. 2001. Casarett and Doull's Toxicology, The Basic Science of Poisons. 6th Edition. New York:McGraw-Hill.

Charles River Laboratories Catalog. 2002. Available: <u>http://www.criver.com</u> [accessed 01 November 2006].

Clemedson C, McFarlane-Abdulla E, Andersson M, Barile FA, Calleja MC, Chesné C, et al. 1996a. MEIC evaluation of acute systemic toxicity. Part I. Methodology of 68 *in vitro* toxicity assays used to test the first 30 reference chemicals. Altern Lab Anim 24 (suppl 1):51-272.

Clemedson C, McFarlane-Abdulla E, Andersson M, Barile FA, Calleja MC, Chesné C, et al. 1996b. MEIC evaluation of acute systemic toxicity. Part II. *In vitro* results from 68 toxicity assays used to test the first 30 reference chemicals and a comparative cytotoxicity analysis. Altern Lab Anim 24 (suppl 1):273-311.

Clemedson C, Barile FA, Ekwall Ba, Gómez-Lechón MJ, Hall T, Imai K, et al. 1998a. MEIC evaluation of acute systemic toxicity. Part III. *In vitro* results from 16 additional methods used to test the first 30 reference chemicals and a comparative cytotoxicity analysis. Altern Lab Anim 26 (suppl 1):93-129.

Clemedson C, Andersson M, Aoki Y, Barile FA, Bassi AM, Calleja MC, et al. 1998b. MEIC evaluation of acute systemic toxicity. Part IV. *In vitro* results from 67 toxicity assays used to test reference chemicals 31-50 and a comparative cytotoxicity analysis. Altern Lab Anim 26 (suppl 1):131-183.

Clemedson C, Nordin-Andersson M, Bjerregaard H.F, Clausen J, Forsby A, Gustafsson H, Hansson U, Isomaa B, Jorgensen C, et al. 2002. Development of an *in vitro* test battery for the estimation of acute human systemic toxicity: an outline of the EDIT project. Altern Lab Anim 30:313-321.

Clemedson C. 2005. A-Cute-Tox project, an integrated project under the EU 6FP with the aim to optimize and pre-validate an *in vitro* test strategy for predicting human acute toxicity. European Society of Toxicology *In Vitro* Newsletter 18:6.

Clothier R, Willshaw A, Cox H, Garle M, Bowler H, Combes R. 1999. The use of human keratinocytes in the EU/COLIPA international *in vitro* phototoxicity test validation study and the ECVAM/COLIPA study on UV filter chemicals. Altern Lab Anim 27:247-259.

Coeck S, Balls M, Bowe G, Davis J, Gstraunthaler G, Hartung T, et al. 2005. Guidance on Good Cell Culture Proactice. A Report of the Second ECVAM Task Force on Good Cell Culture Practice. Altern Lab Anim 33:261-287.

Coldwell BB, Boyd EM. 1966. The acute rectal toxicity of acetylsalicylic acid. Can J Physiol Pharmacol 44: 909-918.

Conolly RB, Lutz WK. 2004. Nonmonotonic dose-response relationships: mechanistic basis, kinetic modeling, and implications for risk assessment. Toxicol Sci 77:151-157.

Cooper-Hannan R, Harbell JW, Coecke S, Balls M, Bowe G, Cervinka, et al. 1999. The Principles of Good Laboratory Practice: application to *in vitro* toxicology studies. Altern Lab Anim 27:539-577.

Cosmetic Ingredient Review Panel. 1983. Final report on the safety assessment of sodium borate and boric acid. J Am Coll Toxicol 2:87-125.

CPSC. 2003. Commercial Practices. Hazardous Substances and Articles; Administration and Enforcement Regulations. 16CFR1500.42.

Creppy EE, Chiarappa P, Baudrimont I, Borracci P, Moukha S, Carratu MR. 2004. Synergistic effects of fumonisin B1 and ochratoxin A: are *in vitro* cytotoxicity data predictive of in vivo acute toxicity? Toxicology 201:115-23.

Curren R, Bruner L, Goldberg A, Walum E. 1998. 13th meeting of the Scientific Group on Methodologies for the Safety Evaluation of Chemicals (SGOMSEC): validation and acute toxicity testing. Environ Health Perspect 106 (suppl 2): 419-425.

Curren RD, Moyer GO, Wilt N, Clear ML, Sizemore AM, Mun G. 2003. Assessment of protocol variables in cytotoxicity assays utilizing BALB/c 3T3 cells and normal human keratinocytes [Abstract]. Toxicologist 72:157. Available: http://www.iivs.org/pages/publication_view.php?doc_id=43 [accessed 01 November 2006].

Dal Negro G, Vandin L, Bonato M, Sciuscio D. 2006. Toward refinement of the colonyforming unit-granulocyte/macrophage clonogenic assay: inclusion of a metabolic system. Toxicol *In Vitro* 20:743-9.

DOT. 2003. Shippers--General Requirements for Shipments and Packagings. Class 6, Division 6.1 – Definitions. 49CFR173.132. Available: http://www.gpoaccess.gov/cfr/index.html [accessed 01 November 2006].

DOT. 2003. Shippers--General Requirements for Shipments and Packagings. Assignment of Packing Group and Hazard Zones for Division 6.1 Materials. 49CFR173.133. Available: <u>http://www.gpoaccess.gov/cfr/index.html</u> [accessed 01 November 2006].

DOT. 1999. Assignment of packing group and hazard zones for Division 6.1 materials. 49CFR. SubChapter C. Available: <u>http://www.gpoaccess.gov/cfr/index.html</u> [accessed 01 November 2006].

Deichmann WB. 1969. Toxicology of Drugs and Chemicals. New York: Academic Press, Inc., 67.

Dixon WJ, Massey FJ. 1981. Introduction to Statistical Analysis, 4th ed. Milwaukee: Quality Press.

Ekwall B. 1983. Screening of toxic compounds in mammalian cell cultures. Ann New York Acad Sci 407:64-77.

Ekwall B, Clemedson C, Craaford B, Ekwall B, Hallander S, Walum E, Bondesson I. 1998a. MEIC evaluation of acute systemic toxicity. Part V. Rodent and human toxicity data for the 50 reference chemicals. Altern Lab Anim 26 (suppl 2):571-616.

Ekwall B, Clemedson C, Craaford B, Ekwall B, Hallander S, Walum E, Bondesson I. 1998b. MEIC evaluation of acute systemic toxicity. Part VI. The prediction of human toxicity by rodent LD50 values and results from 61 *in vitro* methods. Altern Lab Anim 26 (suppl 2):617-658.

Ekwall B, Clemedson C, Ekwall B, Ring P, Romert L. 1999. EDIT: A new international multicentre programme to develop and evaluate batteries on *in vitro* tests for acute and chronic systemic toxicity. Altern Lab Anim 27:339-349.

Ekwall B, Ekwall B, Sjostrom M. 2000. MEIC evaluation of acute systemic toxicity: Part VIII. Multivariate partial least squares evaluation, including the selection of a battery cell line tests with a good prediction of human acute lethal peak blood concentrations for 50 chemicals. Altern Lab Anim 28 (suppl 1):201-234.

EPA. 1992. Reregistration Eligibility Document Citric Acid. List D, Case 4204. Office of Pesticide Programs. Washington, DC:U.S. Environmental Protection Agency. Available: <u>http://www.epa.gov/oppsrrd1/REDs/factsheets/4024fact.pdf</u> [accessed 01 November 2006].

EPA. 1995. Reregistration Eligibility Decision (RED) Diquat Dibromide. EPA 738-R-95-016. Office of Prevention, Pesticides and Toxic Substances. Washington, DC:U.S. Environmental Protection Agency. Available: <u>http://www.epa.gov/oppsrrd1/REDs/0288.pdf</u> [accessed 01 November 2006].

EPA. 1996. Trichloroacetic acid (CASRN 76-03-9) file in the Integrated Risk Information System. Office of Research and Development. Washington, DC:U.S. Environmental Protection Agency. Available: <u>http://www.epa.gov/iris</u> [accessed 01 November 2006].

EPA. 1998. Product Properties Test Guidelines OPPTS 830.7840 Water Solubility: Column Elution Method; Shake Flask Method. EPA 712–C–98–041. Washington, DC:U.S. Environmental Protection Agency.

EPA. 2000a. High Production Challenge Program. Office of Pollution Prevention and Toxics (OPPT). Washington, DC:U.S. Environmental Protection Agency. Available: <u>http://www.epa.gov/chemrtk/</u> [accessed 01 November 2006].

EPA. 2000b. Toxicological Review of Chloral Hydrate. EPA/635/R-00/006. Washington, DC:U.S. Environmental Protection Agency. Available: <u>www.epa.gov/iris</u> [accessed 01 November 2006].

EPA. 2002a. Health Effects Test Guidelines OPPTS 870.1100 Acute Oral Toxicity. EPA 712–C–02–190. Washington, DC: U.S. Environmental Protection Agency. Available: http://www.epa.gov/opptsfrs/home/testmeth.htm [accessed 01 November 2006].

EPA. 2002b. Statements of Policies and Interpretations. Toxicological and Ecological Studies. 40CFR159.165. Available: <u>http://www.gpoaccess.gov/cfr/index.html</u> [accessed 01 November 2006].

EPA. 2002c. Health Effects Test Guidelines OPPTS 870.1000 Acute Toxicity Testing -Background. EPA 712–C–02–189. Washington, DC: U.S. Environmental Protection Agency. Available: <u>http://www.epa.gov/opptsfrs/home/testmeth.htm/</u> [accessed 01 November 2006].

EPA. 2002d. Emergency Planning and Notification. 40CFR355. Available: <u>http://www.access.gpo.gov/nara/cfr/waisidx_00/40cfr355_00.html</u> [accessed 01 November 2006].

EPA. 2003a. Good Laboratory Practice Standards. Toxic Substances Control Act. 40CFR792. Available: <u>http://www.access.gpo.gov/nara/cfr/waisidx_03/40cfr792_03.html</u> [accessed 01 November 2006].

EPA. 2003b. Good Laboratory Practice Standards. Federal Insecticide, Fungicide, and Rodenticide Act. 40CFR160. Available:

http://www.access.gpo.gov/nara/cfr/waisidx_03/40cfr160_03.html [accessed 01 November 2006].

EPA. 2004. U.S. EPA HPV Challenge Program Submission. Propanoic acid, 2-hydroxy-, compd. with 3-[2-(dimethylamino)ethyl] 1-(2-ethylhexyl) (4-methyl-1,3-phenylene)bis[carbamate] (1:1) [CASRN 68227-46-3]. Submitted by PPG Industries, Inc. Revised December 17, 2004. Available: <u>http://www.epa.gov/chemrtk/pubs/hpvrstp.htm</u> [accessed 01 November 2006].

European Centre for the Validation of Alternative Methods. (ECVAM). 1997. Statement on the scientific validity of the 3T3 NRU PT test (an *in vitro* test for phototoxic potential). Available: <u>http://ecvam.jrc.it/index.htm</u> [accessed 01 November 2006].

EU. 2003. Report from the Commission to the Council and the European Parliament. Third Report from the commission to the Council and the European Parliament of the statistics on the number of animals used for experimental and other scientific purposes in the member states of the European Union. Brussels, 22.01.2003, COM (2003) 19 final.

Fautrel A, Chesné C, Guillouzo A, De Sousa G, Placidi M, Rahmani R, et al. 1993. A multicentre study of acute *in vitro* cytotoxicity in rat hepatocytes: tentative correlation between *in vitro* toxicity and *in vivo* data. Altern Lab Anim 21:281-284.

FDA. 1993. Toxicological Principles for the Safety Assessment of Direct Food Additives and Color Additives Used in Food. Center for Food Safety and Applied Nutrition. Washington, DC: U.S. Food and Drug Administration.

FDA. 2003. Good Laboratory Practice for Nonclinical Laboratory Studies. 21CFR Part 58. Available: <u>http://www.access.gpo.gov/nara/cfr/waisidx_03/21cfr58_03.html</u> [accessed 01 November 2006].

Fentem J, Fry J, Garle M, Gülden M, Seibert H, Voss J-U, et al. 1993. An International Evaluation of Selected *In Vitro* Toxicity Test Systems for Predicting Acute Systemic Toxicity. A report prepared for DGXI, CEC; Contract Numbers B92/B4-3063/14086 & B92/B4-3040/14087. Nottingham, UK:Fund for Replacement of Animals in Medical Experiments.

Fentem JH, Archer GEB, Balls M, Botham PA, Curren RD, Earl LK, et al. 1998. The ECVAM international validation study on *in vitro* tests for skin corrosivity. 2. Results and evaluation by the Management Team. Toxicol *In Vitro* 12:483-524.

Fentem JH, Briggs D, Chesne C, Elliott GR, Harbell JW, Heylings JR, et al. 2001. A prevalidation study on *in vitro* tests for acute skin irritation: results and evaluation by the Management Team. Toxicol *In Vitro* 15:57-93.

Freshney RI. 2000. Culture of Animal Cells: A Manual of Basic Technique, 4th edition. New York: Wiley-Liss.

Garle M., Fentem JH, Fry JR. 1994. *In vitro* cytotoxicity tests for the prediction of acute toxicity *in vivo*. Toxicol *In Vitro* 8:1303-1312.

Gennari A, van den Berghe C, Casati S, Castell J, Clemedson C, Coecke S, et al. 2004. Strategies to replace *in vivo* acute systemic toxicity testing. The report and recommendations of ECVAM Workshop 50. Altern Lab Anim 32:437-459.

Gettings SD, Bagley DM, Demetrulias JL, Dipasquale LC, Hintze KL, Rozen MG, et al. 1991. The CTFA evaluation alternatives program: An evaluation of *in vitro* alternatives to the Draize primary eye irritation test. (Phase I) Hydro-alcoholic formulations; (Part 2) Data analysis and biological significance. *In Vitro* Toxicol 4:247-288.

Gettings SD, Bagley DM, Chudkowski M, Demetrulias JL, Dipasquale LC, Galli CL et al. 1992. Development of potential alternatives to the Draize eye test - The CTFA evaluation of alternatives program - Phase II - Review of materials and methods. Altern Lab Anim 20:164-171.

Gettings SD, Dipasquale LC, Bagley DM, Casterton PL, Chudkowski M, Curren RD, et al. 1994a. The CTFA evaluation of alternatives program: An evaluation of *in vitro* alternatives to the Draize primary eye irritation test. (Phase II) Oil/water emulsions. Food Chem Toxicol 32:943-976.

Gettings SD, Hintze KL, Bagley DM, Casterton PL, Chudkowski M, Curren RD, et al. 1994b. The CTFA evaluation of alternatives program: Phase III (surfactant-based formulations). *In Vitro* Toxicol 7:166.

Gettings SD, Lordo RA, Hintze KL, Bagley DM, Casterton PL, Chudkowski M, et al. 1996. The CFTA evaluation of alternatives program: An evaluation of *in vitro* alternatives to the Draize primary eye irritation test. (Phase III) Surfactant-based Formulations. Food Chem Toxicol 34:79-117.

Gilman AG, Goodman LS, Rall TW, Murad F (eds.). 1985. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 7th Edition. New York:Macmillan Publishing Co.

Glaxo Wellcome. 2000. Myleran (busulfan) Product Information. Research Triangle Park, NC:Glaxo Wellcome, Inc.

GraphPad Software. 1994-2000. Prism[®] version 3.0a for Macintosh. GraphPad Software, San Diego, California. Available: <u>www.graphpad.com</u> [accessed 01 November 2006].

Grisham JW, Smith GJ. 1984. Predictive and Mechanistic Evaluation of Toxic Responses in Mammalian Cell Culture Systems. Pharmacol Rev 36(suppl):151S-171S.

Gülden M, Dierickx P, Seibert H. 2006. Validation of a prediction model for estimating serum concentrations of chemicals which are equivalent to toxic concentrations *in vitro*. Toxicol *In Vitro* 20:1114-1124.

Guzzie PJ. 1994. Lethality testing. In: *In Vitro* Toxicology (Gad SC, ed). New York:Raven Press, 57-86.

Hackenberg U, Bartling H. 1959. Messen und Rechnen im pharmakologischen Laboratorium mit einem speziellen Zahlensystem (WL24-System). Arch Exp Pathol Pharmakol 235:437-463.

Halle W, Liebsch M, Traue D, Spielmann H. 1997. Reduktion der Tierzahlen bei der Einstufung von Stoffen in die EU-Toxizitätsklassen fur akute orale Toxizität mit Hilfe von Daten aus dem Register der Zytotoxizität (RC). ALTEX 14:8-15.

Halle W. 1998. Toxizitätsprüfungen in Zellkulturen für eine Vorhersage der akuten Toxizität (LD₅₀) zur Einsparung von Tierversuchen. Life Sciences/ Lebenswissenschaften, Volume 1, Jülich: Forschungszentrum Jülich.

Halle W. 2003. The Registry of Cytotoxicity: Toxicity testing in cell cultures to predict acute toxicity (LD50) and to reduce testing in animals. Altern Lab Anim 31:89-198. (*English translation of Halle 1998*)

Halle W, Spielmann H. 1992. Two procedures for the prediction of acute toxicity (LD50) from cytotoxicity data. Altern Lab Anim 20:40-49.

Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. 1996. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th Edition. New York:McGraw-Hill.

Harlan Company. 2002. Available: <u>http://www.harlan.com/us/index.htm</u> [accessed 01 November 2006].

Harbell JW, Koontz SW, Lewis RW, Lovell D, Acosta D. 1997. IRAG working group 4. Cell cytotoxicity assays. Interagency Regulatory Alternatives Group. Food Chem Toxicol 35:79-126.

Hartung T, Balls M, Bardouille C, Blanck O, Coecke S, Gstrauthaler G, et al. 2002. Good cell culture practice: ECVAM Good Cell Culture Practice Task Force report 1. Altern Lab Anim 30:407-414. Available: <u>http://ecvam.jrc.it/publication/index5007.html</u> [accessed 01 November 2006].

Heimann R, Rice RH. 1983. Rat esophageal and epidermal-keratinocytes - intrinsic differences in culture and derivation of continuous lines. J Cell Physiol 117:362-367.

Hintze KL, Janus J, Marenus KD, Muscatiello MJ, Pape WJW, Renskers KJ, et al. 1992. Development of potential alternatives to the Draize eye test - The CTFA evaluation of alternatives program - Phase II - Review of materials and methods. Altern Lab Anim 20:164-171.

Hunter WJ, Lingk W, Recht JP. 1979. Intercomparison study on the determination of single administration toxicity in rats. J Assoc Off Anal Chem 62:864-873.

Hyclone[®]. 1996. Heat inactivation – are you wasting your time? Art to Science 15:1-5. Available: <u>http://www.hyclone.com/library/arttoscience.htm</u> [accessed 27 July 2006].

ICCVAM. 2000. The Revised Up-and-Down Procedure: A Test Method for Determining the Acute Oral Toxicity of Chemicals and Products. Proposed Test Method and Background Review Document. Research Triangle Park, NC:National Institute for Environmental Health Sciences. Available: <u>http://iccvam.niehs.nih.gov/</u> [01 November 2006].

ICCVAM. 2001a. Report Of The International Workshop On *In Vitro* Methods For Assessing Acute Systemic Toxicity. NIH Publication No. 01-4499. Research Triangle Park, NC:National Institute for Environmental Health Sciences. Available: <u>http://iccvam.niehs.nih.gov/</u> [accessed 01 November 2006].

ICCVAM. 2001b. Guidance Document On Using *In Vitro* Data To Estimate In Vivo Starting Doses For Acute Toxicity. NIH Publication No. 01-4500. Research Triangle Park, NC:National Institute for Environmental Health Sciences. Available: <u>http://iccvam.niehs.nih.gov/</u> [accessed 01 November 2006].

ICCVAM. 2001c. The Revised Up-and-Down Procedure: A Test Method for Determining the Acute Oral Toxicity of Chemicals. NIH Publication No. 02-4501. Research Triangle Park, NC:National Institute for Environmental Health Sciences. Available: <u>http://iccvam.niehs.nih.gov/</u> [accessed 01 November 2006].

ICCVAM. 2003. ICCVAM Guidelines for the Nomination and Submission of New, Revised, and Alternative Test Methods. NIH Publication No. 03-4508. Research Triangle Park, NC:National Institute for Environmental Health Sciences. Available: <u>http://iccvam.niehs.nih.gov/</u> [accessed 01 November 2006].

ICCVAM. 2006. Peer Review Panel Report: The Use of *In Vitro* Basal Cytotoxicity Test Methods for Estimating Starting Doses for Acute Oral Systemic Toxicity Testing. Research Triangle Park, NC: National Institute for Environmental Health Sciences. Available: <u>http://iccvam.niehs.nih.gov/methods/invitro.htm</u> [accessed 02 August 2006].

IOM. 2004. Forging a Poison Prevention and Control System. Washington: National Academies Press.

INVITTOX. 1991. The FRAME Modified Neutral Red Uptake Cytotoxicity Test. Protocol Number 3 (IP-3A). Available: <u>http://embryo.ib.amwaw.edu.pl/invittox/</u> [accessed 01 November 2006].

Karczmar A. 1998. Invited review: Anticholinesterases: dramatic aspects of their use and misuse. Neurochem Int 32:401-411.

King AV, Jones PA. 2003. In-house assessment of a modified *in vitro* cytotoxicity assay for higher throughput estimation of acute toxicity. Toxicol *In Vitro* 17:717-22.

Knox P, Uphill PF, Fry JR, Benford J, Balls M. 1986. The FRAME multicentre project on *in vitro* cytotoxicity. Food Chem Toxicol 24:457-463.

Kohn J, Durham HD. 1993. S9 liver fraction is cytotoxic to neurons in dissociated culture. Neurotoxicology 14:381-386.

Life Technologies, Inc. 1997. Culture of human keratinocytes in defined serum-free medium. Focus 19:1-5. Available: <u>http://www.invitrogen.co.jp/focus/191002.pdf</u> [accessed 27 July 2006].

Lipnick RL, Cotruvo JA, Hill RN, Bruce RD, Stitzel KA, Walker AP, et al. 1995. Comparison of the up-and-down, conventional LD50, and fixed-dose acute toxicity procedures. Food Chem Toxicol 33:223-231.

Litchfield JT, Wilcoxon F. 1949. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Therap 96:99-113.

Litovitz TL, Klein-Schwartz W, White S, Cobaugh DJ, Youniss J, Drab A, et al. 2000. 1999 Annual report of the american association of poison control centers toxic exposure surveillance system. Am J Emerg Med 18:517-574.

The MathWorks. 1996-2004. MATLAB® software. Natick, MA: The MathWorks, Inc.

Matsuno T, Masuda, Shimizu. 1971. Pipobroman: acute toxicity and general toxicological reaction. Kiso to Rinsho Clinical Report 5:1894-1917.

MDL Information Systems 2001, 2002. Registry of Toxic Effects of Chemical Substances (RTECS) accessed online by subscription.

Mediatech, Inc. 2006. Heat Inactivation of Serum. Technical Information #S055.0303.001. Available: <u>http://cellgro.bizatomic.net/shop/customer/home.php</u> [accessed 27 July 2006].

Microsoft Corporation. 1998-2001. Microsoft[®] Excel[®] 2000 software for Mac[®]. Redmond, WA:Microsoft Corporation.

Miller LC, Tainter ML. 1944. Estimation of the LD50 and its error by means of logarithmicprobit graph paper. Proc Soc Exp Biol Med 57:261-264.

Miyazaki H, Sekine T, Endou H. 2004. The multispecific organic anion transport family: properties and pharmacological significance. Trends Pharmacol Sci 25:654-662.

National Toxicology Program. 2002. Annual Plan For Fiscal Year 2002. Public Health Service, Department of Health and Human Services. NIH Publication No. 03-5309. Research Triangle Park, NC:National Institute for Environmental Health Sciences. Available: <u>http://ntp.niehs.nih.gov/index.cfm?objectid=03611496-026C-BB0F-B2A1527014B2D4B1</u> [accessed 01 November 2006].

NLM. 2005. Haz-Map, Occupational Exposure to Hazardous Agents, Specialized Information Services, National Institutes of Health, Department of Health & Human Services. Washington, DC:National Library of Medicine. Available: <u>http://hazmap.nlm.nih.gov/</u> [accessed 01 November 2006].

NLM. 2000, 2001, 2002, 2005. Hazardous Substances Data Bank. Accessed online via TOXNET. National Institutes of Health, Department of Health & Human Services. Washington, DC:National Library of Medicine. Available: <u>http://toxnet.nlm.nih.gov/cgibin/sis/htmlgen?HSDB</u> [accessed 01 November 2006].

Occupational Safety and Health Act. 2003. Toxic and Hazardous Substances. Hazard Communication 29CFR1910.1200. Available: <u>http://www.gpoaccess.gov/cfr/index.html</u> [accessed 01 November 2006].

Occupational Safety and Health Act. 2000. Labeling Requirements for Pesticides and Devices. Labeling Requirements. 40CFR156.10. Available: <u>http://www.gpoaccess.gov/cfr/index.html</u> [accessed 01 November 2006].

OECD. 1998. OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring Number 1: OECD principles on Good Laboratory Practice. (as revised in 1997). ENV/MC/CHEM(98)17. Paris:Organisation for Economic Co-operation and Development. Available: <u>http://www.oecd.org</u> [accessed 01 November 2006]. OECD. 2000. Guidance Document on the Recognition, Assessment and Use of Clinical Signs as Humane Endpoints for Experimental Animals Used in Safety Evaluation. Environmental Health and Safety Monograph Series on Testing and Assessment No. 19. Paris, France:Organisation for Economic Co-operation and Development. Available: <u>http://www.oecd.org</u> [accessed 01 November 2006].

OECD. 2001a. Guideline for Testing of Chemicals, 425, Acute Oral Toxicity – Up-and-Down Procedure. Paris, France:Organisation for Economic Co-operation and Development. Available: <u>http://www.oecd.org</u> [accessed 01 November 2006].

OECD. 2001b. OECD Series on Testing and Assessment, 33, Harmonized Integrated Classification System for Human Health and Environmental Hazards of Chemical Substances and Mixtures. ENV/JM/MONO(2001)6. Paris, France:Organisation for Economic Co-operation and Development. Available: <u>http://www.oecd.org</u> [accessed 01 November 2006].

OECD. 2001c. Guideline for Testing of Chemicals, 420, Acute Oral Toxicity – Fixed Dose Method. Paris, France:Organisation for Economic Co-operation and Development. Available: <u>http://www.oecd.org</u> [accessed 01 November 2006].

OECD. 2001d. Guideline For Testing of Chemicals, 423, Acute Oral Toxicity – Acute Toxic Class Method. Paris, France:Organisation for Economic Co-operation and Development. Available: <u>http://www.oecd.org</u> [accessed 01 November 2006].

OECD. 2001e. Guidance Document on Acute Oral Toxicity Testing. 24. Paris, France:Organisation for Economic Co-operation and Development. Available: <u>http://www.oecd.org</u> [accessed 01 November 2006].

OECD. 2004a. OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring Number 14: Advisory Document of the Working Group on Good Laboratory Practice: The Application of the Principles of GLP to *In Vitro* Studies. ENV/JM/MONO (2004)26. Paris, France:Organisation for Economic Co-operation and Development. Available: <u>http://www.oecd.org</u> [accessed 01 November 2006].

OECD. 2004b. Guideline for Testing of Chemicals, 432, *In Vitro* 3T3 NRU Phototoxicity Test. Paris, France:Organisation for Economic Co-operation and Development. Available: <u>http://www.oecd.org</u> [accessed 01 November 2006].

Orphan Medical, Inc. 1999. NDA 20-954 Busulfex[™] (busulfan) Injection. NDA 20-954. Available: <u>www.fda.gov/cder/foi/label/1999/20954lbl.pdf</u> [accessed 01 November 2006].

Pesticide Action Network North America. 2005. Pesticide Action Network [PAN] Pesticides Database. Available: <u>http://www.pesticideinfo.org/Index.html</u> [accessed 01 November 2006].

Peloux AF, Federici C, Bichet N, Gouy D, Cano JP. 1992. Hepatocytes in primary culture: an alternative to LD₅₀ testing? Validation of a predictive model by multivariate analysis. Altern Lab Anim 20:8-26.

Phillips JC, Gibson WB, Yam J, Alden CL, Hard GC. 1990. Survey of the QSAR and *in vitro* approaches for developing non-animal methods to supersede the *in vivo* LD50 test. Food Chem Toxicol 28:375-394.

Raabe HA, Moyer GO, Mun GC, Sizemore AM, Harbell JW, Merrill JC. 2004. Induction of a zone of cell death in multi-well plates by refeeding [Abstract]. Toxicologist 78:50. Available: <u>http://www.iivs.org/pages/publication_view.php?doc_id=45</u> [accessed 28 August 2006].

Rasmussen ES. 1999 Cytotoxicity of MEIC chemicals nos. 11-30 in 3T3 mouse fibroblasts with and without microsomal activation. In Vitr Mol Toxicol 12:125-132.

Riddell RJ, Panacer DS, Wilde SM, Clothier RH, Balls M. 1986. The importance of exposure period and cell type in *in vitro* cytotoxicity tests. Altern Lab Anim 14:86-92.

Roguet R. Colovio J, Gaetani Q., Sossou KG, Rogier A. 1993. Cytotoxicity of 28 MEIC chemicals to rat hepatocytes using two viability endpoints: correlation with acute toxicity data in rat and man. Altern Lab Anim 21:216-224.

SAS Institute, Inc. 1999. SAS/STAT User's Guide Version 8. Cary, NC:SAS Institute, Inc.

Schlede E, Mischke U, Roll R, Kayser D. 1992. A national validation study of the acute-toxic-class method--an alternative to the LD50 test. Arch Toxicol 66:455-470.

Schlede E, Mischke U, Diener W, Kayser D. 1995. The international study of the acute toxic class method (oral). Arch Toxicol 69:659-670.

Schmahl D, Osswald H. 1970. Experimental studies on the carcinogenic effects of anticancer chemotherapeutics and immunosuppressive agents. Arzneimittelforschung 20:1461-1467.

Seibert H, Gulden M, Kolossa M, Schepers G. 1992. Evaluation of the relevance of selected *in vitro* toxicity test systems for acute systemic toxicity. Altern Lab Anim 20:240-245.

Seibert H, Balls M, Fentem JH, Bianchi V, Clothier RH, Dierickx PJ, et al. 1996. Acute toxicity testing *in vitro* and the classification and labelling of chemicals. The report and recommendations of ECVAM Workshop 16. Altern Lab Anim 24:499-510.

Sina JF, Galer DM, Sussman RG, Gautheron PD, Sargent EV, Leong B, et al. 1995. A collaborative evaluation of seven alternatives to the Draize eye irritation test using pharmaceutical intermediates. Fundam Appl Toxicol 26:20-31.

Sekine T, Cha SH, Endou H. 2000. The multispecific organic anion transporter (OAT) family. Pflugers Arch 440:337-350.

Spielmann H, Genschow E, Liebsch M, Halle W. 1999. Determination of the starting dose for acute oral toxicity (LD_{50}) testing in the up and down procedure (UDP) from cytotoxicity data. Altern Lab Anim 27:957-966.

Spielmann H, Balls M, Dupuis J, Pape WJW, Pechovitch G, de Silva O, et al. 1998. EU/COLIPA "*In Vitro Phototoxicity*" Validation Study, Results of Phase II (blind trial), Part 1: the 3T3 NRU phototoxicity test. Toxicol *In Vitro* 12:305-327.

Spielmann H, Balls M, Dupuis J, Pape WJW, De Silva O, Holzhütter HG, et al. 1998b. A study on the phototoxic potential of UV filter chemicals from Annex VII of EU Directive 76/768/EEC in the 3T3 NRU *in vitro* phototoxicity test. Altern Lab Anim 26:679-705.

Spielmann H, Liebsch M, Kalweit S, Moldenhauer F, Wirnsberger T, Holzhütter HG, et al. 1996. Results of a validation study in Germany on two *in vitro* alternatives to the Draize eye irritation test, the HET-CAM test and the 3T3 NRU cytotoxicity test. Altern Lab Anim 24:741-858.

Spielmann H, Kalweit S, Liebsch M, Wirnsberger T, Gerner I, Bertram-Neis E, et al. 1993. Validation study of alternatives to the Draize eye irritation test in Germany: Cytotoxicity testing and HET-CAM test with 136 industrial chemicals. Toxicol *In Vitro* 7:505-510.

Spielmann H, Gerner S, Kalweit S, Moog R, Wirnserberger T, Krauser K, et al. 1991. Interlaboratory assessment of alternatives to the Draize eye irritation test in Germany. Toxicol *In Vitro* 5:539-542.

Stallard N, Whitehead A. 2004. A statistical evaluation of the fixed dose procedure. Altern Lab Anim 32(suppl 2):13-21.

Taconic Farms, Inc. 2002. Taconic Farms Animal Models, Sprague Dawley[®] Outbred Rats. Available: <u>http://www.taconic.com/anmodels/spragued.htm</u> [accessed 01 November 2006].

Thompson WR. 1947. Use of moving averages and interpolation to estimate medianeffective dose. Bacteriol Rev 11:115-145.

Thomson PDR[®]. 2004. Physicians' Desk Reference, 58th edition. Montvale, NJ:Thomson PDR.

Triglia D, Wegener PT, Harbell J, Wallace K, Mathesen D, Shopsis C. 1989. Interlaboratory validation study of the keratinocyte neutral red bioassay from Clonetics Corporation. In: *In Vitro* Toxicology, New Directions (Goldberg A, ed). Alternative Methods in Toxicology, Volume 7. New York:Mary Ann Liebert, 357-365.

Tsao MC, Walthall BJ, Ham RG. 1982. Clonal growth of normal human epidermalkeratinocytes in a defined medium. J Cell Physiol 110: 219-229. UN. 1977. United Nations Economic and Social Council. Joint meeting of the RID safety committee and the group of experts on the transportation of dangerous goods. Trans/GE 15/R 274, 2. New York and Geneva:United Nations.

UN. 2005. Globally Harmonized System of Classification and Labelling of Chemicals (GHS), First Revised Edition. [ST/SG/AC.10/30/Rev.1]. New York and Geneva:United Nations. Available: <u>http://www.unece.org/trans/danger/publi/ghs/ghs_rev01/01files_e.html</u> [accessed 01 November 2006].

Vernot EH, MacEwen JD, Haun CC, Kinkead ER. 1977. Acute toxicity and skin corrosion data for some organic and inorganic compounds and aqueous solutions. Toxicol Appl Pharmacol 42:417-423.

Wallum E. 1998. Acute oral toxicity. Environ Health Perspect 106:497-503.

Weil CS. 1952. Tables for convenient calculation of median effective dose (LD50 or ED50) and instructions in their use. Biometrics 8:249-263.

Weil CS, Wright GJ. 1967. Intra- and interlaboratory comparative evaluation of single oral test. Toxicol Appl Pharmacol 11:378-388.

WHO. 1998. The WHO Recommended Classification of Pesticides by Hazard and Guidelines to Classification 1998-1999. International Programme of Chemical Safety. WHO/PCS/98.21. Geneva:World Health Organization.

Willshaw A, Moore LJ, Balls M. 1994. *In vitro* alternatives for the detection of photoirritant chemicals - the EEC COLIPA trial. Toxicol *In Vitro* 8:723-725.

Zbinden G, Flury-Roversi M. 1981. Significance of the LD50-test for the toxicological evaluation of chemical substances. Arch Toxicol 47:77-99.

Zuang V, Balls M, Botham PA, Coquett A, Corsini E, Curren RD, et al. 2002. Follow-up to the ECVAM prevalidation study on *in vitro* tests for acute skin irritation. Altern Lab Anim 30:109-129.

[This Page Intentionally Left Blank]

13.0 GLOSSARY¹

Accuracy²: (a) The closeness of agreement between a test method result and an accepted reference value. (b) The proportion of correct outcomes of a test method. It is a measure of test method performance and one aspect of "relevance". Accuracy is highly dependent on the prevalence of positives in the population being examined.

Acute Toxic Class (ATC) method: An acute oral systemic toxicity test method based on testing groups of animals at fixed doses in a sequential manner. The lethality outcomes are used to classify a test substance into the appropriate GHS acute oral toxicity category.

ANOVA: One-way (and two-way) analysis of variance. ANOVA compares the measurements (continuous variables) of three or more groups when the data are categorized in one way (one-way) or two ways (two-way). ANOVA assumes that the populations compared are normally distributed and that the variances for the groups to be compared are approximately equal.

Assay²: The experimental system used. Often used interchangeably with "test" and "test method."

Biphasic dose-response: Dose-response in which cytotoxicity increases (as dose increases), plateaus, and then increases again. See Section 2.6.3.

Category prediction: The acute oral GHS hazard category that includes the predicted LD_{50} value for a test chemical.

Coded substances: Substances labeled by code rather than name so that they can be tested and evaluated without knowledge of their identity or anticipation of test results. Coded substances are used to avoid intentional or unintentional bias when evaluating laboratory or test method performance.

Coefficient of determination: In linear regression, it denotes the proportion of the variance in Y and X that is shared. Its value ranges between zero and one and it is commonly called called " \mathbb{R}^2 ." For example, $\mathbb{R}^2 = 0.45$, indicates that 45% of the variance in Y can be explained by the variation in X and that 45% of the variance in X can be explained by the variation in Y.

¹ The definitions in this Glossary are restricted to their uses with respect to *in vitro* cytotoxicity testing and the NRU test methods.

² Definition used by the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM 2003).

Coefficient of variation: A statistical representation of the precision of a test. It is expressed as a percentage and is calculated as follows:

$$\left(\frac{\text{standard deviation}}{\text{mean}}\right) \times 100\%$$

Concordance²: The proportion of all substances tested that are correctly classified as positive or negative. It is a measure of test method performance and one aspect of "relevance." The term is often used interchangeably with "accuracy." Concordance is highly dependent on the prevalence of positives in the population being examined. In the NICEATM/ECVAM study, concordance was used to describe the proportion of test substances that were correctly classified into GHS acute oral toxicity hazard categories, or to describe the proportion of test substances for which the laboratories obtained the same classification result.

Confluence: A state in which cells in culture come into contact with other cells in the same culture to form a complete sheet of cells (monolayer). For this study, confluence is determined as a percentage of cell coverage of the tissue culture vessel growth surface (e.g., cell monolayer has 80% confluency).

Cytotoxicity: The adverse effects resulting from interference with structures and/or processes essential for cell survival, proliferation, and/or function. For most chemicals, toxicity is a consequence of non-specific alterations in "basal cell functions" (i.e., via mitochondria, plasma membrane integrity, etc.), which may then lead to effects on organ-specific functions and/or death of the organism. These effects may involve the integrity of membranes and the cytoskeleton, cellular metabolism, the synthesis and degradation or release of cellular constituents or products, ion regulation, and cell division.

Definitive test: The main test of the cytotoxicity assay for determining the IC_{50} . The concentration closest to the range finder test IC_{50} serves as the midpoint of the concentrations tested in a definitive test. Compared to the range finder test, the definitive test uses a smaller dilution factor for the concentrations tested.

Discordant chemicals: Chemicals for which the LD_{50} is not accurately predicted by the IC_{50} (and the associated regression formula) or the GHS toxicity category is not accurately predicted by the IC_{50} (and the associated regression formula). Also referred to as "outliers."

EDIT: Evaluation-guided Development of New *In vitro* Test Batteries. An international project initiated by Björn Ekwall in 1998 and continued by the Scandinavian Society for Cell Toxicology to develop new *in vitro* tests for toxicity and toxicokinetics to be incorporated into test batteries for predicting acute and chronic systemic toxicity.

Endpoint²: The biological process, response, or effect assessed by a test method.

Fixed Dose Procedure (FDP): An acute oral systemic toxicity test method based on testing groups of animals at fixed doses. Evident toxicity outcomes are used to classify a test substance into the appropriate GHS acute oral toxicity category.

Geometric mean: The antilog of the mean of the logarithm of the values. It is less affected by extreme values than the arithmetic mean.

Globally Harmonized System (GHS): A classification system presented by the United Nations that provides (a) a harmonized criteria for classifying substances and mixtures according to their health, environmental and physical hazards, and (b) a harmonized hazard communication elements, including requirements for labeling and safety data sheets.

Good Laboratory Practices (GLP)²: Regulations promulgated by the U.S. Food and Drug Administration and the U.S. Environmental Protection Agency, and principles and procedures adopted by the Organization for Economic Cooperation and Development and Japanese authorities that describe record keeping and quality assurance procedures for laboratory records that will be the basis for data submissions to national regulatory agencies.

Guidance Document: *Guidance Document on Using In Vitro Data to Estimate In Vivo Starting Doses for Acute Toxicity* (ICCVAM 2001b).

Hazard²: The potential for an adverse health or ecological effect. A hazard potential results only if an exposure occurs that leads to the possibility of an adverse effect being manifested.

Hill function: The IC_{50} values are determined from the concentration-response using a Hill function which is a four parameter logistic mathematical model relating the concentration of the test chemical to the response (typically following a sigmoidal shape).

$$Y = Bottom + \frac{Top - Bottom}{1 + 10^{(logEC50 - log X)HillSlope}}$$

where Y=response (i.e., % viability), X is the substance concentration producing the response, Bottom is the minimum response (0% viability, maximum toxicity), Top is the maximum response (maximum viability), EC_{50} is the substance concentration at the response midway between Top and Bottom, and HillSlope describes the slope of the curve. When Top=100% viability and Bottom=0% viability, the EC_{50} is the equal to the IC₅₀.

Hill function (rearranged): Some unusual dose-responses did not fit the Hill function well. To obtain a better model fit, the Bottom parameter was estimated without constraints (the previous practice was to use Bottom=0). However, when Bottom \neq 0, the EC₅₀ reported by the Hill function was not the same as the IC₅₀ since the Hill function defines EC₅₀ as the point midway between Top and Bottom. Thus, the Hill function calculation using the Prism[®] software was rearranged to calculate the concentration corresponding to the IC₅₀ as follows:

$$\log IC_{50} = \log EC_{50} - \frac{\log \left(\frac{Top - Bottom}{Y - Bottom} - 1\right)}{HillSlope}$$

where IC_{50} is the concentration producing 50% toxicity, EC_{50} is the concentration producing a response midway between the Top and Bottom responses; Top is the maximum response (maximum survival), Bottom is the minimum response (0% viability, maximum toxicity), Y=50 (i.e., 50% response), and HillSlope describes the slope of the response. The X from the standard Hill function equation is replaced, in the rearranged Hill function equation, by the IC_{50} .

Hormesis: a dose-response characterized by a compound's ability to cause an opposite effect at low doses than it causes at high doses. A stimulatory effect at low doses and an inhibitory effect in high doses is often the observed manifestation of hormesis.

IC₅₀: test chemical concentration producing 50% inhibition of the endpoint measured (i.e., cell viability).

Interlaboratory reproducibility²: A measure of whether different qualified laboratories using the same protocol and test substances can produce qualitatively and quantitatively similar results. Interlaboratory reproducibility is determined during the prevalidation and validation processes and indicates the extent to which a test method can be transferred successfully among laboratories.

Intralaboratory repeatability²: The closeness of agreement between test results obtained within a single laboratory when the procedure is performed on the same substance under identical conditions within a given time period.

Intralaboratory reproducibility²: The first stage of validation; a determination of whether qualified people within the same laboratory can successfully replicate results using a specific test protocol at different times.

In vitro: In glass. Refers to assays that are carried out in an artificial system (e.g., in a test tube or petri dish) and typically use single-cell organisms, cultured cells, cell-free extracts, or purified cellular components.

In vivo: In the living organism. Refers to assays performed in multicellular organisms.

Kow: Octanol:water partition coefficient.

LC₅₀: Acute lethal serum or blood concentrations.

 LD_{50} : The calculated value of the oral dose that produces lethality in 50% of test animals (rats and mice). The LD_{50} values serve as reference values for the *in vitro* tests.

LD₅₀ (initial): Acute oral rat and mouse LD_{50} values used during the chemical selection process. For RC chemicals, LD_{50} values were those used in the RC database, which were largely from the 1983/84 RTECS[®]. For chemicals that were not included in the RC, the initial LD_{50} values came from HSDB or 2002 RTECS[®].

 LD_{50} (reference): Acute oral rodent LD_{50} values from rats and mice were located through literature searches and references from major toxicity databases such as RTECS[®]. Studies were reviewed to identify the most appropriate LD_{50} values for each chemical. Values obtained using feral animals, preanesthetized animals, or animals less than 4 weeks of age were not used. Values reported as inequalities were not used. Reference LD_{50} values were determined by calculating the geometric mean of the acceptable LD_{50} values. Data were used in generation of the laboratory-specific and combined-laboratory 3T3 and NHK NRU regressions.

Maximum:minimum value: Ratio of minimum acceptable LD_{50} (or IC_{50}) to maximum acceptable LD_{50} (or IC_{50}).

MEIC: Multicentre Evaluation of *In Vitro* Cytotoxicity. An international effort established by the Scandinavian Society for Cell Toxicology and initiated in 1983 to evaluate the relationship and relevance of *in vitro* cytotoxicity for predicting the acute toxicity of chemicals in humans.

Millimolar regressions: Linear regressions with IC_{50} values in mmol/L and LD_{50} values in mmol/kg.

Negative control: An untreated sample containing all components of a test system, except the test substance solvent, which is replaced with a known non-reactive material, such as water. This sample is processed with test substance-treated samples and other control samples to determine whether the solvent interacts with the test system.

Neutral red (NR): A weakly cationic water-soluble dye that stains living cells by readily diffusing through the plasma membrane and concentrating in lysosomes where it electrostatically binds to the anionic lysosomal matrix.

Neutral red uptake (NRU): Concentration of neutral red dye in the lysosomes of living cells. Altering the cell surface or the lysosomal membrane by a toxicological agent causes lysosomal fragility and other adverse changes that gradually become irreversible. The NRU test method makes it possible to distinguish between viable, damaged, or dead cells because these changes result in decreased uptake and binding of NR measurable by optical density absorption readings in a spectrophotometer.

NHK: Normal Human epidermal Keratinocytes (from neonatal foreskin).

Optical density (OD): The absorption (i.e., OD measurement) of the resulting colored solution (colorimetric endpoint) in the NRU assay measured at 540 nm \pm 10 nm in a spectrophotometric microtiter plate reader using blanks as a reference

Outlier: For any measurement, an extreme value in the NICEATM/ECVAM study was referred to as an "outlier" if it passes a statistical test for outliers at the 99% level. With respect to chemicals, it refers to chemicals that do not fit (using the specified criteria) an IC₅₀-LD₅₀ linear regression model. It may also refer to chemicals for which the predicted

acute oral GHS toxicity category does not match the reference *in vivo* GHS acute oral toxicity category.

Performance²: The accuracy and reliability characteristics of a test method (see "accuracy", "reliability").

pH: A measure of the acidity or alkalinity of a solution. pH 7.0 is neutral; higher pHs are alkaline, lower pHs are acidic.

Plate reader: A spectrophotometric device for measuring light intensity as a function of color/wavelength (i.e., optical density/absorption at 540 nm \pm 10 nm for NRU) in 96-well microtiter tissue culture plates.

Positive control: A sample containing all components of a test system and treated with a substance known to induce a positive response, which is processed with the test substance-treated and other control samples to demonstrate the sensitivity of each experiment and to allow for an assessment of variability in the conduct of the assay over time.

Predictivity²: Proportion of *in vivo* category matches for all substances with *in vitro* predictions for a particular category. Predictivity is an indicator of test accuracy.

Protocol²: The precise, step-by-step description of a test, including the listing of all necessary reagents, criteria and procedures for the evaluation of the test data.

Quality assurance (QA)²: A management process by which adherence to laboratory testing standards, requirements, and record keeping procedures is assessed independently by individuals other than those performing the testing.

Quality control (QC): A management process for ensuring products or services are designed and produced to adhere to a defined set of quality criteria to meet or exceed customer requirements; similar to quality assurance.

Range finder: Initial test performed to determine starting doses for the main (definitive) test. The NRU assays test eight concentrations of the test chemical or the PC by diluting the stock solution in log dilutions to cover a large concentration range.

RC millimole regression: log (LD₅₀) = 0.435 x log (IC₅₀) + 0.625; for estimating an LD₅₀ value in mmol/kg (body weight) from an IC₅₀ value in mM. Developed using the 347 IC₅₀ and oral LD₅₀ (282 rat and 65 mouse) values from the RC.

RC rat-only millimole regression: $\log (LD_{50}) = 0.439 \times \log (IC_{50}) + 0.621$; for estimating an LD_{50} value in mmol/kg (body weight) from an IC_{50} value in mM. Developed from the IC_{50} values (in mM) and acute oral LD_{50} values (in mmol/kg) for the 282 substances with rat LD_{50} values in the RC database (Halle 1998, 2003).

RC rat-only weight regression: $\log (LD_{50}) = 0.372 \text{ x} \log (IC_{50}) + 2.024$; for estimating an LD_{50} value in mg/kg (body weight) from an IC_{50} value in μ g/mL. Developed from the IC_{50} values (in μ g/mL) and acute oral LD_{50} values (in mg/kg) for the 282 substances with rat LD_{50} values in the RC database (Halle 1998, 2003).

Reduction alternative²: A new or modified test method that reduces the number of animals required.

Reference substances: Substances selected for use during the research, development, prevalidation, and validation of a proposed test method because their response in the *in vivo* reference test method or the species of interest is known (see "reference test"). Reference substances should represent the classes of chemicals for which the proposed test method is expected to be used and cover the range of expected responses (negative, weak to strong positive).

Reference test method²: The accepted *in vivo* test method used for regulatory purposes to evaluate the potential of a test substance to be hazardous to the species of interest.

Refinement alternative²: A new or modified test method that refines procedures to lessen or eliminate pain or distress in animals or enhances animal well-being.

Registry of Cytotoxicity (RC): Database that consists of *in vivo* acute oral toxicity data (i.e., LD_{50} values) from rats and mice and *in vitro* cytotoxicity data (i.e., IC_{50} values) from multiple cell lines and cytotoxicity endpoints for 347 chemicals with known molecular weights (Halle 1998, 2003). A regression model constructed from these data was proposed by ZEBET, as a method to reduce animal use by identifying the most appropriate starting doses for acute oral systemic toxicity tests.

Relevance²: The extent to which a test method correctly predicts or measures the biological effect of interest in humans or another species of interest. Relevance incorporates consideration of the "accuracy" or "concordance" of a test method.

Reliability²: A measure of the degree to which a test method can be performed reproducibly within and among laboratories over time. It is assessed by calculating intra- and inter-laboratory reproducibility and intralaboratory repeatability.

Replacement alternative²: A new or modified test method that replaces animals with nonanimal systems or one animal species with a phylogenetically lower one (e.g., a mammal with an invertebrate).

Reproducibility²: The consistency of individual test results obtained in a single laboratory (intralaboratory reproducibility) or in different laboratories (interlaboratory reproducibility) using the same protocol and test substances (see intra- and inter-laboratory reproducibility).

RTECS[®]: Registry of Toxic Effects for Chemical Substances. Compendium of data extracted from the open scientific literature. The database includes toxicity data (e.g., acute

toxicity) and specific numeric toxicity values (e.g., LD₅₀). Compiled by the U.S. National Institute for Occupational Safety and Health (NIOSH) and now licensed to MDL Information Systems, Inc.

Sensitivity²: The proportion of all positive substances that are classified correctly as positive in a test method. It is a measure of test method accuracy.

Simulation modeling: Computer simulation modeling of the acute systemic toxicity assays to determine animal use. The simulation process uses a simulated population of animals for testing, a reference endpoint (i.e., "true" LD_{50} value), and its assumed log-normal distribution. Mortality is assumed to have a mean equal to the log of the true LD_{50} . The SD, which reflects the variability of the simulated population, is the inverse of the slope of the dose-mortality curve. Due to a lack of information for the real dose-mortality curve, the simulations assumed slopes of 0.5, 0.8, 2, 4, and 8.3.

Solubility: The amount of a test substance that can be dissolved (or thoroughly mixed with) culture medium or solvent. The solubility protocol was based on a U.S. EPA guideline (EPA 1998) that involves testing for solubility in a particular solvent, beginning at a relatively high concentration and proceeding to successively lower concentrations by adding more solvent as necessary for dissolution. Testing stops when, upon visual observation, the procedure produces a clear solution with no cloudiness or precipitate.

Solvent control: An untreated sample containing all components of a test system, including the solvent that is processed with the test substance-treated and other control samples to establish the baseline response for the samples treated with the test substance dissolved in the same solvent. When tested with a concurrent negative control, this sample also demonstrates whether the solvent interacts with the test system.

Specificity²: The proportion of all negative substances that are classified correctly as negative in a test method. It is a measure of test method accuracy.

Spirit of GLP: Guidance provided in the Statement of Work specifically for the non GLPcompliant laboratory that participated in the validation study. Based on the GLP standards referenced in the ECVAM Workshop 37 Report (Cooper-Hannan et al. 1999) and the OECD Principles of GLP (OECD 1998). "Laboratories that are non GLP-compliant shall adhere to GLP principles and other method parameters. Documentation and accountability shall be equal to GLP requirements. Laboratories must make assurances that they are equal in performance criteria and that there is parity amongst the laboratories."

TESS: Toxic Exposure Surveillance System. A comprehensive poisoning surveillance database maintained by the American Association of Poison Control Centers (AAPCC).

Test²: The experimental system used; used interchangeably with "test method" and "assay".

Test method²: A process or procedure used to obtain information on the characteristics of a substance or agent. Toxicological test methods generate information regarding the ability of a

substance or agent to produce a specified biological effect under specified conditions. Used interchangeably with "test" and "assay". See also "validated test method" and "reference test".

Test method component: Structural, functional, and procedural elements of a test method that are used to develop the test method protocol. These components include unique characteristics of the test method, critical procedural details, and quality control measures.

3T3: BALB/c 3T3 clone A31 mouse fibroblasts developed in 1968 from disaggregated 14- to 17-day-old BALB/c mouse embryos (American Type Culture Collection [ATCC]; # CCL-163).

Tiered testing: A testing strategy where all existing information on a test substance is reviewed, in a specified order, before *in vivo* testing.

Toxicity underpredicted: Measured 1 LD_{50} value of a test substance is lower than the predicted LD_{50} value.

Toxicity overpredicted: Measured LD_{50} value of a test substance is higher than the predicted LD_{50} value.

Transferability²: The ability of a test method or procedure to be accurately and reliably performed in different, competent laboratories.

Up-and-Down Procedure (UDP): An acute oral systemic toxicity test method used to minimize the number of animals required to estimate the acute oral toxicity of a chemical, estimate the LD₅₀ and confidence interval (CI), and observe signs of toxicity. Single animals are tested sequentially. Subsequent doses are based on the outcome of the previous animal.

Validated test method²: An accepted test method for which validation studies have been completed to determine the accuracy and reliability of this method for a specific proposed use.

Validation²: The process by which the reliability and accuracy of a procedure are established for a specific purpose.

Vehicle control (VC): The VC consists of appropriate cell culture medium for the cells in the test (i.e., DMEM for 3T3 cells and keratinocyte growth medium for the NHK cells). For chemicals dissolved in DMSO, the VC consists of medium with the same amount of solvent as that used in the test chemical concentrations that are applied to the 96-well test plate. The final DMSO concentration is $\leq 0.5\%$ (v/v) in the VCs.

Volatility: Ability of a test chemical to evaporate. A general indicator of volatility issues in the NRU test methods is the percent difference in the mean OD values for the two VC columns on the test plate. If the difference is greater than 15%, then chemical volatility can be suspected, especially if the VC adjacent to the highest test concentration had a

significantly reduced OD value. Volatility may be an issue for compounds with a specific gravity of less than 1.

Weight of evidence (process): The strengths and weaknesses of a collection of information are used as the basis for a conclusion that may not be evident from the individual data.

Weight regressions: Linear regressions with IC_{50} values in $\mu g/mL$ and LD_{50} values in mg/kg.

ZEBET: The German National Center for the Documentation and Evaluation of Alternative Methods to Animal Experiments.